efavirenz profile

Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with other antiretroviral medications to treat HIV infection. It was first synthesized in the early 1990s by researchers at DuPont Pharmaceuticals. Efavirenz works by blocking the activity of reverse transcriptase, an enzyme that HIV uses to convert its genetic material into DNA. This prevents the virus from replicating and spreading. Efavirenz is a highly potent anti-HIV drug, but it can cause side effects such as dizziness, drowsiness, and nightmares. However, its ability to penetrate the central nervous system has led to its study for potential use in treating other neurological conditions such as Alzheimer's disease and Parkinson's disease. Its effectiveness in treating HIV infection and its potential applications in other neurological disorders make it a significant research target.'

efavirenz: HIV-1 reverse transcriptase inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	64139
CHEMBL ID	223228
CHEBI ID	119486
SCHEMBL ID	37762
MeSH ID	M0258297
PubMed CID	3203
CHEMBL ID	59507
SCHEMBL ID	464769
MeSH ID	M0258297

Synonym
BIDD:GT0383
bdbm2483
(4s)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-2,4-dihydro-1h-3,1-benzoxazin-2-one
sustiva
HMS3393J08
viraday
CHEMBL223228
efavirenz teva
efavirenzum
(-)-efavirenz
met-stromal cell-derived factor-1.beta. (human) & efavirenz
met-sdf-1.beta. & efavirenz
l-743726
stocrin
(-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2h-3,1-benzoxazin-2-one
MLS001424087
C08088
154598-52-4
efavirenz
sustiva (tm)
dmp-266
nsc742403
eravirenz
l-743,726
efv ,
strocin (tm)
(4s)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1h-3,1-benzoxazin-2-one
2h-3,1-benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4s)-
MLS000759465
smr000466351
1IKW
(s)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
(s)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-(s)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2h-3,1-benzoxazin-2-one4-(trifluoromethyl)-2h-3,1-benzoxazin-2-one
DB00625
6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4s)-1,4-dihydro-2h-benzo[d][1,3]oxazin-2-one
1IKV
sustiva (tn)
D00896
efavirenz (jan/usp/inn)
dmp 266
(4s)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2h-3,1-benzoxazin-2-one
l 743726
hsdb 7163
(s)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2h-3,1-benzoxazin-2-one
(s)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2h-3,1-benzoxazin-2-one
HMS2051J08
HMS2090N16
CHEBI:119486 ,
(4s)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2h-3,1-benzoxazin-2-one
2h-3, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4s)-
nsc-742403
A809555
(4s)-6-chloranyl-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1h-3,1-benzoxazin-2-one
dtxsid9046029 ,
dtxcid7026029
tox21_111582
cas-154598-52-4
BCP9000636
S4685
CCG-101011
(s)-efavirenz
je6h2o27p8 ,
nsc 742403
efavirenz [usp:inn:ban]
efavirenz, (s)
unii-je6h2o27p8
(4s)-6-chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2h-3,1-benzoxazin-2-one
BCPP000245
AB21723
efavirenz [mi]
efavirenz [usp-rs]
efavirenz [orange book]
efavirenz [jan]
efavirenz [who-ip]
efavirenz [vandf]
telura component efavirenz
efavirenz [who-dd]
efavirenz [ema epar]
efavirenz [mart.]
efavirenz [hsdb]
efavirenz [inn]
efavirenz [usan]
efavirenzum [who-ip latin]
efavirenz [usp monograph]
atripla component efavirenz
efavirenz component of atripla
AKOS015894951
DL-535
HY-10572
AB00639956-06
efv & plga
efavirenz & plga
NC00261
SCHEMBL37762
NCGC00159337-04
tox21_111582_1
AB00639956-08
(s)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2h-3,1-benzoxazin-2-one
(s)-6-chloro-4-(cyclopropyl-ethynyl)-1,4-dihydro-4-(trifluoromethyl)-2h-3,1-benzoxazine-2-one
(s)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2h-3,1-ben zoxazin-2-one
efavirenz & interleukin 28a
efv & interleukin 29
efavirenz & ifnl1
efv & ifnl1
efavirenz & interferon lambda-1
efv & ifnl3
efv & interleukin 28a
efavirenz & il-28a
efv & il-29
efv & il-28a
efavirenz & interferon lambda-3
efavirenz & il-28b
efv & interferon lambda-3
efv & ifnl2
efavirenz & ifnl2
efv & interferon lambda-2
efavirenz & interleukin 29
efv & interleukin 28b
efv & interferon lambda-1
efavirenz & interferon lambda-2
efavirenz & interleukin 28b
efavirenz & ifnl3
efavirenz & il-29
efv & il-28b
(s)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2h-benzo[d][1,3]oxazin-2-one
AC-25006
E0997
J-520431
sr-01000759360
SR-01000759360-4
SR-01000759360-5
KS-5380
efavirenz, united states pharmacopeia (usp) reference standard
efavirenz, >=98% (hplc)
(s)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1h-benzo[d][1,3]oxazin-2(4h)-one
HMS3713M14
NCGC00271713-05
dmp-266; efavirenz
Q422645
F17329
Z2177953192
BCP27719
AMY229
NCGC00159337-12
NCGC00271713-08
(rac)-efavirenz
(rac)-dmp 266; (rac)-efv; (rac)-l-743726
dmp266
gtpl11287
efavirenz 100 microg/ml in acetonitrile
EN300-219935
BC164402
efavirenz- bio-x
l-741211
NCGC00159337-02
NCGC00159337-03
l 741211
2h-3,1-benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-
6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2h-3,1-benzoxazin-2-one
smr000718784
MLS001304019
154635-17-3
177530-93-7
FT-0667824
6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1h-3,1-benzoxazin-2-one
CHEMBL59507
BBL010771
6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2h-3,1-benzoxazin-2-one
STK582240
HMS2231D09
AKOS005506207
racemic-efavirenz
6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2h-3,1-benzoxazin-3-one
rac-efavirenz
l741211
6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1h-benzo[d][1,3]oxazin-2(4h)-one
FT-0625647
NCGC00159337-06
2h-3,1-benzoxazin-2-one, 6-chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4s)-
HMS3373J19
AB00876268-06
(+/-) 6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2h-3,1-benzoxazin-2-one
(+) 6-chloro-4-cyclopropylethynyl-4-trifluoromethyl- 1,4-dihydro-2h-3,1-benzoxazin-2-one
(+) 6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2h-3,1-benzoxazin-2-one
(+/-)6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2h-3,1-benzoxazin-2-one
SCHEMBL464769
MLS006011825
tox21 111582
mfcd05662344
6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-4h-3,1-benzoxazin-2-ol
STL454184
efavirenz racemic; ((+/-)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2h-3,1-benzoxazin-2-one)
efavirenz racemic
6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2h-benzo[d][1,3]oxazin-2-one
VS-02672
6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-2,4-dihydro-1h-3,1-benzoxazin-2-one
6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2h-3,1-benzoxazin-2-one
DTXSID00861416
(+/-)-efavirenz
efavirenz racemic (20mg)
(s)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-2,4-dihydro-1h-3,1-benzoxazin-2-one
SY009682

Excerpt	Reference	Relevance
"Eight patients who were infected with human immunodeficiency virus, and who had each sustained an adverse drug reaction while following a regimen including nevirapine, were switched to a regimen including efavirenz."	( The tolerability of efavirenz after nevirapine-related adverse events. Barry, M; Clarke, S; Harrington, P; Mulcahy, F, 2000)	0.31
"The rate of adverse events was examined in 250 subjects enrolled in the expanded access program in a single institution located in Madrid, Spain."	( [Toxicity associated to efavirenz in HIV-infected persons enrolled in an expanded access program]. Barreiro, P; Dona, C; González-Lahoz, J; Jiménez-Náchera, I; Soriano, V, 2000)	0.31
"The rate of adverse events grade moderate-to-severe in patients receiving EFV is relatively low (13."	( [Toxicity associated to efavirenz in HIV-infected persons enrolled in an expanded access program]. Barreiro, P; Dona, C; González-Lahoz, J; Jiménez-Náchera, I; Soriano, V, 2000)	0.31
" Similar serious psychiatric adverse effects have been associated with this agent."	( Central nervous system adverse effects with efavirenz: case report and review. Puzantian, T, 2002)	0.31
"To evaluate the incidence and severity of adverse events (AEs) and treatment interruption (TI) with efavirenz in a population with a high rate of intravenous drug use (IVDU)."	( Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients. Pérez-Molina, JA, )	0.13
" Most patients experienced at least one drug-related adverse event that was not considered treatment-limiting by the investigator."	( Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in antiretroviral treatment-naive HIV-1-infected adults: La Francilienne. Chemlal, K; de Truchis, P; Devidas, A; Force, G; Mamet, JP; Mechali, D; Praindhui, D; Pulik, M; Rouveix, E; Welker, Y, 2002)	0.31
"Safety and efficacy results from this study demonstrated that the quadruple regimen Combivir/abacavir/efavirenz is generally safe and displays potent and durable antiretroviral activity in antiretroviral treatment-naive HIV-1-infected patients, offering a promising therapeutic option in a PI-sparing strategy."	( Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in antiretroviral treatment-naive HIV-1-infected adults: La Francilienne. Chemlal, K; de Truchis, P; Devidas, A; Force, G; Mamet, JP; Mechali, D; Praindhui, D; Pulik, M; Rouveix, E; Welker, Y, 2002)	0.31
"Simplification is safe and effective, but it should be offered to patients with shorter treatment duration, and in good clinical and immunovirological conditions."	( Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes. Adorni, F; Bini, T; Bongiovanni, M; Capetti, A; Castelnuovo, B; Chiesa, E; Cicconi, P; d'Arminio Monforte, A; Faggion, I; Melzi, S; Mussini, C; Rizzardini, G; Rusconi, S; Sollima, S; Tordato, F, 2003)	0.32
" Severe adverse events due to HAART have been already reported for post exposure prophylaxis in HIV infected patients."	( [Acute liver toxicity of antiretroviral therapy (HAART) after liver transplantation in a patient with HIV-HCV coinfection and associated hepatocarcinoma (HCC)]. Antonini, M; Boschetto, A; D'Offizzi, G; Del Nonno, F; Ettorre, GM; Lonardo, MT; Maritti, M; Moricca, P; Narciso, P; Palmieri, GP; Perracchio, L; Santoro, E; Vennarecci, G; Visco, G, )	0.13
" Assessment consisted of CD4+ cell count, plasma HIV-1 RNA load, and adverse effects of study medications."	( Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection. Carroll, H; Conlon, V; Green, A; Green, DC; Green, R; Jefferson, R; Jordan, WC; Tolbert, L; Yemofio, F, 2003)	0.32
" Although data from observational studies and follow-up of children enrolled in clinical trials have not shown uninfected, zidovudine-exposed children to be at increased risk of adverse events including cancer in the short- to medium-term, the possibility that they may be at risk of cancer at older ages cannot be excluded."	( Antenatal and neonatal antiretroviral therapy in HIV-infected women and their infants: a review of safety issues. Newell, ML; Thorne, C, )	0.13
" Adverse events were consistent with prior data for each of the separate agents."	( Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers. Ballow, C; Hendrix, CW; Lou, Y; Piliero, PJ; Preston, SL; Stein, DS; Wire, MB, 2004)	0.32
" Patients in both groups tolerated the therapy well; the adverse effects profile was comparable except that group A patients had a higher incidence of hepatitis than group B patients (13."	( Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1. Patel, A; Patel, B; Patel, J; Patel, K; Rani, S; Shah, N, 2004)	0.32
" Severe adverse reactions included rash (two), toxic hepatitis (six), Immune Reconstitution Syndrome (seven), and four deaths."	( Efficacy and safety of Efavirenz in HIV patients on Rifampin for tuberculosis. Alves, CR; Badaro, R; Brites, C; Netto, EM; Oliveira, AS; Pedral-Sampaio, DB, 2004)	0.32
" The incidence of rash in the NVP group was significantly higher in female patients with higher CD4 cell counts, while adverse events in the EFV group were not associated with CD4 cell count."	( The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. Andrews, S; Grinsztejn, B; Lange, JM; Lazanas, MK; Montaner, J; van Leth, F; Wilkins, E, 2005)	0.33
" These data have now provided a clear and clinically relevant understanding of the individual profiles of drugs within the nucleoside analogue reverse transcriptase inhibitor , HIV protease inhibitor and non-nucleoside analogue reverse transcriptase inhibitor drug classes, and have provided a rational basis for assessing and monitoring these adverse effects in clinical practice."	( Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics. Mallal, S; Nolan, D; Reiss, P, 2005)	0.33
"The relationships between adverse events (AEs) and plasma concentrations of nevirapine (NVP) and efavirenz (EFV) were investigated as part of the large, international, randomized 2NN study."	( Are adverse events of nevirapine and efavirenz related to plasma concentrations? Baraldi, E; Beijnen, JH; Huitema, AD; Kappelhoff, BS; Lange, JM; MacGregor, TR; Montella, F; Robinson, PA; Russell, DB; Thompson, MA; Uip, DE; van Leth, F, 2005)	0.33
" We aimed to determine whether monitoring the plasma concentration of efavirenz could predict neuropsychiatric adverse events associated with long-term therapy with efavirenz."	( Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Antón, R; Borrás, J; Gutiérrez, F; Martín-Hidalgo, A; Masiá, M; Navarro, A; Padilla, S, 2005)	0.33
"8%) of the patients experienced CNS-related adverse effects, ranging from insomnia and abnormal dreams to depression with suicidal ideation."	( Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Antón, R; Borrás, J; Gutiérrez, F; Martín-Hidalgo, A; Masiá, M; Navarro, A; Padilla, S, 2005)	0.33
" Patients achieving higher plasma levels are at increased risk of experiencing neuropsychiatric adverse events."	( Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Antón, R; Borrás, J; Gutiérrez, F; Martín-Hidalgo, A; Masiá, M; Navarro, A; Padilla, S, 2005)	0.33
" This is a retrospective analysis of virologic efficacy and changes in adverse neuropsychiatric effects and serum lipid levels after this switch."	( Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles. Curtin, JM; Ward, DJ, 2006)	0.33
" Both regimens were reasonably well tolerated, although more gastrointestinal adverse events were reported with saquinavir-SGC/ritonavir."	( Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin capsule/ritonavir in antiretroviral-naive, HIV-infected patients. Burnside, AF; Jayaweera, DT; Montaner, JS; Saag, MS; Schutz, M; Schwartz, R; Walmsley, S, 2006)	0.33
" Gastrointestinal adverse effects were commonly associated with treatment failure in the saquinavir-SGC/ritonavir arm of the study."	( Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin capsule/ritonavir in antiretroviral-naive, HIV-infected patients. Burnside, AF; Jayaweera, DT; Montaner, JS; Saag, MS; Schutz, M; Schwartz, R; Walmsley, S, 2006)	0.33
" All available safety data (including data beyond 48 weeks) were used in all analyses, which included calculation of treatment emergent laboratory values, adverse events (AEs), serious AEs, fatalities, drug discontinuations and any summaries by study week of safety data."	( Long-term safety and tolerability of the lamivudine/abacavir combination as components of highly active antiretroviral therapy. Brothers, CH; Castillo, SA; Hernandez, JE, 2006)	0.33
"This analysis indicates that the combination of lamivudine/abacavir is generally safe for the majority of patients when used as part of combination therapy."	( Long-term safety and tolerability of the lamivudine/abacavir combination as components of highly active antiretroviral therapy. Brothers, CH; Castillo, SA; Hernandez, JE, 2006)	0.33
"Liver toxicity is one of the most relevant adverse effects of antiretroviral therapy."	( Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. Mira, JA; Pineda, JA; Rivero, A, 2007)	0.34
" Study medication administration was stopped for 14 children, mostly because of nonadherence (4 cases) or virologic rebound (5 cases) and because of adverse events (unrelated death and grade 2 liver toxicity) in 2 cases."	( Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen. Bekker, V; Jurriaans, S; Kuijpers, TW; Lange, JM; Pajkrt, D; Scherpbier, HJ, 2007)	0.34
" No patient discontinued due to renal adverse events."	( The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients. Cassetti, I; Cheng, AK; Enejosa, J; Etzel, A; Madruga, JV; Suleiman, JM; Zhong, L, )	0.13
" TDF treatment was not associated with renal adverse events or limb fat loss in antiretroviral-naïve patients."	( The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients. Cassetti, I; Cheng, AK; Enejosa, J; Etzel, A; Madruga, JV; Suleiman, JM; Zhong, L, )	0.13
" Two subjects with rashes during the first 2 weeks of therapy were the only adverse events leading to study-drug discontinuation."	( Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021. Abrams, E; Blum, MR; Britto, P; Chittick, GE; Cunningham, C; Dickover, R; Draper, L; Flynn, P; Hu, C; Hughes, M; Kraimer, J; McKinney, RE; Ortiz, AA; Rathore, M; Reynolds, L; Rodman, J; Scites, M; Serchuck, LK; Smith, ME; Spector, S; Tran, P; Weinberg, A; Yogev, R, 2007)	0.34
"A once-daily regimen of emtricitabine, didanosine, and efavirenz proved to be safe and tolerable and demonstrated good immunologic and virologic efficacy in this 2-year study."	( Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021. Abrams, E; Blum, MR; Britto, P; Chittick, GE; Cunningham, C; Dickover, R; Draper, L; Flynn, P; Hu, C; Hughes, M; Kraimer, J; McKinney, RE; Ortiz, AA; Rathore, M; Reynolds, L; Rodman, J; Scites, M; Serchuck, LK; Smith, ME; Spector, S; Tran, P; Weinberg, A; Yogev, R, 2007)	0.34
" Adverse CNS effects were observed in 19 patients soon after therapy onset."	( No observable correlation between central nervous system side effects and EFV plasma concentrations in Japanese HIV type 1-infected patients treated with EFV containing HAART. Hamaguchi, M; Hirano, A; Ibe, S; Kaneda, T; Kudaka, Y; Mamiya, N; Okumura, N; Suzuki, T; Takahashi, M, 2007)	0.34
"Simplification to a once-daily regimen containing TDF, 3TC, and EFV is virologically and immunologically effective, well-tolerated, and safe with benefits in the lipid profile in the majority of patients."	( Effectiveness and safety of simplification therapy with once-daily tenofovir, lamivudine, and efavirenz in HIV-1-infected patients with undetectable plasma viral load on HAART. Aguirrebengoa, K; Alvarez, ML; Arazo, P; Arrizabalaga, J; Chocarro, A; Echevarría, S; Fariñas, MC; Ferrer, P; García-Palomo, D; Iribarren, JA; Labarga, P; Letona, S; Muñoz-Sánchez, MJ; Oteo, JA; Peralta, G; Pinilla, J; Uriz, J, )	0.13
" Overall, 29 adverse events were recorded in 23 patients, the majority associated with neuropsychiatric symptoms of EFV."	( Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV Infection: the ELADI study. Asensi, V; Barreiro, P; de Mendoza, C; Estrada, V; González-Lahoz, J; Jiménez-Nacher, I; Palacios, R; Rivas, P; Rodríguez-Novoa, S; Sánchez-Conde, M; Santos, J; Sanz, J; Sola, J; Soriano, V, 2007)	0.34
" All papers, abstracts, or presentations, regardless of study design, that made reference to the response of patients who were switched from one NNRTI to another as a result of an adverse drug reaction were included."	( Is it safe to switch between efavirenz and nevirapine in the event of toxicity? Maartens, G; Mehta, U, 2007)	0.34
"HIV-infected women on selected ARV regimens or no ARV were administered DMPA 150 mg intramuscularly and evaluated for 12 weeks for adverse events, changes in CD4+ count and HIV RNA levels, and ovulation."	( Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093. Clax, PA; Cohn, SE; Hitti, J; Lertora, JJ; Muderspach, L; Park, JG; Stek, A; Watts, DH; Yu, S, 2008)	0.35
" Nine Grade 3 or 4 adverse events occurred in seven subjects; none were judged related to DMPA."	( Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093. Clax, PA; Cohn, SE; Hitti, J; Lertora, JJ; Muderspach, L; Park, JG; Stek, A; Watts, DH; Yu, S, 2008)	0.35
"The aim of this study was to measure the cumulative incidence of adverse events (AEs) related to nevirapine in patients switched from efavirenz to immediate full-dose nevirapine (FDN)."	( Efavirenz replacement by immediate full-dose nevirapine is safe in HIV-1-infected patients in Cambodia. Chhneang, V; Fernandez, M; Laureillard, D; Moeung, S; Ngeth, C; Piketty, C; Prak, N; Quillet, C; Riel, V; Song, S, 2008)	0.35
" These effects were seen without any documented adverse drug reactions or changes in viral and immunologic control."	( Safety and efficacy of simvastatin for the treatment of dyslipidemia in human immunodeficiency virus-infected patients receiving efavirenz-based highly active antiretroviral therapy. Bain, AM; Bedimo, R; Busti, AJ; Eaton, SA; Nguyen, ST; Payne, KD; Rahman, AP, 2008)	0.35
" Although mild neuropsychiatric symptoms are a well-known adverse effect of this medication, to our knowledge, this is the first report of status epilepticus with routine efavirenz dosing."	( Status epilepticus resulting from severe efavirenz toxicity in an HIV-infected patient. Kwara, A; Nijhawan, AE; Venna, N; Zachary, KC, 2008)	0.35
"Mood disorders and other neuropsychiatric disorders are common adverse events limiting tolerability of alpha-interferon (IFN) therapy for hepatitis C virus (HCV)."	( Effect of treatment with efavirenz on neuropsychiatric adverse events of interferon in HIV/HCV-coinfected patients. Casado, JL; Corral, I; Dronda, F; Hernández, B; Moreno, A; Moreno, S; Pérez-Elías, MJ; Quereda, C; Rodríguez-Sagrado, MA, 2008)	0.35
" Adverse events and concomitant medications were systematically recorded once monthly."	( Effect of treatment with efavirenz on neuropsychiatric adverse events of interferon in HIV/HCV-coinfected patients. Casado, JL; Corral, I; Dronda, F; Hernández, B; Moreno, A; Moreno, S; Pérez-Elías, MJ; Quereda, C; Rodríguez-Sagrado, MA, 2008)	0.35
"Neuropsychiatric adverse events are common in HIV/HCV patients receiving IFN, usually mild or moderate."	( Effect of treatment with efavirenz on neuropsychiatric adverse events of interferon in HIV/HCV-coinfected patients. Casado, JL; Corral, I; Dronda, F; Hernández, B; Moreno, A; Moreno, S; Pérez-Elías, MJ; Quereda, C; Rodríguez-Sagrado, MA, 2008)	0.35
" Although frequency of severe renal toxicity was higher than has been reported in the literature, it was safe in patients with no comorbid renal conditions."	( Effectiveness and safety of generic fixed-dose combination of tenofovir/emtricitabine/efavirenz in HIV-1-infected patients in Western India. Bele, V; Dravid, A; Gupte, N; Joshi, K; Pujari, S, 2008)	0.35
" The patient showed prompt and stable suppression of cryptococcosis and plasma viremia of HIV at long-term follow-up (66 wk), with no significant adverse events."	( Long-term efficacy and safety of TDM-assisted combination of voriconazole plus efavirenz in an AIDS patient with cryptococcosis and liver cirrhosis. Carbonara, S; Ciracì, E; Cusato, M; Heichen, M; Monno, L; Regazzi, M; Stano, F; Villani, P, 2009)	0.35
"More than 50% of patients who start efavirenz treatment develop limiting neuropsychiatric adverse events (NPAEs)."	( Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial. Gutiérrez-Valencia, A; López-Cortés, LF; Lozano, F; Palacios, R; Rivero, A; Ruiz-Valderas, R; Terrón, A; Viciana, P, 2009)	0.35
" Significantly fewer drug-related clinical adverse events occurred in patients on raltegravir (n=124 [44."	( Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Barnard, RJ; Berger, DS; DeJesus, E; DiNubile, MJ; Lazzarin, A; Leavitt, R; Lennox, JL; Madruga, JV; Miller, MD; Nguyen, BY; Pollard, RB; Rodgers, AJ; Sklar, P; Williams-Diaz, A; Xu, X; Zhao, J, 2009)	0.35
"In AIDS Clinical Trials Group A5095, 9% of participants who experienced an adverse event related to efavirenz substituted nevirapine."	( Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095. Gulick, RM; Kmack, A; Krambrink, A; Kuritzkes, DR; Ribaudo, HJ; Schouten, JT; Shikuma, C; Webb, N, 2010)	0.36
" The adverse event rate was similar between arms (except drug hypersensitivity, reported more in the abacavir/lamivudine arm)."	( Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. Branco, T; Cavassini, M; Domingo, P; Fisher, M; Givens, N; Khuong-Josses, MA; Lim, ML; Moyle, GJ; Norden, AG; Pearce, HC; Podzamczer, D; Post, FA; Rieger, A; Stellbrink, HJ; Vavro, C, 2010)	0.36
"People with HIV infection have several risk factors for developing neuropsychiatric adverse events: preexisting conditions, HIV disease stage, and antiretroviral treatment."	( Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: a systematic review. Balkin, A; Gazzard, B; Hill, A, )	0.13
" Maraviroc recipients had greater CD4 increases (+ 212 vs + 171 cells/mm(3)) and fewer adverse event discontinuations (6."	( Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study. Burnside, R; Craig, C; Di Perri, G; Frank, I; Goodrich, J; Heera, J; Mayer, H; McCracken, J; Pontani, D; Saag, M; Sierra-Madero, J; Wood, R, )	0.13
" Multivariate analyses were performed to compare, between the ddI and ZDV groups, the proportion of patients with a viral load <500 copies/ml during follow-up; the increase in the CD4 cell count; survival; treatment changes and severe adverse events."	( Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal. Delaporte, E; Diouf, A; Etard, JF; Girard, PM; Landman, R; Laurent, C; Molinari, N; Ndoye, I; Ngom Guèye, NF; Sow, PS; Tchatchueng Mbougua, JB, 2011)	0.37
" Safety and tolerability were assessed throughout the study by continuous collection of adverse events (AEs), including adverse drug reactions, illnesses with onset during the study, exacerbation of previous illnesses, and clinically significant changes in physical examination findings."	( Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers. Choo, H; Davis, J; Goodrich, J; Hackman, F; Langdon, G; Lewis, D; Ndongo, MN; Tawadrous, M, 2010)	0.36
"A randomized, double-blind trial in patients with viral suppression but ongoing CNS adverse events after more than 12 weeks EFV."	( A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine. Fisher, M; Garvey, L; Hadley, W; Higgs, C; Mandalia, S; Nelson, M; Nicola, M; Perry, N; Waters, L; Winston, A, 2011)	0.37
" Baseline CNS adverse events were similar."	( A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine. Fisher, M; Garvey, L; Hadley, W; Higgs, C; Mandalia, S; Nelson, M; Nicola, M; Perry, N; Waters, L; Winston, A, 2011)	0.37
"Switching EFV to ETR led to a significant reduction in overall G2-4 CNS adverse events, including insomnia, abnormal dreams and nervousness as individual adverse event."	( A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine. Fisher, M; Garvey, L; Hadley, W; Higgs, C; Mandalia, S; Nelson, M; Nicola, M; Perry, N; Waters, L; Winston, A, 2011)	0.37
"Although efavirenz is a universally recommended treatment for naive HIV-infected individuals, neuropsychiatric adverse events are common."	( A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population. Banhegyi, D; Gazzard, B; Hill, A; Marks, S; Nelson, M; Podzamczer, D; Stark, T; Stellbrink, HJ; van Delft, Y; Vingerhoets, J, 2011)	0.37
" The primary end point was the percentage of patients with grade 1-4 drug-related treatment-emergent neuropsychiatric adverse events up to week 12."	( A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population. Banhegyi, D; Gazzard, B; Hill, A; Marks, S; Nelson, M; Podzamczer, D; Stark, T; Stellbrink, HJ; van Delft, Y; Vingerhoets, J, 2011)	0.37
"After 12 weeks, first-line treatment with etravirine 400 mg once daily with two NRTIs was associated with significantly fewer neuropsychiatric adverse events when compared with efavirenz with two NRTIs."	( A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population. Banhegyi, D; Gazzard, B; Hill, A; Marks, S; Nelson, M; Podzamczer, D; Stark, T; Stellbrink, HJ; van Delft, Y; Vingerhoets, J, 2011)	0.37
" The incidence of drug-related adverse events was similar in raltegravir recipients with and without hepatitis coinfection in both STARTMRK (50 vs."	( Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection. Harvey, C; Leavitt, R; Nguyen, BY; Rockstroh, J; Sklar, P; Strohmaier, K; Teppler, H; Zhao, J, 2012)	0.38
" Primary outcome was a composite of death, virological failure, default, or serious adverse event (SAE) at 24 weeks."	( Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. Bhavani, PK; Dilip, M; Iliayas, S; Menon, PA; Narendran, G; Padmapriyadarsini, C; Ponnuraja, C; Pooranagangadevi, NP; Ramachandran, R; Ramesh Kumar, S; Selvaraju, S; Swaminathan, S; Venkatesan, P, 2011)	0.37
"5%) subjects discontinued ART due to this adverse event."	( Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients. Camacho, A; Collado, A; de Los Santos-Gil, I; González-Serrano, M; Macías, J; Merino, D; Mira, JA; Neukam, K; Parra-García, G; Pineda, JA; Rivero, A; Ruiz-Morales, J; Torres-Cornejo, A, 2011)	0.37
" There were no grade 3 or 4 clinical adverse events."	( Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267. Allen, R; Aweeka, F; Cramer, Y; Dooley, KE; Flexner, C; Gupta, A; Haas, DW; Lizak, P; Park, JG; Qasba, S; Swindells, S; van Heeswijk, R; Wiggins, I, 2012)	0.38
" Adverse events, viral load (VL), PK, and reverse transcriptase mutations were assessed and combined for analysis."	( Safety and efficacy of GSK2248761, a next-generation nonnucleoside reverse transcriptase inhibitor, in treatment-naive HIV-1-infected subjects. Dudas, K; Dumont, E; Kim, J; Lou, Y; Mayers, D; Pietropaolo, K; Piscitelli, S; St Clair, M; White, S; Zala, C; Zhou, XJ, 2012)	0.38
" Rilpivirine compared with efavirenz gave smaller incidences of adverse events leading to discontinuation (3% vs."	( Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials. Boven, K; Cahn, P; Clotet, B; Cohen, CJ; Crauwels, H; Fourie, J; Grinsztejn, B; Johnson, MA; Lefebvre, E; Molina, JM; Rimsky, LT; Saag, M; Supparatpinyo, K; Vanveggel, S; Williams, P; Wu, H, 2012)	0.38
"Hepatic toxicity and metabolic disorders are major adverse effects elicited during the pharmacological treatment of the human immunodeficiency virus (HIV) infection."	( Profile of stress and toxicity gene expression in human hepatic cells treated with Efavirenz. Apostolova, N; Blas-Garcia, A; Esplugues, JV; Gomez-Sucerquia, LJ; Marti-Cabrera, M, 2012)	0.38
" Adverse events were mostly mild and no serious adverse events or drug discontinuations were reported."	( Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study. Aarnoutse, RE; Boeree, MJ; Burger, DM; Fillekes, Q; Kibiki, GS; Kisanga, ER; Kisonga, RM; Mleoh, L; Mtabho, CM; Ndaro, A; Semvua, HH; van den Boogaard, J; van der Ven, A, 2013)	0.39
" Lipodystrophy accounted for 87 of 96 toxic events."	( Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa. Chersich, M; Fairlie, L; Kuhn, L; Meyers, T; Moultrie, H; Palmer, M, 2013)	0.39
" Beyond week 48, the incidence of virologic failure was comparable (3 versus 2%) between treatment groups, rilpivirine resistance-associated mutations were consistent with those observed in year 1, there were few adverse events in both groups and no new safety concerns."	( Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. Boven, K; Cassetti, I; Chetchotisakd, P; Cohen, CJ; Crauwels, H; Lazzarin, A; Li, T; Molina, JM; Orkin, C; Rhame, F; Rimsky, L; Stellbrink, HJ; Vanveggel, S; Williams, P, 2013)	0.39
" Overall incidences of all-causality treatment-related or grade 3/4 adverse events (AEs) or AE-related discontinuations were lower with lersivirine than with efavirenz, and serious AEs occurred at similar rates across treatment groups."	( Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial. Cooper, DA; Craig, C; Goodrich, J; Kaplan, R; Lazzarin, A; Mori, J; Pozniak, A; Pulik, P; Tawadrous, M; Valdez, H; Vernazza, P; Wang, C; Weil, E, 2013)	0.39
"We systematically reviewed adverse events among treatment-naive HIV-positive adults and children receiving either NVP or EFV as part of first-line antiretroviral therapy."	( Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. Andrieux-Meyer, I; Calmy, A; Ford, N; Hargreaves, S; Mills, EJ; Renaud-Théry, F; Shaffer, N; Shubber, Z; Vitoria, M, 2013)	0.39
"Compared to NVP, EFV is associated with a lower frequency of severe adverse events, in particular treatment discontinuations."	( Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. Andrieux-Meyer, I; Calmy, A; Ford, N; Hargreaves, S; Mills, EJ; Renaud-Théry, F; Shaffer, N; Shubber, Z; Vitoria, M, 2013)	0.39
"Overall, 71 of 281 raltegravir recipients (25%) and 98 of 282 efavirenz recipients (35%) discontinued the study; discontinuations due to adverse events occurred in 14 (5%) and 28 (10%) patients in the respective groups."	( Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. DeJesus, E; DiNubile, MJ; Leavitt, R; Lennox, JL; Miller, M; Nguyen, BY; Rockstroh, JK; Rodgers, AJ; Saag, MS; Sklar, P; Teppler, H; Walker, ML; Wan, H; Yazdanpanah, Y, 2013)	0.39
" Over the entire study, fewer patients experienced neuropsychiatric and drug-related adverse events in the raltegravir group than in the efavirenz group."	( Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. DeJesus, E; DiNubile, MJ; Leavitt, R; Lennox, JL; Miller, M; Nguyen, BY; Rockstroh, JK; Rodgers, AJ; Saag, MS; Sklar, P; Teppler, H; Walker, ML; Wan, H; Yazdanpanah, Y, 2013)	0.39
" Neuropsychiatric adverse effects are by far the most common reasons for discontinuation."	( Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects. Larsen, CS; Leutscher, PD; Stecher, C; Storgaard, M, 2013)	0.39
"Cyproheptadine prevention of the neuropsychiatric adverse effects of an antiretroviral regimen including efavirenz has been evaluated in a randomized clinical trial."	( Cyproheptadine for prevention of neuropsychiatric adverse effects of efavirenz: a randomized clinical trial. Akhondzadeh, S; Alimadadi, A; Dabaghzadeh, F; Ghaeli, P; Jafari, S; Khalili, H; Khazaeipour, Z, 2013)	0.39
"A total of 119 HIV-positive patients, in which 1350 EFV plasma concentrations, 68 SNPs and 14 EFV-related adverse effects (AEs) were analyzed."	( Impact of pharmacogenetics on CNS side effects related to efavirenz. Cabrera Figueroa, S; Carracedo Álvarez, A; Cruz Guerrero, R; Hurlé, AD; Hurtado, LP; Sánchez Martín, A, 2013)	0.39
" Efavirenz, especially its major metabolite 8-hydroxy-efavirenz, is toxic in neuron cultures at concentrations found in the cerebrospinal fluid."	( Neuronal toxicity of efavirenz: a systematic review. Decloedt, EH; Maartens, G, 2013)	0.39
" The case illustrates the value of routine monitoring after initiating antiretroviral therapy and the fundamental importance of engaging patients in long-term management to ensure safe treatment."	( Liver transplantation for acute liver failure due to efavirenz hepatotoxicity: the importance of routine monitoring. Bloch, E; Fink, DL, 2013)	0.39
"Due to ongoing neuropsychiatric adverse events in some efavirenz (EFV)-treated patients, a switch to an alternative non-nucleoside reverse transcriptase inhibitor may be considered."	( Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens. Brinson, C; Cheng, AK; Chuck, SK; Cohen, C; Dejesus, E; Mills, AM; Ramanathan, S; Wang, MH; White, K; Williams, S; Yale, KL, )	0.13
" No subjects discontinued the study due to an adverse event."	( Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens. Brinson, C; Cheng, AK; Chuck, SK; Cohen, C; Dejesus, E; Mills, AM; Ramanathan, S; Wang, MH; White, K; Williams, S; Yale, KL, )	0.13
" This case report indicates the possibility of adverse effects developing when the 2 drugs are used together."	( Effect of concomitant use of montelukast and efavirenz on neuropsychiatric adverse events. Ibarra-Barrueta, O; Mayo-Suarez, J; Mora-Atorrasagasti, O; Palacios-Zabalza, I, 2014)	0.4
"There is an urgent need for new antituberculosis (anti-TB) drugs, including agents that are safe and effective with concomitant antiretrovirals (ARV) and first-line TB drugs."	( Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin. Allen, R; Aweeka, F; Bao, J; Cramer, Y; Dooley, KE; Haas, DW; Koletar, SL; Luetkemeyer, AF; Marzan, F; Murray, S; Park, JG; Savic, R; Sutherland, D, 2014)	0.4
" MVC was well tolerated with no grade 3/4 adverse events; all subjects maintained viral suppression to the end of the study."	( Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapy. Back, D; Boffito, M; Else, L; Gazzard, B; Jackson, A; Nelson, M; Newell, S; Rockwood, N; Waters, L, 2015)	0.42
" efavirenz experienced treatment-related adverse events (68."	( Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings. Botes, M; Burnside, R; Clumeck, N; Cooper, DA; Dejesus, E; Heera, J; Ive, P; Lazzarin, A; Mukwaya, G; Saag, M; van Der Ryst, E; Walmsley, S, 2014)	0.4
"Growing evidence associates the non-nucleoside reverse transcriptase inhibitor efavirenz with several adverse events."	( Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: a comparison with efavirenz. Alegre, F; Apostolova, N; Blas-García, A; Esplugues, JV; Funes, HA; Martínez, E; Polo, M, 2014)	0.4
"Darunavir, rilpivirine and raltegravir do not induce toxic effects on Hep3B cells and primary rat neurons, which suggests a safer hepatic and neurological profile than that of efavirenz."	( Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: a comparison with efavirenz. Alegre, F; Apostolova, N; Blas-García, A; Esplugues, JV; Funes, HA; Martínez, E; Polo, M, 2014)	0.4
" Grade 1 or 2 gastrointestinal adverse events were higher among women on lopinavir/ritonavir versus efavirenz."	( Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women. Achan, J; Ades, V; Charlebois, ED; Clark, TD; Cohan, D; Gandhi, M; Havlir, DV; Kamya, MR; Koss, CA; Luwedde, F; Mwesigwa, J; Natureeba, P; Nzarubara, B; Plenty, A; Ruel, T, 2015)	0.42
" No serious adverse event related to tenofovir."	( Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing. Aurpibul, L; Chokephaibulkit, K; Cressey, TR; Phongsamart, W; Sirisanthana, V; Sricharoenchai, S; Sudjaritruk, T; Wittawatmongkol, O, 2015)	0.42
"TDF substitution in children and adolescents who were otherwise stable while receiving a first-line nonnucleoside reverse transcriptase inhibitor-based regimen achieved adequate exposure without clinically significant renal or bone adverse events over 96 weeks."	( Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing. Aurpibul, L; Chokephaibulkit, K; Cressey, TR; Phongsamart, W; Sirisanthana, V; Sricharoenchai, S; Sudjaritruk, T; Wittawatmongkol, O, 2015)	0.42
"Efavirenz (EFV) is widely used for the treatment of antiretroviral-naive HIV-positive individuals, but there are concerns about the risk of adverse neuropsychiatric events."	( Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy: A Systematic Review and Meta-Analysis of Randomized Trials. Calmy, A; Doherty, M; Ford, N; Kirby, C; Pozniak, A; Shubber, Z; Vitoria, M, 2015)	0.42
" The primary outcome was drug discontinuation as a result of any adverse event."	( Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy: A Systematic Review and Meta-Analysis of Randomized Trials. Calmy, A; Doherty, M; Ford, N; Kirby, C; Pozniak, A; Shubber, Z; Vitoria, M, 2015)	0.42
" A lower relative and absolute risk of discontinuations due to adverse drug reactions was seen with EFV compared to nevirapine."	( Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy: A Systematic Review and Meta-Analysis of Randomized Trials. Calmy, A; Doherty, M; Ford, N; Kirby, C; Pozniak, A; Shubber, Z; Vitoria, M, 2015)	0.42
" The relative risk of discontinuations due to adverse events was higher for EFV compared with most other first-line options, but absolute differences were less than 5% for all comparisons."	( Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy: A Systematic Review and Meta-Analysis of Randomized Trials. Calmy, A; Doherty, M; Ford, N; Kirby, C; Pozniak, A; Shubber, Z; Vitoria, M, 2015)	0.42
" Adverse events and serious adverse events were summarised by treatment group."	( Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Amin, J; Belloso, W; Carey, D; Cooper, DA; Crabtree-Ramirez, B; Emery, S; Foulkes, S; Jessen, H; Kumar, S; Lee, MP; Losso, M; Mohapi, L; Phanupak, P; Puls, R; Winston, A, 2015)	0.42
" Adverse events were reported by 291 (91%) of 321 patients in the efavirenz 400 mg group and by 285 (92%) of 309 in the 600 mg group (p=0·48)."	( Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Amin, J; Belloso, W; Carey, D; Cooper, DA; Crabtree-Ramirez, B; Emery, S; Foulkes, S; Jessen, H; Kumar, S; Lee, MP; Losso, M; Mohapi, L; Phanupak, P; Puls, R; Winston, A, 2015)	0.42
" Fewer efavirenz-related adverse events were reported with the 400 mg efavirenz dose than with the 600 mg dose."	( Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Amin, J; Belloso, W; Carey, D; Cooper, DA; Crabtree-Ramirez, B; Emery, S; Foulkes, S; Jessen, H; Kumar, S; Lee, MP; Losso, M; Mohapi, L; Phanupak, P; Puls, R; Winston, A, 2015)	0.42
" Moreover, the possibility of common cellular impacts underlying adverse effects of efavirenz in sperm cells and neurons deserved investigation."	( Impaired sperm motility in HIV-infected men: an unexpected adverse effect of efavirenz? De Almeida, M; Dulioust, E; Frapsauce, C; Gayet, V; Grabar, S; Jouannet, P; Launay, O; Leruez-Ville, M; Sogni, P; Viard, JP, 2015)	0.42
" We also found no significant differences between the two groups for adverse events and death."	( Efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV infected children and adolescents: a systematic review and meta-analysis. Adetokunboh, OO; Balogun, TA; Schoonees, A; Wiysonge, CS, 2015)	0.42
" Additional assessments included CD4 cell counts, genotypic/phenotypic resistance, adverse events, patient-reported outcomes, and quality of life questionnaires."	( Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study. Antinori, A; Arribas, JR; Bloch, M; Bosse, M; Chuck, SK; Cohen, CJ; De-Oertel, S; Garner, W; Piontkowsky, D; Porter, D; Rachlis, A; Rieger, A; Segal-Maurer, S; van Lunzen, J; Wohl, DA, 2016)	0.43
" Compared with EFV/FTC/TDF, RPV/FTC/TDF was associated with fewer adverse event-related discontinuations (3."	( Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study. Antinori, A; Arribas, JR; Bloch, M; Bosse, M; Chuck, SK; Cohen, CJ; De-Oertel, S; Garner, W; Piontkowsky, D; Porter, D; Rachlis, A; Rieger, A; Segal-Maurer, S; van Lunzen, J; Wohl, DA, 2016)	0.43
"This combination ART regimen is safe and effective for patients with HIV/HBV co-infection."	( Efficacy and Safety of Tenofovir and Lamivudine in Combination with Efavirenz in Patients Co-infected with Human Immunodeficiency Virus and Hepatitis B Virus in China. Cai, WP; He, HL; Huang, SB; Ling, XM; Liu, YF; Wang, H; Wang, M; Wang, XC; Wei, FL; Wu, H; Wu, YS; Wu, ZY; Yang, L; Zhang, FJ; Zhang, WW, 2016)	0.43
"WHO recommends tenofovir, efavirenz, and lamivudine or emtricitabine for first-line antiretroviral therapy (ART) in adults, which replaced more toxic regimens using stavudine, zidovudine or nevirapine."	( Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen. Cohen, K; Maartens, G; Mouton, JP, 2016)	0.43
" In sub-Saharan Africa, efavirenz (EFV) forms the preferred first-line ART but adverse drug events have also been reported."	( Rolling out Efavirenz for HIV Precision Medicine in Africa: Are We Ready for Pharmacovigilance and Tackling Neuropsychiatric Adverse Effects? Dandara, C; Leutscher, PD; Masimirembwa, C, 2016)	0.43
" However, EFV administration has also led to severe adverse effects, several reports highlighted the role of EFV in mitochondrial dysfunction and toxicity but the molecular mechanism has been poorly understood."	( Depolarization of mitochondrial membrane potential is the initial event in non-nucleoside reverse transcriptase inhibitor efavirenz induced cytotoxicity. Chaubey, B; Ganta, KK; Mandal, A, 2017)	0.46
" We extracted data on trial and patient characteristics, and the following primary outcomes: viral suppression, mortality, AIDS defining illnesses, discontinuations, discontinuations due to adverse events, and serious adverse events."	( Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis. Bansback, N; Doherty, M; Ford, N; Forrest, JI; Kanters, S; Mills, EJ; Nsanzimana, S; Popoff, E; Socias, ME; Thorlund, K; Vitoria, M, 2016)	0.43
" Both low-dose efavirenz and integrase strand transfer inhibitors tended to be protective of discontinuations due to adverse events relative to normal-dose efavirenz."	( Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis. Bansback, N; Doherty, M; Ford, N; Forrest, JI; Kanters, S; Mills, EJ; Nsanzimana, S; Popoff, E; Socias, ME; Thorlund, K; Vitoria, M, 2016)	0.43
" Of the nine patients excluded from the study, only one was withdrawn due to adverse events."	( Effectiveness and safety of generic version of abacavir/lamivudine and efavirenz in treatment naïve HIV-infected patients: a nonrandomized, open-label, phase IV study in Cali-Colombia, 2011-2012. Amariles, P; Galindo, J; Galindo-Orrego, X; González-Avendaño, S; Hincapié, JA; Mueses-Marín, HF, 2016)	0.43
" We conducted a thorough review of the reported studies to elucidate the relationship between polymorphisms in CYP2B6 with adverse events and treatment response, including virologic suppression, immunologic response, resistance, and discontinuation of treatment."	( Role of Cytochrome P450 2B6 Pharmacogenomics in Determining Efavirenz-Mediated Central Nervous System Toxicity, Treatment Outcomes, and Dosage Adjustments in Patients with Human Immunodeficiency Virus Infection. Varghese Gupta, S; Vo, TT, 2016)	0.43
" Relevant articles were hand-searched for renal (Grade 3-4 serum creatinine/estimated glomerular filtration rate elevations, renal adverse events [AEs], discontinuation due to renal AEs, and urinary biomarkers) and bone outcomes (bone mineral density [BMD] reductions, bone turnover markers, and fracture), and results compiled qualitatively."	( Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection. Bedimo, R; Myers, J; Rosenblatt, L, 2016)	0.43
"Several neuropsychiatric adverse effects of efavirenz are known."	( Effect of Valerian in Preventing Neuropsychiatric Adverse Effects of Efavirenz in HIV-Positive Patients: A Pilot Randomized, Placebo-Controlled Clinical Trial. Abbasian, L; Ahmadi, M; Ghaeli, P; Khalili, H, 2017)	0.46
"To evaluate the efficacy and safety of valerian in preventing neuropsychiatric adverse effects of efavirenz in HIV-positive patients."	( Effect of Valerian in Preventing Neuropsychiatric Adverse Effects of Efavirenz in HIV-Positive Patients: A Pilot Randomized, Placebo-Controlled Clinical Trial. Abbasian, L; Ahmadi, M; Ghaeli, P; Khalili, H, 2017)	0.46
" Nausea was the second common adverse effect that 84% and 76."	( Effect of Valerian in Preventing Neuropsychiatric Adverse Effects of Efavirenz in HIV-Positive Patients: A Pilot Randomized, Placebo-Controlled Clinical Trial. Abbasian, L; Ahmadi, M; Ghaeli, P; Khalili, H, 2017)	0.46
" Valerian may be considered as a potential option in preventing neuropsychiatric adverse effects of efavirenz in HIV-positive patients."	( Effect of Valerian in Preventing Neuropsychiatric Adverse Effects of Efavirenz in HIV-Positive Patients: A Pilot Randomized, Placebo-Controlled Clinical Trial. Abbasian, L; Ahmadi, M; Ghaeli, P; Khalili, H, 2017)	0.46
"Efavirenz is an anti-HIV drug that presents relevant short- and long-term central nervous system adverse reactions."	( Unmasking efavirenz neurotoxicity: Time matters to the underlying mechanisms. Antunes, AMM; Cipriano, M; Diogo, LN; Grilo, NM; João Correia, M; Matilde Marques, M; Miranda, JP; Monteiro, EC; Pereira, SA; Serpa, J, 2017)	0.46
"This study aimed to identify the 516 G>T polymorphism of the CYP2B6 gene and evaluate its influence on central nervous system (CNS) side effect development in HIV-positive individuals undergoing Efavirenz (EFV) treatment in a population from southern Brazil."	( CYP2B6 516 G>T polymorphism and side effects of the central nervous system in HIV-positive individuals under Efavirenz treatment: Study of a sample from southern Brazil. Ellwanger, JH; Matte, MCC; Michita, RT; Müller, TE; Renner, JDP, 2017)	0.46
" The toxic and genotoxic potential of EFV and TDF alone and in combinations {EFV+combivir [zidovudine (AZT)+lamivudine (3TC)] and TDF+3TC} were assessed using the comet assay and the somatic mutation and recombination test (SMART) in Drosophila melanogaster."	( In vivo genotoxicity evaluation of efavirenz (EFV) and tenofovir disoproxil fumarate (TDF) alone and in their clinical combinations in Drosophila melanogaster. Chen-Chen, L; Cunha, KS; de Jesus Silva Carvalho, C; de Melo E Silva, D; de Moraes Filho, AV; Gonçalves, MW; Rohde, C; Verçosa, CJ, 2017)	0.46
" Some of its toxic effects on hepatic cells have been reported to display features of mitochondrial dysfunction through bioenergetic stress and autophagy, etc."	( Increased MMAB level in mitochondria as a novel biomarker of hepatotoxicity induced by Efavirenz. Feng, Y; Jia, X; Jin, JO; Liu, L; Lu, H; Ma, F; Tan, Z; Wu, D; Yin, L; Zhang, L, 2017)	0.46
"Results from nonrandomized cohort studies suggest higher risks of CNS adverse events for dolutegravir, versus other ARVs."	( Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals: meta-analysis of randomized trials. Hill, AM; Hughes, S; Mitchell, N; Pozniak, AL, 2018)	0.48
"There was a higher risk of Grade 1-4 insomnia adverse events for DTG (6."	( Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals: meta-analysis of randomized trials. Hill, AM; Hughes, S; Mitchell, N; Pozniak, AL, 2018)	0.48
"In this meta-analysis, there was no significant effect of dolutegravir on the risk of cardiac, IRIS or suicide-related serious adverse events."	( Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals: meta-analysis of randomized trials. Hill, AM; Hughes, S; Mitchell, N; Pozniak, AL, 2018)	0.48
" The form is designed to obtain information on the demographics of the patients, WHO clinical stage of their HIV infection, HAART regimen for the patients, and suspected adverse events associated with the antiretroviral drugs used by the patients."	( A prospective study of adverse events to antiretroviral therapy in HIV- infected adults in Ekiti State, Nigeria. Awodele, O; Oshikoya, KA; Popoola, TD, 2016)	0.43
" About half (57%) of the participants reported clinical adverse events; 92% of which were reported within two weeks of HAART initiation."	( A prospective study of adverse events to antiretroviral therapy in HIV- infected adults in Ekiti State, Nigeria. Awodele, O; Oshikoya, KA; Popoola, TD, 2016)	0.43
"Antiretroviral drugs exposure often presents with adverse events, an observation similar to other studies."	( A prospective study of adverse events to antiretroviral therapy in HIV- infected adults in Ekiti State, Nigeria. Awodele, O; Oshikoya, KA; Popoola, TD, 2016)	0.43
" EFV is well known to cause neuropsychiatric side-effects on initiation, and a recent adult case series described late-onset neurotoxicity in the form of subacute ataxia and encephalopathy in patients treated with EFV for a median of 2 years, in association with toxic plasma levels of the drug."	( A proposed management algorithm for late-onset efavirenz neurotoxicity. Asukile, MT; Chetty, S; Cross, HM; Hussey, HS; Lee Pan, EB; Tucker, LM, 2018)	0.48
"We characterized associations between central nervous system (CNS) adverse events and brain neurotransmitter transporter/receptor genomics among participants randomized to efavirenz-containing regimens in AIDS Clinical Trials Group studies in the USA."	( Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Acosta, EP; Bradford, Y; Daar, ES; Eron, JJ; Gulick, RM; Haas, DW; Morse, GD; Riddler, SA; Ritchie, MD; Sax, PE; Verma, A; Verma, SS, 2018)	0.48
"Analyses included 167 cases with grade 2 or greater efavirenz-consistent CNS adverse events within 48 weeks of study entry, and 653 efavirenz-tolerant controls."	( Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Acosta, EP; Bradford, Y; Daar, ES; Eron, JJ; Gulick, RM; Haas, DW; Morse, GD; Riddler, SA; Ritchie, MD; Sax, PE; Verma, A; Verma, SS, 2018)	0.48
"Efavirenz-related CNS adverse events were not associated with predicted neurotransmitter transporter/receptor gene expression levels in brain or with polymorphisms in these genes."	( Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Acosta, EP; Bradford, Y; Daar, ES; Eron, JJ; Gulick, RM; Haas, DW; Morse, GD; Riddler, SA; Ritchie, MD; Sax, PE; Verma, A; Verma, SS, 2018)	0.48
" In a Brazilian cohort, we sought to characterize associations between efavirenz adverse effects (all-cause and CNS) and polymorphisms in seven genes known or suspected to affect efavirenz metabolism and transport."	( Drug metabolism and transport gene polymorphisms and efavirenz adverse effects in Brazilian HIV-positive individuals. Baker, P; Cardoso, CC; da Silva, GAR; de Almeida, TB; de Azevedo, MCVM; de Castro, IJ; Ferry, FRA; Haas, DW; Pinto, JFDC; Tanuri, A, 2018)	0.48
" Eighty-nine cases had efavirenz adverse effects, including 43 with CNS adverse effects, while 136 controls had no adverse effect of any antiretroviral after treatment for at least 6 months."	( Drug metabolism and transport gene polymorphisms and efavirenz adverse effects in Brazilian HIV-positive individuals. Baker, P; Cardoso, CC; da Silva, GAR; de Almeida, TB; de Azevedo, MCVM; de Castro, IJ; Ferry, FRA; Haas, DW; Pinto, JFDC; Tanuri, A, 2018)	0.48
" Increased all-cause adverse effects were associated with the CYP2B6 genotype combination 15582CC-516TT-983TT (OR = 7."	( Drug metabolism and transport gene polymorphisms and efavirenz adverse effects in Brazilian HIV-positive individuals. Baker, P; Cardoso, CC; da Silva, GAR; de Almeida, TB; de Azevedo, MCVM; de Castro, IJ; Ferry, FRA; Haas, DW; Pinto, JFDC; Tanuri, A, 2018)	0.48
"In a highly admixed Brazilian cohort, the CYP2B6 slow metabolizer genotype was associated with an increased risk of efavirenz adverse effects."	( Drug metabolism and transport gene polymorphisms and efavirenz adverse effects in Brazilian HIV-positive individuals. Baker, P; Cardoso, CC; da Silva, GAR; de Almeida, TB; de Azevedo, MCVM; de Castro, IJ; Ferry, FRA; Haas, DW; Pinto, JFDC; Tanuri, A, 2018)	0.48
" The primary outcomes were the combined endpoints of any adverse outcome (stillbirth, preterm birth [<37 weeks' gestation], small for gestational age [SGA; less than the tenth percentile of birthweight by gestational age], or neonatal death [within 28 days of age]) and severe adverse outcomes (stillbirth, neonatal death, very preterm birth [<32 weeks' gestation], and very SGA [less than the third percentile of birthweight by gestational age])."	( Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study. Diseko, M; Essex, M; Gaolethe, T; Holmes, LB; Jacobson, DL; Lockman, S; Makhema, J; Mayondi, G; Mmalane, M; Petlo, C; Shapiro, RL; Zash, R, 2018)	0.48
" The risk for any adverse birth outcome among women on dolutegravir versus efavirenz was similar (33·2% vs 35·0%; aRR 0·95, 95% CI 0·88-1·03), as was the risk of any severe birth outcome (10·7% vs 11·3%; 0·94, 0·81-1·11)."	( Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study. Diseko, M; Essex, M; Gaolethe, T; Holmes, LB; Jacobson, DL; Lockman, S; Makhema, J; Mayondi, G; Mmalane, M; Petlo, C; Shapiro, RL; Zash, R, 2018)	0.48
"Our findings suggest that ART drugs are not associated with an increased risk of CMs, yet some may increase adverse birth events."	( Comparative safety and effectiveness of perinatal antiretroviral therapies for HIV-infected women and their children: Systematic review and network meta-analysis including different study designs. Antony, J; Ashoor, HM; Blondal, E; Finkelstein, Y; Ghassemi, M; Gough, K; Hemmelgarn, BR; Hutton, B; Ivory, JD; Khan, PA; Lillie, E; Straus, SE; Tricco, AC; Vafaei, A; Veroniki, AA, 2018)	0.48
" EFV, relative to GSK3532795, had more serious adverse events (9% versus 5%) and adverse events leading to discontinuation (17% versus 5%)."	( Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial. Bogner, JR; DeGrosky, M; Dicker, IB; Gartland, M; Joshi, SR; Lataillade, M; Llamoso, C; Lombaard, J; Min, S; Molina, JM; Morales-Ramirez, J; Pene Dumitrescu, T; Stock, DA, 2018)	0.48
" Ten CNS toxicities were graded according to the ACTG adverse events scale."	( Tryptophan metabolism and its relationship with central nervous system toxicity in people living with HIV switching from efavirenz to dolutegravir. Boasso, A; Fuchs, D; Higgs, C; Keegan, MR; Nelson, M; Winston, A, 2019)	0.51
"In this small group of patients, the generic scheme 3TC/TDF/EFV is effective and safe in the treatment of patients with HIV/AIDS naïve, and its effectiveness and safety profile is similar to show by innovator scheme 3TC/TDF/EFV in patients with similar clinical conditions."	( [Effectiveness and safety of generic version of lamivudine/tenofovir and efavirenz in treatment naïve HIV-infected patients: a nonrandomized, open-label, phase IV study in Cali-Colombia, 2012-2014]. Amariles, P; Castañeda, C; Galindo, J; Mueses-Marín, HF, 2019)	0.51
" Day-42 adequate clinical and parasitological response (ACPR) and incidence of adverse events was assessed in HIV-infected individuals on efavirenz-based ART with uncomplicated falciparum malaria treated with AL."	( Efficacy and safety of artemether-lumefantrine as treatment for Plasmodium falciparum uncomplicated malaria in adult patients on efavirenz-based antiretroviral therapy in Zambia: an open label non-randomized interventional trial. Banda, CG; Chaponda, M; Hachizovu, S; Kabuya, JB; Kalilani-Phiri, L; Khoo, SH; Lalloo, DG; Mukaka, M; Mulenga, J; Mulenga, M; Mwapasa, V; Sikalima, J; Terlouw, DJ, 2019)	0.51
" There were only two cases of grade 3 neutropaenia and one serious adverse event of lobar pneumonia, none of which was judged as probably related to intake of AL."	( Efficacy and safety of artemether-lumefantrine as treatment for Plasmodium falciparum uncomplicated malaria in adult patients on efavirenz-based antiretroviral therapy in Zambia: an open label non-randomized interventional trial. Banda, CG; Chaponda, M; Hachizovu, S; Kabuya, JB; Kalilani-Phiri, L; Khoo, SH; Lalloo, DG; Mukaka, M; Mulenga, J; Mulenga, M; Mwapasa, V; Sikalima, J; Terlouw, DJ, 2019)	0.51
" Primary outcomes were the proportion of participants with HIV-1 RNA <40 copies/ml at week 24, and central nervous system (CNS) adverse events (AEs) by weeks 8 and 24 (Parts I+II combined)."	( Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial. Arastéh, K; Dretler, R; Frobose, C; Gatell, JM; Hagins, DP; Harvey, C; Hoffmann, C; Hwang, C; Kumar, S; Morales-Ramirez, JO; Osiyemi, O; Plettenberg, A; Portilla, J; Raffi, F; Rodgers, A; Rugina, S; Smith, DE; Teppler, H; Thompson, M; Wan, H; Xu, X, 2019)	0.51
" Proportions of women engaged in care, incidence of DAIDS grade ≥ 2 laboratory toxicity, grade ≥ 3 adverse events (AEs), viral suppression (<1000 copies/mL), birth outcomes and infant HIV infections are reported."	( Safety and efficacy of Option B+ ART in Malawi: few severe maternal toxicity events or infant HIV infections among pregnant women initiating tenofovir/lamivudine/efavirenz. Chagomerana, MB; DiPrete, BL; Harrington, BJ; Hosseinipour, MC; Jumbe, AN; Limarzi, L; Ngongondo, M; Wallie, SD, 2019)	0.51
" While some women experienced adverse laboratory events, clinical symptom monitoring is likely reasonable."	( Safety and efficacy of Option B+ ART in Malawi: few severe maternal toxicity events or infant HIV infections among pregnant women initiating tenofovir/lamivudine/efavirenz. Chagomerana, MB; DiPrete, BL; Harrington, BJ; Hosseinipour, MC; Jumbe, AN; Limarzi, L; Ngongondo, M; Wallie, SD, 2019)	0.51
" They received a directly-observed 3-day standard treatment of DPQ and were followed up until day 63 for malaria infection and adverse events."	( Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium falciparum uncomplicated malaria in adult patients on antiretroviral therapy in Malawi and Mozambique: an open label non-randomized interventional trial. Banda, CG; Kalilani-Phiri, L; Khoo, SH; Lalloo, DG; Macuacua, S; Maculuve, S; Mallewa, J; Mukaka, M; Mwapasa, V; Piqueras, M; Sevene, E; Terlouw, DJ; Vala, A, 2019)	0.51
"DPQ was highly efficacious and safe for the treatment of malaria in HIV-infected patients concurrently taking efavirenz- or nevirapine-based ART, despite known pharmacokinetic interactions between dihydroartemisinin-piperaquine and efavirenz- or nevirapine-based ART regimens."	( Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium falciparum uncomplicated malaria in adult patients on antiretroviral therapy in Malawi and Mozambique: an open label non-randomized interventional trial. Banda, CG; Kalilani-Phiri, L; Khoo, SH; Lalloo, DG; Macuacua, S; Maculuve, S; Mallewa, J; Mukaka, M; Mwapasa, V; Piqueras, M; Sevene, E; Terlouw, DJ; Vala, A, 2019)	0.51
" Both regimens were well-tolerated with no significant differences in frequency of adverse events (two on DTG-ART, one on EFV-ART, all considered unrelated to drug)."	( Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study). Amara, A; Byakika-Kibwika, P; Byamugisha, J; Coombs, JA; Else, L; Gini, J; Heiburg, C; Hill, A; Hodel, EM; Kaboggoza, J; Khoo, S; Kintu, K; Lamorde, M; Malaba, T; Mehta, U; Myer, L; Orrell, C; Reynolds, H; Sihlangu, M; Simmons, B; Singh, Y; Waitt, C; Walimbwa, S, 2019)	0.51
" However, there are several reasons as to why patients may discontinue their antiretroviral therapy, with adverse events being one of the main reasons reported in the literature."	( Factors associated to modification of first-line antiretroviral therapy due to adverse events in people living with HIV/AIDS. Azevedo, LN; Miranda-Filho, DB; Montarroyos, UR; Monteiro, P; Ximenes, RAA, )	0.13
" Nonetheless, neuropsychiatric adverse events (AE) occur in almost half of the EFV users and it is the main reason for treatment discontinuation."	( Predictors of Discontinuation of Efavirenz as Treatment for HIV, Due to Neuropsychiatric Side Effects, in a Multi-Ethnic Sample in the United Kingdom. Butler, LT; Hamill, MM; Law, JKC, 2020)	0.56
" Drug-related adverse events occurred more frequently in the participants receiving the standard dose regimen compared with the lower dose one (63."	( Efficacy and safety of lower dose tenofovir disoproxil fumarate and efavirenz versus standard dose in HIV-infected, antiretroviral-naive adults: a multicentre, randomized, noninferiority trial. Chen, J; Chen, R; Hu, Z; Huang, Q; Liu, L; Lu, H; Qi, T; Shen, Y; Song, W; Sun, J; Tang, Y; Wang, J; Wang, X; Wang, Z; Wei, H; Xie, R; Zhang, R, 2020)	0.56
" Early identification of this uncommon side effect in select patients can prevent irreversible vision loss due to efavirenz-associated retinal toxicity."	( Efavirenz-Associated Retinal Toxicity Presenting with Night Vision Defects in Patients with Human Immunodeficiency Virus. Bhende, M; Biswas, J; Kumar, KD; Selvamuthu, P; Sudharshan, S, 2020)	0.56
" There were no clinically relevant toxicities nor adverse events in both control and test arms."	( Effect of nevirapine, efavirenz and lopinavir/ritonavir on the therapeutic concentration and toxicity of lumefantrine in people living with HIV at Lagos University Teaching Hospital, Nigeria. Abideen, G; Adeniji, H; Adeuja, O; Agbaje, EO; Akanmu, AS; Akinleye, MO; Akinyede, AA; Busari, AW; Hassan, OO; Ken-Owotor, C; Kogbe, S; Ogunfowokan, T; Onwujuobi, AG; Oreagba, IA; Owolabi, ET; Usman, SO, 2020)	0.56
" Grade 3/4 adverse events (especially efavirenz-related neuropsychiatric adverse events) leading to regimen discontinuation were also noted."	( Efficacy and safety of a single-tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV-1-infected subjects on nonnucleoside reverse transcriptase inhibito Betha, TP; Dravid, A; Dravid, M; Gawali, R; Kore, S; Kulkarni, M; Mahajan, U; Rathod, N; Saraf, C; Sharma, AK, 2020)	0.56
" Grade 3/4 adverse events leading to TLE400 STR discontinuation were seen in 11 (2."	( Efficacy and safety of a single-tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV-1-infected subjects on nonnucleoside reverse transcriptase inhibito Betha, TP; Dravid, A; Dravid, M; Gawali, R; Kore, S; Kulkarni, M; Mahajan, U; Rathod, N; Saraf, C; Sharma, AK, 2020)	0.56
"Despite the high efficacy of antiretroviral treatment, no drug is free from adverse events (AEs)."	( Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study. Balboa-Barreiro, V; Castro-Iglesias, Á; Cid-Silva, P; Fernández-Bargiela, N; López-Calvo, S; Margusino-Framiñán, L; Martín-Herranz, I; Mena-De-Cea, Á; Míguez-Rey, E; Rotea-Salvo, S; Vázquez-Rodríguez, P, 2022)	0.72
"The use of patient-reported outcomes (PROs) to systematically quantify adverse events (AE) will assist in the improvement of medical care and the QoL of patients living with HIV (PLWH)."	( Longitudinal trends and determinants of patient-reported side effects on ART-a Swedish national registry study. Eriksson, LE; Marrone, G; Mellgren, Å; Reinius, M; Svedhem, V, 2020)	0.56
" Rilpivirine (RPV) is better tolerated, and switching from EFV to RPV in virologically suppressed adults has been safe and efficacious, but data in adolescents are limited."	( Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi-centre 48-week efficacy and safety study in Thailand. Anugulruengkitt, S; Chantaratin, S; Chokephaibulkit, K; Jantarabenjakul, W; Kosalaraksa, P; Maleesatharn, A; Phongsamart, W; Sirikutt, P; Suntarattiwong, P, 2022)	0.72
" HIV RNA viral load, CD4 cell count, fasting total cholesterol (TC), triglyceride, glucose, neuropsychiatric adverse events, depression and QOL were assessed over 48 weeks."	( Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi-centre 48-week efficacy and safety study in Thailand. Anugulruengkitt, S; Chantaratin, S; Chokephaibulkit, K; Jantarabenjakul, W; Kosalaraksa, P; Maleesatharn, A; Phongsamart, W; Sirikutt, P; Suntarattiwong, P, 2022)	0.72
" We also assessed antiretroviral therapy safety, analyzing treatment discontinuation for adverse events."	( Brief Report: Efficacy and Safety of Efavirenz, Raltegravir, and Dolutegravir in HIV-1/TB Coinfection. A Multicenter Retrospective Cohort Study in France. Brun, A; de Castro, N; Hamet, G; Joly, V; Kherabi, Y; Méchaï, F; Molina, JM; Sellier, PO; Yazdanpanah, Y, 2022)	0.72
" Rate of treatment discontinuation for drug-related adverse events was 10."	( Brief Report: Efficacy and Safety of Efavirenz, Raltegravir, and Dolutegravir in HIV-1/TB Coinfection. A Multicenter Retrospective Cohort Study in France. Brun, A; de Castro, N; Hamet, G; Joly, V; Kherabi, Y; Méchaï, F; Molina, JM; Sellier, PO; Yazdanpanah, Y, 2022)	0.72
" The safety data analysis of laboratory indicators showed that there was no significant difference in the incidence of adverse events between the 2 groups."	( Effectiveness and Safety of Dolutegravir Versus Efavirenz-Based Antiviral Regimen in People Living With HIV-1 in Sichuan Province of China: A Real-World Study. Chunrong, L; Huanxia, L; Ke, Y; Lin, C; Ruifeng, Z; Shenghua, H; Tongtong, Y; Xiaojing, Y; Yin, W; Yuan, Y; Yuanhong, H, 2022)	0.72
" DTG + 3TC achieved virological suppression more rapidly and stably versus TDF + 3TC + EFV in ART-naïve HIV-1-infected adults, with better immunological response and less adverse drug effect, and reduced total HIV-1 DNA effectively."	( Real-world efficacy and safety of dolutegravir plus lamivudine versus tenofovir plus lamivudine and efavirenz in ART-naïve HIV-1-infected adults. Chen, D; Du, Y; Huang, Z; Li, J; Wang, Y; Wen, Z; Yin, S; Zhong, H, 2022)	0.72
" The results of the cytotoxicity assay and drug uptake study showed that PPG4ER was safe and biocompatible up to 12."	( Effect of PEGylation on drug uptake, biodistribution, and tissue toxicity of efavirenz-ritonavir loaded PAMAM G4 dendrimers. Dhobley, A; Kharwade, R; Mahajan, N; Mendhi, S; More, S; Palve, D; Warokar, A, 2023)	0.91
" Primary safety analyses were pairwise comparisons between ART regimens of the proportion of maternal and infant adverse events of grade 3 or higher up to 50 weeks post partum."	( Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial. Amico, KR; Boyce, C; Brummel, S; Cassim, H; Chakhtoura, N; Chinula, L; Coletti, A; Currier, JS; Fairlie, L; Frenkel, LM; Hoffman, R; Jean-Philippe, P; Johnston, B; Knowles, K; Korutaro, V; Krotje, C; Lockman, S; Masheto, G; McCarthy, K; Mmbaga, BT; Moyo, S; Patel, F; Purdue, L; Rooney, JF; Sax, PE; Shapiro, R; Stranix-Chibanda, L; Stringer, J; van Wyk, J; Ziemba, L, 2023)	0.91
" Up to the week 50 post-partum visit, the estimated probability of experiencing an adverse event of grade 3 or higher was 25% in the dolutegravir, emtricitabine, and tenofovir alafenamide group; 31% in the dolutegravir, emtricitabine, and tenofovir disoproxil fumarate group; and 28% in the efavirenz, emtricitabine, and tenofovir disoproxil fumarate group (no significant difference between groups)."	( Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial. Amico, KR; Boyce, C; Brummel, S; Cassim, H; Chakhtoura, N; Chinula, L; Coletti, A; Currier, JS; Fairlie, L; Frenkel, LM; Hoffman, R; Jean-Philippe, P; Johnston, B; Knowles, K; Korutaro, V; Krotje, C; Lockman, S; Masheto, G; McCarthy, K; Mmbaga, BT; Moyo, S; Patel, F; Purdue, L; Rooney, JF; Sax, PE; Shapiro, R; Stranix-Chibanda, L; Stringer, J; van Wyk, J; Ziemba, L, 2023)	0.91
" However, EFV also demonstrates several adverse effects, like hepatotoxicity, altered lipid profile, neuropsychological symptoms, and behavioral effects in children after in utero exposure."	( Comparison of Efavirenz and Doravirine Developmental Toxicity in an Embryo Animal Model. Castelli, F; Ferretti, S; Mignani, L; Monti, E; Quiros-Roldan, E; Tiecco, G; Zanella, I; Zizioli, D, 2023)	0.91
" Safety endpoints assessed included all the adverse events (AEs) related to the study treatment (TLE400 and TLE600)."	( Safety of low dose efavirenz regimen in Indian adults with HIV-1 infection: Insights from a phase 4 interventional randomised trial. Anuradha, S; Bhrusundi, M; Dravid, AN; Kulkarni, V; Madhukarrao, KM; Morkar, DN; Nageswaramma, S; Naik, KS; Pilawan, AS; Ramapuram, JT; Raveendra, KR, 2023)	0.91

Excerpt	Reference	Relevance
" Higher doses in both species led to disproportionate increases in the AUC and higher Tmax values, suggesting saturation of metabolism and/or prolongation of absorption."	( Nonlinear pharmacokinetics of efavirenz (DMP-266), a potent HIV-1 reverse transcriptase inhibitor, in rats and monkeys. Balani, SK; deLuna, FA; Kauffman, LR; Lin, JH, 1999)	0.3
"To define the pharmacokinetic profile of efavirenz (EFV) in HIV-1 infected patients, when administered alone or with nelfinavir (NFV)."	( Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients. Castelli, F; Maserati, R; Regazzi, MB; Seminari, E; Torti, C; Viale, P; Villani, P, 1999)	0.3
" Blood samples for pharmacokinetic analysis were obtained during a dosage interval."	( Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients. Castelli, F; Maserati, R; Regazzi, MB; Seminari, E; Torti, C; Viale, P; Villani, P, 1999)	0.3
"No significant difference was found between the principal pharmacokinetic parameters of EFV when administered alone or in combination with NFV (mean AUC: 57."	( Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients. Castelli, F; Maserati, R; Regazzi, MB; Seminari, E; Torti, C; Viale, P; Villani, P, 1999)	0.3
" In this study we analysed the pharmacokinetic profile of nelfinavir after multiple oral doses in 18 HIV-infected patients during a combination regimen of nelfinavir plus efavirenz and stavudine."	( Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patients. Fiocchi, C; Gambarana, E; LoCaputo, F; Maserati, R; Pan, A; Regazzi, MB; Seminari, E; Villani, P, 2000)	0.31
" The differences between the pharmacokinetic parameters of efavirenz with and without nevirapine were analyzed, and the pharmacokinetics of nevirapine were compared with those in historical control patients."	( The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons. Beijnen, JH; Carlier, H; Gazzard, B; Harris, M; Hoetelmans, RM; Johnson, M; Kwakkelstein, MO; Lange, JM; Montaner, JS; Moyle, G; Reiss, P; van Leeuwen, R; Veldkamp, AI; Youle, M, 2001)	0.31
" Although possessing a common mechanism of action, these agents can be differentiated by both molecular and pharmacokinetic characteristics."	( Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. DiCenzo, R; Morse, GD; Smith, PF, 2001)	0.31
"To evaluate the pharmacokinetic interactions between efavirenz and rifampicin (rifampin) in patients with HIV infection and tuberculosis."	( Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Alarcón-González, A; Gómez-Mateos, J; León-Jimenez, E; López-Cortés, LF; López-Pua, Y; Pachón, J; Ruiz-Valderas, R; Sarasanacenta, M; Viciana, P, 2002)	0.31
"Nonblind, randomised, pharmacokinetic study."	( Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Alarcón-González, A; Gómez-Mateos, J; León-Jimenez, E; López-Cortés, LF; López-Pua, Y; Pachón, J; Ruiz-Valderas, R; Sarasanacenta, M; Viciana, P, 2002)	0.31
"Plasma concentrations of efavirenz and rifampicin were quantified by using validated high performance liquid chromatography assays, and pharmacokinetic parameter values were determined by noncompartmental methods."	( Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Alarcón-González, A; Gómez-Mateos, J; León-Jimenez, E; López-Cortés, LF; López-Pua, Y; Pachón, J; Ruiz-Valderas, R; Sarasanacenta, M; Viciana, P, 2002)	0.31
"There was a correlation between the pharmacokinetic parameters of efavirenz and the dose/kg administered."	( Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Alarcón-González, A; Gómez-Mateos, J; León-Jimenez, E; López-Cortés, LF; López-Pua, Y; Pachón, J; Ruiz-Valderas, R; Sarasanacenta, M; Viciana, P, 2002)	0.31
"The present population pharmacokinetic (PK) and pharmacodynamic (PD) study modeled the effects of covariates including drug adherence and the coadministration of protease inhibitors (PIs) on the pharmacokinetics of efavirenz (EFV) and the relationship between EFV exposure and virological failure in patients who failed initial PI treatment in Adult AIDS Clinical Trial Group (AACTG) study 398."	( Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Bennett, KK; Hammer, SM; Labbé, L; Mellors, J; Pfister, M; Rosenkranz, S; Sheiner, LB, 2003)	0.32
" This study aimed to assess the efavirenz pharmacokinetic profile and interpatient versus intrapatient variability in patients who are positive for human immunodeficiency virus, to explore the relationship between drug exposure, efficacy, and central nervous system toxicity and to build up a Bayesian approach for dosage adaptation."	( Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Biollaz, J; Buclin, T; Csajka, C; Décosterd, LA; Fattinger, K; Fellay, J; Marzolini, C; Telenti, A, 2003)	0.32
"The population pharmacokinetic analysis was performed by use of NONMEM based on plasma samples from a cohort of unselected patients receiving efavirenz."	( Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Biollaz, J; Buclin, T; Csajka, C; Décosterd, LA; Fattinger, K; Fellay, J; Marzolini, C; Telenti, A, 2003)	0.32
"A population-based pharmacokinetic (PK) model has been developed for efavirenz based on 16 phase I studies."	( Population pharmacokinetic meta-analysis with efavirenz. Barrett, JS; Chai, M; Fiske, WD; Joshi, AS; Ludden, TM; Pieniaszek, HJ, 2002)	0.31
"At week 4 of the study, 12-hour pharmacokinetic profiles for indinavir/ritonavir were obtained for 20 HIV-infected subjects."	( Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects. Aarnoutse, RE; Boyd, MA; Burger, DM; Cooper, DA; Lange, JM; Phanuphak, P; Ruxrungtham, K; Stek, M; van Heeswijk, RP, 2003)	0.32
" A >10-fold variation in indinavir Cmin was observed."	( Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects. Aarnoutse, RE; Boyd, MA; Burger, DM; Cooper, DA; Lange, JM; Phanuphak, P; Ruxrungtham, K; Stek, M; van Heeswijk, RP, 2003)	0.32
"Despite the known pharmacokinetic interaction between efavirenz and indinavir/ritonavir, the combination of indinavir/ritonavir at 800/100 mg bid and efavirenz at 600 mg qd results in adequate minimum concentrations of both indinavir and efavirenz for treatment-naive patients."	( Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects. Aarnoutse, RE; Boyd, MA; Burger, DM; Cooper, DA; Lange, JM; Phanuphak, P; Ruxrungtham, K; Stek, M; van Heeswijk, RP, 2003)	0.32
" The following pharmacokinetic (PK) parameters were determined over 24 h at steady-state after 4 weeks of treatment: area under the plasma concentration vs."	( Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial). Chene, G; Lascoux-Combes, C; Molina, JM; Perusat, S; Peytavin, G; Rozenbaum, W; Sereni, D, 2004)	0.32
" EFV Cmax and Cmin were lower than expected, but the data may have been slightly underestimated in this study."	( Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial). Chene, G; Lascoux-Combes, C; Molina, JM; Perusat, S; Peytavin, G; Rozenbaum, W; Sereni, D, 2004)	0.32
"To evaluate the safety and pharmacokinetic interaction between GW433908, ritonavir (RTV), and efavirenz (EFV)."	( Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers. Ballow, C; Hendrix, CW; Lou, Y; Piliero, PJ; Preston, SL; Stein, DS; Wire, MB, 2004)	0.32
" Amprenavir (APV) pharmacokinetic sampling and safety assessments were performed on the last day of each period."	( Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers. Ballow, C; Hendrix, CW; Lou, Y; Piliero, PJ; Preston, SL; Stein, DS; Wire, MB, 2004)	0.32
" The main pharmacokinetic parameters were calculated using noncompartmental methods."	( Effect of efavirenz treatment on the pharmacokinetics of nelfinavir boosted by ritonavir in healthy volunteers. Burger, DM; Colbers, EP; de Graaff-Teulen, MJ; Hekster, YA; Ibanez, SM; Koopmans, PP; la Porte, CJ; Voncken, DS, 2004)	0.32
"The aim of this 2NN pharmacokinetic substudy was to investigate the population pharmacokinetics of nevirapine and efavirenz."	( Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Beijnen, JH; Huitema, AD; Kappelhoff, BS; Lange, J; MacGregor, TR; van Leth, F, 2005)	0.33
"The aim of this study was to characterise the pharmacokinetic and pharmacodynamic monitoring of low doses of mycophenolate mofetil (0."	( Pharmacokinetics and pharmacodynamics of low dose mycophenolate mofetil in HIV-infected patients treated with abacavir, efavirenz and nelfinavir. Brunet, M; Gallart, T; García, F; Gatell, JM; Martorell, J; Millán, O; Miró, JM; Plana, M; Pumarola, T; Rojo, I; Vidal, E, 2005)	0.33
"Mycophenolate mofetil pharmacokinetic profiles in HIV patients under HAART are not significantly different from those found in transplant patients."	( Pharmacokinetics and pharmacodynamics of low dose mycophenolate mofetil in HIV-infected patients treated with abacavir, efavirenz and nelfinavir. Brunet, M; Gallart, T; García, F; Gatell, JM; Martorell, J; Millán, O; Miró, JM; Plana, M; Pumarola, T; Rojo, I; Vidal, E, 2005)	0.33
" Pharmacokinetic parameters were dose proportional, and the maximum concentration of drug in serum at all doses exceeded the 90% effective concentration for wild-type HIV-1."	( Safety, pharmacokinetics, and efficacy of (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine with efavirenz and stavudine in antiretroviral-naïve human immunodeficiency virus-infected patients. Arastèh, K; Beard, A; Cartee, L; Drauz, D; Herzmann, C; Kreckel, P; Murphy, RL; Otto, MJ; Schinazi, RF; Schulbin, H, 2005)	0.33
" The influence of patient characteristics on the pharmacokinetic parameters of efavirenz was explored."	( Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. Beijnen, JH; Huitema, AD; Kappelhoff, BS; Meenhorst, PL; Mulder, JW; Prins, JM; Yalvaç, Z, 2005)	0.33
"From 172 patients, 40 full pharmacokinetic curves and 315 efavirenz plasma concentrations at a single timepoint were available, resulting in a database of 1009 efavirenz plasma concentrations."	( Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. Beijnen, JH; Huitema, AD; Kappelhoff, BS; Meenhorst, PL; Mulder, JW; Prins, JM; Yalvaç, Z, 2005)	0.33
"The pharmacokinetic parameters of efavirenz were adequately described with the developed population pharmacokinetic model."	( Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. Beijnen, JH; Huitema, AD; Kappelhoff, BS; Meenhorst, PL; Mulder, JW; Prins, JM; Yalvaç, Z, 2005)	0.33
"Adult AIDS Clinical Trials Group 5043 examined pharmacokinetic (PK) interactions between amprenavir (APV) and efavirenz (EFV) both by themselves and when nelfinavir (NFV), indinavir (IDV), ritonavir (RTV), or saquinavir (SQV) is added."	( Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals. Adams, E; Brizz, B; Difrancesco, R; Morse, GD; Para, MF; Reichman, RC; Rosenkranz, S; Segal, Y; Yarasheski, KE, 2005)	0.33
" Reductions of 25% and 45% were observed in the mean nelfinavir area under the concentration-time curve and minimum concentration of the drug in serum, and there was a 31% more rapid half-life for patients receiving both drugs compared to patients receiving nelfinavir alone."	( Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors. Fischl, MA; Forrest, A; Hirsch, MS; Merigan, TC; Morse, GD; Park, JG; Robbins, GK; Shafer, RW; Smith, PF; Wu, H; Yu, S, 2005)	0.33
" The objective was to find cutoff values of the Cmin and AUC24 below which the risk of virologic failure increased."	( Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy. Beijnen, JH; Boron-Kaczmarska, A; Hall, DB; Huitema, AD; Johnson, D; Kappelhoff, BS; Lange, JM; Leith, J; Leth, FV; Livrozet, JM; Losso, MH; Saag, MS; Wit, FW, 2006)	0.33
"A population pharmacokinetic analysis was performed in the context of therapeutic drug monitoring (87 patients, 121 samples)."	( Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients. Arvieux, C; Dailly, E; Jolliet, P; Perré, P; Raffi, F; Tattevin, P; Tribut, O, 2006)	0.33
" The pharmacokinetic profile of saquinavir-SGC was analyzed in a subset of randomly selected patients."	( Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin capsule/ritonavir in antiretroviral-naive, HIV-infected patients. Burnside, AF; Jayaweera, DT; Montaner, JS; Saag, MS; Schutz, M; Schwartz, R; Walmsley, S, 2006)	0.33
" Pharmacokinetic profiles in 6 patients showed an observed median Cmin at 24 hours of 429 ng/mL (range, 68-1750 ng/mL)."	( Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin capsule/ritonavir in antiretroviral-naive, HIV-infected patients. Burnside, AF; Jayaweera, DT; Montaner, JS; Saag, MS; Schutz, M; Schwartz, R; Walmsley, S, 2006)	0.33
" Both drugs have demonstrated interindividual pharmacokinetic variability."	( Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring? Dahri, K; Ensom, MH, 2007)	0.34
"Twelve HIV-infected patients were assigned into a one-sequence, two-period pharmacokinetic interaction study."	( Effect of efavirenz on the pharmacokinetics of ketoconazole in HIV-infected patients. Jaruratanasirikul, S; Mahatthanatrakul, W; Ridtitid, W; Sriwiriyajan, S, 2007)	0.34
" We evaluated the possibility of a pharmacokinetic interaction between TFV and EFV by assessing cross-sectional and longitudinal data in 169 individuals receiving EFV."	( Does tenofovir influence efavirenz pharmacokinetics? Buclin, T; Colombo, S; Décosterd, L; Furrer, H; Rotger, M; Telenti, A, 2007)	0.34
"Although there is no clear evidence for a pharmacokinetic interaction between TFV and EFV, we cannot rule out an interaction between these drugs restricted to individuals who are slow EFV metabolizers."	( Does tenofovir influence efavirenz pharmacokinetics? Buclin, T; Colombo, S; Décosterd, L; Furrer, H; Rotger, M; Telenti, A, 2007)	0.34
" EFV levels in plasma were assayed by high-performance liquid chromatography (HLPC) predose (C(trough)) and at 1, 2, 3, 4, 5, 6, 8, 10, 11, 12, 13, 14, 16, 18, 22 and 24 hours post-dose, and pharmacokinetic parameters were determined by non-compartmental methods."	( Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients. Caligaris, S; Capone, S; Carosi, G; Carvalho, AC; Cusato, M; De Iaco, G; Manfrin, M; Matteelli, A; Regazzi, M; Tomasoni, L; Villani, P, 2007)	0.34
" Pharmacokinetic evaluations were performed at weeks 2, 6, and 56."	( Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial. Alvero, CG; Brundage, RC; Fenton, T; Fletcher, CV; Mofenson, LM; Powell, C; Spector, SA, 2008)	0.35
"This open-label, crossover study investigated the pharmacokinetic interaction between TMC114 (darunavir [Prezista]), administered with low-dose ritonavir (TMC114/r) and efavirenz (EFV) in HIV-negative, healthy volunteers."	( Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers. De Pauw, M; Hoetelmans, RM; Lefebvre, E; Mariën, K; Peeters, M; Sekar, VJ, 2007)	0.34
" TMC114/r and EFV coadministration resulted in TMC114 Cmin, Cmax and AUC12h decreases of 31%, 15% and 13%, respectively."	( Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers. De Pauw, M; Hoetelmans, RM; Lefebvre, E; Mariën, K; Peeters, M; Sekar, VJ, 2007)	0.34
"The clinical significance of the changes in AUC and Cmin seen with TMC114/r and EFV coadministration has not been established; this combination should be used with caution."	( Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers. De Pauw, M; Hoetelmans, RM; Lefebvre, E; Mariën, K; Peeters, M; Sekar, VJ, 2007)	0.34
"Fourteen patients participated in the study and seven participated in the intensified pharmacokinetic protocol."	( Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. Abbara, C; Barrail, A; Boissonnas, A; Bonhomme-Faivre, L; Duclos-Vallée, JC; Samuel, D; Taburet, AM; Teicher, E; Vincent, I; Vittecoq, D, 2007)	0.34
" Coadministration of these drugs might result in complex pharmacokinetic drug-drug interactions."	( Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz. Barditch-Crovo, P; Carson, KA; Flexner, C; Hendrix, CW; Khan, W; Pakes, GE; Parish, M; Parsons, T; Pham, PA; Qaqish, R; Radebaugh, C, 2007)	0.34
"37) or Cmax (10."	( Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz. Barditch-Crovo, P; Carson, KA; Flexner, C; Hendrix, CW; Khan, W; Pakes, GE; Parish, M; Parsons, T; Pham, PA; Qaqish, R; Radebaugh, C, 2007)	0.34
"EFV did not appear to significantly alter APV and LPV pharmacokinetic parameters in HIV-infected patients taking APV 750 mg twice daily + LPV 533/133 mg twice daily."	( Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz. Barditch-Crovo, P; Carson, KA; Flexner, C; Hendrix, CW; Khan, W; Pakes, GE; Parish, M; Parsons, T; Pham, PA; Qaqish, R; Radebaugh, C, 2007)	0.34
" The 400-mg qd efavirenz dose substantially reduced the steady-state mean voriconazole area under the curve over the dosing interval (AUC0-12) by 80% (90% confidence interval [CI], 75%-84%) and peak concentration (Cmax) by 66% (90% CI, 57%-73%)."	( Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects. Foster, G; Gutierrez, MJ; LaBadie, RR; Liu, P; Sharma, A, 2008)	0.35
" The objective of the present study was to evaluate the potential pharmacokinetic interaction between efavirenz and dual PIs."	( Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers. Forrest, A; Ma, Q; Morse, GD; Para, MF; Reichman, RC; Rosenkranz, SL; Yarasheski, KE, 2008)	0.35
"The study sought to investigate the relationship between efavirenz exposure and the CYP2B6 516G-->T(*6) genotype in HIV/AIDS outpatients, using pharmacokinetic modelling and simulation."	( High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Ashton, M; Chigutsa, E; Chonzi, P; Masimirembwa, C; Nhachi, C; Nyakutira, C; Röshammar, D, 2008)	0.35
" Population pharmacokinetic modelling and simulation of the data were performed in NONMEM VI."	( High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Ashton, M; Chigutsa, E; Chonzi, P; Masimirembwa, C; Nhachi, C; Nyakutira, C; Röshammar, D, 2008)	0.35
" Pharmacokinetic parameter estimates indicate that a dose reduction to 400 mg efavirenz per day is possible in patients homozygous for the CYP2B6*6 genotype without compromising therapeutic efficacy."	( High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Ashton, M; Chigutsa, E; Chonzi, P; Masimirembwa, C; Nhachi, C; Nyakutira, C; Röshammar, D, 2008)	0.35
"The influence of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics was investigated in HIV-infected patients with a population pharmacokinetic approach."	( Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients. Allavena, C; Biron, C; Dailly, E; Jolliet, P; Raffi, F, 2008)	0.35
" In summary, a 2-way pharmacokinetic interaction between efavirenz and carbamazepine was demonstrated in this study."	( Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects. Damle, B; Grasela, DM; Ji, P; Kaul, S; Unger, SE; Xie, J, 2008)	0.35
" LPV Cmin was lower than expected in the hemodialysis group."	( The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis. Amorosa, V; Cramer, YS; Gupta, SK; Hall, SD; Koletar, SL; Rosenkranz, SL; Szczech, LA, 2008)	0.35
" A non-linear mixed effect pharmacokinetic model was developed."	( A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations. Beijnen, JH; Bekker, V; Crommentuyn, KM; Huitema, AD; Kuijpers, TW; Scherpbier, HJ; ter Heine, R, 2008)	0.35
" A complete pharmacokinetic study was conducted with 19 HIV-TB patients on two occasions (with and without RMP)."	( CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India. Anitha, S; Gomathi, C; Hemanth Kumar, AK; Kumar, P; Menon, P; Narendran, G; Rajasekaran, S; Ramachandran, G; Ramesh, K; Swaminathan, S, 2009)	0.35
" Efavirenz Cmin was not significantly different during vs."	( Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis. Eley, BS; Maartens, G; McIlleron, HM; Meyers, TM; Nuttall, JJ; Ren, Y; Smith, PJ, 2009)	0.35
" The substantial proportion of participants with estimated Cmin <1 mg/L could result in the rapid emergence of efavirenz-resistant mutations and treatment failure."	( Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis. Eley, BS; Maartens, G; McIlleron, HM; Meyers, TM; Nuttall, JJ; Ren, Y; Smith, PJ, 2009)	0.35
" Plasma samples from 169 human immunodeficiency virus (HIV) patients characterized for CYP2B6, CYP2A6, and CYP3A4/5 allelic diversity were used to build up a population pharmacokinetic model using NONMEM (non-linear mixed effects modeling), the aim being to seek a general approach combining genetic and demographic covariates."	( Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Arab-Alameddine, M; Biollaz, J; Buclin, T; Cavassini, M; Csajka, C; Décosterd, LA; Di Iulio, J; Eap, CB; Fayet, A; Lubomirov, R; Rotger, M; Telenti, A, 2009)	0.35
" A 600-mg oral dose of efavirenz was subsequently administered, and pharmacokinetic sampling was repeated."	( Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans. Acosta, EP; Floyd, M; Gebretsadik, T; Haas, DW; Mayo, G; Menon, UN; Shintani, A; Stein, CM; Wilkinson, GR, 2009)	0.35
" As a result of these actions, co-administration of these drugs may result in changes in the pharmacokinetic parameters of one or both of them."	( Pharmacokinetic interaction between efavirenz and ketoconazole in rats. Peris, JE; Saadeddin, A, 2009)	0.35
" Plasma concentrations of efavirenz were determined by a validated high performance liquid chromatography (HPLC) method with UV detection, and pharmacokinetic parameters were calculated."	( Effect of African potato (Hypoxis hemerocallidea) on the pharmacokinetics of efavirenz. Kanfer, I; Mills, E; Mogatle, S; Skinner, M, 2008)	0.35
" Pharmacokinetic studies of higher dosages of rifampin are urgently needed in children to assist in placing the dosage of rifampin used in childhood on a more scientific foundation."	( Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis. Cilliers, K; Donald, PR; Hussey, GD; Labadarios, D; Maritz, JS; McIlleron, H; Schaaf, HS; Smith, P; Willemse, M, 2009)	0.35
"Small intensive pharmacokinetic (PK) studies of medications in early-phase trials cannot identify the range of factors that influence drug exposure in heterogenous populations."	( Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women. Anastos, K; Bacchetti, P; Benet, LZ; Cohen, M; Gandhi, M; Gange, SJ; Greenblatt, RM; Kalinowski, A; Minkoff, H; Wolfe, AR; Young, M, 2009)	0.35
"A population pharmacokinetic model for efavirenz has been developed from therapeutic drug monitoring data in human immunodeficiency virus (HIV)-positive patients by using a nonlinear mixed-effect model."	( Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients. Cabrera, SE; Domínguez-Gil, A; García, MJ; González, F; Luna, G; Santos, D; Valverde, MP, 2009)	0.35
" Eighteen patients completed the pharmacokinetic study: TT genotype gave the longest half-life (t 1/2), highest plasma EFV concentration, and largest area under the curve."	( Pharmacokinetics of plasma efavirenz and CYP2B6 polymorphism in southern Chinese. Chan, DP; Chan, RC; Cheung, SW; Lee, SS; Liu, ST; To, KW, 2009)	0.35
" Pharmacokinetic parameters were compared (before and after efavirenz 14-day intake) by determining geometric mean ratios and 90% confidence intervals."	( Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers. Asboe, D; Back, D; Boffito, M; Gazzard, B; Jackson, A; Lamorde, M; Pozniak, A; Taylor, J; Waters, L; Watson, V, 2009)	0.35
"A phase 1, open-label, randomized, crossover, drug interaction study was conducted to assess the pharmacokinetic effects of coadministration of posaconazole (400 mg twice daily), with atazanavir (ATV) (300 mg/d alone) and with ritonavir (100 mg/d) or with efavirenz (400 mg/d) in healthy volunteers."	( Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteers. Krishna, G; Ma, L; Martinho, M; McLeod, J; Moton, A; Seiberling, M, 2009)	0.35
" Intensive pharmacokinetic (PK) sampling was done on days 10 and 24."	( Lack of effect of efavirenz on the pharmacokinetics of tipranavir-ritonavir in healthy volunteers. Béïque, L; Cameron, DW; la Porte, CJ; Sabo, JP, 2009)	0.35
"Efavirenz exhibits pharmacokinetic variability causing varied clinical response."	( A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Aklillu, E; Andersson, M; Fukasawa, T; Gustafsson, LL; Milani, L; Mukonzo, JK; Ogwal-Okeng, J; Röshammar, D; Svensson, JO; Waako, P, 2009)	0.35
" Use of mixed-effects modelling allowed the analysis and integration of multiple pharmacogenetic and demographic covariates in a pharmacokinetic population model."	( A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Aklillu, E; Andersson, M; Fukasawa, T; Gustafsson, LL; Milani, L; Mukonzo, JK; Ogwal-Okeng, J; Röshammar, D; Svensson, JO; Waako, P, 2009)	0.35
" The differences in these pharmacokinetic parameters could possibly be due to differences in body weight and composition, drug-food interactions, metabolism, environmental factors and genetic background."	( Pharmacokinetics of low-dose protease inhibitors and efavirenz in low- and middle-income countries. Burger, D; Gorowara, M; Hill, A; Ruxrungtham, K, 2010)	0.36
" Six-point pharmacokinetic sampling (0, 2, 4, 6, 8, and 12 h) was undertaken after observed intake with a standardized breakfast."	( Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults. Dickinson, L; Gibb, DM; Gilks, CF; Kayiwa, J; Khoo, S; Kityo, C; Lutwama, F; Munderi, P; Nalumenya, R; Reid, A; Ssali, F; Tumukunde, D; Walker, AS, 2010)	0.36
"Efavirenz (EFV) is characterized by interindividual pharmacokinetic variability causing inconsistent clinical responses."	( Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. Elens, L; Haufroid, V; Lison, D; Vandercam, B; Wallemacq, P; Yombi, JC, 2010)	0.36
" The pharmacokinetic parameters were: plasma drug concentration-time profile from 0 to 72 h (AUC0-72), plasma drug concentration-time profile from 0 h to infinity (AUC0-inf), maximal drug concentration (Cmax), time to reach maximal drug concentration (tmax), and time to reach half the initial drug concentration in elimination phase (t1/2)."	( Pharmacokinetic interaction between efavirenz and rifampicin in healthy volunteers. Djoerban, Z; Setiabudy, R, 2011)	0.37
" However, current pharmacokinetic data are insufficient to guide optimized concurrent dosing."	( Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteers. Court, MH; Dumond, JB; Greenblatt, DJ; Kashuba, AD; Kurpewski, J; Kwara, A; Poethke, P; Tashima, KT, 2011)	0.37
" We report the pharmacokinetic parameters of tenofovir in combination with efavirenz, darunavir-ritonavir, or atazanavir-ritonavir in HIV-infected children."	( Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients. Acosta, EP; Britto, P; Carey, V; Graham, B; Hazra, R; Jean-Philippe, P; King, JR; Wiznia, A; Yogev, R, 2011)	0.37
" The lopinavir/ritonavir dose of 500/125 mg bid administered with efavirenz most closely approximates the pharmacokinetic exposure of lopinavir/ritonavir 400/100 mg bid administered alone."	( Pharmacokinetics and safety of the lopinavir/ritonavir tablet 500/125 mg twice daily coadministered with efavirenz in healthy adult participants. Awni, W; Bernstein, B; Causemaker, SJ; Chiu, YL; Klein, CE; Ng, J, 2012)	0.38
"To evaluate international pediatric efavirenz dosing recommendations using full pharmacokinetic (PK) information."	( Pediatric underdosing of efavirenz: a pharmacokinetic study in Uganda. Balungi, J; Burger, DM; Bwakura-Dangarembizi, M; Ferrier, A; Fillekes, Q; Gibb, DM; Keishanyu, R; Kendall, L; Lutakome, J; Natukunda, E; Walker, AS, 2011)	0.37
" NONMEM was used for the population pharmacokinetic modelling."	( Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children. Dandara, C; Gous, H; Karlsson, MO; Meyers, TM; Rheeders, M; Viljoen, M, 2012)	0.38
"This was a phase 1 pharmacokinetic drug interaction trial."	( Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267. Allen, R; Aweeka, F; Cramer, Y; Dooley, KE; Flexner, C; Gupta, A; Haas, DW; Lizak, P; Park, JG; Qasba, S; Swindells, S; van Heeswijk, R; Wiggins, I, 2012)	0.38
" We performed a prospective case-control association study to identify the incidence, pharmacogenetic, pharmacokinetic and biochemical predictors for anti-tubercular and antiretroviral drugs induced liver injury (DILI) in HIV and tuberculosis (TB) co-infected patients."	( Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. Aderaye, G; Aklillu, E; Amogne, W; Burhenne, J; Habtewold, A; Lindquist, L; Makonnen, E; Riedel, KD; Suda, A; Ueda, N; Yimer, G, 2011)	0.37
"Healthy HIV-negative subjects underwent 12 hr intensive pharmacokinetic (PK) sampling following single dose LNG alone and after 14 days of EFV."	( Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B), and Efavirenz. Carten, ML; Cu-Uvin, S; Kiser, JJ; Kwara, A; Mawhinney, S, 2012)	0.38
"Co-administration of artemether/lumefantrine with antiretroviral therapy has potential for pharmacokinetic drug interactions."	( Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. Back, D; Byakika-Kibwika, P; de Vries, PJ; Hanpithakpong, W; Katabira, E; Khoo, S; Lamorde, M; Lindegardh, N; Mayanja-Kizza, H; Mayito, J; Merry, C; Nabukeera, L; Namakula, R; Ntale, M; Pakker, N; Ryan, M; Tarning, J, 2012)	0.38
" Clinical data from population pharmacokinetic and pharmacodynamic trials evaluating the impact of these drug interactions are urgently needed."	( Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. Back, D; Byakika-Kibwika, P; de Vries, PJ; Hanpithakpong, W; Katabira, E; Khoo, S; Lamorde, M; Lindegardh, N; Mayanja-Kizza, H; Mayito, J; Merry, C; Nabukeera, L; Namakula, R; Ntale, M; Pakker, N; Ryan, M; Tarning, J, 2012)	0.38
"002) with EFV, but the LR half-life was unchanged."	( Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers. Aweeka, FT; Dorsey, G; Havlir, D; Huang, L; Lizak, P; Marzan, F; Parikh, S; Rosenthal, PJ, 2012)	0.38
"To determine pharmacokinetic and pharmacogenomic correlates of efavirenz central nervous system (CNS) side effects following a single dose."	( Neuropsychometric correlates of efavirenz pharmacokinetics and pharmacogenetics following a single oral dose. Acosta, EP; Gebretsadik, T; Haas, DW; Johnson, DH; Mayo, G; Shintani, A; Stein, CM, 2013)	0.39
"001) and Cmax (P = 0."	( Neuropsychometric correlates of efavirenz pharmacokinetics and pharmacogenetics following a single oral dose. Acosta, EP; Gebretsadik, T; Haas, DW; Johnson, DH; Mayo, G; Shintani, A; Stein, CM, 2013)	0.39
" Strategies that lower Cmax during initial dosing may decrease CNS side effects."	( Neuropsychometric correlates of efavirenz pharmacokinetics and pharmacogenetics following a single oral dose. Acosta, EP; Gebretsadik, T; Haas, DW; Johnson, DH; Mayo, G; Shintani, A; Stein, CM, 2013)	0.39
"This was a Phase II open-label multiple dose pharmacokinetic and safety study."	( Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study. Aarnoutse, RE; Boeree, MJ; Burger, DM; Fillekes, Q; Kibiki, GS; Kisanga, ER; Kisonga, RM; Mleoh, L; Mtabho, CM; Ndaro, A; Semvua, HH; van den Boogaard, J; van der Ven, A, 2013)	0.39
"A total of 25 patients (56% male) completed the study; 21 had evaluable pharmacokinetic profiles."	( Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study. Aarnoutse, RE; Boeree, MJ; Burger, DM; Fillekes, Q; Kibiki, GS; Kisanga, ER; Kisonga, RM; Mleoh, L; Mtabho, CM; Ndaro, A; Semvua, HH; van den Boogaard, J; van der Ven, A, 2013)	0.39
"Coadministration of efavirenz, tenofovir and emtricitabine with a standard first-line TB treatment regimen did not significantly alter the pharmacokinetic parameters of these drugs and was tolerated well by Tanzanian TB patients who are coinfected with HIV."	( Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study. Aarnoutse, RE; Boeree, MJ; Burger, DM; Fillekes, Q; Kibiki, GS; Kisanga, ER; Kisonga, RM; Mleoh, L; Mtabho, CM; Ndaro, A; Semvua, HH; van den Boogaard, J; van der Ven, A, 2013)	0.39
"This is the first pharmacokinetic modelling of antiretroviral disposition in BP and CVF."	( Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women. Cohen, MS; Dumond, JB; Forrest, A; Garonzik, SM; Kashuba, AD; Kendrick, RN; Nicol, MR; Patterson, KB, 2012)	0.38
" Log-transformed trough efavirenz concentrations (Cmin) were previously estimated by population pharmacokinetic modeling."	( Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Acosta, EP; Clifford, DB; Daar, ES; Grady, B; Gulick, RM; Haas, DW; Holzinger, ER; McLaren, P; Morse, GD; Ribaudo, HJ; Ritchie, MD; Robbins, GK, 2012)	0.38
"Among 856 individuals, CYP2B6 516G→T was associated with efavirenz estimated Cmin (P=8."	( Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Acosta, EP; Clifford, DB; Daar, ES; Grady, B; Gulick, RM; Haas, DW; Holzinger, ER; McLaren, P; Morse, GD; Ribaudo, HJ; Ritchie, MD; Robbins, GK, 2012)	0.38
"Three CYP2B6 polymorphisms were independently associated with efavirenz estimated Cmin at genome-wide significance, and explained one-third of interindividual variability."	( Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Acosta, EP; Clifford, DB; Daar, ES; Grady, B; Gulick, RM; Haas, DW; Holzinger, ER; McLaren, P; Morse, GD; Ribaudo, HJ; Ritchie, MD; Robbins, GK, 2012)	0.38
" Noncompartmental pharmacokinetic analysis was used to estimate PK parameters [area under the concentration-time curve over 24 h (AUC0-24h ) and maximal concentration (Cmax )]."	( Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study. Adams, JL; Corbett, AH; Dumond, JB; Forrest, A; Jennings, SH; Kashuba, AD; Kendrick, RL; Malone, S; Patterson, KB; Prince, HM; Sykes, C; Wang, R; White, N, 2013)	0.39
" Compared with the general population, these elderly subjects had 8-13% decreased TFV AUC0-24h and Cmax , and 19-78% increased FTC and RTV AUC0-24h and Cmax ."	( Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study. Adams, JL; Corbett, AH; Dumond, JB; Forrest, A; Jennings, SH; Kashuba, AD; Kendrick, RL; Malone, S; Patterson, KB; Prince, HM; Sykes, C; Wang, R; White, N, 2013)	0.39
" Pharmacokinetics and drug-drug interaction were simulated using the full physiologically based pharmacokinetic model implemented in the Simcyp™ ADME simulator."	( Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach. Almond, L; Back, D; Khoo, S; Kirov, A; Marzolini, C; Owen, A; Seden, K; Siccardi, M, 2013)	0.39
" Although the simulated drug-drug interactions with antidepressants were overall weak to moderate according to the classification of the US FDA, fluoxetine and venlafaxine represent better candidates from a pharmacokinetic standpoint for patients on efavirenz and venlafaxine or citalopram for patients on boosted protease inhibitors."	( Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach. Almond, L; Back, D; Khoo, S; Kirov, A; Marzolini, C; Owen, A; Seden, K; Siccardi, M, 2013)	0.39
" Based on data from a phase I, single-dose pharmacokinetic study, a nonlinear mixed-effects model characterizing BDQ pharmacokinetics and interaction with multiple-dose EFV was developed."	( Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis. Aweeka, F; Dooley, KE; Karlsson, MO; Marzan, F; Park, JG; Svensson, EM, 2013)	0.39
" We conducted a cross-sectional study of HIV-positive women to determine if protease inhibitor (PI) and non-nucleoside reverse transcriptase inhibitor (NNRTI) C(min) and Cmax values were significantly different than historical general population (predominantly male) averages and to evaluate correlates of higher concentrations."	( Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study. Angel, JB; Blitz, SL; Burdge, D; Cohen, J; Conway, B; de Pokomandy, A; Gough, K; Haase, D; Klein, MB; la Porte, CJ; Loemba, H; Loutfy, MR; Pick, N; Raboud, J; Rachlis, AR; Smaill, FM; Trottier, S; Tseng, AL; Walmsley, SL, 2013)	0.39
" Timed blood samples for C(min) and Cmax were drawn weekly for 3 weeks."	( Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study. Angel, JB; Blitz, SL; Burdge, D; Cohen, J; Conway, B; de Pokomandy, A; Gough, K; Haase, D; Klein, MB; la Porte, CJ; Loemba, H; Loutfy, MR; Pick, N; Raboud, J; Rachlis, AR; Smaill, FM; Trottier, S; Tseng, AL; Walmsley, SL, 2013)	0.39
"Compared to historical control data, C(min) in the women enrolled was significantly higher whereas Cmax was significantly lower."	( Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study. Angel, JB; Blitz, SL; Burdge, D; Cohen, J; Conway, B; de Pokomandy, A; Gough, K; Haase, D; Klein, MB; la Porte, CJ; Loemba, H; Loutfy, MR; Pick, N; Raboud, J; Rachlis, AR; Smaill, FM; Trottier, S; Tseng, AL; Walmsley, SL, 2013)	0.39
" The long terminal elimination half-life of etravirine should support once-daily dosing."	( Pharmacokinetics and pharmacodynamics of etravirine 400 mg once daily in treatment-naïve patients. Bickel, M; Di Perri, G; Faetkenheuer, G; Green, B; Hill, A; Kakuda, T; Kurowski, M; Morrish, G; van Delft, Y, )	0.13
" Area under the curve over the dosing interval (AUC24h) and trough concentration (C0h) were estimated using a population pharmacokinetic model and compared with previous results using the 200-mg twice-daily dosage."	( Pharmacokinetics and pharmacodynamics of etravirine 400 mg once daily in treatment-naïve patients. Bickel, M; Di Perri, G; Faetkenheuer, G; Green, B; Hill, A; Kakuda, T; Kurowski, M; Morrish, G; van Delft, Y, )	0.13
" To test the hypothesis that incorporation of mechanism of reduced efavirenz metabolism by the CYP2B6*6 allele can predict the genetic effect on efavirenz pharmacokinetics, in vitro-in vivo extrapolation of efavirenz clearance was performed by physiologically based pharmacokinetic modeling (Simcyp Simulator; Simcyp Ltd."	( CYP2B6 pharmacogenetics-based in vitro-in vivo extrapolation of efavirenz clearance by physiologically based pharmacokinetic modeling. Desta, Z; Guo, Y; Hall, SD; Li, L; Quinney, SK; Xu, C, 2013)	0.39
"The pharmacokinetic data support coadministration of daclatasvir with atazanavir/ritonavir, efavirenz and/or tenofovir."	( Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. Bertz, R; Bifano, M; Grasela, D; Hartstra, J; Hwang, C; Kandoussi, H; Oosterhuis, B; Sevinsky, H; Tiessen, R; Velinova-Donga, M, 2013)	0.39
" A population pharmacokinetic (PK) model was developed from a randomized, cross-over, drug-interaction study in healthy male Korean subjects (n = 17)."	( Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz. Abdelhady, AM; Desta, Z; Jiang, F; Overholser, BR; Shin, JG; Yeo, CW, 2014)	0.4
" Samples were obtained for pharmacokinetic assessment on day 8 of each study cycle."	( Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance. Cao, L; Court, MH; Kurpewski, J; Kwara, A; Mahjoub, BD; Peloquin, CA; Poethke, P; Tashima, KT; Yang, H, 2014)	0.4
" We evaluated the effect of 2 highly active antiretroviral therapy (HAART) regimens (1 including efavirenz and the other ritonavir-boosted lopinavir) on the pharmacokinetic (PK) parameters of an ENG-releasing implant in HIV-positive women."	( Effect of antiretroviral therapy including lopinavir/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women. Amaral, E; Bahamondes, L; Bahamondes, MV; Brito, MB; de Souza, RM; Duarte, G; Ferriani, RA; Quintana, SM; Rocha Prandini, TR; Scaranari, C; Vieira, CS, 2014)	0.4
" Pharmacokinetic sampling occurred at the end of each dosing period."	( Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin. Allen, R; Aweeka, F; Bao, J; Cramer, Y; Dooley, KE; Haas, DW; Koletar, SL; Luetkemeyer, AF; Marzan, F; Murray, S; Park, JG; Savic, R; Sutherland, D, 2014)	0.4
" SLNs were prepared and analyzed for physical parameters, stability, and pharmacokinetic profile."	( Enhanced oral bioavailability of efavirenz by solid lipid nanoparticles: in vitro drug release and pharmacokinetics studies. Bajpai, M; Gaur, PK; Mishra, A; Mishra, S, 2014)	0.4
" Pharmacokinetic sampling was performed at gestation week 37 and during the postpartum period."	( Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection. Castel, S; Chaisson, RE; Cohn, S; Denti, P; Dooley, KE; Haas, DW; Hoffmann, J; Hull, J; Martinson, N; Mashabela, F; McIlleron, H; Msandiwa, R; Wiesner, L, 2015)	0.42
" A PAS population pharmacokinetic model in two dosing regimens was developed; potential covariates affecting its pharmacokinetics were examined, and Monte Carlo simulations were conducted evaluating the pharmacokinetic-pharmacodynamic index."	( Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis. de Kock, L; Derendorf, H; Diacon, AH; Donald, PR; Hernandez, KR; Prescott, K; Rosenkranz, B; Sy, SK; Yu, M, 2014)	0.4
" Co-administration with EFV resulted in decreases of 57, 39 and 75% in DTG AUC(0-τ), Cmax and Cτ, respectively."	( Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir. Borland, J; Castellino, S; Chen, S; Guta, P; Hosking, L; Lou, Y; Mosteller, M; Peppercorn, A; Piscitelli, SC; Rubio, JP; Savina, P; Song, I; Wagner, D; Wajima, T; Wilfret, D, 2014)	0.4
"The drug-drug interactions between pitavastatin and darunavir/ritonavir (DRV/r) as well as pitavastatin and efavirenz (EFV) were examined in an open-label, parallel-arm, pharmacokinetic (PK) study in HIV-uninfected healthy volunteers."	( Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir. Aberg, JA; Ma, Q; Malvestutto, CD; Morse, GD; Underberg, JA, 2014)	0.4
"In the EFV arm, the geometric mean area under the concentration time curve (AUC0-τ) and Cmax of pitavastatin were 85."	( Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir. Aberg, JA; Ma, Q; Malvestutto, CD; Morse, GD; Underberg, JA, 2014)	0.4
" When stratified based on CYP2B6 516G>T (n = 29 ; 11 GG, 10 GT and 8 TT), efavirenz pharmacokinetic parameters in plasma and breast milk differed significantly between patient groups."	( Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational study. Adejuyigbe, E; Amara, A; Back, D; Bolaji, O; Else, L; Khoo, S; Olagunju, A; Owen, A; Siccardi, M; Waitt, C, 2015)	0.42
" A pharmacokinetic model was built in a forward and reverse procedure using nonlinear mixed effect modeling in NONMEM VI followed by model-based simulations for optimal doses."	( CYP2B66, CYP2B618, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe. Chonzi, P; Dhoro, M; Kadzirange, G; Masimirembwa, C; Ngara, B; Nhachi, C; Zvada, S, 2015)	0.42
" The effect of EFV and/or NVP on lumefantrine pharmacokinetic profile among HIV-malaria co-infected patients on ART and treated with AL was investigated."	( The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2015)	0.42
" Pharmacokinetic analysis of lumefantrine was done using non-linear mixed effect modelling."	( The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2015)	0.42
"Of the evaluated models, a two-compartment pharmacokinetic model with first order absorption and lag-time described well lumefantrine plasma concentrations time profile."	( The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2015)	0.42
"Participants receiving daily rifapentine and isoniazid with efavirenz had pharmacokinetic evaluations at baseline and weeks 2 and 4 of concomitant therapy."	( Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention. Andersen, JW; Bao, Y; Benson, CA; Chaisson, RE; Fletcher, CV; Gupta, A; Kim, P; Mohapi, L; Mwelase, T; Podany, AT; Supparatpinyo, K; Swindells, S, 2015)	0.42
"This nonrandomized, parallel group, pharmacokinetic evaluation was conducted in three groups of human immunodeficiency virus-infected Ugandan women: ART-naive (n = 17), efavirenz-based ART (n = 20), and nevirapine-based ART (n = 20)."	( Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks. Back, DJ; Buzibye, A; Byakika-Kibwika, P; Cohn, SE; Darin, KM; Dilly Penchala, S; Else, LJ; Lamorde, M; Merry, C; Nakalema, S; Scarsi, KK, 2016)	0.43
"To study pharmacokinetic effect of Aikeqing Granule (AG) by different medication ways on zidovudine (AZT) in highly active antiretroviral therapy ( HAART) of rats."	( [Pharmacokinetic Effect of Aikeqing Granule by Different Medication Ways on Zidovudine in HAART of Rats]. Fu, LC; Lu, ZZ; Ma, JB; Song, C; Su, QJ; Tang, DH, 2015)	0.42
" Pharmacokinetic parameters [such as t1/2, Tmax, Cmax, AUCo-t, plasma clearance rate (CL)] were calculated by DAS2."	( [Pharmacokinetic Effect of Aikeqing Granule by Different Medication Ways on Zidovudine in HAART of Rats]. Fu, LC; Lu, ZZ; Ma, JB; Song, C; Su, QJ; Tang, DH, 2015)	0.42
"AG combined HAART could enhance the Cmax of AZT."	( [Pharmacokinetic Effect of Aikeqing Granule by Different Medication Ways on Zidovudine in HAART of Rats]. Fu, LC; Lu, ZZ; Ma, JB; Song, C; Su, QJ; Tang, DH, 2015)	0.42
"Population pharmacokinetic (PopPK) analyses often rely on steady state and full adherence to prescribed dosage regimen assumptions from data gathered during therapeutic drug monitoring (TDM)."	( Comparison of Population Pharmacokinetics Based on Steady-State Assumption Versus Electronically Monitored Adherence to Lopinavir, Atazanavir, Efavirenz, and Etravirine: A Retrospective Study. Buclin, T; Bugnon, O; Cavassini, M; Csajka, C; Fuchs, A; Rotzinger, A; Schneider, MP, 2016)	0.43
" A population pharmacokinetic (PPK) model was developed using data from three studies in HIV-1-infected pediatric subjects (n = 168) and one study in healthy adults (n = 24)."	( Population Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years. Bertz, R; Chapel, S; Cirincione, B; Luo, M; Roy, A; Savant, I; Sevinsky, H, 2016)	0.43
"We compared the pharmacokinetic (PK) exposure parameters of efavirenz (EFV) and its major inactive metabolite, 8-hydroxy-efavirenz (8-OH-EFV), in an open-label, single-sequence, and parallel design of HIV-infected and tuberculosis (TB)-HIV-coinfected Ethiopian patients in the HIV-TB Pharmagene study with 20 and 33 patients, respectively."	( Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients. Aderaye, G; Aklillu, E; Amogne, W; Bertilsson, L; Burhenne, J; Habtewold, A; Makonnen, E; Owen, JS; Yimer, G, 2016)	0.43
"A physiologically based pharmacokinetic (PBPK) model was developed for cobimetinib using in vitro data."	( Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation. Budha, NR; Chen, Y; Dresser, M; Eppler, S; Ji, T; Jin, JY; Musib, L, 2016)	0.43
"The PBPK model described cobimetinib pharmacokinetic profiles after both intravenous and oral administration of cobimetinib well and accurately simulated the itraconazole-cobimetinib DDI."	( Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation. Budha, NR; Chen, Y; Dresser, M; Eppler, S; Ji, T; Jin, JY; Musib, L, 2016)	0.43
"Based on ibrutinib pharmacokinetics and potential sensitivity towards CYP3A4-mediated drug-drug interactions (DDIs), a physiologically based pharmacokinetic approach was developed to mechanistically describe DDI with various CYP3A4 perpetrators in healthy men under fasting conditions."	( Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling. De Jong, J; de Zwart, L; Mannaert, E; Monshouwer, M; Snoeys, J; Sukbuntherng, J, 2016)	0.43
"This study predicted the magnitude of the DDI between efavirenz, an inducer of CYP3A4 and inhibitor of CYP2C8, and dual CYP3A4/CYP2C8 substrates (repaglinide, montelukast, pioglitazone, paclitaxel) using a physiologically based pharmacokinetic (PBPK) modeling approach integrating concurrent effects on CYPs."	( Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes. Back, D; Battegay, M; Elzi, L; Marzolini, C; Rajoli, R; Siccardi, M, 2017)	0.46
" A population-based pharmacokinetic model was developed using 1,132 plasma efavirenz concentrations obtained from 73 HIV-seronegative volunteers administered a single oral dose of 600 mg efavirenz."	( Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition. Bies, RR; Desta, Z; Lu, J; Metzger, IF; Robarge, JD; Skaar, TC; Thong, N, 2017)	0.46
" The pharmacokinetic studies demonstrated improved pharmacokinetic parameters for the formulation containing SLS and HPC."	( Efavirenz dissolution enhancement III: Colloid milling, pharmacokinetics and electronic tongue evaluation. Bilatto, SE; Cabral, LM; Corrêa, DS; da Costa, MA; Fandaruff, C; Hoffmeister, CR; Pitta, LR; Prado, LD; Rocha, HV; Silva, MA; Tasso, L, 2017)	0.46
" Simulations of efavirenz clearance after oral administrations in individual cynomolgus monkeys were performed using individual simplified physiologically based pharmacokinetic (PBPK) modeling consisting of gut, liver and central compartments."	( Efavirenz clearances in vitro and in vivo in six cynomolgus monkeys associated with polymorphic cytochrome P450 2C9 and simulated by individual physiologically based pharmacokinetic models. Kusama, T; Miura, T; Shimizu, M; Uehara, S; Uno, Y; Utoh, M; Yamazaki, H, 2017)	0.46
"Sparse pharmacokinetic sampling of ENG, NVP, or EFV were performed at screening, entry, and then 1, 4, 12, and 24-week postimplant insertion."	( Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy. Achilles, SL; Chappell, CA; Chen, BA; Cohn, SE; Darin, KM; Lamorde, M; Mackline, H; Nakalema, S; Riddler, SA; Scarsi, KK, 2017)	0.46
" In addition, a subgroup of patients underwent intensive DBS and plasma sampling (0-24 hours) to provide full-profile data for pharmacokinetic parameters."	( Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial-The ENCORE1 Study. Amara, AB; Amin, J; Back, DJ; Carey, D; Else, LJ; Emery, S; Khoo, S; Puls, RL, 2017)	0.46
" Population pharmacokinetic modelling was used to explore pharmacokinetic endpoints at 200, 400 and 600 mg daily doses in pregnant women stratified by CYP2B6 metabolic status."	( Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modelling. Bolaji, O; Khoo, S; Olagunju, A; Owen, A; Schipani, A, 2018)	0.48
" The results of clinical pharmacokinetic (PK) studies indicate that guanfacine is sensitive to drug-drug interactions (DDIs) perpetrated by strong inhibitors and inducers of CYP3A4."	( Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers. Li, A; Rong, H; Welty, D; Yeo, K, 2018)	0.48
"To investigate clinically applicable dose-adjustment strategies to overcome the known drug-drug interaction (DDI) between levonorgestrel and efavirenz, using a physiologically based pharmacokinetic (PBPK) modelling-based approach."	( Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug-drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART. Back, DJ; Darin, KM; Fletcher, CV; Lamorde, M; Owen, A; Rajoli, RKR; Roberts, O; Scarsi, KK; Siccardi, M, 2018)	0.48
"We developed a mechanistic population pharmacokinetic model using pooled data from women included in seven studies (1968 samples, 774 collected during pregnancy)."	( A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women. Best, BM; Burger, DM; Capparelli, E; Colbers, AC; Cressey, TR; Denti, P; Dooley, KE; Greupink, R; Huitema, ADR; Mirochnick, M; Russel, FGM; Schalkwijk, S; Ter Heine, R, 2018)	0.48
" Genetic polymorphisms and pharmacokinetic (PK) parameters of EFV400 without (PK1) and with INH/RIF following 4 (PK2) and 12 (PK3) weeks of coadministration were evaluated."	( Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus-Infected Individuals. Boffito, M; Cerrone, M; Day-Weber, I; Fedele, S; Hill, A; McClure, M; Neary, M; Owen, A; Wang, X; Weaver, C, 2019)	0.51
" Weekly therapeutic drug monitoring (TDM), steady-state pharmacokinetic profiles (TT and PP), safety, virological efficacy, and CYP2B6 polymorphisms at positions 516 (C > T) and 938 (T > C) were evaluated."	( Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum. Bisdomini, E; Boffito, M; Byakika-Kibwika, P; Khan, W; Lamorde, M; McClure, M; Mukonzo, JK; Nakalema, S; Neary, M; Owen, A; Wang, X, 2018)	0.48
"Although EFV400 pharmacokinetic parameters were slightly lower for TT compared with PP values, efavirenz concentrations exceeded cutoff levels established by the study and those measured in antiretroviral-naive patients receiving EFV400 in ENCORE1."	( Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum. Bisdomini, E; Boffito, M; Byakika-Kibwika, P; Khan, W; Lamorde, M; McClure, M; Mukonzo, JK; Nakalema, S; Neary, M; Owen, A; Wang, X, 2018)	0.48
"To describe the pharmacokinetics of isoniazid and acetyl-isoniazid in TB/HIV-coinfected patients, and assess the effects of efavirenz co-administration and a 50% increase in the dose of rifampicin on the pharmacokinetic parameters of isoniazid and acetyl-isoniazid."	( Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid. Affolabi, D; Bah-Sow, O; Chirehwa, MT; Denti, P; McIlleron, H; Merle, C; Wiesner, L, 2019)	0.51
" Pharmacokinetic samplings were done 16 weeks after initiation of efavirenz-based anti-retroviral therapy and eight weeks after completion of rifampicin-based anti-tuberculosis treatment."	( Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype. Aklillu, E; Bertilsson, L; Burhenne, J; Janabi, M; Kitabi, EN; Minzi, OMS; Mugusi, F; Mugusi, S; Sasi, P, 2018)	0.48
"This is a pharmacokinetic (PK) substudy of a prospective study that examined the interactions between anti-TB therapy and efavirenz in HIV-infected children with and without TB."	( Population pharmacokinetics of efavirenz in HIV and TB/HIV coinfected children: the significance of genotype-guided dosing. Alghamdi, WA; Antwi, S; Dompreh, A; Enimil, A; Kwara, A; Langaee, T; Peloquin, CA; Wiesner, L; Yang, H, 2019)	0.51
" Associations between patient genotype and etonogestrel pharmacokinetic parameters were determined through univariate and multivariate linear regression."	( Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART. Achilles, SL; Chappell, CA; Chen, BA; Lamorde, M; Matovu, J; Nakalema, S; Neary, M; Owen, A; Scarsi, KK; Siccardi, M, 2019)	0.51
"Within the control group, CYP2B6 983 T>C was associated with 27% higher etonogestrel Cmax and 28% higher AUC0-24weeks."	( Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART. Achilles, SL; Chappell, CA; Chen, BA; Lamorde, M; Matovu, J; Nakalema, S; Neary, M; Owen, A; Scarsi, KK; Siccardi, M, 2019)	0.51
"We did a parallel, three-group, pharmacokinetic evaluation at HIV clinics in Asia (two sites), South America (five), sub-Saharan Africa (three), and the USA (11) between Dec 30, 2014, and Sept 12, 2016."	( Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study. Akelo, V; Aweeka, F; Aziz, M; Berzins, B; Cohn, SE; Coombs, RW; Coughlin, K; Cramer, YS; Friedman, RK; Gingrich, D; Godfrey, C; Moran, LE; Rosenkranz, SL; Scarsi, KK; Swaminathan, S; Zorrilla, CD, 2019)	0.51
" Further studies designed to examine pharmacodynamic endpoints, such as ovulation, when intravaginal ring hormones are combined with efavirenz are warranted."	( Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study. Akelo, V; Aweeka, F; Aziz, M; Berzins, B; Cohn, SE; Coombs, RW; Coughlin, K; Cramer, YS; Friedman, RK; Gingrich, D; Godfrey, C; Moran, LE; Rosenkranz, SL; Scarsi, KK; Swaminathan, S; Zorrilla, CD, 2019)	0.51
"Maternofoetal physiologically-based pharmacokinetic models integrating multi-compartmental maternal and foetal units were developed using Simbiology® to estimate prenatal drug exposure."	( Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies. Adejuyigbe, E; Atoyebi, SA; Bolaji, O; Olagunju, A; Owen, A; Rajoli, RKR; Siccardi, M, 2019)	0.51
" Intensive pharmacokinetic sampling of DTG was undertaken at day 14 and 2wPP following administration of a medium-fat breakfast, with additional paired sampling between maternal plasma and cord blood, breastmilk and infant plasma."	( Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study). Amara, A; Byakika-Kibwika, P; Byamugisha, J; Coombs, JA; Else, L; Gini, J; Heiburg, C; Hill, A; Hodel, EM; Kaboggoza, J; Khoo, S; Kintu, K; Lamorde, M; Malaba, T; Mehta, U; Myer, L; Orrell, C; Reynolds, H; Sihlangu, M; Simmons, B; Singh, Y; Waitt, C; Walimbwa, S, 2019)	0.51
"A simple and rapid ultra-high-performance liquid chromatography (UHPLC) method for determination of efavirenz (EFV) in plasma was developed and applied in a preclinical pharmacokinetic study."	( Simple and Rapid Method by Ultra High-Performance Liquid Chromatography (UHPLC) with Ultraviolet Detection for Determination of Efavirenz in Plasma: Application in a Preclinical Pharmacokinetic Study. Cândido, CD; Dos Santos Martins, E; Franchin, TB; Oliveira, JA; Peccinini, RG; Silva, BCU, 2020)	0.56
" A physiologically based pharmacokinetic (PBPK) model incorporating the metabolites was developed to predict the effect of other strong and moderate CYP3A4 inhibitors and inducers."	( Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling. Dickinson, GL; Hall, SD; Kulanthaivel, P; Morse, BL; Posada, MM; Turner, PK, 2020)	0.56
" Plasma concentration of each antiretroviral drug was tested for calculation of pharmacokinetic parameters."	( Influence of a herbal preparation on the pharmacokinetics of highly active antiretroviral therapy drugs in rats. Jiang, F; Lu, Z; Su, Q; Tang, Y; Wei, S; Zhou, Z, 2020)	0.56
" Pharmacokinetic parameters were obtained from intensive plasma concentration-time data."	( Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz. Adeagbo, BA; Adegbola, AJ; Bolaji, OO; Bolarinwa, RA; Olagunju, AE; Owen, A; Rana, A; Siccardi, M, 2020)	0.56
" This study aimed to develop a population model of the pharmacokinetic properties of efavirenz, and to investigate the impact of patients' characteristics and CYP2B6 516G > T polymorphism on the pharmacokinetic properties of efavirenz."	( Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand. Avihingsanon, A; Chaivichacharn, P; Manosuthi, W; Punyawudho, B; Shotelersuk, V; Tongkobpetch, S; Ubolyam, S, 2020)	0.56
" A 1-compartment model with first-order absorption and elimination was used for describing the pharmacokinetic properties of efavirenz."	( Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand. Avihingsanon, A; Chaivichacharn, P; Manosuthi, W; Punyawudho, B; Shotelersuk, V; Tongkobpetch, S; Ubolyam, S, 2020)	0.56
" We investigated pregnancy-induced and pharmacogenetic-associated pharmacokinetic changes and drug-drug interactions between isoniazid and efavirenz in pregnant women."	( Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping. Aaron, L; Aurpibul, L; Bhosale, R; Bradford, S; Browning, R; Chakhtoura, N; Chanaiwa, V; Chipato, T; Costello, D; Denti, P; Gausi, K; Gupta, A; Haas, DW; Hesseling, A; Jean-Philippe, P; Kabugho, E; Masheto, GR; McCarthy, K; Mhembere, T; Mmbaga, BT; Montepiedra, G; Mutambanengwe, M; Nevrekhar, N; Norman, J; Nyati, M; Onyango-Makumbi, C; Rouzier, V; Shin, K; Sterling, TR; Stranix-Chibanda, L; Theron, G; Tongprasert, F; Vhembo, T; Violari, A; Wallis, CL; Weinberg, A; Wiesner, L; Zimmer, B, 2021)	0.62
" As M9 concentrations have not been quantified in previous clinical studies, a physiologically based pharmacokinetic model was developed to investigate the change in M9 exposure when doravirine is coadministered with CYP3A inducers."	( Physiologically Based Pharmacokinetic Modeling of Doravirine and Its Major Metabolite to Support Dose Adjustment With Rifabutin. Cabalu, TD; Dreyer, D; Fillgrove, KL; Iwamoto, M; Khalilieh, SG; Kuo, Y; Liu, Y; McClain, S; Sanchez, RI; Stoch, SA; Triantafyllou, I; Wenning, L; Yee, KL, 2021)	0.62
"Population pharmacokinetic (popPK) approaches have spread widely throughout clinical pharmacology research, and every clinician should have some understanding of them."	( Parametric Approaches in Population Pharmacokinetics. Buclin, T; Csajka, C; Guidi, M, 2022)	0.72
"Population pharmacokinetic (PK) modeling is a widely used approach to analyze PK data obtained from groups of individuals, in both industry and academic research."	( Nonparametric Methods in Population Pharmacokinetics. Bourguignon, L; Goutelle, S; Neely, M; Woillard, JB; Yamada, W, 2022)	0.72
" The efavirenz population pharmacokinetic profile among HIV-positive smokers is still unknown."	( The association between cigarette smoking and efavirenz plasma concentration using the population pharmacokinetic approach. Chow, NK; Harun, SN; Khan, AH; Low, LL; Sheikh Ghadzi, SM; Wong, EJ, 2021)	0.62
" The association between smoking and efavirenz pharmacokinetic parameters was determined using the nonlinear mixed-effect model."	( The association between cigarette smoking and efavirenz plasma concentration using the population pharmacokinetic approach. Chow, NK; Harun, SN; Khan, AH; Low, LL; Sheikh Ghadzi, SM; Wong, EJ, 2021)	0.62
" A pooled population pharmacokinetic analysis with 744 plasma medroxyprogesterone acetate concentrations from 138 women treated with depot medroxyprogesterone and antiretroviral/antituberculosis treatment across three clinical trials was performed."	( A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment. Cohn, SE; Denti, P; Dooley, KE; Firnhaber, C; Francis, J; Godfrey, C; Kendall, MA; McIlleron, H; Mngqibisa, R; Wu, X, 2021)	0.62
" Minimum duration of nonadherence resulting in a negative drug level test was assessed by simulation of treatment cessation using validated population pharmacokinetic models."	( Point-of-Care Detection of Nonadherence to Antiretroviral Treatment for HIV-1 in Resource-Limited Settings Using Drug Level Testing for Efavirenz, Lopinavir, and Dolutegravir: A Validation and Pharmacokinetic Simulation Study. Burger, DM; Heine, RT; Hermans, LE; Houts, T; Nijhuis, M; Schuurman, R; Tempelman, HA; Wensing, AMJ, 2021)	0.62
"A total of 769 plasma samples from 376 HIV-infected Han Chinese outpatients were collected to develop a population pharmacokinetic model using NONMEM software."	( Effect of albumin and CYP2B6 polymorphisms on exposure of efavirenz: A population pharmacokinetic analysis in Chinese HIV-infected adults. Li, ZR; Liu, YX; Lu, HZ; Meng, XM; Niu, WJ; Qiu, XY; Zheng, XY, 2021)	0.62
"Polymorphisms of CYP2B6, along with albumin and weight, resulted as the predictors of efavirenz pharmacokinetic variability, which could be used in prescribing optimal efavirenz doses."	( Effect of albumin and CYP2B6 polymorphisms on exposure of efavirenz: A population pharmacokinetic analysis in Chinese HIV-infected adults. Li, ZR; Liu, YX; Lu, HZ; Meng, XM; Niu, WJ; Qiu, XY; Zheng, XY, 2021)	0.62
"Pharmacokinetic data were combined in a population pharmacokinetic model."	( Impact of CYP2B6 genotype, tuberculosis therapy, and formulation on efavirenz pharmacokinetics in infants and children under 40 months of age. Benns, A; Bolton Moore, C; Bwakura-Dangarembizi, M; Capparelli, EV; Chadwick, EG; Chakhtoura, N; Frenkel, L; Jean-Philippe, P; Libous, J; Nikanjam, M; Samson, P; Spector, SA; Tran, L; Zimmer, B, 2022)	0.72
" Median age at the first pharmacokinetic visit was 17."	( Impact of CYP2B6 genotype, tuberculosis therapy, and formulation on efavirenz pharmacokinetics in infants and children under 40 months of age. Benns, A; Bolton Moore, C; Bwakura-Dangarembizi, M; Capparelli, EV; Chadwick, EG; Chakhtoura, N; Frenkel, L; Jean-Philippe, P; Libous, J; Nikanjam, M; Samson, P; Spector, SA; Tran, L; Zimmer, B, 2022)	0.72
" This study aimed to develop a population pharmacokinetic model to characterize the disposition of maraviroc in neonates to inform dosing regimens and expand available options."	( Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life. Best, BM; Bradford, S; Capparelli, EV; Chadwick, EG; Jean-Philippe, P; Liyanage, M; McFadyen, L; Mirochnick, M; Moye, J; Nikanjam, M; Rogg, L; Vourvahis, M; Whitson, K, 2022)	0.72
"Using maraviroc concentrations from neonates who received either a single dose or multiple doses of 8 mg/kg of maraviroc in the first 6 weeks of life, a population pharmacokinetic model was developed to determine the effects of age, sex, maternal efavirenz exposure and concomitant ARV therapy on maraviroc disposition."	( Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life. Best, BM; Bradford, S; Capparelli, EV; Chadwick, EG; Jean-Philippe, P; Liyanage, M; McFadyen, L; Mirochnick, M; Moye, J; Nikanjam, M; Rogg, L; Vourvahis, M; Whitson, K, 2022)	0.72
" Levonorgestrel pharmacokinetic parameters were compared between groups using geometric mean ratios (GMR) with 90% confidence intervals."	( Pharmacokinetics of dose-adjusted levonorgestrel emergency contraception combined with efavirenz-based antiretroviral therapy or rifampicin-containing tuberculosis regimens. Badal-Faesen, S; Barr, E; Belaunzaran-Zamudio, PF; Cohn, SE; Gadama, L; Gatechompol, S; Godfrey, C; Jalil, EM; Mawlana, S; Mngqibisa, R; Olefsky, M; Pham, M; Podany, AT; Scarsi, KK; Smeaton, LM; Supparatpinyo, K; Woolley, E, 2023)	0.91
"5 mg to 3 mg improves levonorgestrel pharmacokinetic exposure in participants receiving either efavirenz-based antiretroviral regimens or rifampicin-containing tuberculosis therapy."	( Pharmacokinetics of dose-adjusted levonorgestrel emergency contraception combined with efavirenz-based antiretroviral therapy or rifampicin-containing tuberculosis regimens. Badal-Faesen, S; Barr, E; Belaunzaran-Zamudio, PF; Cohn, SE; Gadama, L; Gatechompol, S; Godfrey, C; Jalil, EM; Mawlana, S; Mngqibisa, R; Olefsky, M; Pham, M; Podany, AT; Scarsi, KK; Smeaton, LM; Supparatpinyo, K; Woolley, E, 2023)	0.91
"Despite the potential for efavirenz (EFV) to be an effective alternative antiretroviral agent, its sources of wide inter- and intra-individual pharmacokinetic (PK) variability are not well-characterized in children."	( Genetic and non-genetic factors influencing efavirenz population pharmacokinetics among human immunodeficiency virus-1-infected children in Ethiopia. Ahmed, JH; Aklillu, E; Chaka, TE; Chala, A; Kitabi, EN; Makonnen, E; Tadesse, BT, 2023)	0.91
" Predicted pharmacokinetic parameters for mothers, breastfeeding infants, and children aged ≥ 3 months were reasonably consistent with observed data, irrespective of CYP2B6 genotype."	( Physiologically Based Pharmacokinetic Modeling to Determine the Impact of CYP2B6 Genotype on Efavirenz Exposure in Children, Mothers and Breastfeeding Infants. Pan, X; Rowland Yeo, K, 2023)	0.91

Excerpt	Reference	Relevance
"Nelfinavir is a novel protease inhibitor that exhibits good inhibitory activity against human immunodeficiency virus type 1 (HIV-1) and is currently used in combination with reverse transcriptase inhibitors for the management of HIV infection."	( Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patients. Fiocchi, C; Gambarana, E; LoCaputo, F; Maserati, R; Pan, A; Regazzi, MB; Seminari, E; Villani, P, 2000)	0.31
" Efavirenz, DPC082, DPC083, DPC961, and DPC963 used in combination with the NRTIs zidovudine and lamivudine acted synergistically to inhibit RT activity in the HIV-1 RT enzyme assay and additively to slightly synergistically to inhibit HIV-1 (RF) replication in the yield reduction assay."	( Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors. Erickson-Viitanen, SK; King, RW; Klabe, RM; Reid, CD, 2002)	0.31
"The steady-state pharmacokinetics and pharmacodynamics of two oral doses of lopinavir-ritonavir (lopinavir/r; 400/100 and 533/133 mg) twice daily (BID) when dosed in combination with efavirenz, plus two nucleoside reverse transcriptase inhibitors, were assessed in a phase II, open-label, randomized, parallel arm study in 57 multiple protease inhibitor-experienced but non-nucleoside reverse transcriptase inhibitor-naive human immunodeficiency virus (HIV)-infected subjects."	( Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Bernstein, B; Bertz, R; Brun, S; Foit, C; Granneman, GR; Hsu, A; Isaacson, J; Kempf, DJ; King, M; Lam, W; Richards, B; Rode, R; Rynkiewicz, K; Sun, E, 2003)	0.32
" This study evaluated the steady-state pharmacokinetics of indinavir/ritonavir at 800/100 mg twice daily (bid) in combination with efavirenz at 600 mg once daily (qd) in HIV-infected Thai subjects who used this nucleoside-sparing combination in The HIV Netherlands Australia Thailand Research Collaboration 009 study."	( Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects. Aarnoutse, RE; Boyd, MA; Burger, DM; Cooper, DA; Lange, JM; Phanuphak, P; Ruxrungtham, K; Stek, M; van Heeswijk, RP, 2003)	0.32
"A randomized, double-blind, double-dummy, active-controlled, 2-arm study comparing the antiviral efficacy and safety of atazanavir 400 mg administered once daily with efavirenz 600 mg administered once daily in combination with open-label fixed-dose zidovudine plus lamivudine twice daily."	( Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. Delfraissy, JF; Gatell, JM; Giordano, M; Jemsek, J; Lazzarin, A; Pokrovskiy, V; Powderly, WG; Rivero, A; Rozenbaum, W; Schrader, S; Sension, M; Squires, K; Thiry, A; Vibhagool, A, 2004)	0.32
"Abacavir provided an effective and durable antiretroviral response that was noninferior to zidovudine, when combined with lamivudine and efavirenz."	( Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Bonny, T; Brand, JD; Brothers, CH; Buendia, CB; Castillo, SA; DeJesus, E; Gerstoft, J; Hernandez, J; Herrera, G; Lanier, ER; Scott, TR; Teofilo, E, 2004)	0.32
" A randomized double-blind clinical trial compared the efficacy and safety of 600 mg of ABC administered once daily (n = 384) versus 300 mg of ABC administered twice daily (n = 386) in combination with 300 mg of lamivudine (3TC) and 600 mg of efavirenz (EFV) administered once daily in antiretroviral-naive patients over 48 weeks."	( Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study. Cahn, P; Castillo, SA; Craig, C; DeJesus, E; Gordon, DN; Moyle, GJ; Scott, TR; Zhao, H, 2005)	0.33
"Because of drug-drug interactions mediated by hepatic cytochrome P450, tuberculosis treatment guidelines recommend an increase in rifabutin from 300 mg to 450 or 600 mg when combined with efavirenz-based antiretroviral therapy."	( Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis. Benator, D; Burman, W; Engle, M; Khan, A; Peloquin, CA; Vernon, A; Weiner, M; Zhao, Z, 2005)	0.33
"Tenofovir disoproxil fumarate (DF) has been studied in combination with efavirenz in healthy volunteers and no interaction was found."	( Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients. Burger, DM; Droste, JA; Hekster, YA; Kearney, BP, 2006)	0.33
" Six different groups were studied: 200 mg nevirapine twice daily, 400 mg nevirapine once daily, 600 mg efavirenz once daily, all without tenofovir DF (groups 1, 2, and 3, respectively), and the same groups with the drugs combined with tenofovir 300 mg once daily (groups 4, 5, and 6, respectively)."	( Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients. Burger, DM; Droste, JA; Hekster, YA; Kearney, BP, 2006)	0.33
"HIV-positive patients with CD4 cell counts > or = 100 cells/mm3 were randomized to 1 of 2 treatment arms: (1) atazanavir, 400 mg given once daily, plus efavirenz placebo; or (2) efavirenz, 600 mg given once daily, plus atazanavir placebo; each drug was administered with fixed-dose zidovudine (300 mg) and lamivudine (150 mg) given twice daily, and patients were treated for at least 48 weeks."	( Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Arathoon, E; Arlotti, M; Giordano, M; Jemsek, JG; Noor, MA; Perez, C; Pokrovskiy, V; Soccodato, M; Sosa, N; Thiry, A, 2006)	0.33
"Study 903 is a phase 3 trial with a completed 144-week, double-blind phase comparing tenofovir DF (TDF) to stavudine (d4T) in combination with lamivudine (3TC) and efavirenz (EFV) and an ongoing additional 336-week open-label extension phase."	( The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients. Cassetti, I; Cheng, AK; Enejosa, J; Etzel, A; Madruga, JV; Suleiman, JM; Zhong, L, )	0.13
"Although there is a presumed drug-drug interaction between itraconazole and nonnucleoside reverse-transcriptase inhibitors, the medical literature lacks such documentation."	( Drug-drug interaction between itraconazole and efavirenz in a patient with AIDS and disseminated histoplasmosis. Andrade, RA; Hamill, RJ; Koo, HL, 2007)	0.34
" We evaluated the effect of preexisting drug-associated resistance mutations to the response in treatment-naive patients to therapy with emtricitabine (FTC) or stavudine (d4T) in combination with didanosine (ddI) and efavirenz (EFV)."	( Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz. Bae, AS; Borroto-Esoda, K; Harris, JL; Hinkle, JE; Quinn, JB; Rousseau, FS; Waters, JM, 2007)	0.34
"Study 903 is a phase 3 trial with a completed 144-week, double-blind phase comparing tenofovir DF (TDF) with stavudine (d4T), in combination with lamivudine (3TC) and efavirenz (EFV), and an ongoing 336-week open-label extension phase."	( The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapy. Cassetti, I; Cheng, AK; Enejosa, J; Etzel, A; Holmes, CB; Madruga, JR; Suleiman, JM; Zhong, L, )	0.13
" In some patients on the nucleoside-sparing arm, the nucleoside-resistance mutation L74V was selected for in combination with the uncommonly occurring EFV-resistance mutations K103N+L100I; L74V was not detected as a minority variant, using clonal sequence analysis, when the nucleoside-sparing regimen was initiated."	( Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. Bettendorf, D; DeGruttola, V; Demeter, LM; Eron, JJ; Eshleman, S; Fischl, M; Hammer, S; Koval, CE; Lustgarten, S; Nguyen, BY; Spreen, W; Squires, K, )	0.13
" In addition, L74V, when combined with K103N+L100I, may confer a selective advantage to the virus that is independent of its effects on nucleoside resistance."	( Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. Bettendorf, D; DeGruttola, V; Demeter, LM; Eron, JJ; Eshleman, S; Fischl, M; Hammer, S; Koval, CE; Lustgarten, S; Nguyen, BY; Spreen, W; Squires, K, )	0.13
" Pharmacokinetic profiles were also determined in HIV-1-infected patients dosed with raltegravir monotherapy versus raltegravir in combination with TDF and lamivudine."	( Lack of a significant drug interaction between raltegravir and tenofovir. Breidinger, SA; Chen, J; Friedman, EJ; Gottesdiener, KM; Iwamoto, M; Kost, JT; Lasseter, KC; Stek, JE; Stone, JA; Teppler, H; Wagner, JA; Wenning, LA, 2008)	0.35
" These mt-QSARs offer also a good opportunity to construct drug-drug Complex Networks (CNs) that can be used to explore large and complex drug-viral species databases."	( Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E, 2009)	0.35
" Because 3'-azido-3'-deoxythymidine (AZT), one of the most current nucleotide reverse transcriptase inhibitors prescribed in combination with EFV, is also conjugated by UGT2B7, the potential metabolic interaction between EFV and AZT has been studied using human liver microsomes."	( Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Bélanger, AS; Caron, P; Guillemette, C; Harvey, M; Mehlotra, RK; Zimmerman, PA, 2009)	0.35
"Similar virological efficacy was observed for efavirenz and lopinavir/r, when administered with Kivexa in antiretroviral-naïve patients, while immunological improvement was slightly superior for efavirenz."	( Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral-naïve patients: a 48-week, multicentre, randomized study (Lake Study). Bravo, I; Carosi, G; Clotet, B; del Arco, A; Echeverría, P; Gálvez, J; Gómez, JL; López, JC; López-Blazquez, R; Mariño, A; Moreno, A; Negredo, E; Ocampo, A; Pedrol, E; Pérez-Alvarez, N; Portilla, J; Prieto, A; Rubio, R; Viladés, C, 2010)	0.36
"Forty-eight-week data are presented from this multicenter, randomized, open-label study comparing the safety profiles of abacavir/lamivudine and tenofovir/emtricitabine, both administered with efavirenz, in HLA-B*5701-negative HIV-1-infected adults."	( Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. Branco, T; Cavassini, M; Domingo, P; Fisher, M; Givens, N; Khuong-Josses, MA; Lim, ML; Moyle, GJ; Norden, AG; Pearce, HC; Podzamczer, D; Post, FA; Rieger, A; Stellbrink, HJ; Vavro, C, 2010)	0.36
"To determine which NNRTI, EFV or NVP, is more efficacious when given in combination with two NRTIs as part of initial ART for HIV infection in adults and children."	( Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Irlam, JH; Mbuagbaw, LC; Rutherford, GW; Siegfried, N; Spaulding, A, 2010)	0.36
"Both drugs have equivalent efficacies in initial treatment of HIV infection when combined with two NRTIs, but different side effects."	( Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Irlam, JH; Mbuagbaw, LC; Rutherford, GW; Siegfried, N; Spaulding, A, 2010)	0.36
" The lopinavir/ritonavir dose of 500/125 mg bid administered with efavirenz most closely approximates the pharmacokinetic exposure of lopinavir/ritonavir 400/100 mg bid administered alone."	( Pharmacokinetics and safety of the lopinavir/ritonavir tablet 500/125 mg twice daily coadministered with efavirenz in healthy adult participants. Awni, W; Bernstein, B; Causemaker, SJ; Chiu, YL; Klein, CE; Ng, J, 2012)	0.38
"Eligible patients with HIV-1 RNA (vRNA) levels >5000 copies/mL and without baseline resistance to efavirenz, tenofovir, or emtricitabine were randomized in a double-blind, noninferiority study to receive raltegravir or efavirenz, each combined with tenofovir/emtricitabine."	( Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Dejesus, E; Dinubile, MJ; Lazzarin, A; Leavitt, R; Lennox, JL; Nguyen, BY; Rockstroh, JK; Rodgers, AJ; Saag, MS; Sklar, P; Teppler, H; Walker, ML; Wan, H; Xu, X; Zhao, J, 2011)	0.37
"When combined with tenofovir/emtricitabine in treatment-naive patients, raltegravir produced durable viral suppression and immune restoration that was at least equivalent to efavirenz through 156 weeks of therapy."	( Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Dejesus, E; Dinubile, MJ; Lazzarin, A; Leavitt, R; Lennox, JL; Nguyen, BY; Rockstroh, JK; Rodgers, AJ; Saag, MS; Sklar, P; Teppler, H; Walker, ML; Wan, H; Xu, X; Zhao, J, 2011)	0.37
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."	( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012)	0.38
"To explore the durability of three first-line tenofovir/emtricitabine-based regimens in combination with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in HIV-1-infected patients."	( Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort. Borghi, V; Capetti, A; Cicconi, P; Di Biagio, A; Di Giambenedetto, S; Francisci, D; Giacometti, A; Giannarelli, D; Maggiolo, F; Monno, L; Penco, G; Prinapori, R; Sterrantino, G; Zoncada, A, 2013)	0.39
" For TB drugs, equivalence was suggested for peak plasma concentrations when administered with and without efavirenz/tenofovir/emtricitabine."	( Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study. Aarnoutse, RE; Boeree, MJ; Burger, DM; Fillekes, Q; Kibiki, GS; Kisanga, ER; Kisonga, RM; Mleoh, L; Mtabho, CM; Ndaro, A; Semvua, HH; van den Boogaard, J; van der Ven, A, 2013)	0.39
"Comprehensive information on the effects of cytochrome P450 2B6 (CYP2B6) polymorphisms, clinical factors, and drug-drug interactions on efavirenz concentrations in HIV/tuberculosis-coinfected (HIV/TB) patients is unavailable."	( Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients. Lueangniyomkul, A; Mankatitham, W; Manosuthi, S; Manosuthi, W; Nilkamhang, S; Sukasem, C; Sungkanuparph, S; Thongyen, S, 2013)	0.39
"Drugs most likely to interact with combined oral contraceptives, transdermal and implant contraceptives include protease inhibitors, the NNRTIs efavirenz and nevirapine, and cobicistat-boosted elvitegravir."	( Drug interactions between antiretrovirals and hormonal contraceptives. Hills-Nieminen, C; Tseng, A, 2013)	0.39
" Although antidepressants are prescribed to a significant proportion of patients treated with antiretrovirals, there are limited clinical data on drug-drug interactions."	( Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach. Almond, L; Back, D; Khoo, S; Kirov, A; Marzolini, C; Owen, A; Seden, K; Siccardi, M, 2013)	0.39
" Pharmacokinetics and drug-drug interaction were simulated using the full physiologically based pharmacokinetic model implemented in the Simcyp™ ADME simulator."	( Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach. Almond, L; Back, D; Khoo, S; Kirov, A; Marzolini, C; Owen, A; Seden, K; Siccardi, M, 2013)	0.39
"Simulated pharmacokinetics and drug-drug interactions were in concordance with available clinical data."	( Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach. Almond, L; Back, D; Khoo, S; Kirov, A; Marzolini, C; Owen, A; Seden, K; Siccardi, M, 2013)	0.39
" These findings indicate that IVIVE is a useful tool for predicting drug-drug interactions and designing prospective clinical trials, giving insight into the variability of exposure, sample size and time-dependent induction or inhibition."	( Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach. Almond, L; Back, D; Khoo, S; Kirov, A; Marzolini, C; Owen, A; Seden, K; Siccardi, M, 2013)	0.39
" Finally, observed/predicted drug-drug interactions between antiretrovirals and antifungals are summarized along with clinical recommendations."	( Clinically relevant drug-drug interactions between antiretrovirals and antifungals. Mitra, AK; Pal, D; Patel, M; Paturi, DK; Vadlapatla, RK, 2014)	0.4
" Posaconazole is contraindicated in combination with either efavirenz or fosamprenavir."	( Clinically relevant drug-drug interactions between antiretrovirals and antifungals. Mitra, AK; Pal, D; Patel, M; Paturi, DK; Vadlapatla, RK, 2014)	0.4
" Evaluation of a drug-drug interaction (DDI) study and supportive semi-mechanistic population pharmacokinetic (PK) analyses were undertaken to help delineate this issue."	( Why did the FDA approve efavirenz 800 mg when co-administered with rifampin? Arya, V; Chan-Tack, KM; Jadhav, P; Kraft, J; Liu, J; Robertson, SM; Seo, S; Singer, ME; Struble, KA, 2014)	0.4
" Simulations compared EFV exposure at various doses in combination with RIF to EFV exposures at 600 mg once daily (QD)."	( Why did the FDA approve efavirenz 800 mg when co-administered with rifampin? Arya, V; Chan-Tack, KM; Jadhav, P; Kraft, J; Liu, J; Robertson, SM; Seo, S; Singer, ME; Struble, KA, 2014)	0.4
"An in vivo study of efavirenz metabolites in rats and human patients with ultra high performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry combined with MetabolitePilot(MT) software is reported for the first time."	( Rapid identification of efavirenz metabolites in rats and humans by ultra high performance liquid chromatography combined with quadrupole time-of-flight tandem mass spectrometry. Deng, Y; Liang, J; Liu, R; Yang, P, 2015)	0.42
" These predictions were in good agreement with clinical single dose drug-drug interaction studies, but not with reports of imatinib interactions at steady-state."	( Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation. Beumer, JH; Christner, SM; Kiesel, BF; Parise, RA; Pillai, VC; Rudek, MA; Venkataramanan, R, 2015)	0.42
" The 3D regimen of 150/100 mg daily paritaprevir/ritonavir, 25 mg daily ombitasvir, and 400 mg twice-daily dasabuvir was administered alone or in combination with 200 mg daily of emtricitabine and 300 mg daily of tenofovir disoproxil fumarate (tenofovir DF), 25 mg daily of rilpivirine, or 400 mg of raltegravir twice daily."	( Evaluation of Drug-Drug Interactions between Direct-Acting Anti-Hepatitis C Virus Combination Regimens and the HIV-1 Antiretroviral Agents Raltegravir, Tenofovir, Emtricitabine, Efavirenz, and Rilpivirine. Awni, W; Dunbar, M; Dutta, S; Khatri, A; Menon, R; Podsadecki, T; Trinh, R, 2016)	0.43
" A clinical drug-drug interaction (DDI) study with the potent CYP3A4 inhibitor itraconazole resulted in an approximately sevenfold increase in cobimetinib exposure."	( Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation. Budha, NR; Chen, Y; Dresser, M; Eppler, S; Ji, T; Jin, JY; Musib, L, 2016)	0.43
" Three studies were conducted to evaluate the potential drug-drug interactions between delamanid and antiretroviral drugs, including ritonavir, a strong inhibitor of CYP3A4, and selected anti-TB drugs, including rifampin, a strong inducer of cytochrome P450 (CYP) isozymes."	( Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects. Geiter, L; Mallikaarjun, S; Paccaly, A; Patil, S; Petersen, C; Shoaf, SE; Wells, C, 2016)	0.43
"Antiretroviral drugs are among the therapeutic agents with the highest potential for drug-drug interactions (DDIs)."	( Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes. Back, D; Battegay, M; Elzi, L; Marzolini, C; Rajoli, R; Siccardi, M, 2017)	0.46
" Plasma drug-concentration profiles were simulated at steady state in virtual individuals for each drug given alone or in combination with efavirenz."	( Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes. Back, D; Battegay, M; Elzi, L; Marzolini, C; Rajoli, R; Siccardi, M, 2017)	0.46
"In general, DTG 50 mg given once daily combined with an active background drug is a better choice in terms of both efficacy and safety."	( Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials. Chen, H; Guo, W; Huang, J; Jiang, J; Liang, B; Liang, H; Liao, Y; Su, J; Xu, X; Ye, L; Zang, N, 2016)	0.43
"To determine which non-nucleoside reverse transcriptase inhibitor, either EFV or NVP, is more effective in suppressing viral load when given in combination with two nucleoside reverse transcriptase inhibitors as part of initial antiretroviral therapy for HIV infection in adults and children."	( Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Irlam, JH; Mbuagbaw, L; Mursleen, S; Rutherford, GW; Siegfried, N; Spaulding, AB, 2016)	0.43
"Both drugs have similar benefits in initial treatment of HIV infection when combined with two NRTIs."	( Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Irlam, JH; Mbuagbaw, L; Mursleen, S; Rutherford, GW; Siegfried, N; Spaulding, AB, 2016)	0.43
" The results of clinical pharmacokinetic (PK) studies indicate that guanfacine is sensitive to drug-drug interactions (DDIs) perpetrated by strong inhibitors and inducers of CYP3A4."	( Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers. Li, A; Rong, H; Welty, D; Yeo, K, 2018)	0.48
"To investigate clinically applicable dose-adjustment strategies to overcome the known drug-drug interaction (DDI) between levonorgestrel and efavirenz, using a physiologically based pharmacokinetic (PBPK) modelling-based approach."	( Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug-drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART. Back, DJ; Darin, KM; Fletcher, CV; Lamorde, M; Owen, A; Rajoli, RKR; Roberts, O; Scarsi, KK; Siccardi, M, 2018)	0.48
" Conversely, increased-dose levonorgestrel in combination with either 600 or 400 mg of efavirenz was sufficient to restore levonorgestrel concentrations to levels similar to those observed in the 150 mg levonorgestrel control group 48 weeks post-implant-placement (efavirenz:control geometric mean ratio = 0."	( Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug-drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART. Back, DJ; Darin, KM; Fletcher, CV; Lamorde, M; Owen, A; Rajoli, RKR; Roberts, O; Scarsi, KK; Siccardi, M, 2018)	0.48
" Therefore, a clinical drug-drug interaction (DDI) study to evaluate the effects of evocalcet on the pharmacokinetics (PKs) of probe substrates for CYP isozymes (CYP1A2, CYP2B6, CYP2C8, CYP2C9, and CYP3A) was conducted in healthy male volunteers using a novel cocktail combination."	( Assessment of CYP-Mediated Drug Interactions for Evocalcet, a New Calcimimetic Agent, Based on In Vitro Investigations and a Cocktail Study in Humans. Akizawa, T; Endo, Y; Fukagawa, M; Kannami, A; Maeda, H; Nagata, Y; Nakamura, H; Narushima, K; Ohtsuka, S; Shimazaki, R; Shiramoto, M; Uchimura, T, 2019)	0.51
"To investigate the genetic contribution to this previously observed drug-drug interaction through studying SNPs in genes known to be involved in efavirenz, nevirapine or etonogestrel metabolism in the same group of women."	( Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART. Achilles, SL; Chappell, CA; Chen, BA; Lamorde, M; Matovu, J; Nakalema, S; Neary, M; Owen, A; Scarsi, KK; Siccardi, M, 2019)	0.51
"This study demonstrates the influence of pharmacogenetics on the extent of drug-drug interactions between etonogestrel and efavirenz- or nevirapine-based ART."	( Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART. Achilles, SL; Chappell, CA; Chen, BA; Lamorde, M; Matovu, J; Nakalema, S; Neary, M; Owen, A; Scarsi, KK; Siccardi, M, 2019)	0.51
"Open-label Phase 2 drug-drug interaction randomized trial."	( Effect of high-dose rifampicin on efavirenz pharmacokinetics: drug-drug interaction randomized trial. Atwine, D; Barrail-Tran, A; Baudin, E; Bonnet, M; Furlan, V; Gelé, T; K T Nanjebe, D; Kananura, K; Kyohairwe, R; Muyindike, W; Mworozi, K; Nyehangane, D; Orikiriza, P; Taburet, AM; Verstuyft, C, 2020)	0.56
" This warrants further investigations of other drug-drug interactions for optimising dosing in genetically defined subgroups, particularly during drug development."	( Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz. Adeagbo, BA; Adegbola, AJ; Bolaji, OO; Bolarinwa, RA; Olagunju, AE; Owen, A; Rana, A; Siccardi, M, 2020)	0.56
" We investigated pregnancy-induced and pharmacogenetic-associated pharmacokinetic changes and drug-drug interactions between isoniazid and efavirenz in pregnant women."	( Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping. Aaron, L; Aurpibul, L; Bhosale, R; Bradford, S; Browning, R; Chakhtoura, N; Chanaiwa, V; Chipato, T; Costello, D; Denti, P; Gausi, K; Gupta, A; Haas, DW; Hesseling, A; Jean-Philippe, P; Kabugho, E; Masheto, GR; McCarthy, K; Mhembere, T; Mmbaga, BT; Montepiedra, G; Mutambanengwe, M; Nevrekhar, N; Norman, J; Nyati, M; Onyango-Makumbi, C; Rouzier, V; Shin, K; Sterling, TR; Stranix-Chibanda, L; Theron, G; Tongprasert, F; Vhembo, T; Violari, A; Wallis, CL; Weinberg, A; Wiesner, L; Zimmer, B, 2021)	0.62
" Due to its widespread use and CYP3A4-mediated metabolism, there is concern regarding drug-drug interactions (DDIs), particularly a suboptimal LNG exposure when co-administered with CYP3A4 inducers, potentially leading to unintended pregnancies."	( Quantitative Assessment of Levonorgestrel Binding Partner Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling. Chaturvedula, A; Cicali, B; Cristofoletti, R; Hoechel, J; Lingineni, K; Schmidt, S; Vozmediano, V; Wendl, T; Wiesinger, H, 2021)	0.62
"To assess the pharmacokinetic of itraconazole capsule formulation and its active metabolite, hydroxyitraconazole, in adults with HIV diagnosed with talaromycosis in an endemic area, and to evaluate the drug-drug interaction between itraconazole/hydroxyitraconazole (ITC/OH-ITC) and efavirenz."	( Drug-drug interaction between itraconazole capsule and efavirenz in adults with HIV for talaromycosis treatment. Chaiwarith, R; Chindamporn, A; Cressey, TR; Kaewpoowat, Q; Sirisanthana, T; Worasilchai, N; Yasri, S, 2021)	0.62
" The clinical impact of this drug-drug interaction on talaromycosis treatment or prophylaxis in the era of potent ART needs further evaluation."	( Drug-drug interaction between itraconazole capsule and efavirenz in adults with HIV for talaromycosis treatment. Chaiwarith, R; Chindamporn, A; Cressey, TR; Kaewpoowat, Q; Sirisanthana, T; Worasilchai, N; Yasri, S, 2021)	0.62
"To evaluate the effect of methadone maintenance treatment (MMT) combined with rilpivirine (RPV)-based regimens on drug use of HIV individuals."	( Outcomes of Methadone Maintenance Therapy Combined with Rilpivirine/Efavirenz in Treatment-Naive HIV-Infected Patients. Dong, X; Hong, L; Huang, S; Lei, S; Li, H; Li, X; Xie, R; Xin, J; Yang, C; Yang, X; Zhang, B; Zhang, R, 2021)	0.62
"This study was a prospective, open-label, controlled, drug-drug interaction trial at a single center for 24 weeks."	( Outcomes of Methadone Maintenance Therapy Combined with Rilpivirine/Efavirenz in Treatment-Naive HIV-Infected Patients. Dong, X; Hong, L; Huang, S; Lei, S; Li, H; Li, X; Xie, R; Xin, J; Yang, C; Yang, X; Zhang, B; Zhang, R, 2021)	0.62
" As medroxyprogesterone acetate is a cytochrome P450 (CYP3A4) substrate, drug-drug interactions (DDIs) with antiretroviral or antituberculosis treatment may lead to subtherapeutic medroxyprogesterone acetate concentrations (< 0."	( A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment. Cohn, SE; Denti, P; Dooley, KE; Firnhaber, C; Francis, J; Godfrey, C; Kendall, MA; McIlleron, H; Mngqibisa, R; Wu, X, 2021)	0.62
"To determine if double-dose levonorgestrel emergency contraception (EC) in combination with efavirenz or rifampicin, 2 drugs known to decrease levonorgestrel exposure, resulted in similar pharmacokinetics compared to standard-dose levonorgestrel EC without drug-drug interactions."	( Pharmacokinetics of dose-adjusted levonorgestrel emergency contraception combined with efavirenz-based antiretroviral therapy or rifampicin-containing tuberculosis regimens. Badal-Faesen, S; Barr, E; Belaunzaran-Zamudio, PF; Cohn, SE; Gadama, L; Gatechompol, S; Godfrey, C; Jalil, EM; Mawlana, S; Mngqibisa, R; Olefsky, M; Pham, M; Podany, AT; Scarsi, KK; Smeaton, LM; Supparatpinyo, K; Woolley, E, 2023)	0.91
"The predictive performance of the PBPK model to simulate dolutegravir and raltegravir pharmacokinetics and to reproduce the strength of induction was verified using clinical drug-drug interaction studies (steady-state induction) and switch studies (residual induction)."	( Management of Drug Interactions with Inducers: Onset and Disappearance of Induction on Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyltransferase 1A1 Substrates. Battegay, M; Berton, M; Bettonte, S; Marzolini, C; Stader, F, 2023)	0.91
" To this end, the drug-drug interaction between efavirenz and the uridine 5'-diphospho-glucuronosyltransferase 1A1 substrates dolutegravir and raltegravir was first simulated in nonpregnant subjects."	( Mechanistic Modeling of the Drug-Drug Interaction Between Efavirenz and Dolutegravir: Is This Interaction Clinically Relevant When Switching From Efavirenz to Dolutegravir During Pregnancy? Ahmadzia, HK; Dallmann, A; Rakhmanina, N; van den Anker, J, 2023)	0.91

Excerpt	Reference	Relevance
" Studies of L-743, 726 in rats, monkeys, and a chimpanzee demonstrated the compound's potential for good oral bioavailability and pharmacokinetics in humans."	( L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Anderson, PS; Britcher, SF; Carroll, SS; Huff, JR; Lumma, WC; Lyle, TA; Olsen, DB; Payne, LS; Tran, LO; Young, SD, 1995)	0.29
" After oral dosing, the bioavailability of EFV in rats (10 mg/kg) and monkeys (2 mg/kg) was 16% and 42%, respectively."	( Nonlinear pharmacokinetics of efavirenz (DMP-266), a potent HIV-1 reverse transcriptase inhibitor, in rats and monkeys. Balani, SK; deLuna, FA; Kauffman, LR; Lin, JH, 1999)	0.3
" Preliminary pharmacokinetics in rats showed that compound 18 is orally bioavailable and penetrates well into the brain."	( Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues. Bäckbro, K; Engelhardt, P; Fridborg, K; Högberg, M; Johansson, NG; Kangasmetsä, J; Lövgren, S; Noréen, R; Oberg, B; Sahlberg, BL; Sahlberg, C; Unge, T; Vrang, L; Zhang, H, 1999)	0.3
" The best compounds are potent orally bioavailable inhibitors of both wild-type HIV-1 and its clinically relevant K103N mutant virus, but are highly protein-bound in human plasma."	( 4,1-Benzoxazepinone analogues of efavirenz (Sustiva) as HIV-1 reverse transcriptase inhibitors. Bacheler, LT; Chidester, DR; Cocuzza, AJ; Cordova, BC; Diamond, S; Erickson-Viitanen, SK; Jeffrey, S; Klabe, RM; Ko, SS; Rodgers, JD; Weigelt, CA, 2001)	0.31
" Through an integrated effort involving synthesis, docking studies, and biological and pharmacokinetic evaluation, we investigated the structural dependence of the poor bioavailability and rapid clearance within the thioureidic series of antivirals."	( Quinoxalinylethylpyridylthioureas (QXPTs) as potent non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors. Further SAR studies and identification of a novel orally bioavailable hydrazine-based antiviral agent. Aiello, F; Armaroli, S; Bergamini, A; Bolacchi, F; Bongiovanni, B; Caccia, S; Campiani, G; Capozzi, M; Coletta, M; Fabbrini, M; Garofalo, A; Greco, G; Guiso, G; Maga, G; Marini, S; Morelli, E; Nacci, V; Novellino, E; Ramunno, A; Spadari, S; Ventura, L, 2001)	0.31
" Volume of distribution and absorption rate constant were 77."	( Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Beijnen, JH; Huitema, AD; Kappelhoff, BS; Lange, J; MacGregor, TR; van Leth, F, 2005)	0.33
"Ideally, an anti-HIV drug should (1) be highly active against wild-type and mutant HIV without allowing breakthrough; (2) have high oral bioavailability and long elimination half-life, allowing once-daily oral treatment at low doses; (3) have minimal adverse effects; and (4) be easy to synthesize and formulate."	( In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). Andries, K; Arnold, E; Bohets, H; Clark, AD; Daeyaert, F; Das, K; de Béthune, MP; De Clerck, F; de Jonge, M; De Knaep, F; Frenkel, YV; Guillemont, J; Heeres, J; Hughes, SH; Janssen, PA; Koymans, L; Kukla, M; Lampo, A; Lewi, PJ; Ludovici, D; Medaer, B; Pasquier, E; Pauwels, R; Stoffels, P; Vinkers, M; Williams, P, 2005)	0.33
" Asian race and baseline total bilirubin (TBR) increased the relative bioavailability of efavirenz by 56% and 57%, respectively."	( Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. Beijnen, JH; Huitema, AD; Kappelhoff, BS; Meenhorst, PL; Mulder, JW; Prins, JM; Yalvaç, Z, 2005)	0.33
" Asian race and baseline TBR were found to be significantly correlated with the bioavailability of efavirenz."	( Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. Beijnen, JH; Huitema, AD; Kappelhoff, BS; Meenhorst, PL; Mulder, JW; Prins, JM; Yalvaç, Z, 2005)	0.33
"0%, suggesting that the two capsule formulations resulted in similar rate and extent of bioavailability under fasting conditions."	( Comparative bioavailability of a generic capsule formulation of the reverse transcriptase inhibitor efavirenz and the innovator product. Al-Numani, D; Di Marco, M; Garg, M; Marier, JF; Monif, T; Morelli, G; Morin, I; Singla, AK; Stiles, M; Tippabhotla, SK; Vijan, T, 2006)	0.33
" Pharmacokinetic studies of 5a in rat and dog demonstrated that this compound has good oral bioavailability in animal species."	( Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase. Dunn, JP; Dunten, P; Elworthy, TR; Han, X; Harris, SF; Heilek, G; Hirschfeld, DR; Hogg, JH; Huber, W; Kaiser, AC; Kertesz, DJ; Kim, W; Klumpp, K; Li, Y; Mirzadegan, T; Roepel, MG; Saito, YD; Silva, TM; Swallow, S; Sweeney, ZK; Tracy, JL; Villasenor, A; Vora, H; Zhou, AS, 2008)	0.35
" Further refinement of key compounds in this series to optimize physical properties and pharmacokinetics has resulted in the identification of 8e (MK-4965), which has high levels of potency against wild-type and key mutant viruses, excellent oral bioavailability and overall pharmacokinetics, and a clean ancillary profile."	( Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses. Felock, PJ; Flynn, JA; Lai, MT; Liang, Y; Liu, M; McGaughey, G; Miller, M; Moyer, G; Munshi, V; Perlow-Poehnelt, R; Prasad, S; Reid, JC; Sanchez, R; Sisko, JT; Torrent, M; Tucker, TJ; Tynebor, RM; Vacca, JP; Wan, BL; Williams, TM; Yan, Y, 2008)	0.35
" Efavirenz relative bioavailability was 26% higher in subjects homozygous for ABCB1 (rs3842)."	( A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Aklillu, E; Andersson, M; Fukasawa, T; Gustafsson, LL; Milani, L; Mukonzo, JK; Ogwal-Okeng, J; Röshammar, D; Svensson, JO; Waako, P, 2009)	0.35
" Efavirenz (EFV; aqueous solubility 4 microg/ml, bioavailability 40-45%) is a first-line agent in the pediatric therapeutic cocktail."	( Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailability [corrected]. Chiappetta, DA; Hocht, C; Sosnik, A; Taira, C, 2010)	0.36
"To encapsulate EFV in polymeric micelles to improve the aqueous solubility and the the oral bioavailability of the drug."	( Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailability [corrected]. Chiappetta, DA; Hocht, C; Sosnik, A; Taira, C, 2010)	0.36
"This work demonstrates that the encapsulation of EFV, which is poorly water soluble, into polymeric micelles of different poly(ethylene oxide)-poly(propylene oxide) block copolymers significantly improves the oral bioavailability of the drug, and reduces the interindividual variability."	( Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailability [corrected]. Chiappetta, DA; Hocht, C; Sosnik, A; Taira, C, 2010)	0.36
"The effect of mixing the contents of efavirenz capsules (sprinkles) with a small amount of food on the bioavailability and pharmacokinetics of efavirenz in healthy adults was evaluated."	( Bioavailability in healthy adults of efavirenz capsule contents mixed with a small amount of food. Grasela, D; Ji, P; Kaul, S; Lu, M; Nguyen, KL; Shangguan, T, 2010)	0.36
" To assure therapeutic plasma concentrations, the low oral bioavailability demands the administration of relatively high EFV doses."	( A highly concentrated and taste-improved aqueous formulation of efavirenz for a more appropriate pediatric management of the anti-HIV therapy. Chiappetta, DA; Hocht, C; Sosnik, A, 2010)	0.36
" A two-compartment model in which the slope of distribution is assumed to be equal to the absorption rate constant adequately described the data."	( Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? Bardin, C; Blanche, S; Bouazza, N; Diagbouga, S; Hien, H; Hirt, D; Msellati, P; Nacro, B; Ouiminga, A; Rouet, F; Tréluyer, JM; Urien, S; Van De Perre, P; Zoure, E, 2010)	0.36
" The aqueous solubility of the drug was increased more than 8400 times (up to 34mg/mL) and preliminary preclinical data suggested the significantly greater oral bioavailability with respect to an extemporaneous suspension and an oleous solution (similar to the only "commercially available" pediatric formulation)."	( Oral pharmacokinetics of the anti-HIV efavirenz encapsulated within polymeric micelles. Chiappetta, DA; Hocht, C; Sosnik, A; Taira, C, 2011)	0.37
" This study evaluated efavirenz bioavailability after rifampicin administration to healthy volunteers."	( Pharmacokinetic interaction between efavirenz and rifampicin in healthy volunteers. Djoerban, Z; Setiabudy, R, 2011)	0.37
"Co-administration of a single dose of efavirenz 600 mg/day with 1-week rifampicin 450 mg/day significantly reduced efavirenz bioavailability in healthy volunteers."	( Pharmacokinetic interaction between efavirenz and rifampicin in healthy volunteers. Djoerban, Z; Setiabudy, R, 2011)	0.37
"63), while HIV/AIDS patients were found to have 30% lower relative bioavailability (95% CI 18."	( HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects. Aklillu, E; Ashton, M; Gustafsson, LL; Mukonzo, JK; Nanzigu, S; Ogwal-Okeng, J; Rekić, D; Röshammar, D; Waako, P, 2011)	0.37
" HIV/AIDS disease is associated with reduced relative bioavailability of efavirenz."	( HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects. Aklillu, E; Ashton, M; Gustafsson, LL; Mukonzo, JK; Nanzigu, S; Ogwal-Okeng, J; Rekić, D; Röshammar, D; Waako, P, 2011)	0.37
"The oral bioavailability of the antiretroviral efavirenz (EFV) undergoes high inter and intra-individual variability, this fact supporting its therapeutic drug monitoring."	( Efavirenz is a substrate and in turn modulates the expression of the efflux transporter ABCG2/BCRP in the gastrointestinal tract of the rat. Bramuglia, GF; Chiappetta, DA; Di Gennaro, SS; Hocht, C; Peroni, RN; Rubio, MC; Sosnik, A, 2011)	0.37
" Bioavailability decreased."	( Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics. Bedynek, PS; Campbell, S; Crafford, A; Ensign, D; Hoffer, C; Kharasch, ED; Kim, T; London, A; Stubbert, K; Whittington, D, 2012)	0.38
" The developed EFV-loaded particles appear as a useful platform to investigate the intranasal administration to increase the bioavailability in the CNS."	( Poly(ε-caprolactone), Eudragit® RS 100 and poly(ε-caprolactone)/Eudragit® RS 100 blend submicron particles for the sustained release of the antiretroviral efavirenz. Chiappetta, DA; Seremeta, KP; Sosnik, A, 2013)	0.39
"The bioavailability of the drug in the CNS was increased fourfold and the relative exposure index (ratio between the area under the curve in the CNS and plasma) was increased fivefold with respect to the same system administered intravenously."	( Intranasal administration of antiretroviral-loaded micelles for anatomical targeting to the brain in HIV. Chiappetta, DA; Hocht, C; Opezzo, JA; Sosnik, A, 2013)	0.39
"The purpose of this study was to develop NS of efavirenz (EFV) and to investigate its potential in enhancing the oral bioavailability of EFV."	( Nanosuspension of efavirenz for improved oral bioavailability: formulation optimization, in vitro, in situ and in vivo evaluation. Patel, GV; Patel, VB; Pathak, A; Rajput, SJ, 2014)	0.4
"Thus, it can be concluded that NS formulation of EFV can provide improved oral bioavailability due to enhanced solubility, dissolution velocity, permeability and hence absorption."	( Nanosuspension of efavirenz for improved oral bioavailability: formulation optimization, in vitro, in situ and in vivo evaluation. Patel, GV; Patel, VB; Pathak, A; Rajput, SJ, 2014)	0.4
" The simulation of gastrointestinal bioavailability and IVIVC obtained from immediate-release tablet formulations suggests that GastroPlus™ is a valuable in silico method for IVIVC and for studies directed at developing formulations of class II drugs."	( In vitro-in vivo correlation of efavirenz tablets using GastroPlus®. Cabral, LM; Castro, HC; de Sousa, VP; dos Santos, TC; Esteves, VS; Honório, Tda S; Pinto, EC; Rocha, HV; Rodrigues, CR, 2013)	0.39
" In vivo studies confirm bioavailability benefits with an approximately four-fold higher pharmacokinetic exposure after oral administration to rodents, and predictive modeling suggests dose reduction with the new formulation may be possible."	( Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation. Curley, P; Foster, AJ; Giardiello, M; Khoo, SH; Liptrott, NJ; Long, J; Martin, P; McDonald, TO; Owen, A; Rannard, SP; Roberts, P; Schipani, A; Siccardi, M; Smith, D, 2014)	0.4
" Subjects taking concomitant PIs exhibited increases in CsA and TAC exposure (AUC/dose) due to the increased apparent oral bioavailability and decreased apparent oral clearance."	( Changes in clearance, volume and bioavailability of immunosuppressants when given with HAART in HIV-1 infected liver and kidney transplant recipients. Barin, B; Benet, L; Browne, M; Carlson, L; Christians, U; Floren, L; Frassetto, L; Roland, M; Stock, P; Wolfe, A, 2013)	0.39
"The aim of the present study was to prepare surface stabilized nanoparticles for oral bioavailability enhancement of efavirenz (EFZ)."	( Surface stabilized efavirenz nanoparticles for oral bioavailability enhancement. Agrawal, AK; Jain, S; Mahajan, RR; Sharma, JM, 2013)	0.39
" The liquid formulation bioavailability relative to the capsule was found to increase with age to reach 90% of its mature value by the age of 8 years."	( Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected children. Brundage, RC; Fletcher, CV; Salem, AH, 2014)	0.4
"The objective of the present work is to develop a dose adjustable nanotechnology based liquid formulation of efavirenz with improved bioavailability for HIV therapy."	( Anti HIV nanoemulsion formulation: optimization and in vitro-in vivo evaluation. Ali, J; Ansari, SH; Khan, AW; Kotta, S; Sharma, RK, 2014)	0.4
"The EFV-based HAART regimen was associated with a reduction in the bioavailability of ENG, which showed decreases of 63."	( Effect of antiretroviral therapy including lopinavir/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women. Amaral, E; Bahamondes, L; Bahamondes, MV; Brito, MB; de Souza, RM; Duarte, G; Ferriani, RA; Quintana, SM; Rocha Prandini, TR; Scaranari, C; Vieira, CS, 2014)	0.4
"The coadministration of EFV decreased the bioavailability of ENG released from the implant, which could impair contraceptive efficacy."	( Effect of antiretroviral therapy including lopinavir/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women. Amaral, E; Bahamondes, L; Bahamondes, MV; Brito, MB; de Souza, RM; Duarte, G; Ferriani, RA; Quintana, SM; Rocha Prandini, TR; Scaranari, C; Vieira, CS, 2014)	0.4
"Solid lipid nanoparticle is an efficient lipid based drug delivery system which can enhance the bioavailability of poorly water soluble drugs."	( Enhanced oral bioavailability of efavirenz by solid lipid nanoparticles: in vitro drug release and pharmacokinetics studies. Bajpai, M; Gaur, PK; Mishra, A; Mishra, S, 2014)	0.4
"Due to the differences between bioavailability of efavirenz (EFV) and tenofovir (TDF), the single-tablet regimen of EFV/emtricitabine (FTC)/TDF is not approved as initial antiretroviral therapy (ART) in Europe by the European Medical Agency."	( Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1. De Castro, N; Delaugerre, C; Flandre, P; Gallien, S; Molina, JM; Nguyen, N, 2015)	0.42
" A 30 mg/mL solution in a medium-chain triglyceride vehicle is the only pediatric formulation available with an oral bioavailability 20% lower than the solid form."	( Formulation and development of bicontinuous nanostructured liquid crystalline particles of efavirenz. Avachat, AM; Parpani, SS, 2015)	0.42
"Polymorphism and particle size distribution can impact the dissolution behaviour and, as a consequence, bioavailability and bioequivalence of poorly soluble drugs, such as Efavirenz (EFV)."	( Correlation between microstructure and bioequivalence in anti-HIV drug efavirenz. Azanza Ricardo, CL; Cuffini, SL; de Santana, DP; Fandaruff, C; Galindo Bedor, DC; Rebuffi, L; Rocha, HV; Scardi, P; Segatto Silva, MA, 2015)	0.42
" Its erratic oral absorption and poor bioavailability make it a potential candidate for being formulated as a nanosuspension."	( Formulation and optimization of efavirenz nanosuspensions using the precipitation-ultrasonication technique for solubility enhancement. Khatri, K; Shilpi, S; Taneja, S, 2016)	0.43
" Compared to RRC, Ugandan children exhibited reduced bioavailability of EFV and LPV; 11% (P=0."	( The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda. Achan, J; Aweeka, F; Bartelink, IH; Capparelli, E; Charlebois, E; Dorsey, G; Gingrich, D; Havlir, D; Jullien, V; Kamya, M; Plenty, A; Ruel, T; Savic, RM; Scherpbier, HJ; Young, SL, 2015)	0.42
" Patients in the EFV-arm but not in the NVP-arm had significantly lower lumefantrine bioavailability compared to that in the control-arm."	( The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2015)	0.42
"Co-treatment of AL with EFV-based ART but not NVP-based ART significantly reduces lumefantrine bioavailability and consequently total exposure."	( The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2015)	0.42
" Thus, PA-SLN improved the EFV bioavailability and maintained therapeutic levels in the brain for an extended period of time that can result in significant eradication of the viral load therein."	( Targeting of AIDS related encephalopathy using phenylalanine anchored lipidic nanocarrier. Hurkat, P; Jain, A; Jain, SK; Vyas, A, 2015)	0.42
"Over the past few decades, nanocrystal formulations have evolved as promising drug delivery systems owing to their ability to enhance the bioavailability and maintain the stability of poorly water-soluble drugs."	( Conjugation of Hot-Melt Extrusion with High-Pressure Homogenization: a Novel Method of Continuously Preparing Nanocrystal Solid Dispersions. Feng, X; Gryczke, A; Kolter, K; Langley, N; Lu, J; Majumdar, S; Mishra, SR; Neupane, D; Patil, H; Repka, MA; Tiwari, RV; Ye, X, 2016)	0.43
"70%) of the EFV reaching to liver indicates that major amount of EFV bypasses the liver and thereby, enhances the oral bioavailability of the EFV."	( Solid lipid nanoparticles (SLN) of Efavirenz as lymph targeting drug delivery system: Elucidation of mechanism of uptake using chylomicron flow blocking approach. Jain, R; Joshi, A; Makwana, V; Nivsarkar, M; Patel, K, 2015)	0.42
" The current study was aimed to prepare SNEDDS to augment solubility, release rate, and oral bioavailability of BCS class II drug, efavirenz (EFV)."	( Efavirenz Self-Nano-Emulsifying Drug Delivery System: In Vitro and In Vivo Evaluation. Kamble, RN; Kumar, A; Mehta, PP, 2016)	0.43
"Although sex-related differences in gastrointestinal physiology have been vastly reported, its impact on drug oral bioavailability and bioequivalence (product discrimination) is often ignored."	( Sex-by-formulation interaction assessed through a bioequivalence study of efavirenz tablets. Fagiolino, P; Ibarra, M; Lorier, M; Magallanes, L; Vázquez, M, 2016)	0.43
" Body weight was identified as a significant predictor of efavirenz apparent clearance (CL), oral central volume of distribution (VC), and absorption rate constant (Ka)."	( Population Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years. Bertz, R; Chapel, S; Cirincione, B; Luo, M; Roy, A; Savant, I; Sevinsky, H, 2016)	0.43
"This study aims to develop a self-nanoemulsifying drug delivery system (SNEDDS) based on non-ionic surfactant mixtures to improve the oral bioavailability of efavirenz (EFZ) categorized as a class II according to the BCS, for HIV- therapy."	( Mixed surfactant based (SNEDDS) self-nanoemulsifying drug delivery system presenting efavirenz for enhancement of oral bioavailability. Sahoo, SK; Sahu, AN; Senapati, PC, 2016)	0.43
" In conclusion, ECNPs are significantly safe and exhibit higher bioavailability thus constitute an effective MPT against HIV."	( Triple combination MPT vaginal microbicide using curcumin and efavirenz loaded lactoferrin nanoparticles. Bhaskar, C; Kishore, G; Kondapi, AK; Kumar, P; Lakshmi, YS, 2016)	0.43
" Co-administration with some antiretroviral therapies (ART) changes the bioavailability of the etonogestrel (ENG)-releasing contraceptive implant, possibly affecting the bleeding pattern."	( Bleeding patterns of HIV-infected women using an etonogestrel-releasing contraceptive implant and efavirenz-based or lopinavir/ritonavir-based antiretroviral therapy. Amaral, E; Bahamondes, L; Bahamondes, MV; Brito, MB; Duarte, G; Ferriani, RA; Prandini, TR; Quintana, SM; Ragazini, CS; Vieira, CS, 2016)	0.43
" It is poorly soluble and exhibits variable bioavailability hence, a high oral dose is recommended for therapy."	( Engineered nanoparticles of Efavirenz using methacrylate co-polymer (Eudragit-E100) and its biological effects in-vivo. Dhevendaran, K; Hari, BNV; Narayanan, N; Ramyadevi, D, 2016)	0.43
" This study investigated the differences in bioavailability between WHO-prequalified first-line antiretroviral generics by means of adjusted indirect comparisons to ensure interchangeability between these generics."	( Interchangeability between first-line generic antiretroviral products prequalified by WHO using adjusted indirect comparisons. García-Arieta, A; Gordon, J; Gwaza, L; Leufkens, H; Potthast, H; Stahl, M; Welink, J, 2017)	0.46
" Ternary nanosponge complexes were found to have 2-fold increase in oral bioavailability of efavirenz as compared to plain drug."	( Enhancement of Bioavailability of Non-nucleoside Reverse Transciptase Inhibitor Using Nanosponges. Rao, MRP; Shirsath, C, 2017)	0.46
"To enhance efficacy, bioavailability and reduce toxicity of first-line highly active anti-retroviral regimen, zidovudine + efavirenz + lamivudine loaded lactoferrin nanoparticles were prepared (FLART-NP) and characterized for physicochemical properties, bioactivity and pharmacokinetic profile."	( Triple Drug Combination of Zidovudine, Efavirenz and Lamivudine Loaded Lactoferrin Nanoparticles: an Effective Nano First-Line Regimen for HIV Therapy. Kondapi, AK; Kumar, P; Lakshmi, YS, 2017)	0.46
" Decreased bioavailability and increased toxicity limit its use."	( An oral formulation of efavirenz-loaded lactoferrin nanoparticles with improved biodistribution and pharmacokinetic profile. Kondapi, AK; Kumar, P; Lakshmi, YS, 2017)	0.46
"Compared with free EFV, lacto-EFV-nano is a promising oral nanoformulation with enhanced bioavailability and efficacy of EFV and improved safety."	( An oral formulation of efavirenz-loaded lactoferrin nanoparticles with improved biodistribution and pharmacokinetic profile. Kondapi, AK; Kumar, P; Lakshmi, YS, 2017)	0.46
"The nonnucleoside reverse transcriptase inhibitors, used for the treatment of HIV infections, are reported to have low bioavailability pertaining to high first-pass metabolism, high protein binding, and enzymatic metabolism."	( Systematic Approach for the Formulation and Optimization of Solid Lipid Nanoparticles of Efavirenz by High Pressure Homogenization Using Design of Experiments for Brain Targeting and Enhanced Bioavailability. Chotai, N; Gupta, S; Kesarla, R; Misra, A; Omri, A, 2017)	0.46
" Enhanced CNS bioavailability (12."	( Intranasal chitosan-g-HPβCD nanoparticles of efavirenz for the CNS targeting. Belgamwar, A; Khan, S; Yeole, P, 2018)	0.48
"Efavirenz is a fundamental drug in the HIV therapy; however, it has a low bioavailability due to low water solubility."	( Efavirenz Dissolution Enhancement IV-Antisolvent Nanocrystallization by Sonication, Physical Stability, and Dissolution. Prado, LD; Rocha, HVA; Sartori, GJ, 2017)	0.46
" The modeled hepatic intrinsic clearances were also significantly associated with the P450 2C9 genotypes, however, absorption rate constants or volumes of the systemic circulation were not likely determining factors for the individual efavirenz clearance variations in the six cynomolgus monkeys."	( Efavirenz clearances in vitro and in vivo in six cynomolgus monkeys associated with polymorphic cytochrome P450 2C9 and simulated by individual physiologically based pharmacokinetic models. Kusama, T; Miura, T; Shimizu, M; Uehara, S; Uno, Y; Utoh, M; Yamazaki, H, 2017)	0.46
" We hypothesized that the presence of multiple drugs would reduce crystallization tendency, thereby providing stable, supersaturating formulations for bioavailability enhancement."	( Multidrug, Anti-HIV Amorphous Solid Dispersions: Nature and Mechanisms of Impacts of Drugs on Each Other's Solution Concentrations. Arca, HÇ; Dahal, D; Edgar, KJ; Mosquera-Giraldo, LI; Taylor, LS, 2017)	0.46
"Recent work has developed solid drug nanoparticles (SDNs) of efavirenz that have been demonstrated, preclinically, improved oral bioavailability and the potential to enable up to a 50% dose reduction, and is currently being studied in a healthy volunteer clinical trial."	( Assessment of interactions of efavirenz solid drug nanoparticles with human immunological and haematological systems. Giardiello, M; Liptrott, NJ; McDonald, TO; Owen, A; Rannard, SP, 2018)	0.48
" The versatile HA-PQ10 entrapped all drugs and achieved an enhanced relative bioavailability of EFV, TDF, and FTC compared to the market formulation for potentially enhanced HIV treatment."	( 3D printed, controlled release, tritherapeutic tablet matrix for advanced anti-HIV-1 drug delivery. Choonara, YE; du Toit, LC; Kondiah, PPPD; Kumar, P; Pillay, V; Siyawamwaya, M, 2019)	0.51
" The effect of the mechanical activation on the dissolution behavior and bioavailability was investigated revealing possible correlations with the grinding action, in terms of crystallinity, particle size and morphology."	( Mechanical activation of Efavirenz: the effects on the dissolution and inhibitory behavior. Cappelletto, E; Firrito, C; Pizzato, M; Rebuffi, L; Scardi, P, 2018)	0.48
"Present investigation aimed to prepare, optimise, and characterise lipid nanocapsules (LNCs) for improving the solubility and bioavailability of efavirenz (EFV)."	( Efavirenz oral delivery via lipid nanocapsules: formulation, optimisation, and ex-vivo gut permeation study. Alizadeh, A; Jahanian-Najafabadi, A; Taymouri, S; Varshosaz, J, 2018)	0.48
" Recent studies indicate that the bioavailability is higher for antiretroviral drugs delivered by LFNPs than when the drugs are administered alone."	( Evaluation of the reproductive toxicity of antiretroviral drug loaded lactoferrin nanoparticles. Kondapi, AK; Madugulla, L; Ravula, AR; Yenugu, S, 2019)	0.51
" male and female subjects exhibiting different discriminatory potential to detect bioavailability differences between formulations."	( Sex-by-formulation interaction in bioequivalence studies: the importance of formulations and experimental conditions. Fagiolino, P; Ibarra, M; Vázquez, M, 2019)	0.51
"" The objective of this study was to improve solubility and oral bioavailability by formulating liquid-SNEDDS and to mask bitter taste and minimize BMS."	( Taste Evaluation by Electronic Tongue and Bioavailability Enhancement of Efavirenz. Bhutada, K; Kaushal, P; Rao, MRP, 2019)	0.51
" To improve solubility and bioavailability of highly potent anti-retroviral drugs, we explored the use of a nanoparticle (NP) for formulating a combination of two water-insoluble HIV inhibitors."	( Antiretroviral Hydrophobic Core Graft-Copolymer Nanoparticles: The Effectiveness against Mutant HIV-1 Strains and in Vivo Distribution after Topical Application. Alfaro, J; Bogdanov, AA; Bolotin, E; Castillo, G; Gottikh, MB; Gupta, S; Leporati, A, 2019)	0.51
"Amorphous solid dispersions (ASDs) are found to be a well-established strategy for overcoming limited aqueous solubility and poor oral bioavailability of active pharmaceutical ingredients (APIs)."	( Determination of drug-polymer solubility from supersaturated spray-dried amorphous solid dispersions: A case study with Efavirenz and Soluplus®. Costa, BLA; Del Confetto, S; Ré, MI; Sauceau, M; Sescousse, R, 2019)	0.51
" Thus, quality evaluation of different crystal forms should be assessed especially the solubility and dissolution behaviors among polymorphic forms, which correlate to bioavailability and therapy efficacy."	( Polymorphic properties and dissolution profile of efavirenz due to solvents recrystallization. Soewandhi, SN; Suendo, V; Wardhana, YW; Wikarsa, S, 2019)	0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" Both sex and CD4 cell count affected the bioavailability of isoniazid."	( Model-Based Assessment of Variability in Isoniazid Pharmacokinetics and Metabolism in Patients Co-Infected With Tuberculosis and HIV: Implications for a Novel Dosing Strategy. Äbelö, A; Ashton, M; Bienvenu, E; Birgersson, S; Janzén, D; Sundell, J, 2020)	0.56
" An absolute bioavailability study informed the hepatic and gastric availability."	( Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling. Dickinson, GL; Hall, SD; Kulanthaivel, P; Morse, BL; Posada, MM; Turner, PK, 2020)	0.56
"The aim of the study was to evaluate organogel nanoparticles as a lipophilic vehicle to increase the oral bioavailability of poorly soluble compounds."	( Organogel Nanoparticles as a New Way to Improve Oral Bioavailability of Poorly Soluble Compounds. Beyssac, E; Franceschi, S; Garrait, G; Goudouneche, D; Martin, B; Perez, E, 2020)	0.56
" Various parameters have been investigated in the current study such as (i) the release profile of organogel assessed by USP 4 cell flow dialysis, (ii) the impact of organogel on intestinal absorption, using Caco-2 cells as in vitro model and jejunum segments as ex vivo assay and (iii) the bioavailability of organogel following oral pharmacokinetic study."	( Organogel Nanoparticles as a New Way to Improve Oral Bioavailability of Poorly Soluble Compounds. Beyssac, E; Franceschi, S; Garrait, G; Goudouneche, D; Martin, B; Perez, E, 2020)	0.56
"Organogel nanoparticles increase the bioavailability of BCS Class II drugs."	( Organogel Nanoparticles as a New Way to Improve Oral Bioavailability of Poorly Soluble Compounds. Beyssac, E; Franceschi, S; Garrait, G; Goudouneche, D; Martin, B; Perez, E, 2020)	0.56
" The immission distributional kinetics model is applied in projecting bioavailability (F = 0."	( Modelling the influx and efflux waves in drug movement: a basis for Pharmacokinetic-Pharmacodynamic link of efavirenz. Nemaura, T, 2019)	0.51
" Rifampicin bioavailability was also lower in patients on concomitant ART."	( Effect of efavirenz-based ART on the pharmacokinetics of rifampicin and its primary metabolite in patients coinfected with TB and HIV. Äbelö, A; Ashton, M; Bienvenu, E; Sundell, J, 2021)	0.62
" Liquid formulation led to a 42% decrease in bioavailability compared with opened capsules."	( Impact of CYP2B6 genotype, tuberculosis therapy, and formulation on efavirenz pharmacokinetics in infants and children under 40 months of age. Benns, A; Bolton Moore, C; Bwakura-Dangarembizi, M; Capparelli, EV; Chadwick, EG; Chakhtoura, N; Frenkel, L; Jean-Philippe, P; Libous, J; Nikanjam, M; Samson, P; Spector, SA; Tran, L; Zimmer, B, 2022)	0.72
"Efavirenz (EFV) is an anti-HIV drug with high dose and 40% oral bioavailability (BA)."	( Cationic Solid SMEDDS of Efavirenz for Improved Oral Delivery: Development by Central Composite Design, In Vitro and In Vivo Evaluation. Dudhipala, N; Katla, V; Thota, SK; Veerabrahma, K, 2023)	0.91
" The typical estimates of oral clearance, volume of distribution, and absorption rate constant for typical 22 kg children with CYP2B6 1/1 and ABCB1c."	( Genetic and non-genetic factors influencing efavirenz population pharmacokinetics among human immunodeficiency virus-1-infected children in Ethiopia. Ahmed, JH; Aklillu, E; Chaka, TE; Chala, A; Kitabi, EN; Makonnen, E; Tadesse, BT, 2023)	0.91
" Age affected the bioavailability of rifampicin and isoniazid; at birth, children had 48."	( Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis. Aarnoutse, R; Chabala, C; Cotton, MF; Denti, P; Galileya, LT; Gibb, D; Hesseling, A; Lee, J; McIlleron, H; Njahira Mukui, I; Rabie, H; Turkova, A; Wasmann, RE; Zar, H, 2023)	0.91
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" An increase in dosage of indinavir from 800 to 1000 mg 3 times daily is recommended during coadministration with efavirenz."	( Efavirenz. Adkins, JC; Noble, S, 1998)	0.3
" The delayed gastric emptying in monkeys also was observed when the animals dosed at 160 mg/kg exhibited emesis, 8 h postdose, which was found to contain a substantial portion of the dose."	( Nonlinear pharmacokinetics of efavirenz (DMP-266), a potent HIV-1 reverse transcriptase inhibitor, in rats and monkeys. Balani, SK; deLuna, FA; Kauffman, LR; Lin, JH, 1999)	0.3
" Electrospray ionization-liquid chromatography/mass spectrometry analyses of bile samples from rats dosed with either efavirenz or with 8-OH efavirenz revealed three polar metabolites, M9, M12, and M13, with pseudomolecular ions [M-H](-) at m/z 733, 602, and 749, respectively."	( Liquid chromatography/mass spectrometry and high-field nuclear magnetic resonance characterization of novel mixed diconjugates of the non-nucleoside human immunodeficiency virus-1 reverse transcriptase inhibitor, efavirenz. Chen, H; Christ, DD; Gan, LS; Mutlib, AE; Nemeth, G, 1999)	0.3
" Blood samples for pharmacokinetic analysis were obtained during a dosage interval."	( Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients. Castelli, F; Maserati, R; Regazzi, MB; Seminari, E; Torti, C; Viale, P; Villani, P, 1999)	0.3
" EFV exhibits a relatively low interindividual variability and a dosing regimen of 600 mg day-1 assures plasma concentrations that are adequate for inhibition of viral replication."	( Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients. Castelli, F; Maserati, R; Regazzi, MB; Seminari, E; Torti, C; Viale, P; Villani, P, 1999)	0.3
" The pharmacokinetics of efavirenz allow for once daily dosing without regard to meals of normal composition."	( Clinical history of efavirenz. Ruiz, N, 1999)	0.3
" Although protease inhibitor (PI) containing therapies are very potent, many problems have now been identified that reduce quality of life such as a high pill burden, multiple daily dosing and dietary constraints."	( Review of NNRTIs: 'today and tomorrow'. Katlama, C, 1999)	0.3
"25 mg/L and the mean AUC during the dosing interval was 17."	( Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patients. Fiocchi, C; Gambarana, E; LoCaputo, F; Maserati, R; Pan, A; Regazzi, MB; Seminari, E; Villani, P, 2000)	0.31
" Oral dosing is administered three times daily for delavirdine (DLV), twice daily for nevirapine (NVP), and once daily for efavirenz (EFV)."	( Clinical uses of non-nucleoside reverse transcriptase inhibitors. Harris, M; Montaner, JS, )	0.13
" The spectrum of mutations observed in cases of virological treatment failure was similar for patients initially dosed with efavirenz at 200, 400, or 600 mg once a day and for patients treated with efavirenz in combination with indinavir, stavudine, or ZDV-3TC."	( Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Abremski, K; Anton, ED; Aujay, M; Bacheler, LT; Baker, D; Becker, MF; Bolling, L; Bunville, J; Ellis, D; George, HJ; Hollis, G; Krakowski, K; Kudish, P; Lasut, AL; Spalding, DR; Wang, XV, 2000)	0.31
" Further processing of this glutathione adduct was also important in producing the lesion and was demonstrated by inhibiting gamma-glutamyltranspeptidase with acivicin pretreatment (10 mg/kg, IV) prior to dosing with efavirenz."	( The species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in rats. Chen, H; Christ, DD; Davies, MH; Gan, LS; Gemzik, B; Gerson, RJ; Haley, PJ; Krahn, DF; Markwalder, JA; Meunier, PC; Miwa, GT; Mutlib, AE; Robertson, RT; Seitz, SP, 2000)	0.31
" Combining d4T/ddI with protease inhibitors presents problems, such as a complicated dosing schedule and harsh gastrointestinal side effects."	( Dethroning AZT. Falkenberg, J; Gilden, D; Torres, G, 1997)	0.3
" Situations to avoid include using dosing schedules that do not sufficiently suppress the virus, waiting for viral load to return to pre-treatment levels before switching drugs, and not switching drugs to at least two new potent compounds when changing combination therapy."	( Update on antivirals. , 1997)	0.3
" All three drugs are currently available through expanded access programs, are dosed either once or twice daily, and can be taken with or without food."	( I want a new drug. An overview of three new anti-HIV drugs. Simmons, P, 1998)	0.3
" The dosage regimens and limitations are described for each drug."	( Four new antiretroviral medications will soon offer more options to HIV patients. Murphy, MJ, )	0.13
" Abacavir is also attracting attention due to its potency and dosing convenience."	( Dupont pharmaceuticals study 006 for Sustiva. Bartlett, JG, 1998)	0.3
" Food and Drug Administration (FDA) has approved Sustiva (efavirenz) as the first HIV drug to have a once-daily dosing schedule."	( FDA approves Sustiva (efavirenz) capsules, first once-daily anti-HIV drug. Food and Drug Administration. , 1998)	0.3
" Clinical trial results indicate that the low dosage and efficacy of Sustiva make it a good treatment option for many patients."	( New drug approved. , 1998)	0.3
"Efavirenz (Sustiva) is the first once-daily dosing anti-HIV drug approved by the Food and Drug Administration."	( First once-daily drug simplifies dosing, offers new options in HIV-1 treatment. , 1998)	0.3
"DuPont Pharmaceuticals' Sustiva (efavirenz) was approved by the FDA as the first once-daily- dosing anti-HIV drug."	( Now approved: Sustiva in combination offers patients a new first-line therapy. , )	0.13
"Information is provided on efavirenz (Sustiva, formerly DMP-266), including dosage information, resistance and clinical trial results, and pharmacology."	( Product information. Bartlett, JG, 1999)	0.3
" Information on each drug, such as the name of the drug, the dosage normally prescribed, and cost of treatment is listed."	( What they say about: non-nucleoside drugs. , )	0.13
" The studies showed twice-daily dosing is inferior to taking the drug every 8 hours."	( No more twice-a-day Crixivan. Vazquez, E, )	0.13
" Dosing is recommended at bedtime to avert side effects, which are described."	( Sustiva (efavirenz) is approved. Vazquez, E, )	0.13
" Common side effects and dosing information are described."	( Efavirenz (Sustiva) receives FDA approval. Food and Drug Administration. , 1998)	0.3
" Dosage and cost data are included."	( What they say about non-nucleoside drugs. , )	0.13
" Progress is also highlighted about dosing regimens, antiretroviral resistance, and reconstitution of the immune system."	( Moving forward: a treatment overview from the 12th World AIDS Conference. Agosto, M, 1998)	0.3
" In addition, the favorable side-effect profile, diminished pill burden for clients, and daily dosing have contributed to its popularity."	( Evidence of hypertriglyceridemia in managing HIV patients on efavirenz. Cohen, DM; James, CW; Miller, JL; Perlada, DE; Savini, CJ; Wilson, SA, )	0.13
" For levofloxacin, plasma samples were obtained at steady state during a 24-h dosing interval."	( Pharmacokinetic evaluation of oral levofloxacin in human immunodeficiency virus-infected subjects receiving concomitant antiretroviral therapy. Cadeo, B; Carosi, G; Fiocchi, C; Marchetti, F; Regazzi, MB; Signorini, L; Viale, P; Villani, A; Villani, P, 2001)	0.31
" In addition to a potent antiretroviral activity, efavirenz is an easy-to-take drug with once-daily dosing and is usually well tolerated."	( [Apropos of atypical melancholia with Sustiva (efavirenz)]. Danion, JM; Halleguen, O; Lang, JM; Lang, JP; Picard, A, )	0.13
" More conveniently dosed and patient-friendly regimens are needed."	( Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. Maggiolo, F; Maserati, R; Migliorino, M; Pan, A; Provettoni, G; Rizzi, L; Rizzi, M; Suter, F, 2001)	0.31
"Although the minimal effective efavirenz plasma concentration that assures virological success is not currently known, it may be advisable to increase the dosage of efavirenz to 800 mg once daily when it is coadministered with rifampicin."	( Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Alarcón-González, A; Gómez-Mateos, J; León-Jimenez, E; López-Cortés, LF; López-Pua, Y; Pachón, J; Ruiz-Valderas, R; Sarasanacenta, M; Viciana, P, 2002)	0.31
" Discontinuation of atenolol, and nifedipine dosage reduction by 50% were effective in managing his orthostatic changes."	( Symptomatic orthostasis with extended-release nifedipine and protease inhibitors. Rathbun, RC; Rossi, DR; Slater, LN, 2002)	0.31
" During the dosing interval, no single SPrcolon;BP EFV-concentration ratio was significantly predictive of the absolute measure of exposure in SP."	( Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of human immunodeficiency virus type 1-infected men. Cohen, MS; Eron, JJ; Fiscus, SA; Fiske, WD; Gotzkowsky, SK; Kashuba, AD; Kim, JY; Petch, L; Reddy, YS, 2002)	0.31
"The protease inhibitor (PI) ritonavir is used as a strong inhibitor of cytochrome P450 3A4, which boosts the activities of coadministered PIs, resulting in augmented plasma PI levels, simplification of the dosage regimen, and better efficacy against resistant viruses."	( Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients. Bidault, R; Bollens, D; Choudet, N; Demarles, D; Gillotin, C; Goujard, C; Meynard, JL; Rousseau, C; Taburet, AM; Vincent, I, 2003)	0.32
"The steady-state pharmacokinetics and pharmacodynamics of two oral doses of lopinavir-ritonavir (lopinavir/r; 400/100 and 533/133 mg) twice daily (BID) when dosed in combination with efavirenz, plus two nucleoside reverse transcriptase inhibitors, were assessed in a phase II, open-label, randomized, parallel arm study in 57 multiple protease inhibitor-experienced but non-nucleoside reverse transcriptase inhibitor-naive human immunodeficiency virus (HIV)-infected subjects."	( Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Bernstein, B; Bertz, R; Brun, S; Foit, C; Granneman, GR; Hsu, A; Isaacson, J; Kempf, DJ; King, M; Lam, W; Richards, B; Rode, R; Rynkiewicz, K; Sun, E, 2003)	0.32
" However, dosage individualization based on plasma concentration monitoring might be indicated."	( Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Biollaz, J; Buclin, T; Csajka, C; Décosterd, LA; Fattinger, K; Fellay, J; Marzolini, C; Telenti, A, 2003)	0.32
" The average drug exposure during 1 dosing interval was estimated for each patient and correlated with markers of efficacy and toxicity."	( Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Biollaz, J; Buclin, T; Csajka, C; Décosterd, LA; Fattinger, K; Fellay, J; Marzolini, C; Telenti, A, 2003)	0.32
" This enabled the derivation of a dosing adaptation strategy suitable to bring the average concentration into a therapeutic target from 1000 to 4000 microg/L to optimize viral load suppression and to minimize central nervous system toxicity."	( Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Biollaz, J; Buclin, T; Csajka, C; Décosterd, LA; Fattinger, K; Fellay, J; Marzolini, C; Telenti, A, 2003)	0.32
" However, further evaluation is needed before individualization of an efavirenz dosage regimen based on routine drug level monitoring should be recommended for optimal patient management."	( Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Biollaz, J; Buclin, T; Csajka, C; Décosterd, LA; Fattinger, K; Fellay, J; Marzolini, C; Telenti, A, 2003)	0.32
"37) were similar regardless of the dosing regimen."	( Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects. Cha, R; DiCenzo, R; Fischl, MA; Forrest, A; Hammer, SM; Morse, GD; Squires, KE; Wu, H, 2003)	0.32
" For efavirenz, the concentrations at 12 hours and 24 hours (Cmin) after dosing were assessed."	( Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects. Aarnoutse, RE; Boyd, MA; Burger, DM; Cooper, DA; Lange, JM; Phanuphak, P; Ruxrungtham, K; Stek, M; van Heeswijk, RP, 2003)	0.32
"When EFV is coadministered with the GW433908 700 mg + RTV 100 mg BID regimen, no dosage adjustment is recommended."	( Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers. Ballow, C; Hendrix, CW; Lou, Y; Piliero, PJ; Preston, SL; Stein, DS; Wire, MB, 2004)	0.32
" PI-based therapies often fail due to poor adherence caused by heavy pill burden, complex dosing schedules and undesirable side effects."	( Clinical utility of current NNRTIs and perspectives of new agents in this class under development. Hamatake, R; Hong, Z; Zhang, Z, 2004)	0.32
" HIV type 1 (HIV-1)-infected patients receiving EFV or lopinavir-ritonavir (LPV/r) had 9 or 10 blood samples drawn over 8 to 24 h of a dosing interval at steady state before and after receiving 250 mg of VPA twice daily for 7 days."	( Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults. Cruttenden, K; DiCenzo, R; Gelbard, H; Morse, G; Peterson, D; Riggs, G; Schifitto, G, 2004)	0.32
" Blood samples were collected up to 24 h after dosing on days 10 (period 1) and 20 (period 2)."	( Effect of efavirenz treatment on the pharmacokinetics of nelfinavir boosted by ritonavir in healthy volunteers. Burger, DM; Colbers, EP; de Graaff-Teulen, MJ; Hekster, YA; Ibanez, SM; Koopmans, PP; la Porte, CJ; Voncken, DS, 2004)	0.32
" After the dosage of efavirenz was lowered, all neuropsychiatric symptoms subsided."	( Efavirenz intoxication due to slow hepatic metabolism. Bleiber, G; Günthard, HF; Hasse, B; Krause, M, 2005)	0.33
" ABC administered once daily in combination with 3TC and EFV administered once daily was non-inferior to the ABC twice-daily dosing schedule when combined with 3TC and EFV over 48 weeks."	( Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study. Cahn, P; Castillo, SA; Craig, C; DeJesus, E; Gordon, DN; Moyle, GJ; Scott, TR; Zhao, H, 2005)	0.33
"No adequate substitute for collecting blood 24 hours after dosing emerged from this analysis, which might explain the weak association observed between EFV plasma levels and treatment outcomes in the studies available."	( Therapeutic drug monitoring of efavirenz: trough levels cannot be estimated on the basis of earlier plasma determinations. López-Cortés, LF; Lucero-Muñoz, MJ; Marín-Niebla, A; Pascual-Carrasco, R; Rodríguez-Díez, M; Ruiz-Valderas, R, 2005)	0.33
" Plasma efavirenz levels can be reduced by rifampicin, but the appropriate daily dosage of efavirenz is unclear."	( Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. Kiertiburanakul, S; Mahanontharit, A; Manosuthi, W; Prasithsirikul, W; Rattanasiri, S; Ruxrungtham, K; Sankote, J; Sungkanuparph, S; Thakkinstian, A; Vibhagool, A, 2005)	0.33
" Plasma efavirenz levels were measured (at 12 h after dosing and on day 14) by high-performance liquid chromatography."	( Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. Kiertiburanakul, S; Mahanontharit, A; Manosuthi, W; Prasithsirikul, W; Rattanasiri, S; Ruxrungtham, K; Sankote, J; Sungkanuparph, S; Thakkinstian, A; Vibhagool, A, 2005)	0.33
"Venous blood samples from 10 HIV-infected patients receiving efavirenz (600 mg once a day plus two nucleoside reverse transcriptase inhibitors) were collected over the 24 h dosing interval."	( Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. Almond, LM; Back, DJ; Edirisinghe, D; Hoggard, PG; Khoo, SH, 2005)	0.33
" When atazanavir 300 mg was coadministered with ritonavir 100 mg on a once-daily dosage regimen, atazanavir AUC from 0 to 24 hours and minimum plasma concentration were increased by 3- to 4-fold and approximately 10-fold, respectively, compared with atazanavir 300 mg alone."	( Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Barrail, A; Goujard, C; Le Tiec, C; Taburet, AM, 2005)	0.33
" The optimal efavirenz dosage is still unclear."	( Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. Kiertiburanakul, S; Manosuthi, W; Rattanasiri, S; Ruxrungtham, K; Sungkanuparph, S; Thakkinstian, A; Vibhagool, A, 2006)	0.33
" Despite therapeutic drug monitoring and subsequent efavirenz dosage reductions, side-effects did not resolve completely and lopinavir concentrations remained relatively low."	( Genotyping of CYP2B6 and therapeutic drug monitoring in an HIV-infected patient with high efavirenz plasma concentrations and severe CNS side-effects. Hansen, AB; Justesen, US; Mathiesen, S; Von Lüttichau, HR, 2006)	0.33
"For moderately pre-treated HIV-infected patients with few mutations who switched to efavirenz from previous successful HAART, the proposed plasma efficacy-threshold was reached without any dosage adaptation."	( Intracellular and plasma efavirenz concentrations in HIV-infected patients switching from successful protease inhibitor-based highly active antiretroviral therapy (HAART) to efavirenz-based HAART (SUSTIPHAR Study). Breilh, D; Camou, F; Caubet, O; Djabarouti, S; Fleury, H; Lavit, M; Pellegrin, I; Pellegrin, JL; Saux, MC, 2006)	0.33
"The data show insufficient plasma concentrations for some children despite efavirenz dosing according to recommendations."	( Need for therapeutic drug monitoring in HIV-1 infected children receiving efavirenz doses according to international guidelines. Dunsch, D; Elanjikal, S; Funk, MB; Koenigs, C; Kreuz, W; Linde, R; von Hentig, N, 2006)	0.33
"Efavirenz is dosed once daily, and is generally administered in the evening owing to its central nervous system side-effects."	( Can efavirenz be taken in the morning? Maeland, A; Skeie, L, 2006)	0.33
" Individually, these agents have long half-lifes that allow for once-daily dosing and may provide a pharmacologic bridge for the occasional missed dose."	( Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all? Best, B; Goicoechea, M, 2007)	0.34
"Most antiretrovirals are metabolized in the liver, and lower dosing could be advisable in patients with severe liver insufficiency."	( Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. Barreiro, P; Gonzalez-Lahoz, J; Jiménez-Nácher, I; Labarga, P; Martín-Carbonero, L; Rodríguez-Novoa, S; Ruiz, A; Soriano, V, 2007)	0.34
" The method quantitates BUP and NBUP plasma concentrations within the range of expected values from current BUP dosing guidelines."	( Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users. DiFrancesco, R; Donnelly, J; Fischl, MA; Gripshover, B; McCance-Katz, EF; Moody, DE; Morse, GD; Reichman, RC; Zingman, BS, 2007)	0.34
"Efavirenz-containing regimens using concentration-controlled dosing have been shown to provide potent antiretroviral activity in children."	( High prevalence of subtherapeutic plasma concentrations of efavirenz in children. Egbers, C; Eley, BS; Maartens, G; McIlleron, HM; Meyers, TM; Nuttall, JJ; Ren, Y; Smith, PJ, 2007)	0.34
"Three consecutive blood samples were drawn between 12 and 24 hours after dosing in 15 HIV-infected children receiving the recommended daily doses of efavirenz."	( High prevalence of subtherapeutic plasma concentrations of efavirenz in children. Egbers, C; Eley, BS; Maartens, G; McIlleron, HM; Meyers, TM; Nuttall, JJ; Ren, Y; Smith, PJ, 2007)	0.34
"Our findings, together with those of previous studies, indicate that many children dosed according to the current guidelines do not achieve adequate efavirenz exposure."	( High prevalence of subtherapeutic plasma concentrations of efavirenz in children. Egbers, C; Eley, BS; Maartens, G; McIlleron, HM; Meyers, TM; Nuttall, JJ; Ren, Y; Smith, PJ, 2007)	0.34
" Efavirenz is administered once-daily and its simple dosing schedule improves adherence to therapy allowing for durability of the virologic and clinical responses."	( Efavirenz. Maggiolo, F, 2007)	0.34
" Although in vivo dosage form disintegration was faster for Tablet A as compared to Tablet B and was similar between Tablet A and the capsule, Tablet A showed a slower rate and extent of drug absorption than Tablet B and the capsule."	( Investigation of human pharmacoscintigraphic behavior of two tablets and a capsule formulation of a high dose, poorly water soluble/highly permeable drug (efavirenz). Benedek, IH; Digenis, GA; Doll, WJ; Fiske, WD; Gao, JZh; Gray, DA; Hussain, MA; Motheram, R; Page, RC; Sandefer, E, 2007)	0.34
"A novel, once-daily dosing regimen of 3 antiretroviral drugs, emtricitabine, didanosine, and efavirenz, was tested in 37 therapy-naive HIV-infected children and adolescents between 3 and 21 years of age (inclusive)."	( Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021. Abrams, E; Blum, MR; Britto, P; Chittick, GE; Cunningham, C; Dickover, R; Draper, L; Flynn, P; Hu, C; Hughes, M; Kraimer, J; McKinney, RE; Ortiz, AA; Rathore, M; Reynolds, L; Rodman, J; Scites, M; Serchuck, LK; Smith, ME; Spector, S; Tran, P; Weinberg, A; Yogev, R, 2007)	0.34
" This study evaluated the pharmacokinetics (PK) and bioequivalence of an investigational coformulation of EFV/FTC/TDF (test) single-tablet regimen compared with the commercially available individual dosage forms (EFV+FTC+TDF; reference treatment) in healthy subjects."	( Bioequivalence of efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen. Hinkle, J; Hui, J; Kaul, S; Kearney, BP; Mathias, AA; Menning, M, 2007)	0.34
" EFV dose was reduced in CYP2B6 516G-->T carriers who had high plasma EFV concentrations while receiving the standard dosage (600 mg)."	( Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 6 and 26. Fujimoto, K; Gatanaga, H; Gejyo, F; Hamaguchi, M; Hayashida, T; Horiba, M; Kimura, A; Kimura, S; Koike, T; Kuwahara, T; Matsushita, S; Oka, S; Sato, I; Shirasaka, T; Takata, N; Tsuchiya, K; Tsukada, H; Ueda, M; Yamamoto, M; Yoshino, M, 2007)	0.34
" When efavirenz (four patients) or a nucleoside analogue combination (one patient) was added, very little change in tacrolimus dosing was required."	( Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. Abbara, C; Barrail, A; Boissonnas, A; Bonhomme-Faivre, L; Duclos-Vallée, JC; Samuel, D; Taburet, AM; Teicher, E; Vincent, I; Vittecoq, D, 2007)	0.34
" Tacrolimus dosing must be optimised according to therapeutic drug monitoring and the antiretroviral drug combination."	( Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. Abbara, C; Barrail, A; Boissonnas, A; Bonhomme-Faivre, L; Duclos-Vallée, JC; Samuel, D; Taburet, AM; Teicher, E; Vincent, I; Vittecoq, D, 2007)	0.34
" The 400-mg qd efavirenz dose substantially reduced the steady-state mean voriconazole area under the curve over the dosing interval (AUC0-12) by 80% (90% confidence interval [CI], 75%-84%) and peak concentration (Cmax) by 66% (90% CI, 57%-73%)."	( Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects. Foster, G; Gutierrez, MJ; LaBadie, RR; Liu, P; Sharma, A, 2008)	0.35
" The results of the calculations revealed that the variant that survives in patients dosed with either nevirapine or efavirenz had a more positive Delta Delta G value than other variants that were not observed in patients."	( Energetic effects for observed and unobserved HIV-1 reverse transcriptase mutations of residues L100, V106, and Y181 in the presence of nevirapine and efavirenz. Franklin, AM; Jorgensen, WL; Rader, LH; Smith, KD; Smith, MB; Smith, RH; Taylor, EV; Tirado-Rives, J, 2008)	0.35
" TDM is useful to determine the best dosage regimen adapted to each patient."	( Determination of abacavir, amprenavir, didanosine, efavirenz, nevirapine, and stavudine concentration in human plasma by MALDI-TOF/TOF. Alonzi, T; Ascenzi, P; Mancone, C; Narciso, P; Notari, S; Tripodi, M, 2008)	0.35
" Sometimes literature references are submitted to the FDA to support dosing recommendations."	( Are literature references sufficient for dose recommendations? An FDA case study of efavirenz and rifampin. Chan-Tack, KM; DiGiacinto, JL; Reynolds, KS; Robertson, SM; Struble, KA, 2008)	0.35
"HIV-1-infected children received efavirenz capsules or tablets in accordance with manufacturer's dosing recommendations."	( Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children. Burger, D; Hoffmann, F; Huss, K; Jansson, A; Kurowski, M; Notheis, G; Wintergerst, U, 2008)	0.35
"In antiretroviral (ARV) therapy, pill burden, dosing frequency, and regimen complexity adversely affect adherence."	( Randomization to once-daily stavudine extended release/lamivudine/efavirenz versus a more frequent regimen improves adherence while maintaining viral suppression. Boyle, BA; Grimm, K; Jayaweera, D; Maa, JF; Seekins, DW; Witt, MD, )	0.13
" Pharmacokinetic profiles were also determined in HIV-1-infected patients dosed with raltegravir monotherapy versus raltegravir in combination with TDF and lamivudine."	( Lack of a significant drug interaction between raltegravir and tenofovir. Breidinger, SA; Chen, J; Friedman, EJ; Gottesdiener, KM; Iwamoto, M; Kost, JT; Lasseter, KC; Stek, JE; Stone, JA; Teppler, H; Wagner, JA; Wenning, LA, 2008)	0.35
" This case raises several significant questions regarding the adverse effects and dosing of this medication, including which patient characteristics predispose to efavirenz toxicity, the relevance of the CYP2B6 mutation, and indications for therapeutic drug monitoring."	( Status epilepticus resulting from severe efavirenz toxicity in an HIV-infected patient. Kwara, A; Nijhawan, AE; Venna, N; Zachary, KC, 2008)	0.35
"The pharmacokinetics of EFV and LPV/RTV in hemodialysis suggests that no dosing adjustments are necessary in treatment-naive patients."	( The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis. Amorosa, V; Cramer, YS; Gupta, SK; Hall, SD; Koletar, SL; Rosenkranz, SL; Szczech, LA, 2008)	0.35
"Our main objectives were to study the population pharmacokinetics of efavirenz and to explore the adequacy of dosing guidelines."	( A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations. Beijnen, JH; Bekker, V; Crommentuyn, KM; Huitema, AD; Kuijpers, TW; Scherpbier, HJ; ter Heine, R, 2008)	0.35
" Current dosing guidelines can result in subtherapeutic concentrations in children carrying the CYP2B6-516-G/G genotype and with the liquid formulation."	( A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations. Beijnen, JH; Bekker, V; Crommentuyn, KM; Huitema, AD; Kuijpers, TW; Scherpbier, HJ; ter Heine, R, 2008)	0.35
" The pharmacokinetic profile of GS-9160 in healthy human volunteers revealed that once-daily dosing was not likely to achieve antiviral efficacy; hence, the clinical development of this compound was discontinued."	( Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. Chen, J; Chen, X; Geleziunas, R; Hesselgesser, J; Jin, H; Jones, GS; Kim, CU; Tsiang, M; Wright, M; Yu, F; Zeynalzadegan, A, 2009)	0.35
" In addition, the detection and determination limits, reproducibility and applicability of the analysis to pharmaceutical dosage forms were also investigated."	( Voltammetric studies on the HIV-1 inhibitory drug Efavirenz: the interaction between dsDNA and drug using electrochemical DNA biosensor and adsorptive stripping voltammetric determination on disposable pencil graphite electrode. Dogan-Topal, B; Ozkan, SA; Uslu, B, 2009)	0.35
" Therefore, dosage adjustment in accordance with the type of polymorphism (CYP2B6, CYP2A6, or CYP3A4) is required in order to maintain EFV within the therapeutic target levels."	( Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Arab-Alameddine, M; Biollaz, J; Buclin, T; Cavassini, M; Csajka, C; Décosterd, LA; Di Iulio, J; Eap, CB; Fayet, A; Lubomirov, R; Rotger, M; Telenti, A, 2009)	0.35
" Pharmacokinetic studies of higher dosages of rifampin are urgently needed in children to assist in placing the dosage of rifampin used in childhood on a more scientific foundation."	( Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis. Cilliers, K; Donald, PR; Hussey, GD; Labadarios, D; Maritz, JS; McIlleron, H; Schaaf, HS; Smith, P; Willemse, M, 2009)	0.35
" The population model can be implemented in pharmacokinetic clinical software for dosage optimization by using the Bayesian approach."	( Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients. Cabrera, SE; Domínguez-Gil, A; García, MJ; González, F; Luna, G; Santos, D; Valverde, MP, 2009)	0.35
" Efavirenz and nevirapine concentrations at 12 h after dosing (C12) were monitored at weeks 6 and 12."	( A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Burapatarawong, S; Likanonsakul, S; Lueangniyomkul, A; Mankatitham, W; Manosuthi, W; Prasithsirskul, W; Prommool, V; Ruxrungtham, K; Sungkanuparph, S; Tantanathip, P; Thawornwa, U; Thongyen, S, 2009)	0.35
"Concerns have been raised about the possibility of subtherapeutic efavirenz (EFV) plasma levels in children with the current dosing guideline."	( Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children. Aurpibul, L; Cressey, TR; Puthanakit, T; Sirisanthana, V; Tanpaiboon, P, 2009)	0.35
"Current EFV dosing guidelines provide adequate plasma drug concentrations in Thai HIV-infected children."	( Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children. Aurpibul, L; Cressey, TR; Puthanakit, T; Sirisanthana, V; Tanpaiboon, P, 2009)	0.35
"To assess whether stepwise dosing of efavirenz decreases the incidence and severity of NPAEs while maintaining virologic efficacy."	( Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial. Gutiérrez-Valencia, A; López-Cortés, LF; Lozano, F; Palacios, R; Rivero, A; Ruiz-Valderas, R; Terrón, A; Viciana, P, 2009)	0.35
" An optimized dosing schedule that would place the highest percentage of children in the interval of effective and nontoxic concentrations was simulated."	( Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children? Diagbouga, S; Hien, H; Hirt, D; Msellati, P; Nacro, B; Olivier, M; Peyrière, H; Rouet, F; Tréluyer, JM; Urien, S; Van De Perre, P; Zoure, E, 2009)	0.35
"Multicenter, double-blind, randomized study of raltegravir (100, 200, 400, or 600 mg twice a day) vs efavirenz (600 mg every day), both with tenofovir/lamivudine (TDF/3TC), for 48 weeks, after which raltegravir arms were combined and all dosed at 400 mg twice a day."	( Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. Campbell, H; Crumpacker, CS; Danovich, RM; Gotuzzo, E; Isaacs, RD; Kovacs, C; Markowitz, M; Mendo, F; Morales-Ramirez, JO; Nguyen, BY; Prada, G; Ratanasuwan, W; Strohmaier, KM; Teppler, H; Wan, H, 2009)	0.35
" Fasting efavirenz concentrations at 12 h after dosing (C12) were monitored."	( Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin. Eampokarap, B; Kaewsaard, S; Lueangniyomkul, A; Mankatitham, W; Manosuthi, W; Ruxrungtham, K; Sungkanuparph, S; Suwanvattana, P; Tantanathip, P; Thongyen, S; Uttayamakul, S, 2009)	0.35
" After dosing with TPV/r for 10 days, EFV 600 mg once a day was added to the regimen."	( Lack of effect of efavirenz on the pharmacokinetics of tipranavir-ritonavir in healthy volunteers. Béïque, L; Cameron, DW; la Porte, CJ; Sabo, JP, 2009)	0.35
" Dosing convenience predicts adherence, and studies have demonstrated that patients can be switched from PI-based therapy to simplified, once-daily efavirenz-based regimens without losing virological control."	( Efavirenz: a decade of clinical experience in the treatment of HIV. Maggiolo, F, 2009)	0.35
"To determine the impact of once-nightly versus twice-daily dosing and beliefs about highly active antiretroviral therapy (HAART) on adherence to efavirenz-based HAART in antiretroviral-naive patients."	( The impact of once-nightly versus twice-daily dosing and baseline beliefs about HAART on adherence to efavirenz-based HAART over 48 weeks: the NOCTE study. Cooper, V; Fisher, M; Gellaitry, G; Horne, R; Lange, AC; Vrijens, B; White, D, 2010)	0.36
"The difference in adherence observed between once-nightly and twice-daily dosing was driven by a difference in persistence with treatment."	( The impact of once-nightly versus twice-daily dosing and baseline beliefs about HAART on adherence to efavirenz-based HAART over 48 weeks: the NOCTE study. Cooper, V; Fisher, M; Gellaitry, G; Horne, R; Lange, AC; Vrijens, B; White, D, 2010)	0.36
" These data suggest that 2 tablets of lopinavir-ritonavir BD may be inadequate when dosed with NNRTIs in Ugandan adults, and the dosage should be increased by the addition of an additional adult tablet or a half-dose tablet (100/25 mg), where available."	( Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults. Dickinson, L; Gibb, DM; Gilks, CF; Kayiwa, J; Khoo, S; Kityo, C; Lutwama, F; Munderi, P; Nalumenya, R; Reid, A; Ssali, F; Tumukunde, D; Walker, AS, 2010)	0.36
" Measurement of the patient's efavirenz plasma concentrations revealed a mean minimum steady-state concentration during a dosage interval (C(min,ss)) of 12."	( Long-term efficacy and safety of efavirenz dose reduction to 200 mg once daily in a Caucasian patient with HIV. Cabrera Figueroa, S; Cordero Sánchez, M; de la Paz Valverde Merino, M; Domínguez-Gil Hurlé, A; Iglesias Gómez, A; Sánchez Martín, A, 2010)	0.36
" Pharmacogenetic testing together with TDM links genotype to phenotypic differences in drug concentrations and adverse events, providing additional support for dosage adjustment and a more efficient use of both approaches."	( The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy. Bustos Bernal, C; Cabrera Figueroa, S; Domínguez-Gil Hurlé, A; Fernández de Gatta, M; García Sánchez, MJ; Hernández García, L; Sepúlveda Correa, R, 2010)	0.36
" After receiving the standard efavirenz dosage of 600 mg daily, the patient had subtherapeutic plasma efavirenz concentrations."	( Decreased plasma efavirenz concentrations in a patient receiving rifabutin. Hill, CJ; Hsu, O; Kim, M; O'Brien, JG; Tan, B, 2010)	0.36
" These findings may have relevance to pharmacokinetics and dosing of efavirenz in African populations."	( Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in the UK: implications for efavirenz dosing in HIV infection. Andrews, S; Holt, DW; Jamshidi, Y; McKeown, DA; Moreton, M; Nithiyananthan, T; Sadiq, ST; Tinworth, L, 2010)	0.36
"Lersivirine appeared to be well tolerated after 28 days of continuous dosing in this small, selected group of young, healthy male volunteers."	( Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers. Choo, H; Davis, J; Goodrich, J; Hackman, F; Langdon, G; Lewis, D; Ndongo, MN; Tawadrous, M, 2010)	0.36
" In turn, ART commonly requires complex dosing schedules and leads to the emergence of viral resistance and treatment failures."	( Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. Balkundi, S; Bronich, T; Gendelman, HE; Kabanov, AV; Kanmogne, G; Martinez-Skinner, A; McMillan, J; Mosley, RL; Nowacek, AS; Roy, U, 2011)	0.37
"No data on once-daily dosing of nucleoside analogues in African children currently exist."	( Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial. Adkison, K; Bakeera-Kitaka, S; Burger, D; Gibb, DM; Kekitiinwa, A; Kendall, L; Mugyenyi, P; Musiime, V; Musoke, P; Odongo, F; Snowden, WB; Thomason, M; Walker, AS, 2010)	0.36
" For both children and caregivers, once-daily dosing of lamivudine plus abacavir was highly acceptable and strongly preferred over twice-daily."	( Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial. Adkison, K; Bakeera-Kitaka, S; Burger, D; Gibb, DM; Kekitiinwa, A; Kendall, L; Mugyenyi, P; Musiime, V; Musoke, P; Odongo, F; Snowden, WB; Thomason, M; Walker, AS, 2010)	0.36
" Once-daily dosing of abacavir and lamivudine could provide an alternative dosing strategy for HIV-1-infected children, with high acceptability and strong preference suggesting the potential for improved adherence."	( Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial. Adkison, K; Bakeera-Kitaka, S; Burger, D; Gibb, DM; Kekitiinwa, A; Kendall, L; Mugyenyi, P; Musiime, V; Musoke, P; Odongo, F; Snowden, WB; Thomason, M; Walker, AS, 2010)	0.36
"All randomised controlled trials comparing EFV to NVP in HIV-infected individuals without prior exposure to ART, irrespective of the dosage or NRTI backbone."	( Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Irlam, JH; Mbuagbaw, LC; Rutherford, GW; Siegfried, N; Spaulding, A, 2010)	0.36
" Data were analysed on an intention-to-treat basis and reported as per dosage of NVP."	( Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Irlam, JH; Mbuagbaw, LC; Rutherford, GW; Siegfried, N; Spaulding, A, 2010)	0.36
"The trials were pooled as per dosage of NVP."	( Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Irlam, JH; Mbuagbaw, LC; Rutherford, GW; Siegfried, N; Spaulding, A, 2010)	0.36
"This study aimed to test whether a pharmacokinetic simulation model could extrapolate nonclinical drug data to predict human efavirenz exposure after single and continuous dosing as well as the effects of concomitant rifampicin and further to evaluate the weight-based dosage recommendations used to counteract the rifampicin-efavirenz interaction."	( In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype. Ashton, M; Mukonzo, J; Rekić, D; Röshammar, D, 2011)	0.37
" Decreases in estimated glomerular filtration rate occurred within the first few weeks of dosing in participants receiving EVG/COBI/FTC/TDF, remained within the normal range and did not progress at week 24 or 48; no participant experienced a clinical adverse event or discontinued study drug due to changes in serum creatinine or renal function."	( Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. Chuck, SL; Cohen, C; DeJesus, E; Elion, R; Kearney, BP; Liu, HC; Ramanathan, S; Rashbaum, B; Ruane, P; Shamblaw, D; Warren, DR; Yale, K, 2011)	0.37
" The peak plasma concentration (C(max)), area under the concentration-time curve for a dosing interval (AUC([τ])), and lowest plasma concentration (C(min)) for EE and NGMN during cycles of treatment with Ortho Cyclen with and without coadministration of efavirenz were compared."	( The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women. Bertz, R; Eley, T; Garner, D; Krantz, K; Nettles, R; Persson, A; Sevinsky, H; Yones, C; Zhang, J, 2011)	0.37
"There are potential benefits to individualizing dosage in patients treated with efavirenz (EFV)."	( Successful efavirenz dose reduction guided by therapeutic drug monitoring. Buclin, T; Calmy, A; Cavassini, M; Decosterd, LA; Delhumeau, C; di Iulio, J; Fayet Mello, A; Fleurent, A; Hirschel, B; Schneider, MP; Telenti, A, 2011)	0.37
" All consenting participants with EFV concentrations above P75 on standard dosage were included in a dose-reduction cycle."	( Successful efavirenz dose reduction guided by therapeutic drug monitoring. Buclin, T; Calmy, A; Cavassini, M; Decosterd, LA; Delhumeau, C; di Iulio, J; Fayet Mello, A; Fleurent, A; Hirschel, B; Schneider, MP; Telenti, A, 2011)	0.37
"Among the 3 trials, 522 subjects were treated with FTC dosed once daily and 841 subjects were treated with 3TC dosed twice daily."	( Reduced emergence of the M184V/I resistance mutation when antiretroviral-naïve subjects use emtricitabine versus lamivudine in regimens composed of two NRTIs plus the NNRTI efavirenz. Borroto-Esoda, K; Chen, SS; Harris, J; Margot, N; McColl, DJ; Miller, MD, )	0.13
" Body weight and genetic factors will be important covariates in dosing algorithms."	( Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteers. Court, MH; Dumond, JB; Greenblatt, DJ; Kashuba, AD; Kurpewski, J; Kwara, A; Poethke, P; Tashima, KT, 2011)	0.37
"Individuals from the CIPRA-South Africa cohort taking EFV-based antiretroviral therapy with concomitant tuberculosis (TB) were dosed with either increased (800 mg) or standard (600 mg) dose EFV during TB treatment."	( Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy? Cohen, K; Conradie, F; Ive, P; Orrell, C; Sanne, I; Wood, R; Zeinecker, J, 2011)	0.37
" Lopinavir was active at levels well below those achieved with standard dosing of coformulated lopinavir-ritonavir."	( In vitro activity of antiretroviral drugs against Plasmodium falciparum. Nsanzabana, C; Rosenthal, PJ, 2011)	0.37
"To evaluate international pediatric efavirenz dosing recommendations using full pharmacokinetic (PK) information."	( Pediatric underdosing of efavirenz: a pharmacokinetic study in Uganda. Balungi, J; Burger, DM; Bwakura-Dangarembizi, M; Ferrier, A; Fillekes, Q; Gibb, DM; Keishanyu, R; Kendall, L; Lutakome, J; Natukunda, E; Walker, AS, 2011)	0.37
"African children aged 3-12 years, on efavirenz dosed according to 2006 WHO/manufacturer's recommendations, had lower and highly variable efavirenz PK parameters compared with adult data from manufacturer's leaflet."	( Pediatric underdosing of efavirenz: a pharmacokinetic study in Uganda. Balungi, J; Burger, DM; Bwakura-Dangarembizi, M; Ferrier, A; Fillekes, Q; Gibb, DM; Keishanyu, R; Kendall, L; Lutakome, J; Natukunda, E; Walker, AS, 2011)	0.37
" Information on how polymorphisms influence drug metabolism and transport to target sites is important in guiding dosage or selection of appropriate alternative therapies."	( Prevalence of MDR1 C3435T and CYP2B6 G516T polymorphisms among HIV-1 infected South African patients. Bessong, PO; Masebe, TM; Meyer, D; Ndip, RN; Nwobegahay, J, 2012)	0.38
" Because a dose-response relationship was not identified, a second study examined a lower, 30-mg QD dose in 8 subjects (6 active and 2 placebo)."	( Safety and efficacy of GSK2248761, a next-generation nonnucleoside reverse transcriptase inhibitor, in treatment-naive HIV-1-infected subjects. Dudas, K; Dumont, E; Kim, J; Lou, Y; Mayers, D; Pietropaolo, K; Piscitelli, S; St Clair, M; White, S; Zala, C; Zhou, XJ, 2012)	0.38
" The significant reduction in the AUC of 5-hydroxyomeprazole after repeated efavirenz dosing suggests induction of sequential metabolism and mixed inductive/inhibitory effects of efavirenz on CYP2C19."	( Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers. Aregbe, AO; Desta, Z; Flockhart, DA; Michaud, V; Ogburn, E; Quigg, TC; Thong, N, 2012)	0.38
" Observed ART dosing took place for at least 2 weeks."	( Untreated HIV infection is associated with higher blood alcohol levels. Beatty, G; Gruber, VA; Lum, PJ; McCance-Katz, EF; Peters, M; Rainey, PM, 2012)	0.38
" Adherence by type of ART and dosing frequency were compared by Brown-Mood median tests."	( Impact of antiretroviral dosing frequency and pill burden on adherence among newly diagnosed, antiretroviral-naive HIV patients. Buscher, A; Giordano, TP; Hartman, C; Kallen, MA, 2012)	0.38
"We determined the pharmacokinetics of efavirenz in plasma and cerebrospinal fluid (CSF) over a 24-h dosing interval in a patient who had undergone a lumbar drain because of cryptococcal meningitis."	( Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval. Back, D; Dickinson, L; Watson, V; Yilmaz, A, 2012)	0.38
" To identify risk factors for nonoptimal anticoagulation and to determine if warfarin dosing is differentially affected by specific antiretroviral agents."	( Warfarin therapy in the HIV medical home model: low rates of therapeutic anticoagulation despite adherence and differences in dosing based on specific antiretrovirals. Anderson, AM; Chane, T; Chen, S; Easley, KA; Patel, M; Xue, W, 2012)	0.38
" RPV is dosed once daily with food and has been coformulated into a single tablet containing tenofovir and emtricitabine."	( Rilpivirine, a novel non-nucleoside reverse transcriptase inhibitor for the management of HIV-1 infection: a systematic review. Schafer, JJ; Short, WR, 2012)	0.38
" However, the observed modest changes probably do not warrant dosage adjustment during co-administration of AL with EFV."	( Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers. Aweeka, FT; Dorsey, G; Havlir, D; Huang, L; Lizak, P; Marzan, F; Parikh, S; Rosenthal, PJ, 2012)	0.38
" Neuropsychometric testing with drowsiness visual analogue scale, grooved pegboard and letter digit substitution tests was done the day prior to dosing and at 1, 2, 3, 4 and 6 h post-dose."	( Neuropsychometric correlates of efavirenz pharmacokinetics and pharmacogenetics following a single oral dose. Acosta, EP; Gebretsadik, T; Haas, DW; Johnson, DH; Mayo, G; Shintani, A; Stein, CM, 2013)	0.39
" Strategies that lower Cmax during initial dosing may decrease CNS side effects."	( Neuropsychometric correlates of efavirenz pharmacokinetics and pharmacogenetics following a single oral dose. Acosta, EP; Gebretsadik, T; Haas, DW; Johnson, DH; Mayo, G; Shintani, A; Stein, CM, 2013)	0.39
" Model-predicated area under the concentration-time curve during the dosing interval (AUC(τ)) and exposure ratios of CVF AUC(τ):BP AUC(τ) were calculated for each drug."	( Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women. Cohen, MS; Dumond, JB; Forrest, A; Garonzik, SM; Kashuba, AD; Kendrick, RN; Nicol, MR; Patterson, KB, 2012)	0.38
" Through dose-response experiments, we established relative inhibitory potencies of NRTIs on in vitro telomerase activity as compared to the inhibitory potencies of the corresponding dideoxynucleotide triphosphates."	( In vitro and ex vivo inhibition of human telomerase by anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs) but not by non-NRTIs. Côté, HC; Hukezalie, KR; Thumati, NR; Wong, JM, 2012)	0.38
"Timed plasma samples obtained throughout the dosing interval were analyzed for efavirenz concentrations with liquid chromatography/tandem mass spectrometry."	( Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor. Chaikan, A; Cortes, CP; la Porte, CJ; Owen, A; Siccardi, M; Zhang, G, 2013)	0.39
"Literature data pertaining to the decision to allow a waiver of in vivo bioequivalence testing for the approval of immediate-release (IR) solid oral dosage forms containing efavirenz as the only active pharmaceutical ingredient (API) are reviewed."	( Biowaiver monographs for immediate release solid oral dosage forms: efavirenz. Abrahamsson, B; Cristofoletti, R; Dressman, JB; Groot, DW; Kopp, S; Langguth, P; Nair, A; Polli, JE; Shah, VP, 2013)	0.39
" Using available pharmacokinetic data, an EFV dosing schedule was developed for young co-infected children and implemented as the standard of care at Macha Hospital in Southern Province, Zambia."	( Effectiveness of efavirenz-based regimens in young HIV-infected children treated for tuberculosis: a treatment option for resource-limited settings. Bositis, C; Hamangaba, F; Moss, WJ; Sutcliffe, CG; van Dijk, JH; Watson, DC, 2013)	0.39
" Blood plasma (for TFV, FTC, EFV, ATV and RTV concentrations) and peripheral blood mononuclear cells [PBMCs; for tenofovir diphosphate (TFV-DP) and emtricitabine triphosphate (FTC-TP) concentrations] were collected at 11 time-points over a 24-hour dosing interval."	( Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study. Adams, JL; Corbett, AH; Dumond, JB; Forrest, A; Jennings, SH; Kashuba, AD; Kendrick, RL; Malone, S; Patterson, KB; Prince, HM; Sykes, C; Wang, R; White, N, 2013)	0.39
" Evaluation in clinical trials of adjusted regimens is necessary to ensure appropriate dosing for HIV-infected TB patients on an EFV-based regimen."	( Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis. Aweeka, F; Dooley, KE; Karlsson, MO; Marzan, F; Park, JG; Svensson, EM, 2013)	0.39
" These data do not support weight-based dosing of EFV with RIF."	( Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Aweeka, F; Benson, CA; Grinsztejn, B; Havlir, DV; Hogg, E; Ive, P; Lu, D; Luetkemeyer, AF; Marzan, F; Rosenkranz, SL; Sanne, IM; Swindells, S, 2013)	0.39
"Regimen simplification can be defined as a change in established effective therapy to reduce pill burden and dosing frequency, to enhance tolerability, or to decrease specific food and fluid requirements."	( Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV. Bosco, O; Cruciani, M; Malena, M; Mengoli, C; Parisi, SG; Serpelloni, G, 2013)	0.39
" SJS can occur in children at any age, with any level of immunosuppression, and can occur during the lead-in dosing period of NVP."	( Stevens-Johnson syndrome and HIV in children in Swaziland. Blank, DA; Draper, HR; Dziuban, EJ; Hughey, AB; Kochelani, D; Schutze, GE; Stewart, DA, 2013)	0.39
" However, the clinical utility or validity of introducing genotype-assisted dosing is not known."	( High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients. Dandara, C; Ren, Y; Skelton, M; Smith, P; Swart, M; Takuva, S, 2013)	0.39
"Screening for CYP2B6 516G>T SNP has a high specificity and positive predictive value for efavirenz levels above 4 µg/ml and could be used in deciding on efavirenz dosage among individuals homozygous for this variant, which could lead to better precision medication."	( High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients. Dandara, C; Ren, Y; Skelton, M; Smith, P; Swart, M; Takuva, S, 2013)	0.39
" Area under the curve over the dosing interval (AUC24h) and trough concentration (C0h) were estimated using a population pharmacokinetic model and compared with previous results using the 200-mg twice-daily dosage."	( Pharmacokinetics and pharmacodynamics of etravirine 400 mg once daily in treatment-naïve patients. Bickel, M; Di Perri, G; Faetkenheuer, G; Green, B; Hill, A; Kakuda, T; Kurowski, M; Morrish, G; van Delft, Y, )	0.13
"In the SENSE trial, etravirine 400 mg once daily achieved similar exposures to historical reference data on etravirine when dosed at 200 mg twice daily."	( Pharmacokinetics and pharmacodynamics of etravirine 400 mg once daily in treatment-naïve patients. Bickel, M; Di Perri, G; Faetkenheuer, G; Green, B; Hill, A; Kakuda, T; Kurowski, M; Morrish, G; van Delft, Y, )	0.13
" No clinically relevant interactions between daclatasvir and tenofovir disoproxil fumarate were observed for either drug, and no dosing adjustments were indicated."	( Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. Bertz, R; Bifano, M; Grasela, D; Hartstra, J; Hwang, C; Kandoussi, H; Oosterhuis, B; Sevinsky, H; Tiessen, R; Velinova-Donga, M, 2013)	0.39
" However, no orally dosed HIV nanomedicines are available clinically to patients."	( Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation. Curley, P; Foster, AJ; Giardiello, M; Khoo, SH; Liptrott, NJ; Long, J; Martin, P; McDonald, TO; Owen, A; Rannard, SP; Roberts, P; Schipani, A; Siccardi, M; Smith, D, 2014)	0.4
" The developed model may serve as the foundation for further exploration of pharmacogenetic-based dosing of EFV."	( Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz. Abdelhady, AM; Desta, Z; Jiang, F; Overholser, BR; Shin, JG; Yeo, CW, 2014)	0.4
"At weeks 12 and 24, all 49 dosed subjects remained suppressed on RPV/FTC/TDF."	( Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens. Brinson, C; Cheng, AK; Chuck, SK; Cohen, C; Dejesus, E; Mills, AM; Ramanathan, S; Wang, MH; White, K; Williams, S; Yale, KL, )	0.13
" Plasma efavirenz concentrations 12 h after dosing were measured using a validated high-performance liquid chromatography."	( Low level of efavirenz in HIV-1-infected Thai adults is associated with the CYP2B6 polymorphism. Chamnanphol, M; Jantararoungtong, T; Koomdee, N; Manosuthi, W; Prommas, S; Puangpetch, A; Santon, S; Sukasem, C; Sungkanuparph, S, 2014)	0.4
" At 12 weeks after ART, plasma efavirenz concentrations at 12h after dosing were measured."	( CYP2B6 haplotype and biological factors responsible for hepatotoxicity in HIV-infected patients receiving efavirenz-based antiretroviral therapy. Lueangniyomkul, A; Mankatitham, W; Manosuthi, S; Manosuthi, W; Nilkamhang, S; Sukasem, C; Sungkanuparph, S; Thongyen, S, 2014)	0.4
"Differences in drug metabolism due to cytochrome P450 (CYP) polymorphisms may be significant enough to warrant different dosing strategies in carriers of specific cytochrome P450 (CYP) polymorphisms, especially for drugs with a narrow therapeutic index."	( Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz. Chetty, M; Chetty, VV; Naidoo, P, 2014)	0.4
" The corresponding dosing strategies developed for carriers of specific CYP2B6 genotypes were also reviewed."	( Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz. Chetty, M; Chetty, VV; Naidoo, P, 2014)	0.4
" Ethnic differences and the associated prevalence of CYP2B6 polymorphisms result in significant differences in the PKPD associated with a standard 600 mg per day dose of EFV, warranting dosage reduction in carriers of specific CYP2B6 polymorphisms."	( Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz. Chetty, M; Chetty, VV; Naidoo, P, 2014)	0.4
"Using EFV as an example of a drug with a narrow therapeutic index and a high inter-patient variability in plasma concentrations corresponding to a standard dose of the drug, this review demonstrates how genotyping of the primary metabolising enzyme can be useful for appropriate dosage adjustments in individuals."	( Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz. Chetty, M; Chetty, VV; Naidoo, P, 2014)	0.4
" At 12 and 24 weeks after antiretroviral therapy, plasma efavirenz concentrations at 12 h after dosing were measured."	( CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype 1/1. Manosuthi, S; Manosuthi, W; Nilkamhang, S; Sukasem, C; Sungkanuparph, S; Thongyen, S, 2014)	0.4
"The individualization of EFV dosage guided by genotyping 516G>T CYP2B6 and therapeutic drug monitoring could increase the efficiency of EFV use in antiretroviral treatment."	( Dose reduction of efavirenz: an observational study describing cost-effectiveness, pharmacokinetics and pharmacogenetics. Calvo Hernández, MV; Figueroa, SC; García-Berrocal, B; Gómez, AI; Gonzalez-Buitrago, JM; Isidoro-García, M; Martín, AF; Martín, AS; Sánchez, MC; Tovar, CB; Valverde Merino, MP, 2014)	0.4
" Pharmacokinetic sampling occurred at the end of each dosing period."	( Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin. Allen, R; Aweeka, F; Bao, J; Cramer, Y; Dooley, KE; Haas, DW; Koletar, SL; Luetkemeyer, AF; Marzan, F; Murray, S; Park, JG; Savic, R; Sutherland, D, 2014)	0.4
" A PAS population pharmacokinetic model in two dosing regimens was developed; potential covariates affecting its pharmacokinetics were examined, and Monte Carlo simulations were conducted evaluating the pharmacokinetic-pharmacodynamic index."	( Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis. de Kock, L; Derendorf, H; Diacon, AH; Donald, PR; Hernandez, KR; Prescott, K; Rosenkranz, B; Sy, SK; Yu, M, 2014)	0.4
" EFV concentrations from DBS were approximately 42% lower than the paired plasma values, and the ratio of blood/plasma did not change over the dosing interval."	( A validated method for quantification of efavirenz in dried blood spots using high-performance liquid chromatography-mass spectrometry. Amara, AB; Back, DJ; Else, LJ; Khoo, S; Olagunju, A; Puls, RL; Tjia, J, 2015)	0.42
" This modelling technique is able to inform the design of clinical studies, and allows assessment of pragmatic dosing strategies under complex therapeutic scenarios."	( Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapine. Back, D; Davies, G; Khoo, S; Owen, A; Schipani, A; Siccardi, M, 2015)	0.42
" Therefore, no efavirenz dosage adjustment during rifampicin cotreatment is required in Ugandans."	( CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure. Aklillu, E; Gustafson, LL; Mukonzo, JK; Nanzigu, S; Ogwal-Okeng, J; Waako, P, 2014)	0.4
" Polymorphisms in important drug metabolizing enzymes and the implications for EFV dosing were investigated."	( Efavirenz dosing: influence of drug metabolizing enzyme polymorphisms and concurrent tuberculosis treatment. Abdool Karim, SS; Botha, JH; Gengiah, TN; Naidoo, K; Yende-Zuma, N, 2015)	0.42
" Whether standard antiretroviral drug dosage is adequate in heavy individuals remains unresolved."	( Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults. Ammassari, A; Battegay, M; Bonora, S; Burger, D; Chêne, G; Dauchy, FA; Fehr, J; Ghosn, J; Gianotti, N; Gogos, C; Grarup, J; Launay, O; Marzolini, C; Mocroft, A; Mussini, C; Obel, N; Raffi, F; Roca, B; Sabin, C; Siccardi, M; Torti, C; Zangerle, R, 2015)	0.42
"Virological and immunological responses to initial EFV-containing regimens were not impaired in heavy individuals, suggesting that the standard 600 mg EFV dosage is appropriate across a wide weight range."	( Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults. Ammassari, A; Battegay, M; Bonora, S; Burger, D; Chêne, G; Dauchy, FA; Fehr, J; Ghosn, J; Gianotti, N; Gogos, C; Grarup, J; Launay, O; Marzolini, C; Mocroft, A; Mussini, C; Obel, N; Raffi, F; Roca, B; Sabin, C; Siccardi, M; Torti, C; Zangerle, R, 2015)	0.42
" Geometric mean CSF efavirenz, 7OH-, and 8OH-efavirenz concentrations (with 90% confidence intervals [CIs]) for the 400-mg and 600-mg dosing groups were 16."	( Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trial. Amara, A; Amin, J; Avihingsanon, A; Avinghsanon, A; Barber, T; Chetchotisakd, P; Clarke, A; Cooper, DA; Else, L; Emery, S; Jessen, H; Khoo, S; Owen, A; Puls, R; Winston, A, 2015)	0.42
" In conclusion, this genotypic resistance analysis strongly suggests that the latest NNRTI, rilpivirine, may retain activity in a large proportion of HIV-1 patients in whom resistance failed while they were on an efavirenz- or nevirapine-containing regimen, and may present an attractive option for second-line treatment given its good safety profile and dosing convenience."	( Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine. Camacho, RJ; Gomes, P; Rhee, SY; Theys, K; Vandamme, AM, 2015)	0.42
" Here, we used mass spectrometry imaging with infrared matrix-assisted laser desorption-electrospray ionization to quantify the distribution of efavirenz within tissues from a macaque dosed orally to a steady state."	( Mass spectrometry imaging reveals heterogeneous efavirenz distribution within putative HIV reservoirs. Adamson, L; Bokhart, MT; Fedoriw, Y; Kashuba, AD; Luciw, PA; Muddiman, DC; Rosen, EP; Sykes, C; Thompson, CG, 2015)	0.42
" Infant plasma concentrations did not change significantly during the dosing interval, 157 ng/mL (28."	( Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational study. Adejuyigbe, E; Amara, A; Back, D; Bolaji, O; Else, L; Khoo, S; Olagunju, A; Owen, A; Siccardi, M; Waitt, C, 2015)	0.42
" This study used population pharmacokinetics modeling to explore the influence of demographic and pharmacogenetic factors including efavirenz-rifampicin interaction on EFV pharmacokinetics, towards safer dosing of EFV."	( CYP2B66, CYP2B618, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe. Chonzi, P; Dhoro, M; Kadzirange, G; Masimirembwa, C; Ngara, B; Nhachi, C; Zvada, S, 2015)	0.42
" Optimal lumefantrine dosage regimen for patients on EFV-based ART was determined by population pharmacokinetics and simulation."	( The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2015)	0.42
" The predictive model through simulation of lumefantrine exposure at different dosage regimen scenarios for patients on EFV-based ART, suggest that AL taken twice daily for five days using the current dose could improve lumefantrine exposure and consequently malaria treatment outcomes."	( The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2015)	0.42
" The impact of HAART on imatinib may depend on whether it is being initiated or has already been dosed chronically in patients."	( Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation. Beumer, JH; Christner, SM; Kiesel, BF; Parise, RA; Pillai, VC; Rudek, MA; Venkataramanan, R, 2015)	0.42
" Simulations for a normalized population receiving US Food and Drug Administration weight-band dosing predicted that 15% of children would have a C12 below target threshold (<1."	( Efavirenz Concentrations and Probability of HIV Replication in Children. Aurpibul, L; Bouazza, N; Chanta, C; Cressey, TR; Homkham, N; Ingsrisawang, L; Jourdain, G; Kamonpakorn, N; Krikajornkitti, S; Lallemant, M; Narkbunnam, T; Salvadori, N; Treluyer, JM; Urien, S, 2015)	0.42
" EFV area under the plasma concentration-time curve over 1 dosing interval from time 0 to 24 hours postdose values were generally suboptimal (<110 μM × h) in subjects younger than 3 years treated with oral solution; these subjects switched to capsule sprinkle."	( Efavirenz Capsule Sprinkle and Liquid Formulations With Didanosine and Emtricitabine in HIV-1-infected Infants and Children 3 Months to 6 Years of Age: Study AI266-922. Biguenet, S; Bunupuradah, T; Krystal, M; Lataillade, M; Pavia-Ruz, N; Rossouw, M; Sáez-Llorens, X; Seekins, D; Sevinsky, H; Taylor, M; Yang, R, 2015)	0.42
" Absence of hypersensitivity reactions, superior resistance profile and once-daily dosing favours abacavir for African children, supporting WHO 2013 guidelines."	( Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial. Abongomera, G; Asiimwe, A; Burger, D; Chabala, C; Chintu, C; Cook, AD; Gibb, DM; Kekitiinwa, A; Kenny, J; Kityo, C; Klein, N; McIlleron, H; Mirembe, G; Mulenga, V; Musiime, V; Owen-Powell, E; Thomason, MJ; Walker, AS, 2016)	0.43
" The erosion and drug release kinetics from organogels under conventional (filling gelatin capsules) or multiparticulate (beads obtained by prilling) dosage forms were measured in simulated gastric and intestinal fluids."	( Factors influencing the erosion rate and the drug release kinetics from organogels designed as matrices for oral controlled release of a hydrophobic drug. Franceschi, S; Girod Fullana, S; Pereira Camelo, SR; Perez, E; Ré, MI, 2016)	0.43
"To assess the cost-effectiveness of CYP2B6 genotyping to guide efavirenz dosing for initial HIV therapy in the USA."	( Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice. Freedberg, KA; Haas, DW; Li, XC; Park, SS; Schackman, BR, 2015)	0.42
"Current care without CYP2B6 genotyping has an incremental cost-effectiveness ratio >$100,000/QALY compared with genotype-guided dosing, even if lower dosing reduces efficacy."	( Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice. Freedberg, KA; Haas, DW; Li, XC; Park, SS; Schackman, BR, 2015)	0.42
"CYP2B6 genotyping can inform efavirenz dosing and decrease HIV therapy cost."	( Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice. Freedberg, KA; Haas, DW; Li, XC; Park, SS; Schackman, BR, 2015)	0.42
"9% for the GG genotype (reduced dosage required), 36."	( Prevalence of CYP2B6 polymorphisms in Argentinians: the role of genetic testing. Argibay, PF; Belloso, WH; Cajal, AR; Scibona, P; Vazquez, C, 2015)	0.42
" The population pharmacokinetic-pharmacodynamic (PK-PD) model shows that favorable HDL cholesterol changes can be expected in children with current efavirenz dosing guidelines over 5 years of treatment."	( A Population Pharmacokinetic/Pharmacodynamic Model Predicts Favorable HDL Cholesterol Changes Over the First 5 Years in Children Treated With Current Efavirenz-Based Regimens. Bhakeecheep, S; Bouazza, N; Coeur, SL; Cressey, TR; Homkham, N; Hongsiriwon, S; Ingsrisawang, L; Jourdain, G; Kanjanavanit, S; Ngampiyaskul, C; Salvadori, N; Srirojana, S; Treluyer, JM; Urien, S, 2016)	0.43
"Twenty-nine subjects completed both dosing cohorts."	( Efavirenz but Not Atazanavir/Ritonavir Significantly Reduces Atovaquone Concentrations in HIV-Infected Subjects. Alfaro, RM; Calderón, MM; Kovacs, JA; Kumar, P; McManus, M; Pau, AK; Penzak, SR, 2016)	0.43
"Population pharmacokinetic (PopPK) analyses often rely on steady state and full adherence to prescribed dosage regimen assumptions from data gathered during therapeutic drug monitoring (TDM)."	( Comparison of Population Pharmacokinetics Based on Steady-State Assumption Versus Electronically Monitored Adherence to Lopinavir, Atazanavir, Efavirenz, and Etravirine: A Retrospective Study. Buclin, T; Bugnon, O; Cavassini, M; Csajka, C; Fuchs, A; Rotzinger, A; Schneider, MP, 2016)	0.43
"Published PopPK models for lopinavir, atazanavir, efavirenz, and etravirine were applied to estimate PK parameters and individual concentrations in 140 HIV patients taking part in a medication adherence program using 2 dosing data sets."	( Comparison of Population Pharmacokinetics Based on Steady-State Assumption Versus Electronically Monitored Adherence to Lopinavir, Atazanavir, Efavirenz, and Etravirine: A Retrospective Study. Buclin, T; Bugnon, O; Cavassini, M; Csajka, C; Fuchs, A; Rotzinger, A; Schneider, MP, 2016)	0.43
"Clearance estimates and likewise predicted concentrations did not markedly differ between the 2 dosing histories."	( Comparison of Population Pharmacokinetics Based on Steady-State Assumption Versus Electronically Monitored Adherence to Lopinavir, Atazanavir, Efavirenz, and Etravirine: A Retrospective Study. Buclin, T; Bugnon, O; Cavassini, M; Csajka, C; Fuchs, A; Rotzinger, A; Schneider, MP, 2016)	0.43
"PopPK analysis assuming steady state with full adherence produced similar results to those based on detailed electronic dosing history reconciled with patients' allegations."	( Comparison of Population Pharmacokinetics Based on Steady-State Assumption Versus Electronically Monitored Adherence to Lopinavir, Atazanavir, Efavirenz, and Etravirine: A Retrospective Study. Buclin, T; Bugnon, O; Cavassini, M; Csajka, C; Fuchs, A; Rotzinger, A; Schneider, MP, 2016)	0.43
"Around 450 and 250 mg daily doses might meet EFV dosing needs of HIV-TB infected Ugandans in general and CYP2B66/6 genotypes, respectively."	( CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population. Aklillu, E; Bisaso, RK; Gustafsson, LL; Mukonzo, JK; Ogwal-Okeng, J; Owen, JS, 2016)	0.43
" Further evaluation of the impact of CYP2B6 polymorphisms on EFV PK showed that the identification of CYP2B6 genetic status is not predictive of EFV exposure and thus not informative to guide pediatric dosing regimens."	( Population Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years. Bertz, R; Chapel, S; Cirincione, B; Luo, M; Roy, A; Savant, I; Sevinsky, H, 2016)	0.43
" The DDI risk for cobimetinib with other CYP3A4 inhibitors and inducers needs to be assessed in order to provide dosing instructions."	( Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation. Budha, NR; Chen, Y; Dresser, M; Eppler, S; Ji, T; Jin, JY; Musib, L, 2016)	0.43
"This study demonstrates the value of using PBPK simulation to assess the clinical DDI risk inorder to provide dosing instructions with other CYP3A4 perpetrators."	( Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation. Budha, NR; Chen, Y; Dresser, M; Eppler, S; Ji, T; Jin, JY; Musib, L, 2016)	0.43
" Coadministration of Kaletra (lopinavir/ritonavir) with delamanid resulted in an approximately 25% higher delamanid area under the concentration-time curve from time 0 to the end of the dosing interval (AUCτ)."	( Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects. Geiter, L; Mallikaarjun, S; Paccaly, A; Patil, S; Petersen, C; Shoaf, SE; Wells, C, 2016)	0.43
"The first-generation integrase inhibitors (INIs) raltegravir (RAL) and elvitegravir (EVG) have shown efficacy against HIV infection, but they have the limitations of once-more daily dosing and extensive cross-resistance."	( Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials. Chen, H; Guo, W; Huang, J; Jiang, J; Liang, B; Liang, H; Liao, Y; Su, J; Xu, X; Ye, L; Zang, N, 2016)	0.43
"According to simulations, a paediatric efavirenz/lamivudine/abacavir fixed-dose formulation of 150 mg efavirenz, 75 mg lamivudine and 150 mg abacavir provided the most effective and safe concentrations across WHO weight bands, with the flexibility of dosage required across the paediatric population."	( Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients. Bienczak, A; Bouazza, N; Burger, D; Capparelli, EV; Cressey, TR; Denti, P; Foissac, F; Lallemant, M; McIlleron, H; Penazzato, M; Treluyer, JM; Urien, S, 2017)	0.46
"We included all randomized controlled trials (RCTs) that compared EFV to NVP in people with HIV without prior exposure to ART, irrespective of the dosage or NRTI's given in combination."	( Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Irlam, JH; Mbuagbaw, L; Mursleen, S; Rutherford, GW; Siegfried, N; Spaulding, AB, 2016)	0.43
" We performed subgroup analyses for concurrent treatment for tuberculosis and dosage of NVP."	( Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Irlam, JH; Mbuagbaw, L; Mursleen, S; Rutherford, GW; Siegfried, N; Spaulding, AB, 2016)	0.43
" The powders obtained, which present enhanced dissolution properties, can be incorporated in a solid dosage form for treatment of AIDS in paediatric patients with promising results."	( Efavirenz dissolution enhancement III: Colloid milling, pharmacokinetics and electronic tongue evaluation. Bilatto, SE; Cabral, LM; Corrêa, DS; da Costa, MA; Fandaruff, C; Hoffmeister, CR; Pitta, LR; Prado, LD; Rocha, HV; Silva, MA; Tasso, L, 2017)	0.46
"We compared the pharmacokinetics of moxifloxacin during rifampicin co-treatment or when dosed alone in African patients with drug-susceptible recurrent TB."	( Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB. Adamson, J; Chirehwa, M; Denti, P; Essack, S; Govender, K; Kimba-Phongi, E; McIlleron, H; Naidoo, A; Naidoo, K; Padayatchi, N; Yende-Zuma, N, 2017)	0.46
" Genotype-directed dosing yields therapeutic EFV concentrations and appears to outperform other dosing approaches."	( CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3-36 months with HIV infection. Benns, A; Bolton Moore, C; Borkowsky, W; Bwakura-Dangarembizi, M; Capparelli, EV; Chadwick, EG; Hawkins, E; Heckman, B; Jean-Philippe, P; Loftis, A; Purdue, L; Samson, P; Spector, SA; Wallis, C; Worrell, C, 2017)	0.46
" It is desirable for multidrug combinations to be coformulated into single dosage forms where possible, to promote patient convenience and adherence to dosage regimens, for which amorphous solid dispersion (ASD) is particularly well-suited."	( Multidrug, Anti-HIV Amorphous Solid Dispersions: Nature and Mechanisms of Impacts of Drugs on Each Other's Solution Concentrations. Arca, HÇ; Dahal, D; Edgar, KJ; Mosquera-Giraldo, LI; Taylor, LS, 2017)	0.46
" There are concerns about the appropriateness of current EFV dosing and it has been discussed whether EFV dosing should be adapted according to genotype in children as suggested for adults."	( Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin. Dahl, ML; Eriksen, J; Gustafsson, LL; Navér, L; Österberg, E; Rubin, J; Soeria-Atmadja, S, 2017)	0.46
"To investigate if pediatric EFV dosing should be guided by genetic variation in drug metabolizing enzymes rather than by body weight."	( Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin. Dahl, ML; Eriksen, J; Gustafsson, LL; Navér, L; Österberg, E; Rubin, J; Soeria-Atmadja, S, 2017)	0.46
" Knowledge about individual variants in key drug metabolizing enzyme genes could improve clinical safety and genotype directed dosing could achieve more predictable EFV plasma concentrations in HIV-infected children."	( Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin. Dahl, ML; Eriksen, J; Gustafsson, LL; Navér, L; Österberg, E; Rubin, J; Soeria-Atmadja, S, 2017)	0.46
"For HIV-infected pregnant women receiving efavirenz, low daily DHA-PQ dosing was predicted to improve protection against parasitemia and reduce risk of toxicity compared to monthly dosing."	( Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virus-Infected Women Receiving Efavirenz. Aweeka, F; Dorsey, G; Havlir, D; Huang, L; Jagannathan, P; Kakuru, A; Kamya, M; Muhindo, M; Nakalembe, M; Natureeba, P; Rosenthal, PJ; Savic, RM; Vucicevic, K; Wallender, E, 2018)	0.48
" According to the World Health Organization, a similar dosing strategy for all patient populations is desirable for universal roll-out; however, it remains unknown whether the 400 mg daily dose is adequate during pregnancy."	( A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women. Best, BM; Burger, DM; Capparelli, E; Colbers, AC; Cressey, TR; Denti, P; Dooley, KE; Greupink, R; Huitema, ADR; Mirochnick, M; Russel, FGM; Schalkwijk, S; Ter Heine, R, 2018)	0.48
" CYP2B6 genotyping but not anti-tuberculosis co-treatment should guide efavirenz dosing to optimize treatment outcomes."	( Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype. Aklillu, E; Bertilsson, L; Burhenne, J; Janabi, M; Kitabi, EN; Minzi, OMS; Mugusi, F; Mugusi, S; Sasi, P, 2018)	0.48
" Adult rhesus macaques were dosed daily with 200 mg EFV (as part of a four-drug regimen) for 10 days."	( Predicting Efavirenz Concentrations in the Brain Tissue of HIV-Infected Individuals and Exploring their Relationship to Neurocognitive Impairment. Adamson, L; Blake, KH; Eron, JJ; Forrest, A; Joseph, SB; Kashuba, ADM; Kincer, LP; Luciw, P; Menezes, P; Price, RW; Robertson, K; Schauer, AP; Spudich, S; Srinivas, N; Swanstrom, R; Sykes, C; White, N, 2019)	0.51
"Pharmacokinetics studies recommend increasing efavirenz dosage in tuberculosis/HIV patients using rifampicin."	( Daily 800 mg versus 600 mg Efavirenz for HIV Patients Treating Tuberculosis with a Rifampicin-Based Regimen: An Open Label Randomized Controlled Trial. do Brasil, PEAA; Hadad, DJ; Maia, IR; Rolla, V; Sant'anna, FM; Schmaltz, CAS; Trajman, A; Xavier, MS, 2018)	0.48
"CYP2B6 516 genotype-directed dosing improves efavirenz (EFV) exposures in HIV-infected children younger than 36 months, but such data are lacking in those with tuberculosis (TB) coinfection."	( Establishing Dosing Recommendations for Efavirenz in HIV/TB-Coinfected Children Younger Than 3 Years. Benns, A; Bwakura Dangarembizi, M; Capparelli, EV; Chadwick, EG; Chakhtoura, N; Jackson, C; Jean-Philippe, P; Libous, JL; Moore, CB; Purdue, L; Samson, P; Spector, SA; Wallis, C; Zimmer, B, 2019)	0.51
"Genotype-directed dosing safely achieved therapeutic EFV concentrations and virologic suppression in HIV/TB-coinfected children younger than 24 months, but further study is needed to confirm appropriate dosing in those aged 24-36 months."	( Establishing Dosing Recommendations for Efavirenz in HIV/TB-Coinfected Children Younger Than 3 Years. Benns, A; Bwakura Dangarembizi, M; Capparelli, EV; Chadwick, EG; Chakhtoura, N; Jackson, C; Jean-Philippe, P; Libous, JL; Moore, CB; Purdue, L; Samson, P; Spector, SA; Wallis, C; Zimmer, B, 2019)	0.51
"The current WHO weight-based dosing recommendations for efavirenz result in a wide variability of drug exposure in children."	( Population pharmacokinetics of efavirenz in HIV and TB/HIV coinfected children: the significance of genotype-guided dosing. Alghamdi, WA; Antwi, S; Dompreh, A; Enimil, A; Kwara, A; Langaee, T; Peloquin, CA; Wiesner, L; Yang, H, 2019)	0.51
" In addition, dosing efavirenz in children based only on weight results in a large variability in drug exposure."	( Population pharmacokinetics of efavirenz in HIV and TB/HIV coinfected children: the significance of genotype-guided dosing. Alghamdi, WA; Antwi, S; Dompreh, A; Enimil, A; Kwara, A; Langaee, T; Peloquin, CA; Wiesner, L; Yang, H, 2019)	0.51
" Therefore, the physicochemical properties of polymorphic forms from active pharmaceutical ingredients (APIs) should be carefully considered in dosage forms pre-formulation approaches."	( Polymorphic properties and dissolution profile of efavirenz due to solvents recrystallization. Soewandhi, SN; Suendo, V; Wardhana, YW; Wikarsa, S, 2019)	0.51
" Additionally, we observe additive inhibitory activity against pseudotyped viruses when B#24 is dosed in competition with the clinically used non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz."	( Biological evaluation of molecules of the azaBINOL class as antiviral agents: Inhibition of HIV-1 RNase H activity by 7-isopropoxy-8-(naphth-1-yl)quinoline. Banerjee, S; Blakemore, PR; Brack-Werner, R; Herrmann, A; Loesgen, S; Milicevic Sephton, S; Neuhaus, GF; Overacker, RD; Strother, JA, 2019)	0.51
" To promote the tolerance of efavirenz, it is better to adjust the dosage of efavirenz according to the polymorphisms of CYP2B6-516 in HIV-infected adults."	( Meta-analysis of the associations of CYP2B6-516G>T polymorphisms with efavirenz-induced central nervous system side effects and virological outcome in HIV-infected adults. Cheng, L; Feng, W; Li, X; Sun, F; Wang, Y; Weng, B; Xia, P; Yuan, Q, 2020)	0.56
" Lopinavir TDM excluded pharmacokinetic reasons for failure in patients failing treatment when lopinavir dosing was supervised."	( Pediatric Antiretroviral Therapeutic Drug Monitoring: A Five and a Half Year Experience from a South African Tertiary Hospital. Decloedt, EH; Engelbrecht, AE; Norman, J; Rabie, H; Wiesner, L, 2020)	0.56
" These data suggest that malaria and HIV coinfected pregnant women may require adjustments in AL dosage or treatment duration to achieve exposure comparable with HIV-uninfected pregnant women."	( Efavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women. Aweeka, F; Huang, L; Hughes, E; Kajubi, R; Mwebaza, N; Mwima, MW; Nguyen, V; Nyunt, MM; Orukan, F; Parikh, S, 2020)	0.56
" A novel dosing strategy that has the potential to reduce isoniazid-related toxicity and treatment failure is presented."	( Model-Based Assessment of Variability in Isoniazid Pharmacokinetics and Metabolism in Patients Co-Infected With Tuberculosis and HIV: Implications for a Novel Dosing Strategy. Äbelö, A; Ashton, M; Bienvenu, E; Birgersson, S; Janzén, D; Sundell, J, 2020)	0.56
" The current PBPK model, which considers changes in unbound potency-adjusted active species, can be used to inform dosing recommendations when abemaciclib is coadministered with CYP3A4 perpetrators."	( Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling. Dickinson, GL; Hall, SD; Kulanthaivel, P; Morse, BL; Posada, MM; Turner, PK, 2020)	0.56
" This warrants further investigations of other drug-drug interactions for optimising dosing in genetically defined subgroups, particularly during drug development."	( Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz. Adeagbo, BA; Adegbola, AJ; Bolaji, OO; Bolarinwa, RA; Olagunju, AE; Owen, A; Rana, A; Siccardi, M, 2020)	0.56
" However, dosage recommendations incorporating CYP2B6 516G > T polymorphism have not been investigated in the Thai population."	( Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand. Avihingsanon, A; Chaivichacharn, P; Manosuthi, W; Punyawudho, B; Shotelersuk, V; Tongkobpetch, S; Ubolyam, S, 2020)	0.56
" Vaginal film is becoming more acceptable and a convenient dosage form compared to cream, gel and suppository."	( Efavirenz nanomicelles loaded vaginal film (EZ film) for preexposure prophylaxis (PrEP) of HIV. Cetindag, E; Dave, R; Fu, Y; Gandhi, T; Jablonski, J; Mediouni, S; Patel, K; Patki, M; Valente, ST; Vartak, R, 2020)	0.56
" It has several advantages for pediatric patients, as the dosage form disintegrates quickly in the mouth and does not require water for administration, thereby improving patient compliance with the treatment."	( Development of Pediatric Orodispersible Tablets Based on Efavirenz as a New Therapeutic Alternative. Ângelos, MA; da Silva, RMF; de Freitas Neto, JL; de Melo, CG; do Nascimento Gomes Barbosa, I; Dos Santos Mendes, LM; Ferreira, MRA; Neto, PJR; Rolim, LA; Soares, LAL, 2020)	0.56
"Supersaturable SMEDDS, a versatile dosage form, was investigated for improving the biopharmaceutical attributes and eradicating the food effect of poorly water soluble drug efavirenz."	( Polymeric Precipitation Inhibitor Assisted Supersaturable SMEDDS of Efavirenz Based on Experimental Observations and Molecular Mechanics. Bedi, N; Mahajan, S; Sheikh, BA; Singh, D; Singh, M, 2021)	0.62
"Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)."	( Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022)	0.72
" The objectives of this article are to present an overview of nonparametric methods used in population pharmacokinetic modeling and to explain their specific characteristics to inform scientists and clinicians about their potential value for data analysis, simulation, dosage design, and therapeutic drug monitoring (TDM)."	( Nonparametric Methods in Population Pharmacokinetics. Bourguignon, L; Goutelle, S; Neely, M; Woillard, JB; Yamada, W, 2022)	0.72
" "Untimed" EFV concentrations with unknown dosing and collection time were assessed using a validated liquid chromatography-tandem mass spectrometry method."	( Untimed Efavirenz Drug Levels After Switching From Brand to Generic Formulations: A Short Communication. Atkinson, K; Auyeung, K; Barrios, R; Baynes, KA; Brumme, CJ; Lepik, KJ; Sereda, P; Toy, J; Watson, BE, 2021)	0.62
"The present study endeavors quality by design (QbD) assisted chromatographic method for the quantification of Efavirenz (ERZ) in bulk and tablet dosage form."	( Quantification and Validation of Stability-Indicating RP-HPLC Method for Efavirenz in Bulk and Tablet Dosage Form using Quality by Design (QbD): A Shifting Paradigm. Bari, SB; Gurumukhi, VC, 2022)	0.72
"1 ng/mL), resulting in contraception failure, when depot medroxyprogesterone is dosed at 12-week intervals."	( A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment. Cohn, SE; Denti, P; Dooley, KE; Firnhaber, C; Francis, J; Godfrey, C; Kendall, MA; McIlleron, H; Mngqibisa, R; Wu, X, 2021)	0.62
"Study A5338 suggested that more frequent depot MPA dosing may be appropriate for women receiving rifampicin, isoniazid, and efavirenz."	( Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis. Angira, F; Badal-Faesen, S; Baker, P; Cohn, SE; Denti, P; Francis, J; Haas, DW; Kendall, MA; Mawlana, S; McIlleron, H; Mngqibisa, R; Omoz-Oarhe, A; Robinson, JA; Samaneka, WP, 2022)	0.72
" TB therapy (isoniazid and rifampin) led to a 29% decreased clearance, however Monte Carlo simulations demonstrated the majority of participants on TB therapy receiving standard EFV dosing to be in the target area under the curve range."	( Impact of CYP2B6 genotype, tuberculosis therapy, and formulation on efavirenz pharmacokinetics in infants and children under 40 months of age. Benns, A; Bolton Moore, C; Bwakura-Dangarembizi, M; Capparelli, EV; Chadwick, EG; Chakhtoura, N; Frenkel, L; Jean-Philippe, P; Libous, J; Nikanjam, M; Samson, P; Spector, SA; Tran, L; Zimmer, B, 2022)	0.72
"EFV dosing should account for CYP2B6 516 genotype and formulation, but does not require adjustment for concurrent TB therapy."	( Impact of CYP2B6 genotype, tuberculosis therapy, and formulation on efavirenz pharmacokinetics in infants and children under 40 months of age. Benns, A; Bolton Moore, C; Bwakura-Dangarembizi, M; Capparelli, EV; Chadwick, EG; Chakhtoura, N; Frenkel, L; Jean-Philippe, P; Libous, J; Nikanjam, M; Samson, P; Spector, SA; Tran, L; Zimmer, B, 2022)	0.72
" There are only 200 mg and 600 mg dosage forms of EFV in China."	( Efficacy and safety of Efavirenz 400 mg-based regimens switching from 600 mg-based regimens in people living with HIV with virological suppression in China: a randomized, open-label, non-inferiority study. Han, J; Li, B; Liu, Y; Xiao, J; Zhang, L; Zhao, H, 2022)	0.72
" This study aimed to develop a population pharmacokinetic model to characterize the disposition of maraviroc in neonates to inform dosing regimens and expand available options."	( Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life. Best, BM; Bradford, S; Capparelli, EV; Chadwick, EG; Jean-Philippe, P; Liyanage, M; McFadyen, L; Mirochnick, M; Moye, J; Nikanjam, M; Rogg, L; Vourvahis, M; Whitson, K, 2022)	0.72
" The final model was used in Monte Carlo simulations to generate expected exposures with recommended dosing regimens."	( Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life. Best, BM; Bradford, S; Capparelli, EV; Chadwick, EG; Jean-Philippe, P; Liyanage, M; McFadyen, L; Mirochnick, M; Moye, J; Nikanjam, M; Rogg, L; Vourvahis, M; Whitson, K, 2022)	0.72
" Monte Carlo simulations with FDA-approved weight band dosing resulted in the majority of simulated patients (84."	( Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life. Best, BM; Bradford, S; Capparelli, EV; Chadwick, EG; Jean-Philippe, P; Liyanage, M; McFadyen, L; Mirochnick, M; Moye, J; Nikanjam, M; Rogg, L; Vourvahis, M; Whitson, K, 2022)	0.72
"While maraviroc apparent clearance is decreased in the first few days of life, the current FDA-approved maraviroc weight band dosing provides maraviroc exposures for neonates in the first 6 weeks of life, which were consistent with adult maraviroc exposure range."	( Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life. Best, BM; Bradford, S; Capparelli, EV; Chadwick, EG; Jean-Philippe, P; Liyanage, M; McFadyen, L; Mirochnick, M; Moye, J; Nikanjam, M; Rogg, L; Vourvahis, M; Whitson, K, 2022)	0.72
"Dolutegravir concentrations are reduced by efavirenz induction effect necessitating twice-daily dolutegravir dosing when coadministered."	( Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial. Griesel, R; Hill, A; Keene, C; Maartens, G; Meintjes, G; Omar, Z; Simmons, B; van Zyl, G; Zhao, Y, 2023)	0.91
" Therefore, in addition to body weight, pediatric dosing of EFV should consider pharmacogenetic variability, duration of therapy, and individual treatment outcomes."	( Genetic and non-genetic factors influencing efavirenz population pharmacokinetics among human immunodeficiency virus-1-infected children in Ethiopia. Ahmed, JH; Aklillu, E; Chaka, TE; Chala, A; Kitabi, EN; Makonnen, E; Tadesse, BT, 2023)	0.91
" A verified PBPK model for efavirenz describing the CYP3A4- and CYP2B6-mediated auto-induction during multiple dosing was reported previously and was applied in this study to predict the exposure of efavirenz in vulnerable populations, including children (down to the age of 3 months), mothers, and breastfeeding infants, accounting for the various CYP2B6 genotypes."	( Physiologically Based Pharmacokinetic Modeling to Determine the Impact of CYP2B6 Genotype on Efavirenz Exposure in Children, Mothers and Breastfeeding Infants. Pan, X; Rowland Yeo, K, 2023)	0.91
"Our simulations support the common practice of maintaining the adjusted dosage of a drug for another 2 weeks after stopping an inducer."	( Management of Drug Interactions with Inducers: Onset and Disappearance of Induction on Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyltransferase 1A1 Substrates. Battegay, M; Berton, M; Bettonte, S; Marzolini, C; Stader, F, 2023)	0.91
" Due to their long dosing interval, clinical studies with IM CAB/RPV are challenging."	( Intramuscular cabotegravir and rilpivirine concentrations after switching from efavirenz-containing regimen. Battegay, M; Berton, M; Bettonte, S; Marzolini, C; Stader, F, 2023)	0.91
"The current World Health Organization (WHO) pediatric tuberculosis dosing guidelines lead to suboptimal drug exposures."	( Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis. Aarnoutse, R; Chabala, C; Cotton, MF; Denti, P; Galileya, LT; Gibb, D; Hesseling, A; Lee, J; McIlleron, H; Njahira Mukui, I; Rabie, H; Turkova, A; Wasmann, RE; Zar, H, 2023)	0.91
" The importance of the drug-drug interactions with lopinavir/ritonavir and efavirenz should be evaluated further and considered in future dosing guidance."	( Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis. Aarnoutse, R; Chabala, C; Cotton, MF; Denti, P; Galileya, LT; Gibb, D; Hesseling, A; Lee, J; McIlleron, H; Njahira Mukui, I; Rabie, H; Turkova, A; Wasmann, RE; Zar, H, 2023)	0.91

Role	Description
HIV-1 reverse transcriptase inhibitor	An entity which inhibits the activity of HIV-1 reverse transcriptase.
antiviral drug	A substance used in the prophylaxis or therapy of virus diseases.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
benzoxazine
acetylenic compound	Any organic molecule containing a C#C bond.
organochlorine compound	An organochlorine compound is a compound containing at least one carbon-chlorine bond.
organofluorine compound	An organofluorine compound is a compound containing at least one carbon-fluorine bond.
cyclopropanes	Cyclopropane and its derivatives formed by substitution.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Ferritin light chain	Equus caballus (horse)	Potency	31.6228	5.6234	17.2929	31.6228	AID485281
hypoxia-inducible factor 1 alpha subunit	Homo sapiens (human)	Potency	26.8325	3.1890	29.8841	59.4836	AID1224846
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	26.6032	0.0060	38.0041	19,952.5996	AID1159523
SMAD family member 2	Homo sapiens (human)	Potency	13.4481	0.1737	34.3047	61.8120	AID1346924
PPM1D protein	Homo sapiens (human)	Potency	44.0783	0.0052	9.4661	32.9993	AID1347411
SMAD family member 3	Homo sapiens (human)	Potency	13.4481	0.1737	34.3047	61.8120	AID1346924
TDP1 protein	Homo sapiens (human)	Potency	23.3222	0.0008	11.3822	44.6684	AID686978; AID686979
GLI family zinc finger 3	Homo sapiens (human)	Potency	15.6040	0.0007	14.5928	83.7951	AID1259369; AID1259392
AR protein	Homo sapiens (human)	Potency	19.1052	0.0002	21.2231	8,912.5098	AID1259243; AID1259247; AID743035; AID743042; AID743054; AID743063
caspase 7, apoptosis-related cysteine protease	Homo sapiens (human)	Potency	29.8493	0.0133	26.9810	70.7614	AID1346978
estrogen receptor 2 (ER beta)	Homo sapiens (human)	Potency	23.7101	0.0006	57.9133	22,387.1992	AID1259378
progesterone receptor	Homo sapiens (human)	Potency	15.6040	0.0004	17.9460	75.1148	AID1346784; AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	8.8920	0.0123	7.9835	43.2770	AID1346984; AID1645841
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	25.3735	0.0002	14.3764	60.0339	AID720691; AID720692
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	29.2874	0.0030	41.6115	22,387.1992	AID1159552; AID1159555
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	23.0181	0.0015	30.6073	15,848.9004	AID1224841; AID1224848; AID1224849; AID1259403
farnesoid X nuclear receptor	Homo sapiens (human)	Potency	33.4889	0.3758	27.4851	61.6524	AID743217
pregnane X nuclear receptor	Homo sapiens (human)	Potency	23.1253	0.0054	28.0263	1,258.9301	AID1346982; AID1346985
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	27.0398	0.0002	29.3054	16,493.5996	AID1259244; AID1259248; AID743069; AID743078; AID743079; AID743080; AID743091
G	Vesicular stomatitis virus	Potency	17.3768	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2D6	Homo sapiens (human)	Potency	27.5404	0.0010	8.3798	61.1304	AID1645840
peroxisome proliferator activated receptor gamma	Homo sapiens (human)	Potency	33.4889	0.0010	19.4141	70.9645	AID743191
caspase-3	Homo sapiens (human)	Potency	29.8493	0.0133	26.9810	70.7614	AID1346978
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	23.7101	0.0017	23.8393	78.1014	AID743083
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	12.2352	0.0016	28.0151	77.1139	AID1224843; AID1224895
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a	Homo sapiens (human)	Potency	26.8325	19.7391	45.9784	64.9432	AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)	Homo sapiens (human)	Potency	15.5961	0.0578	21.1097	61.2679	AID1159526; AID1159528
nuclear receptor subfamily 1, group I, member 2	Rattus norvegicus (Norway rat)	Potency	28.1838	0.1000	9.1916	31.6228	AID1346983
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	26.6032	0.0003	23.4451	159.6830	AID743065; AID743067
heat shock protein beta-1	Homo sapiens (human)	Potency	33.4889	0.0420	27.3789	61.6448	AID743210; AID743228
mitogen-activated protein kinase 1	Homo sapiens (human)	Potency	15.8489	0.0398	16.7842	39.8107	AID1454
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	15.5554	0.0006	27.2152	1,122.0200	AID743202; AID743219
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	12.5893	0.0079	8.2332	1,122.0200	AID2546
neuropeptide S receptor isoform A	Homo sapiens (human)	Potency	10.0000	0.0158	12.3113	615.5000	AID1461
Voltage-dependent calcium channel gamma-2 subunit	Mus musculus (house mouse)	Potency	21.1317	0.0015	57.7890	15,848.9004	AID1259244
Interferon beta	Homo sapiens (human)	Potency	40.2638	0.0033	9.1582	39.8107	AID1347411; AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	17.3768	0.0123	8.9648	39.8107	AID1645842
Cellular tumor antigen p53	Homo sapiens (human)	Potency	33.4915	0.0023	19.5956	74.0614	AID651631; AID720552
Glutamate receptor 2	Rattus norvegicus (Norway rat)	Potency	21.1317	0.0015	51.7393	15,848.9004	AID1259244
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	28.1838	0.0096	10.5250	35.4813	AID1479145
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	17.3768	0.0123	8.9648	39.8107	AID1645842
ATPase family AAA domain-containing protein 5	Homo sapiens (human)	Potency	29.8493	0.0119	17.9420	71.5630	AID651632
Ataxin-2	Homo sapiens (human)	Potency	29.8493	0.0119	12.2221	68.7989	AID651632
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	17.3768	0.0123	8.9648	39.8107	AID1645842
Chain A, Ferritin light chain	Equus caballus (horse)	Potency	11.2202	5.6234	17.2929	31.6228	AID485281
glp-1 receptor, partial	Homo sapiens (human)	Potency	19.9526	0.0184	6.8060	14.1254	AID624417
Fumarate hydratase	Homo sapiens (human)	Potency	37.2212	0.0030	8.7949	48.0869	AID1347053
USP1 protein, partial	Homo sapiens (human)	Potency	56.2341	0.0316	37.5844	354.8130	AID504865
TDP1 protein	Homo sapiens (human)	Potency	23.2626	0.0008	11.3822	44.6684	AID686978; AID686979
Smad3	Homo sapiens (human)	Potency	15.8489	0.0052	7.8098	29.0929	AID588855
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	13.4504	0.0123	7.9835	43.2770	AID1645841
EWS/FLI fusion protein	Homo sapiens (human)	Potency	24.9178	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
nonstructural protein 1	Influenza A virus (A/WSN/1933(H1N1))	Potency	11.2202	0.2818	9.7212	35.4813	AID2326
G	Vesicular stomatitis virus	Potency	11.9877	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2D6	Homo sapiens (human)	Potency	16.9330	0.0010	8.3798	61.1304	AID1645840
polyprotein	Zika virus	Potency	37.2212	0.0030	8.7949	48.0869	AID1347053
IDH1	Homo sapiens (human)	Potency	32.6427	0.0052	10.8652	35.4813	AID686970
nuclear factor erythroid 2-related factor 2 isoform 2	Homo sapiens (human)	Potency	32.6427	0.0041	9.9848	25.9290	AID504444
parathyroid hormone/parathyroid hormone-related peptide receptor precursor	Homo sapiens (human)	Potency	5.0119	3.5481	19.5427	44.6684	AID743266
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	28.1838	0.0079	8.2332	1,122.0200	AID2546
geminin	Homo sapiens (human)	Potency	27.8922	0.0046	11.3741	33.4983	AID624296
peripheral myelin protein 22	Rattus norvegicus (Norway rat)	Potency	36.1254	0.0056	12.3677	36.1254	AID624032
Rap guanine nucleotide exchange factor 3	Homo sapiens (human)	Potency	112.2020	6.3096	60.2008	112.2020	AID720707
Interferon beta	Homo sapiens (human)	Potency	11.9877	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	11.9877	0.0123	8.9648	39.8107	AID1645842
TAR DNA-binding protein 43	Homo sapiens (human)	Potency	35.4813	1.7783	16.2081	35.4813	AID652104
Rap guanine nucleotide exchange factor 4	Homo sapiens (human)	Potency	31.6228	3.9811	46.7448	112.2020	AID720708
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	11.9877	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	11.9877	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, POL POLYPROTEIN	Human immunodeficiency virus 1	IC50 (µMol)	0.2612	0.0025	0.2612	0.5200	AID977608
Chain A, POL POLYPROTEIN	Human immunodeficiency virus 1	IC50 (µMol)	0.2612	0.0025	0.2612	0.5200	AID977608
Chain B, POL POLYPROTEIN	Human immunodeficiency virus 1	IC50 (µMol)	0.2612	0.0025	0.2612	0.5200	AID977608
Chain A, POL POLYPROTEIN	Human immunodeficiency virus 1	IC50 (µMol)	0.2612	0.0025	0.2612	0.5200	AID977608
Chain B, POL POLYPROTEIN	Human immunodeficiency virus 1	IC50 (µMol)	0.2612	0.0025	0.2612	0.5200	AID977608
Chain A, Pol Polyprotein	Human immunodeficiency virus 1	IC50 (µMol)	0.2612	0.0025	0.2612	0.5200	AID977608
Chain B, Pol Polyprotein	Human immunodeficiency virus 1	IC50 (µMol)	0.2612	0.0025	0.2612	0.5200	AID977608
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	133.0000	0.1100	7.1903	10.0000	AID1473738
Prothrombin	Bos taurus (cattle)	IC50 (µMol)	0.0220	0.0089	0.8857	6.0000	AID1191671
Gag-Pol polyprotein	HIV-1 M:B_HXB2R	IC50 (µMol)	2.1778	0.0006	0.9141	8.3200	AID1795395; AID1795423; AID1795433; AID1795434; AID1795435; AID1795436; AID1795437; AID1795438; AID1795727; AID1795743; AID1798815; AID1801910; AID1802513; AID1802514; AID1802605
Gag-Pol polyprotein	HIV-1 M:B_HXB2R	Ki	0.1400	0.0000	0.5144	9.0000	AID1798816
Gag-Pol polyprotein	Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE)	IC50 (µMol)	0.0200	0.0002	0.1042	1.7000	AID1801804
Kappa-type opioid receptor	Cavia porcellus (domestic guinea pig)	IC50 (µMol)	0.0180	0.0003	0.7123	7.0700	AID573468
Cannabinoid receptor 1	Mus musculus (house mouse)	Ki	0.0100	0.0006	0.7246	7.2000	AID736440
Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)	IC50 (µMol)	0.0540	0.0000	0.7263	5.7500	AID266346
Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)	IC50 (µMol)	0.0040	0.0002	1.0140	10.0000	AID299022
Envelope glycoprotein gp160 [Cleaved into: Surface protein gp120	Human immunodeficiency virus 1	IC50 (µMol)	0.0035	0.0035	2.7022	8.7000	AID1624241
Reverse transcriptase/RNaseH	Human immunodeficiency virus 1	IC50 (µMol)	1.3653	0.0001	1.0768	10.0000	AID104448; AID1059142; AID1069710; AID1126511; AID1141975; AID1141976; AID1165079; AID1171593; AID1171594; AID1171595; AID1171596; AID1171598; AID1191404; AID1191671; AID1198749; AID1198752; AID1198754; AID1206939; AID1231487; AID1235381; AID1248227; AID1249724; AID1272056; AID1298247; AID1298248; AID1298249; AID1298250; AID1298251; AID1298253; AID1304407; AID1316359; AID1320869; AID1352323; AID1373153; AID1379964; AID1391076; AID1391088; AID1410405; AID1410486; AID1418468; AID143393; AID1457063; AID1457064; AID1457065; AID1485966; AID1485969; AID1485970; AID1485971; AID1485972; AID1485973; AID1485974; AID1485975; AID1520066; AID1535529; AID1558858; AID1565088; AID1572530; AID1594861; AID1596756; AID1609110; AID1627029; AID1687691; AID1693803; AID1705194; AID1705195; AID1729163; AID1731753; AID1750722; AID1767116; AID1811038; AID1815396; AID1822283; AID1847040; AID1880369; AID1884230; AID1884494; AID197777; AID197783; AID197931; AID197932; AID197933; AID197934; AID198099; AID198237; AID198385; AID198399; AID198563; AID199102; AID200153; AID241471; AID241472; AID241533; AID241665; AID266345; AID266346; AID266347; AID266348; AID267644; AID279321; AID279324; AID279325; AID282736; AID282737; AID282738; AID282739; AID282740; AID299022; AID342718; AID347085; AID347086; AID347087; AID360705; AID386493; AID391221; AID391222; AID391223; AID397176; AID404605; AID430054; AID457955; AID457959; AID457960; AID457961; AID518734; AID518735; AID518737; AID518738; AID557019; AID557043; AID557044; AID573464; AID573465; AID573466; AID573468; AID573469; AID573470; AID583849; AID583863; AID620437; AID649485; AID649486; AID649488; AID698145; AID698146; AID757621; AID779524; AID82961
Reverse transcriptase/RNaseH	Human immunodeficiency virus 1	Ki	0.2939	0.0003	1.5523	10.0000	AID1594861; AID198768; AID198769; AID198911; AID198912; AID198913; AID198915; AID198916; AID198917; AID302259; AID302260; AID368564; AID368565; AID368566; AID368567; AID368568; AID368569; AID370724; AID370725; AID370726; AID370727; AID605176; AID605177; AID605178; AID622047; AID622049; AID622052; AID736038; AID736040; AID736041; AID736438; AID736439; AID736440
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)	IC50 (µMol)	20.6000	0.0040	1.9666	10.0000	AID1873200
Reverse transcriptase	Human immunodeficiency virus 1	IC50 (µMol)	0.0643	0.0100	0.5356	7.1300	AID1815391; AID1815397; AID1815398; AID1815399; AID1815400; AID1815401; AID1815402
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Reverse transcriptase/RNaseH	Human immunodeficiency virus 1	EC50 (µMol)	0.0900	0.0004	0.6153	9.7000	AID1326646; AID1326647; AID1373152; AID1373158; AID1373159; AID1373160; AID1373161; AID1373162; AID1373163; AID1407642; AID1410481; AID1410482; AID1421325; AID1456307; AID1456308; AID1483271; AID1483272; AID1483273; AID1483274; AID1483275; AID1483276; AID1483277; AID1750717; AID1750718; AID1750719; AID240140; AID267854; AID267855; AID267856; AID267858; AID366548; AID366549; AID366550
Reverse transcriptase	Human immunodeficiency virus 1	EC50 (µMol)	0.1053	0.0002	1.1683	9.0740	AID1731746; AID1731747; AID1731749; AID1731750; AID1731751; AID1741393; AID1741394; AID1741395; AID1741396; AID1741397
Cholesterol 24-hydroxylase	Homo sapiens (human)	Kd	5.3333	0.0500	2.0000	5.0000	AID1653622; AID1653623; AID1653636
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
5-hydroxytryptamine receptor 1A	Rattus norvegicus (Norway rat)	ID50	0.4000	0.4000	0.4000	0.4000	AID298089
Cytochrome P450 2B6	Homo sapiens (human)	Km	0.4500	0.4500	0.4500	0.4500	AID1168819
Acetylcholinesterase	Rattus norvegicus (Norway rat)	ID50	0.0800	0.0800	0.0800	0.0800	AID650690
Reverse transcriptase/RNaseH	Human immunodeficiency virus 1	Activity	0.2394	0.0009	1.3073	8.0000	AID199980
Reverse transcriptase/RNaseH	Human immunodeficiency virus 1	C90	7.3000	7.3000	7.3000	7.3000	AID141362
Reverse transcriptase/RNaseH	Human immunodeficiency virus 1	ED50	0.0552	0.0002	0.9935	9.8000	AID105535; AID105537; AID105539; AID105543
Reverse transcriptase/RNaseH	Human immunodeficiency virus 1	IC90 (µMol)	0.0493	0.0017	0.0385	0.3100	AID1272056; AID141361; AID141363; AID143399; AID1594861; AID198577; AID198578; AID216433; AID81627; AID81765; AID81766; AID82967; AID94447
Reverse transcriptase/RNaseH	Human immunodeficiency virus 1	ID50	1.9248	0.0060	2.1898	9.0000	AID1155813; AID1155814; AID1155815; AID1574384; AID1574385; AID1574386; AID242820; AID253490; AID253492; AID253493; AID253494; AID253495; AID257163; AID257164; AID257165; AID267851; AID267862; AID267863; AID298087; AID298088; AID298089; AID366526; AID366527; AID366529; AID368555; AID368556; AID368557; AID650689; AID650690; AID650691; AID663305; AID663306; AID663308
Protease	Human immunodeficiency virus 1	IC90 (µMol)	3.7260	0.0020	0.6784	7.3000	AID143396; AID143398; AID143402; AID94449
Fructose-1,6-bisphosphatase 1	Mus musculus (house mouse)	ID50	0.4000	0.4000	4.2000	8.0000	AID368556
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
proteolysis	Prothrombin	Bos taurus (cattle)
acute-phase response	Prothrombin	Bos taurus (cattle)
positive regulation of blood coagulation	Prothrombin	Bos taurus (cattle)
protein polymerization	Prothrombin	Bos taurus (cattle)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
viral life cycle	Gag-Pol polyprotein	HIV-1 M:B_HXB2R
establishment of integrated proviral latency	Gag-Pol polyprotein	HIV-1 M:B_HXB2R
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2B6	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2B6	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2B6	Homo sapiens (human)
cellular ketone metabolic process	Cytochrome P450 2B6	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2B6	Homo sapiens (human)
lipid metabolic process	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
triglyceride metabolic process	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
circadian rhythm	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
protein secretion	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
phospholipid transport	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
sterol transport	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
triglyceride transport	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
low-density lipoprotein particle remodeling	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
plasma lipoprotein particle assembly	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
chylomicron assembly	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
very-low-density lipoprotein particle assembly	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
lipoprotein transport	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
response to calcium ion	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
establishment of localization in cell	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
intermembrane lipid transfer	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
ceramide 1-phosphate transport	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
lipoprotein metabolic process	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
cholesterol homeostasis	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathway	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
response to hypoxia	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
neutrophil mediated immunity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
germinal center formation	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of leukocyte chemotaxis	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
proteolysis	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
membrane protein ectodomain proteolysis	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cell adhesion	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
Notch receptor processing	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of cell population proliferation	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
response to xenobiotic stimulus	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of T cell chemotaxis	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
protein processing	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
signal release	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
B cell differentiation	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of cell growth	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of cell migration	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
response to lipopolysaccharide	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of chemokine production	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of tumor necrosis factor production	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
regulation of mast cell apoptotic process	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
T cell differentiation in thymus	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cell adhesion mediated by integrin	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
wound healing, spreading of epidermal cells	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
amyloid precursor protein catabolic process	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of blood vessel endothelial cell migration	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of epidermal growth factor-activated receptor activity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathway	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
spleen development	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cell motility	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
defense response to Gram-positive bacterium	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cellular response to high density lipoprotein particle stimulus	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
commissural neuron axon guidance	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycle	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathway	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of vascular endothelial cell proliferation	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
Notch signaling pathway	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell population proliferation	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of B cell proliferation	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nuclear DNA replication	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
signal transduction in response to DNA damage	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
isotype switching	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of DNA replication	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of isotype switching to IgG isotypes	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA clamp unloading	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
regulation of mitotic cell cycle phase transition	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of cell cycle G2/M phase transition	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
negative regulation of receptor internalization	Ataxin-2	Homo sapiens (human)
regulation of translation	Ataxin-2	Homo sapiens (human)
RNA metabolic process	Ataxin-2	Homo sapiens (human)
P-body assembly	Ataxin-2	Homo sapiens (human)
stress granule assembly	Ataxin-2	Homo sapiens (human)
RNA transport	Ataxin-2	Homo sapiens (human)
lipid transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
organic anion transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
urate transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
biotin transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
sphingolipid biosynthetic process	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
riboflavin transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
urate metabolic process	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
transmembrane transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
transepithelial transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
renal urate salt excretion	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
export across plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
transport across blood-brain barrier	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
cellular detoxification	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
protein localization to membrane raft	Cholesterol 24-hydroxylase	Homo sapiens (human)
bile acid biosynthetic process	Cholesterol 24-hydroxylase	Homo sapiens (human)
cholesterol catabolic process	Cholesterol 24-hydroxylase	Homo sapiens (human)
xenobiotic metabolic process	Cholesterol 24-hydroxylase	Homo sapiens (human)
nervous system development	Cholesterol 24-hydroxylase	Homo sapiens (human)
sterol metabolic process	Cholesterol 24-hydroxylase	Homo sapiens (human)
progesterone metabolic process	Cholesterol 24-hydroxylase	Homo sapiens (human)
regulation of long-term synaptic potentiation	Cholesterol 24-hydroxylase	Homo sapiens (human)
angiogenesis	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
adaptive immune response	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
signal transduction	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
associative learning	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
Rap protein signal transduction	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
regulation of actin cytoskeleton organization	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
negative regulation of syncytium formation by plasma membrane fusion	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
intracellular signal transduction	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
positive regulation of GTPase activity	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
regulation of angiogenesis	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
positive regulation of angiogenesis	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
positive regulation of protein export from nucleus	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
positive regulation of stress fiber assembly	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusion	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
establishment of endothelial barrier	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
cellular response to cAMP	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
Ras protein signal transduction	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
regulation of insulin secretion	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
negative regulation of protein phosphorylation	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA processing	TAR DNA-binding protein 43	Homo sapiens (human)
RNA splicing	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of protein stability	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of insulin secretion	TAR DNA-binding protein 43	Homo sapiens (human)
response to endoplasmic reticulum stress	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of protein import into nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of circadian rhythm	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of apoptotic process	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation by host of viral transcription	TAR DNA-binding protein 43	Homo sapiens (human)
rhythmic process	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of cell cycle	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA destabilization	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA stabilization	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear inner membrane organization	TAR DNA-binding protein 43	Homo sapiens (human)
amyloid fibril formation	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
adaptive immune response	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
calcium-ion regulated exocytosis	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
regulation of exocytosis	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
insulin secretion	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
positive regulation of insulin secretion	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
regulation of synaptic vesicle cycle	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
Ras protein signal transduction	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
regulation of insulin secretion	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
serine-type endopeptidase activity	Prothrombin	Bos taurus (cattle)
calcium ion binding	Prothrombin	Bos taurus (cattle)
protein binding	Prothrombin	Bos taurus (cattle)
fibrinogen binding	Prothrombin	Bos taurus (cattle)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptidase activity	Gag-Pol polyprotein	HIV-1 M:B_HXB2R
integrase activity	Gag-Pol polyprotein	HIV-1 M:B_HXB2R
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2B6	Homo sapiens (human)
iron ion binding	Cytochrome P450 2B6	Homo sapiens (human)
testosterone 16-alpha-hydroxylase activity	Cytochrome P450 2B6	Homo sapiens (human)
heme binding	Cytochrome P450 2B6	Homo sapiens (human)
testosterone 16-beta-hydroxylase activity	Cytochrome P450 2B6	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 2B6	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 2B6	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 2B6	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 2B6	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2B6	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2B6	Homo sapiens (human)
lipid transporter activity	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
protein binding	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
lipid binding	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
apolipoprotein binding	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
protein-containing complex binding	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
protein heterodimerization activity	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
phospholipid transfer activity	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
phosphatidylcholine transfer activity	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
cholesterol transfer activity	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
triglyceride transfer activity	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
ceramide 1-phosphate transfer activity	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
phosphatidylethanolamine transfer activity	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
phospholipid transporter activity	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
endopeptidase activity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
metalloendopeptidase activity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
Notch binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
interleukin-6 receptor binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
integrin binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
protein binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
peptidase activity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
metallopeptidase activity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
SH3 domain binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cytokine binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
PDZ domain binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
tumor necrosis factor binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
metal ion binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
metalloendopeptidase activity involved in amyloid precursor protein catabolic process	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
protein binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP hydrolysis activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA clamp unloader activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
RNA binding	Ataxin-2	Homo sapiens (human)
epidermal growth factor receptor binding	Ataxin-2	Homo sapiens (human)
protein binding	Ataxin-2	Homo sapiens (human)
mRNA binding	Ataxin-2	Homo sapiens (human)
protein binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATP binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
organic anion transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
urate transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
biotin transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
efflux transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATP hydrolysis activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
riboflavin transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
identical protein binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
protein homodimerization activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
sphingolipid transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
iron ion binding	Cholesterol 24-hydroxylase	Homo sapiens (human)
steroid hydroxylase activity	Cholesterol 24-hydroxylase	Homo sapiens (human)
heme binding	Cholesterol 24-hydroxylase	Homo sapiens (human)
cholesterol 24-hydroxylase activity	Cholesterol 24-hydroxylase	Homo sapiens (human)
testosterone 16-beta-hydroxylase activity	Cholesterol 24-hydroxylase	Homo sapiens (human)
guanyl-nucleotide exchange factor activity	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
protein binding	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
protein domain specific binding	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
cAMP binding	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
double-stranded DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
RNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA 3'-UTR binding	TAR DNA-binding protein 43	Homo sapiens (human)
protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
lipid binding	TAR DNA-binding protein 43	Homo sapiens (human)
identical protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
pre-mRNA intronic binding	TAR DNA-binding protein 43	Homo sapiens (human)
molecular condensate scaffold activity	TAR DNA-binding protein 43	Homo sapiens (human)
guanyl-nucleotide exchange factor activity	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
protein binding	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
cAMP binding	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
protein-macromolecule adaptor activity	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
small GTPase binding	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
plasma membrane	Glutamate receptor 2	Rattus norvegicus (Norway rat)
endoplasmic reticulum membrane	Cytochrome P450 2B6	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2B6	Homo sapiens (human)
cytoplasm	Cytochrome P450 2B6	Homo sapiens (human)
endoplasmic reticulum	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
endoplasmic reticulum lumen	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
Golgi apparatus	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
cytosol	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
brush border membrane	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
microvillus membrane	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
vesicle	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
receptor complex	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
Golgi apparatus	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
endoplasmic reticulum	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
basolateral plasma membrane	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
cell-cell junction	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
focal adhesion	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
ruffle membrane	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
Golgi membrane	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cytoplasm	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
endoplasmic reticulum lumen	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cytosol	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
plasma membrane	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cell surface	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
actin cytoskeleton	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
membrane	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
apical plasma membrane	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
membrane raft	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
plasma membrane	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
Elg1 RFC-like complex	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nucleus	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
cytoplasm	Ataxin-2	Homo sapiens (human)
Golgi apparatus	Ataxin-2	Homo sapiens (human)
trans-Golgi network	Ataxin-2	Homo sapiens (human)
cytosol	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
membrane	Ataxin-2	Homo sapiens (human)
perinuclear region of cytoplasm	Ataxin-2	Homo sapiens (human)
ribonucleoprotein complex	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
nucleoplasm	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
apical plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
brush border membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
mitochondrial membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
membrane raft	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
external side of apical plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
endoplasmic reticulum	Cholesterol 24-hydroxylase	Homo sapiens (human)
endoplasmic reticulum membrane	Cholesterol 24-hydroxylase	Homo sapiens (human)
dendrite	Cholesterol 24-hydroxylase	Homo sapiens (human)
presynapse	Cholesterol 24-hydroxylase	Homo sapiens (human)
postsynapse	Cholesterol 24-hydroxylase	Homo sapiens (human)
plasma membrane	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
cortical actin cytoskeleton	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
plasma membrane	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
microvillus	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
endomembrane system	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
membrane	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
lamellipodium	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
filopodium	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
extracellular exosome	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
intracellular non-membrane-bounded organelle	TAR DNA-binding protein 43	Homo sapiens (human)
nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
perichromatin fibrils	TAR DNA-binding protein 43	Homo sapiens (human)
mitochondrion	TAR DNA-binding protein 43	Homo sapiens (human)
cytoplasmic stress granule	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear speck	TAR DNA-binding protein 43	Homo sapiens (human)
interchromatin granule	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
chromatin	TAR DNA-binding protein 43	Homo sapiens (human)
cytosol	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
plasma membrane	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
membrane	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
hippocampal mossy fiber to CA3 synapse	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
plasma membrane	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (2857)

Assay ID	Title	Year	Journal	Article
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID686947	qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen	2013	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15	Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1798816	Reverse Transcriptase Assay from Article 10.1021/jm801395v: \\Specific Targeting of Highly Conserved Residues in the HIV-1 Reverse Transcriptase Primer Grip Region. 2. Stereoselective Interaction to Overcome the Effects of Drug Resistant Mutations.\\	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations.
AID1795395	HIV-1 RT Assay from Article 10.1021/jm0211063: \\Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies.\\	2003	Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12	Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies.
AID1795743	HIV-1 RT Assay from Article 10.1016/j.bmc.2004.08.050: \\Studies of nonnucleoside HIV-1 reverse transcriptase inhibitors. Part 1: Design and synthesis of thiazolidenebenzenesulfonamides.\\	2004	Bioorganic & medicinal chemistry, Dec-01, Volume: 12, Issue:23	Studies of nonnucleoside HIV-1 reverse transcriptase inhibitors. Part 1: Design and synthesis of thiazolidenebenzenesulfonamides.
AID1795423	HIV-1 RT Assay from Article 10.1021/jm990095j: \\Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues.\\	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues.
AID1802513	DNA Polymerase Assay from Article 10.1002/cbic.201600592: \\Natural Product Kuwanon-L Inhibits HIV-1 Replication through Multiple Target Binding.\\	2017	Chembiochem : a European journal of chemical biology, 02-16, Volume: 18, Issue:4	Natural Product Kuwanon-L Inhibits HIV-1 Replication through Multiple Target Binding.
AID1801910	HIV-1 RT Colorimetric Assay from Article 10.1016/j.bioorg.2016.05.009: \\Rational design, synthesis, anti-HIV-1 RT and antimicrobial activity of novel 3-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-1-(piperazin-1-yl)propan-1-one derivatives.\\	2016	Bioorganic chemistry, 08, Volume: 67	Rational design, synthesis, anti-HIV-1 RT and antimicrobial activity of novel 3-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-1-(piperazin-1-yl)propan-1-one derivatives.
AID1795438	HIV-1 RT Assay from Article 10.1016/S0960-894X(01)00331-6: \\Synthesis and evaluation of novel quinolinones as HIV-1 reverse transcriptase inhibitors.\\	2001	Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14	Synthesis and evaluation of novel quinolinones as HIV-1 reverse transcriptase inhibitors.
AID1795433	HIV-1 RT Assay from Article 10.1021/jm990580e: \\Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.\\	2000	Journal of medicinal chemistry, May-18, Volume: 43, Issue:10	Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID1802514	RNAse H-Polymerase-Independent Cleavage Assay from Article 10.1002/cbic.201600592: \\Natural Product Kuwanon-L Inhibits HIV-1 Replication through Multiple Target Binding.\\	2017	Chembiochem : a European journal of chemical biology, 02-16, Volume: 18, Issue:4	Natural Product Kuwanon-L Inhibits HIV-1 Replication through Multiple Target Binding.
AID1795727	HIV-1 RT Assay from Article 10.1016/j.bmc.2004.11.045: \\Studies of non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: synthesis and structure-activity relationships of 2-cyano and 2-hydroxy thiazolidenebenzenesulfonamide derivatives.\\	2005	Bioorganic & medicinal chemistry, Feb-15, Volume: 13, Issue:4	Studies of non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: synthesis and structure-activity relationships of 2-cyano and 2-hydroxy thiazolidenebenzenesulfonamide derivatives.
AID1795435	HIV-1 RT Assay from Article 10.1016/s0960-894x(99)00486-2: \\Synthesis and evaluation of analogs of Efavirenz (SUSTIVA) as HIV-1 reverse transcriptase inhibitors.\\	1999	Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19	Synthesis and evaluation of analogs of Efavirenz (SUSTIVA) as HIV-1 reverse transcriptase inhibitors.
AID1795437	HIV-1 RT Assay from Article 10.1016/s0960-894x(00)00321-8: \\Synthesis and evaluation of quinoxalinones as HIV-1 reverse transcriptase inhibitors.\\	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Synthesis and evaluation of quinoxalinones as HIV-1 reverse transcriptase inhibitors.
AID1798815	Reverse Transcriptase Assay from Article 10.1021/jm801322h: \\Novel Indazole Non-Nucleoside Reverse Transcriptase Inhibitors Using Molecular Hybridization Based on Crystallographic Overlays (dagger).\\	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays.
AID1795436	HIV-1 RT Assay from Article 10.1016/s0960-894x(99)00565-x: \\Synthesis and evaluation of benzoxazinones as HIV-1 reverse transcriptase inhibitors. Analogs of Efavirenz (SUSTIVA).\\	1999	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22	Synthesis and evaluation of benzoxazinones as HIV-1 reverse transcriptase inhibitors. Analogs of Efavirenz (SUSTIVA).
AID1801530	In-vitro HIV-1 RT Screening from Article 10.1016/j.bioorg.2015.12.005: \\Design, synthesis and in-vitro evaluation of novel tetrahydroquinoline carbamates as HIV-1 RT inhibitor and their antifungal activity.\\	2016	Bioorganic chemistry, Feb, Volume: 64	Design, synthesis and in-vitro evaluation of novel tetrahydroquinoline carbamates as HIV-1 RT inhibitor and their antifungal activity.
AID1801804	RNA-dependent DNA Polymerase (RDDP) Assay from Article 10.1002/cbic.201500668: \\Inhibition of HIV-1 Reverse Transcriptase Dimerization by Small Molecules.\\	2016	Chembiochem : a European journal of chemical biology, Apr-15, Volume: 17, Issue:8	Inhibition of HIV-1 Reverse Transcriptase Dimerization by Small Molecules.
AID1802605	HIV-1 RT In-Vitro Assay from Article 10.1016/j.bioorg.2017.03.013: \\Synthesis and study of anti-HIV-1 RT activity of 5-benzoyl-4-methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one derivatives.\\	2017	Bioorganic chemistry, 06, Volume: 72	Synthesis and study of anti-HIV-1 RT activity of 5-benzoyl-4-methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one derivatives.
AID1795434	HIV-1 RT Assay from Article 10.1016/s0960-894x(01)00239-6: \\4,1-Benzoxazepinone analogues of efavirenz (Sustiva) as HIV-1 reverse transcriptase inhibitors.\\	2001	Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11	4,1-Benzoxazepinone analogues of efavirenz (Sustiva) as HIV-1 reverse transcriptase inhibitors.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID586360	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase T66I mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficiency vir	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID1292013	Selectivity index, ratio of CC50 for mock infected human MT4 cells to EC50 for HIV1 RES056 harboring reverse transcriptase K103N/YI81C double mutant infected in human MT4 cells	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket.
AID248880	Inhibitory concentration against human immunodeficiency virus type 1 (with K103N/Y181C resistant mutation) was determined in HeLa-CD4 MAGI assay	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
AID587749	Antiviral activity against single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef infected in human HeLa-T4 cells assessed as inhibition of 2 mins magnetic nanopartials-medated infectiv	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID342718	Inhibition of HIV1 reverse transcriptase RNA-dependent DNA polymerase activity assessed as incorporation of radioactive dTTP into poly(rA)/oligo(DT)	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Novel N1-substituted 1,3-dihydro-2H-benzimidazol-2-ones as potent non-nucleoside reverse transcriptase inhibitors.
AID1212882	Drug metabolism in microsomes expressing CYP2B6.1 (unknown origin) assessed as enzyme-mediated 8-hydroxyefavirenz metabolite formation measured per pmol of P450 after 15 mins by HPLC/UV system in presence of Cyt b5 coexpression	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
AID1457056	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human ML4 cells assessed as protection against virus-induced cytopathic effect measured on day 5 post infection by MTT assay	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
AID1884225	Antiviral activity against HIV-1 harboring K103N mutant infected in human MT4 cells assessed as reduction in virus induced cytotoxicity incubated for 5 to 7 days by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Chemical space exploration around indolylarylsulfone scaffold led to a novel class of highly active HIV-1 NNRTIs with spiro structural features.
AID1729149	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect by MTT assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp
AID557040	Antiviral activity against HIV1 isolate R8 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs in presence of 10% FBS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID1435502	Antiviral activity against HIV1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
AID416758	Antiviral activity against HIV1 with reverse transcriptase Y181I mutation in human CEM cells assessed as protection against virus-induced cytopathicity	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID586486	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase E138A/S147G/Q148R mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunod	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID1348220	Antiviral activity against HIV1 pNL4-3 infected in HEK293 cells assessed as reduction in viral transcription by measuring decrease in luciferase activity at 1 uM after 20 hrs by luciferase reporter gene assay	2017	Journal of natural products, 12-22, Volume: 80, Issue:12	Oxazole-Containing Diterpenoids from Cell Cultures of Salvia miltiorrhiza and Their Anti-HIV-1 Activities.
AID279397	Antiviral activity against HIV1 isolate with RT 188L mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1157592	Antiviral activity against 6-[(3,5-Dimethylphenyl)fluoromethyl]-5-ethyl-1-{[[4-(3-hydroxyprop-1-ynyl)benzyl]oxy]methyl}pyrimidine-2,4(1H,3H)-dione-resistant HIV1 harboring RT 106I, 181C mutant infected in human MT4 cells assessed as inhibition of virus-in	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID1171588	Resistance index, ratio of EC50 for HIV1 NL4-3 expressing reverse transcriptase K103N mutant to EC50 for wild type HIV1 NL4-3	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID522368	Antiviral activity against wild type HIV1 infected in MAGIC-5 cells using 5-bromo4-chloro-3-indolyl-beta-D-galactopyranoside staining based light microscopy	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
AID1069710	Inhibition of GST-tagged recombinant wild type HIV-1 reverse transcriptase p66/p51 RNA-dependent DNA polymerase activity expressed in Escherichia coli JM109 using dTTP as substrate after 40 mins by spectrofluorometric analysis	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Design and synthesis of N₁-aryl-benzimidazoles 2-substituted as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID198563	The compound was evaluated for the inhibition of HIV-1 reverse transcriptase	2000	Bioorganic & medicinal chemistry letters, Jan-17, Volume: 10, Issue:2	Novel 2,2-dioxide-4,4-disubstituted-1,3-H-2,1,3-benzothiadiazines as non-nucleoside reverse transcriptase inhibitors.
AID709836	Ratio of EC50 for HIV1 expressing wild type reverse transcriptase in presence of human serum albumin and human alpha-1 acid glycoprotein to EC50 for HIV1 expressing wild type reverse transcriptase	2012	Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23	Rational design of potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID1784586	Inhibition of HIV-1 reverse transcriptase using Cy5-CAGGAAACAGCTATGAC/3'-GTCCTTTGTCGATACTGTTTTTTT-5' as primer/template at 5 to 50 uM preincubated for 20 min followed by dATP addition measured after 5 to 10 mins by gel electrophoresis analysis	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Exploring the dNTP -binding site of HIV-1 reverse transcriptase for inhibitor design.
AID1059143	Cytotoxicity against human MT4 cells after 5 days by MTT assay	2013	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24	Novel piperidinylamino-diarylpyrimidine derivatives with dual structural conformations as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID496630	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase Y181C/V35T, V60I, I135V, S162A, K173T, Q174K, N175Y, D177E, T200A, Q207E, R211K, H221Y mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID523481	Antiviral activity against HIV1 with RT connection domain G190S/T369I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID1574388	Resistance index, ratio of ID50 for recombinant HIV-1 His-tagged reverse transcriptase p66/p51 K103N mutant to ID50 for recombinant wild type HIV-1 reverse transcriptase His-tagged p66/p51	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.
AID557019	Inhibition of HIV1 isolate R8 reverse transcriptase after 90 mins	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID248261	In vitro inhibitory concentration against HIV L100I mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
AID1197832	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.
AID266347	Inhibition of HIV1 reverse transcriptase Y181C mutant in 293T cells	2006	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11	New HIV-1 reverse transcriptase inhibitors based on a tricyclic benzothiophene scaffold: synthesis, resolution, and inhibitory activity.
AID293563	Antiviral activity against HIV1 LAI with RT L100I and K103N mutation in MT4 cells by EGFP based replication assay	2007	European journal of medicinal chemistry, May, Volume: 42, Issue:5	Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains.
AID279472	Antiviral activity against HIV1 isolate with RT 103S mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID247500	Inhibitory activity against HIV-1 mutant strain 179E	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID527562	Antiviral activity against HIV1 NL4-3 containing reverse transcriptase K103N mutation infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Discovery and SAR of a series of 4,6-diamino-1,3,5-triazin-2-ol as novel non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1057040	Antiviral activity against wild-type HIV1 3B infected in MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Design, synthesis and biological evaluation of 3-benzyloxy-linked pyrimidinylphenylamine derivatives as potent HIV-1 NNRTIs.
AID508752	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase V179I, Y181C mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID141359	Potency of second-generation NNRTIs against Mutant HIV-1 sV179D/L100I/Y181C free drug	2000	Journal of medicinal chemistry, May-18, Volume: 43, Issue:10	Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID1572525	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytotoxicity after 5 days by MTT assay
AID1457069	Downregulation of iNOS mRNA levels in C57BL/6 mouse BV2 cells at 1000 nM after 24 hrs by RT-PCR assay	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
AID698299	Selectivity index, ratio of EC50 for HIV1 containing reverse transcriptase Y188L mutant to EC50 for wild type HIV1 NL4-3	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID199980	Inhibitory activity against human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT)	2002	Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14	Prediction of activity for nonnucleoside inhibitors with HIV-1 reverse transcriptase based on Monte Carlo simulations.
AID1750721	Inhibition of HIV-1 p66/p51 reverse transcriptase E138K mutant incubated for 40 mins by picogreen dye-based spectrofluorometric analysis	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from
AID443680	Antiviral activity against HIV with reverse transcriptase Y188L mutant assessed as inhibition of viral replication	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
AID1059146	Antiviral activity against HIV1 3B infected in human MT-4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay	2013	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24	Novel piperidinylamino-diarylpyrimidine derivatives with dual structural conformations as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID443684	Antiviral activity against HIV with reverse transcriptase K103N/Y181C double mutant assessed as inhibition of viral replication	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
AID519866	Antiviral activity against HIV1 subtype B-93US143 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID1729153	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for antiviral activity against HIV HIV1 RES056 harboring K103N/Y181C double mutant infected in human MT4 cells	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp
AID1884223	Selectivity index, ratio of CC50 for cytotoxicity against human MT4 cells to EC50 for antiviral activity against wildtype HIV-1 3B infected in human MT4 cells	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Chemical space exploration around indolylarylsulfone scaffold led to a novel class of highly active HIV-1 NNRTIs with spiro structural features.
AID1435505	Antiviral activity against HIV1 expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
AID541171	Selectivity ratio of EC50 for antiviral activity against HIV1 harboring L74M and E92V mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1198749	Inhibition of HIV1 reverse transcriptase-associated RNA-dependent DNA polymerase activity after 30 mins	2015	European journal of medicinal chemistry, Mar-26, Volume: 93	(3Z)-3-(2-[4-(aryl)-1,3-thiazol-2-yl]hydrazin-1-ylidene)-2,3-dihydro-1H-indol-2-one derivatives as dual inhibitors of HIV-1 reverse transcriptase.
AID361920	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase P225H mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1773458	Resistance factor, ratio of EC50 for HIV1 harboring K103N mutant infected in human MT4 cells to EC50 for HIV1 3B infected in MT4 cells
AID1456310	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	2017	Bioorganic & medicinal chemistry, 04-15, Volume: 25, Issue:8	Structural modifications of diarylpyrimidines (DAPYs) as HIV-1 NNRTIs: Synthesis, anti-HIV activities and SAR.
AID361924	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/V108I mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID496624	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase E138A/A33E, V35T, T39A, D123E, S162A, Q174G, T200E, I202V, Q207E mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID241472	Inhibitory concentration against HIV-1 mutant reverse transcriptase (Y181C)	2005	Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11	Structure-based design, parallel synthesis, structure-activity relationship, and molecular modeling studies of thiocarbamates, new potent non-nucleoside HIV-1 reverse transcriptase inhibitor isosteres of phenethylthiazolylthiourea derivatives.
AID1561717	Antiviral activity against HIV1 3B infected in human MT4 cells grown under 30 passages in presence of (E)-4-((4-((4-(4-(2-Cyanovinyl)-2,6-dimethylphenoxy)thieno[2,3- d]pyrimidin-2-yl)amino)piperidin-1-yl)methyl)benzenesulfonamide assessed as protection ag
AID446239	Cytotoxicity against human SupT1 cells	2009	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20	Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
AID698300	Selectivity index, ratio of EC50 for HIV1 containing reverse transcriptase Y181C mutant to EC50 for wild type HIV1 NL4-3	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1815390	Selectivity index, ratio of CC50 for cytotoxicity against human MT4 cells to EC50 of Anti-HIV activity against HIV-1 IIIB infected in human MT4	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID279480	Antiviral activity against HIV1 isolate with RT 100F mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1750719	Inhibition of HIV-1 p66/p51 reverse transcriptase Y181C mutant incubated for 40 mins by picogreen dye-based spectrofluorometric analysis	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from
AID1264550	Selectivity ratio for antiviral activity against HIV-1 expressing reverse transcriptase K101P mutant to HIV-1 expressing wild-type reverse transcriptase	2015	ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10	Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine Resistance.
AID1750723	Selectivity index, ratio of CC50 for cytotoxicity against human MT-4 cells to EC50 for inhibition of HIV-1 p66/51 reverse transcriptase L100I mutant	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from
AID541167	Selectivity ratio of EC50 for antiviral activity against HIV1 harboring Q148K mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID519891	Selectivity ratio of EC50 for 0.02 MOI HIV1 NL4-3 infected in human MT2 cells by MTS assay to EC50 for 0.02 MOI HIV1 NL4-3 infected in human MT2 cells by RT assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID619638	Antiviral activity against HIV-1 3B harboring RT Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
AID519876	Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID508768	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase M230I mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID386492	Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	2008	Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7	Thiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: Parallel synthesis, molecular modelling and structure-activity relationship studies on analogues of O-(2-phenylethyl)-N-phenylthiocarbamate.
AID665272	Antiviral activity against HIV1 RES056 harboring K103N/Y181C RT mutant infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2012	European journal of medicinal chemistry, Jul, Volume: 53	Chiral resolution, absolute configuration assignment and biological activity of racemic diarylpyrimidine CH(OH)-DAPY as potent nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID1884489	Antiviral activity against drug-resistant HIV-1 L100I mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.
AID490362	Antiviral activity against wild type HIV1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect in presence of 10 % fetal bovine serum	2010	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14	Discovery of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-benzyl derivatives with broad potency against resistant mutant viruses.
AID1880374	Selectivity index, ratio of CC50 for cytotoxicity against human MT4 cells to EC50 for antiviral activity against wild type HIV-1 IIIB infected in human MT4 cells	2022	Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12	Structure-Based Discovery of Novel NH
AID573246	Cmin in HIV-1 infected children at 10 to 15 mg/kg, po administered once daily by HPLC	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children?
AID508769	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase H221Y mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID253493	Dose required to inhibit HIV-1 reverse transcriptase activity (Y181I mutant) by 50%	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13	Novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. A structure-activity relationship investigation.
AID347607	Antiviral activity against wild type HIV HXB2 in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay in presence of 40% human serum	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.
AID448395	Inhibition of wild type HIV reverse transcriptase in presence of poly(rA) 300 template, (dT) 16 primer	2009	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19	Pyrazole NNRTIs 3: optimisation of physicochemical properties.
AID1157580	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID1171593	Inhibition of wild type HIV1 reverse transcriptase assessed as reduction in enzyme activity	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1736361	Antiviral activity against VSVG/HIV-1 harboring reverse transcriptase V108I/K103N double mutant infected in human HEK 293T cells assessed as inhibition of virus replication preincubated with cells for 15 mins prior to viral infection and measured at 48 hr
AID508758	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase K103N, Y181I mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1316335	Selectivity index, ratio of CC50 for human mock-infected MT4 cells to EC50 for HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID1583022	Selectivity index, ratio of CC50 for cytotoxicity in mock-infected human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay to EC50 for antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection	2020	Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3	Discovery and Characterization of Fluorine-Substituted Diarylpyrimidine Derivatives as Novel HIV-1 NNRTIs with Highly Improved Resistance Profiles and Low Activity for the hERG Ion Channel.
AID1815400	Inhibition of HIV1 reverse transcriptase Y188L mutant using oligo(dT)16 as primer measured after 40 mins by picogreen-dye based spectrofluorimetric analysis	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID1212918	Drug metabolism in microsomes expressing CYP2B6.6 (unknown origin) assessed as enzyme-mediated 8-hydroxyefavirenz metabolite formation measured per pmol of P450 after 15 mins by HPLC/UV system in absence of Cyt b5 coexpression	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
AID279464	Antiviral activity against HIV1 isolate with RT 101Q, 103N, 225H mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1379964	Inhibition of recombinant wild type HIV1 reverse transcriptase p66/p51 assessed as reduction in biotin-dUTP incorporation incubated for 40 mins using poly(rA) template and oligo(dT)16 primer by picogreen dye based spectrofluorometry	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives as potent HIV-1 NNRTIs.
AID82272	Effective concentration required to achieve 50% inhibition of HIV-1 multiplication in MT-4-infected wild type cells	2002	Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26	Synthesis of novel N-1 (allyloxymethyl) analogues of 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine) with improved activity against HIV-1 and its mutants.
AID523356	Antiviral activity against HIV1 with RT connection domain Y181C/T369I/N348I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID302270	Resistance index, ratio of Ki for HIV1 reverse transcriptase Y181I mutant to Ki for wild type HIV1 3B reverse transcriptase	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID82141	Effective concentration required to achieve 50% inhibition of HIV-1 multiplication in MT-4-infected K103N strain	2002	Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26	Synthesis of novel N-1 (allyloxymethyl) analogues of 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine) with improved activity against HIV-1 and its mutants.
AID1069707	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV-1 3B	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Design and synthesis of N₁-aryl-benzimidazoles 2-substituted as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1435504	Antiviral activity against HIV1 expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
AID1316336	Antiviral activity against HIV1 3B harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID586367	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase F121Y mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficiency vi	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID1731747	Inhibition of reverse transcriptase K103N mutant in HIV-1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay
AID368569	Inhibition of HIV1 recombinant reverse transcriptase K103N mutant-DNA-dNTP ternary complex expressed in Escherichia coli BL21	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.
AID562698	Antiviral activity against HIV1 NL4-3 infected in HEK293 cells assessed as decrease in virus production at 2 times EC90 after 72 hrs by beta-galactosidase reporter gene assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation.
AID698303	Cytotoxicity against mock-infected human MT4 cells measured after 5 days by MTT assay	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID464767	Binding affinity to human serum albumin	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	N1-Heterocyclic pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID1352318	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 4 days by MTT assay	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.
AID293176	Antiviral activity against HIV1 RT 181C mutant assessed as inhibition of viral-induced cytopathicity in MT4 cells by MTT method	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Structure-activity relationship in the 3-iodo-4-phenoxypyridinone (IOPY) series: The nature of the C-3 substituent on anti-HIV activity.
AID391224	Antiviral activity against wild type HIV1 infected in human MT4 cells after 72 hrs in presence of 10% fetal bovine serum	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID152959	Antiviral activity of Protein Binding of compound was evaluated for Thai 9466 virus expressed PBMC by P24	2000	Journal of medicinal chemistry, May-18, Volume: 43, Issue:10	Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID1171597	Inhibition of wild type HIV1 reverse transcriptase V106A mutant assessed as reduction in enzyme activity	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1186000	Antiviral activity against HIV1 harboring reverse transcriptase K103N/P225H double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
AID650690	Inhibition of HIV 1 reverse transcriptase Y181I mutant assessed as inhibition of time-dependent incorporation of [3H]dTTP into poly(rA)n.oligo(dT)	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
AID1261312	Antiviral activity against BVDV infected in MDBK cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID1165074	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.
AID1736349	Inhibition of RNase H activity of HIV-1 reverse transcriptase using DNA/RNA hybrid as substrate incubated for 30 mins by fluorescence based analysis
AID464765	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT2 cells	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	N1-Heterocyclic pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID1653628	Activation of recombinant human C-terminal 4His-tagged CYP46A1 delta(2 to 50) F416A mutant expressed in Escherichia coli at 20 uM using cholesterol as substrate measured after 30 mins in presence of cytochrome P450 oxidoreductase by gas chromatography-mas	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds.
AID476471	Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase Y181C mutation by MTT assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives.
AID1457057	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human ML4 cells assessed as protection against virus-induced cytopathic effect measured on day 5 post infection by MTT assay	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
AID240140	Concentration required to inhibit HIV-1 reverse transcriptase activity (wild-type) by 50%	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13	Novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. A structure-activity relationship investigation.
AID572179	Antiviral activity against HIV-1 subtype O V029524 harboring NNRTI A98G, V179E and Y181C mutant infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID1157581	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID665549	Cytotoxicity against human MT4 cells after 5 days by MTT assay	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors.
AID1773459	Resistance factor, ratio of EC50 for HIV1 harboring Y18IC mutant infected in human MT4 cells to EC50 for HIV1 3B infected in MT4 cells
AID298079	Antiviral activity against HIV1 RT 112 mutant in lymphocytes assessed as reduction of p24 antigen production	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity.
AID263513	Antiviral activity against HIV1 K103N mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2.
AID279488	Antiviral activity against HIV1 isolate with RT G190S mutation	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID82271	Effective concentration required to achieve 50% inhibition of HIV-1 multiplication in MT-4-infected Y181C strain	2002	Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26	Synthesis of novel N-1 (allyloxymethyl) analogues of 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine) with improved activity against HIV-1 and its mutants.
AID279402	Antiviral activity against HIV1 isolate with RT 103N, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID508658	Antiviral activity against Human immunodeficiency virus 1 subtype O isolate BCF03 infected in human PBMC cells by cell based assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1880380	Antiviral activity against HIV-1 IIIB harboring reverse transcriptase E138K mutant infected in human MT4 cells by MTT assay	2022	Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12	Structure-Based Discovery of Novel NH
AID1736348	Antiviral activity against VSVG/HIV-1 harboring reverse transcriptase K103N mutant infected in human HEK 293T cells assessed as inhibition of virus replication preincubated with cells for 15 mins prior to viral infection and measured at 48 hrs post-infect
AID279414	Antiviral activity against HIV1 isolate with RT 108I, 181C mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1750716	Selectivity index, ratio of CC50 for human MT-4 cells to EC50 for HIV-1 infected in MT-4 cells	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from
AID1773446	Antiviral activity against HIV1 harboring K103N mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenic effect by MTT assay
AID1609105	Selectivity index, ratio of CC50 for human MT4 cells to EC50 of antiviral activity against HIV-1 IIIB infected in human MT4 cells	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID508756	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase V179D, Y181C mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID576026	Half life in healthy human plasma at 400 mg, po measured on day 1 post dose by liquid chromatography-tandem mass spectrometry	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.
AID465423	Volume of distribution at steady state in Beagle dog at 0.5 mg/kg, iv or. 5 mg/kg, po	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	N1-Alkyl pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID519874	Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID573982	Ratio of EC50 for Human immunodeficiency virus 1 3B to EC50 for Simian immunodeficiency virus MAC 251	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.
AID247501	Inhibitory activity against HIV-1 mutant strain 181C	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID523482	Antiviral activity against HIV1 with RT connection domain G190S/T369I/N348I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID226236	Fold resistance (L100I/ WT) (as per ref 10 in the article)	2001	Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21	Antiviral drug design: computational analyses of the effects of the L100I mutation for HIV-RT on the binding of NNRTIs.
AID576048	Reduction in ABCC1 mRNA expression in healthy human at 400 mg, po qd for 14 days by RT-PCR	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.
AID519962	Selectivity ratio of EC50 for 0.05 MOI HIV1 NL4-3 infected in 2 hrs pretreated human MT2 cells by MTS assay to EC50 for 0.05 MOI HIV1 NL4-3 infected in 2 hrs pretreated human MT2 cells by RT assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID586384	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase N155S mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficiency vi	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID1379961	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by measuring virus-induced syncytium formation by MTT assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives as potent HIV-1 NNRTIs.
AID293558	Antiviral activity against HIV1 LAI with RT L100I mutation in MT4 cells by EGFP based replication assay	2007	European journal of medicinal chemistry, May, Volume: 42, Issue:5	Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains.
AID269686	Antiviral activity against HIV1 NNTRI resistant Y188L mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269686	Antiviral activity against HIV1 NNTRI resistant Y188L mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269686	Antiviral activity against HIV1 NNTRI resistant Y188L mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1731745	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for antiviral activity against HIV IIIB
AID267859	Cytotoxicity against MT4 cells by MTT assay	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Synthesis and biological investigation of S-aryl-S-DABO derivatives as HIV-1 inhibitors.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1773449	Antiviral activity against wild type HIV1 harboring E138K mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenic effect by MTT assay
AID464772	Oral bioavailability in Beagle dog at 4 mg/kg, po	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	N1-Heterocyclic pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID366557	Antiviral activity against HIV1 with reverse transcriptase G190A mutation in human MT4 cells assessed as reduction of virus-induced cytopathic effect	2008	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 18, Issue:15	Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID1596751	Antiviral activity against wild type HIV-1 3B infected in MT4 cells measured after 5 days by MTT assay	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Synthesis and biological evaluation of dihydroquinazoline-2-amines as potent non-nucleoside reverse transcriptase inhibitors of wild-type and mutant HIV-1 strains.
AID508830	Antiviral activity against Human immunodeficiency virus 1 subtype B isolate WEJO infected in human PBMC cells by cell based assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1357795	Resistance factor, ratio of EC50 for HIV1 harboring reverse transcriptase K103N mutant to EC50 for wild-type HIV-1 3B	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID443699	Antiviral activity against HIV with reverse transcriptase G190S mutant assessed as inhibition of viral replication relative to wild type	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
AID1212893	Drug metabolism in human liver microsomes harboring CYP2B61/1 genotype assessed as CYP2B6 variant-mediated 8-hydroxyefavirenz metabolite formation measured per mg protein after 15 mins by LC/MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
AID449492	Selective index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1435509	Antiviral activity against HIV1 RES056 expressing reverse transcriptase mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
AID1457058	Antiviral activity against HIV1 harboring reverse transcriptase K103N /Y1881C double mutant infected in human ML4 cells assessed as protection against virus-induced cytopathic effect measured on day 5 post infection by MTT assay	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
AID1126506	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay	2014	Bioorganic & medicinal chemistry, Apr-15, Volume: 22, Issue:8	Structural modifications of CH(OH)-DAPYs as new HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1558855	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Ligand-Based Design of Nondimethylphenyl-Diarylpyrimidines with Improved Metabolic Stability, Safety, and Oral Pharmacokinetic Profiles.
AID1653620	Inhibition of recombinant human C-terminal 4His-tagged CYP46A1 delta(2 to 50) mutant expressed in Escherichia coli at 60 to 100 uM using cholesterol as substrate measured after 30 mins in presence of cytochrome P450 oxidoreductase by gas chromatography-ma	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds.
AID298081	Selectivity index, ratio of TC50 for lymphocytes to ED50 for HIV1 3B	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity.
AID1435516	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 expressing reverse transcriptase E138K mutant
AID508782	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase E138Q mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1609110	Inhibition of recombinant HIV-1 reverse transcriptase p66/p51 incubated for 40 mins by picogreen dye based spectrofluorometric assay	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID607875	Cytotoxic activity against human MT4 cells assessed as viability of mock-infected cells after 5 days by MTT assay	2011	Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14	Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6-((3,4-dihydroquinolin-1(2H)-yl)methyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1736357	Antiviral activity against VSVG/HIV-1 harboring reverse transcriptase K103N/Y181C double mutant infected in human HEK 293T cells assessed as inhibition of virus replication preincubated with cells for 15 mins prior to viral infection and measured at 48 hr
AID541170	Selectivity ratio of EC50 for antiviral activity against HIV1 harboring N155S mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1212915	Drug metabolism in microsomes expressing CYP2B6.1 (unknown origin) assessed as enzyme-mediated 8-hydroxyefavirenz metabolite formation measured per pmol of P450 after 15 mins by HPLC/UV system in absence of Cyt b5 coexpression	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
AID1736346	Selectivity index, ratio of CC50 for human HEK 293T cells to EC50 for VSVG/wild type HIV1 infected in human HEK 293T cells
AID573985	Antiviral activity against Reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.
AID557025	Antiviral activity against HIV1 isolate R8 harboring reverse transcriptase K103N and G190A mutant relative to drug-sensitive HIV1 CNDO	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID443704	Antiviral activity against HIV with reverse transcriptase K103N/P225H double mutant assessed as inhibition of viral replication relative to wild type	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
AID587739	Cytotoxicity against human HeLaT4 cells by WST-1 assay	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID675390	Antiviral activity against HIV1 infected in human MT4 cells assessed as virus-induced cytopathogenicity after 4 days by MTT assay	2012	European journal of medicinal chemistry, Sep, Volume: 55	Disubstituted thiourea derivatives and their activity on CNS: synthesis and biological evaluation.
AID556525	Antiviral activity against Human immunodeficiency virus 1 clone 38086 harboring K49R, V60I, I135V, Q145M, Q174H, G196E, Q207E, R211K, V245K mutation in reverse transcriptase by phenosense assay relative to wild type	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
AID1390711	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8	First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain.
AID1220368	Drug metabolism in human seminal plasma assessed as formation of N- and O-linked glucuronidated metabolite at 100 mg administered every 4 hrs by UPLC-MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2	Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid.
AID1815402	Inhibition of HIV1 reverse transcriptase F227L/V106A double mutant using oligo(dT)16 as primer measured after 40 mins by picogreen-dye based spectrofluorimetric analysis	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID1736367	Selectivity index, ratio of EC50 for antiviral activity against VSVG/HIV-1 harboring reverse transcriptase G190A/K103N double mutant infected in human HEK 293T cells to EC50 for antiviral activity against VSVG/wild type HIV-1 infected in human HEK293T cel
AID519877	Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID622058	Ratio of Ki for HIV1 RT p66/p66 homodimer K103N/Y181C double mutant to Ki for wild-type HIV1 RT p66/p66 homodimer	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID82967	Inhibitory activity against HIV-1 reverse transcriptase	1999	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22	Synthesis and evaluation of benzoxazinones as HIV-1 reverse transcriptase inhibitors. Analogs of Efavirenz (SUSTIVA).
AID1750726	Selectivity index, ratio of CC50 for cytotoxicity against human MT-4 cells to EC50 for inhibition of HIV-1 p66/51 reverse transcriptase Y188L mutant	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from
AID1754639	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for Antiviral activity against HIV-1 IIIB infected in human MT4 cells	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses.
AID1884486	Antiviral activity against NNRTI resistant wild type HIV-1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.
AID1418468	Inhibition of recombinant wild-type HIV1 GST-fused reverse transcriptase p66/p51 RNA-dependent DNA polymerase activity expressed in Escherichia coli assessed as reduction in biotin-dUTP incorporation using poly(rA)/oligo(dT)16 as template/primer after 40	2018	Bioorganic & medicinal chemistry letters, 12-01, Volume: 28, Issue:22	Design and synthesis of a novel series of non-nucleoside HIV-1 inhibitors bearing pyrimidine and N-substituted aromatic piperazine.
AID658566	Resistance factor, ratio of EC50 for multidrug-resistant HIV1 695-RT infected in HEK293T cells to wildtype HIV1 infected in HEK293T cells	2012	Journal of natural products, Mar-23, Volume: 75, Issue:3	Library-based discovery and characterization of daphnane diterpenes as potent and selective HIV inhibitors in Daphne gnidium.
AID370724	Inhibition of RNA dependent DNA polymerase activity of HIV1 recombinant reverse transcriptase p66/p51 expressed in Escherichia coli JM109	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations.
AID82461	Antiviral activity against K103N/L100I strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1316346	Selectivity index, ratio of CC50 for human mock-infected MT4 cells to EC50 for HIV1 3B harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID583847	Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase V108I, E138K mutant infected in human SupT1 cells derived from 9 viral passages with lersivirine assessed as inhibition of viral replication after 21 days relative to drug sensitive HIV	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID1163230	Antitrypanocidal activity against suramin-sensitive Trypanosoma brucei brucei Squib427 assessed as reduction in parasite growth after 72 hrs	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID738333	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs.
AID1057036	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Design, synthesis and biological evaluation of 3-benzyloxy-linked pyrimidinylphenylamine derivatives as potent HIV-1 NNRTIs.
AID1457065	Inhibition of HIV1 reverse transcriptase p66 Y181I mutant associated RNA dependent DNA polymerase activity expressed in Escherichia coli assessed as reduction in [3H]dTTP incorporation using poly(rA)/oligo(dT) as template/primer by scintillation counting	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
AID1212895	Drug metabolism in human liver microsomes harboring CYP2B66/6 genotype assessed as CYP2B6 variant-mediated 8-hydroxyefavirenz metabolite formation measured per mg protein after 15 mins by LC/MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
AID279407	Antiviral activity against HIV1 isolate with RT 98G, 103N mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID572176	Antiviral activity against HIV-1 subtype H V022827 harboring NNRTI V179I mutant infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID1168820	Activity of CYP2B6 (unknown origin) assessed as maximum depletion rate constant pre-incubated for 5 mins in presence of NADPH by uHPLC-MS/MS based substrate depletion kinetics assay	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Structure-Activity Studies Reveal the Oxazinone Ring Is a Determinant of Cytochrome P450 2B6 Activity Toward Efavirenz.
AID635346	Cytotoxicity against human MT4 cells measured by MTT assay	2011	Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23	Design, synthesis and biological evaluation of cycloalkyl arylpyrimidines (CAPYs) as HIV-1 NNRTIs.
AID1212894	Drug metabolism in human liver microsomes harboring CYP2B61/6 genotype assessed as CYP2B6 variant-mediated 8-hydroxyefavirenz metabolite formation measured per mg protein after 15 mins by LC/MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
AID523350	Antiviral activity against HIV1 with RT connection domain K103N/N348I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID1763906	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 06-15, Volume: 40	Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs.
AID738334	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs.
AID586371	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase Y143C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficiency vi	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID263518	Antiviral activity against HIV1 V179E mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2.
AID1198753	Inhibition of HIV1 reverse transcriptase Lys103Asn mutant-associated DNA polymerase-independent RNase H activity after 1 hr	2015	European journal of medicinal chemistry, Mar-26, Volume: 93	(3Z)-3-(2-[4-(aryl)-1,3-thiazol-2-yl]hydrazin-1-ylidene)-2,3-dihydro-1H-indol-2-one derivatives as dual inhibitors of HIV-1 reverse transcriptase.
AID313876	Antiviral activity against HIV1 in MT4 cells	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3	Triazole derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase--structure-activity relationships and crystallographic analysis.
AID1483285	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for reverse transcriptase F227L/V106A double mutant in human MT4 cells infected HIV1 3B	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
AID1077223	Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach.
AID328844	Inhibition of human MRP2 expressed in MDCK2 cells assessed as increase in intracellular CMF fluorescence at 10 uM by CMFDA assay	2007	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3	Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.
AID361918	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K101E mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID527376	Toxicity in human CEM-SS cells	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Discovery and SAR of a series of 4,6-diamino-1,3,5-triazin-2-ol as novel non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1155819	Fold resistance, ratio of ID50 for HIV-1 recombinant NNTRI-resistant reverse transcriptase L100I mutant to ID50 for wild type HIV-1 recombinant reverse transcriptase	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.
AID1565090	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay
AID1572530	Inhibition of HIV1 reverse transcriptase p66/p51 using poly(rA)/oligo(dT)16 as template/primer measured after 40 mins by pico-green based spectrofluorometric analysis
AID1357798	Resistance factor, ratio of EC50 for HIV1 harboring reverse transcriptase Y188L mutant to EC50 for wild-type HIV-1 3B	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID1156488	Selectivity index, ratio of CC50 for human MT4 cells to IC50 for wild type HIV1 3B	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.
AID279466	Antiviral activity against HIV1 isolate with RT 103N, 190S mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID293565	Antiviral activity against HIV1 LAI with RT F227C and V106A mutation in MT4 cells by EGFP based replication assay	2007	European journal of medicinal chemistry, May, Volume: 42, Issue:5	Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains.
AID246343	Effective concentration of the compound to inhibit HIV-1 mutant K103N+Y181C replication in HIV-infected MT-4 cells	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID584046	Ratio of IC50 for HIV1 reverse transcriptase F227C mutant to IC50 for wild type HIV1 reverse transcriptase	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID1435503	Antiviral activity against HIV1 expressing reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
AID279438	Antiviral activity against HIV1 isolate with RT 98G, 103N, 108I mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1741390	Inhibition of reverse transcriptase in HIV-1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID1327987	Antiviral activity against VSV-G pseudotyped HIV1 infected in human SupT1 cells after 48 hrs by luciferase reporter gene assay	2016	Journal of natural products, 09-23, Volume: 79, Issue:9	Eremophilane Sesquiterpenes from an Endophytic Fungus Periconia Species.
AID613687	Antitumor activity against human A375 cells xenografted in athymic nude Harlan mouse assessed as reduced tumor growth at 20 mg/kg, ip administered daily 5 days pre week measured every day	2011	Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16	Modulation of cell differentiation, proliferation, and tumor growth by dihydrobenzyloxopyrimidine non-nucleoside reverse transcriptase inhibitors.
AID1157598	Antiviral activity against HIV1 MP1308 infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID576041	Drug concentration in PBMCs of healthy human at 400 mg, po measured after 5 hrs on day 1 post dose by liquid chromatography-tandem mass spectrometry	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.
AID269797	Antiviral activity against HIV1 I135V mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269797	Antiviral activity against HIV1 I135V mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269797	Antiviral activity against HIV1 I135V mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID279453	Antiviral activity against HIV1 isolate with RT 98G, 100I, 103N mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID440082	Antiviral activity against HIV1 HXB2 harboring 190S mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
AID1705188	Antiviral activity against HIV1 harboring RT Y188L mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect by MTT assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains.
AID1594861	Inhibition of HIV1 reverse transcriptase	2019	Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10	The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.
AID573989	Ratio of EC50 for Human immunodeficiency virus 1 3B to EC50 for non nucleoside reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.
AID522374	Resistance index, ratio of EC50 for recombinant HIV1 harboring reverse transcriptase V106A mutant clone to EC50 for wild type HIV1	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
AID1653636	Binding affinity to recombinant human C-terminal 4His-tagged CYP46A1 delta(2 to 50) mutant expressed in Escherichia coli in absence of substrate at 24 degC by stopped-flow spectrophotometric method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds.
AID279460	Antiviral activity against HIV1 isolate with RT 103N, 108I, 181C, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1483269	Antiviral activity against wild type HIV1 3B harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
AID263507	Antiviral activity against HIV1 in HEK293T cells	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2.
AID663313	Resistance ratio of ID50 for HIV1 reverse transcriptase Y181I mutant to ID50 HIV1 wild type reverse transcriptase	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.
AID1884230	Inhibition of wild type HIV-1 reverse transcriptase assessed as reduction of biotin-dUTP incorporation into protein using ABTS as substrate incubated for 1 hrs by ELISA analysis	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Chemical space exploration around indolylarylsulfone scaffold led to a novel class of highly active HIV-1 NNRTIs with spiro structural features.
AID766431	Cytotoxicity against human MT2 cells by MTT assay	2013	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18	Extension into the entrance channel of HIV-1 reverse transcriptase--crystallography and enhanced solubility.
AID246244	Effective concentration against human immunodeficiency virus type 1 wild type srtain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).
AID279509	Antiviral activity against HIV1 isolate with RT F227L mutation in Hela-JC-53 cells	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1059145	Antiviral activity against drug-resistant HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT-4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay	2013	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24	Novel piperidinylamino-diarylpyrimidine derivatives with dual structural conformations as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID263517	Antiviral activity against HIV1 E138K mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2.
AID368556	Inhibition of HIV1 recombinant reverse transcriptase K103N mutant-mediated RNA-dependent DNA polymerase activity expressed in Escherichia coli BL21 assessed as [3H]dTTP incorporation by cell free-based scintillation counting	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.
AID1763900	Antiviral activity against HIV-1 IIIB harboring RT Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity incubated for 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 06-15, Volume: 40	Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs.
AID82470	Antiviral activity against V106I strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID105693	Anti-HIV-1 activity against K1001 strain was determined in MT-4 cells by the MTT method	2003	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24	3-iodo-4-phenoxypyridinones (IOPY's), a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID1784587	Inhibition of HIV-1 reverse transcriptase using 5'-Cy5CAGGAAACAGCTATGAC/3'-GTCCTTTGTCGATACTGTTTTTTT-5' as primer/template at 0.5 uM preincubated for 20 min followed by dATP addition measured after 5 to 10 mins by gel electrophoresis analysis	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Exploring the dNTP -binding site of HIV-1 reverse transcriptase for inhibitor design.
AID88370	Antiviral activity against K103N/Y181C mutant virus in the HeLa MAGI assay.	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1773840	Antiviral activity against HIV1 harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18	Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies.
AID1331267	Inhibition of HIV-1 reverse transcriptase assessed as reduction in biotin-labeled dNTP incorporation using streptavidine bound template measured after 1 hr by ELISA	2017	Bioorganic & medicinal chemistry letters, 01-01, Volume: 27, Issue:1	Design, synthesis and anti-HIV-1 RT evaluation of 2-(benzyl(4-chlorophenyl)amino)-1-(piperazin-1-yl)ethanone derivatives.
AID88377	Antiviral activity against V106A mutant virus in the HeLa MAGI assay.	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1687686	Cytotoxicity against human MT4 cells assessed as inhibition of cell viability by measuring reduction in absorbance at OD540 by MTT assay	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities.
AID586379	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase I151L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficiency vi	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID1316338	Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID1171411	Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay	2014	ACS medicinal chemistry letters, Nov-13, Volume: 5, Issue:11	Picomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl Ethers.
AID1705194	Inhibition of RNA-dependent DNA polymerase activity of wild type recombinant HIV-1 His-tagged p66/p51 reverse transcriptase assessed as inhibition of [3H]dTTP incorporation using poly(rA)/oligo(dT) as templates incubated for 15 mins by MicroBeta scintilla	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains.
AID523483	Antiviral activity against HIV1 with RT connection domain L100I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID302253	Antiviral activity against HIV1 with reverse transcriptase K103N mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID1264540	Antiviral activity against HIV-1 X4 expressing reverse transcriptase K103N mutant infected in human CD4+ T cells for 3 days by FACS analysis	2015	ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10	Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine Resistance.
AID1884490	Antiviral activity against drug-resistant HIV-1 K103 N mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.
AID253490	Dose required to inhibit HIV-1 reverse transcriptase activity (K103N mutant) by 50%	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13	Novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. A structure-activity relationship investigation.
AID246393	Effective concentration against human immunodeficiency virus type 1 mutated at 103N+181C	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.
AID366517	Antiviral activity against HIV1 NL4-3 in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.
AID1165079	Inhibition of HIV1 reverse transcriptase assessed as reduction in biotin-dUTP incorporation using poly(rA)-oligo(dT) as template/primer and digoxigenin-/biotin-labeled dUTP nucleotides incubated for 1 hr	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.
AID1691436	Antiviral activity against HIV1 RES056 infected in human MT4 cells assessed as reduction in virus-induced cell death incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, May-01, Volume: 193	In situ click chemistry-based rapid discovery of novel HIV-1 NNRTIs by exploiting the hydrophobic channel and tolerant regions of NNIBP.
AID105543	Inhibition of wild type HIV-1 in MT-4 cell culture (human T cell line)	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues.
AID1888691	Toxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
AID1163255	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 infected in human O positive erythrocyte assessed as reduction in parasitemia after 72 hrs	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID1286670	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in primary MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS assay	2016	Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5	Discovery of the Aryl-phospho-indole IDX899, a Highly Potent Anti-HIV Non-nucleoside Reverse Transcriptase Inhibitor.
AID1572522	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells
AID1761018	Antiviral activity against HIV-1 harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect measured after 5 days by MTT assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Design, synthesis, and evaluation of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase.
AID1157599	Antiviral activity against NRTI-resistant HIV1 MP1315 infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID198385	Inhibitory concentration for 50% inhibition of HIV-1 reverse transcriptase	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Synthesis and evaluation of quinoxalinones as HIV-1 reverse transcriptase inhibitors.
AID1191668	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenic effect	2015	Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5	Scaffold hopping: exploration of acetanilide-containing uracil analogues as potential NNRTIs.
AID541159	Selectivity ratio of EC50 for antiviral activity against GS-9160-resistant HIV1 selected after 8 passages to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1335213	Antiviral activity against HIV-1 NL4-3 harboring RT-Y188L mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID523357	Antiviral activity against HIV1 with RT connection domain G190A mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID248491	In vitro inhibitory concentration against HIV F227L and V106A mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
AID1206935	Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection from virus-induced cytopathicity after 4 days by MTT assay	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	Discovery of piperidin-4-yl-aminopyrimidine derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1750717	Inhibition of HIV-1 p66/p51 reverse transcriptase L100I mutant incubated for 40 mins by picogreen dye-based spectrofluorometric analysis	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from
AID586376	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase Q148H mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficiency vi	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID1729151	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp
AID1761014	Antiviral activity against HIV-1 harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect measured after 5 days by MTT assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Design, synthesis, and evaluation of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase.
AID1743618	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.
AID279479	Antiviral activity against HIV1 isolate with RT 179D, 181C mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID419085	Inhibition of HIV1 replication in human 293T cells preincubated 15 mins prior to infection measured after 48 hrs postinfection by luciferase reporter gene assay	2009	Bioorganic & medicinal chemistry, Apr-01, Volume: 17, Issue:7	Synthesis and biological evaluation of N4-(hetero)arylsulfonylquinoxalinones as HIV-1 reverse transcriptase inhibitors.
AID573975	Antiretroviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.
AID1636930	Antiviral activity against HIV1 3B harboring reverse transcriptase K103N/Y181C double mutant infected in human MT2 cells assessed as protection against viral infection by MTT method	2016	Bioorganic & medicinal chemistry, 10-15, Volume: 24, Issue:20	Computer-aided discovery of anti-HIV agents.
AID1847040	Inhibition of HIV-1 reverse transcriptase associated RNA-dependent DNA polymerase activity using poly(A)-oligo(dT) as template/primer incubated for 30 mins by multilabel counter plate reader analysis	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Quinolinonyl Non-Diketo Acid Derivatives as Inhibitors of HIV-1 Ribonuclease H and Polymerase Functions of Reverse Transcriptase.
AID490368	Antiviral activity against HIV1 expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect	2010	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14	Discovery of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-benzyl derivatives with broad potency against resistant mutant viruses.
AID508648	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase L100I, K103N, T386A mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID619636	Antiviral activity against HIV-1 3B harboring RT L100I mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
AID1357790	Antiviral activity against HIV1 harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID614139	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV1 IIIB infected in human MT4 cells	2011	Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17	Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs.
AID227244	The compound was evaluated for antiviral activity using whole cell assay	2000	Bioorganic & medicinal chemistry letters, Jan-17, Volume: 10, Issue:2	Novel 2,2-dioxide-4,4-disubstituted-1,3-H-2,1,3-benzothiadiazines as non-nucleoside reverse transcriptase inhibitors.
AID1220370	Blood plasma protein binding in human at 100 mg administered every 4 hrs by ultrafiltration method	2013	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2	Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid.
AID1574374	Antiviral activity against HIV-1 IRLL98 harboring reverse transcriptase M41L, D67N, Y181C, M184V, R211K, and T215Y mutants infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.
AID1888697	Antiviral activity against HIV1 with RT Y188L mutant infected in human MT4 cells cells assessed as protection against viral-induced cytopathogenecity by MTT assay
AID1773830	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 RES056 infected in human MT4 cells	2021	Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18	Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies.
AID1335201	Ratio of IC50 for HIV-1 NL4-3 harboring RT-K103N/V108I double mutant infected in HEK293T cells co-expressing vesicular stomatitis virus glycoprotein to IC50 for wild-type HIV-1 NL4-3 infected in HEK293T cells co-expressing vesicular stomatitis virus glyco	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID541164	Selectivity ratio of EC50 for antiviral activity against HIV1 harboring E92V mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1627029	Inhibition of HIV1 RT using 17-mer DNA/Alexa Fluor 488 5'-end labeled DNA/Alexa Fluor 555-aha-dUTP as primer/template/substrate preincubated for 10 mins followed substarte addition measured after 30 mins by FRET assay	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Discovery, characterization, and lead optimization of 7-azaindole non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID279446	Antiviral activity against HIV1 isolate with RT 101Q, 181C mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1126511	Inhibition of wild-type HIV1 reverse transcriptase p66/p51 after 40 mins by spectrophotometry	2014	Bioorganic & medicinal chemistry, Apr-15, Volume: 22, Issue:8	Structural modifications of CH(OH)-DAPYs as new HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID82276	Effective concentration required to achieve 50% inhibition of HIV-1 multiplication in MT-4-infected Y181C+K103N strain	2002	Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26	Synthesis of novel N-1 (allyloxymethyl) analogues of 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine) with improved activity against HIV-1 and its mutants.
AID1457066	Inhibition of HIV1 reverse transcriptase p66 K103N/Y1881C double mutant associated RNA dependent DNA polymerase activity expressed in Escherichia coli assessed as reduction in [3H]dTTP incorporation using poly(rA)/oligo(dT) as template/primer by scintilla	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
AID198237	Inhibitory activity against HIV-1 reverse transcriptase	2001	Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5	Synthesis and biological activities of potential metabolites of the non-nucleoside reverse transcriptase inhibitor efavirenz.
AID1773835	Antiviral activity against HIV1 harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18	Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies.
AID541156	Selectivity ratio of EC50 for antiviral activity against GS-9160-resistant HIV1 selected after 5 passages to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID496620	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase K101E/K30E, I31P, V35Q, T39S, E44G, E53G, A62G, N81H, Q91H,I135V,S162A, K173S, Q174R, D177E, V179I, T200I, Q207N, R211K, F214L mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID247620	Inhibitory activity against HIV-1 double mutants strain 227L and 106A	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID448401	Fold resistance, ratio of IC50 for HIV reverse transcriptase with Y188C mutant to IC50 for HIV wild type reverse transcriptase	2009	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19	Pyrazole NNRTIs 3: optimisation of physicochemical properties.
AID1316334	Selectivity index, ratio of CC50 for human mock-infected MT4 cells to EC50 for wild type HIV1 3B harboring reverse transcriptase infected in human MT4 cells	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID1456307	Inhibition of HIV-1 reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured at 5 days post infection by MTT assay	2017	Bioorganic & medicinal chemistry, 04-15, Volume: 25, Issue:8	Structural modifications of diarylpyrimidines (DAPYs) as HIV-1 NNRTIs: Synthesis, anti-HIV activities and SAR.
AID1731748	Inhibition of reverse transcriptase Y183C mutant in HIV-1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay
AID1888696	Antiviral activity against HIV1 with RT Y181C mutant infected in human MT4 cells cells assessed as protection against viral-induced cytopathogenecity by MTT assay
AID1357804	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 harboring reverse transcriptase Y188L mutant	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID1069709	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Design and synthesis of N₁-aryl-benzimidazoles 2-substituted as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID586478	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase G140S/Q148R mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficie	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID1596755	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV-1 3B infected in MT4 cells	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Synthesis and biological evaluation of dihydroquinazoline-2-amines as potent non-nucleoside reverse transcriptase inhibitors of wild-type and mutant HIV-1 strains.
AID257165	Inhibition of Y181I mutant HIV1 reverse transcriptase by [3H]-dTTP poly(rA)/oligo(dT) incorporation	2005	Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25	Parallel solution-phase and microwave-assisted synthesis of new S-DABO derivatives endowed with subnanomolar anti-HIV-1 activity.
AID591356	Antiviral activity against wild type HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days by microscopic analysis	2011	Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6	Indolylarylsulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: new cyclic substituents at indole-2-carboxamide.
AID247498	Inhibitory activity against HIV-1 mutant strain 106A	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID518734	Inhibition of RNA-dependent DNA polymerase activity of wild type HIV1 subtype B reverse transcriptase by filter-based filtration assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity.
AID1653619	Activation of recombinant human C-terminal 4His-tagged CYP46A1 delta(2 to 50) mutant expressed in Escherichia coli at 20 uM using cholesterol as substrate measured after 30 mins in presence of cytochrome P450 oxidoreductase by gas chromatography-mass spec	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds.
AID508831	Antiviral activity against Human immunodeficiency virus 1 subtype C isolate 92BR025 infected in human PBMC cells by cell based assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID279427	Antiviral activity against HIV1 isolate with RT 103R, 179D, 188L mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID619635	Antiviral activity against HIV-1 3B harboring RT K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
AID492278	Antiviral activity against HIV1 with reverse transcriptase K103N, Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID257164	Inhibition of K103N mutant HIV1 reverse transcriptase by [3H]-dTTP poly(rA)/oligo(dT) incorporation	2005	Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25	Parallel solution-phase and microwave-assisted synthesis of new S-DABO derivatives endowed with subnanomolar anti-HIV-1 activity.
AID1326644	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by cell titer glo based luciferase reporter gene assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Novel (2,6-difluorophenyl)(2-(phenylamino)pyrimidin-4-yl)methanones with restricted conformation as potent non-nucleoside reverse transcriptase inhibitors against HIV-1.
AID619639	Antiviral activity against HIV-1 3B harboring RT F227L and V106A mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
AID443705	Antiviral activity against HIV with reverse transcriptase K101E/G190A double mutant assessed as inhibition of viral replication relative to wild type	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
AID583854	Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.5 multiplicities of infection after 6 days	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID1220363	Drug level in human cerebrospinal fluid	2013	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2	Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid.
AID576031	AUC (0 to 24 hrs) in healthy human plasma at 400 mg, po qd for 14 days by liquid chromatography-tandem mass spectrometry	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.
AID1185996	Antiviral activity against HIV1 harboring reverse transcriptase L1001/K103N double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
AID446410	Fold resistance, ratio of IC50 for HIV reverse transcriptase with L234I mutant to IC50 for HIV wild type reverse transcriptase	2009	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20	Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
AID1637393	Antiviral activity against human HIV-1 3B harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection from virus-induced cytopathic effect measured 5 days post infection by MTT assay	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.
AID519873	Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID1773439	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenic effect by MTT assay
AID446256	Fold resistance, ratio of IC50 for HIV reverse transcriptase with Y188C mutant to IC50 for HIV wild type reverse transcriptase	2009	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20	Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
AID508784	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase E138G mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID616199	Antiviral activity against vesicular stomatitis virus G-pseudotyped Human immunodeficiency virus 1 NL4-3 infected in human MT2 cells assessed as inhibition of viral replication after 48 hrs by luciferase activity reporter gene assay	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Synthesis of new 2'-deoxy-2'-fluoro-4'-azido nucleoside analogues as potent anti-HIV agents.
AID1212897	Drug metabolism in human liver microsomes harboring CYP2B61/6 genotype assessed as CYP2B6 variant-mediated 8-hydroxyefavirenz metabolite formation after 15 mins by LC/MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID298062	Antiviral activity against HIV2 ROD in human MT4 cells by XTT assay	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability.
AID573475	Antiviral activity of wild-type Human immunodeficiency virus 1 isolate 5331 by cell based assay	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
AID1069122	Antiviral activity against HIV harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of viral infection in presence of 50% normal human serum	2014	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3	Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses.
AID152958	Antiviral activity of Protein Binding of compound was evaluated for A 018C virus expressed PBMC by P24	2000	Journal of medicinal chemistry, May-18, Volume: 43, Issue:10	Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID1736354	Antiviral activity against VSVG/wild-type HIV-1 infected in human HEK 293T cells assessed as time during which compound exhibits 50% virologic failure at 1 uM treated at post-viral infection and measured at 48 hrs post-infection by luciferase reporter gen
AID718372	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	2012	Bioorganic & medicinal chemistry, Dec-01, Volume: 20, Issue:23	Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach.
AID88382	Antiviral activity against Y188C mutant virus in the HeLa MAGI assay.	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1157596	Antiviral activity against HIV1 W5269 infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID271413	Antiviral activity against wild type HIV1 in HeLa-JC53 cells	2006	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17	Tri-substituted triazoles as potent non-nucleoside inhibitors of the HIV-1 reverse transcriptase.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID279398	Antiviral activity against HIV1 isolate with RT 103N, 108I mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1741398	Inhibition of reverse transcriptase F227L and V106A mutant in HIV-1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID1379962	Cytotoxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives as potent HIV-1 NNRTIs.
AID82463	Antiviral activity against K103N/V108I strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1421325	Inhibition of wild-type HIV1 3B reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post infection by MTT assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Advances in diarylpyrimidines and related analogues as HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID1446811	Antiviral activity against HIV1 RES056 harboring K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured at 5 days post infection by MTT assay	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.
AID1141964	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1298247	Inhibition of HIV1 wild type reverse transcriptase p66/p51 using poly(rA) template and measured after 40 mins by picogreen based spectrofluorometry	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.
AID1627027	Cytotoxicity against HIV1 infected human CEM cells assessed as reduction in cell viability after 7 days by MTT assay	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Discovery, characterization, and lead optimization of 7-azaindole non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID508792	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase K101P mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID541166	Selectivity ratio of EC50 for antiviral activity against HIV1 harboring G140S mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID523349	Antiviral activity against HIV1 with RT connection domain K103N mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID1161107	Cytotoxicity against human MT4 cells by MTT assay	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	Arylazolyl(azinyl)thioacetanilides. Part 16: Structure-based bioisosterism design, synthesis and biological evaluation of novel pyrimidinylthioacetanilides as potent HIV-1 inhibitors.
AID1503321	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 96 hrs by MTT assay	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Inhibitors of Yellow Fever Virus replication based on 1,3,5-triphenyl-4,5-dihydropyrazole scaffold: Design, synthesis and antiviral evaluation.
AID541152	Selectivity ratio of EC50 for antiviral activity against EFV-resistant HIV1 selected after 3 passages to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID431619	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as virus-induced cytopathic effect by MTT assay	2009	Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16	Synthesis and biological evaluation of imidazole thioacetanilides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1811038	Inhibition of recombinant wild-type HIV1 p66/p51 reverse transcriptase assessed as inhibition of [3H]dGTP incorporation using poly (rA) as templates incubated for 40 mins by spectrofluorometer	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.
AID1168821	Activity of CYP2B6 (unknown origin) assessed per pmol protein pre-incubated for 5 mins in presence of NADPH by uHPLC-MS/MS based substrate depletion kinetics assay	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Structure-Activity Studies Reveal the Oxazinone Ring Is a Determinant of Cytochrome P450 2B6 Activity Toward Efavirenz.
AID279473	Antiviral activity against HIV1 isolate with RT 230L mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1882468	Antiviral activity against wild type HIV-1 IIIB infected in human MT2 cells assessed as protection against virus-induced cytopathicity by MTT assay	2022	Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5	Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.
AID584084	Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase Y181C mutant infected in human SupT1 cells assessed as inhibition of viral replication after 21 days relative to wild type HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID279515	Antiviral activity against HIV1 isolate with RT V106I, D123G, Y181C, F227L, T369I mutation in Hela-JC-53 cells	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1141969	Ratio of EC50 for HIV1 harboring reverse transcriptase K103N/Y181C double mutant to EC50 for wild type HIV1 NL4.3	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1157593	Antiviral activity against MC1220-resistant HIV1 harboring RT 100I, 179D, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID1884228	Antiviral activity against HIV-1 harboring E138K mutant infected in human MT4 cells assessed as reduction in virus induced cytotoxicity incubated for 5 to 7 days by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Chemical space exploration around indolylarylsulfone scaffold led to a novel class of highly active HIV-1 NNRTIs with spiro structural features.
AID1206934	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathicity after 4 days by MTT assay	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	Discovery of piperidin-4-yl-aminopyrimidine derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1286671	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in primary MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS assay	2016	Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5	Discovery of the Aryl-phospho-indole IDX899, a Highly Potent Anti-HIV Non-nucleoside Reverse Transcriptase Inhibitor.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1572520	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
AID1773453	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 harboring Y18IC mutant infected in human MT4 cells
AID246780	Compound concentration required to reduce the amount of p24 by 90% in wtIIIBinfected C8166 cells	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.
AID650541	Resistance ratio of EC50 for multidrug-resistant HIV 1 IRLL98 harboring reverse transcriptase K101Q/Y181C/G190a mutant to EC50 for wild type HIV 1 NL4-3 infected in human MT4 cells	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
AID143396	Compound was evaluated for its ability to inhibit the mutant K103N L1001 NNRTI HIV-1 enzyme	2001	Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3	Trifluoromethyl-containing 3-alkoxymethyl- and 3-aryloxymethyl-2-pyridinones are potent inhibitors of HIV-1 non-nucleoside reverse transcriptase.
AID508653	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase K103N, V179I, Y181C mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID771796	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	2014	Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 23	Synthesis and structure evaluation of new complex butylarylpiperazin-1-yl derivatives.
AID347796	Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 181I mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.
AID632796	Antiviral activity against Human immunodeficiency virus 1 NL4.3 reverse transcriptase Y181C mutant infected in human MT2 cells assessed as inhibition of viral infection	2011	Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24	Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.
AID299022	Inhibition of RNA dependent DNA polymerase activity of HIV1 recombinant reverse transcriptase	2007	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7	Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains.
AID1574378	Antiviral activity against HIV-1 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.
AID1335219	Ratio of IC50 for HIV-1 NL4-3 harboring RT-K103N/Y181C double mutant infected in HEK293T cells co-expressing vesicular stomatitis virus glycoprotein to IC50 for wild-type HIV-1 NL4-3 infected in HEK293T cells co-expressing vesicular stomatitis virus glyco	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID371906	Antiviral activity against HIV1 NL4-3 with K103N/V108I double mutant in human TZM-b1 cells assessed as beta-galactosidase activity after 48 hrs by single round replication assay	2009	Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12	New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID1141959	Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID235444	Selective index as the ratio of CD50 to that of ED50 against HIV-1 HxB2 strain.	2002	Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26	Synthesis of novel N-1 (allyloxymethyl) analogues of 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine) with improved activity against HIV-1 and its mutants.
AID508826	Antiviral activity against Human immunodeficiency virus 1 subtype B isolate 93BR021 infected in human PBMC cells by cell based assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID198768	Binding affinity towards L100I mutant HIV-1 reverse transcriptase (as per ref 10 in the article)	2001	Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21	Antiviral drug design: computational analyses of the effects of the L100I mutation for HIV-RT on the binding of NNRTIs.
AID1168819	Activity of CYP2B6 (unknown origin) pre-incubated for 5 mins in presence of NADPH by uHPLC-MS/MS based substrate depletion kinetics assay	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Structure-Activity Studies Reveal the Oxazinone Ring Is a Determinant of Cytochrome P450 2B6 Activity Toward Efavirenz.
AID368561	Antiviral activity against HIV1 reverse transcriptase Y188L mutant infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.
AID197777	Compound was evaluated for its ability to inhibit HIV-1 Reverse Transcriptase in an in vitro enzyme assay	2001	Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11	4,1-Benzoxazepinone analogues of efavirenz (Sustiva) as HIV-1 reverse transcriptase inhibitors.
AID1884222	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 to 7 days by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Chemical space exploration around indolylarylsulfone scaffold led to a novel class of highly active HIV-1 NNRTIs with spiro structural features.
AID88367	Antiviral activity against K103N/L100I mutant virus in the HeLa MAGI assay.	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID623214	Antiviral activity against HIV1 3B expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID282738	Inhibition of HIV1 RT V106A mutant	2005	Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23	Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.
AID347619	Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 138K mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.
AID508645	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase Y181C, G190S mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1561721	Resistance index, ratio of EC50 for antiviral activity against HIV1 3B infected in human MT4 cells grown under 30 passages in presence of 4-[[4-[[4-(4-cyano-2,6-dimethylphenoxy)thieno[3,2-d]pyrimidin-2-yl]amino]-1-piperidyl]methyl]benzenesulfonamide to EC
AID496632	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase V90I/V35T, T39L, K122E, D123N, S162A, E169T, K173E, Q174E, D177E,T200A, I202V, Q207E mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID730232	Antiviral activity Vesicular stomatitis virus pseudotype	2013	Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4	Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 12. Structure-activity relationships associated with 4-fluoro-6-azaindole derivatives leading to the identification of 1-(4-benzoylpiperazin-1-yl)-2-(4-fluoro-7-[1,2,3]triazol-1-yl-1h-p
AID1222793	Dissociation constant, pKa of the compound	2013	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5	Which metabolites circulate?
AID562697	Antiviral activity against HIV1 NL4-3 infected in human HeLa cells assessed as decrease in single-cycle viral infection after 72 hrs by beta-galactosidase reporter gene assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation.
AID269685	Antiviral activity against HIV1	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269685	Antiviral activity against HIV1	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269685	Antiviral activity against HIV1	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID416755	Antiviral activity against HIV1 with reverse transcriptase L100I mutation in human CEM cells assessed as protection against virus-induced cytopathicity	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID279491	Antiviral activity against HIV1 isolate with RT K101E mutant	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1457061	Ratio of EC50 for HIV-1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells to EC50 for HIV1 NL4-3 infected in human MT4 cells	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
AID519875	Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID1157586	Antiviral activity against MDR-resistant HIV1 harboring 41L, 74V, 106A, 215Y mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID508640	Antiviral activity against Human immunodeficiency virus 1 subtype BG infected in human MT4 cells assessed as reduction in virus induced cytopathicity	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID370732	Cytotoxicity against human C8166 cells by MTT method	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations.
AID571979	Antiviral activity against HIV-1 subtype B V022811 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID1373161	Inhibition of reverse transcriptase E138K mutant in HIV1 infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3	Structural optimization of N
AID235446	Selective index (CD50 compared to ED50 against HIV-1 IIIB strain).	2002	Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26	Synthesis of novel N-1 (allyloxymethyl) analogues of 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine) with improved activity against HIV-1 and its mutants.
AID293178	Antiviral activity against HIV1 RT 100I mutant assessed as inhibition of viral-induced cytopathicity in MT4 cells by MTT method	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Structure-activity relationship in the 3-iodo-4-phenoxypyridinone (IOPY) series: The nature of the C-3 substituent on anti-HIV activity.
AID293175	Antiviral activity against HIV1 with RT 103N mutant assessed as inhibition of viral-induced cytopathicity in MT4 cells by MTT method	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Structure-activity relationship in the 3-iodo-4-phenoxypyridinone (IOPY) series: The nature of the C-3 substituent on anti-HIV activity.
AID279410	Antiviral activity against HIV1 isolate with RT 179E mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1298253	Inhibition of HIV1 3B reverse transcriptase p66/p51 K103N/Y181C mutant using poly(rA) template and measured after 40 mins by picogreen based spectrofluorometry	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.
AID586370	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase G140S mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficiency vi	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID709868	Antiviral activity against NNRTI-resistant HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs by HeLa-CD4-LTR-beta-gal assay	2012	Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23	Rational design of potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID94445	Potency of second-generation NNRTIs against Mutant HIV-1 K103N plasma; Vlaue ranges from 3400-8100	2000	Journal of medicinal chemistry, May-18, Volume: 43, Issue:10	Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID246344	Effective concentration of the compound to inhibit HIV-1 mutant L100I+K103N replication in HIV-infected MT-4 cells	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID587740	Selectivity index, ratio of CC50 for human HeLa-T4 cells to EC50 for single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID457956	Antiviral activity against HIV1 3B infected in human MT4 cells assessed inhibition of viral-induced cytopathic effect after 5 days	2010	Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4	Novel 1,3-dihydro-benzimidazol-2-ones and their analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID586901	Activity at MRP1	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Interaction potential of etravirine with drug transporters assessed in vitro.
AID441314	Fold resistance, ratio of IC50 for HIV reverse transcriptase with K101E mutant to IC50 for HIV wild type reverse transcriptase	2009	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19	Pyrazole NNRTIs 1: design and initial optimisation of a novel template.
AID1212884	Drug metabolism in microsomes expressing CYP2B6.6 (unknown origin) assessed as enzyme-mediated 8-hydroxyefavirenz metabolite formation after 15 mins by HPLC/UV system in presence of Cyt b5 coexpression	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
AID1326643	Inhibition of wild type HIV-1 3B reverse transcriptase infected in human MT4 cells assessed as inhibition of viral replication after 5 days by cell titer glo based luciferase reporter gene assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Novel (2,6-difluorophenyl)(2-(phenylamino)pyrimidin-4-yl)methanones with restricted conformation as potent non-nucleoside reverse transcriptase inhibitors against HIV-1.
AID1561718	Antiviral activity against HIV1 3B infected in human MT4 cells grown under 30 passages in presence of 4-[[4-[[4-(4-cyano-2,6-dimethylphenoxy)thieno[3,2-d]pyrimidin-2-yl]amino]-1-piperidyl]methyl]benzenesulfonamide assessed as protection against virus-indu
AID1304409	Antiviral activity against HIV-1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	2016	Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13	Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
AID1157582	Antiviral activity against efavirenz-resistant HIV1 harboring RT 100I, 103R, 179D, 225H mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID508798	Ratio of EC50 for HIV1 in presence of 50% human serum to EC50 for HIV1 in absence of serum proteins by GFP assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1060628	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs.
AID1186328	Antiviral activity against HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents.
AID366524	Antiviral activity against HIV1 isolates with reverse transcriptase Y188L mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.
AID368557	Inhibition of HIV1 recombinant reverse transcriptase Y181I mutant-mediated RNA-dependent DNA polymerase activity assessed as [3H]dTTP incorporation by cell free-based scintillation counting	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.
AID279393	Antiviral activity against HIV1 isolate with RT 106I mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID522577	Resistance index, ratio of EC50 for recombinant HIV1 harboring reverse transcriptase V106I mutant clone to EC50 for wild type HIV1	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
AID263152	Antiviral activity against HIV1 in HEK293T cells	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID263152	Antiviral activity against HIV1 in HEK293T cells	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID263152	Antiviral activity against HIV1 in HEK293T cells	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1157595	Antiviral activity against TMC125-resistant HIV1 harboring RT 109M, 138K, 190E mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID361912	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190A mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID267650	Antiviral activity against HIV1 K103N/L100I mutant	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1.
AID586378	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase Q148R mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficiency vi	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID1335209	Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/V108I double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID1565098	Antiviral activity against drug resistant HIV-1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay
AID508763	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase L100I, K103N mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID557022	Antiviral activity against HIV1 CRF01_AE harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID1884226	Antiviral activity against HIV-1 harboring Y181C mutant infected in human MT4 cells assessed as reduction in virus induced cytotoxicity incubated for 5 to 7 days by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Chemical space exploration around indolylarylsulfone scaffold led to a novel class of highly active HIV-1 NNRTIs with spiro structural features.
AID1379959	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by measuring virus-induced syncytium formation by MTT assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives as potent HIV-1 NNRTIs.
AID1884539	Fold resistance, ratio of EC50 for antiviral activity against drug-resistant HIV-1 K103 N mutant infected in human MT4 cells to EC50 for antiviral activity against NNRTI resistant wild type HIV-1 infected in human MT4 cells	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.
AID302256	Resistance index, Ratio of EC50 for drug-resistant HIV1 with RT K103N mutation in MT3 cells to EC50 for HIV1 NL43 in MT3 cells	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID650543	Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
AID440079	Antiviral activity against HIV1 HXB2 harboring 138K mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
AID279498	Antiviral activity against HIV1 isolate with RT K103N-V108I-A98G mutation	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1212896	Drug metabolism in human liver microsomes harboring CYP2B61/1 genotype assessed as CYP2B6 variant-mediated 8-hydroxyefavirenz metabolite formation after 15 mins by LC/MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
AID1574380	Resistance index, ratio of EC50 for HIV-1 harboring reverse transcriptase Y181C mutant to EC50 for wild type HIV-1 NL4-3	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.
AID465421	Binding affinity to human serum albumin	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	N1-Alkyl pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID666972	Cytotoxicity against human MT4 cells after 5 days by MTT assay	2012	European journal of medicinal chemistry, Aug, Volume: 54	Diverse combinatorial design, synthesis and in vitro evaluation of new HEPT analogues as potential non-nucleoside HIV-1 reverse transcription inhibitors.
AID541157	Selectivity ratio of EC50 for antiviral activity against GS-9160-resistant HIV1 selected after 6 low passages to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1572526	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytotoxicity after 5 days by MTT assay
AID88381	Antiviral activity against Y181C mutant virus in the HeLa MAGI assay.	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID328845	Inhibition of human MRP3 expressed in MDCK2 cells assessed as increase in intracellular CMF fluorescence at 10 uM by CMFDA assay	2007	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3	Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.
AID573254	Apparent oral clearance in HIV-1 infected children at 12 mg/kg, po administered once daily by HPLC	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children?
AID279523	Antiviral activity against HIV1 NL4-3 with Y188L mutation in Hela-JC53 cells after 48 hrs	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID665274	Cytotoxicity against human MT4 cells after 5 days by MTT assay	2012	European journal of medicinal chemistry, Jul, Volume: 53	Chiral resolution, absolute configuration assignment and biological activity of racemic diarylpyrimidine CH(OH)-DAPY as potent nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID279404	Antiviral activity against HIV1 isolate with RT 103N, 181C, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID106069	Inhibitory activity against 188L strain of HIV-I in MT-4 cells	2001	Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17	Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.
AID698306	Antiviral activity against HIV1 containing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1357803	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 harboring reverse transcriptase Y181C mutant	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID508650	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase L100I, K103N, Y181C mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID279318	Inhibition of HIV1 RT assessed as natural endogenous reverse transcription at 50 nM	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Development of a new methodology for screening of human immunodeficiency virus type 1 microbicides based on real-time PCR quantification.
AID457955	Inhibition of RNA-dependent DNA polymerase activity of HIV1 reverse transcriptase using poly(rA)/pligo(dT) template	2010	Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4	Novel 1,3-dihydro-benzimidazol-2-ones and their analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID613677	Antiproliferative activity against human A375 cells assessed as cell growth at 15 uM after 96 hrs by trypan blue assay	2011	Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16	Modulation of cell differentiation, proliferation, and tumor growth by dihydrobenzyloxopyrimidine non-nucleoside reverse transcriptase inhibitors.
AID299025	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1	2007	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7	Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains.
AID443676	Antiviral activity against HIV with reverse transcriptase CNDO mutant assessed as inhibition of viral replication	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
AID718370	Cytotoxicity against HIV1 3B infected in human MT4 cells by MTT assay	2012	Bioorganic & medicinal chemistry, Dec-01, Volume: 20, Issue:23	Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach.
AID1773461	Resistance factor, ratio of EC50 for HIV1 harboring E138K mutant infected in human MT4 cells to EC50 for HIV1 3B infected in MT4 cells
AID443702	Antiviral activity against HIV with reverse transcriptase K103N/G190A double mutant assessed as inhibition of viral replication relative to wild type	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
AID299026	Antiviral activity against HIV1 3B in CEM cells assessed as inhibition of virus-induced giant cell formation	2007	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7	Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains.
AID106049	Inhibitory activity against 100I strain and 103N strain of HIV-I in MT-4 cells	2001	Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17	Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.
AID1609107	Antiviral activity against HIV-1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 4 days by MTT assay	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1574383	Resistance index, ratio of EC50 for HIV-1 harboring reverse transcriptase K103N/Y181C double mutant to EC50 for wild type HIV-1 NL4-3	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.
AID271415	Antiviral activity against HIV1 Y188L mutant in HeLa-JC53 cells	2006	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17	Tri-substituted triazoles as potent non-nucleoside inhibitors of the HIV-1 reverse transcriptase.
AID342719	Antiviral activity against HIV1 3B in human MT4 cells assessed as virus-induced cytopathogenicity after 5 days	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Novel N1-substituted 1,3-dihydro-2H-benzimidazol-2-ones as potent non-nucleoside reverse transcriptase inhibitors.
AID248016	Inhibitory concentration against wild-type HIV-1 LAI Virus was determined	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity.
AID1483279	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV1 3B harboring reverse transcriptase infected in human MT4 cells	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
AID1767121	Ratio of antiviral activity against HIV1 NL4-3 Env-deficient VSV-G pseudotyped virus infected in human SUP-T1 cells assessed as inhibition of late stage viral production when host cells were infected with compound pretreated viral particles to antiviral a	2021	European journal of medicinal chemistry, Aug-05, Volume: 220	Design and biological evaluation of cinnamic and phenylpropionic amide derivatives as novel dual inhibitors of HIV-1 protease and reverse transcriptase.
AID302254	Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID605181	Antiviral activity against HIV1 R8 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of viral spread in presence of 10% fetal bovine serum	2010	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 20, Issue:15	Biaryl ethers as potent allosteric inhibitors of reverse transcriptase and its key mutant viruses: aryl substituted pyrazole as a surrogate for the pyrazolopyridine motif.
AID496627	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase E138A/K32R, V35E, T39S, S48T, V60I, D121Y, K122E, I135T, S162A, K173A, Q174K, D177E, V179I, T200E, Q207D, R211K mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID279411	Antiviral activity against HIV1 isolate with RT 103N, 108I, 181C mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID519967	Antiviral activity against 0.005 MOI HIV1 NL4-3 harboring M184V mutant RT infected in human MT2 cells by phenosense assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID269690	Antiviral activity against HIV1 NNTRI resistant K103N/L100I mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269690	Antiviral activity against HIV1 NNTRI resistant K103N/L100I mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269690	Antiviral activity against HIV1 NNTRI resistant K103N/L100I mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1736364	Selectivity index, ratio of EC50 for antiviral activity against VSVG/HIV-1 harboring reverse transcriptase K103N/Y181C double mutant infected in human HEK 293T cells to EC50 for antiviral activity against VSVG/wild type HIV-1 infected in human HEK293T cel
AID586479	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase Y143H/N155H mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficie	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID449489	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus induced cytotoxicity after 5 days by MTT assay	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID541169	Selectivity ratio of EC50 for antiviral activity against HIV1 harboring N155H mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1141968	Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1574371	Therapeutic index, ratio of CC50 for human MT4 cells to EC50 for HIV-1 NL4-3 infected in human MT4 cells	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.
AID1059144	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B	2013	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24	Novel piperidinylamino-diarylpyrimidine derivatives with dual structural conformations as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID105325	Inhibition of Efavirenz resistant HIV-1 (Y181C) induced cytopathicity in MT-4 cells.	2004	Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15	Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations.
AID557044	Inhibition of HIV1 isolate R8 reverse transcriptase K103N mutant after 90 mins by electrochemiluminescence analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID257173	Cytotoxicity against MT4 cells by MTT method	2005	Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25	Parallel solution-phase and microwave-assisted synthesis of new S-DABO derivatives endowed with subnanomolar anti-HIV-1 activity.
AID267851	Inhibition of wild type HIV1 reverse transcriptase	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Synthesis and biological investigation of S-aryl-S-DABO derivatives as HIV-1 inhibitors.
AID81591	Antiviral activity against HIV-1 using antiinfectivity assay	2001	Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14	Synthesis and evaluation of novel quinolinones as HIV-1 reverse transcriptase inhibitors.
AID1231486	Antiviral activity against HIV1 harboring K103N/Y181C double mutant infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anti-HIV diarylpyrimidine-quinolone hybrids and their mode of action.
AID492046	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV1 3B	2010	Bioorganic & medicinal chemistry, Jul-01, Volume: 18, Issue:13	Synthesis and anti-HIV activity of 2-naphthyl substituted DAPY analogues as non-nucleoside reverse transcriptase inhibitors.
AID366559	Antiviral activity against HIV1 with reverse transcriptase K103N/Y181C mutation in human MT4 cells assessed as reduction of virus-induced cytopathic effect	2008	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 18, Issue:15	Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID508766	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase M230V mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID105202	Antiviral activity against MT-4 cells infected with Nev-R strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1457071	Effect on CD163 mRNA levels in C57BL/6 mouse BV2 cells at 1000 nM after 24 hrs by RT-PCR assay	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
AID1485966	Inhibition of recombinant wild-type HIV-1 reverse transcriptase p66/p51 RNA-dependent DNA polymerase activity expressed in Escherichia coli JM109 assessed as reduction in dTTP incorporation using poly(rA)/oligo(dT)16 as template/primer after 40 mins by Pi	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Searching for novel N
AID1743637	Resistance index, ratio of EC50 for antiviral activity against HIV1 expressing RT Y188L mutant infected in human MT4 cells to EC50 for antiviral activity against HIV1 3B infected in human MT4 cells	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.
AID586910	Induction of BCRP activity	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Interaction potential of etravirine with drug transporters assessed in vitro.
AID279443	Antiviral activity against HIV1 isolate with RT 106A, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID368567	Inhibition of HIV1 recombinant free reverse transcriptase K103N mutant expressed in Escherichia coli BL21	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID269799	Antiviral activity against HIV1 L100I mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269799	Antiviral activity against HIV1 L100I mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269799	Antiviral activity against HIV1 L100I mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1763904	Antiviral activity against HIV-1 RES056 infected in human MT4 cells assessed as protection against virus-induced cytotoxicity incubated for 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 06-15, Volume: 40	Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs.
AID1212919	Drug metabolism in microsomes expressing CYP2B6.6 (unknown origin) assessed as intrinsic clearance for enzyme-mediated 8-hydroxyefavirenz metabolite formation measured per pmol of P450 after 15 mins by HPLC/UV system in absence of Cyt b5 coexpression	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
AID83552	Potency evaluated against NNRTI-Resistant HIV-1 strain Tyr188Leu	2004	Journal of medicinal chemistry, May-06, Volume: 47, Issue:10	Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 varian
AID541131	Selectivity ratio of EC50 for antiviral activity against NRTI-resistant HIV1 harboring RT-6TAMs mutant gene to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID313877	Selectivity index, ratio of EC50 for MT4 cells to EC50 for HIV1	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3	Triazole derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase--structure-activity relationships and crystallographic analysis.
AID82460	Antiviral activity against K103N/G190A strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID440086	Antiviral activity against HIV1 HXB2 harboring K103N and Y181C mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
AID573998	Ratio of EC50 for Human immunodeficiency virus 1 3B to EC50 for CHI/1043-resistant Human immunodeficiency virus harboring T66I and Q146K mutations in integrase	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.
AID583853	Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.05 multiplicities of infection after 6 days	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID88378	Antiviral activity against V106A/Y181C mutant virus in the HeLa MAGI assay.	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1304400	Antiviral activity against HIV-1 RF infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by XTT assay	2016	Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13	Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
AID1171578	Cytotoxic activity against human MT4 cells by MTT assay	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID699541	Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID663905	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	2012	European journal of medicinal chemistry, Jul, Volume: 53	5-acetyl-2-arylbenzimidazoles as antiviral agents. Part 4.
AID611909	Antiviral activity against Human immunodeficiency virus 1 NL 4.3 harboring reverse transcriptase Y181C mutant pseudotyped with VSV-G envelope co-transfected with luciferase gene infected in 293T cells assessed as inhibition of HIV1 replication administere	2011	Journal of natural products, Jun-24, Volume: 74, Issue:6	Lindenane disesquiterpenoids with anti-HIV-1 activity from Chloranthus japonicus.
AID622049	Inhibition of DNA-dependent DNA polymerase activity of HIV1 reverse transcriptase p66/p66 homodimer Y181C mutant using activated DNA and [alpha-32P]dATP after 30 mins by liquid scintillation counting	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID448402	Fold resistance, ratio of IC50 for HIV reverse transcriptase with K101E mutant to IC50 for HIV wild type reverse transcriptase	2009	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19	Pyrazole NNRTIs 3: optimisation of physicochemical properties.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID263512	Antiviral activity against HIV1 L100I mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2.
AID269794	Cytotoxicity against HEK293T cells	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269794	Cytotoxicity against HEK293T cells	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269794	Cytotoxicity against HEK293T cells	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID519871	Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID699540	Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID370727	Inhibition of RNA dependent DNA polymerase activity of HIV1 recombinant reverse transcriptase p66/p51 Y181I mutant expressed in Escherichia coli JM109	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations.
AID562703	Antiviral activity against HIV1 harboring spacer peptide A1V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation.
AID1245795	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 96 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19	Isolation and anticancer, anthelminthic, and antiviral (HIV) activity of acylphloroglucinols, and regioselective synthesis of empetrifranzinans from Hypericum roeperianum.
AID279490	Antiviral activity against HIV1 isolate with RT Y188L mutation	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1884487	Cytotoxicity against human MT4 cells assessed as cell growth inhibition incubated for 5 days by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.
AID476473	Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase K103N/Y181C mutation by MTT assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives.
AID1637399	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for human HIV-1 3B harboring L100I mutant infected in human MT4 cells	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.
AID279507	Antiviral activity against HIV1 isolate with RT D123G mutation in Hela-JC-53 cells	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID767497	Cytotoxicity against human MT2 cells assessed as growth inhibition	2013	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18	Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.
AID572173	Antiviral activity against HIV-1 subtype CRF05_DF V022824 harboring NNRTI V106I mutant infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID248846	Inhibitory concentration against human immunodeficiency virus type 1 (with Y188C resistant mutation) was determined in HeLa-CD4 MAGI assay	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
AID366518	Cytotoxicity against human MT4 cells by MTT assay	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.
AID1731749	Inhibition of reverse transcriptase Y188L mutant in HIV-1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay
AID371901	Antiviral activity against HIV1 NL4-3 with Y181C mutant in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay	2009	Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12	New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID457957	Cytotoxicity in human MT4 cells assessed as reduction in cell viability	2010	Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4	Novel 1,3-dihydro-benzimidazol-2-ones and their analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1574386	Inhibition of recombinant HIV-1 His-tagged reverse transcriptase p66/p51 Y181I mutant expressed in Escherichia coli assessed as reduction in [3H]dTTP incorporation using poly(rA)/oligo(dT) as template/primer after 20 mins by scintillation counting analysi	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.
AID1637389	Antiviral activity against human HIV-1 3B harboring RES056 mutant infected in human MT4 cells assessed as protection from virus-induced cytopathic effect measured 5 days post infection by MTT assay	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.
AID386498	Antiviral activity against HIV1 with reverse transcriptase K103N/Y181C mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	2008	Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7	Thiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: Parallel synthesis, molecular modelling and structure-activity relationship studies on analogues of O-(2-phenylethyl)-N-phenylthiocarbamate.
AID302263	Inhibition of HIV1 reverse transcriptase V179D mutant	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID279527	Antiviral activity against HIV1 NL4-3 with Y188L mutation in Hela-JC53 cells in the presence of 30% human serum after 48 hrs	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1811034	Anti-viral activity against HIV1 harboring RT E138K mutant infected MV4 cells assessed as protection against virus-induced cytopathic effect by MTT assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.
AID1565097	Antiviral activity against drug resistant HIV-1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay
AID279448	Antiviral activity against HIV1 isolate with RT 101H, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1637395	Antiviral activity against human HIV-1 3B harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection from virus-induced cytopathic effect measured 5 days post infection by MTT assay	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.
AID508636	Antiviral activity against Human immunodeficiency virus 1 subtype G infected in human MT4 cells assessed as reduction in virus induced cytopathicity	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID508629	Antiviral activity against Human immunodeficiency virus 1 subtype F isolate 93BR029 infected in human PBMC cells by cell based assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID443695	Antiviral activity against HIV with reverse transcriptase K103N mutant assessed as inhibition of viral replication relative to wild type	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
AID698144	Inhibition of HIV1 reverse transcriptase L100I mutant RNA-dependent DNA polymerase activity using poly(rA)/oligo(dT)10:1 and [3H]-dTTP substrate	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID441316	Fold resistance, ratio of IC50 for HIV reverse transcriptase with V108I mutant to IC50 for HIV wild type reverse transcriptase	2009	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19	Pyrazole NNRTIs 1: design and initial optimisation of a novel template.
AID1763898	Antiviral activity against HIV-1 IIIB harboring RT L100I mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity incubated for 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 06-15, Volume: 40	Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs.
AID443678	Antiviral activity against HIV with reverse transcriptase K103N mutant assessed as inhibition of viral replication	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
AID508647	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase L100I, K103N, E138G mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID519884	Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID621981	Resistance index, ratio of EC50 for HIV1 3B expressing reverse transcriptase K103N/Y181C double mutant to EC50 for wild-type HIV1 3B	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID508773	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase Y181V mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID492045	Cytotoxicity against human MT4 cells after 4 days by MTT assay	2010	Bioorganic & medicinal chemistry, Jul-01, Volume: 18, Issue:13	Synthesis and anti-HIV activity of 2-naphthyl substituted DAPY analogues as non-nucleoside reverse transcriptase inhibitors.
AID267651	Selectivity for wild type HIV1 virus over HIV1 K103N mutant	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1.
AID302250	Selectivity index, ratio of CC50 for MT4 cells to EC50 for HIV1 NL43 infected MT4 cells	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID293556	Cytotoxicity against human MT4 cells after 3 days by EGFP based replication assay	2007	European journal of medicinal chemistry, May, Volume: 42, Issue:5	Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains.
AID1636146	Antiviral activity against wild type HIV1 NL4-3	2016	Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15	Discovery and Structure-Based Optimization of 2-Ureidothiophene-3-carboxylic Acids as Dual Bacterial RNA Polymerase and Viral Reverse Transcriptase Inhibitors.
AID255644	Effective concentration required to inhibit HTLV-III B induced cytopathicity in human CEM cells	2005	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 15, Issue:20	Synthesis and evaluation of anti-HIV activity of isatin beta-thiosemicarbazone derivatives.
AID253494	Dose required to inhibit HIV-1 reverse transcriptase activity (Y188L mutant) by 50%	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13	Novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. A structure-activity relationship investigation.
AID347089	Metabolic stability in human liver microsomes assessed as half life	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays.
AID571982	Antiviral activity against HIV-1 subtype B V022814 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID427975	Antiviral activity against HIV1 infected in human HeLa cells expressing CD4-LTR assessed as inhibition of viral entry-related beta galactosidase expression treated for 2 hrs measured after 48 hrs by MAGI assay	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative evaluation of the inhibitory activities of a series of pyrimidinedione congeners that inhibit human immunodeficiency virus types 1 and 2.
AID1171579	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1348212	Antiviral activity against wild-type VSV-G pseudotyped HIV1 infected in HEK293 cells at 10 uM pretreated for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene assay relative to control	2017	Journal of natural products, 12-22, Volume: 80, Issue:12	Oxazole-Containing Diterpenoids from Cell Cultures of Salvia miltiorrhiza and Their Anti-HIV-1 Activities.
AID82457	Antiviral activity against G190A strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1348214	Antiviral activity against VSV-G pseudotyped HIV1 infected in human MT2 cells pretreated for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene assay	2017	Journal of natural products, 12-22, Volume: 80, Issue:12	Oxazole-Containing Diterpenoids from Cell Cultures of Salvia miltiorrhiza and Their Anti-HIV-1 Activities.
AID1435511	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B expressing wild type reverse transcriptase
AID279493	Antiviral activity against HIV1 isolate V106I-Y188L mutant	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID330489	Antiviral activity against HIV1 RES056 infected in MT4 cells by MTT	2008	Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7	Synthesis and biological evaluation of novel 6-substituted 5-alkyl-2-(arylcarbonylmethylthio)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID302257	Resistance index, Ratio of EC50 for drug-resistant HIV1 with RT Y181C mutation in MT3 cells to EC50 for HIV1 NL43 in MT3 cells	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID621980	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B expressing reverse transcriptase K103N/Y181C double mutant	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID141362	Ratio of Inhibitory activity against mutant K103N HIV-1 Reverse transcriptase to mutant L1001 HIV-1 Reverse transcriptase	2001	Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14	Synthesis and evaluation of novel quinolinones as HIV-1 reverse transcriptase inhibitors.
AID685335	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV-1 3B	2012	Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 10: design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors.
AID1815393	Resistance fold, ratio of EC50 for HIV1 harboring reverse transcriptase E138K mutant infected MV4 cells to EC50 for wild type HIV1 infected MV4 cells	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID1249723	Antiviral activity against HIV1 expressing reverse transcriptase F227L + V106A mutant	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue.
AID143398	Compound was evaluated for its ability to inhibit the mutant K103N NNRTI HIV-1 enzyme	2001	Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3	Trifluoromethyl-containing 3-alkoxymethyl- and 3-aryloxymethyl-2-pyridinones are potent inhibitors of HIV-1 non-nucleoside reverse transcriptase.
AID1552555	Antiviral activity against HIV1 YU2 pseudovirus infected in human TZM-bl cells assessed as inhibition of viral infection incubated for 20 mins prior to infection and measured after 48 hrs post infection by bright Glo-luciferase reporter gene assay	2019	Bioorganic & medicinal chemistry, 08-15, Volume: 27, Issue:16	Biological evaluation of molecules of the azaBINOL class as antiviral agents: Inhibition of HIV-1 RNase H activity by 7-isopropoxy-8-(naphth-1-yl)quinoline.
AID1552557	Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability after 48 hrs by MTT assay	2019	Bioorganic & medicinal chemistry, 08-15, Volume: 27, Issue:16	Biological evaluation of molecules of the azaBINOL class as antiviral agents: Inhibition of HIV-1 RNase H activity by 7-isopropoxy-8-(naphth-1-yl)quinoline.
AID1736359	Antiviral activity against VSVG/HIV-1 harboring reverse transcriptase Y188L mutant infected in human HEK 293T cells assessed as inhibition of virus replication preincubated with cells for 15 mins prior to viral infection and measured at 48 hrs post-infect
AID473115	Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	2010	Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7	Synthesis and biological evaluation of 4-(hydroxyimino)arylmethyl diarylpyrimidine analogues as potential non-nucleoside reverse transcriptase inhibitors against HIV.
AID573481	Fold resistance, ratio of EC50 for Human immunodeficiency virus 1 isolate 8117 harboring A98S, G190A mutation in reverse transcriptase to wild-type	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
AID1261813	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 4 days by MTT assay	2015	European journal of medicinal chemistry, Nov-13, Volume: 105	Synthesis, cytotoxicity and antiviral evaluation of new series of imidazo[4,5-g]quinoline and pyrido[2,3-g]quinoxalinone derivatives.
AID523346	Antiviral activity against HIV1 with RT connection domain T369V mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID665273	Antiviral activity against HIV2 ROD mutant infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2012	European journal of medicinal chemistry, Jul, Volume: 53	Chiral resolution, absolute configuration assignment and biological activity of racemic diarylpyrimidine CH(OH)-DAPY as potent nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID665552	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 RES056 harboring reverse transcriptase K103N/Y181C RT mutant	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors.
AID632799	Antiviral activity against Human immunodeficiency virus 1 NL4.3 infected in human MT4 cells assessed as inhibition of viral infection	2011	Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24	Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.
AID541154	Selectivity ratio of EC50 for antiviral activity against APV-resistant HIV1 selected after 2 passages to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID586481	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase N155H/G163K mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficie	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID1761020	Antiviral activity against HIV-1 harboring reverse transcriptase RES056 mutant infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect measured after 5 days by MTT assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Design, synthesis, and evaluation of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase.
AID665275	Selectivity index ratio of CC50 for human MT4 cells to EC50 for HIV1 3B	2012	European journal of medicinal chemistry, Jul, Volume: 53	Chiral resolution, absolute configuration assignment and biological activity of racemic diarylpyrimidine CH(OH)-DAPY as potent nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID1773451	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 harboring L1001 mutant infected in human MT4 cells
AID366550	Inhibition of HIV1 reverse transcriptase Y181C mutant by scintillation counting assay	2008	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 18, Issue:15	Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID1171415	Aqueous solubility of the compound at pH 6.5 after 48 hrs by shake-flask method	2014	ACS medicinal chemistry letters, Nov-13, Volume: 5, Issue:11	Picomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl Ethers.
AID430054	Inhibition of HIV1 recombinant RNA-dependent DNA polymerase activity of reverse transcriptase assessed as incorporation of radioactive dTTP into poly(rA)/oligo(dT)	2009	Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16	Design, synthesis, and structure-activity relationships of 1,3-dihydrobenzimidazol-2-one analogues as anti-HIV agents.
AID279451	Antiviral activity against HIV1 isolate with RT 101E, 108I, 181C, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID508641	Antiviral activity against Human immunodeficiency virus 1 subtype AG infected in human MT4 cells assessed as reduction in virus induced cytopathicity	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID492287	Antiviral activity against HIV1 with reverse transcriptase F227L, V106A mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
AID197932	HIV-1 reverse transcriptase inhibitory activity against Cys181 mutant using (poly)rC600*(oligo)dGT as template primer.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues.
AID605176	Inhibition of wild type HIV1 reverse transcriptase by SPA assay	2010	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 20, Issue:15	Biaryl ethers as potent allosteric inhibitors of reverse transcriptase and its key mutant viruses: aryl substituted pyrazole as a surrogate for the pyrazolopyridine motif.
AID573997	Ratio of EC50 for Human immunodeficiency virus 1 3B to EC50 for MK-0518-resistant Human immunodeficiency virus harboring G140S and Q148H mutations in integrase	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.
AID246265	Effective concentration against human immunodeficiency virus type 1 G190S mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).
AID440670	Antiviral activity against NNRTI-resistant HIV1 N119 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	2009	European journal of medicinal chemistry, Dec, Volume: 44, Issue:12	Activity and molecular modeling of a new small molecule active against NNRTI-resistant HIV-1 mutants.
AID496633	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase V90I/V35T, E36D, K43R, V60I, K101R, K122E, D123S, I135V, S162A, K173T, Q174K, D177E, V179I, G196E, T200A, Q207E mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID88368	Antiviral activity against K103N/P225H mutant virus in the HeLa MAGI assay.	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID246359	Protection of infected MT-4 cells from wtIIIB-HIV-1-induced cytopathogenicity	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.
AID226171	Compound was evaluated for the inhibition of wilde-type RF strain of HIV-1	2000	Journal of medicinal chemistry, May-18, Volume: 43, Issue:10	Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID1141975	Inhibition of HIV1 wild-type reverse transcriptase using [3H]dTTP by scintillation counting	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1155813	Inhibition of wild type HIV-1 recombinant reverse transcriptase assessed as incorporation of [3H]dTTP into poly(rA)/oligo(dT)10:1	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.
AID718369	Selectivity index, ratio of CC50 for HIV1 3B infected in human MT4 cells to EC50 for HIV1 3B	2012	Bioorganic & medicinal chemistry, Dec-01, Volume: 20, Issue:23	Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach.
AID1750725	Selectivity index, ratio of CC50 for cytotoxicity against human MT-4 cells to EC50 for inhibition of HIV-1 p66/51 reverse transcriptase Y181C mutant	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from
AID508635	Antiviral activity against Human immunodeficiency virus 1 subtype (H) infected in human MT4 cells assessed as reduction in virus induced cytopathicity	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1352322	Antiviral activity against HIV1 harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 4 days by MTT assay	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.
AID523484	Antiviral activity against HIV1 with RT connection domain L100I/N348I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID1750715	Cytotoxicity against in human MT-4 cells after 5 days by MTT assay	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from
AID279431	Antiviral activity against HIV1 isolate with RT 103S, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1773455	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 harboring E138K mutant infected in human MT4 cells
AID666973	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 NL4-3	2012	European journal of medicinal chemistry, Aug, Volume: 54	Diverse combinatorial design, synthesis and in vitro evaluation of new HEPT analogues as potential non-nucleoside HIV-1 reverse transcription inhibitors.
AID1815380	Antiviral activity against HIV1 harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID368562	Cytotoxicity against human MT4 cells by MTT assay	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.
AID1320867	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.
AID1483280	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for reverse transcriptase L100I mutant in human MT4 cells infected HIV1 3B	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
AID1743629	Antiviral activity against HIV1 harboring RT Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.
AID675389	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	2012	European journal of medicinal chemistry, Sep, Volume: 55	Disubstituted thiourea derivatives and their activity on CNS: synthesis and biological evaluation.
AID1391085	Antiviral activity against HIV1 harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	The discovery of novel diarylpyri(mi)dine derivatives with high level activity against a wide variety of HIV-1 strains as well as against HIV-2.
AID766430	Aqueous solubility of the compound at pH 6.5 by shake-flask method	2013	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18	Extension into the entrance channel of HIV-1 reverse transcriptase--crystallography and enhanced solubility.
AID279482	Antiviral activity against HIV1 isolate with RT K103N mutation	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID508796	Ratio of EC50 for HIV1 in presence of 1 mg/ml alpha-1 acid-glycoprotein to EC50 for HIV1 in absence of serum proteins by GFP assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1435517	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 expressing reverse transcriptase F227L/V106A double mutant
AID82467	Antiviral activity against P236L strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID490372	Antiviral activity against HIV1 expressing reverse transcriptase V106A mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect	2010	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14	Discovery of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-benzyl derivatives with broad potency against resistant mutant viruses.
AID496616	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase V90I/V35T, T39M, K46Q, V60I, S68G, D123E, I135V, S162A, K173A, Q174K,D177E, T200A, Q207E, R211K mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID252950	Selectivity index of cytotoxic activity (CC50) to inhibitory activity (IC50) relative to LAI cell line	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID1565099	Antiviral activity against drug resistant HIV-1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay
AID1693799	Antiviral activity against HIV-3B infected in human MT-4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 01-15, Volume: 30	Novel indolylarylsulfone derivatives as covalent HIV-1 reverse transcriptase inhibitors specifically targeting the drug-resistant mutant Y181C.
AID1485967	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Searching for novel N
AID465422	Half life in Beagle dog at 0.5 mg/kg, iv or. 5 mg/kg, po	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	N1-Alkyl pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID757624	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2013	European journal of medicinal chemistry, Jul, Volume: 65	Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID267647	Antiviral activity against HIV1 K103N mutant	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1.
AID1335204	Ratio of IC50 for HIV-1 NL4-3 harboring RT-Y188L mutant infected in HEK293T cells co-expressing vesicular stomatitis virus glycoprotein to IC50 for wild-type HIV-1 NL4-3 infected in HEK293T cells co-expressing vesicular stomatitis virus glycoprotein	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID1152370	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay	2014	Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12	Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1285844	Antiviral activity against HIV1 A17 infected in human C8166 cells assessed as reduction in p24 antigen level incubated for 4 hrs followed by cell plating for 72 hrs by ELISA method	2016	Bioorganic & medicinal chemistry, May-01, Volume: 24, Issue:9	Design, synthesis and anti-HIV-1 evaluation of hydrazide-based peptidomimetics as selective gelatinase inhibitors.
AID1736345	Cytotoxicity against human HEK 293T cells assessed as reduction in cell viability measured after 48 hrs by Celltiter-glo assay
AID1443670	Antiviral activity against HIV1 harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	2017	Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8	Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors.
AID557041	Antiviral activity against HIV1 isolate R8 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs in presence of 10% FBS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID1687691	Inhibition of HIV-1BH10 reverse transcriptase expressed in Escherichia coli assessed as polymerization by real time FRET assay	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Rational design and Structure-Activity relationship of coumarin derivatives effective on HIV-1 protease and partially on HIV-1 reverse transcriptase.
AID279391	Antiviral activity against HIV1 isolate with RT 181C mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1248226	Antiviral activity against wild type HIV 2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	2015	Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20	A novel family of diarylpyrimidines (DAPYs) featuring a diatomic linker: Design, synthesis and anti-HIV activities.
AID1220383	Antiviral activity against HIV1	2013	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2	Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid.
AID1483273	Inhibition of HIV1 3B reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
AID279522	Antiviral activity against wild type HIV1 NL4-3 in Hela-JC53 cells in the presence of 50% human serum after 48 hrs	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID541162	Selectivity ratio of EC50 for antiviral activity against HIV1 harboring L74M mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID263508	Cytotoxicity against HEK293T cells	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2.
AID541133	Selectivity ratio of EC50 for antiviral activity against NNRTI-resistant HIV1 harboring RTY181C mutant gene to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID571977	Antiviral activity against HIV-1 subtype B V022809 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID508639	Antiviral activity against Human immunodeficiency virus 1 subtype C infected in human MT4 cells assessed as reduction in virus induced cytopathicity	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1729163	Inhibition of HIV1 reverse transcriptase assessed as reduction in biotin-dUTP incorporation into template incubated for 1 hr by ELISA	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp
AID1763897	Antiviral activity against HIV-1 IIIB infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 06-15, Volume: 40	Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs.
AID279324	Inhibition of reverse transcriptase activity in HIV1 NL4-3 infected MT4 cells after dialysis	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Development of a new methodology for screening of human immunodeficiency virus type 1 microbicides based on real-time PCR quantification.
AID519861	Antiviral activity against HIV1 subtype B-3B infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID586483	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase N155H/D232N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficie	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID1352314	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.
AID1565088	Inhibition of HIV1 reverse transcriptase assessed as inhibition of biotin-dUTP incorporation into template incubated for 1 hr by ELISA
AID779524	Inhibition of recombinant wild type HIV-1 reverse transcriptase p66/p51 expressed in Escherichia coli JM109 using poly(rA)/oligo(dT)16 (1:1.2) as template/primer after 40 mins by spectrofluorometric analysis	2013	Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21	Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.
AID1298252	Inhibition of HIV1 reverse transcriptase p66/p51 G190A mutant using poly(rA) template and measured after 40 mins by picogreen based spectrofluorometry	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.
AID584083	Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase K103N mutant infected in human SupT1 cells assessed as inhibition of viral replication after 21 days relative to wild type HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1705186	Antiviral activity against HIV1 harboring RT K103N mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect by MTT assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains.
AID1743620	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.
AID1261315	Antiviral activity against human CVB5 infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 3 days by plaque reduction assay	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID106609	Cytotoxic concentration that reduces the MT-4 cell viability by 50%	2004	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12	5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series.
AID366529	Inhibition of RNA dependent DNA polymerase activity of HIV1 reverse transcriptase Y181I mutant	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.
AID519859	Antiviral activity against HIV1 subtype B-RF infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID572169	Antiviral activity against HIV-1 subtype D V022832 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID508624	Antiviral activity against Human immunodeficiency virus 1 subtype E isolate 92TH006 infected in human PBMC cells by cell based assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1743631	Antiviral activity against HIV1 harboring RT F227L/V106Amutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.
AID1741397	Inhibition of reverse transcriptase E138K mutant in HIV-1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID416757	Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in human CEM cells assessed as protection against virus-induced cytopathicity	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID248069	Inhibitory concentration against 103N and 181C mutant strains was determined	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity.
AID508656	Antiviral activity against Human immunodeficiency virus 1 subtype O misolate BCF01 infected in human PBMC cells by cell based assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID523477	Antiviral activity against HIV1 with RT connection domain G190A/T369I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID586373	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase Y143R mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficiency vi	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID571986	Antiviral activity against HIV-1 subtype C V022829 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID1212914	Drug metabolism in microsomes expressing CYP2B6.1 (unknown origin) assessed as enzyme-mediated 8-hydroxyefavirenz metabolite formation after 15 mins by HPLC/UV system in absence of Cyt b5 coexpression	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
AID1446819	Antiviral activity against HIV1 harboring E138K mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured at 5 days post infection by MTT assay	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.
AID1435508	Antiviral activity against HIV1 expressing reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
AID508764	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase L100I, K101E mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID82606	The effect of protein binding on the antiviral activity versus wild type virus strain K103N was tested in the presence of acid glycoprotein in HeLa MAGI assay	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID562704	Selectivity ratio of EC50 for HIV1 harboring capsid I201V mutant protein infected in human HeLa cells to EC50 for wild type HIV1 infected in human HeLa cells	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation.
AID1637402	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for human HIV-1 3B harboring Y188L mutant infected in human MT4 cells	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.
AID508634	Antiviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as reduction in virus induced cytopathicity	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1773443	Selectivity ratio of CC50 for human MT4 cells to IC50 for HIV-1 3B infected in MT4 cells
AID620437	Inhibition of wild type HIV1 reverse transcriptase	2011	Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20	Novel diarylpyridinones, diarylpyridazinones and diarylphthalazinones as potential HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs).
AID1653618	Activation of recombinant human C-terminal 4His-tagged CYP46A1 delta(2 to 50) mutant expressed in Escherichia coli using cholesterol as substrate measured after 30 mins in presence of cytochrome P450 oxidoreductase by gas chromatography-mass spectrometry	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds.
AID583863	Inhibition of HIV1 HXB2 reverse transcriptase K103N mutant activity by primer extension assay	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID726438	Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase Y181C mutation infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method	2013	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4	Optimization of benzyloxazoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase to enhance Y181C potency.
AID279435	Antiviral activity against HIV1 isolate with RT 101Q, 103R mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID573480	Fold resistance, ratio of EC50 for Human immunodeficiency virus 1 isolate 8116 harboring A98S, G190A mutation in reverse transcriptase to wild-type	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
AID1220380	Drug metabolism of the compound assessed as CYP2B6 (unknown origin)-mediated formation of metabolites with retention time of 1.92 mins at 5 uM by UPLC-MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2	Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid.
AID573472	Antiviral activity of wild-type Human immunodeficiency virus 1 infected in human TZM-bl cells human assessed as inhibition of viral replication by luciferase reporter gene assay	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
AID276232	Cytotoxicity against MT2 cells	2006	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21	Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID82277	Inhibition of HIV-1 IIIB replication in MT-4-infected wild type cells.	2002	Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26	Synthesis of novel N-1 (allyloxymethyl) analogues of 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine) with improved activity against HIV-1 and its mutants.
AID1743638	Resistance index, ratio of EC50 for antiviral activity against HIV1 expressing RT E138K mutant infected in human MT4 cells to EC50 for antiviral activity against HIV1 3B infected in human MT4 cells	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.
AID1822283	Inhibition of recombinant wild type p66/p51 HIV1 reverse transcriptase incubated for 40 mins by picogreen dye-based spectrofluorometric analysis	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.
AID509268	Inhibition of HIV1 RT by ELISA	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Antiviral efficacy of the novel compound BIT225 against HIV-1 release from human macrophages.
AID492044	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	2010	Bioorganic & medicinal chemistry, Jul-01, Volume: 18, Issue:13	Synthesis and anti-HIV activity of 2-naphthyl substituted DAPY analogues as non-nucleoside reverse transcriptase inhibitors.
AID253492	Dose required to inhibit HIV-1 reverse transcriptase activity (V179D mutant) by 50%	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13	Novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. A structure-activity relationship investigation.
AID698146	Inhibition of wild type HIV1 reverse transcriptase RNA-dependent DNA polymerase activity using poly(rA)/oligo(dT)10:1 and [3H]-dTTP substrate	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID476472	Antiviral activity against HIV1 reverse transcriptase K103N/Y181C double mutant infected in human MT2 cells assessed as inhibition of viral replication by MTT assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives.
AID1320866	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 3B expressing wild type reverse transcriptase	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1754637	Antiviral activity against wild type HIV-1 IIIB infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect measured after 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses.
AID648424	Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	2012	European journal of medicinal chemistry, May, Volume: 51	Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1261308	Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID370730	Inhibition of RNA dependent DNA polymerase activity of HIV1 recombinant reverse transcriptase p66/p51 Y188L mutant expressed in Escherichia coli JM109	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations.
AID572178	Antiviral activity against HIV-1 subtype H V029523 harboring NNRTI K101Q and V179I mutant infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID1761015	Antiviral activity against HIV-1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect measured after 5 days by MTT assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Design, synthesis, and evaluation of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase.
AID1884493	Antiviral activity against drug-resistant HIV-1 E138K mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.
AID1754647	Antiviral activity against HIV1 harboring RT RES056 mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses.
AID573996	Ratio of EC50 for Human immunodeficiency virus 1 3B to EC50 for L-870,810-resistant Human immunodeficiency virus harboring L74M, E92Q and S230N mutations in integrase	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.
AID1141973	Ratio of EC50 for HIV1 harboring reverse transcriptase L1001 mutant to EC50 for wild type HIV1 NL4.3	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID247504	Inhibitory activity against HIV-1 mutant strain 190S	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID82462	Antiviral activity against K103N/P225H strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID508630	Antiviral activity against Human immunodeficiency virus 1 subtype G isolate G3 infected in human PBMC cells by cell based assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1822282	Antiviral activity against HIV-1 harboring RES056 mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity incubated for 5 days by MTT assay	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.
AID430055	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days	2009	Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16	Design, synthesis, and structure-activity relationships of 1,3-dihydrobenzimidazol-2-one analogues as anti-HIV agents.
AID443433	Cytotoxicity against human MT4 cells assessed as reduction of cell viability after 96 hrs by MTT assay	2009	European journal of medicinal chemistry, Dec, Volume: 44, Issue:12	Synthesis, pharmacological and antiviral activity of 1,3-thiazepine derivatives.
AID573976	Antiretroviral activity against Human immunodeficiency virus 1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.
AID328842	Inhibition of human MRP2 expressed in MDCK2 cells assessed as increase in intracellular CMF fluorescence by CMFDA assay	2007	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3	Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.
AID572189	Antiviral activity against HIV-1 SM058 harboring NNTRI 227L and 106A mutant infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID1320865	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.
AID650696	Ratio of ID50 for HIV 1 reverse transcriptase K103N mutant to ID50 for wild type HIV 1 NL4-3 reverse transcriptase	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
AID371911	Antiviral activity against HIV1 NL4-3 with Y181C mutant in human TZM-b1 cells assessed as beta-galactosidase activity after 48 hrs by single round replication assay	2009	Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12	New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID443683	Antiviral activity against HIV with reverse transcriptase L100I/K103N double mutant assessed as inhibition of viral replication	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
AID508637	Antiviral activity against Human immunodeficiency virus 1 subtype D infected in human MT4 cells assessed as reduction in virus induced cytopathicity	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1348217	Antiviral activity against wild-type VSV-G pseudotyped HIV1 infected in HEK293 cells assessed as time of 50% failure at 1 uM measured at 48 hrs post infection by luciferase reporter gene assay	2017	Journal of natural products, 12-22, Volume: 80, Issue:12	Oxazole-Containing Diterpenoids from Cell Cultures of Salvia miltiorrhiza and Their Anti-HIV-1 Activities.
AID571983	Antiviral activity against HIV-1 subtype B V022815 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID464771	Volume of distribution at steady state in Beagle dog at 0.5 mg/kg, iv or 0.5 mg/kg, po	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	N1-Heterocyclic pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID622050	Inhibition of DNA-dependent DNA polymerase activity of HIV1 reverse transcriptase p66/p66 homodimer Y188L mutant using activated DNA and [alpha-32P]dATP after 30 mins by liquid scintillation counting	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID519023	Antiviral activity against Human immunodeficiency virus 1 NL432 infected in human MT-4 cells assessed as increase in viral two-LTR circles	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.
AID279477	Antiviral activity against HIV1 isolate with RT 181V mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID576032	AUC (0 to infinity) in healthy human plasma at 400 mg, measured on day 1 post dose by liquid chromatography-tandem mass spectrometry	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.
AID1811045	Cytotoxicity against mock infected human MT4 cells by MTT assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.
AID1185992	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
AID571967	Antiviral activity against HIV-1 subtype CRF02_AG V022808 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID1653637	Binding affinity to substrate bound recombinant human C-terminal 4His-tagged CYP46A1 delta(2 to 50) mutant expressed in Escherichia coli assessed as Kon rate of cholesterol by stopped-flow spectrophotometric method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds.
AID1171587	Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase K103N-Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID366530	Resistance index, ratio of ID50 for reverse transcriptase Y181I mutant to IC50 for wild-type HIV1 reverse transcriptase	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.
AID279458	Antiviral activity against HIV1 isolate with RT 103Q mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID347612	Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 225H mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.
AID573474	Antiviral activity of wild-type Human immunodeficiency virus 1 isolate 5269 by cell based assay	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID508623	Antiviral activity against Human immunodeficiency virus 1 subtype D isolate 92UG035 infected in human PBMC cells by cell based assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1316332	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID279481	Antiviral activity against HIV1 isolate with RT 101E mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1335214	Antiviral activity against HIV-1 NL4-3 harboring RT-L100I/K103N double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID368559	Antiviral activity against HIV1 reverse transcriptase K103N mutant infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.
AID440087	Antiviral activity against HIV1 HXB2 harboring 227L and 106A mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
AID440072	Selectivity index, ratio of CC50 for human MT4 cells to IC50 for HIV-1 LAI harboring wild type reverse transcriptase infected in human MT4 cells	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
AID1880369	Inhibition of HIV-1 reverse transcriptase using oligo(dT)16 as primer measured after 40 mins by picogreen-dye based spectrofluorometric analysis	2022	Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12	Structure-Based Discovery of Novel NH
AID1773447	Antiviral activity against wild type HIV1 harboring Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenic effect by MTT assay
AID94449	Inhibitory concentration against wild-type virus K103N/L1001 and HIV-1 RT double mutant in whole cell antiviral assay	2001	Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2	3,3a-Dihydropyrano[4,3,2-de]quinazolin-2(1H)-ones are potent non-nucleoside reverse transcriptase inhibitors.
AID586474	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase E138K/Q148R mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficie	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID96295	Potency of second-generation NNRTIs against Mutant HIV-1 sL100I plasma; Value ranges from 6600-15700	2000	Journal of medicinal chemistry, May-18, Volume: 43, Issue:10	Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID1637390	Cytotoxicity against mock-infected human MT4 cells assessed as reduction of cell viability after 5 days by MTT assay	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.
AID248354	Concentration required to inhibit 50% viral production of human immunodeficiency virus type 1 (HIV-1-IIIB)	2005	Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7	Hierarchical database screenings for HIV-1 reverse transcriptase using a pharmacophore model, rigid docking, solvation docking, and MM-PB/SA.
AID1653622	Binding affinity to recombinant human C-terminal 4His-tagged CYP46A1 delta(2 to 50) mutant expressed in Escherichia coli in absence of substrate by UV-spectrophotometric method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds.
AID267653	Selectivity for wild type HIV1 virus over HIV1 L100I mutant	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1.
AID1261313	Antiviral activity against YFV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID347618	Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 236L mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.
AID573477	Antiviral activity of Human immunodeficiency virus 1 isolate 8116 harboring A98S, G190A mutation in reverse transcriptase by cell based assay	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
AID443703	Antiviral activity against HIV with reverse transcriptase Y181C/G190A double mutant assessed as inhibition of viral replication relative to wild type	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
AID1443667	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	2017	Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8	Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors.
AID1773442	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
AID328846	Inhibition of human MRP1 expressed in MDCK2 cells assessed as increase in intracellular CMF fluorescence at 10 uM by CMFDA assay	2007	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3	Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.
AID368565	Inhibition of wild type HIV1 reverse transcriptase-DNA binary complex	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.
AID83554	Potency evaluated against wild type HIV-1 strain IIIB	2004	Journal of medicinal chemistry, May-06, Volume: 47, Issue:10	Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 varian
AID94314	Antiviral activity against HIV-1 K103N mutant virus.	2000	Journal of medicinal chemistry, May-18, Volume: 43, Issue:10	Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID508628	Antiviral activity against Human immunodeficiency virus 1 subtype F isolate 93BR020 infected in human PBMC cells by cell based assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID440077	Antiviral activity against HIV1 HXB2 harboring 101E mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
AID519868	Antiviral activity against HIV1 subtype B-92US076 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID571972	Antiviral activity against HIV-1 subtype CRF01_AE V022821 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID541126	Cytotoxicity against human SupT1 cells infected with HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1198751	Inhibition of HIV1 reverse transcriptase Tyr181Cys mutant-associated DNA polymerase-independent RNase H activity after 1 hr	2015	European journal of medicinal chemistry, Mar-26, Volume: 93	(3Z)-3-(2-[4-(aryl)-1,3-thiazol-2-yl]hydrazin-1-ylidene)-2,3-dihydro-1H-indol-2-one derivatives as dual inhibitors of HIV-1 reverse transcriptase.
AID557043	Inhibition of HIV1 isolate R8 reverse transcriptase Y181C mutant after 90 mins by electrochemiluminescence analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID267854	Antiviral activity against wild type HIV1 NL4-3 in MT4 cells by MTT assay	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Synthesis and biological investigation of S-aryl-S-DABO derivatives as HIV-1 inhibitors.
AID709870	Antiviral activity against HIV1 expressing wild type reverse transcriptase infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs by HeLa-CD4-LTR-beta-gal assay	2012	Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23	Rational design of potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID366549	Inhibition of HIV1 reverse transcriptase K103N mutant by scintillation counting assay	2008	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 18, Issue:15	Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID1220367	Drug metabolism in human blood plasma assessed as formation of N- and O-linked glucuronidated metabolite at 100 mg administered every 4 hrs by UPLC-MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2	Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid.
AID302255	Antiviral activity against HIV1 with reverse transcriptase Y188L mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID82603	The effect of protein binding on the antiviral activity versus wild type virus strain HXB2 was tested in the presence of acid glycoprotein in HeLa MAGI assay	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID443686	Antiviral activity against HIV with reverse transcriptase Y181C/G190A double mutant assessed as inhibition of viral replication	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
AID279437	Antiviral activity against HIV1 isolate with RT 103N, 108I, 225H mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID106769	Cytotoxic dose required to reduce the viability of normal uninfected MT-4 cells by 50%	2002	Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26	Synthesis of novel N-1 (allyloxymethyl) analogues of 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine) with improved activity against HIV-1 and its mutants.
AID1535529	Inhibition of recombinant wild type HIV1 reverse transcriptase assessed as reduction in biotin-dUTP incorporation using poly(A)/oligo(dT)15 as template/primer after 1 hr by ELISA	2019	Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3	Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs.
AID298089	Inhibition of HIV1 RT Y181I mutant	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity.
AID279454	Antiviral activity against HIV1 isolate with RT 100I, 103N, 108I mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID105535	Inhibitory activity against HIV-1 Asn 103 mutant in MT-4 cells.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues.
AID586386	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase T66I/L74M mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficienc	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID1373163	Inhibition of reverse transcriptase K103N/Y181C double mutant in HIV1 infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3	Structural optimization of N
AID298059	Inhibition of HIV1 reverse transcriptase	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability.
AID1275552	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV1 3B infected in human MT4 cells	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
AID1729157	Antiviral activity against HIV1 harboring K103N mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect by MTT assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp
AID465420	Antiviral activity against NNRTI-resistant HIV1 harboring reverse transcriptase K103N mutant infected in human MT2 cells	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	N1-Alkyl pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID279471	Antiviral activity against HIV1 isolate with RT 103N, 238N mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID571981	Antiviral activity against HIV-1 subtype B V022813 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID576038	Ratio of drug concentration in PBMCs to plasma of healthy human administered at 400 mg, po measured after 24 hrs on day 1 post dose	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.
AID299029	Antiviral activity against HIV1 with reverse transcriptase E138K mutation in CEM cells assessed as inhibition of virus-induced giant cell formation	2007	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7	Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains.
AID649488	Inhibition of ribonuclease H activity of wild type Human immunodeficiency virus 1 reverse transcriptase	2012	European journal of medicinal chemistry, Apr, Volume: 50	Identification of HIV-1 reverse transcriptase dual inhibitors by a combined shape-, 2D-fingerprint- and pharmacophore-based virtual screening approach.
AID508777	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase V179F mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1572518	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytotoxicity after 5 days by MTT assay
AID299030	Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in CEM cells assessed as inhibition of virus-induced giant cell formation	2007	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7	Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains.
AID200153	Inhibition of HIV-1 reverse transcriptase.	2001	Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14	Synthesis and evaluation of novel quinolinones as HIV-1 reverse transcriptase inhibitors.
AID247618	Inhibitory activity against HIV-1 double mutants strain 101E and 103N	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID441313	Fold resistance, ratio of IC50 for HIV reverse transcriptase with Y188C mutant to IC50 for HIV wild type reverse transcriptase	2009	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19	Pyrazole NNRTIs 1: design and initial optimisation of a novel template.
AID1165076	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.
AID1535527	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 RES056 RES056 containing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells	2019	Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3	Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs.
AID1298245	Cytotoxicity against human MT4 cells after 5 days MTT assay	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.
AID279470	Antiviral activity against HIV1 isolate with RT 238T mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID256325	Percentage inhibition of proliferation against alive human A-375 cells treated with DMSO (control) at a concentration of 15 uM	2005	Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22	6-[1-(2,6-difluorophenyl)ethyl]pyrimidinones antagonize cell proliferation and induce cell differentiation by inhibiting (a nontelomeric) endogenous reverse transcriptase.
AID1245796	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	2015	Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19	Isolation and anticancer, anthelminthic, and antiviral (HIV) activity of acylphloroglucinols, and regioselective synthesis of empetrifranzinans from Hypericum roeperianum.
AID709867	Antiviral activity against NNRTI-resistant HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs by HeLa-CD4-LTR-beta-gal assay	2012	Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23	Rational design of potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID440076	Antiviral activity against HIV1 HXB2 harboring 100I mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
AID83550	Potency evaluated against NNRTI-Resistant HIV-1 strain Lys103Asn	2004	Journal of medicinal chemistry, May-06, Volume: 47, Issue:10	Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 varian
AID699539	Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1069123	Antiviral activity against HIV harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of viral infection in presence of 50% normal human serum	2014	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3	Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses.
AID1357805	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 harboring reverse transcriptase F227L/V106A mutant	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID573473	Antiviral activity of wild-type Human immunodeficiency virus 1 harboring Y181C mutation in reverse transcriptase infected in human TZM-bl cells human assessed as inhibition of viral replication by luciferase reporter gene assay	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
AID1880379	Antiviral activity against HIV-1 IIIB harboring reverse transcriptase Y188L mutant infected in human MT4 cells by MTT assay	2022	Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12	Structure-Based Discovery of Novel NH
AID1185993	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay relative HIV1	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
AID1558848	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Ligand-Based Design of Nondimethylphenyl-Diarylpyrimidines with Improved Metabolic Stability, Safety, and Oral Pharmacokinetic Profiles.
AID1357784	Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID508649	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase L100I, K103N, V179L mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1815384	Antiviral activity against HIV1 harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID1687682	Antiviral activity against HIV-1 Y181C mutant strain infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities.
AID242820	Dose required to inhibit HIV-1 reverse transcriptase activity (wild-type) by 50%	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13	Novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. A structure-activity relationship investigation.
AID256475	Ratio of CC50 required to reduce the viability of mock-infected human CEM cells to EC50 required to inhibit HTLV-III B induced cytopathicity in that cells	2005	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 15, Issue:20	Synthesis and evaluation of anti-HIV activity of isatin beta-thiosemicarbazone derivatives.
AID573977	Antiretroviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.
AID508762	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase K101E, K103N mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID517493	Antiviral activity against wild type HIV1 infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 40% human serum	2010	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 20, Issue:20	Exploration of piperidine-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Phenyl derivatives with broad potency against resistant mutant viruses.
AID1407645	Cytotoxicity against human CEM-GFP cells after 48 hrs by MTT assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Design, synthesis, docking studies and biological screening of 2-thiazolyl substituted -2,3-dihydro-1H-naphtho[1,2-e][1,3]oxazines as potent HIV-1 reverse transcriptase inhibitors.
AID1320869	Inhibition of recombinant wild type HIV1 p66/p51 using poly(rA) template/oligo(dT)16 primer after 40 mins by PicoGreen-based spectrofluorometric method	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.
AID1729161	Antiviral activity against HIV1 harboring F227L/V106A mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect by MTT assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp
AID246799	Compound concentration required to reduce the amount of p24 by 90% in C8166 cells infected with an efavirenz-resistant strain EFVR carrying mutations K103R, V179D, and P225H	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.
AID279450	Antiviral activity against HIV1 isolate with RT 98G, 103N, 181C mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID586475	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase G140C/Q148R mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficie	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID82465	Antiviral activity against L100I strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID658564	Antiviral activity against multidrug-resistant HIV1 695-RT infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay	2012	Journal of natural products, Mar-23, Volume: 75, Issue:3	Library-based discovery and characterization of daphnane diterpenes as potent and selective HIV inhibitors in Daphne gnidium.
AID1198752	Inhibition of HIV1 reverse transcriptase Tyr181Cys mutant-associated RNA-dependent DNA polymerase activity after 30 mins	2015	European journal of medicinal chemistry, Mar-26, Volume: 93	(3Z)-3-(2-[4-(aryl)-1,3-thiazol-2-yl]hydrazin-1-ylidene)-2,3-dihydro-1H-indol-2-one derivatives as dual inhibitors of HIV-1 reverse transcriptase.
AID198911	Inhibition of HIV-1 Mutant HIV-1 RT enzymes containing the single amino acid substitution K103N	2001	Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3	Quinoxalinylethylpyridylthioureas (QXPTs) as potent non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors. Further SAR studies and identification of a novel orally bioavailable hydrazine-based antiviral agent.
AID279474	Antiviral activity against HIV1 isolate with RT 101R, 103N, 181C, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID586473	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase E138K/Q148K mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficie	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID448399	Fold resistance, ratio of IC50 for HIV reverse transcriptase with F227L mutant to IC50 for HIV wild type reverse transcriptase	2009	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19	Pyrazole NNRTIs 3: optimisation of physicochemical properties.
AID298078	Antiviral activity against wild type HIV1 3B in lymphocytes assessed as reduction of p24 antigen production	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity.
AID198106	Inhibitory activity against R172A mutant reverse transcriptase	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	Identification of a putative binding site for [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase.
AID508770	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase G190S mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1249714	Antiviral activity against HIV1 3B expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity incubated for 4 days by MTT method	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue.
AID1653634	Binding affinity to recombinant human C-terminal 4His-tagged CYP46A1 delta(2 to 50) mutant expressed in Escherichia coli at 50 uM in presence of substrate by UV-spectrophotometric method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds.
AID1687684	Antiviral activity against HIV-1 RES056 mutant strain infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities.
AID508787	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase V106M mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID293560	Antiviral activity against HIV1 LAI with RT K103N mutation in MT4 cells by EGFP based replication assay	2007	European journal of medicinal chemistry, May, Volume: 42, Issue:5	Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains.
AID1750724	Selectivity index, ratio of CC50 for cytotoxicity against human MT-4 cells to EC50 for inhibition of HIV-1 p66/51 reverse transcriptase K103N mutant	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from
AID1815392	Resistance fold, ratio of EC50 for HIV1 harboring reverse transcriptase Y188L mutant infected MV4 cells to EC50 for wild type HIV1 infected MV4 cells	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID279399	Antiviral activity against HIV1 isolate with RT 179D mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1057039	Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Design, synthesis and biological evaluation of 3-benzyloxy-linked pyrimidinylphenylamine derivatives as potent HIV-1 NNRTIs.
AID361910	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y188L mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID726436	Cytotoxicity in human MT2 cells assessed as inhibition of cell growth	2013	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4	Optimization of benzyloxazoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase to enhance Y181C potency.
AID1212898	Drug metabolism in human liver microsomes harboring CYP2B66/6 genotype assessed as CYP2B6 variant-mediated 8-hydroxyefavirenz metabolite formation after 15 mins by LC/MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
AID767495	Aqueous solubility of the compound in Britton-Robinson buffer at pH 6.5 after 48 hrs by shake-flask method	2013	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18	Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.
AID1157587	Antiviral activity against saquinavir-resistant HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID361914	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190E mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID82456	Antiviral activity against E138K strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1407641	Inhibition of recombinant HIV-1 reverse transcriptase RNA-dependent DNA polymerase activity at 1 ug/ml using poly(rA)/oligo(dT)16 as template/primer preincubated for 5 to 10 mins followed by template/primer addition and measured after 16 hrs by colorimetr	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Design, synthesis, docking studies and biological screening of 2-thiazolyl substituted -2,3-dihydro-1H-naphtho[1,2-e][1,3]oxazines as potent HIV-1 reverse transcriptase inhibitors.
AID427973	Antiviral activity against HIV1 infected in human HeLa cells expressing CD4-LTR assessed as inhibition of viral entry-related beta galactosidase expression at 0.2 to 0.4 uM followed by drug wash out and viral infection measured after 48 hrs by MAGI assay	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative evaluation of the inhibitory activities of a series of pyrimidinedione congeners that inhibit human immunodeficiency virus types 1 and 2.
AID517492	Antiviral activity against wild type HIV1 infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS	2010	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 20, Issue:20	Exploration of piperidine-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Phenyl derivatives with broad potency against resistant mutant viruses.
AID1637404	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for human HIV-1 3B harboring F227L/V106A double mutant infected in human MT4 cells	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.
AID241471	Inhibitory concentration against HIV-1 mutant reverse transcriptase (K103R)	2005	Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11	Structure-based design, parallel synthesis, structure-activity relationship, and molecular modeling studies of thiocarbamates, new potent non-nucleoside HIV-1 reverse transcriptase inhibitor isosteres of phenethylthiazolylthiourea derivatives.
AID247497	Inhibitory activity against HIV-1 mutant strain 103N	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID143402	Compound was evaluated for its ability to inhibit the mutant K103N V1081NNRTI HIV-1 enzyme	2001	Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3	Trifluoromethyl-containing 3-alkoxymethyl- and 3-aryloxymethyl-2-pyridinones are potent inhibitors of HIV-1 non-nucleoside reverse transcriptase.
AID1888693	Resistance index, ratio of EC50 for antiviral activity against HIV1 with RT L100I mutant infected in human MT4 cells to EC50 for antiviral activity against wild type HIV1 infected in human MT4 cells
AID1183081	Antiviral activity against HIV-13B infected in MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT method	2014	European journal of medicinal chemistry, Sep-12, Volume: 84	Synthesis and antiviral activity of new phenylimidazopyridines and N-benzylidenequinolinamines derived by molecular simplification of phenylimidazo[4,5-g]quinolines.
AID1736365	Selectivity index, ratio of EC50 for antiviral activity against VSVG/HIV-1 harboring reverse transcriptase L100I/K103N double mutant infected in human HEK 293T cells to EC50 for antiviral activity against VSVG/wild type HIV-1 infected in human HEK293T cel
AID1741396	Inhibition of reverse transcriptase Y188L mutant in HIV-1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID1261324	Antiviral activity against HIV-1 infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID1457063	Inhibition of HIV1 NL4-3 reverse transcriptase His-tagged p66/p51 associated RNA dependent DNA polymerase activity expressed in Escherichia coli assessed as reduction in [3H]dTTP incorporation using poly(rA)/oligo(dT) as template/primer by scintillation c	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
AID269800	Antiviral activity against HIV1 V106A mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269800	Antiviral activity against HIV1 V106A mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269800	Antiviral activity against HIV1 V106A mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID88369	Antiviral activity against K103N/V108I mutant virus in the HeLa MAGI assay.	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID293557	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 LAI	2007	European journal of medicinal chemistry, May, Volume: 42, Issue:5	Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains.
AID404605	Inhibition of HIV1 virion-associated reverse transcriptase	2008	Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12	Parallel one-pot synthesis and structure-activity relationship study of symmetric formimidoester disulfides as a novel class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID247619	Inhibitory activity against HIV-1 double mutants strain 103N and 181C	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID519881	Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID557038	Antiviral activity against HIV1 isolate R8 harboring wild type reverse transcriptase infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs in presence of 50% human serum	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID279424	Antiviral activity against HIV1 isolate with RT 103N, 106A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID371914	Antiviral activity against HIV1 NL4-3 with double K103N/L100I mutant in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay	2009	Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12	New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID1736363	Selectivity index, ratio of EC50 for antiviral activity against VSVG/HIV-1 harboring reverse transcriptase Y181C mutant infected in human HEK 293T cells to EC50 for antiviral activity against VSVG/wild type HIV-1 infected in human HEK293T cells
AID1248223	Cytotoxicity against uninfected human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	2015	Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20	A novel family of diarylpyrimidines (DAPYs) featuring a diatomic linker: Design, synthesis and anti-HIV activities.
AID1446813	Cytotoxicity against human MT4 cells after 5 days by MTT assay	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.
AID1457062	Ratio of EC50 for HIV-1 harboring reverse transcriptase K103N/Y1881C double mutant infected in human MT4 cells to EC50 for HIV1 NL4-3 infected in human MT4 cells	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
AID1636147	Antiviral activity against NNRTI resistant HIV1 harboring reverse transcriptase V106I/Y181C/G190A/H221Y mutant assessed as inhibition of viral infection in human TZM-bl cells after 48 hrs by luciferase reporter gene assay	2016	Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15	Discovery and Structure-Based Optimization of 2-Ureidothiophene-3-carboxylic Acids as Dual Bacterial RNA Polymerase and Viral Reverse Transcriptase Inhibitors.
AID576028	Volume of distribution in healthy human plasma at 400 mg, po qd for 14 days by liquid chromatography-tandem mass spectrometry	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.
AID279423	Antiviral activity against HIV1 isolate with RT 106I, 188L mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1773452	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 harboring K103N mutant infected in human MT4 cells
AID302259	Inhibition of wild type HIV1 3B reverse transcriptase	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID313193	Antiviral activity against HIV1 Y181C mutant	2008	Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1	Synthesis and antiviral activity of new dimeric inhibitors against HIV-1.
AID1815382	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID1171586	Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID658571	Antiviral activity against wild type Human immunodeficiency virus 1 NL4-3 pseudotyped with VSV envelope infected in human HeLa-SxR5 cells assessed as inhibition of viral replication at 65 nM after 3 days by beta-galactosidase assay	2012	Journal of natural products, Mar-23, Volume: 75, Issue:3	Library-based discovery and characterization of daphnane diterpenes as potent and selective HIV inhibitors in Daphne gnidium.
AID473117	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B	2010	Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7	Synthesis and biological evaluation of 4-(hydroxyimino)arylmethyl diarylpyrimidine analogues as potential non-nucleoside reverse transcriptase inhibitors against HIV.
AID519858	Antiviral activity against HIV1 subtype B-HXB2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID1741392	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for antiviral activity against HIV IIIB	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID576039	Ratio of drug concentration in PBMCs to plasma of healthy human administered at 400 mg, po measured after 5 hrs on day 1 post dose	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.
AID1320864	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.
AID1304405	Selectivity index, ratio of CC50 for cytotoxicity against mock-infected human MT4 cells to EC50 for antiviral activity against HIV-1 3B	2016	Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13	Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
AID1391077	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	The discovery of novel diarylpyri(mi)dine derivatives with high level activity against a wide variety of HIV-1 strains as well as against HIV-2.
AID361906	Antiviral activity against wild type HIV1 in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID370731	Antiviral activity against HIV1 3B infected human C8166 cells assessed as inhibition of syncytia formation by p24 antigen based assay	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations.
AID1763902	Antiviral activity against HIV-1 IIIB harboring RT E138K mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity incubated for 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 06-15, Volume: 40	Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs.
AID665553	Fold resistance, ratio of EC50 for HIV1 RES056 harboring reverse transcriptase K103N/Y181C RT mutant to EC50 for wild type HIV1 3B	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors.
AID1457060	Ratio of EC50 for HIV-1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells to EC50 for HIV1 NL4-3 infected in human MT4 cells	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
AID1815381	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID1357797	Resistance factor, ratio of EC50 for HIV1 harboring reverse transcriptase Y181C mutant to EC50 for wild-type HIV-1 3B	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID663308	Inhibition of HIV1 recombinant reverse transcriptase Y181I mutant assessed as [3H]dTTP incorporation into poly(rA)/oligo(dT)	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.
AID1880372	Antiviral activity against wild type HIV-1 IIIB infected in human MT4 cells assessed as protection against virus-induced cytopathic effect by MTT assay	2022	Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12	Structure-Based Discovery of Novel NH
AID82605	The effect of protein binding on the antiviral activity versus wild type virus strain HXB2 was tested in the presence of human serum in HeLa MAGI assay	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1231487	Inhibition of wild-type HIV1 Reverse transcriptase p66/p51 assessed as relative fluorescence signal after 40 mins	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anti-HIV diarylpyrimidine-quinolone hybrids and their mode of action.
AID1457073	Cytotoxicity against C57BL/6 mouse BV2 cells assessed as effect on cell proliferation rate at 10 to 10000 nM up to 48 hrs by MTT assay	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
AID557049	Antiviral activity against HIV1 clade G harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID1457055	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human ML4 cells assessed as protection against virus-induced cytopathic effect measured on day 5 post infection by MTT assay	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
AID1056584	Antiviral activity against wild-type HIV-1 infected in HEK293T cells co-transfected with VSVG protein assessed as time required for 50% failure of viral replication at 10 uM by luciferase reporter gene assay	2013	Journal of natural products, Dec-27, Volume: 76, Issue:12	Phenylspirodrimanes with anti-HIV activity from the sponge-derived fungus Stachybotrys chartarum MXH-X73.
AID718368	Cytotoxicity against HIV2 ROD infected in human MT4 cells by MTT assay	2012	Bioorganic & medicinal chemistry, Dec-01, Volume: 20, Issue:23	Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach.
AID279440	Antiviral activity against HIV1 isolate with RT 101R, 103N mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID735081	Antiviral activity against HIV harboring reverse transcriptase Y181C mutant by cell based assay	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	Synthesis and biological evaluation of phosphonate analogues of nevirapine.
AID573245	Cmin in HIV-1 infected children at 13.9 mg/kg, po administered once daily by HPLC	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children?
AID1750722	Inhibition of recombinant wild type p66/p51 HIV1 reverse transcriptase incubated for 40 mins by picogreen dye-based spectrofluorometric analysis	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from
AID541174	Selectivity ratio of EC50 for antiviral activity against HIV1 harboring E92V, G140S and V151A mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1261309	Cytotoxicity against MDBK cells assessed as cell viability after 48 to 96 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID1565095	Antiviral activity against drug resistant HIV-1 harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay
AID541134	Selectivity ratio of EC50 for antiviral activity against PI-resistant HIV1 harboring RTI84V, L90M mutant gene to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID622048	Inhibition of DNA-dependent DNA polymerase activity of HIV1 reverse transcriptase p66/p66 homodimer V106A mutant using activated DNA and [alpha-32P]dATP after 30 mins by liquid scintillation counting	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID246283	Effective concentration of the compound to inhibit HIV-1 mutant LAI replication in HIV-infected MT-4 cells	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID736038	Inhibition of HIV1 reverse transcriptase p66/p51 K103N/Y181C mutant after 30 mins by liquid scintillation counting	2013	Bioorganic & medicinal chemistry, Mar-01, Volume: 21, Issue:5	N1,N3-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
AID523353	Antiviral activity against HIV1 with RT connection domain Y181C mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID583865	Inhibition of HIV1 histidine-tagged reverse transcriptase L100I mutant activity by primer extension assay	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID586385	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase N155T mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficiency vi	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID241665	Inhibitory concentration against HIV-1 mutant reverse transcriptase (K103N+Y181C)	2005	Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11	Structure-based design, parallel synthesis, structure-activity relationship, and molecular modeling studies of thiocarbamates, new potent non-nucleoside HIV-1 reverse transcriptase inhibitor isosteres of phenethylthiazolylthiourea derivatives.
AID1750718	Inhibition of HIV-1 p66/p51 reverse transcriptase K103N mutant incubated for 40 mins by picogreen dye-based spectrofluorometric analysis	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from
AID584081	Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase V108I, H221Y, F227F/L, M230M/I mutant infected in human SupT1 cells derived from 11 viral passages with lersivirine assessed as inhibition of viral replication after 21 days relative to	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID586387	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase T66I/E92Q mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficienc	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID586466	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase L74M/N155H mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficien	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID1057038	Antiviral activity against HIV2 ROD infected in MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Design, synthesis and biological evaluation of 3-benzyloxy-linked pyrimidinylphenylamine derivatives as potent HIV-1 NNRTIs.
AID1754644	Antiviral activity against HIV1 harboring RT Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses.
AID255623	Concentration required to reduce the viability of mock-infected human CEM cells	2005	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 15, Issue:20	Synthesis and evaluation of anti-HIV activity of isatin beta-thiosemicarbazone derivatives.
AID1316342	Selectivity index, ratio of CC50 for human mock-infected MT4 cells to EC50 for HIV1 3B harboring reverse transcriptase L100I mutant infected in human MT4 cells	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID1884494	Inhibition of recombinant wild-type p66/p51 HIV-1 reverse transcriptase incubated for 40 mins by picogreen dye-based spectrofluorometric analysis	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.
AID279436	Antiviral activity against HIV1 isolate with RT 103R, 179D mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID105704	Anti-HIV-1 activity against Y181C strain, in MT-4 cells by the MTT method	2003	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24	3-iodo-4-phenoxypyridinones (IOPY's), a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID508757	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase E138K, M230L mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID106053	Inhibitory activity against 100I strain of HIV-I in MT-4 cells	2001	Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17	Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.
AID587738	Antiviral activity against single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef infected in human HeLa-T4 cells assessed as luciferase activity after 48 hrs by exogenous RT assay	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID607876	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type Human immunodeficieny virus 1 3B infected in human MT4 cells	2011	Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14	Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6-((3,4-dihydroquinolin-1(2H)-yl)methyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID88366	Antiviral activity against K103N mutant virus in the HeLa MAGI assay.	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID586383	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase N155H mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficiency vi	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID1326646	Inhibition of HIV-1 3B reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by cell titer glo based luciferase reporter gene assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Novel (2,6-difluorophenyl)(2-(phenylamino)pyrimidin-4-yl)methanones with restricted conformation as potent non-nucleoside reverse transcriptase inhibitors against HIV-1.
AID141361	Inhibitory activity against mutant K103N HIV-1 Reverse transcriptase	2001	Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14	Synthesis and evaluation of novel quinolinones as HIV-1 reverse transcriptase inhibitors.
AID576027	Apparent oral clearance in healthy human plasma at 400 mg, po qd for 14 days by liquid chromatography-tandem mass spectrometry	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.
AID313189	Protection against HIV1 HTLV 3B-induced cytopathogenicity in human MT4 cells by MTT assay	2008	Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1	Synthesis and antiviral activity of new dimeric inhibitors against HIV-1.
AID1736362	Selectivity index, ratio of EC50 for antiviral activity against VSVG/HIV-1 harboring reverse transcriptase K103N mutant infected in human HEK 293T cells to EC50 for antiviral activity against VSVG/wild type HIV-1 infected in human HEK293T cells
AID404607	Antiviral activity against HIV1 with reverse transcriptase K103R mutation	2008	Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12	Parallel one-pot synthesis and structure-activity relationship study of symmetric formimidoester disulfides as a novel class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID279499	Antiviral activity against HIV1 isolate with RT A98G mutation	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID269802	Antiviral activity against HIV1 Y188L mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269802	Antiviral activity against HIV1 Y188L mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269802	Antiviral activity against HIV1 Y188L mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID416759	Antiviral activity against HIV1 with reverse transcriptase Y188L mutation in human CEM cells assessed as protection against virus-induced cytopathicity	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID1483281	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for reverse transcriptase K103N mutant in human MT4 cells infected HIV1 3B	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
AID1574376	Antiviral activity against HIV-1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.
AID522378	Resistance index, ratio of EC50 for recombinant HIV1 harboring reverse transcriptase V106I/V179D mutant clone to EC50 for wild type HIV1	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
AID443688	Antiviral activity against HIV with reverse transcriptase K101E/G190A double mutant assessed as inhibition of viral replication	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
AID279447	Antiviral activity against HIV1 isolate with RT 236L mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID105203	Antiviral activity against MT-4 cells infected with wild-type HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID573978	Antiretroviral activity against Human immunodeficiency virus 2 EHO infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.
AID1186001	Antiviral activity against HIV1 harboring reverse transcriptase K103N/P225H double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay r	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
AID1161106	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	Arylazolyl(azinyl)thioacetanilides. Part 16: Structure-based bioisosterism design, synthesis and biological evaluation of novel pyrimidinylthioacetanilides as potent HIV-1 inhibitors.
AID1815389	Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID305058	Cytotoxicity against HEK293T cells after 48 hrs	2007	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 17, Issue:1	4-Aminopyrimidines as novel HIV-1 inhibitors.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID632804	Cytotoxicity against human MT2 cells infected with HIV1 NL4.3 by MTT assay	2011	Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24	Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.
AID1186008	Antiviral activity against HIV1 infected in 293T cells assessed as time of 50% failure	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
AID279508	Antiviral activity against HIV1 isolate with RT Y181C mutation in Hela-JC-53 cells	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1822273	Antiviral activity against wild type HIV-1 IIIB infected in human MT4 cells assessed as protection against virus-induced cytotoxicity incubated for 5 days by MTT assay	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.
AID1155812	Fold resistance, ratio of EC50 for HIV-1 harboring NNTRI-resistant reverse transcriptase Y188L mutant infected in human MT4 cells to EC50 for wild type HIV-1 NL4-3 infected in human MT4 cells	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.
AID368558	Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.
AID279444	Antiviral activity against HIV1 isolate with RT 101Q, 181C, 190S mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID448398	Fold resistance, ratio of IC50 for HIV reverse transcriptase with Y181C mutant to IC50 for HIV wild type reverse transcriptase	2009	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19	Pyrazole NNRTIs 3: optimisation of physicochemical properties.
AID1736366	Selectivity index, ratio of EC50 for antiviral activity against VSVG/HIV-1 harboring reverse transcriptase Y188L mutant infected in human HEK 293T cells to EC50 for antiviral activity against VSVG/wild type HIV-1 infected in human HEK293T cells
AID1729156	Antiviral activity against HIV1 harboring L100I mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect by MTT assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp
AID1186002	Antiviral activity against HIV1 harboring reverse transcriptase K103N/G190A double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
AID81765	Compound was evaluated for its ability to inhibit a virus containing the clinically relevant K103N mutation	2001	Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11	4,1-Benzoxazepinone analogues of efavirenz (Sustiva) as HIV-1 reverse transcriptase inhibitors.
AID1483271	Inhibition of HIV1 3B reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
AID1763901	Antiviral activity against HIV-1 IIIB harboring RT Y188L mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity incubated for 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 06-15, Volume: 40	Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs.
AID1157601	Antiviral activity against HIV1 CRF02 infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID247499	Inhibitory activity against HIV-1 mutant strain 138K	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID257167	Antiviral activity against HIV1 IRLL98 mutant strain infected MT4 cells by MTT method	2005	Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25	Parallel solution-phase and microwave-assisted synthesis of new S-DABO derivatives endowed with subnanomolar anti-HIV-1 activity.
AID1335205	Ratio of IC50 for HIV-1 NL4-3 harboring RT-L100I/K103N double mutant infected in HEK293T cells co-expressing vesicular stomatitis virus glycoprotein to IC50 for wild-type HIV-1 NL4-3 infected in HEK293T cells co-expressing vesicular stomatitis virus glyco	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID282737	Inhibition of HIV1 RT K103N mutant	2005	Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23	Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.
AID1483277	Inhibition of HIV1 3B reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
AID508832	Antiviral activity against Human immunodeficiency virus 1 subtype C isolate 93IN101 infected in human PBMC cells by cell based assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID361915	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106M mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID562701	Antiviral activity against wild type HIV1 infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation.
AID519890	Selectivity ratio of EC50 for 0.01 MOI HIV1 NL4-3 infected in human MT2 cells by MTS assay to EC50 for 0.01 MOI HIV1 NL4-3 infected in human MT2 cells by RT assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID649487	Inhibition of RNA-dependent DNA polymerase activity of Human immunodeficiency virus 1 reverse transcriptase Tyr181Cys mutant	2012	European journal of medicinal chemistry, Apr, Volume: 50	Identification of HIV-1 reverse transcriptase dual inhibitors by a combined shape-, 2D-fingerprint- and pharmacophore-based virtual screening approach.
AID1335210	Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/G190A double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID1884542	Fold resistance, ratio of EC50 for antiviral activity against drug-resistant HIV-1 E138K mutant infected in human MT4 cells to EC50 for antiviral activity against NNRTI resistant wild type HIV-1 infected in human MT4 cells	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.
AID105326	Inhibition of HIV-1 (IIIB) induced cytopathicity in MT-4 cells.	2004	Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15	Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations.
AID389379	Cytotoxicity against human MT4 cells	2008	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20	1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID397177	Antiviral activity against HIV1 3B expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Parallel synthesis, molecular modelling and further structure-activity relationship studies of new acylthiocarbamates as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID279518	Antiviral activity against HIV1 NL4-3 in Hela-JC53 cells in the presence of 10% human serum after 48 hrs	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID106065	Inhibitory activity against 181C strain of HIV-I in MT-4 cells	2001	Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17	Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.
AID440081	Antiviral activity against HIV1 HXB2 harboring 190A mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
AID586369	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase E138K mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficiency vi	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID302258	Resistance index, Ratio of EC50 for drug-resistant HIV1 with RT Y188L mutation in MT3 cells to EC50 for HIV1 NL43 in MT3 cells	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID1583021	Cytotoxicity in mock-infected human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	2020	Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3	Discovery and Characterization of Fluorine-Substituted Diarylpyrimidine Derivatives as Novel HIV-1 NNRTIs with Highly Improved Resistance Profiles and Low Activity for the hERG Ion Channel.
AID276231	Antiviral activity against HIV1 3B in MT2 cells	2006	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21	Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID1191401	Antiviral activity against wild type HIV-2 ROD infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	2015	Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3	Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID1191404	Inhibition of wild type HIV1 p66/p51 reverse transcriptase by spectrofluorometry	2015	Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3	Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID88380	Antiviral activity against V108I/Y181C mutant virus in the HeLa MAGI assay.	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID348906	Antiviral activity against drug-resistant HIV1 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as virus-induced cell death by MTT method	2008	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 18, Issue:21	Towards novel S-DABOC inhibitors: synthesis, biological investigation, and molecular modeling studies.
AID572182	Antiviral activity against HIV-1 SM012 harboring NNTRI 108I mutant infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID1379963	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for antiviral activity against HIV1 3B infected in human MT4 cells	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives as potent HIV-1 NNRTIs.
AID611907	Antiviral activity against wild type Human immunodeficiency virus 1 NL 4.3 pseudotyped with VSV-G envelope co-transfected with luciferase gene infected in human 293T cells assessed as inhibition of HIV1 replication administered 15 mins prior to infection	2011	Journal of natural products, Jun-24, Volume: 74, Issue:6	Lindenane disesquiterpenoids with anti-HIV-1 activity from Chloranthus japonicus.
AID508772	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase Y188L mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1485969	Inhibition of HIV-1 reverse transcriptase L100I mutant assessed as reduction in dTTP incorporation using poly(rA)/oligo(dT)16 as template/primer after 40 mins by PicoGreen dye based spectrofluorometric analysis	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Searching for novel N
AID508774	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase Y181I mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1249722	Antiviral activity against HIV1 expressing reverse transcriptase Y188L mutant	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue.
AID298074	Antiviral activity against HIV1 3B in MT4 cells by MTT assay	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity.
AID279325	Inhibition of reverse transcriptase activity in HIV1 NL4-3 infected MT4 cells before dialysis	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Development of a new methodology for screening of human immunodeficiency virus type 1 microbicides based on real-time PCR quantification.
AID299027	Antiviral activity against HIV1 with reverse transcriptase L100I mutation in CEM cells assessed as inhibition of virus-induced giant cell formation	2007	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7	Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains.
AID649486	Inhibition of RNA-dependent DNA polymerase activity of Human immunodeficiency virus 1 reverse transcriptase Lys103Asn mutant	2012	European journal of medicinal chemistry, Apr, Volume: 50	Identification of HIV-1 reverse transcriptase dual inhibitors by a combined shape-, 2D-fingerprint- and pharmacophore-based virtual screening approach.
AID279452	Antiviral activity against HIV1 isolate with RT 103N, 108I, 238T mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID605178	Inhibition of HIV1 reverse transcriptase Y181C mutant by SPA assay	2010	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 20, Issue:15	Biaryl ethers as potent allosteric inhibitors of reverse transcriptase and its key mutant viruses: aryl substituted pyrazole as a surrogate for the pyrazolopyridine motif.
AID104802	In vitro cytotoxicity against mock infected MT-4 cells.	2004	Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15	Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations.
AID666971	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days	2012	European journal of medicinal chemistry, Aug, Volume: 54	Diverse combinatorial design, synthesis and in vitro evaluation of new HEPT analogues as potential non-nucleoside HIV-1 reverse transcription inhibitors.
AID642209	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	2011	Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23	Quinoline tricyclic derivatives. Design, synthesis and evaluation of the antiviral activity of three new classes of RNA-dependent RNA polymerase inhibitors.
AID105700	Anti-HIV-1 activity against K103N+Y181C strain was determined in MT-4 cells by the MTT method	2003	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24	3-iodo-4-phenoxypyridinones (IOPY's), a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID573479	Antiviral activity of Human immunodeficiency virus 1 isolate 9225 harboring A98S, G190A mutation in reverse transcriptase by cell based assay	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
AID105701	Anti-HIV-1 activity against LAI strain in MT-4 cells by the MTT method	2003	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24	3-iodo-4-phenoxypyridinones (IOPY's), a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID573464	Inhibition of RNA-dependent DNA polymerase activity of wild-type Human immunodeficiency virus 1 subtype B reverse transcriptase by filter-based filtration assay	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
AID443706	Antiviral activity against HIV with reverse transcriptase K101E/Y181C/G190A mutant assessed as inhibition of viral replication relative to wild type	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
AID347610	Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 100I mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.
AID650545	Antiviral activity against HIV 1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1815385	Antiviral activity against HIV1 harboring reverse transcriptase F227L/V106A mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID508621	Antiviral activity against Human immunodeficiency virus 1 subtype D isolate 92UG001 infected in human PBMC cells by cell based assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID572180	Antiviral activity against HIV-1 SM002 harboring NNTRI 181C mutant infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID1691437	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	2020	European journal of medicinal chemistry, May-01, Volume: 193	In situ click chemistry-based rapid discovery of novel HIV-1 NNRTIs by exploiting the hydrophobic channel and tolerant regions of NNIBP.
AID391221	Inhibition of wild type HIV1 RT polymerase by SPA	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses.
AID105537	Inhibitory activity against HIV-1 Cys 181 mutant in MT-4 cells.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues.
AID541127	Antiviral activity against HIV1 infected in SupT1 cells assessed as accumulation of late RT products after 12 hrs	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID573249	Cmax in HIV-1 infected children at 10 to 15 mg/kg, po administered once daily by HPLC	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children?
AID1731751	Inhibition of reverse transcriptase F227L/V106A double mutant in HIV-1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay
AID1743619	Antiviral activity against HIV1 RES056 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.
AID279419	Antiviral activity against HIV1 isolate with RT 101Q, 181C, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID508755	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase V179E, Y181C mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID247617	Inhibitory activity against HIV-1 double mutants strain 100I and 103N	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID371909	Antiviral activity against HIV1 NL4-3 with L100I mutant in human TZM-b1 cells assessed as beta-galactosidase activity after 48 hrs by single round replication assay	2009	Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12	New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID1552560	Antiviral activity against HIV1 LAI infected in human LC5 cells expressing DsRed1 reporter gene assessed as inhibition of viral infection measured after 48 hrs post infection by reporter gene based luminescence assay	2019	Bioorganic & medicinal chemistry, 08-15, Volume: 27, Issue:16	Biological evaluation of molecules of the azaBINOL class as antiviral agents: Inhibition of HIV-1 RNase H activity by 7-isopropoxy-8-(naphth-1-yl)quinoline.
AID1822278	Antiviral activity against HIV-1 harboring Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity incubated for 5 days by MTT assay	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.
AID248068	Inhibitory concentration against 100I and 103N mutant strains was determined	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity.
AID519965	Antiviral activity against 0.005 MOI HIV1 NL4-3 harboring M184V mutant RT infected in human MT2 cells	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID1483282	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for reverse transcriptase Y181C mutant in human MT4 cells infected HIV1 3B	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
AID279468	Antiviral activity against HIV1 isolate with RT 98G, 108I, 181C mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1637396	Antiviral activity against human HIV-1 3B harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection from virus-induced cytopathic effect measured 5 days post infection by MTT assay	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.
AID649489	Inhibition of ribonuclease H activity of Human immunodeficiency virus 1 reverse transcriptase Lys103Asn mutant	2012	European journal of medicinal chemistry, Apr, Volume: 50	Identification of HIV-1 reverse transcriptase dual inhibitors by a combined shape-, 2D-fingerprint- and pharmacophore-based virtual screening approach.
AID279320	Inhibition of reverse transcriptase assessed as decrease in ssDNA level in cell free virion HIV1 by NERT-based real-time PCR at 250 uM	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Development of a new methodology for screening of human immunodeficiency virus type 1 microbicides based on real-time PCR quantification.
AID1204077	Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT method	2015	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11	N-((1,3-Diphenyl-1H-pyrazol-4-yl)methyl)anilines: A novel class of anti-RSV agents.
AID361928	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V108I/Y181C mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID557035	Antiviral activity against HIV1 isolate R8 harboring reverse transcriptase K103N and Y181C mutant infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs in presence of 50% human serum	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID1888692	Selectivity index, ratio of CC50 for toxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay to EC50 for antiviral activity against HIV1 3B infected in human MT4 cells cells assessed as protection against viral-induc
AID557047	Antiviral activity against HIV1 clade D harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID1535523	Antiviral activity against HIV1 RES056 containing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2019	Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3	Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs.
AID496615	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase V90I/V35T, K64R, K102Q, D123E, S162A, K173T, Q174K, D177E, G196E,T200A, Q207E, R211K mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID1069126	Antiviral activity against wild-type HIV infected in human MT4 cells assessed as inhibition of viral infection in presence of 50% normal human serum	2014	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3	Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses.
AID1624241	Binding affinity to HIV1 cYTA48P envelope glycoprotein gp120 infected in human TZM-b1 cells assessed as induction of conformational changes measured after 48 hrs	2019	Bioorganic & medicinal chemistry letters, 03-01, Volume: 29, Issue:5	Soluble-type small-molecule CD4 mimics as HIV entry inhibitors.
AID476469	Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of virus replication by MTT assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives.
AID1729159	Antiviral activity against HIV1 harboring Y188L mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect by MTT assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp
AID584237	Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase V108I mutant derived from 17 days viral passages with lersivirine infected in human SupT1 cells assessed as inhibition of viral replication after 21 days relative to wild type HIV1 NL4-	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID269689	Antiviral activity against HIV1 NNTRI resistant L100I mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269689	Antiviral activity against HIV1 NNTRI resistant L100I mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269689	Antiviral activity against HIV1 NNTRI resistant L100I mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID386623	Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy	2008	Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19	Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID1348213	Antiviral activity against wild-type VSV-G pseudotyped HIV1 infected in HEK293 cells pretreated for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene assay	2017	Journal of natural products, 12-22, Volume: 80, Issue:12	Oxazole-Containing Diterpenoids from Cell Cultures of Salvia miltiorrhiza and Their Anti-HIV-1 Activities.
AID83547	Potency evaluated against NNRTI-Resistant HIV-1 strain Gly190Ala	2004	Journal of medicinal chemistry, May-06, Volume: 47, Issue:10	Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 varian
AID279528	Antiviral activity against HIV1 NL4-3 with Y188L mutation in Hela-JC53 cells in the presence of 40% human serum after 48 hrs	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1457054	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 NL4-3 infected in human MT4 cells	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
AID635302	Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay	2011	Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23	Design, synthesis and biological evaluation of cycloalkyl arylpyrimidines (CAPYs) as HIV-1 NNRTIs.
AID298061	Antiviral activity against HIV1 3B in human MT4 cells by XTT assay	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability.
AID1191402	Cytotoxicity against human MT4 cells after 5 days MTT assay	2015	Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3	Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID465424	Oral bioavailability in Beagle dog at 4 mg/kg	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	N1-Alkyl pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID1171595	Inhibition of wild type HIV1 reverse transcriptase Y181I/Y181C mutant assessed as reduction in enzyme activity	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1180486	Antiviral activity against VSV-G protein pseudotyped HIV1 infected in 293T cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter assay	2014	Journal of natural products, Jul-25, Volume: 77, Issue:7	Uralsaponins M-Y, antiviral triterpenoid saponins from the roots of Glycyrrhiza uralensis.
AID1888704	Resistance index, ratio of EC50 for antiviral activity against HIV1 with RT F227L + V106A mutant infected in human MT4 cells to EC50 for antiviral activity against wild type HIV1 infected in human MT4 cells
AID586482	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase N155H/G163R mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficie	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID1773450	Antiviral activity against HIV1 harboring F227L/V106A mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenic effect by MTT assay
AID619637	Antiviral activity against HIV-1 3B harboring RT Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
AID1126508	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay	2014	Bioorganic & medicinal chemistry, Apr-15, Volume: 22, Issue:8	Structural modifications of CH(OH)-DAPYs as new HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1171412	Antiviral activity against wild type HIV1 harboring reverse transcriptase Y181C mutant infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay	2014	ACS medicinal chemistry letters, Nov-13, Volume: 5, Issue:11	Picomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl Ethers.
AID1822281	Antiviral activity against HIV-1 harboring F227L/V106A double mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity incubated for 5 days by MTT assay	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.
AID1261812	Cytotoxicity against human MT4 cells assessed as reduction in cell proliferation after 96 hrs by MTT assay	2015	European journal of medicinal chemistry, Nov-13, Volume: 105	Synthesis, cytotoxicity and antiviral evaluation of new series of imidazo[4,5-g]quinoline and pyrido[2,3-g]quinoxalinone derivatives.
AID557039	Antiviral activity against HIV1 isolate R8 harboring reverse transcriptase K103N and Y181C mutant infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs in presence of 10% FBS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID279525	Antiviral activity against HIV1 NL4-3 with Y188L mutation in Hela-JC53 cells in the presence of 10% human serum after 48 hrs	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID361913	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190S mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID650548	Resistance ratio of EC50 for HIV 1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells to EC50 for wild type HIV 1 NL4-3 infected in human MT4 cells	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1165078	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.
AID1231485	Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anti-HIV diarylpyrimidine-quinolone hybrids and their mode of action.
AID440669	Cytotoxicity against human MT4 cells assessed as reduction of cell viability after 4 days by MTT assay	2009	European journal of medicinal chemistry, Dec, Volume: 44, Issue:12	Activity and molecular modeling of a new small molecule active against NNRTI-resistant HIV-1 mutants.
AID1316341	Antiviral activity against HIV1 3B harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID583869	Inhibition of HIV1 histidine-tagged reverse transcriptase V108I mutant activity by primer extension assay	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID370728	Inhibition of RNA dependent DNA polymerase activity of HIV1 recombinant reverse transcriptase p66/p51 V106A mutant expressed in Escherichia coli JM109	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations.
AID523479	Antiviral activity against HIV1 with RT connection domain G190S mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID508754	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase V179F, Y181C mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1373162	Inhibition of reverse transcriptase F227L/V106A double mutant in HIV1 infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3	Structural optimization of N
AID265471	Activity against HIV1 3B assessed by inhibition of p24 production in human lymphocytes	2006	Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11	Design, molecular modeling, synthesis, and anti-HIV-1 activity of new indolyl aryl sulfones. Novel derivatives of the indole-2-carboxamide.
AID573248	Cmax in HIV-1 infected children at 12 mg/kg, po administered once daily by HPLC	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children?
AID366527	Inhibition of RNA dependent DNA polymerase activity of HIV1 reverse transcriptase K103N mutant	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.
AID492286	Antiviral activity against HIV1 with reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
AID523354	Antiviral activity against HIV1 with RT connection domain Y181C/N348I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID583852	Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.005 multiplicities of infection after 6 days	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID576029	Apparent oral clearance in healthy human plasma at 400 mg, po measured on day 1 post dose by liquid chromatography-tandem mass spectrometry	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.
AID586382	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase M154I mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficiency vi	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID650688	Inhibition of HIV 1 reverse transcriptase L100I mutant assessed as inhibition of time-dependent incorporation of [3H]dTTP into poly(rA)n.oligo(dT)	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
AID1815387	Resistance fold, ratio of EC50 for HIV1 harboring reverse transcriptase L100I mutant infected MV4 cells to EC50 for wild type HIV1 infected MV4 cells	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID267652	Selectivity for wild type HIV1 virus over HIV1 Y181C mutant	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1.
AID1126507	Antiviral activity against HIV1 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay	2014	Bioorganic & medicinal chemistry, Apr-15, Volume: 22, Issue:8	Structural modifications of CH(OH)-DAPYs as new HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID576037	Half life in healthy human plasma at 400 mg, po qd for 14 days by liquid chromatography-tandem mass spectrometry	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.
AID1320863	Antiviral activity against HIV1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.
AID1235381	Inhibition of HIV1 recombinant wild type reverse transcriptase p66/p51 assessed as reduction in biotin deoxyuridine triphosphate (biotin-dUTP) incorporation using poly(rA)/oligo (dT)16 template and primer by spectrofluorometry	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Hybrid chemistry. Part 4: Discovery of etravirine-VRX-480773 hybrids as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1888694	Antiviral activity against HIV1 with RT L100I mutant infected in human MT4 cells cells assessed as protection against viral-induced cytopathogenecity by MTT assay
AID586467	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase E92Q/N155H mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficien	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID1272056	Inhibition of HIV1 reverse transcriptase	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Efavirenz a nonnucleoside reverse transcriptase inhibitor of first-generation: Approaches based on its medicinal chemistry.
AID1627026	Cytotoxicity against HIV1 infected human PBMC cells assessed as reduction in cell viability after 7 days by MTT assay	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Discovery, characterization, and lead optimization of 7-azaindole non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID519961	Selectivity ratio of EC50 for 0.02 MOI HIV1 NL4-3 infected in 2 hrs pretreated human MT2 cells by MTS assay to EC50 for 0.02 MOI HIV1 NL4-3 infected in 2 hrs pretreated human MT2 cells by RT assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID496742	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase E138A/V35T, K122E, I135V, T139A, S162A, K173T, Q174K, N175Y, D177E, T200A, Q207E, R211K mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID1220382	Antiviral activity against HIV1 expressing Env-green fluorescent fusion protein infected in PBMC assessed as inhibition of viral activity after 72 hrs by flow cytometry analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2	Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid.
AID464768	Half life in human microsomes	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	N1-Heterocyclic pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID1171585	Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID573468	Inhibition of Human immunodeficiency virus 1 subtype B reverse transcriptase DNA-dependent DNA polymerase activity by gel-based primer extension assay	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
AID1822279	Antiviral activity against HIV-1 harboring Y188L mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity incubated for 5 days by MTT assay	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.
AID247505	Inhibitory activity against HIV-1 mutant strain 227C	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID1743634	Resistance index, ratio of EC50 for antiviral activity against HIV1 expressing RT L100I mutant infected in human MT4 cells to EC50 for antiviral activity against HIV1 3B infected in human MT4 cells	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.
AID698302	Antiviral activity against HIV1 containing reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1391086	Antiviral activity against HIV1 harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	The discovery of novel diarylpyri(mi)dine derivatives with high level activity against a wide variety of HIV-1 strains as well as against HIV-2.
AID1888703	Resistance index, ratio of EC50 for antiviral activity against HIV1 with RT E138K mutant infected in human MT4 cells to EC50 for antiviral activity against wild type HIV1 infected in human MT4 cells
AID1410483	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery.
AID1155816	Inhibition of HIV-1 recombinant NNTRI-resistant reverse transcriptase L100I mutant assessed as incorporation of [3H]dTTP into poly(rA)/oligo(dT)10:1	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.
AID586363	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase E92Q mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficiency vir	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID508797	Ratio of EC50 for HIV1 in presence of 45 mg/ml HSA to EC50 for HIV1 in absence of serum proteins by GFP assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1220372	Seminal plasma protein binding in human at 100 mg administered every 4 hrs by ultrafiltration method	2013	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2	Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid.
AID1705189	Antiviral activity against HIV1 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect by MTT assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains.
AID1558857	Antiviral activity against HIV1 harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Ligand-Based Design of Nondimethylphenyl-Diarylpyrimidines with Improved Metabolic Stability, Safety, and Oral Pharmacokinetic Profiles.
AID252955	Ratio of CC50 and EC50 against wild type human immunodeficiency virus type 1 LAI strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.
AID198917	Inhibition of HIV-1 wild-type RT	2001	Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3	Quinoxalinylethylpyridylthioureas (QXPTs) as potent non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors. Further SAR studies and identification of a novel orally bioavailable hydrazine-based antiviral agent.
AID573469	Inhibition of DNA-dependent DNA polymerase activity of wild-type Human immunodeficiency virus 1 subtype B reverse transcriptase G190A mutant by filter-based filtration assay	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
AID1335220	Ratio of IC50 for HIV-1 NL4-3 harboring RT-K103N/Y188L double mutant infected in HEK293T cells co-expressing vesicular stomatitis virus glycoprotein to IC50 for wild-type HIV-1 NL4-3 infected in HEK293T cells co-expressing vesicular stomatitis virus glyco	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID1357792	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID1185995	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay relative HIV1	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
AID248258	In vitro inhibitory concentration against HIV G190S mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
AID1637403	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for human HIV-1 3B harboring E138K mutant infected in human MT4 cells	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.
AID347085	Inhibition of RNA-dependent DNA polymerase activity of wild type HIV1 reverse transcriptase	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays.
AID508827	Antiviral activity against Human immunodeficiency virus 1 subtype A isolate 92UG037 infected in human PBMC cells by cell based assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID88364	Antiviral activity against E138K mutant virus in the HeLa MAGI assay.	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID361926	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106A/Y181C mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1390715	Resistance index, ratio of EC50 for HIV1 RES056 harboring K103N/Y181C double mutant infected in human MT4 cells to EC50 for wild-type HIV1 3B infected in human MT4 cells	2018	Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8	First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain.
AID1636148	Ratio of IC50 for NNRTI resistant HIV1 harboring reverse transcriptase A98G/K101E/Y181C/G190A mutant infected in human TZM-bl cells to IC50 for wild type HIV1 NL4-3 infected in human TZM-bl cells	2016	Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15	Discovery and Structure-Based Optimization of 2-Ureidothiophene-3-carboxylic Acids as Dual Bacterial RNA Polymerase and Viral Reverse Transcriptase Inhibitors.
AID269798	Antiviral activity against HIV1 K103N mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269798	Antiviral activity against HIV1 K103N mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269798	Antiviral activity against HIV1 K103N mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1815397	Inhibition of HIV1 reverse transcriptase L100I mutant using oligo(dT)16 as primer measured after 40 mins by picogreen-dye based spectrofluorimetric analysis	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID1767116	Inhibition of wild type HIV-1 NL4-3 reverse transcriptase using random mRNA as template and GADPH as primer measured at 42 degreeC for 5 mins, 95 degreeC for 10sec and 60 degreeC for 60 sec by qRT-PCR analysis	2021	European journal of medicinal chemistry, Aug-05, Volume: 220	Design and biological evaluation of cinnamic and phenylpropionic amide derivatives as novel dual inhibitors of HIV-1 protease and reverse transcriptase.
AID650546	Antiviral activity against HIV 1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
AID1197833	Resistance index, ratio of EC50 for HIV1 RES056 expressing reverse transcriptase K103N + Y181C double mutant to EC50 for wild type HIV1 3B	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.
AID1535525	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	2019	Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3	Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs.
AID1410482	Inhibition of HIV1 RES056 reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity by MTT assay	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery.
AID371897	Selectivity index, ratio of CC50 for human TZM-b1 cells to EC50 for HIV1 NL4-3	2009	Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12	New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID348904	Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells assessed as virus-induced cell death by MTT method	2008	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 18, Issue:21	Towards novel S-DABOC inhibitors: synthesis, biological investigation, and molecular modeling studies.
AID1059141	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for drug-resistant HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant	2013	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24	Novel piperidinylamino-diarylpyrimidine derivatives with dual structural conformations as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID366558	Antiviral activity against HIV1 with reverse transcriptase K103N/L100I mutation in human MT4 cells assessed as reduction of virus-induced cytopathic effect	2008	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 18, Issue:15	Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID571975	Antiviral activity against HIV-1 subtype CRF01_AE V029525 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID347617	Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 227L mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.
AID1609108	Antiviral activity against HIV-1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 4 days by MTT assay	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID263153	Cytotoxicity against HEK293T cells	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID263153	Cytotoxicity against HEK293T cells	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID263153	Cytotoxicity against HEK293T cells	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1583023	Selectivity index, ratio of CC50 for cytotoxicity in mock-infected human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay to EC50 for antiviral activity against NNRTI-resistant HIV1 RES056 containing reverse transcriptas	2020	Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3	Discovery and Characterization of Fluorine-Substituted Diarylpyrimidine Derivatives as Novel HIV-1 NNRTIs with Highly Improved Resistance Profiles and Low Activity for the hERG Ion Channel.
AID279465	Antiviral activity against HIV1 isolate with RT 98G, 103N, 181C, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1565093	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for antiviral activity against HIV IIIB
AID698294	Antiviral activity against HIV1 IRLL98 containing reverse transcriptase K101Q, Y181C and G190A mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID767498	Antiviral activity against HIV1 3B harboring reverse transcriptase K103N/Y181C double mutant infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay	2013	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18	Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.
AID1163234	Cytotoxicity against human TZM-bl cells assessed as cell viability after 48 hrs by WST1 assay	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID648422	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B	2012	European journal of medicinal chemistry, May, Volume: 51	Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1197830	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.
AID279412	Antiviral activity against HIV1 isolate with RT 103N, 188L mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1705190	Resistance index, ratio of EC50 for antiviral activity against HIV1 harboring RT K103N mutant infected in human MT4 cells to EC50 for antiviral activity against HIV1 NL4-3 infected in human MT4 cells	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains.
AID105205	Potency against non nucleoside reverse transcriptor was determined in MT-4 cells	2004	Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10	Threshold interaction energy of NRTI's (2'-deoxy 3'-substituted nucleosidic analogs of reverse transcriptase inhibitors) to undergo competitive inhibition.
AID1286677	Aqueous solubility of the compound at pH 7	2016	Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5	Discovery of the Aryl-phospho-indole IDX899, a Highly Potent Anti-HIV Non-nucleoside Reverse Transcriptase Inhibitor.
AID584047	Ratio of IC50 for HIV1 reverse transcriptase Y181C, Y188C mutant to IC50 for wild type HIV1 reverse transcriptase	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID248648	Inhibitory concentration against wild type human immunodeficiency virus type 1 was determined by recombinant virus assay	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
AID572170	Antiviral activity against HIV-1 subtype D V022818 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID1171413	Antiviral activity against wild type HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay	2014	ACS medicinal chemistry letters, Nov-13, Volume: 5, Issue:11	Picomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl Ethers.
AID1558847	Antiviral activity against HIV1 3B infected in human MT4 cells incubated assessed as reduction in virus-induced cytopathic effect for 5 days by MTT assay	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Ligand-Based Design of Nondimethylphenyl-Diarylpyrimidines with Improved Metabolic Stability, Safety, and Oral Pharmacokinetic Profiles.
AID1171589	Resistance index, ratio of EC50 for HIV1 NL4-3 expressing reverse transcriptase Y181C mutant to EC50 for wild type HIV1 NL4-3	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1335211	Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/Y188L double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID1198754	Inhibition of HIV1 reverse transcriptase Lys103Asn mutant-associated RNA-dependent DNA polymerase activity after 30 mins	2015	European journal of medicinal chemistry, Mar-26, Volume: 93	(3Z)-3-(2-[4-(aryl)-1,3-thiazol-2-yl]hydrazin-1-ylidene)-2,3-dihydro-1H-indol-2-one derivatives as dual inhibitors of HIV-1 reverse transcriptase.
AID1627030	Antiviral activity against HIV-1 LAI infected in human PBM cells after 7 days	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Discovery, characterization, and lead optimization of 7-azaindole non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1565091	Antiviral activity against drug resistant HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay
AID106949	Anti-HIV-1 activity against WTIIIB HIV-1 strain in MT-4 cells	2001	Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16	Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID143395	Antiviral activity against HIV-1 in MT-2 (human leukemia) cells in vitro.	2001	Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3	Trifluoromethyl-containing 3-alkoxymethyl- and 3-aryloxymethyl-2-pyridinones are potent inhibitors of HIV-1 non-nucleoside reverse transcriptase.
AID1316339	Antiviral activity against HIV1 3B harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID1352312	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 4 days by MTT assay	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.
AID279430	Antiviral activity against HIV1 isolate with RT 103N, 106I mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1373158	Inhibition of reverse transcriptase L100I mutant in HIV1 infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3	Structural optimization of N
AID263516	Antiviral activity against HIV1 I135V mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1275550	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
AID298090	Inhibition of HIV1 RT L100I mutant	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity.
AID441311	Fold resistance, ratio of IC50 for HIV reverse transcriptase with F227L mutant to IC50 for HIV wild type reverse transcriptase	2009	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19	Pyrazole NNRTIs 1: design and initial optimisation of a novel template.
AID508785	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase E138A mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID279511	Antiviral activity against HIV1 isolate with RT V106I, Y181C mutation in Hela-JC-53 cells	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1693802	Inhibition of recombinant HIV-1 BH10 reverse transcriptase using D38/[32P]25PGA as template-primer at 100 uM incubated for 5 mins followed by dTTP addition and measured after 15 to 30 sec by nucleotide incorporation assay relative to control	2021	Bioorganic & medicinal chemistry, 01-15, Volume: 30	Novel indolylarylsulfone derivatives as covalent HIV-1 reverse transcriptase inhibitors specifically targeting the drug-resistant mutant Y181C.
AID247503	Inhibitory activity against HIV-1 mutant strain 190A	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID496618	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase V90I/V35T, E36D, V60I, K122E, D123S, I135V, E138D, S162A, K173T,Q174S, D177E, I178M, V189I, T200A, I202V, Q207E, F214L, V245Q mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID279517	Antiviral activity against wild type HIV1 NL4-3 in Hela-JC53 cells in the presence of 5% human serum after 48 hrs	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID371903	Antiviral activity against HIV1 NL4-3 with L100I/V108I double mutant in human TZM-b1 cells assessed as beta-galactosidase activity after 48 hrs by single round replication assay	2009	Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12	New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID82961	Inhibitory activity against HIV-1 reverse transcriptase	1999	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22	Synthesis and evaluation of benzoxazinones as HIV-1 reverse transcriptase inhibitors. Analogs of Efavirenz (SUSTIVA).
AID621974	Inhibition of DNA-dependent DNA polymerase activity of HIV1 reverse transcriptase p66/p66 homodimer using activated DNA and [alpha-32P]dATP after 30 mins by liquid scintillation counting	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID1242376	Resistance index, ratio of EC50 for NRTI-resistant HIV containing reverse transcriptase K103N/Y181C mutation to EC50 for wild type HIV	2015	ACS medicinal chemistry letters, Jul-09, Volume: 6, Issue:7	Pyrazolo-Piperidines Exhibit Dual Inhibition of CCR5/CXCR4 HIV Entry and Reverse Transcriptase.
AID571978	Antiviral activity against HIV-1 subtype B V022810 harboring NNRTI A98S andK101R mutant infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID1249715	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity incubated for 4 days by MTT method	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue.
AID698145	Inhibition of HIV1 reverse transcriptase K103N mutant RNA-dependent DNA polymerase activity using poly(rA)/oligo(dT)10:1 and [3H]-dTTP substrate	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID248494	In vitro inhibitory concentration against HIV L100I and K103N mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
AID1736344	Antiviral activity against VSVG/wild-type HIV-1 infected in human HEK 293T cells assessed as inhibition of virus replication preincubated with cells for 15 mins prior to viral infection and measured at 48 hrs post-infection by luciferase reporter gene ass
AID650542	Antiviral activity against multidrug-resistant HIV 1 IRLL98 harboring reverse transcriptase K101Q/Y181C/G190a mutant infected in human MT4 cells assessed as virus-induced cytopathic effect after 5 days by MTT assay	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
AID1443660	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	2017	Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8	Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors.
AID591355	Antiviral activity against HIV2 isolate ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days by microscopic analysis	2011	Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6	Indolylarylsulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: new cyclic substituents at indole-2-carboxamide.
AID621978	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID366556	Antiviral activity against HIV1 in human MT4 cells assessed as reduction of viral-induced cytopathic effect in presence of human serum	2008	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 18, Issue:15	Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID592540	Cytotoxicity against human CEM cells by coulter counter analysis	2011	Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6	Indolylarylsulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: new cyclic substituents at indole-2-carboxamide.
AID1316337	Antiviral activity against HIV1 3B harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID1165077	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.
AID1815398	Inhibition of HIV1 reverse transcriptase K103N mutant using oligo(dT)16 as primer measured after 40 mins by picogreen-dye based spectrofluorimetric analysis	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID1773456	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 harboring F227L/V106A double mutant infected in human MT4 cells
AID508644	Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as reduction in virus induced cytopathicity	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1773839	Antiviral activity against HIV1 harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18	Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies.
AID279489	Antiviral activity against HIV1 isolate with RT K103N-V108I-P225H mutation	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1483283	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for reverse transcriptase Y188L mutant in human MT4 cells infected HIV1 3B	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
AID265470	Cytotoxicity against human lymphocytes	2006	Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11	Design, molecular modeling, synthesis, and anti-HIV-1 activity of new indolyl aryl sulfones. Novel derivatives of the indole-2-carboxamide.
AID562119	Apparent oral clearance in patient with HIV infection at 600 mg/kg, iv QD	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients.
AID541132	Selectivity ratio of EC50 for antiviral activity against NNRTI-resistant HIV1 harboring RTK103N mutant gene to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID576040	Ratio of drug concentration in PBMCs to plasma of healthy human administered at 400 mg, po qd for 14 days measured after 5 hrs post last dose	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.
AID265474	Selectivity index, TC50 for human lymphocytes/EC50 for HIV1 3B	2006	Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11	Design, molecular modeling, synthesis, and anti-HIV-1 activity of new indolyl aryl sulfones. Novel derivatives of the indole-2-carboxamide.
AID267862	Inhibition of HIV1 reverse transcriptase K103N mutant	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Synthesis and biological investigation of S-aryl-S-DABO derivatives as HIV-1 inhibitors.
AID1165075	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.
AID1316340	Antiviral activity against HIV1 3B harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID1884488	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for antiviral activity against NNRTI resistant HIV-1 infected in human MT4 cells	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.
AID635347	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B	2011	Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23	Design, synthesis and biological evaluation of cycloalkyl arylpyrimidines (CAPYs) as HIV-1 NNRTIs.
AID522373	Antiviral activity against recombinant HIV1 harboring reverse transcriptase V106I/V179D mutant clone infected in MAGIC-5 cells using 5-bromo4-chloro-3-indolyl-beta-D-galactopyranoside staining based light microscopy	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
AID1485973	Inhibition of HIV-1 reverse transcriptase Y181C mutant assessed as reduction in dTTP incorporation using poly(rA)/oligo(dT)16 as template/primer after 40 mins by PicoGreen dye based spectrofluorometric analysis	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Searching for novel N
AID1141963	Antiviral activity against HIV-2 ROD infected in human CEM cells assessed as protection of cells monitored by giant cell formation by microscopy	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID386493	Inhibition of HIV1 recombinant wild type reverse transcriptase	2008	Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7	Thiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: Parallel synthesis, molecular modelling and structure-activity relationship studies on analogues of O-(2-phenylethyl)-N-phenylthiocarbamate.
AID82474	Antiviral activity against Y181C strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID717257	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs.
AID1352315	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV1 3B	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.
AID1391076	Inhibition of wild type HIV1 reverse transcriptase using poly (A)/oligo (dT)15 as template/primer assessed as decrease in biotin-dUTP incorporation after 1 hr by ELISA	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	The discovery of novel diarylpyri(mi)dine derivatives with high level activity against a wide variety of HIV-1 strains as well as against HIV-2.
AID508783	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase E138K mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID519863	Antiviral activity against HIV1 subtype B-NL4-3 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID573482	Fold resistance, ratio of EC50 for Human immunodeficiency virus 1 isolate 9225 harboring A98S, G190A mutation in reverse transcriptase to wild-type	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
AID1335216	Antiviral activity against HIV-1 NL4-3 harboring RT-K103N mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID1212900	Drug metabolism in human liver microsomes harboring CYP2B61/6 genotype assessed as intrinsic clearance for CYP2B6 variant-mediated 8-hydroxyefavirenz metabolite formation measured per mg protein after 15 mins by LC/MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
AID269687	Antiviral activity against HIV1 NNTRI resistant Y181C mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269687	Antiviral activity against HIV1 NNTRI resistant Y181C mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269687	Antiviral activity against HIV1 NNTRI resistant Y181C mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID573247	Cmin in HIV-1 infected children at 14.4 mg/kg, po administered once daily by HPLC	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children?
AID106950	Anti-HIV-1 activity against Y181C HIV-1 strain in MT-4 cells	2001	Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16	Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID82604	The effect of protein binding on the antiviral activity versus wild type virus strain HXB2 was tested in the presence of both acid glycoprotein and human serum in HeLa MAGI assay	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID247495	Inhibitory activity against HIV-1 mutant strain 100I	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID241533	Inhibitory concentration against HIV-1 wild type reverse transcriptase (IIIB)	2005	Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11	Structure-based design, parallel synthesis, structure-activity relationship, and molecular modeling studies of thiocarbamates, new potent non-nucleoside HIV-1 reverse transcriptase inhibitor isosteres of phenethylthiazolylthiourea derivatives.
AID573478	Antiviral activity of Human immunodeficiency virus 1 isolate 8117 harboring A98S, G190A mutation in reverse transcriptase by cell based assay	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
AID1761019	Antiviral activity against HIV-1 harboring reverse transcriptase F227L/V106A mutant infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect measured after 5 days by MTT assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Design, synthesis, and evaluation of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase.
AID246394	Effective concentration against human immunodeficiency virus type 1 mutated at 227L+106A	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.
AID1636931	Aqueous solubility of compound in pH 6.5 solution by shake flask method	2016	Bioorganic & medicinal chemistry, 10-15, Volume: 24, Issue:20	Computer-aided discovery of anti-HIV agents.
AID757622	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B	2013	European journal of medicinal chemistry, Jul, Volume: 65	Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1636149	Ratio of IC50 for NNRTI resistant HIV1 harboring reverse transcriptase K103N/V179F/Y181C mutant infected in human TZM-bl cells to IC50 for wild type HIV1 NL4-3 infected in human TZM-bl cells	2016	Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15	Discovery and Structure-Based Optimization of 2-Ureidothiophene-3-carboxylic Acids as Dual Bacterial RNA Polymerase and Viral Reverse Transcriptase Inhibitors.
AID1316344	Selectivity index, ratio of CC50 for human mock-infected MT4 cells to EC50 for HIV1 3B harboring reverse transcriptase Y188L mutant infected in human MT4 cells	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID607873	Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	2011	Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14	Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6-((3,4-dihydroquinolin-1(2H)-yl)methyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID198769	Binding affinity towards wild type HIV-1 reverse transcriptase (as per ref 10 in the article)	2001	Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21	Antiviral drug design: computational analyses of the effects of the L100I mutation for HIV-RT on the binding of NNRTIs.
AID105540	Inhibitory activity against HIV-1 Wild Type in MT-4 cell culture (human T-cell line with 50% human AB serum)	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues.
AID1304401	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	2016	Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13	Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
AID374090	Antiviral activity against HIV1 3B Y181C resistant mutant in human MT4 cells assessed as protection against viral induced cytopathogenicity by MTT assay	2009	European journal of medicinal chemistry, Apr, Volume: 44, Issue:4	Novel modifications in the series of O-(2-phthalimidoethyl)-N-substituted thiocarbamates and their ring-opened congeners as non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID446236	Inhibition of HIV reverse transcriptase	2009	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20	Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
AID279426	Antiviral activity against HIV1 isolate with RT 227L mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID508825	Antiviral activity against Human immunodeficiency virus 1 subtype A isolate 92UG029 infected in human PBMC cells by cell based assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID246351	Effective concentration against human immunodeficiency virus type 1 mutated at 188L	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.
AID44797	In vitro reduction of p24 by 90% in Efavirenz resistant HIV-1 (K103R, V179D, P225H) infected C8166 cells.	2004	Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15	Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations.
AID508788	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase V106A mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID508793	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase K101E mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID105698	Anti-HIV-1 activity against K103N+K1001 strain was determined in MT-4 cells by the MTT method	2003	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24	3-iodo-4-phenoxypyridinones (IOPY's), a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID96294	Potency of second-generation NNRTIs against Mutant HIV-1 sL100I free drug	2000	Journal of medicinal chemistry, May-18, Volume: 43, Issue:10	Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID328843	Inhibition of human MRP3 expressed in MDCK2 cells assessed as increase in intracellular CMF fluorescence by CMFDA assay	2007	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3	Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.
AID1457052	Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
AID279502	Antiviral activity against wild type HIV1	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID586485	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase L101I/T124A/S153F mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunod	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID632795	Antiviral activity against Human immunodeficiency virus 1 NL4.3 infected in human MT2 cells assessed as inhibition of viral infection	2011	Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24	Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.
AID663300	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV1 NL4-3	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.
AID1596754	Cytotoxicity against human MT4 cells measured after 5 days by MTT assay	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Synthesis and biological evaluation of dihydroquinazoline-2-amines as potent non-nucleoside reverse transcriptase inhibitors of wild-type and mutant HIV-1 strains.
AID216433	Activity against whole cell using anti-infectivity assay	1999	Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19	Synthesis and evaluation of analogs of Efavirenz (SUSTIVA) as HIV-1 reverse transcriptase inhibitors.
AID648421	Cytotoxicity against human MT4 cells after 5 days by MTT assay	2012	European journal of medicinal chemistry, May, Volume: 51	Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID446409	Fold resistance, ratio of IC50 for HIV reverse transcriptase with L100I mutant to IC50 for HIV wild type reverse transcriptase	2009	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20	Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
AID1558854	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Ligand-Based Design of Nondimethylphenyl-Diarylpyrimidines with Improved Metabolic Stability, Safety, and Oral Pharmacokinetic Profiles.
AID1391079	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	The discovery of novel diarylpyri(mi)dine derivatives with high level activity against a wide variety of HIV-1 strains as well as against HIV-2.
AID279461	Antiviral activity against HIV1 isolate with RT 179D, 188L mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1206938	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	Discovery of piperidin-4-yl-aminopyrimidine derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID279439	Antiviral activity against HIV1 isolate with RT 101P, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1320868	Solubility of the compound	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.
AID446255	Fold resistance, ratio of IC50 for HIV reverse transcriptase with V106A mutant to IC50 for HIV wild type reverse transcriptase	2009	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20	Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
AID1335203	Ratio of IC50 for HIV-1 NL4-3 harboring RT-K103N/P225H double mutant infected in HEK293T cells co-expressing vesicular stomatitis virus glycoprotein to IC50 for wild-type HIV-1 NL4-3 infected in HEK293T cells co-expressing vesicular stomatitis virus glyco	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID1335212	Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/P225H double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID298075	Antiviral activity against HIV1 RT Y181C mutant in MT4 cells by MTT assay	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity.
AID614140	Cytotoxicity against human MT4 cells after 4 days by MTT assay	2011	Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17	Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs.
AID1815394	Resistance fold, ratio of EC50 for HIV1 harboring reverse transcriptase F227L/V106A double mutant infected MV4 cells to EC50 for wild type HIV1 infected MV4 cells	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID298087	Inhibition of wild type HIV1 RT	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity.
AID573979	Antiretroviral activity against Simian immunodeficiency virus MAC 251 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.
AID1574382	Resistance index, ratio of EC50 for HIV-1 harboring reverse transcriptase K103N mutant to EC50 for wild type HIV-1 NL4-3	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.
AID347086	Inhibition of RNA-dependent DNA polymerase activity of HIV1 reverse transcriptase K103N mutant	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays.
AID519964	Antiviral activity against 0.005 MOI HIV1 NL4-3 harboring wild type RT infected in human MT2 cells	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID293559	Antiviral activity against HIV1 LAI with RT Y188L mutation in MT4 cells by EGFP based replication assay	2007	European journal of medicinal chemistry, May, Volume: 42, Issue:5	Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains.
AID1141976	Inhibition of HIV1 wild-type reverse transcriptase K103N mutant using [3H]dTTP by scintillation counting	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1200844	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	2015	European journal of medicinal chemistry, Mar-26, Volume: 93	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.
AID1761012	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV-1 3B infected in human MT4 cells	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Design, synthesis, and evaluation of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase.
AID141360	Potency of second-generation NNRTIs against Mutant HIV-1 sV179D/L100I/Y181C plasma; value ranges from 130000-309500	2000	Journal of medicinal chemistry, May-18, Volume: 43, Issue:10	Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID1884229	Antiviral activity against HIV-1 RES056 infected in human MT4 cells assessed as reduction in virus induced cytotoxicity incubated for 5 to 7 days by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Chemical space exploration around indolylarylsulfone scaffold led to a novel class of highly active HIV-1 NNRTIs with spiro structural features.
AID266346	Inhibition of HIV1 reverse transcriptase K103N mutant in 293T cells	2006	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11	New HIV-1 reverse transcriptase inhibitors based on a tricyclic benzothiophene scaffold: synthesis, resolution, and inhibitory activity.
AID253332	Cytotoxic concentration against wild type human immunodeficiency virus type 1 LA1 strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.
AID611908	Antiviral activity against Human immunodeficiency virus 1 NL 4.3 harboring reverse transcriptase K103N mutant pseudotyped with VSV-G envelope co-transfected with luciferase gene infected in 293T cells assessed as inhibition of HIV1 replication administere	2011	Journal of natural products, Jun-24, Volume: 74, Issue:6	Lindenane disesquiterpenoids with anti-HIV-1 activity from Chloranthus japonicus.
AID465418	Antiviral activity against wild type HIV1 infected in human MT2 cells	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	N1-Alkyl pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID508790	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase K103N mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID269804	Antiviral activity against HIV1 Y181H mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269804	Antiviral activity against HIV1 Y181H mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269804	Antiviral activity against HIV1 Y181H mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID198070	Inhibitory activity against E138K mutant reverse transcriptase	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	Identification of a putative binding site for [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase.
AID1352323	Inhibition of recombinant wild type HIV1 reverse transcriptase p66/p51 using poly (rA)/anoligo (dT)16 as template/primer assessed as inhibition of biotin-dUTP incorporation after 40 mins by Pico-Green staining based fluorescence assay	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.
AID1272057	Tmax in human plasma after the first dose of drug	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Efavirenz a nonnucleoside reverse transcriptase inhibitor of first-generation: Approaches based on its medicinal chemistry.
AID361927	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106I/Y181C mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1264541	Antiviral activity against HIV-1 X4 expressing reverse transcriptase Y181C mutant infected in human CD4+ T cells for 3 days by FACS analysis	2015	ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10	Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine Resistance.
AID1811035	Anti-viral activity against HIV1 harboring RT Y188L mutant infected MV4 cells assessed as protection against virus-induced cytopathic effect by MTT assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.
AID557021	Antiviral activity against HIV1 CRF02_AG harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID347608	Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 190A mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.
AID509269	Inhibition of HIV1 RT at 20 to 0.625 uM by ELISA	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Antiviral efficacy of the novel compound BIT225 against HIV-1 release from human macrophages.
AID279422	Antiviral activity against HIV1 isolate with RT 190E mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID508781	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase E138R mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID517495	Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS	2010	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 20, Issue:20	Exploration of piperidine-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Phenyl derivatives with broad potency against resistant mutant viruses.
AID1316360	Fold resistance, ratio of IC50 for recombinant HIV1 reverse transcriptase K103N/Y181C double mutant to IC50 for wild type HIV1 reverse transcriptase	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID1888695	Antiviral activity against HIV1 with RT K103N mutant infected in human MT4 cells cells assessed as protection against viral-induced cytopathogenecity by MTT assay
AID1636150	Ratio of IC50 for NNRTI resistant HIV1 harboring reverse transcriptase L100I/K103N/H221Y mutant infected in human TZM-bl cells to IC50 for wild type HIV1 NL4-3 infected in human TZM-bl cells	2016	Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15	Discovery and Structure-Based Optimization of 2-Ureidothiophene-3-carboxylic Acids as Dual Bacterial RNA Polymerase and Viral Reverse Transcriptase Inhibitors.
AID1200847	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant	2015	European journal of medicinal chemistry, Mar-26, Volume: 93	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.
AID1691435	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cell death incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, May-01, Volume: 193	In situ click chemistry-based rapid discovery of novel HIV-1 NNRTIs by exploiting the hydrophobic channel and tolerant regions of NNIBP.
AID1141971	Ratio of EC50 for HIV1 harboring reverse transcriptase Y181C mutant to EC50 for wild type HIV1 NL4.3	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1687681	Antiviral activity against HIV-1 K103N mutant strain infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities.
AID1880373	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	2022	Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12	Structure-Based Discovery of Novel NH
AID1156485	Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.
AID508626	Antiviral activity against Human immunodeficiency virus 1 subtype E isolate CMU08 infected in human PBMC cells by cell based assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1316328	Selectivity index, ratio of CC50 for human mock-infected MT4 cells to EC50 for HIV1 3B harboring reverse transcriptase K103N mutant infected in human MT4 cells	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID348907	Ratio of ED50 for drug resistant HIV1 with reverse transcriptase K103N mutant to wild type HIV1 NL4-3	2008	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 18, Issue:21	Towards novel S-DABOC inhibitors: synthesis, biological investigation, and molecular modeling studies.
AID1705193	Resistance index, ratio of EC50 for antiviral activity against HIV1 harboring RT K103N/Y181C double mutant infected in human MT4 cells to EC50 for antiviral activity against HIV1 NL4-3 infected in human MT4 cells	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains.
AID573253	AUC (0 to t) in HIV-1 infected children at 14.4 mg/kg, po administered once daily by HPLC	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children?
AID82476	Antiviral activity against wild-type HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID767501	Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay	2013	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18	Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.
AID106074	Inhibitory activity against LAI strain of HIV-I in MT-4 cells	2001	Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17	Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.
AID574002	Ratio of EC50 for Human immunodeficiency virus 1 3B to EC50 for wild-type Human immunodeficiency virus 2 ROD	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.
AID1773445	Antiviral activity against HIV1 harboring L100I mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenic effect by MTT assay
AID386489	Antiviral activity against HIV1 with reverse transcriptase K103N/Y181C mutation in human MT4 cells assessed as reduction of virus-induced cytopathogenicity by MTT assay	2008	Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7	Thiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 1: Parallel synthesis, molecular modelling and structure-activity relationship studies on O-[2-(hetero)arylethyl]-N-phenylthiocarbamates.
AID496626	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase E138A/K22N, V35T, T39A, K122E, I135V, T139A, S162A, K173T, Q174A, D177E, T200A, Q207E, R211K, F214L mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID1248225	Antiviral activity against HIV 1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	2015	Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20	A novel family of diarylpyrimidines (DAPYs) featuring a diatomic linker: Design, synthesis and anti-HIV activities.
AID619642	Ratio of EC50 for HIV-1 3B harboring RT E138K mutant infected in human MT4 cells to EC50 for wild type HIV-1 3B infected in human MT4 cells	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
AID557037	Antiviral activity against HIV1 isolate R8 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs in presence of 50% human serum	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID518741	Antiviral activity against HIV 1 subtype B harboring reverse transcriptase M230L mutant infected in human TZM-bl cells assessed as inhibition of viral growth by luciferase reporter gene assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity.
AID366523	Resistance index, ratio of EC50 for drug-resistant HIV1 isolate with reverse transcriptase Y181C mutation to EC50 for wild type HIV1 NL4-3	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.
AID492043	Inhibition of HIV1 reverse transcriptase	2010	Bioorganic & medicinal chemistry, Jul-01, Volume: 18, Issue:13	Synthesis and anti-HIV activity of 2-naphthyl substituted DAPY analogues as non-nucleoside reverse transcriptase inhibitors.
AID440074	Antiviral activity against HIV1 HXB2 harboring Y181C mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
AID1171582	Antiviral activity against HIV2 ROD infected in human CEM cells assessed as protection against virus-induced cytopathicity by giant cell formation assay	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1191399	Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	2015	Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3	Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID622053	Ratio of Ki for HIV1 RT p66/p66 homodimer L100I mutant to Ki for wild-type HIV1 RT p66/p66 homodimer	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID361919	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase E138K mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID104408	Antiviral activity of Protein Binding of compound was evaluated for HIV-2 virus expressed MT-2 by yield	2000	Journal of medicinal chemistry, May-18, Volume: 43, Issue:10	Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID246511	Compound concentration required to achieve 50% protection of infected MT-4 cells from K103N-Y181C strain was determined by the MTT method	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.
AID371902	Antiviral activity against wild type HIV1 NL4-3 in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay	2009	Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12	New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID519860	Antiviral activity against HIV1 subtype B-SF-2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID443677	Antiviral activity against HIV with reverse transcriptase L100I mutant assessed as inhibition of viral replication	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
AID443675	Antiviral activity against HIV with reverse transcriptase MDRC4 mutant assessed as inhibition of viral replication	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
AID1168822	Inhibition of CYP2B6 (unknown origin) assessed as reduction in hydroxybupropion formation at 10 uM incubated for 10 mins by uHPLC-MS/MS method	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Structure-Activity Studies Reveal the Oxazinone Ring Is a Determinant of Cytochrome P450 2B6 Activity Toward Efavirenz.
AID1156487	Cytotoxicity against human MT4 cells after 5 days by MTT assay	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.
AID248257	In vitro inhibitory concentration against HIV G190A mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
AID476468	Cytotoxicity against human MT2 cells by MTT assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives.
AID1212885	Drug metabolism in microsomes expressing CYP2B6.6 (unknown origin) assessed as enzyme-mediated 8-hydroxyefavirenz metabolite formation measured per pmol of P450 after 15 mins by HPLC/UV system in presence of Cyt b5 coexpression	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
AID1574372	Antiviral activity against wild type HIV 1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.
AID1391080	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV1 3B infected in human MT4 cells	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	The discovery of novel diarylpyri(mi)dine derivatives with high level activity against a wide variety of HIV-1 strains as well as against HIV-2.
AID397176	Inhibition of wild-type HIV1 reverse transcriptase	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Parallel synthesis, molecular modelling and further structure-activity relationship studies of new acylthiocarbamates as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1561720	Resistance index, ratio of EC50 for antiviral activity against HIV1 3B infected in human MT4 cells grown under 30 passages in presence of (E)-4-((4-((4-(4-(2-Cyanovinyl)-2,6-dimethylphenoxy)thieno[2,3- d]pyrimidin-2-yl)amino)piperidin-1-yl)methyl)benzenes
AID1687683	Antiviral activity against HIV-1 E138K mutant strain infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities.
AID557048	Antiviral activity against HIV1 clade F1 harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID347090	Metabolic stability in human hepatocytes assessed as half life	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays.
AID1736360	Antiviral activity against VSVG/HIV-1 harboring reverse transcriptase G190A/K103N double mutant infected in human HEK 293T cells assessed as inhibition of virus replication preincubated with cells for 15 mins prior to viral infection and measured at 48 hr
AID557068	Plasma protein binding in healthy human at 200 mg/kg	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID1298249	Inhibition of HIV1 reverse transcriptase p66/p51 K103N mutant using poly(rA) template and measured after 40 mins by picogreen based spectrofluorometry	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.
AID1155809	Antiviral activity against HIV-1 harboring NNTRI-resistant reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.
AID586477	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase G140S/Q148K mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficie	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID1220381	Drug metabolism of the compound assessed as CYP2C8 (unknown origin)-mediated formation of dihydroxylated metabolites with retention time of 1.92 mins at 5 uM by UPLC-MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2	Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid.
AID257166	Antiviral activity against wild type HIV1 NL4-3 infected MT4 cells by MTT method	2005	Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25	Parallel solution-phase and microwave-assisted synthesis of new S-DABO derivatives endowed with subnanomolar anti-HIV-1 activity.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID1456306	Inhibition of HIV-1 3B wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured at 5 days post infection by MTT assay	2017	Bioorganic & medicinal chemistry, 04-15, Volume: 25, Issue:8	Structural modifications of diarylpyrimidines (DAPYs) as HIV-1 NNRTIs: Synthesis, anti-HIV activities and SAR.
AID366519	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 NL4-3	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.
AID1186005	Antiviral activity against HIV1 harboring reverse transcriptase K103N/V108I double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay r	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
AID736440	Non-competitive inhibition of wild type HIV1 reverse transcriptase p66/p51 after 30 mins by liquid scintillation counting	2013	Bioorganic & medicinal chemistry, Mar-01, Volume: 21, Issue:5	N1,N3-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
AID267648	Antiviral activity against HIV1 Y181C mutant	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1.
AID443691	Antiviral activity against HIV with reverse transcriptase V106A/G190A/F227L mutant assessed as inhibition of viral replication	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
AID757625	Antiviral activity against HIV1 RES056 expressing RT K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2013	European journal of medicinal chemistry, Jul, Volume: 65	Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID81627	Antiviral activity was evaluated against K103N mutant HIV-1 virus	2001	Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9	Synthesis and evaluation of efavirenz (Sustiva) analogues as HIV-1 reverse transcriptase inhibitors: replacement of the cyclopropylacetylene side chain.
AID313190	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV1	2008	Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1	Synthesis and antiviral activity of new dimeric inhibitors against HIV-1.
AID496622	Antiviral activity against HIV-1 subtype CRF06_cpx ontaining reverse transcriptase V106I/V21I, V35T, V60I, K122T, D123R, I135V, S162A, K173T, Q174K, D177E, I178L, T200A, Q207D, R211K, V245Q, E248D mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID370726	Inhibition of RNA dependent DNA polymerase activity of HIV1 recombinant reverse transcriptase p66/p51 K103N mutant expressed in Escherichia coli JM109	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations.
AID1357785	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID508753	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase V179F, Y181I mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID279455	Antiviral activity against HIV1 isolate with RT 103N, 188H mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID620429	Antiviral activity against wild type HIV1 BaL in human TZM-b1 cells after 48 hrs by luciferase assay	2011	Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20	Novel diarylpyridinones, diarylpyridazinones and diarylphthalazinones as potential HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs).
AID1352317	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 4 days by MTT assay	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.
AID1731752	Inhibition of reverse transcriptase RES056 mutant in HIV-1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay
AID1261316	Antiviral activity against human RSV infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by plaque reduction assay	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID1811037	Anti-viral activity against HIV1 harboring RT K103N mutant infected MV4 cells assessed as protection against virus-induced cytopathic effect by MTT assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.
AID1687687	Selectivity index, ratio of CC50 for cytotoxicity against human MT4 cells reduction in cell viability by MTT assay to EC50 for antiviral activity against wild type HIV-1 strain IIIB infected in human MT4 cells assessed as reduction in virus-induced cytopa	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities.
AID573466	Inhibition of Human immunodeficiency virus 1 subtype B reverse transcriptase Y181C mutant by filter-based filtration assay	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
AID556524	Antiviral activity against Human immunodeficiency virus 1 clone pNL4-3-Q145M harboring K102Q, Q145M, S162C, K277R, I293V mutation in reverse transcriptase by phenosense assay relative to wild type	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
AID508642	Antiviral activity against Human immunodeficiency virus 1 subtype AE infected in human MT4 cells assessed as reduction in virus induced cytopathicity	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1410405	Inhibition of recombinant wild type HIV1 reverse transcriptase assessed as decrease in biotin-dUTP incorporation using DIG-labeled dUTP/biotin-labeled dUTP and dTTP as template and viral nucleotides after 1 hr by ELISA	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Discovery of Novel Diarylpyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the "NNRTI Adjacent" Binding Site.
AID105539	Inhibitory activity against HIV-1 Ile 100 mutant in MT-4 cells.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues.
AID1653625	Activation of recombinant human C-terminal 4His-tagged CYP46A1 delta(2 to 50) R415A mutant expressed in Escherichia coli at 20 uM using cholesterol as substrate measured after 30 mins in presence of cytochrome P450 oxidoreductase by gas chromatography-mas	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds.
AID248316	In vitro inhibitory concentration against HIV-1 Y181C mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
AID279462	Antiviral activity against HIV1 isolate with RT 103N, 108I, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1155814	Inhibition of HIV-1 recombinant NNTRI-resistant reverse transcriptase K103N mutant assessed as incorporation of [3H]dTTP into poly(rA)/oligo(dT)10:1	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1535522	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2019	Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3	Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs.
AID279418	Antiviral activity against HIV1 isolate with RT 98G, 181C mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1558853	Antiviral activity against HIV1 harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Ligand-Based Design of Nondimethylphenyl-Diarylpyrimidines with Improved Metabolic Stability, Safety, and Oral Pharmacokinetic Profiles.
AID1763903	Antiviral activity against HIV-1 IIIB harboring RT F227L/V106A mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity incubated for 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 06-15, Volume: 40	Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs.
AID519867	Antiviral activity against HIV1 subtype B-ASM 034 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID244633	Selective index value (ratio of CC50 to IC50 value)against HIV LAI cell line	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
AID304872	Antiviral activity against HIV1 with reverse transcriptase IRLL98 mutation in MT4 cells after 5 days by MTT method relative to wild type NL4-3	2007	Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26	Dihydro-alkylthio-benzyl-oxopyrimidines as inhibitors of reverse transcriptase: synthesis and rationalization of the biological data on both wild-type enzyme and relevant clinical mutants.
AID1483286	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 RES056 reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
AID522377	Resistance index, ratio of EC50 for recombinant HIV1 harboring reverse transcriptase V106A/V179D mutant clone to EC50 for wild type HIV1	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
AID663301	Resistance ratio of EC50 for HIV1 harboring reverse transcriptase K103N mutant to EC50 for wild type HIV1 NL4-3	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.
AID347615	Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 108I mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.
AID440073	Antiviral activity against HIV1 HXB2 harboring K103N mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
AID1206937	Cytotoxicity against human MT4 cells assessed as reduction of cell viability after 4 days by MTT assay	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	Discovery of piperidin-4-yl-aminopyrimidine derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1637391	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for human HIV-1 3B infected in human MT4 cells	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.
AID1304406	Inhibition of wild type HIV-1 BH10 recombinant reverse transcriptase expressed in Escherichia coli assessed as incorporation of [32P]GTP into poly(rA)/oligo(dT) as template primer	2016	Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13	Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
AID104412	Antiviral activity of Protein Binding of compound was evaluated for RF virus expressed MT-2 by yield	2000	Journal of medicinal chemistry, May-18, Volume: 43, Issue:10	Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID650694	Ratio of ID50 for HIV 1 reverse transcriptase Y181I mutant to ID50 for wild type HIV 1 NL4-3 reverse transcriptase	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
AID508771	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase G190A mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID389378	Antiviral activity against HIV1 3B in human MT4 cells assessed as protection of cell against virus-induced cytopathogenicity	2008	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20	1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID573990	Ratio of EC50 for Human immunodeficiency virus 1 3B to EC50 for non nucleoside Protease inhibitor-resistant Human immunodeficiency virus 1	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.
AID1483276	Inhibition of HIV1 3B reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
AID1373155	Cytotoxicity against human MT4 cells after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3	Structural optimization of N
AID1637397	Antiviral activity against human HIV-1 3B harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection from virus-induced cytopathic effect measured 5 days post infection by MTT assay	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.
AID246267	Effective concentration against human immunodeficiency virus type 1 L100I mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).
AID1558856	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Ligand-Based Design of Nondimethylphenyl-Diarylpyrimidines with Improved Metabolic Stability, Safety, and Oral Pharmacokinetic Profiles.
AID1767118	Antiviral activity against HIV1 NL4-3 Env-deficient VSV-G pseudotyped virus infected in human SUP-T1 cells assessed as inhibition of late stage viral production when host cells were infected with compound pretreated viral particles at 10 uM measured after	2021	European journal of medicinal chemistry, Aug-05, Volume: 220	Design and biological evaluation of cinnamic and phenylpropionic amide derivatives as novel dual inhibitors of HIV-1 protease and reverse transcriptase.
AID508631	Antiviral activity against Human immunodeficiency virus 1 subtype G isolate JV1083 infected in human PBMC cells by cell based assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1292010	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/YI81C double mutant infected in human MT4 cells assessed as cell viability after 4 days by MTT assay	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket.
AID1503322	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 4 days by MTT assay	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Inhibitors of Yellow Fever Virus replication based on 1,3,5-triphenyl-4,5-dihydropyrazole scaffold: Design, synthesis and antiviral evaluation.
AID269801	Antiviral activity against HIV1 Y181C mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269801	Antiviral activity against HIV1 Y181C mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269801	Antiviral activity against HIV1 Y181C mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID265473	Activity against HIV-AB1 assessed by inhibition of p24 production in human lymphocytes	2006	Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11	Design, molecular modeling, synthesis, and anti-HIV-1 activity of new indolyl aryl sulfones. Novel derivatives of the indole-2-carboxamide.
AID1298251	Inhibition of HIV1 reverse transcriptase p66/p51 Y181C mutant using poly(rA) template and measured after 40 mins by picogreen based spectrofluorometry	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.
AID1743626	Antiviral activity against HIV1 harboring RT L100I mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.
AID717258	Cytotoxicity against human MT4 cells by MTT assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs.
AID1691438	Selectivity index, ratio of CC50 for cytotoxicity against human MT4 cells to EC50 for antiviral activity against HIV1 3B infected in human MT4 cells	2020	European journal of medicinal chemistry, May-01, Volume: 193	In situ click chemistry-based rapid discovery of novel HIV-1 NNRTIs by exploiting the hydrophobic channel and tolerant regions of NNIBP.
AID1316359	Inhibition of recombinant HIV1 reverse transcriptase K103N/Y181C double mutant using DIG-dUTP/biotin-dUTP/dTTP assessed as suppression of biotin-dUTP incorporation after 1 hr by ELISA	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID1155807	Antiviral activity against HIV-1 harboring NNTRI-resistant reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.
AID663295	Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.
AID1731743	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay
AID279417	Antiviral activity against HIV1 isolate with RT 106A, F227L mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID572171	Antiviral activity against HIV-1 subtype D V022819 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID198913	Inhibition of HIV-1 Mutant HIV-1 RT enzymes containing the single amino acid substitution V106A	2001	Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3	Quinoxalinylethylpyridylthioureas (QXPTs) as potent non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors. Further SAR studies and identification of a novel orally bioavailable hydrazine-based antiviral agent.
AID1773838	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18	Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies.
AID298080	Antiviral activity against HIV1 RT AB1 mutant in lymphocytes assessed as reduction of p24 antigen production	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity.
AID1880378	Antiviral activity against HIV-1 IIIB harboring reverse transcriptase Y181C mutant infected in human MT4 cells by MTT assay	2022	Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12	Structure-Based Discovery of Novel NH
AID347614	Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 106A mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.
AID246482	Effective concentration for the inhibition of wild type human immunodeficiency virus type 1 LAI strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.
AID293564	Antiviral activity against HIV1 LAI with RT K103N and Y181C mutation in MT4 cells by EGFP based replication assay	2007	European journal of medicinal chemistry, May, Volume: 42, Issue:5	Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains.
AID279526	Antiviral activity against HIV1 NL4-3 with Y188L mutation in Hela-JC53 cells in the presence of 20% human serum after 48 hrs	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1485968	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Searching for novel N
AID279513	Antiviral activity against HIV1 isolate with RT V106I, Y181C, F227L, T369I mutation in Hela-JC-53 cells	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1624242	Cytotoxicity against human TZM-b1 cells assessed as reduction in cell viability by CCK8 assay	2019	Bioorganic & medicinal chemistry letters, 03-01, Volume: 29, Issue:5	Soluble-type small-molecule CD4 mimics as HIV entry inhibitors.
AID1574377	Antiviral activity against HIV-1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.
AID1653638	Binding affinity to substrate bound recombinant human C-terminal 4His-tagged CYP46A1 delta(2 to 50) mutant expressed in Escherichia coli assessed as Koff rate of cholesterol by stopped-flow spectrophotometric method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds.
AID1731753	Inhibition of HIV-1 reverse transcriptase assessed as inhibition of biotin-dUTP incorporation into wild type RT measured after 1 hr by ELISA
AID298076	Antiviral activity against HIV1 RT K103N-Y181C mutant in MT4 cells by MTT assay	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity.
AID1155805	Cytotoxicity against human MT4 cells assessed as induction of cell death by MTT method	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.
AID1446820	Antiviral activity against HIV1 harboring F227L/V106A double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured at 5 days post infection by MTT assay	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.
AID1457053	Antiviral activity against HIV1 NL4-3 infected in human ML4 cells assessed as protection against virus-induced cytopathic effect measured on day 5 post infection by MTT assay	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
AID1693803	Inhibition of recombinant HIV-1 BH10 reverse transcriptase using D38/[32P]25PGA as template-primer incubated for 5 mins in presence of DTT followed by dTTP addition and measured after 15 to 30 sec by nucleotide incorporation assay	2021	Bioorganic & medicinal chemistry, 01-15, Volume: 30	Novel indolylarylsulfone derivatives as covalent HIV-1 reverse transcriptase inhibitors specifically targeting the drug-resistant mutant Y181C.
AID1882476	Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay	2022	Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5	Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.
AID279395	Antiviral activity against HIV1 isolate with RT 101Q mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID342720	Cytotoxicity against human MT4 cells	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Novel N1-substituted 1,3-dihydro-2H-benzimidazol-2-ones as potent non-nucleoside reverse transcriptase inhibitors.
AID1352319	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 4 days by MTT assay	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.
AID1529939	Inhibition of recombinant HIV-1 M:B reverse transcriptase RNA-dependent DNA polymerase activity expressed in Escherichia coli M15 using poly(A)/oligo(dT)16 as template/primer measured after 30 mins by picogreen dye based assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	Novel natural non-nucleoside inhibitors of HIV-1 reverse transcriptase identified by shape- and structure-based virtual screening techniques.
AID767499	Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay	2013	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18	Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.
AID650691	Inhibition of wild type HIV1 NL4-3 reverse transcriptase assessed as inhibition of time-dependent incorporation of [3H]dTTP into poly(rA)n.oligo(dT)	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
AID1773826	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18	Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies.
AID572174	Antiviral activity against HIV-1 subtype CRF05_DF V022833 harboring NNRTI V179I mutant infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID1060626	Fold resistance, ratio of EC50 for HIV1 RES056 expressing K103N/Y181C mutant infected in human MT4 cells to EC50 for wild-type HIV1 3B infected in human MT4 cells	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs.
AID584080	Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase V108I, E138K, F227F/L mutant infected in human SupT1 cells derived from 11 viral passages with lersivirine assessed as inhibition of viral replication after 21 days relative to drug sen	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID508651	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase L100I, V179I, Y181C mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID605180	Antiviral activity against HIV1 R8 harboring reverse transcriptase infected in human MT4 cells assessed as inhibition of viral spread in presence of 50% normal human serum	2010	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 20, Issue:15	Biaryl ethers as potent allosteric inhibitors of reverse transcriptase and its key mutant viruses: aryl substituted pyrazole as a surrogate for the pyrazolopyridine motif.
AID1298243	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.
AID279433	Antiviral activity against HIV1 isolate with RT 179T mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID443682	Antiviral activity against HIV with reverse transcriptase G190S mutant assessed as inhibition of viral replication	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
AID104410	Antiviral activity of Protein Binding of compound was evaluated for PB shift virus expressed MT-2 by RNA	2000	Journal of medicinal chemistry, May-18, Volume: 43, Issue:10	Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID1741399	Inhibition of reverse transcriptase RES056 mutant in HIV-1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID391226	Antiviral activity against HIV1 with reverse transcriptase Y181C mutant infected in human MT4 cells after 72 hrs in presence of 10% fetal bovine serum	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses.
AID1729150	Antiviral activity against HIV1 RES056 harboring K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect by MTT assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp
AID1261314	Antiviral activity against Reo-1 virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID198916	Inhibition of HIV-1 Mutant HIV-1 RT enzymes containing the single amino acid substitution Y188L	2001	Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3	Quinoxalinylethylpyridylthioureas (QXPTs) as potent non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors. Further SAR studies and identification of a novel orally bioavailable hydrazine-based antiviral agent.
AID1565094	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for antiviral activity against HIV RES056
AID347088	Antiviral activity against HIV1 NL4-3 in HeLaP4 reporter cell assessed as virus replication by FluorAceTM beta-galactosidase reporter assay	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays.
AID523347	Antiviral activity against HIV1 with RT connection domain N348I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID1141960	Antiviral activity against HIV1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID508791	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase K101Q mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID771795	Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	2014	Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 23	Synthesis and structure evaluation of new complex butylarylpiperazin-1-yl derivatives.
AID143399	Compound was evaluated for its ability to inhibit the mutant K103N P225H NNRTI HIV-1 enzyme	2001	Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3	Trifluoromethyl-containing 3-alkoxymethyl- and 3-aryloxymethyl-2-pyridinones are potent inhibitors of HIV-1 non-nucleoside reverse transcriptase.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1574381	Resistance index, ratio of EC50 for HIV-1 harboring reverse transcriptase Y188L mutant to EC50 for wild type HIV-1 NL4-3	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.
AID257917	Antiviral activity against HIV1 Y181C mutant using HeLa MAGI assay	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor.
AID586374	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase P145S mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficiency vi	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID736039	Inhibition of HIV1 reverse transcriptase p66/p51 G190A mutant after 30 mins by liquid scintillation counting	2013	Bioorganic & medicinal chemistry, Mar-01, Volume: 21, Issue:5	N1,N3-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
AID1161104	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	Arylazolyl(azinyl)thioacetanilides. Part 16: Structure-based bioisosterism design, synthesis and biological evaluation of novel pyrimidinylthioacetanilides as potent HIV-1 inhibitors.
AID1357796	Resistance factor, ratio of EC50 for HIV1 harboring reverse transcriptase E138K mutant to EC50 for wild-type HIV-1 3B	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID663306	Inhibition of HIV1 recombinant reverse transcriptase K103N mutant assessed as [3H]dTTP incorporation into poly(rA)/oligo(dT)	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.
AID197783	Compound was evaluated for the inhibition of HIV-1 Reverse transcriptase	2000	Journal of medicinal chemistry, May-18, Volume: 43, Issue:10	Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID1561719	Antiviral activity against HIV1 3B infected in human MT4 cells grown under 30 passages in presence of 4-[[4-[[4-[4-[2-cyanovinyl]-2,6-dimethylphenoxy]thieno[3,2-d]pyrimidin-2-yl]amino]-1-piperidyl]methyl]benzenesulfonamide assessed as protection against v
AID1264539	Antiviral activity against HIV-1 X4 expressing reverse transcriptase K101P mutant infected in human CD4+ T cells for 3 days by FACS analysis	2015	ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10	Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine Resistance.
AID257916	Antiviral activity against HIV1 K103N mutant using HeLa MAGI assay	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor.
AID106061	Inhibitory activity against 103N strain of HIV-I in MT-4 cells	2001	Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17	Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.
AID248263	In vitro inhibitory concentration against HIV V179E mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
AID247724	Inhibitory concentration against 103N mutant was determined	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity.
AID440084	Antiviral activity against HIV1 HXB2 harboring 100I and K103N mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
AID1485975	Inhibition of HIV-1 reverse transcriptase G190A mutant assessed as reduction in dTTP incorporation using poly(rA)/oligo(dT)16 as template/primer after 40 mins by PicoGreen dye based spectrofluorometric analysis	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Searching for novel N
AID1163232	Cytotoxicity against human MRC5 SV2 cells assessed as reduction in cell growth after 72 hrs	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID698301	Antiviral activity against HIV1 containing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID302261	Inhibition of HIV1 reverse transcriptase L100I mutant	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID446254	Fold resistance, ratio of IC50 for HIV reverse transcriptase with F227L mutant to IC50 for HIV wild type reverse transcriptase	2009	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20	Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
AID518736	Selectivity ratio of IC50 for RNA-dependent DNA polymerase activity of HIV1 subtype B reverse transcriptase M230L mutant to IC50 for RNA-dependent DNA polymerase activity of wild type HIV1 subtype B reverse transcriptase	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity.
AID557050	Antiviral activity against HIV1 clade H harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID279478	Antiviral activity against HIV1 isolate with RT 106L, 188L mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID519022	Antiviral activity against Human immunodeficiency virus 1 NL432 infected in human MT-4 cells assessed as decrease in the integrated viral DNA	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.
AID583848	Antiviral activity against HIV1 NL4-3 infected in human SupT1 cells derived from 11 viral passages assessed as inhibition of viral replication after 21 days relative to drug sensitive HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID588996	Inhibitors of transporters of clinical importance in the absorption and disposition of drugs, MRP2	2010	Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3	Membrane transporters in drug development.
AID1729160	Antiviral activity against HIV1 harboring E138K mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect by MTT assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp
AID82464	Antiviral activity against K103N/Y181C strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID82275	Effective concentration required to achieve 50% inhibition of HIV-1 multiplication in MT-4-infected Y181C strain	2002	Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26	Synthesis of novel N-1 (allyloxymethyl) analogues of 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine) with improved activity against HIV-1 and its mutants.
AID279409	Antiviral activity against HIV1 isolate with RT 101P, 103N mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1485965	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Searching for novel N
AID1483284	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for reverse transcriptase E138K mutant in human MT4 cells infected HIV1 3B	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
AID166688	Antiviral activity of Protein Binding of compound was evaluated for RF virus expressed plasma; value ranges from 92-220	2000	Journal of medicinal chemistry, May-18, Volume: 43, Issue:10	Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID141358	Potency of second-generation NNRTIs against Mutant HIV-1 sV179D/L100I/Y181C	2000	Journal of medicinal chemistry, May-18, Volume: 43, Issue:10	Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID1754645	Antiviral activity against HIV1 harboring RT E138K mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses.
AID1446872	Inhibition of recombinant HIV-1 group M subtype B RT-RNase H activity expressed in Escherichia coli M15 using 18-nucleotide 3'-fluorescein-labeled RNA annealed to a complementary 18-nucleotide 5'-dabsyl-labeled DNA as substrate measured after 1 hr	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Natural product-inspired esters and amides of ferulic and caffeic acid as dual inhibitors of HIV-1 reverse transcriptase.
AID685330	Antiviral activity against HIV-1 RES056 harboring RT K103N/Y181C mutant gene infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay	2012	Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 10: design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors.
AID279389	Antiviral activity against HIV1 isolate with RT 103N mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1200846	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells	2015	European journal of medicinal chemistry, Mar-26, Volume: 93	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.
AID82475	Antiviral activity against Y188C strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1888705	Resistance index, ratio of EC50 for antiviral activity against HIV1 with RT RES056 mutant infected in human MT4 cells to EC50 for antiviral activity against wild type HIV1 infected in human MT4 cells
AID1457074	Neuroprotective activity against glutamate-induced excitotoxicity in C57BL/6 mouse BV2 cells assessed as increase in cell viability at 1000 nM preincubated for 30 mins followed by reincubation in conditioned culture media for 18 hrs in presence of glutama	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
AID508652	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase K101P, K103N, V108I mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1435515	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 expressing reverse transcriptase Y188L mutant
AID1391087	Antiviral activity against HIV1 harboring reverse transcriptase RES056 double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	The discovery of novel diarylpyri(mi)dine derivatives with high level activity against a wide variety of HIV-1 strains as well as against HIV-2.
AID1157603	Antiviral activity against HIV1 MP411 infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID279497	Antiviral activity against HIV1 isolate with RT K103N-K101Q-P225H mutation	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID298060	Antiviral activity against HIV1 RF in human CEM-SS cells by XTT assay	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability.
AID1446812	Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured at 5 days post infection by MTT assay	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.
AID248882	Inhibitory concentration against human immunodeficiency virus type 1 (with V108I/Y181C resistant mutation) was determined in HeLa-CD4 MAGI assay	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
AID347611	Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 101E mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.
AID519882	Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID557023	Antiviral activity against HIV1 clade A harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID1161105	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	Arylazolyl(azinyl)thioacetanilides. Part 16: Structure-based bioisosterism design, synthesis and biological evaluation of novel pyrimidinylthioacetanilides as potent HIV-1 inhibitors.
AID1574375	Antiviral activity against HIV 1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.
AID330488	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B	2008	Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7	Synthesis and biological evaluation of novel 6-substituted 5-alkyl-2-(arylcarbonylmethylthio)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID457959	Inhibition of HIV1 reverse transcriptase L100I mutant by RNA-dependent DNA polymerase activity assay	2010	Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4	Novel 1,3-dihydro-benzimidazol-2-ones and their analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID492279	Cytotoxicity against human MT4 cells after 4 days by MTT assay	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
AID302252	Resistance index, Ratio of EC50 for drug-resistant HIV1 with RT IRLL98 mutation in MT3 cells to EC50 for HIV1 NL43 in MT3 cells	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID1141970	Ratio of EC50 for HIV1 harboring reverse transcriptase K103N mutant to EC50 for wild type HIV1 NL4.3	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID293181	Selectivity index, ratio of CC50 for MT4 cells to IC50 for HIV1 LAI	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Structure-activity relationship in the 3-iodo-4-phenoxypyridinone (IOPY) series: The nature of the C-3 substituent on anti-HIV activity.
AID1637401	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for human HIV-1 3B harboring Y181C mutant infected in human MT4 cells	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.
AID1275548	Antiviral activity against HIV1 3B expressing reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
AID197931	HIV-1 reverse transcriptase inhibitory activity against Asn103 mutant using (poly)rC600*(oligo)dGT as template primer.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues.
AID366521	Resistance index, ratio of EC50 for drug-resistant HIV1 isolate with reverse transcriptase K103N mutation to EC50 for wild type HIV1 NL4-3	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.
AID576035	Cmax in healthy human plasma at 400 mg, po measured on day 1 post dose by liquid chromatography-tandem mass spectrometry	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.
AID82608	The effect of protein binding on the antiviral activity versus wild type virus strain K103N was tested in the presence of human serum in HeLa MAGI assay	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1357800	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 harboring reverse transcriptase L100I mutant	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID1446818	Antiviral activity against HIV1 harboring Y188L mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured at 5 days post infection by MTT assay	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.
AID1822277	Antiviral activity against HIV-1 harboring K103N mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity incubated for 5 days by MTT assay	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.
AID1275545	Antiviral activity against HIV1 3B expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
AID1815399	Inhibition of HIV1 reverse transcriptase Y181C mutant using oligo(dT)16 as primer measured after 40 mins by picogreen-dye based spectrofluorimetric analysis	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID622055	Ratio of Ki for HIV1 RT p66/p66 homodimer Y181C mutant to Ki for wild-type HIV1 RT p66/p66 homodimer	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID247502	Inhibitory activity against HIV-1 mutant strain 188L	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID1200845	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay	2015	European journal of medicinal chemistry, Mar-26, Volume: 93	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.
AID635301	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay	2011	Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23	Design, synthesis and biological evaluation of cycloalkyl arylpyrimidines (CAPYs) as HIV-1 NNRTIs.
AID779529	Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	2013	Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21	Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.
AID1212917	Drug metabolism in microsomes expressing CYP2B6.6 (unknown origin) assessed as enzyme-mediated 8-hydroxyefavirenz metabolite formation after 15 mins by HPLC/UV system in absence of Cyt b5 coexpression	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
AID1077219	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach.
AID541135	Selectivity ratio of EC50 for antiviral activity against PI-resistant HIV1 harboring RTG48V, V82A and L90M mutant gene to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID650549	Resistance ratio of EC50 for HIV 1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells to EC50 for wild type HIV 1 NL4-3 infected in human MT4 cells	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
AID1191403	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV-1 3B infected in human MT4 cells	2015	Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3	Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID509270	Inhibition of HIV1 protease assessed as substrate cleavage by cell free assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Antiviral efficacy of the novel compound BIT225 against HIV-1 release from human macrophages.
AID508767	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase M230L mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1884491	Antiviral activity against drug-resistant HIV-1 Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.
AID519960	Selectivity ratio of EC50 for 0.01 MOI HIV1 NL4-3 infected in 2 hrs pretreated human MT2 cells by MTS assay to EC50 for 0.01 MOI HIV1 NL4-3 infected in 2 hrs pretreated human MT2 cells by RT assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID246340	Effective concentration against human immunodeficiency virus type 1 K103N and Y181C mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).
AID248492	In vitro inhibitory concentration against HIV K101E and K103N mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
AID293180	Antiviral activity against HIV1 RT 103N/181C mutant assessed as inhibition of viral-induced cytopathicity in MT4 cells by MTT method	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Structure-activity relationship in the 3-iodo-4-phenoxypyridinone (IOPY) series: The nature of the C-3 substituent on anti-HIV activity.
AID1391083	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	The discovery of novel diarylpyri(mi)dine derivatives with high level activity against a wide variety of HIV-1 strains as well as against HIV-2.
AID1335208	Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/Y181C double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID1185991	Cytotoxicity against HEK293T cells at 10 uM after 48 hrs	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
AID440671	Antiviral activity against NNRTI-resistant HIV1 A17 with reverse transcriptase K103N, Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	2009	European journal of medicinal chemistry, Dec, Volume: 44, Issue:12	Activity and molecular modeling of a new small molecule active against NNRTI-resistant HIV-1 mutants.
AID82607	The effect of protein binding on the antiviral activity versus wild type virus strain K103N was tested in the presence of both acid glycoprotein and human serum in HeLa MAGI assay	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1743636	Resistance index, ratio of EC50 for antiviral activity against HIV1 expressing RT Y181C mutant infected in human MT4 cells to EC50 for antiviral activity against HIV1 3B infected in human MT4 cells	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.
AID1357794	Resistance factor, ratio of EC50 for HIV1 harboring reverse transcriptase L100I mutant to EC50 for wild-type HIV-1 3B	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID1761011	Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Design, synthesis, and evaluation of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase.
AID1261340	Antiviral activity against HSV1	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID1653623	Binding affinity to recombinant human C-terminal 4His-tagged CYP46A1 delta(2 to 50) mutant expressed in Escherichia coli in presence of substrate by UV-spectrophotometric method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds.
AID562702	Antiviral activity against HIV1 harboring capsid I201V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation.
AID361921	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase P236L mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1391084	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	The discovery of novel diarylpyri(mi)dine derivatives with high level activity against a wide variety of HIV-1 strains as well as against HIV-2.
AID1811046	Selectivity index, ratio of CC50 for mock infected human MT4 cells to IC50 for HIV1 IIIB infected human MT4 cells	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.
AID492276	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
AID717256	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs.
AID1884492	Antiviral activity against drug-resistant HIV-1 Y188L mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.
AID1220361	Total blood plasma concentration in human	2013	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2	Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid.
AID586365	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase L101I mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficiency vi	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID717844	Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation at 20 uM after 45 mins by spectrophotometric analysis relative to control	2012	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24	Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
AID279506	Antiviral activity against HIV1 isolate with RT V106I mutation in Hela-JC-53 cells	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID650692	Inhibition of HIV 1 reverse transcriptase Y188L mutant assessed as inhibition of time-dependent incorporation of [3H]dTTP into poly(rA)n.oligo(dT)	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
AID518739	Selectivity ratio of IC50 for DNA-dependent DNA polymerase activity of HIV1 subtype B reverse transcriptase M230L mutant to IC50 for DNA-dependent DNA polymerase activity of wild type HIV1 subtype B reverse transcriptase	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity.
AID1653624	Activation of recombinant human C-terminal 4His-tagged CYP46A1 delta(2 to 50) mutant expressed in Escherichia coli at 20 uM using cholesterol as substrate measured after 30 mins in presence of cytochrome P450 oxidoreductase and L-Glu by gas chromatography	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds.
AID1220362	Total seminal plasma concentration in human	2013	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2	Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid.
AID541172	Selectivity ratio of EC50 for antiviral activity against HIV1 harboring E92V and V151A mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID279529	Antiviral activity against HIV1 NL4-3 with Y188L mutation in Hela-JC53 cells in the presence of 50% human serum after 48 hrs	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID473116	Cytotoxicity against human MT4 cells after 4 days by MTT assay	2010	Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7	Synthesis and biological evaluation of 4-(hydroxyimino)arylmethyl diarylpyrimidine analogues as potential non-nucleoside reverse transcriptase inhibitors against HIV.
AID443681	Antiviral activity against HIV with reverse transcriptase G190A mutant assessed as inhibition of viral replication	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
AID1156484	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.
AID663296	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.
AID1163231	Antitrypanocidal activity against suramin-sensitive Trypanosoma brucei rhodesiense STIB-900 assessed as reduction in parasite growth after 72 hrs	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID246266	Effective concentration against human immunodeficiency virus type 1 K103N mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).
AID1077220	Cytotoxicity against human MT4 cells assessed as growth inhibition after 5 days by MTT assay	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach.
AID1520066	Inhibition of recombinant wild type HIV-1 His-tagged reverse transcriptase p66/p51 expressed in Escherichia coli JM109 using poly(rA)/oligo(dT)16 as template/primer incubated for 40 mins by pico-green based spectrofluorometric analysis	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID247526	Inhibitory activity against wild type HIV-1 LAI cell line	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID735082	Antiviral activity against wild type HIV by cell based assay	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	Synthesis and biological evaluation of phosphonate analogues of nevirapine.
AID1773454	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 harboring Y188L mutant infected in human MT4 cells
AID279429	Antiviral activity against HIV1 isolate with RT 103N, 106M mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID299028	Antiviral activity against HIV1 with reverse transcriptase K103N mutation in CEM cells assessed as inhibition of virus-induced giant cell formation	2007	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7	Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains.
AID1352316	Antiviral activity against HIV1 harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 4 days by MTT assay	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.
AID371899	Antiviral activity against HIV1 NL4-3 with L100I mutant in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay	2009	Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12	New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID663298	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.
AID541150	Selectivity ratio of EC50 for antiviral activity against 3TC-resistant HIV1 selected after 4 passages to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1249719	Antiviral activity against HIV1 expressing reverse transcriptase K103N mutant	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue.
AID496629	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase E138A/K20R, V35T, E36D, T39N, V60I, D123N, I135V, S162A, K173T, Q174K, D177E, T200A, Q207E, R211K mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID1352168	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Quinoxaline derivatives as new inhibitors of coxsackievirus B5.
AID279432	Antiviral activity against HIV1 isolate with RT 181I mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID279510	Antiviral activity against HIV1 isolate with RT T369I mutation in Hela-JC-53 cells	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID496631	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase V90I,Y181C/V35T, T39M, P119S, D123E, S162A, E169D, K173T, Q174K, D177E, T200A, Q207E, K219N, V245Q, E248D mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID1141966	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1249720	Antiviral activity against HIV1 expressing reverse transcriptase E138K mutant	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue.
AID391225	Antiviral activity against HIV1 with reverse transcriptase K103N mutant infected in human MT4 cells after 72 hrs in presence of 10% fetal bovine serum	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses.
AID348905	Antiviral activity against drug-resistant HIV1 with reverse transcriptase K103N mutant infected in human MT4 cells assessed as virus-induced cell death by MTT method	2008	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 18, Issue:21	Towards novel S-DABOC inhibitors: synthesis, biological investigation, and molecular modeling studies.
AID541161	Selectivity ratio of EC50 for antiviral activity against HIV1 harboring T66I mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1171592	Resistance index, ratio of EC50 for HIV1 NL4-3 expressing reverse transcriptase K103N-Y181C mutant to EC50 for wild type HIV1 NL4-3	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID366531	Inhibition of RNA dependent DNA polymerase activity of HIV1 reverse transcriptase L100I mutant	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.
AID430057	Selectivity index, CC50 for human MT4 cells to EC50 for HIV1 3B	2009	Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16	Design, synthesis, and structure-activity relationships of 1,3-dihydrobenzimidazol-2-one analogues as anti-HIV agents.
AID265467	Antiviral activity against HIV1 3B in MT4 cell line	2006	Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11	Design, molecular modeling, synthesis, and anti-HIV-1 activity of new indolyl aryl sulfones. Novel derivatives of the indole-2-carboxamide.
AID366520	Antiviral activity against HIV1 isolates with reverse transcriptase K103N mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.
AID282735	Inhibition of HIV1 RT	2005	Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23	Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.
AID576033	Tmax in healthy human plasma at 400 mg, po measured on day 1 post dose by liquid chromatography-tandem mass spectrometry	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.
AID614141	Antiviral activity against wild type Human immunodeficiency virus 1 3B bearing reverse transcriptase K103N and Y181C double mutation infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	2011	Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17	Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs.
AID1155811	Fold resistance, ratio of EC50 for HIV-1 harboring NNTRI-resistant reverse transcriptase Y181C mutant infected in human MT4 cells to EC50 for wild type HIV-1 NL4-3 infected in human MT4 cells	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.
AID248259	In vitro inhibitory concentration against HIV K101E mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
AID1483272	Inhibition of HIV1 3B reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
AID104448	Concentration required to protect the cell against HIV-1 strain IIIB viral cytopathogenicity by 50% in MT-4 cells	2004	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12	5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series.
AID1558858	Inhibition of recombinant wild type HIV1 reverse transcriptase p66/p51 incubated for 40 mins by picogreen dye-based spectrofluorometric analysis	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Ligand-Based Design of Nondimethylphenyl-Diarylpyrimidines with Improved Metabolic Stability, Safety, and Oral Pharmacokinetic Profiles.
AID1574379	Resistance index, ratio of EC50 for HIV-1 IRLL98 harboring reverse transcriptase M41L, D67N, Y181C, M184V, R211K, and T215Y mutants to EC50 for wild type HIV-1 NL4-3	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.
AID572181	Antiviral activity against HIV-1 SM007 harboring NNTRI 103N mutant infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID166708	Inhibitory activity against RNA	2001	Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5	Synthesis and biological activities of potential metabolites of the non-nucleoside reverse transcriptase inhibitor efavirenz.
AID1456308	Inhibition of HIV1 RES056 reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured at 5 days post infection by MTT assay	2017	Bioorganic & medicinal chemistry, 04-15, Volume: 25, Issue:8	Structural modifications of diarylpyrimidines (DAPYs) as HIV-1 NNRTIs: Synthesis, anti-HIV activities and SAR.
AID665551	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors.
AID1815383	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID1653626	Activation of recombinant human C-terminal 4His-tagged CYP46A1 delta(2 to 50) F405A mutant expressed in Escherichia coli at 20 uM using cholesterol as substrate measured after 30 mins in presence of cytochrome P450 oxidoreductase by gas chromatography-mas	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds.
AID586359	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase T66A mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficiency vir	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID222294	Effect of human plasma protein binding on antiviral efficacy.	2000	Journal of medicinal chemistry, May-18, Volume: 43, Issue:10	Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID650540	Antiviral activity against wild type HIV 1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
AID443679	Antiviral activity against HIV with reverse transcriptase Y181C mutant assessed as inhibition of viral replication	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
AID231368	Ratio of wild type IIIB to that of Y181C HIV-1 induced cytopathogenicity	2004	Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4	Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C varia
AID361904	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/L100I mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID736041	Inhibition of HIV1 reverse transcriptase p66/p51 V106A mutant after 30 mins by liquid scintillation counting	2013	Bioorganic & medicinal chemistry, Mar-01, Volume: 21, Issue:5	N1,N3-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1191671	Inhibition of HIV1 recombinant wild type reverse transcriptase p66/p51 pre-incubated with compound before enzyme addition using poly(rA) template and measured after 40 mins by picogreen based spectrofluorometry	2015	Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5	Scaffold hopping: exploration of acetanilide-containing uracil analogues as potential NNRTIs.
AID1446814	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild-type HIV1 3B infected in human MT4 cells	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.
AID622047	Inhibition of DNA-dependent DNA polymerase activity of HIV1 reverse transcriptase p66/p66 homodimer K103N mutant using activated DNA and [alpha-32P]dATP after 30 mins by liquid scintillation counting	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID583864	Ratio of IC50 for HIV1 HXB2 reverse transcriptase K103N mutant to IC50 for wild type HIV1 reverse transcriptase	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID1316343	Selectivity index, ratio of CC50 for human mock-infected MT4 cells to EC50 for HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT4 cells	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID571984	Antiviral activity against HIV-1 subtype C V022816 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID1304408	Antiviral activity against HIV-1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	2016	Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13	Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
AID1750720	Inhibition of HIV-1 p66/p51 reverse transcriptase Y188L mutant incubated for 40 mins by picogreen dye-based spectrofluorometric analysis	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID247725	Inhibitory concentration against 181C mutant was determined	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity.
AID1609103	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 4 days by MTT assay	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID279469	Antiviral activity against HIV1 isolate with RT 238N mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID88371	Antiviral activity against P236L mutant virus in the HeLa MAGI assay.	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1773836	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18	Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies.
AID1743635	Resistance index, ratio of EC50 for antiviral activity against HIV1 expressing RT K103N mutant infected in human MT4 cells to EC50 for antiviral activity against HIV1 3B infected in human MT4 cells	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.
AID1163233	Antiviral activity against HIV1 infected in human TZM-bl cells assessed as viral inhibition pre-incubated for 30 mins prior to infection measured after 48 hrs by	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID361911	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase L100I mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID347616	Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 179D mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.
AID104450	Concentration required to protect the cell against HIV-2 strain ROD viral cytopathogenicity by 50% in MT-4 cells; NA denotes not active	2004	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12	5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series.
AID279413	Antiviral activity against HIV1 isolate with RT 106A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1750727	Selectivity index, ratio of CC50 for cytotoxicity against human MT-4 cells to EC50 for inhibition of HIV-1 p66/51 reverse transcriptase E138K mutant	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from
AID279400	Antiviral activity against HIV1 isolate with RT 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1186003	Antiviral activity against HIV1 harboring reverse transcriptase K103N/G190A double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay r	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
AID1204078	Antiviral activity against HIV1 infected in human MT4 cells assessed as protection against viral-induced cytopathogenecity after 4 days by MTT method	2015	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11	N-((1,3-Diphenyl-1H-pyrazol-4-yl)methyl)anilines: A novel class of anti-RSV agents.
AID1873200	Inhibition of human ABCG2 expressed in dog MDCK-II-BCRP cells mediated pheophorbide A efflux preincubated with PhA followed by compound addition and measured after 60 mins by flow cytometry	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
AID1155808	Antiviral activity against HIV-1 harboring NNTRI-resistant reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.
AID573981	Ratio of EC50 for Human immunodeficiency virus 1 3B to EC50 for Human immunodeficiency virus 2 EHO	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.
AID632801	Antiviral activity against Human immunodeficiency virus 1 NL4.3 reverse transcriptase K103N and Y181C double mutant infected in human MT4 cells assessed as inhibition of viral infection	2011	Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24	Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.
AID1212881	Drug metabolism in microsomes expressing CYP2B6.1 (unknown origin) assessed as enzyme-mediated 8-hydroxyefavirenz metabolite formation after 15 mins by HPLC/UV system in presence of Cyt b5 coexpression	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
AID586909	Induction of MRP3 activity	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Interaction potential of etravirine with drug transporters assessed in vitro.
AID96290	In vitro antiviral activity against HIV-1 (L100I).	2000	Journal of medicinal chemistry, May-18, Volume: 43, Issue:10	Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID1304407	Inhibition of HIV-1 BH10 recombinant reverse transcriptase K103N mutant expressed in Escherichia coli assessed as incorporation of [32P]GTP into poly(rA)/oligo(dT) as template primer	2016	Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13	Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
AID1316333	Cytotoxicity against human mock-infected MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID269793	Antiviral activity against HIV1	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269793	Antiviral activity against HIV1	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269793	Antiviral activity against HIV1	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID522369	Antiviral activity against recombinant HIV1 harboring reverse transcriptase V106A mutant clone infected in MAGIC-5 cells using 5-bromo4-chloro-3-indolyl-beta-D-galactopyranoside staining based light microscopy	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
AID663299	Cytotoxicity against human MT4 cells after 5 days by MTT assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID246299	Effective concentration of the compound to inhibit HIV-1 mutant L100I replication in HIV-infected MT-4 cells	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID1264543	Cytotoxicity against human CD4-positive T cells	2015	ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10	Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine Resistance.
AID1316330	Antiviral activity against wild type HIV1 3B harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID576045	Fraction unbound in healthy human plasma at 400 mg, po measured on day 1 post dose by liquid chromatography-tandem mass spectrometry	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.
AID404606	Antiviral activity against HIV1 with reverse transcriptase Y181C mutation	2008	Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12	Parallel one-pot synthesis and structure-activity relationship study of symmetric formimidoester disulfides as a novel class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID523345	Antiviral activity against HIV1 with RT connection domain T369I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID635345	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay	2011	Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23	Design, synthesis and biological evaluation of cycloalkyl arylpyrimidines (CAPYs) as HIV-1 NNRTIs.
AID1197829	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.
AID1246228	Cytotoxicity against human MT4 cells	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Synthesis, cytotoxicity and antimicrobial activity of thiourea derivatives incorporating 3-(trifluoromethyl)phenyl moiety.
AID650547	Resistance ratio of EC50 for HIV 1 harboring reverse transcriptase K103N mutant infected in human MT4 cells to EC50 for wild type HIV 1 NL4-3 infected in human MT4 cells	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
AID576044	Drug concentration in PBMCs of healthy human at 400 mg, po ad for 14 days measured after 24 hrs post last dose by liquid chromatography-tandem mass spectrometry	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.
AID82459	Antiviral activity against K103N strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID586377	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase Q148K mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficiency vi	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID279457	Antiviral activity against HIV1 isolate with RT 98G, 101E, 181C, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1811044	Antiviral activity against HIV1 IIIB infected human MT4 cells assessed as protection against virus-induced cytopathic effect by MTT assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.
AID1231488	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anti-HIV diarylpyrimidine-quinolone hybrids and their mode of action.
AID1822280	Antiviral activity against HIV-1 harboring E138K mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity incubated for 5 days by MTT assay	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.
AID446257	Fold resistance, ratio of IC50 for HIV reverse transcriptase with K101E mutant to IC50 for HIV wild type reverse transcriptase	2009	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20	Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
AID1171414	Cytotoxicity against human MT2 cells assessed as reduction in cell viability by MTT assay	2014	ACS medicinal chemistry letters, Nov-13, Volume: 5, Issue:11	Picomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl Ethers.
AID83549	Potency evaluated against NNRTI-Resistant HIV-1 strain Leu100Ile	2004	Journal of medicinal chemistry, May-06, Volume: 47, Issue:10	Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 varian
AID586388	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase T66K/L74M mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficienc	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID1261311	Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining method	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID330485	Antiviral activity against HIV1 3B infected in MT4 cells by MTT	2008	Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7	Synthesis and biological evaluation of novel 6-substituted 5-alkyl-2-(arylcarbonylmethylthio)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID541163	Selectivity ratio of EC50 for antiviral activity against HIV1 harboring E92Q mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1197831	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.
AID619640	Antiviral activity against HIV-1 3B harboring RT K103N and Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
AID464764	Antiviral activity against wild type HIV1 infected in human MT2 cells	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	N1-Heterocyclic pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID1163254	Antileishmanial activity against Leishmania infantum MHOM/MA (BE)/67 infected in primary peritoneal mouse macrophages assessed as reduction in parasite burdun	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID279463	Antiviral activity against HIV1 isolate with RT 108I, 181C, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID492280	Selectivity index, CC50 for human MT4 cells to EC50 for wild type HIV1 3B	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
AID279401	Antiviral activity against HIV1 isolate with RT 181C, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID508795	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase V090I mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID464766	Antiviral activity against NNRTI-resistant HIV1 harboring reverse transcriptase K103N mutant infected in human MT2 cells	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	N1-Heterocyclic pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID492284	Antiviral activity against HIV1 with reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
AID347087	Inhibition of RNA-dependent DNA polymerase activity of HIV1 reverse transcriptase Y181C mutant	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays.
AID1316345	Selectivity index, ratio of CC50 for human mock-infected MT4 cells to EC50 for HIV1 3B harboring reverse transcriptase E138K mutant infected in human MT4 cells	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID1520060	Selectivity index, ratio of CC50 for cytotoxicity against human MT4 cells to EC50 for antiviral activity against HIV1 3B infected in human MT4 cells	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID1741395	Inhibition of reverse transcriptase Y181C mutant in HIV-1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID279521	Antiviral activity against wild type HIV1 NL4-3 in Hela-JC53 cells in the presence of 40% human serum after 48 hrs	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID279467	Antiviral activity against HIV1 isolate with RT 106A, 181C mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID302621	Cytotoxicity against human MT2 cells by MTT assay	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	From docking false-positive to active anti-HIV agent.
AID1197834	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 RES056 expressing reverse transcriptase K103N + Y181C double mutant	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.
AID1773828	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay	2021	Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18	Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies.
AID1272058	Half life in human administered as single dose	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Efavirenz a nonnucleoside reverse transcriptase inhibitor of first-generation: Approaches based on its medicinal chemistry.
AID366526	Inhibition of RNA dependent DNA polymerase activity of wild-type HIV1 reverse transcriptase	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.
AID738332	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for wild type HIV1 3B	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs.
AID440085	Antiviral activity against HIV1 HXB2 harboring 101E and K103N mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
AID1171598	Inhibition of wild type HIV1 reverse transcriptase Y181I mutant assessed as reduction in enzyme activity	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1754638	Cytotoxicity against mock-infected human MT4 cells incubated for 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses.
AID279459	Antiviral activity against HIV1 isolate with RT 101H mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID246392	Effective concentration against human immunodeficiency virus type 1 mutated at 100I+103N	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.
AID556526	Antiviral activity against Human immunodeficiency virus 1 clone Q9016 harboring K122E, Q145M, I202V, F214L mutation in reverse transcriptase by phenosense assay relative to wild type	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
AID779528	Antiviral activity against HIV-1 RESO56 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	2013	Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21	Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.
AID267855	Antiviral activity against HIV1 IRLL98 in MT4 cells by MTT assay	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Synthesis and biological investigation of S-aryl-S-DABO derivatives as HIV-1 inhibitors.
AID508780	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase E138S mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID88379	Antiviral activity against V108I mutant virus in the HeLa MAGI assay.	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID557024	Antiviral activity against HIV1 isolate R8 harboring reverse transcriptase L100I mutant relative to drug-sensitive HIV1 CNDO	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID571969	Antiviral activity against HIV-1 subtype CRF02_AG V022826 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID576042	Drug concentration in PBMCs of healthy human at 400 mg, po ad for 14 days measured after 5 hrs post last dose by liquid chromatography-tandem mass spectrometry	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.
AID508833	Antiviral activity against Human immunodeficiency virus 1 subtype C isolate 93MW959 infected in human PBMC cells by cell based assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1693801	Antiviral activity against HIV2 ROD infected in human MT-4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 01-15, Volume: 30	Novel indolylarylsulfone derivatives as covalent HIV-1 reverse transcriptase inhibitors specifically targeting the drug-resistant mutant Y181C.
AID1729158	Antiviral activity against HIV1 harboring Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect by MTT assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp
AID571973	Antiviral activity against HIV-1 subtype CRF01_AE V022822 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID1410397	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Discovery of Novel Diarylpyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the "NNRTI Adjacent" Binding Site.
AID508622	Antiviral activity against Human immunodeficiency virus 1 subtype D isolate 92UG024 infected in human PBMC cells by cell based assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID361923	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/G190A mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1705192	Resistance index, ratio of EC50 for antiviral activity against HIV1 harboring RT Y188L mutant infected in human MT4 cells to EC50 for antiviral activity against HIV1 NL4-3 infected in human MT4 cells	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains.
AID1457064	Inhibition of HIV1 reverse transcriptase p66 K103N mutant associated RNA dependent DNA polymerase activity expressed in Escherichia coli assessed as reduction in [3H]dTTP incorporation using poly(rA)/oligo(dT) as template/primer by scintillation counting	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
AID279494	Antiviral activity against HIV1 isolate with RT G190A mutation	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1731746	Inhibition of reverse transcriptase L100I mutant in HIV-1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay
AID571968	Antiviral activity against HIV-1 subtype CRF02_AG V022825 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID1743630	Antiviral activity against HIV1 harboring RT E138K mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.
AID1520061	Selectivity index, ratio of CC50 for cytotoxicity against human MT4 cells to EC50 for antiviral activity against HIV1 3B harbouring NNRTI K103N mutant infected in human MT4 cells	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID1141972	Ratio of EC50 for HIV1 harboring reverse transcriptase Y188L mutant to EC50 for wild type HIV1 NL4.3	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID441309	Fold resistance, ratio of IC50 for HIV reverse transcriptase with K103N mutant to IC50 for HIV wild type reverse transcriptase	2009	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19	Pyrazole NNRTIs 1: design and initial optimisation of a novel template.
AID441315	Fold resistance, ratio of IC50 for HIV reverse transcriptase with P236L mutant to IC50 for HIV wild type reverse transcriptase	2009	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19	Pyrazole NNRTIs 1: design and initial optimisation of a novel template.
AID508829	Antiviral activity against Human immunodeficiency virus 1 subtype B isolate JR-CSF infected in human PBMC cells by cell based assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID541168	Selectivity ratio of EC50 for antiviral activity against HIV1 harboring V151A mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID443701	Antiviral activity against HIV with reverse transcriptase K103N/Y181C double mutant assessed as inhibition of viral replication relative to wild type	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
AID519888	Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID1126510	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to IC50 for HIV1 3B infected in human MT4 cells	2014	Bioorganic & medicinal chemistry, Apr-15, Volume: 22, Issue:8	Structural modifications of CH(OH)-DAPYs as new HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1069708	Cytotoxicity against human MT4 cells assessed as cell viability	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Design and synthesis of N₁-aryl-benzimidazoles 2-substituted as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID571987	Antiviral activity against HIV-1 subtype C V022831 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID448403	Fold resistance, ratio of IC50 for HIV reverse transcriptase with P236L mutant to IC50 for HIV wild type reverse transcriptase	2009	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19	Pyrazole NNRTIs 3: optimisation of physicochemical properties.
AID457961	Inhibition of HIV1 reverse transcriptase K103N mutant by RNA-dependent DNA polymerase activity assay	2010	Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4	Novel 1,3-dihydro-benzimidazol-2-ones and their analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID573987	Antiviral activity against Protease inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.
AID508633	Cytotoxicity against human MT4 cells by cell based assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID519870	Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID1390710	Antiviral activity against HIV1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8	First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain.
AID1773457	Resistance factor, ratio of EC50 for HIV1 harboring L1001 mutant infected in human MT4 cells to EC50 for HIV1 3B infected in MT4 cells
AID282740	Inhibition of HIV1 RT Y188L mutant	2005	Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23	Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.
AID572186	Antiviral activity against HIV-1 SM034 harboring NNTRI 188L mutant infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID443689	Antiviral activity against HIV with reverse transcriptase K101E/Y181C/G190A mutant assessed as inhibition of viral replication	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
AID105324	Inhibition of Efavirenz resistant HIV-1 (K103N-Y181C) induced cytopathicity in MT-4 cells.	2004	Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15	Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations.
AID519856	Antiviral activity against pseudotype HIV1 NL-RLuc infected in human MT2 cells measured on day 5 postinfection by luciferase reporter gene assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID541175	Selectivity ratio of EC50 for antiviral activity against HIV1 harboring G140S and Q148H mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID440083	Antiviral activity against HIV1 HXB2 harboring 227C mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
AID576034	Tmax in healthy human plasma at 400 mg, po qd for 14 days by liquid chromatography-tandem mass spectrometry	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.
AID1155815	Inhibition of HIV-1 recombinant NNTRI-resistant reverse transcriptase Y181I mutant assessed as incorporation of [3H]dTTP into poly(rA)/oligo(dT)10:1	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.
AID517497	Antiviral activity against HIV1 harboring reverse transcriptase V106A mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS	2010	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 20, Issue:20	Exploration of piperidine-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Phenyl derivatives with broad potency against resistant mutant viruses.
AID490370	Antiviral activity against HIV1 expressing reverse transcriptase K103N/L100I double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect	2010	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14	Discovery of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-benzyl derivatives with broad potency against resistant mutant viruses.
AID523478	Antiviral activity against HIV1 with RT connection domain G190A/T369I/N348I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID1773837	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18	Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies.
AID1171584	Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1292011	Cytotoxicity against mock infected human MT4 cells after 4 days by MTT assay	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket.
AID1261317	Antiviral activity against Human poliovirus 1 Sabin infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity by plaque reduction assay	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID1316329	Inhibition of recombinant wild type HIV1 reverse transcriptase using DIG-dUTP/biotin-dUTP/dTTP assessed as suppression of biotin-dUTP incorporation after 1 hr by ELISA	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID519883	Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID1884220	Antiviral activity against HIV-1 harboring F227L/V106A double mutant infected in human MT4 cells assessed as reduction in virus induced cytotoxicity incubated for 5 to 7 days by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Chemical space exploration around indolylarylsulfone scaffold led to a novel class of highly active HIV-1 NNRTIs with spiro structural features.
AID279476	Antiviral activity against HIV1 isolate with RT 101N, 103N mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID82469	Antiviral activity against V106A/Y181C strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1126509	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	2014	Bioorganic & medicinal chemistry, Apr-15, Volume: 22, Issue:8	Structural modifications of CH(OH)-DAPYs as new HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1574373	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.
AID263515	Antiviral activity against HIV1 I135T mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2.
AID508775	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase Y181C mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1457072	Effect on fizz mRNA levels in C57BL/6 mouse BV2 cells at 1000 nM after 24 hrs by RT-PCR assay	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
AID584029	Inhibition of HIV1 histidine-tagged reverse transcriptase E233V mutant activity by primer extension assay	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID1191669	Cytotoxicity against human MT4 cells assessed as reduction in cell viability	2015	Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5	Scaffold hopping: exploration of acetanilide-containing uracil analogues as potential NNRTIs.
AID573988	Ratio of EC50 for Human immunodeficiency virus 1 3B to EC50 for Reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.
AID738335	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs.
AID571970	Antiviral activity against HIV-1 subtype CRF02_AG V022830 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID443692	Antiviral activity against HIV with reverse transcriptase MDRC4 mutant assessed as inhibition of viral replication relative to wild type	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
AID726437	Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase K103N and Y181C mutation infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method	2013	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4	Optimization of benzyloxazoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase to enhance Y181C potency.
AID519865	Antiviral activity against HIV1 subtype B-NL4-3 infected in 3 hrs pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID541153	Selectivity ratio of EC50 for antiviral activity against EFV-resistant HIV1 selected after 7 passages to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID541151	Selectivity ratio of EC50 for antiviral activity against 3TC-resistant HIV1 selected after 8 passages to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1552563	Antiviral activity against HIV1 V13-03413B infected in human LC5 cells expressing DsRed1 reporter gene assessed as inhibition of viral infection measured after 48 hrs post infection by reporter gene based luminescence assay	2019	Bioorganic & medicinal chemistry, 08-15, Volume: 27, Issue:16	Biological evaluation of molecules of the azaBINOL class as antiviral agents: Inhibition of HIV-1 RNase H activity by 7-isopropoxy-8-(naphth-1-yl)quinoline.
AID571980	Antiviral activity against HIV-1 subtype B V022812 harboring NNRTI V179I mutant infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID519892	Selectivity ratio of EC50 for 0.05 MOI HIV1 NL4-3 infected in human MT2 cells by MTS assay to EC50 for 0.05 MOI HIV1 NL4-3 infected in human MT2 cells by RT assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID750863	Antiviral activity against HIV1 infected in human 293T cells assessed as inhibition of viral replication incubated for 15 mins prior to infection measured after 48 hrs by luciferase reporter gene assay	2013	Journal of natural products, Jun-28, Volume: 76, Issue:6	Diterpenoids with diverse skeletons from the roots of Euphorbia micractina.
AID1171596	Inhibition of wild type HIV1 reverse transcriptase L100I mutant assessed as reduction in enzyme activity	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1069124	Antiviral activity against HIV harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of viral infection in presence of 50% normal human serum	2014	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3	Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses.
AID392513	Antiviral activity against HIV1	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID371904	Antiviral activity against HIV1 NL4-3 with K103N/L100I double mutant in human TZM-b1 cells assessed as beta-galactosidase activity after 48 hrs by single round replication assay	2009	Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12	New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID368555	Inhibition of wild type HIV1 reverse transcriptase-mediated RNA-dependent DNA polymerase activity assessed as [3H]dTTP incorporation by cell free-based scintillation counting	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.
AID246349	Effective concentration against human immunodeficiency virus type 1 mutated at 103N	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.
AID1212916	Drug metabolism in microsomes expressing CYP2B6.1 (unknown origin) assessed as intrinsic clearance for enzyme-mediated 8-hydroxyefavirenz metabolite formation measured per pmol of P450 after 15 mins by HPLC/UV system in absence of Cyt b5 coexpression	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
AID663311	Resistance ratio of ID50 for HIV1 reverse transcriptase K103N mutant to ID50 HIV1 wild type reverse transcriptase	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.
AID735080	Ratio of EC50 for HIV harboring reverse transcriptase Y181C mutant to EC50 for wild type HIV	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	Synthesis and biological evaluation of phosphonate analogues of nevirapine.
AID1155804	Antiviral activity against wild type HIV-1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.
AID1220376	Drug metabolism in human liver microsomes assessed as formation of metabolites with retention time of 1.92 mins at 20 uM by UPLC-MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2	Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid.
AID573257	Antiviral activity against HIV1 infected in children assessed as decrease in viral burden at 14.4 mg/kg once daily measured after 3 months	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children?
AID279321	Inhibition of reverse transcriptase activity in HIV1 infected HeLa-MAGI cells at 37 deg C after 48 hrs	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Development of a new methodology for screening of human immunodeficiency virus type 1 microbicides based on real-time PCR quantification.
AID541130	Selectivity ratio of EC50 for antiviral activity against NRTI-resistant HIV1 harboring RTM184V mutant gene to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID151310	percentage in tissue culture medium	2000	Journal of medicinal chemistry, May-18, Volume: 43, Issue:10	Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID586472	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase E138K/Q148H mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficie	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID253495	Dose required to inhibit HIV-1 reverse transcriptase activity ( L100I mutant) by 50%	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13	Novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. A structure-activity relationship investigation.
AID576030	Volume of distribution in healthy human plasma at 400 mg, po measured on day 1 post dose by liquid chromatography-tandem mass spectrometry	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.
AID248841	Inhibitory concentration against human immunodeficiency virus type 1 (with G190A resistant mutation) was determined in HeLa-CD4 MAGI assay	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
AID1761009	Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect measured after 5 days by MTT assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Design, synthesis, and evaluation of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase.
AID279500	Antiviral activity against HIV1 isolate with RT V106I mutation	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID81628	Antiviral activity was evaluated against wild-type HIV-1 virus	2001	Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9	Synthesis and evaluation of efavirenz (Sustiva) analogues as HIV-1 reverse transcriptase inhibitors: replacement of the cyclopropylacetylene side chain.
AID328841	Inhibition of human MRP1 expressed in MDCK2 cells assessed as increase in intracellular CMF fluorescence by CMFDA assay	2007	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3	Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.
AID572183	Antiviral activity against HIV-1 SM024 harboring NNTRI 190A mutant infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID1443663	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	2017	Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8	Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors.
AID508786	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase V108I mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID572187	Antiviral activity against HIV-1 SM051 harboring NNTRI 100I and 103N mutant infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID1435513	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 expressing reverse transcriptase K103N mutant
AID1152373	Cytotoxicity against human MT4 cells by MTT assay	2014	Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12	Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1171583	Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID573986	Antiviral activity against non nucleoside reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.
AID1435514	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 expressing reverse transcriptase Y181C mutant
AID523486	Antiviral activity against HIV1 with RT connection domain L100I/T369I/N348I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID263514	Antiviral activity against HIV1 V106A mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2.
AID1443669	Antiviral activity against HIV1 harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	2017	Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8	Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors.
AID366522	Antiviral activity against HIV1 isolates with reverse transcriptase Y181C mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.
AID586480	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase Q148R/N155H mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficie	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID105707	Anti-HIV-1 activity against Y188L strain was determined in MT-4 cells by the MTT method	2003	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24	3-iodo-4-phenoxypyridinones (IOPY's), a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID1653627	Activation of recombinant human C-terminal 4His-tagged CYP46A1 delta(2 to 50) K358A mutant expressed in Escherichia coli at 20 uM using cholesterol as substrate measured after 30 mins in presence of cytochrome P450 oxidoreductase by gas chromatography-mas	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds.
AID1815388	Resistance fold, ratio of EC50 for HIV1 harboring reverse transcriptase K103N mutant infected MV4 cells to EC50 for wild type HIV1 infected MV4 cells	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID572184	Antiviral activity against HIV-1 SM026 harboring NNTRI 103N and 181C mutant infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID1884540	Fold resistance, ratio of EC50 for antiviral activity against drug-resistant HIV-1 Y181C mutant infected in human MT4 cells to EC50 for antiviral activity against NNRTI resistant wild type HIV-1 infected in human MT4 cells	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.
AID1077222	Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach.
AID1572523	Antiviral activity against HIV1 harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as inhibition of virus-induced cytotoxicity after 5 days by MTT assay
AID557046	Antiviral activity against HIV1 clade C harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID1773829	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells	2021	Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18	Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies.
AID586484	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase V72I/F121Y/T125K mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunode	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID605183	Antiviral activity against HIV1 R8 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as concentration required to inhibit >95% viral spread in presence of 10% FBS	2010	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 20, Issue:15	Biaryl ethers as potent allosteric inhibitors of reverse transcriptase and its key mutant viruses: aryl substituted pyrazole as a surrogate for the pyrazolopyridine motif.
AID632797	Antiviral activity against Human immunodeficiency virus 1 NL4.3 reverse transcriptase K103N and Y181C double mutant infected in human MT2 cells assessed as inhibition of viral infection	2011	Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24	Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.
AID246203	Concentration required to achieve 50% protection of infected MT-4 cells from Y181C-HIV-1 strain	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.
AID446238	Antiviral activity against HIV RF infected in human SupT1 cells	2009	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20	Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
AID1141967	Antiviral activity against HIV1 harboring reverse transcriptase L1001 mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1455949	Antiviral activity against VSV pseudotyped HIV1 infected in SupT1 cells after 48 hrs by luciferase reporter gene assay	2017	Journal of natural products, 02-24, Volume: 80, Issue:2	Griseofulvin Derivative and Indole Alkaloids from Penicillium griseofulvum CPCC 400528.
AID1754640	Antiviral activity against wild type HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect measured after 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses.
AID279392	Antiviral activity against HIV1 isolate with RT 100I, 103N mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID576046	Fraction unbound in healthy human plasma at 400 mg, po qd for 14 days by liquid chromatography-tandem mass spectrometry	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.
AID446408	Fold resistance, ratio of IC50 for HIV reverse transcriptase with V108I mutant to IC50 for HIV wild type reverse transcriptase	2009	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20	Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
AID1736358	Antiviral activity against VSVG/HIV-1 harboring reverse transcriptase L100I/K103N double mutant infected in human HEK 293T cells assessed as inhibition of virus replication preincubated with cells for 15 mins prior to viral infection and measured at 48 hr
AID269688	Antiviral activity against HIV1 NNTRI resistant K103N mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269688	Antiviral activity against HIV1 NNTRI resistant K103N mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269688	Antiviral activity against HIV1 NNTRI resistant K103N mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID518737	Inhibition of DNA-dependent DNA polymerase activity of wild type HIV1 subtype B reverse transcriptase by gel-based primer extension assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity.
AID247726	Inhibitory concentration against 188L mutant was determined	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity.
AID473114	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay	2010	Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7	Synthesis and biological evaluation of 4-(hydroxyimino)arylmethyl diarylpyrimidine analogues as potential non-nucleoside reverse transcriptase inhibitors against HIV.
AID267856	Antiviral activity against HIV1 K103N mutant in MT4 cells by MTT assay	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Synthesis and biological investigation of S-aryl-S-DABO derivatives as HIV-1 inhibitors.
AID735083	Inhibition of HIV reverse transcriptase	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	Synthesis and biological evaluation of phosphonate analogues of nevirapine.
AID492281	Antiviral activity against wild type HIV1 LAI infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID519893	Selectivity ratio of EC50 for 0.005 MOI HIV1 NL4-3 infected in 2 hrs pretreated human MT2 cells by MTS assay to EC50 for 0.005 MOI HIV1 NL4-3 infected in 2 hrs pretreated human MT2 cells by RT assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID82458	Antiviral activity against K101E strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1773460	Resistance factor, ratio of EC50 for HIV1 harboring Y188L mutant mutant infected in human MT4 cells to EC50 for HIV1 3B infected in MT4 cells
AID465419	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT2 cells	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	N1-Alkyl pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID269796	Antiviral activity against HIV1 F227L mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269796	Antiviral activity against HIV1 F227L mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269796	Antiviral activity against HIV1 F227L mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1705183	Antiviral activity against HIV-1 NL4-3 infected in human MT-4 cells assessed as virus induced cytopathic effect by MTT assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains.
AID573256	Apparent oral clearance in HIV-1 infected children at 14.4 mg/kg, po administered once daily by HPLC	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children?
AID508765	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase M236L mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID541160	Selectivity ratio of EC50 for antiviral activity against GS-9160-resistant HIV1 selected after 9 passages to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID517494	Selectivity ratio of IC50 for wild type HIV1 in presence of 40% human serum to IC50 for wild type HIV1 in presence of 10% FBS	2010	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 20, Issue:20	Exploration of piperidine-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Phenyl derivatives with broad potency against resistant mutant viruses.
AID1736347	Inhibition of HIV-1 reverse transcriptase RNA-dependent DNA polymerase activity assessed as reduction in dTTP incorporation using poly(rA)/oligo(dT) as template/primer incubated for 1 hr followed by transferring into streptavidin plate for 1 hr by absorba
AID360704	Inhibition of HIV1 RT mediated DNA-dependent DNA synthesis initiation using RNA/DNAM duplex primed substrate by scintillation proximity assay	2007	The Journal of biological chemistry, Mar-16, Volume: 282, Issue:11	HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro.
AID517496	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS	2010	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 20, Issue:20	Exploration of piperidine-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Phenyl derivatives with broad potency against resistant mutant viruses.
AID1520057	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID1443668	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	2017	Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8	Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors.
AID368560	Antiviral activity against HIV1 reverse transcriptase Y181C mutant infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.
AID1705185	Selectivity ratio of CC50 for human MT4 cells to EC50 for antiviral activity against HIV-1 NL4-3 infected in human MT4 cells	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains.
AID1596756	Inhibition of recombinant wild-type HIV1 3B reverse transcriptase assessed as reduction in biotin-dUTP incorporation using poly(rA)/oligo(dT)16 as template primer incubated for 1 hr followed by the addition of (DIG)-dUTP and biotin-labeled dNTPs by ELISA	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Synthesis and biological evaluation of dihydroquinazoline-2-amines as potent non-nucleoside reverse transcriptase inhibitors of wild-type and mutant HIV-1 strains.
AID263519	Antiviral activity against HIV1 Y181C mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2.
AID1446873	Inhibition of wild-type HIV1 RT associated RNA dependent DNA polymerase activity using poly(A) template/oligo(dT) primer after 30 mins by picogreen staining based method	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Natural product-inspired esters and amides of ferulic and caffeic acid as dual inhibitors of HIV-1 reverse transcriptase.
AID523355	Antiviral activity against HIV1 with RT connection domain Y181C/T369I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID361925	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/Y181C mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1503175	Antiviral activity against VSV-G pseudotyped HIV1 infected in human SupT1 cells at 100 uM after 48 hrs by luciferase reporter gene assay relative to control	2017	Journal of natural products, 10-27, Volume: 80, Issue:10	Metabolites from the Plant Endophytic Fungus Aspergillus sp. CPCC 400735 and Their Anti-HIV Activities.
AID586380	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase S153F mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficiency vi	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID1191400	Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	2015	Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3	Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID1410481	Inhibition of wild-type HIV1 3B reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytotoxicity by MTT assay	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery.
AID584239	Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase Y181C, V179V/D mutant derived from 17 days viral passages with lersivirine infected in human SupT1 cells assessed as inhibition of viral replication after 21 days relative to wild type	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID1815386	Resistance fold, ratio of EC50 for HIV1 harboring reverse transcriptase Y181C mutant infected MV4 cells to EC50 for wild type HIV1 infected MV4 cells	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID248012	In vitro inhibitory concentration against HIV LAI cell line	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
AID1761007	Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability measured after 1 day by CytoTox-Glo assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Design, synthesis, and evaluation of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase.
AID232750	Selectivity index is the ratio between CC50 for MT-4 cells and IC50 against HIV-1 infection	2004	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12	5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series.
AID293174	Antiviral activity against HIV1 LAI assessed as inhibition of viral-induced cytopathicity in MT4 cells by MTT method	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Structure-activity relationship in the 3-iodo-4-phenoxypyridinone (IOPY) series: The nature of the C-3 substituent on anti-HIV activity.
AID557042	Antiviral activity against HIV1 isolate R8 harboring wild type reverse transcriptase infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs in presence of 10% FBS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID527375	Antiviral activity against wild type HIV1 NL4-3 infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Discovery and SAR of a series of 4,6-diamino-1,3,5-triazin-2-ol as novel non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID222921	percentage in human serum; value ranges from -0.2-0.5	2000	Journal of medicinal chemistry, May-18, Volume: 43, Issue:10	Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID94447	Inhibitory concentration against wild-type virus K103N and HIV-1 RT mutant in a whole cell antiviral assay	2001	Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2	3,3a-Dihydropyrano[4,3,2-de]quinazolin-2(1H)-ones are potent non-nucleoside reverse transcriptase inhibitors.
AID313194	Antiviral activity against HIV1 K103N/Y181C mutant	2008	Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1	Synthesis and antiviral activity of new dimeric inhibitors against HIV-1.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1261310	Cytotoxicity against BHK cells assessed as cell viability after 48 to 96 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID1552554	Antiviral activity against HIV1 HXB2 pseudovirus infected in human TZM-bl cells assessed as inhibition of viral infection incubated for 20 mins prior to infection and measured after 48 hrs by bright Glo-luciferase reporter gene assay	2019	Bioorganic & medicinal chemistry, 08-15, Volume: 27, Issue:16	Biological evaluation of molecules of the azaBINOL class as antiviral agents: Inhibition of HIV-1 RNase H activity by 7-isopropoxy-8-(naphth-1-yl)quinoline.
AID431622	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B	2009	Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16	Synthesis and biological evaluation of imidazole thioacetanilides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID622057	Ratio of Ki for HIV1 RT p66/p66 homodimer G190A mutant to Ki for wild-type HIV1 RT p66/p66 homodimer	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID440078	Antiviral activity against HIV1 HXB2 harboring 106A mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
AID1407647	Therapeutic index, ratio of CC50 for human CEM-GFP cells to IC50 for HIV-1 NL4-3 infected in human CEM-GFP cells	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Design, synthesis, docking studies and biological screening of 2-thiazolyl substituted -2,3-dihydro-1H-naphtho[1,2-e][1,3]oxazines as potent HIV-1 reverse transcriptase inhibitors.
AID663309	Inhibition of HIV1 recombinant reverse transcriptase V106A mutant assessed as [3H]dTTP incorporation into poly(rA)/oligo(dT)	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.
AID1335218	Antiviral activity against wild-type HIV-1 NL4-3 harboring vesicular stomatitis virus glycoprotein infected in HEK293T cells pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene assay	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID279445	Antiviral activity against HIV1 isolate with RT 101E, 103N mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1185997	Antiviral activity against HIV1 harboring reverse transcriptase L1001/K103N double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay r	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
AID1376906	Antiviral activity against VSV-G pseudotyped HIV1 infected in human SupT1 cells after 48 hrs by firefly luciferase reporter gene assay	2017	Journal of natural products, 06-23, Volume: 80, Issue:6	Stachybotrysins A-G, Phenylspirodrimane Derivatives from the Fungus Stachybotrys chartarum.
AID1335206	Ratio of IC50 for HIV-1 NL4-3 harboring RT-Y181C mutant infected in HEK293T cells co-expressing vesicular stomatitis virus glycoprotein to IC50 for wild-type HIV-1 NL4-3 infected in HEK293T cells co-expressing vesicular stomatitis virus glycoprotein	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID1435506	Antiviral activity against HIV1 expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
AID508638	Antiviral activity against Human immunodeficiency virus 1 subtype F1 infected in human MT4 cells assessed as reduction in virus induced cytopathicity	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID441303	Inhibition of wild type HIV reverse transcriptase in presence of poly(rA) 300 template, (dT) 16 primer	2009	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19	Pyrazole NNRTIs 1: design and initial optimisation of a novel template.
AID1888702	Resistance index, ratio of EC50 for antiviral activity against HIV1 with RT Y188L mutant infected in human MT4 cells to EC50 for antiviral activity against wild type HIV1 infected in human MT4 cells
AID279512	Antiviral activity against HIV1 isolate with RT V106I, Y181C, F227L mutation in Hela-JC-53 cells	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID94443	Potency of second-generation NNRTIs against Mutant HIV-1 K103N	2000	Journal of medicinal chemistry, May-18, Volume: 43, Issue:10	Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID279420	Antiviral activity against HIV1 isolate with RT 190S mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1249718	Antiviral activity against HIV1 expressing reverse transcriptase L100I mutant	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue.
AID519885	Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID622054	Ratio of Ki for HIV1 RT p66/p66 homodimer K103N mutant to Ki for wild-type HIV1 RT p66/p66 homodimer	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID1596753	Antiviral activity against HIV-1 3B harboring reverse transcriptase RES056 mutant infected in MT4 cells measured after 5 days by MTT assay	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Synthesis and biological evaluation of dihydroquinazoline-2-amines as potent non-nucleoside reverse transcriptase inhibitors of wild-type and mutant HIV-1 strains.
AID586471	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase E138A/Q148R mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficie	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID1483278	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
AID1410484	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild-type HIV1 3B reverse transcriptase infected in human MT4 cells	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery.
AID1574389	Resistance index, ratio of ID50 for recombinant HIV-1 His-tagged reverse transcriptase p66/p51 Y181I mutant to ID50 for recombinant wild type HIV-1 reverse transcriptase His-tagged p66/p51	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.
AID1741400	Inhibition of recombinant HIV-1 reverse transcriptase p66/p51 incubated for 40 mins by picogreen dye based fluorescence assay	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID490371	Antiviral activity against HIV1 expressing reverse transcriptase G190A mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect	2010	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14	Discovery of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-benzyl derivatives with broad potency against resistant mutant viruses.
AID508627	Antiviral activity against Human immunodeficiency virus 1 subtype F isolate 93BR019 infected in human PBMC cells by cell based assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1741393	Inhibition of reverse transcriptase L100I mutant in HIV-1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID1761017	Antiviral activity against HIV-1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect measured after 5 days by MTT assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Design, synthesis, and evaluation of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase.
AID779525	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV-1 3B infected in human MT4 cells	2013	Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21	Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.
AID83551	Potency evaluated against NNRTI-Resistant HIV-1 strain Tyr181Cys	2004	Journal of medicinal chemistry, May-06, Volume: 47, Issue:10	Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 varian
AID1535526	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for wild type HIV1 3B infected in human MT4 cells	2019	Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3	Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs.
AID106057	Inhibitory activity against 103N strain and 181C strain of HIV-I in MT-4 cells	2001	Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17	Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.
AID347613	Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 103N mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.
AID430056	Cytotoxicity against human MT4 cells after 5 days	2009	Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16	Design, synthesis, and structure-activity relationships of 1,3-dihydrobenzimidazol-2-one analogues as anti-HIV agents.
AID198399	Tested for inhibitory concentration against HIV-1 non-nucleoside reverse transcriptase	2001	Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2	3,3a-Dihydropyrano[4,3,2-de]quinazolin-2(1H)-ones are potent non-nucleoside reverse transcriptase inhibitors.
AID1822276	Antiviral activity against HIV-1 harboring RT L100I mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity incubated for 5 days by MTT assay	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.
AID1705191	Resistance index, ratio of EC50 for antiviral activity against HIV1 harboring RT Y181C mutant infected in human MT4 cells to EC50 for antiviral activity against HIV1 NL4-3 infected in human MT4 cells	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains.
AID266345	Inhibition of wild type HIV1 reverse transcriptase in 293T cells	2006	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11	New HIV-1 reverse transcriptase inhibitors based on a tricyclic benzothiophene scaffold: synthesis, resolution, and inhibitory activity.
AID1443662	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	2017	Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8	Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors.
AID1171590	Resistance index, ratio of EC50 for HIV1 NL4-3 expressing reverse transcriptase Y188L mutant to EC50 for wild type HIV1 NL4-3	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID347609	Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 190S mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.
AID650544	Antiviral activity against HIV 1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
AID1761016	Antiviral activity against HIV-1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect measured after 5 days by MTT assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Design, synthesis, and evaluation of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1407642	Inhibition of recombinant HIV-1 reverse transcriptase RNA-dependent DNA polymerase activity using poly(rA)/oligo(dT)16 as template/primer preincubated for 5 to 10 mins followed by template/primer addition and measured after 16 hrs by colorimetric assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Design, synthesis, docking studies and biological screening of 2-thiazolyl substituted -2,3-dihydro-1H-naphtho[1,2-e][1,3]oxazines as potent HIV-1 reverse transcriptase inhibitors.
AID586476	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase G140S/Q148H mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficie	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID1373160	Inhibition of reverse transcriptase Y188L mutant in HIV1 infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3	Structural optimization of N
AID584241	Ratio of EC50 for wild type HIV1 NL4-3 to EC50 for HIV1 NL4-3 harboring reverse transcriptase V179V/D mutant	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID299031	Antiviral activity against HIV1 with reverse transcriptase Y188H mutation in CEM cells assessed as inhibition of virus-induced giant cell formation	2007	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7	Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains.
AID1157585	Antiviral activity against zidovudine-resistant HIV1 harboring RT 67N, 70R, 215F, 219Q mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID279484	Antiviral activity against HIV1 isolate with RT K103N-P225H mutation	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID757623	Cytotoxicity against human MT4 cells after 5 days by MTT assay	2013	European journal of medicinal chemistry, Jul, Volume: 65	Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1186327	Cytotoxicity against mock-infected human MT4 cells after 96 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents.
AID1060630	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs.
AID232055	Selectivity index (Ratio of CC50/EC50).	2004	Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15	Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations.
AID198912	Inhibition of HIV-1 Mutant HIV-1 RT enzymes containing the single amino acid substitution L1001	2001	Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3	Quinoxalinylethylpyridylthioureas (QXPTs) as potent non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors. Further SAR studies and identification of a novel orally bioavailable hydrazine-based antiviral agent.
AID586902	Activity at MRP2	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Interaction potential of etravirine with drug transporters assessed in vitro.
AID105905	Effective dose required to achieve protection of MT-4 cells from Y181C HIV-1 induced cytopathogenicity	2004	Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4	Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C varia
AID347621	Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 181C mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.
AID1171580	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 NL4-3 infected in human MT4 cells	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1155818	Fold resistance, ratio of ID50 for HIV-1 recombinant NNTRI-resistant reverse transcriptase Y181I mutant to ID50 for wild type HIV-1 recombinant reverse transcriptase	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.
AID572185	Antiviral activity against HIV-1 SM030 harboring NNTRI 100I mutant infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID1503177	Cytotoxicity against human SupT1 cells assessed as decrease in cell viability after 48 hrs by CCK-8 assay	2017	Journal of natural products, 10-27, Volume: 80, Issue:10	Metabolites from the Plant Endophytic Fungus Aspergillus sp. CPCC 400735 and Their Anti-HIV Activities.
AID267645	Antiviral activity against wild type HIV1 virus	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1.
AID293555	Antiviral activity against wild type HIV1 LAI infected in MT4 cells by EGFP based replication assay	2007	European journal of medicinal chemistry, May, Volume: 42, Issue:5	Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains.
AID1741394	Inhibition of reverse transcriptase K103N mutant in HIV-1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID293562	Antiviral activity against HIV1 LAI with RT F227C mutation in MT4 cells by EGFP based replication assay	2007	European journal of medicinal chemistry, May, Volume: 42, Issue:5	Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains.
AID248881	Inhibitory concentration against human immunodeficiency virus type 1 (with V106A/Y181C resistant mutation) was determined in HeLa-CD4 MAGI assay	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
AID685333	Cytotoxicity against mock-infected human MT4 cells by MTT assay	2012	Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 10: design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors.
AID1059142	Inhibition of recombinant HIV1 reverse transcriptase using poly rA:dT as template/primer after 1 hr by ELISA	2013	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24	Novel piperidinylamino-diarylpyrimidine derivatives with dual structural conformations as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1705195	Inhibition of RNA-dependent DNA polymerase activity of recombinant HIV-1 p66/p51 reverse transcriptase K103N mutant assessed as inhibition of [3H]dTTP incorporation using poly(rA)/oligo(dT) as templates incubated for 15 mins by MicroBeta scintillation cou	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains.
AID1637398	Antiviral activity against human HIV-1 3B harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as protection from virus-induced cytopathic effect measured 5 days post infection by MTT assay	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.
AID1057037	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild-type HIV1 3B infected in MT4 cells	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Design, synthesis and biological evaluation of 3-benzyloxy-linked pyrimidinylphenylamine derivatives as potent HIV-1 NNRTIs.
AID226250	Y181C/WTIIIB ratio of the compound	2001	Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16	Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID1574384	Inhibition of recombinant wild type HIV-1 His-tagged reverse transcriptase p66/p51 expressed in Escherichia coli assessed as reduction in [3H]dTTP incorporation using poly(rA)/oligo(dT) as template/primer after 20 mins by scintillation counting analysis	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.
AID246350	Effective concentration against human immunodeficiency virus type 1 mutated at 181C	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.
AID94313	Antiviral activity toward K103N mutant HIV-1 virus as protein binding adjusted (PB adj).	2000	Journal of medicinal chemistry, May-18, Volume: 43, Issue:10	Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID313191	Antiviral activity against HIV1 HTLV-3B	2008	Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1	Synthesis and antiviral activity of new dimeric inhibitors against HIV-1.
AID576050	Effect on P-gp activity in PBMCs isolated from healthy human receiving compound dose at 400 mg, po qd for 14 days by rhodamine -123 efflux assay	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.
AID1773444	Selectivity ratio of CC50 for human MT4 cells to IC50 for HIV1 RES056 infected in MT4 cells
AID527563	Antiviral activity against HIV1 NL4-3 containing reverse transcriptase Y181C mutation infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Discovery and SAR of a series of 4,6-diamino-1,3,5-triazin-2-ol as novel non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1335207	Ratio of IC50 for HIV-1 NL4-3 harboring RT-K103N mutant infected in HEK293T cells co-expressing vesicular stomatitis virus glycoprotein to IC50 for wild-type HIV-1 NL4-3 infected in HEK293T cells co-expressing vesicular stomatitis virus glycoprotein	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID1754646	Antiviral activity against HIV1 harboring RT F227L/V106A mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses.
AID440075	Antiviral activity against HIV1 HXB2 harboring Y188L mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
AID1705187	Antiviral activity against HIV1 harboring RT Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect by MTT assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains.
AID586470	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase F121Y/T125K mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficie	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID541129	Selectivity ratio of EC50 for antiviral activity against NRTI-resistant HIV1 harboring RTK65R mutant gene to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1292009	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as cell viability after 4 days by MTT assay	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket.
AID1880376	Antiviral activity against HIV-1 IIIB harboring reverse transcriptase L1001 mutant infected in human MT4 cells by MTT assay	2022	Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12	Structure-Based Discovery of Novel NH
AID1304399	Inhibition of HIV-1 BH10 recombinant reverse transcriptase expressed in Escherichia coli assessed as incorporation of [32P]GTP into poly(rC)/oligo(dG) as template primer	2016	Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13	Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
AID779526	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	2013	Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21	Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.
AID622056	Ratio of Ki for HIV1 RT p66/p66 homodimer Y188L mutant to Ki for wild-type HIV1 RT p66/p66 homodimer	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID1880377	Antiviral activity against HIV-1 IIIB harboring reverse transcriptase K103N mutant infected in human MT4 cells by MTT assay	2022	Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12	Structure-Based Discovery of Novel NH
AID371907	Antiviral activity against HIV1 NL4-3 with Y181L mutant in human TZM-b1 cells assessed as beta-galactosidase activity after 48 hrs by single round replication assay	2009	Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12	New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID448400	Fold resistance, ratio of IC50 for HIV reverse transcriptase with V106A mutant to IC50 for HIV wild type reverse transcriptase	2009	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19	Pyrazole NNRTIs 3: optimisation of physicochemical properties.
AID1261341	Antiviral activity against VSV	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID1352320	Antiviral activity against HIV1 harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 4 days by MTT assay	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.
AID371908	Antiviral activity against HIV1 NL4-3 with V108I mutant in human TZM-b1 cells assessed as beta-galactosidase activity after 48 hrs by single round replication assay	2009	Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12	New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID518738	Inhibition of DNA-dependent DNA polymerase activity of HIV1 subtype B reverse transcriptase M230L mutant by gel-based primer extension assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity.
AID1572521	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells
AID1248224	Selectivity index, ratio of CC50 for uninfected human MT4 cells to EC50 for wild type HIV 1 3B infected in human MT4 cells	2015	Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20	A novel family of diarylpyrimidines (DAPYs) featuring a diatomic linker: Design, synthesis and anti-HIV activities.
AID1298248	Inhibition of HIV1 reverse transcriptase p66/p51 L100I mutant using poly(rA) template and measured after 40 mins by picogreen based spectrofluorometry	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.
AID1264542	Aqueous solubility of compound	2015	ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10	Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine Resistance.
AID1304404	Selectivity index, ratio of CC50 for cytotoxicity against mock-infected human CEM-SS cells to EC50 for antiviral activity against HIV-1 RF	2016	Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13	Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
AID248878	Inhibitory concentration against human immunodeficiency virus type 1 (with K103N/G190A resistant mutation) was determined in HeLa-CD4 MAGI assay	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
AID1155817	Fold resistance, ratio of ID50 for HIV-1 recombinant NNTRI-resistant reverse transcriptase K103N mutant to ID50 for wild type HIV-1 recombinant reverse transcriptase	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.
AID717260	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs.
AID1410486	Inhibition of wild-type HIV1 reverse transcriptase infected in human MT4 cells assessed as reduction in biotin-dUTP incorporation	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery.
AID605175	Antiviral activity against HIV1 R8 harboring wild type reverse transcriptase infected in human MT4 cells assessed as inhibition of viral spread in presence of 10% fetal bovine serum	2010	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 20, Issue:15	Biaryl ethers as potent allosteric inhibitors of reverse transcriptase and its key mutant viruses: aryl substituted pyrazole as a surrogate for the pyrazolopyridine motif.
AID642208	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	2011	Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23	Quinoline tricyclic derivatives. Design, synthesis and evaluation of the antiviral activity of three new classes of RNA-dependent RNA polymerase inhibitors.
AID1186004	Antiviral activity against HIV1 harboring reverse transcriptase K103N/V108I double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
AID361916	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V108I mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1583019	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3	Discovery and Characterization of Fluorine-Substituted Diarylpyrimidine Derivatives as Novel HIV-1 NNRTIs with Highly Improved Resistance Profiles and Low Activity for the hERG Ion Channel.
AID1653631	Activation of recombinant human C-terminal 4His-tagged CYP46A1 delta(2 to 50) K358L mutant expressed in Escherichia coli at 20 uM using cholesterol as substrate measured after 30 mins in presence of cytochrome P450 oxidoreductase by gas chromatography-mas	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds.
AID246352	Effective concentration against human immunodeficiency virus type 1 mutated at 227C	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.
AID457960	Inhibition of HIV1 reverse transcriptase Y181I mutant by RNA-dependent DNA polymerase activity assay	2010	Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4	Novel 1,3-dihydro-benzimidazol-2-ones and their analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID248493	In vitro inhibitory concentration value against HIV K103N and Y181C mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
AID632800	Antiviral activity against Human immunodeficiency virus 1 NL4.3 reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of viral infection	2011	Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24	Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.
AID518735	Inhibition of RNA-dependent DNA polymerase activity of HIV1 subtype B reverse transcriptase M230L mutant by filter-based filtration assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity.
AID1357799	Resistance factor, ratio of EC50 for HIV1 harboring reverse transcriptase F227L/V106A mutant to EC50 for wild-type HIV-1 3B	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID496634	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase V90I,A98G/V35T, E36D, T39K, S48A, I50V, V60I, S68G, I135V, S162A, K173T, Q174K, D177E, G196E, T200A, E203G, Q207D, R211K, Q222P mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID1171581	Antiviral activity against HIV1 3B infected in human CEM cells assessed as protection against virus-induced cytopathicity by giant cell formation assay	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID293179	Antiviral activity against HIV1 RT 100I/103N mutant assessed as inhibition of viral-induced cytopathicity in MT4 cells by MTT method	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Structure-activity relationship in the 3-iodo-4-phenoxypyridinone (IOPY) series: The nature of the C-3 substituent on anti-HIV activity.
AID198230	Inhibitory activity against wild-type HIV-1 reverse transcriptase	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	Identification of a putative binding site for [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase.
AID541155	Selectivity ratio of EC50 for antiviral activity against APV-resistant HIV1 selected after 4 passages to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID440664	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	2009	European journal of medicinal chemistry, Dec, Volume: 44, Issue:12	Activity and molecular modeling of a new small molecule active against NNRTI-resistant HIV-1 mutants.
AID492283	Antiviral activity against HIV1 with reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
AID347620	Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 188H mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.
AID446258	Fold resistance, ratio of IC50 for HIV reverse transcriptase with P236L mutant to IC50 for HIV wild type reverse transcriptase	2009	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20	Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
AID88384	Antiviral activity against wild-type HIV-1 in the HeLa MAGI assay.	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1357783	Antiviral activity against wild-type HIV-1 3B infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID1161103	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	Arylazolyl(azinyl)thioacetanilides. Part 16: Structure-based bioisosterism design, synthesis and biological evaluation of novel pyrimidinylthioacetanilides as potent HIV-1 inhibitors.
AID584238	Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase K103N, V108V/I mutant derived from 10 days viral passages with lersivirine infected in human SupT1 cells assessed as inhibition of viral replication after 21 days relative to wild type	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID279416	Antiviral activity against HIV1 isolate with RT 179A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1552578	Selectivity ratio of IC50 for HIV1 V13-03413B infected in human LC5 cells to IC50 for HIV1 LAI infected in human LC5 cells	2019	Bioorganic & medicinal chemistry, 08-15, Volume: 27, Issue:16	Biological evaluation of molecules of the azaBINOL class as antiviral agents: Inhibition of HIV-1 RNase H activity by 7-isopropoxy-8-(naphth-1-yl)quinoline.
AID441312	Fold resistance, ratio of IC50 for HIV reverse transcriptase with V106A mutant to IC50 for HIV wild type reverse transcriptase	2009	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19	Pyrazole NNRTIs 1: design and initial optimisation of a novel template.
AID279501	Antiviral activity against HIV1 isolate with RT Y181C mutation	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1077218	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV-1 3B infected in human MT4 cells	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach.
AID1503176	Antiviral activity against VSV-G pseudotyped HIV1 infected in human SupT1 cells after 48 hrs by luciferase reporter gene assay	2017	Journal of natural products, 10-27, Volume: 80, Issue:10	Metabolites from the Plant Endophytic Fungus Aspergillus sp. CPCC 400735 and Their Anti-HIV Activities.
AID248844	Inhibitory concentration against human immunodeficiency virus type 1 (with V108I resistant mutation) was determined in HeLa-CD4 MAGI assay	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
AID583849	Inhibition of HIV1 reverse transcriptase activity by primer extension assay	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1231489	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anti-HIV diarylpyrimidine-quinolone hybrids and their mode of action.
AID1435518	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 RES056 expressing reverse transcriptase mutant
AID572188	Antiviral activity against HIV-1 SM052 harboring NNTRI 101E and 103N mutant infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID1773440	Antiviral activity against HIV1 RES056 infected in human MT4 cells assessed as reduction in virus-induced cytopathogenic effect by MTT assay
AID302265	Inhibition of HIV1 reverse transcriptase Y188L mutant	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID1754643	Antiviral activity against HIV1 harboring RT Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses.
AID522372	Antiviral activity against recombinant HIV1 harboring reverse transcriptase V106A/V179D mutant clone infected in MAGIC-5 cells using 5-bromo4-chloro-3-indolyl-beta-D-galactopyranoside staining based light microscopy	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
AID1731750	Inhibition of reverse transcriptase E138K mutant in HIV-1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay
AID1191670	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells	2015	Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5	Scaffold hopping: exploration of acetanilide-containing uracil analogues as potential NNRTIs.
AID586908	Induction of MRP1 activity	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Interaction potential of etravirine with drug transporters assessed in vitro.
AID519887	Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID1335202	Ratio of IC50 for HIV-1 NL4-3 harboring RT-K103N/G190A double mutant infected in HEK293T cells co-expressing vesicular stomatitis virus glycoprotein to IC50 for wild-type HIV-1 NL4-3 infected in HEK293T cells co-expressing vesicular stomatitis virus glyco	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID1326647	Inhibition of reverse transcriptase Y181C mutant in HIV-1 3B infected in human MT4 cells assessed as inhibition of viral replication after 5 days by cell titer glo based luciferase reporter gene assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Novel (2,6-difluorophenyl)(2-(phenylamino)pyrimidin-4-yl)methanones with restricted conformation as potent non-nucleoside reverse transcriptase inhibitors against HIV-1.
AID1275543	Antiviral activity against HIV1 RES056 expressing reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
AID1888701	Resistance index, ratio of EC50 for antiviral activity against HIV1 with RT Y181C mutant infected in human MT4 cells to EC50 for antiviral activity against wild type HIV1 infected in human MT4 cells
AID82468	Antiviral activity against V106A strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1391088	Inhibition of HIV1 reverse transcriptase K103N/Y181C double mutant using poly (A)/oligo (dT)15 as template/primer assessed as decrease in biotin-dUTP incorporation after 1 hr by ELISA	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	The discovery of novel diarylpyri(mi)dine derivatives with high level activity against a wide variety of HIV-1 strains as well as against HIV-2.
AID557067	Plasma protein binding in HIV1 infected patient	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1594858	Half life in human serum at 600 mg, qd	2019	Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10	The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.
AID248260	In vitro inhibitory concentration against HIV K103N mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
AID736439	Inhibition of HIV1 reverse transcriptase p66/p51 L100I mutant after 30 mins by liquid scintillation counting	2013	Bioorganic & medicinal chemistry, Mar-01, Volume: 21, Issue:5	N1,N3-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
AID397178	Ratio of EC50 for HIV1 3B expressing reverse transcriptase Y181C mutant to EC50 for HIV1 3B	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Parallel synthesis, molecular modelling and further structure-activity relationship studies of new acylthiocarbamates as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1572527	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytotoxicity after 5 days by MTT assay
AID665550	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV1 3B	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors.
AID586468	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase T97A/N155H mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficien	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID361908	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID105906	Effective dose required to achieve protection of MT-4 cells from wild type IIIB HIV-1 induced cytopathogenicity	2004	Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4	Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C varia
AID541173	Selectivity ratio of EC50 for antiviral activity against HIV1 harboring E138K and Q148K mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID583842	Ratio of IC50 for HIV1 reverse transcriptase Y181I, Y188L mutant to IC50 for wild type HIV1 reverse transcriptase	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID496628	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase E138A/K20R, V35T, E36A, T39D, V60I, I135V, T139I, K173A, Q174K, T200E, Q207A, R211K, F214L mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID508828	Antiviral activity against Human immunodeficiency virus 1 subtype A isolate 92RW020 infected in human PBMC cells by cell based assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1520058	Antiviral activity against HIV1 3B harbouring NNRTI K103N mutant infected in human MT4 cells assessed as virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID1357788	Antiviral activity against HIV1 harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID371910	Antiviral activity against HIV1 NL4-3 with K103N mutant in human TZM-b1 cells assessed as beta-galactosidase activity after 48 hrs by single round replication assay	2009	Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12	New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID779527	Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	2013	Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21	Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.
AID523352	Antiviral activity against HIV1 with RT connection domain K103N/T369I/N348I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID1763899	Antiviral activity against HIV-1 IIIB harboring RT K103N mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity incubated for 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 06-15, Volume: 40	Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs.
AID1185994	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
AID246786	Concentration required to reduce the amount of p24 by 90% in C8166 cells infected with an efavirenz-resistant strain EFVR	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.
AID1572524	Antiviral activity against HIV1 harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as inhibition of virus-induced cytotoxicity after 5 days by MTT assay
AID492285	Antiviral activity against HIV1 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
AID299024	Cytotoxicity against MT4 cells assessed as reduction of cell viability	2007	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7	Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains.
AID199102	Inhibitory concentration against wild-type reverse transcriptase of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1636927	Antiviral activity against HIV1 3B infected in human MT2 cells assessed as protection against viral infection by MTT method	2016	Bioorganic & medicinal chemistry, 10-15, Volume: 24, Issue:20	Computer-aided discovery of anti-HIV agents.
AID1446817	Antiviral activity against HIV1 harboring Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured at 5 days post infection by MTT assay	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.
AID298088	Inhibition of HIV1 RT K103N mutant	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity.
AID1565100	Antiviral activity against drug resistant HIV-1 harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay
AID279514	Antiviral activity against HIV1 isolate with RT V106I, D123G, Y181C, F227L mutation in Hela-JC-53 cells	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID586906	Inhibition of BCRP activity	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Interaction potential of etravirine with drug transporters assessed in vitro.
AID1212886	Drug metabolism in microsomes expressing CYP2B6.6 (unknown origin) assessed as intrinsic clearance for enzyme-mediated 8-hydroxyefavirenz metabolite formation measured per pmol of P450 after 15 mins by HPLC/UV system in presence of Cyt b5 coexpression	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
AID1884541	Fold resistance, ratio of EC50 for antiviral activity against drug-resistant HIV-1 Y188L mutant infected in human MT4 cells to EC50 for antiviral activity against NNRTI resistant wild type HIV-1 infected in human MT4 cells	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.
AID1882469	Antiviral activity against HIV-1 harboring Y181C mutant infected in human MT2 cells assessed as protection against virus-induced cytopathicity by MTT assay	2022	Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5	Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.
AID279492	Antiviral activity against HIV1 isolate with RT K103N-F227L mutation	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID766432	Antiviral activity against HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity by MTT assay	2013	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18	Extension into the entrance channel of HIV-1 reverse transcriptase--crystallography and enhanced solubility.
AID576043	Drug concentration in PBMCs of healthy human at 400 mg, po measured after 24 hrs on day 1 post dose by liquid chromatography-tandem mass spectrometry	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID443687	Antiviral activity against HIV with reverse transcriptase K103N/P225H double mutant assessed as inhibition of viral replication	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
AID443693	Antiviral activity against HIV with reverse transcriptase CNDO mutant assessed as inhibition of viral replication relative to wild type	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
AID698305	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1373156	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B expressing wild type reverse transcriptase	2018	Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3	Structural optimization of N
AID663310	Inhibition of HIV1 recombinant reverse transcriptase Y188L mutant assessed as [3H]dTTP incorporation into poly(rA)/oligo(dT)	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.
AID267863	Inhibition of HIV1 reverse transcriptase Y181I mutant	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Synthesis and biological investigation of S-aryl-S-DABO derivatives as HIV-1 inhibitors.
AID416431	Antiviral activity against HIV1 bearing VSV envelope infected in human HeLa CD4 cells coexpressing LTR/beta-Gal gene assessed as reduction in virus-induced beta-galactosidase reporter gene activity after 72 hrs by single-cycle infection assay	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Identification and characterization of UK-201844, a novel inhibitor that interferes with human immunodeficiency virus type 1 gp160 processing.
AID573252	AUC (0 to t) in HIV-1 infected children at 10 to 15 mg/kg, po administered once daily by HPLC	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children?
AID360705	Inhibition of HIV1 RT mediated DNA-dependent DNA synthesis initiation using RNA PPT primed substrate by scintillation proximity assay	2007	The Journal of biological chemistry, Mar-16, Volume: 282, Issue:11	HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro.
AID269795	Antiviral activity against HIV1 E138K mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269795	Antiviral activity against HIV1 E138K mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269795	Antiviral activity against HIV1 E138K mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID623217	Cytotoxicity against human MT4 cells after 4 days by MTT assay	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID1348215	Antiviral activity against HIV1 NL4-3 infected in human MT2 cells measured after 72 hrs post infection by fluorAce beta-galactosidase reporter gene assay	2017	Journal of natural products, 12-22, Volume: 80, Issue:12	Oxazole-Containing Diterpenoids from Cell Cultures of Salvia miltiorrhiza and Their Anti-HIV-1 Activities.
AID1198748	Inhibition of HIV1 reverse transcriptase-associated DNA polymerase-independent RNase H activity after 1 hr	2015	European journal of medicinal chemistry, Mar-26, Volume: 93	(3Z)-3-(2-[4-(aryl)-1,3-thiazol-2-yl]hydrazin-1-ylidene)-2,3-dihydro-1H-indol-2-one derivatives as dual inhibitors of HIV-1 reverse transcriptase.
AID508657	Antiviral activity against Human immunodeficiency virus 1 subtype O isolate BCF02 infected in human PBMC cells by cell based assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1357786	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild-type HIV1 3B	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID573255	Apparent oral clearance in HIV-1 infected children at 13.3 mg/kg, po administered once daily by HPLC	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children?
AID738331	Cytotoxicity against mock-infected human MT4 cells assessed as cell viability after 5 days by MTT assay	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs.
AID523480	Antiviral activity against HIV1 with RT connection domain G190S/N348I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID416756	Antiviral activity against HIV1 with reverse transcriptase K103N mutation in human CEM cells assessed as protection against virus-induced cytopathicity	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID476470	Antiviral activity against HIV1 reverse transcriptase Y181C mutant infected in human MT2 cells assessed as inhibition of viral replication by MTT assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives.
AID1811036	Anti-viral activity against HIV1 harboring RT Y181C mutant infected MV4 cells assessed as protection against virus-induced cytopathic effect by MTT assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.
AID246348	Effective concentration against human immunodeficiency virus type 1 mutated at 100I	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.
AID267858	Antiviral activity against HIV1 Y188L mutant in MT4 cells by MTT assay	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Synthesis and biological investigation of S-aryl-S-DABO derivatives as HIV-1 inhibitors.
AID279406	Antiviral activity against HIV1 isolate with RT 103N, 238T mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1275544	Antiviral activity against HIV1 3B expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
AID572175	Antiviral activity against HIV-1 subtype F V029522 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID96293	Potency of second-generation NNRTIs against Mutant HIV-1 sL100I	2000	Journal of medicinal chemistry, May-18, Volume: 43, Issue:10	Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID248843	Inhibitory concentration against human immunodeficiency virus type 1 (with V106A resistant mutation) was determined in HeLa-CD4 MAGI assay	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
AID523351	Antiviral activity against HIV1 with RT connection domain K103N/T369I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID605182	Antiviral activity against HIV1 R8 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of viral spread in presence of 10% fetal bovine serum	2010	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 20, Issue:15	Biaryl ethers as potent allosteric inhibitors of reverse transcriptase and its key mutant viruses: aryl substituted pyrazole as a surrogate for the pyrazolopyridine motif.
AID1157597	Antiviral activity against HIV1 MP582 infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID279396	Antiviral activity against HIV1 isolate with RT 103N, 225H mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1152372	Antiviral activity against HIV1 RES056 harboring RT K103N,Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay	2014	Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12	Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1882470	Antiviral activity against HIV-1 harboring K103N/Y181C mutant infected in human MT2 cells assessed as protection against virus-induced cytopathicity by MTT assay	2022	Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5	Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.
AID1352169	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 3 to 4 days by MTT assay	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Quinoxaline derivatives as new inhibitors of coxsackievirus B5.
AID1743628	Antiviral activity against HIV1 harboring RT Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.
AID1185990	Antiviral activity against wild type HIV1 infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
AID573476	Antiviral activity of wild-type Human immunodeficiency virus 1 isolate 5512 by cell based assay	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
AID293177	Antiviral activity against HIV1 RT 188L mutant assessed as inhibition of viral-induced cytopathicity in MT4 cells by MTT method	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Structure-activity relationship in the 3-iodo-4-phenoxypyridinone (IOPY) series: The nature of the C-3 substituent on anti-HIV activity.
AID361907	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y181C mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1286669	Antiviral activity against HIV1 BH10 harboring wild type reverse transcriptase infected in primary MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS assay	2016	Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5	Discovery of the Aryl-phospho-indole IDX899, a Highly Potent Anti-HIV Non-nucleoside Reverse Transcriptase Inhibitor.
AID279415	Antiviral activity against HIV1 isolate with RT 101E, 181C, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1767120	Antiviral activity against HIV1 NL4-3 VSV-G pseudotyped virus infected in human SUP-T1 cells assessed as inhibition of early stage viral production at 10 uM measured after 48 hrs by luciferase assay relative to control	2021	European journal of medicinal chemistry, Aug-05, Volume: 220	Design and biological evaluation of cinnamic and phenylpropionic amide derivatives as novel dual inhibitors of HIV-1 protease and reverse transcriptase.
AID586364	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase E92V mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficiency vir	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID619641	Ratio of EC50 for HIV-1 3B harboring RT K103N mutant infected in human MT4 cells to EC50 for wild type HIV-1 3B infected in human MT4 cells	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
AID1483274	Inhibition of HIV1 3B reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
AID246556	Concentration required for 50% protection of infected MT-4 cells from wtIIIB-HIV-1-induced cytopathogenicity was determined by the MTT method	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.
AID586907	Induction of ABCB1 activity	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Interaction potential of etravirine with drug transporters assessed in vitro.
AID508778	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase V179E mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1357791	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID517499	Antiviral activity against HIV1 harboring reverse transcriptase K103N/L100I double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS	2010	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 20, Issue:20	Exploration of piperidine-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Phenyl derivatives with broad potency against resistant mutant viruses.
AID313192	Antiviral activity against efavirenz-resistant HIV1	2008	Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1	Synthesis and antiviral activity of new dimeric inhibitors against HIV-1.
AID519966	Antiviral activity against 0.005 MOI HIV1 NL4-3 harboring wild type RT infected in human MT2 cells by phenosense assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID726439	Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method	2013	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4	Optimization of benzyloxazoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase to enhance Y181C potency.
AID370729	Inhibition of RNA dependent DNA polymerase activity of HIV1 recombinant reverse transcriptase p66/p51 V179D mutant expressed in Escherichia coli JM109	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations.
AID443697	Antiviral activity against HIV with reverse transcriptase Y188L mutant assessed as inhibition of viral replication relative to wild type	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
AID1705196	Inhibition of RNA-dependent DNA polymerase activity of recombinant HIV-1 p66/p51 reverse transcriptase Y188L mutant assessed as inhibition of [3H]dTTP incorporation using poly(rA)/oligo(dT) as templates incubated for 15 mins by MicroBeta scintillation cou	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains.
AID1326645	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV-1 3B reverse transcriptase infected in human MT4 cells	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Novel (2,6-difluorophenyl)(2-(phenylamino)pyrimidin-4-yl)methanones with restricted conformation as potent non-nucleoside reverse transcriptase inhibitors against HIV-1.
AID1822274	Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.
AID592539	Selectivity index, CC50 for human CEM cells to IC50 for HIV1 3B	2011	Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6	Indolylarylsulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: new cyclic substituents at indole-2-carboxamide.
AID1888690	Antiviral activity against HIV1 3B infected in human MT4 cells cells assessed as protection against viral-induced cytopathogenecity by MTT assay
AID1637400	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for human HIV-1 3B harboring K103N mutant infected in human MT4 cells	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.
AID649490	Inhibition of ribonuclease H activity of Human immunodeficiency virus 1 reverse transcriptase Tyr181Cys mutant	2012	European journal of medicinal chemistry, Apr, Volume: 50	Identification of HIV-1 reverse transcriptase dual inhibitors by a combined shape-, 2D-fingerprint- and pharmacophore-based virtual screening approach.
AID1705184	Cytotoxicity against human MT-4 cells assessed as reduction in cell viability by MTT assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains.
AID269805	Antiviral activity against HIV1 Y181S mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269805	Antiviral activity against HIV1 Y181S mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269805	Antiviral activity against HIV1 Y181S mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1435507	Antiviral activity against HIV1 expressing reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
AID648420	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	2012	European journal of medicinal chemistry, May, Volume: 51	Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1249724	Inhibition of HIV1 reverse transcriptase p66/p51 assessed as inhibition of biotin-dUTP incorporation using poly (rA)/oligo(dT)16 as template/primer incubated for 40 mins	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue.
AID522371	Antiviral activity against recombinant HIV1 harboring reverse transcriptase V179D mutant clone infected in MAGIC-5 cells using 5-bromo4-chloro-3-indolyl-beta-D-galactopyranoside staining based light microscopy	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
AID1212901	Drug metabolism in human liver microsomes harboring CYP2B66/6 genotype assessed as intrinsic clearance for CYP2B6 variant-mediated 8-hydroxyefavirenz metabolite formation measured per mg protein after 15 mins by LC/MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
AID1155806	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV-1 NL4-3 infected in human MT4 cells	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.
AID257163	Inhibition of wild type HIV1 reverse transcriptase by [3H]dTTP poly(rA)/oligo(dT) incorporation	2005	Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25	Parallel solution-phase and microwave-assisted synthesis of new S-DABO derivatives endowed with subnanomolar anti-HIV-1 activity.
AID557051	Antiviral activity against PI-resistant HIV1 harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID583846	Ratio of IC50 for HIV1 reverse transcriptase V106A, F227L mutant to IC50 for wild type HIV1 reverse transcriptase	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID1060632	Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs.
AID1157583	Antiviral activity against N119-sensitive HIV1 harboring Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID1275554	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV2 ROD infected in human MT4 cells	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
AID279483	Antiviral activity against HIV1 isolate with RT K103N-Y181C mutation	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID650689	Inhibition of HIV 1 reverse transcriptase K103N mutant assessed as inhibition of time-dependent incorporation of [3H]dTTP into poly(rA)n.oligo(dT)	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
AID508646	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase Y181C, Y188L mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1691439	Selectivity index, ratio of CC50 for cytotoxicity against human MT4 cells to EC50 for antiviral activity against HIV1 RES056 infected in human MT4 cells	2020	European journal of medicinal chemistry, May-01, Volume: 193	In situ click chemistry-based rapid discovery of novel HIV-1 NNRTIs by exploiting the hydrophobic channel and tolerant regions of NNIBP.
AID279495	Antiviral activity against HIV1 isolate with RT K103N-Y188L mutation	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID663303	Resistance ratio of EC50 for HIV1 harboring reverse transcriptase Y188L mutant to EC50 for wild type HIV1 NL4-3	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.
AID586911	Induction of SLCO1B1 activity	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Interaction potential of etravirine with drug transporters assessed in vitro.
AID440672	Antiviral activity against HIV1 EFV with reverse transcriptase K103R, V179D, P225H mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	2009	European journal of medicinal chemistry, Dec, Volume: 44, Issue:12	Activity and molecular modeling of a new small molecule active against NNRTI-resistant HIV-1 mutants.
AID572172	Antiviral activity against HIV-1 subtype CRF05_DF V022823 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID584240	Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase Y181C, V108V/I, V179V/D mutant derived from 17 days viral passages with lersivirine infected in human SupT1 cells assessed as inhibition of viral replication after 21 days relative to w	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID1373154	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3	Structural optimization of N
AID1882473	Antiviral activity against wild type HIV-1 IIIB infected in human MT4 cells assessed as protection against virus-induced cytopathicity by MTT assay	2022	Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5	Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.
AID446252	Fold resistance, ratio of IC50 for HIV reverse transcriptase with K103N mutant to IC50 for HIV wild type reverse transcriptase	2009	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20	Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
AID1264538	Antiviral activity against HIV-1 X4 expressing wild-type reverse transcriptase infected in human CD4+ T cells for 3 days by FACS analysis	2015	ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10	Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine Resistance.
AID1457068	Antineuroinflammatory activity in C57BL/6 mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production at 1 to 10 uM after 24 hrs by Griess assay	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
AID443696	Antiviral activity against HIV with reverse transcriptase Y181C mutant assessed as inhibition of viral replication relative to wild type	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
AID391223	Inhibition of HIV1 RT polymerase Y181C mutant by SPA	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses.
AID82473	Antiviral activity against V108I/Y181C strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1249721	Antiviral activity against HIV1 expressing reverse transcriptase Y181C mutant	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue.
AID605177	Inhibition of HIV1 reverse transcriptase K103N mutant by SPA assay	2010	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 20, Issue:15	Biaryl ethers as potent allosteric inhibitors of reverse transcriptase and its key mutant viruses: aryl substituted pyrazole as a surrogate for the pyrazolopyridine motif.
AID523348	Antiviral activity against HIV1 with RT connection domain T369I/N348I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID448404	Fold resistance, ratio of IC50 for HIV reverse transcriptase with V108I mutant to IC50 for HIV wild type reverse transcriptase	2009	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19	Pyrazole NNRTIs 3: optimisation of physicochemical properties.
AID508789	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase K103S mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID586368	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase T124A mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficiency vi	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID366525	Resistance index, ratio of EC50 for drug-resistant HIV1 isolate with reverse transcriptase Y188L mutation to EC50 for wild type HIV1 NL4-3	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.
AID1457059	Ratio of EC50 for HIV-1 harboring reverse transcriptase K103N mutant infected in human MT4 cells to EC50 for HIV1 NL4-3 infected in human MT4 cells	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
AID685331	Antiviral activity against HIV-1 3B infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay	2012	Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 10: design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors.
AID1185999	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay relative HIV1	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
AID267654	Selectivity for wild type HIV1 virus over HIV1 K103N/L100I mutant	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1.
AID446253	Fold resistance, ratio of IC50 for HIV reverse transcriptase with Y181C mutant to IC50 for HIV wild type reverse transcriptase	2009	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20	Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
AID586375	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase Q146R mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficiency vi	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID1636928	Cytotoxicity against human MT2 cells assessed as growth inhibition by MTT method	2016	Bioorganic & medicinal chemistry, 10-15, Volume: 24, Issue:20	Computer-aided discovery of anti-HIV agents.
AID586904	Activity at BCRP	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Interaction potential of etravirine with drug transporters assessed in vitro.
AID1888689	Antiviral activity against HIV1 with RT F227L + V106A mutant infected in human MT4 cells cells assessed as protection against viral-induced cytopathogenecity by MTT assay
AID1693800	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 01-15, Volume: 30	Novel indolylarylsulfone derivatives as covalent HIV-1 reverse transcriptase inhibitors specifically targeting the drug-resistant mutant Y181C.
AID1304402	Cytotoxicity against mock-infected human CEM-SS cells	2016	Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13	Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
AID562870	Selectivity ratio of EC50 for HIV1 harboring spacer peptide A1V mutant protein infected in human HeLa cells to EC50 for wild type HIV1 infected in human HeLa cells	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation.
AID663302	Resistance ratio of EC50 for HIV1 harboring reverse transcriptase Y181C mutant to EC50 for wild type HIV1 NL4-3	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.
AID269803	Antiviral activity against HIV1 V179E mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269803	Antiviral activity against HIV1 V179E mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269803	Antiviral activity against HIV1 V179E mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID496621	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase K101E/V35T, E36D, K49R, V60I, K122P, I135R, S162A, E169R, K173T, Q174E,D177E, V189I, T200A, I202V, Q207E, R211K, V245Q mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID663307	Inhibition of HIV1 recombinant reverse transcriptase L100I mutant assessed as [3H]dTTP incorporation into poly(rA)/oligo(dT)	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.
AID298064	Cytotoxicity against human MT4 cells by MTT assay	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability.
AID1485974	Inhibition of HIV-1 reverse transcriptase Y188L mutant assessed as reduction in dTTP incorporation using poly(rA)/oligo(dT)16 as template/primer after 40 mins by PicoGreen dye based spectrofluorometric analysis	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Searching for novel N
AID282739	Inhibition of HIV1 RT Y181I mutant	2005	Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23	Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.
AID1183080	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in proliferation after 96 hrs by MTT method	2014	European journal of medicinal chemistry, Sep-12, Volume: 84	Synthesis and antiviral activity of new phenylimidazopyridines and N-benzylidenequinolinamines derived by molecular simplification of phenylimidazo[4,5-g]quinolines.
AID279487	Antiviral activity against HIV1 isolate with RT K103N-L100I mutation	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1731744	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
AID1897020	Antiviral activity against HIV-1 KP-5mvcR infected in human TZM-bl cells assessed as inhibition of viral entry by measuring reduction in RLU by single round assay	2022	Bioorganic & medicinal chemistry, 12-15, Volume: 76	Hybrids of small CD4 mimics and gp41-related peptides as dual-target HIV entry inhibitors.
AID519872	Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID1487425	Aqueous solubility of the compound in buffer at pH 6.4 after 48 hrs UV spectroscopy based shake flask method	2017	Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16	Discovery of novel dengue virus entry inhibitors via a structure-based approach.
AID1636929	Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT2 cells assessed as protection against viral infection by MTT method	2016	Bioorganic & medicinal chemistry, 10-15, Volume: 24, Issue:20	Computer-aided discovery of anti-HIV agents.
AID1272059	Half life in human administered as multiple doses	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Efavirenz a nonnucleoside reverse transcriptase inhibitor of first-generation: Approaches based on its medicinal chemistry.
AID348908	Ratio of ED50 for drug resistant HIV1 with reverse transcriptase Y181C mutant to wild type HIV1 NL4-3	2008	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 18, Issue:21	Towards novel S-DABOC inhibitors: synthesis, biological investigation, and molecular modeling studies.
AID267644	Inhibition of HIV1 reverse transcriptase	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1.
AID1882474	Antiviral activity against HIV-1 harboring E138K mutant infected in human MT4 cells assessed as protection against virus-induced cytopathicity by MTT assay	2022	Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5	Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.
AID698298	Selectivity index, ratio of EC50 for HIV1 containing reverse transcriptase K103N mutant to EC50 for wild type HIV1 NL4-3	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1693805	Inhibition of recombinant HIV-1 BH10 reverse transcriptase Y181C mutant using D38/[32P]25PGA as template-primer incubated for 60 mins in absence of DTT followed by dTTP addition and measured after 15 to 30 sec by nucleotide incorporation assay	2021	Bioorganic & medicinal chemistry, 01-15, Volume: 30	Novel indolylarylsulfone derivatives as covalent HIV-1 reverse transcriptase inhibitors specifically targeting the drug-resistant mutant Y181C.
AID1736368	Selectivity index, ratio of EC50 for antiviral activity against VSVG/HIV-1 harboring reverse transcriptase V108I/K103N double mutant infected in human HEK 293T cells to EC50 for antiviral activity against VSVG/wild type HIV-1 infected in human HEK293T cel
AID1060631	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs.
AID492282	Antiviral activity against HIV1 with reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
AID1882471	Cytotoxicity against human MT2 cells assessed as cell viability by MTT assay	2022	Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5	Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.
AID1141961	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 NL4.3 infected in human MT4 cells	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1141962	Antiviral activity against HIV1 3B infected in human CEM cells assessed as protection of cells monitored by giant cell formation by microscopy	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID248879	Inhibitory concentration against human immunodeficiency virus type 1 (with K103N/V108I resistant mutation) was determined in HeLa-CD4 MAGI assay	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
AID1888700	Resistance index, ratio of EC50 for antiviral activity against HIV1 with RT K103N mutant infected in human MT4 cells to EC50 for antiviral activity against wild type HIV1 infected in human MT4 cells
AID523485	Antiviral activity against HIV1 with RT connection domain L100I/T369I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID1888698	Antiviral activity against HIV1 with RT E138K mutant infected in human MT4 cells cells assessed as protection against viral-induced cytopathogenecity by MTT assay
AID1754642	Antiviral activity against HIV1 harboring K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses.
AID443700	Antiviral activity against HIV with reverse transcriptase L100I/K103N double mutant assessed as inhibition of viral replication relative to wild type	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
AID1152371	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay	2014	Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12	Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID266348	Inhibition of HIV1 reverse transcriptase Y188C mutant in 293T cells	2006	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11	New HIV-1 reverse transcriptase inhibitors based on a tricyclic benzothiophene scaffold: synthesis, resolution, and inhibitory activity.
AID1653630	Activation of recombinant human C-terminal 4His-tagged CYP46A1 delta(2 to 50) K358R mutant expressed in Escherichia coli at 20 uM using cholesterol as substrate measured after 30 mins in presence of cytochrome P450 oxidoreductase by gas chromatography-mas	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds.
AID1884227	Antiviral activity against HIV-1 harboring Y188L mutant infected in human MT4 cells assessed as reduction in virus induced cytotoxicity incubated for 5 to 7 days by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Chemical space exploration around indolylarylsulfone scaffold led to a novel class of highly active HIV-1 NNRTIs with spiro structural features.
AID1410410	Fold resistance, ratio of EC50 for HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells to EC50 for wild type HIV1 3B infected in human MT4 cells	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Discovery of Novel Diarylpyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the "NNRTI Adjacent" Binding Site.
AID619634	Antiviral activity against HIV-1 3B harboring RT E138K mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
AID370725	Inhibition of RNA dependent DNA polymerase activity of HIV1 recombinant reverse transcriptase p66/p51 L100I mutant expressed in Escherichia coli JM109	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations.
AID1292012	Selectivity index, ratio of CC50 for mock infected human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket.
AID519862	Antiviral activity against HIV1 subtype B-LAI infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID1565092	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
AID571974	Antiviral activity against HIV-1 subtype CRF01_AE V029521 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID342721	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Novel N1-substituted 1,3-dihydro-2H-benzimidazol-2-ones as potent non-nucleoside reverse transcriptase inhibitors.
AID1483275	Inhibition of HIV1 RES056 reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
AID571971	Antiviral activity against HIV-1 subtype CRF01_AE V022820 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID611888	Antiviral activity against Human immunodeficiency virus 1 assessed as inhibition of viral replication at 0.001 uM	2011	Journal of natural products, Jun-24, Volume: 74, Issue:6	Bioactive neolignans and lignans from the bark of Machilus robusta.
AID298077	Cytotoxicity against lymphocytes	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity.
AID541158	Selectivity ratio of EC50 for antiviral activity against GS-9160-resistant HIV1 selected after 6 passages to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1741391	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID1141977	Inhibition of HIV1 wild-type reverse transcriptase Y181I/Y181C mutant using [3H]dTTP by scintillation counting	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1743622	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for antiviral activity against HIV1 RES056 infected in human MT4 cells	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.
AID246298	Effective concentration of the compound to inhibit HIV-1 mutant K103N replication in HIV-infected MT-4 cells	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID263522	Antiviral activity against HIV1 F227L mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2.
AID1157600	Antiviral activity against HIV1 CRF01 infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID248262	In vitro inhibitory concentration against HIV V106A mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
AID1171591	Resistance index, ratio of EC50 for HIV1 NL4-3 expressing reverse transcriptase L100I mutant to EC50 for wild type HIV1 NL4-3	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1373159	Inhibition of reverse transcriptase K103N mutant in HIV1 infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3	Structural optimization of N
AID279516	Antiviral activity against wild type HIV1 NL4-3 in Hela-JC53 cells after 48 hrs	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID299023	Antiviral activity against HIV1 assessed as reduction of virus-induced cytopathic effect in MT4 cells	2007	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7	Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains.
AID279405	Antiviral activity against HIV1 isolate with RT 101E, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID519864	Antiviral activity against HIV1 subtype B-NL4-3 infected in 2 hrs pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID366528	Resistance index, ratio of ID50 for reverse transcriptase K103N mutant to IC50 for wild-type HIV1 sreverse transcriptase	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.
AID279390	Antiviral activity against HIV1 isolate with RT 103N, 181C mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID371896	Antiviral activity against wild type HIV1 NL4-3 in human TZM-b1 cells assessed as beta-galactosidase activity after 48 hrs	2009	Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12	New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID665547	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors.
AID576036	Cmax in healthy human plasma at 400 mg, po qd for 14 days by liquid chromatography-tandem mass spectrometry	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.
AID586469	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase L101I/S153F mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficie	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID586362	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase E92I mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficiency vir	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID519021	Antiviral activity against Human immunodeficiency virus 1 NL432 infected in human MT-4 cells assessed as effect on total viral DNA	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.
AID1572519	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytotoxicity after 5 days by MTT assay
AID508794	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase L100I mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID391227	Antiviral activity against wild type HIV1 infected in human MT4 cells after 72 hrs in presence of 50% normal human serum	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses.
AID1390713	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B expressing wild type reverse transcriptase infected in human MT4 cells	2018	Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8	First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain.
AID586487	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase V72I/F121Y/T125K/I151V mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human im	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID1407646	Antiviral activity against Human immunodeficiency virus 1 NL4-3 infected in human CEM-GFP cells after 7 days by p24 ELISA	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Design, synthesis, docking studies and biological screening of 2-thiazolyl substituted -2,3-dihydro-1H-naphtho[1,2-e][1,3]oxazines as potent HIV-1 reverse transcriptase inhibitors.
AID584082	Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase L100I, K103Q, H221H/Y mutant infected in human SupT1 cells derived from 11 viral passages with efavirenz assessed as inhibition of viral replication after 21 days relative to drug sensi	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID1754641	Antiviral activity against HIV1 harboring RT L100I mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses.
AID302249	Antiviral activity against HIV1 NL43 in MT4 cells assessed as inhibition of viral induced cytopathic effect after 4 days by MTT method	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID279519	Antiviral activity against wild type HIV1 NL4-3 in Hela-JC53 cells in the presence of 20% human serum after 48 hrs	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1736356	Antiviral activity against VSVG/HIV-1 harboring reverse transcriptase Y181C mutant infected in human HEK 293T cells assessed as inhibition of virus replication preincubated with cells for 15 mins prior to viral infection and measured at 48 hrs post-infect
AID1246230	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity by MTT assay	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Synthesis, cytotoxicity and antimicrobial activity of thiourea derivatives incorporating 3-(trifluoromethyl)phenyl moiety.
AID441310	Fold resistance, ratio of IC50 for HIV reverse transcriptase with Y181C mutant to IC50 for HIV wild type reverse transcriptase	2009	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19	Pyrazole NNRTIs 1: design and initial optimisation of a novel template.
AID1357801	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 harboring reverse transcriptase K103N mutant	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID496619	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase A98G/V35T, V60I, I135L, S162A, K173A, Q174K, D177E, I178M, T200A,Q207E, R211K, V245Q, D250E mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID263521	Antiviral activity against HIV1 F227C mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2.
AID263520	Antiviral activity against HIV1 Y188L mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2.
AID583871	Inhibition of HIV1 histidine-tagged reverse transcriptase Y181C mutant activity by primer extension assay	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID198577	Inhibitory concentration for 90% inhibition of HIV-1 reverse transcriptase, whole cell based antiviral assay	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Synthesis and evaluation of quinoxalinones as HIV-1 reverse transcriptase inhibitors.
AID573467	Inhibition of Human immunodeficiency virus 1 subtype B reverse transcriptase G190A-81C mutant by filter-based filtration assay	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
AID508632	Antiviral activity against Human immunodeficiency virus 1 subtype G isolate RU132 infected in human PBMC cells by cell based assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1446815	Antiviral activity against HIV1 harboring L100I mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured at 5 days post infection by MTT assay	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.
AID1815401	Inhibition of HIV1 reverse transcriptase E138K mutant using oligo(dT)16 as primer measured after 40 mins by picogreen-dye based spectrofluorimetric analysis	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID361909	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106A mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1815391	Inhibition of HIV1 reverse transcriptase K103N/Y181C double mutant using oligo(dT)16 as primer measured after 40 mins by picogreen-dye based spectrofluorimetric analysis	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID573465	Inhibition of Human immunodeficiency virus 1 subtype B reverse transcriptase G190A mutant by filter-based filtration assay	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
AID1847042	Antiviral activity against HIV 1 infected in human HeLa-MAGI cells assessed as inhibition of viral replication measured 24 hrs post infection by fluorescence based analysis	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Quinolinonyl Non-Diketo Acid Derivatives as Inhibitors of HIV-1 Ribonuclease H and Polymerase Functions of Reverse Transcriptase.
AID105695	Anti-HIV-1 activity against K103N strain in MT-4 cells by the MTT method	2003	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24	3-iodo-4-phenoxypyridinones (IOPY's), a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID1155810	Fold resistance, ratio of EC50 for HIV-1 harboring NNTRI-resistant reverse transcriptase K103N mutant infected in human MT4 cells to EC50 for wild type HIV-1 NL4-3 infected in human MT4 cells	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.
AID492047	Antiviral activity against HIV1 bearing reverse transcriptase K103N and Y181C double mutation infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	2010	Bioorganic & medicinal chemistry, Jul-01, Volume: 18, Issue:13	Synthesis and anti-HIV activity of 2-naphthyl substituted DAPY analogues as non-nucleoside reverse transcriptase inhibitors.
AID1249713	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity incubated for 4 days by MTT method	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue.
AID508654	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase V179F, Y181C, F227C mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID279421	Antiviral activity against HIV1 isolate with RT 101E, 190S mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1443661	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	2017	Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8	Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors.
AID573999	Ratio of EC50 for Human immunodeficiency virus in presence of 10% FCS to EC50 for Human immunodeficiency virus in presence of 50% human serum	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.
AID709869	Antiviral activity against NNRTI-resistant HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs by HeLa-CD4-LTR-beta-gal assay	2012	Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23	Rational design of potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID658572	Antiviral activity against wild type Human immunodeficiency virus 1 NL4-3 pseudotyped with HIV envelope infected in human HeLa-SxR5 cells assessed as inhibition of viral replication at 65 nM after 3 days by beta-galactosidase assay	2012	Journal of natural products, Mar-23, Volume: 75, Issue:3	Library-based discovery and characterization of daphnane diterpenes as potent and selective HIV inhibitors in Daphne gnidium.
AID279434	Antiviral activity against HIV1 isolate with RT 101E, 181C, 190S mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1275547	Antiviral activity against HIV1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
AID557052	Antiviral activity against NRTI-resistant HIV1 harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID1884221	Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as reduction in virus induced cytotoxicity incubated for 5 to 7 days by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Chemical space exploration around indolylarylsulfone scaffold led to a novel class of highly active HIV-1 NNRTIs with spiro structural features.
AID279524	Antiviral activity against HIV1 NL4-3 with Y188L mutation in Hela-JC53 cells in the presence of 5% human serum after 48 hrs	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1069125	Inhibition of HIV wild-type reverse transcriptase by electrochemiluminescence assay	2014	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3	Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses.
AID361922	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y188C mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID588997	Inhibitors of transporters of clinical importance in the absorption and disposition of drugs, MPR3	2010	Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3	Membrane transporters in drug development.
AID257169	Antiviral activity against HIV1 Y188L mutant strain infected MT4 cells by MTT method	2005	Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25	Parallel solution-phase and microwave-assisted synthesis of new S-DABO derivatives endowed with subnanomolar anti-HIV-1 activity.
AID717261	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs.
AID1693804	Inhibition of recombinant HIV-1 BH10 reverse transcriptase Y181C mutant using D38/[32P]25PGA as template-primer incubated for 5 mins in presence of DTT followed by dTTP addition and measured after 15 to 30 sec by nucleotide incorporation assay	2021	Bioorganic & medicinal chemistry, 01-15, Volume: 30	Novel indolylarylsulfone derivatives as covalent HIV-1 reverse transcriptase inhibitors specifically targeting the drug-resistant mutant Y181C.
AID663904	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	2012	European journal of medicinal chemistry, Jul, Volume: 53	5-acetyl-2-arylbenzimidazoles as antiviral agents. Part 4.
AID416432	Antiviral activity against HIV1 bearing HIV1 NL4-3 envelope infected in human HeLa CD4 cells coexpressing LTR/beta-Gal gene assessed as reduction in virus-induced beta-galactosidase reporter gene activity after 72 hrs by single-cycle infection assay	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Identification and characterization of UK-201844, a novel inhibitor that interferes with human immunodeficiency virus type 1 gp160 processing.
AID1815395	Resistance fold, ratio of EC50 for HIV1 harboring reverse transcriptase K103N/Y181C double mutant infected MV4 cells to EC50 for wild type HIV1 infected MV4 cells	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID522370	Antiviral activity against recombinant HIV1 harboring reverse transcriptase V106I mutant clone infected in MAGIC-5 cells using 5-bromo4-chloro-3-indolyl-beta-D-galactopyranoside staining based light microscopy	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
AID302260	Inhibition of HIV1 reverse transcriptase K103N mutant	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID302248	Cytotoxicity against MT4 cells after 4 days by MTT method	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID496617	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase V90I/V35T, E36D, T39K, I50V, V60I, S68G, I135V, S162A, K173V, Q174K,D177E, T200A, E203Q, Q207D, R211K mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID397179	Antiviral activity against HIV1 3B expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Parallel synthesis, molecular modelling and further structure-activity relationship studies of new acylthiocarbamates as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID508761	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase K103N, F227L mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID508779	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase V179D mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID573250	Cmax in HIV-1 infected children at 14.4 mg/kg, po administered once daily by HPLC	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children?
AID82466	Antiviral activity against P225H strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID573470	Inhibition of DNA-dependent DNA polymerase activity of wild-type Human immunodeficiency virus 1 subtype B reverse transcriptase Y181C mutant by filter-based filtration assay	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1357793	Antiviral activity against HIV1 harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID279485	Antiviral activity against HIV1 isolate with RT K103N-V108I mutation	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1609109	Antiviral activity against HIV-1 harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 4 days by MTT assay	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1060627	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs.
AID665271	Antiviral activity against HIV1 3B harboring wild type RT infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2012	European journal of medicinal chemistry, Jul, Volume: 53	Chiral resolution, absolute configuration assignment and biological activity of racemic diarylpyrimidine CH(OH)-DAPY as potent nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID443694	Antiviral activity against HIV with reverse transcriptase L100I mutant assessed as inhibition of viral replication relative to wild type	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
AID1888699	Antiviral activity against HIV1 with RT RES056 mutant infected in human MT4 cells cells assessed as protection against viral-induced cytopathogenecity by MTT assay
AID279408	Antiviral activity against HIV1 isolate with RT 101Q, 103N mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1298250	Inhibition of HIV1 reverse transcriptase p66/p51 V106A mutant using poly(rA) template and measured after 40 mins by picogreen based spectrofluorometry	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.
AID1750714	Antiviral activity against HIV-1 infected in human MT-4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from
AID246779	Concentration required to reduce the amount of p24 by 90% in wtIIIB-HIV-1-infected C8166 cells	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.
AID443708	Antiviral activity against HIV with reverse transcriptase V106A/G190A/F227L mutant assessed as inhibition of viral replication relative to wild type	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
AID1773462	Resistance factor, ratio of EC50 for HIV1 harboring F227L/V106A double mutant infected in human MT4 cells to EC50 for HIV1 3B infected in MT4 cells
AID197934	HIV-1 reverse transcriptase inhibitory activity against Wild Type Reverse transcriptase using (poly)rC600*(oligo)dGT as template primer.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues.
AID1609106	Antiviral activity against HIV-1 harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 4 days by MTT assay	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1249717	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue.
AID1882475	Antiviral activity against HIV-1 harboring K103N mutant infected in human MT4 cells assessed as protection against virus-induced cytopathicity by MTT assay	2022	Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5	Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.
AID361917	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106I mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1348216	Antiviral activity against wild-type VSV-G pseudotyped MLV infected in HEK293 cells pretreated for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene assay	2017	Journal of natural products, 12-22, Volume: 80, Issue:12	Oxazole-Containing Diterpenoids from Cell Cultures of Salvia miltiorrhiza and Their Anti-HIV-1 Activities.
AID1248222	Antiviral activity against wild type HIV 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	2015	Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20	A novel family of diarylpyrimidines (DAPYs) featuring a diatomic linker: Design, synthesis and anti-HIV activities.
AID265472	Activity against HIV-112 assessed by inhibition of p24 production in human lymphocytes	2006	Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11	Design, molecular modeling, synthesis, and anti-HIV-1 activity of new indolyl aryl sulfones. Novel derivatives of the indole-2-carboxamide.
AID279441	Antiviral activity against HIV1 isolate with RT 101Q, 190S mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID573471	Inhibition of DNA-dependent DNA polymerase activity of wild-type Human immunodeficiency virus 1 subtype B reverse transcriptase G190A-81C mutant by filter-based filtration assay	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
AID279442	Antiviral activity against HIV1 isolate with RT 98G, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1773448	Antiviral activity against wild type HIV1 harboring Y188L mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenic effect by MTT assay
AID1264544	Ratio of EC50 for HIV-1 expressing reverse transcriptase K101P mutant to EC50 for HIV-1 X4 expressing wild-type reverse transcriptase	2015	ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10	Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine Resistance.
AID248255	In vitro inhibitory concentration against HIV E138K mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
AID279428	Antiviral activity against HIV1 isolate with RT 101E, 181C mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID586903	Activity at MRP3	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Interaction potential of etravirine with drug transporters assessed in vitro.
AID143393	Inhibition of the NNRTI HIV-1 enzyme by 50% using enzyme assay.	2001	Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3	Trifluoromethyl-containing 3-alkoxymethyl- and 3-aryloxymethyl-2-pyridinones are potent inhibitors of HIV-1 non-nucleoside reverse transcriptase.
AID248842	Inhibitory concentration against human immunodeficiency virus type 1 (with K103N resistant mutation) was determined in HeLa-CD4 MAGI assay	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
AID302262	Inhibition of HIV1 reverse transcriptase V106A mutant	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID1141965	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID302251	Antiviral activity against HIV1 with reverse transcriptase IRLL98 mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID1561722	Resistance index, ratio of EC50 for antiviral activity against HIV1 3B infected in human MT4 cells grown under 30 passages in presence of 4-[[4-[[4-[4-[2-cyanovinyl]-2,6-dimethylphenoxy]thieno[3,2-d]pyrimidin-2-yl]amino]-1-piperidyl]methyl]benzenesulfonam
AID1637394	Antiviral activity against human HIV-1 3B harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection from virus-induced cytopathic effect measured 5 days post infection by MTT assay	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.
AID519886	Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID457958	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B	2010	Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4	Novel 1,3-dihydro-benzimidazol-2-ones and their analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID257918	Antiviral activity against HIV1 V106A mutant using HeLa MAGI assay	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor.
AID1761006	Antiviral activity against wild type HIV1 NL4-3 infected in human TZM-bl cells assessed as reduction in viral infection measured after 1 day by luciferase reporter gene assay based luminiscence assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Design, synthesis, and evaluation of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID293561	Antiviral activity against HIV1 LAI with RT Y181C mutation in MT4 cells by EGFP based replication assay	2007	European journal of medicinal chemistry, May, Volume: 42, Issue:5	Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains.
AID391222	Inhibition of HIV1 RT polymerase K103N mutant by SPA	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses.
AID141363	Inhibitory activity against mutant L1001 HIV-1 Reverse transcriptase	2001	Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14	Synthesis and evaluation of novel quinolinones as HIV-1 reverse transcriptase inhibitors.
AID1572528	Antiviral activity against HIV1 harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytotoxicity after 5 days by MTT assay
AID246300	Effective concentration of the compound to inhibit HIV-1 mutant Y181C replication in HIV-infected MT-4 cells	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID1811039	Anti-viral activity against HIV1 harboring RT L100I mutant infected MV4 cells assessed as protection against virus-induced cytopathic effect by MTT assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.
AID271414	Antiviral activity against HIV1 K103N-Y181C mutant in HeLa-JC53 cells	2006	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17	Tri-substituted triazoles as potent non-nucleoside inhibitors of the HIV-1 reverse transcriptase.
AID1248227	Inhibition of recombinant HIV1 Reverse transcriptase p66/p51 using poly (rA)-oligo (dT) as template primer after 40 mins by spectrofluorometric analysis	2015	Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20	A novel family of diarylpyrimidines (DAPYs) featuring a diatomic linker: Design, synthesis and anti-HIV activities.
AID371905	Antiviral activity against HIV1 NL4-3 with K103N/Y181C double mutant in human TZM-b1 cells assessed as beta-galactosidase activity after 48 hrs by single round replication assay	2009	Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12	New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID518740	Antiviral activity against HIV 1 subtype B harboring wild type reverse transcriptase infected in human TZM-bl cells assessed as inhibition of viral growth by luciferase reporter gene assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity.
AID1212899	Drug metabolism in human liver microsomes harboring CYP2B61/1 genotype assessed as intrinsic clearance for CYP2B6 variant-mediated 8-hydroxyefavirenz metabolite formation measured per mg protein after 15 mins by LC/MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
AID279520	Antiviral activity against wild type HIV1 NL4-3 in Hela-JC53 cells in the presence of 30% human serum after 48 hrs	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID248264	In vitro inhibitory concentration against HIV Y188L mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
AID246323	Effective concentration against human immunodeficiency virus type 1 Y181C mutant was determined	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).
AID298065	Metabolic stability in rat plasma	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability.
AID443423	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus induced cytopathogenicity after 4 days by MTT assay	2009	European journal of medicinal chemistry, Dec, Volume: 44, Issue:12	Synthesis, pharmacological and antiviral activity of 1,3-thiazepine derivatives.
AID622052	Inhibition of DNA-dependent DNA polymerase activity of HIV1 reverse transcriptase p66/p66 homodimer K103N/Y181C mutant using activated DNA and [alpha-32P]dATP after 30 mins by liquid scintillation counting	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID698304	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 NL4-3 infected in human MT4 cells	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID623212	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID1373153	Inhibition of recombinant wild-type HIV-1 3B reverse transcriptase p66/p51 RNA-dependent DNA polymerase activity expressed in Escherichia coli JM109 assessed as reduction in dTTP incorporation using poly(rA)/oligo(dT)16 as template/primer after 40 mins by	2018	Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3	Structural optimization of N
AID440071	Antiviral activity against HIV-1 LAI harboring wild type reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
AID576049	Reduction in ABCC2 mRNA expression in healthy human at 400 mg, po qd for 14 days by RT-PCR	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.
AID449491	Cytotoxicity against human MT4 cells as reduction in cell viability after 5 days by MTT assay	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID282736	Inhibition of HIV1 RT L100I mutant	2005	Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23	Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.
AID1485972	Inhibition of HIV-1 reverse transcriptase E138K mutant assessed as reduction in dTTP incorporation using poly(rA)/oligo(dT)16 as template/primer after 40 mins by PicoGreen dye based spectrofluorometric analysis	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Searching for novel N
AID279486	Antiviral activity against HIV1 isolate with RT K103N-K101Q mutation	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID522376	Resistance index, ratio of EC50 for recombinant HIV1 harboring reverse transcriptase V179D mutant clone to EC50 for wild type HIV1	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
AID246269	Effective concentration against human immunodeficiency virus type 1 Y188L mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).
AID1171594	Inhibition of wild type HIV1 reverse transcriptase K103N mutant assessed as reduction in enzyme activity	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID556527	Antiviral activity against Human immunodeficiency virus 1 clone 14682 harboring 122E, 135V, Q145V, 200A mutation in reverse transcriptase by phenosense assay relative to wild type	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
AID541124	Antiviral activity against HIV1 3B infected in SupT1 cells assessed as fold decrease in viral 2-LTR circles accumulation after 3 hrs postinfection by TaqMan real-time PCR	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1391081	Antiviral activity against HIV1 harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	The discovery of novel diarylpyri(mi)dine derivatives with high level activity against a wide variety of HIV-1 strains as well as against HIV-2.
AID519869	Antiviral activity against HIV1 subtype B-ASM 044 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID736040	Inhibition of HIV1 reverse transcriptase p66/p51 Y181C mutant after 30 mins by liquid scintillation counting	2013	Bioorganic & medicinal chemistry, Mar-01, Volume: 21, Issue:5	N1,N3-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
AID1435510	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
AID427967	Antiviral activity against HIV1 infected in human HeLa cells expressing CD4-LTR assessed as inhibition of viral entry-related beta galactosidase expression treated for 2 hrs followed by drug wash out measured after 48 hrs by MAGI assay	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative evaluation of the inhibitory activities of a series of pyrimidinedione congeners that inhibit human immunodeficiency virus types 1 and 2.
AID443690	Antiviral activity against HIV with reverse transcriptase K103N/Y181C/G190A mutant assessed as inhibition of viral replication	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
AID557053	Antiviral activity against NRTI-, PI-resistant HIV1 harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID736438	Inhibition of HIV1 reverse transcriptase p66/p51 K103N mutant after 30 mins by liquid scintillation counting	2013	Bioorganic & medicinal chemistry, Mar-01, Volume: 21, Issue:5	N1,N3-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
AID82472	Antiviral activity against V108I strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID508643	Antiviral activity against Human immunodeficiency virus 1 subtype A1 infected in human MT4 cells assessed as reduction in virus induced cytopathicity	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID440080	Antiviral activity against HIV1 HXB2 harboring 179E mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
AID83553	Potency evaluated against NNRTI-Resistant HIV-1 strain Val106Ala	2004	Journal of medicinal chemistry, May-06, Volume: 47, Issue:10	Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 varian
AID622051	Inhibition of DNA-dependent DNA polymerase activity of HIV1 reverse transcriptase p66/p66 homodimer G190A mutant using activated DNA and [alpha-32P]dATP after 30 mins by liquid scintillation counting	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID279475	Antiviral activity against HIV1 isolate with RT 101E, 103N, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID248845	Inhibitory concentration against human immunodeficiency virus type 1 (with Y181C resistant mutation) was determined in HeLa-CD4 MAGI assay	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
AID305057	Antiviral activity against HIV in HEK293T cells after 48 hrs	2007	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 17, Issue:1	4-Aminopyrimidines as novel HIV-1 inhibitors.
AID257168	Antiviral activity against HIV1 K103N mutant strain infected MT4 cells by MTT method	2005	Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25	Parallel solution-phase and microwave-assisted synthesis of new S-DABO derivatives endowed with subnanomolar anti-HIV-1 activity.
AID573244	Cmin in HIV-1 infected children at 12 mg/kg, po administered once daily by HPLC	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children?
AID1335215	Antiviral activity against HIV-1 NL4-3 harboring RT-Y181C mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID1435512	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 expressing reverse transcriptase L100I mutant
AID198915	Inhibition of HIV-1 Mutant HIV-1 RT enzymes containing the single amino acid substitution Y181I	2001	Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3	Quinoxalinylethylpyridylthioureas (QXPTs) as potent non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors. Further SAR studies and identification of a novel orally bioavailable hydrazine-based antiviral agent.
AID279403	Antiviral activity against HIV1 isolate with RT 108I mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1352321	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103 N/Y181C double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 4 days by MTT assay	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.
AID279394	Antiviral activity against HIV1 isolate with RT 98G mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID198578	Inhibitory concentration against HIV-1 reverse transcriptase	2001	Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2	3,3a-Dihydropyrano[4,3,2-de]quinazolin-2(1H)-ones are potent non-nucleoside reverse transcriptase inhibitors.
AID389380	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B	2008	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20	1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1574387	Inhibition of recombinant HIV-1 His-tagged reverse transcriptase p66/p51 L100I mutant expressed in Escherichia coli assessed as reduction in [3H]dTTP incorporation using poly(rA)/oligo(dT) as template/primer after 20 mins by scintillation counting analysi	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.
AID1773827	Antiviral activity against HIV1 RES056 infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18	Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies.
AID82471	Antiviral activity against V106I/Y181C strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID279425	Antiviral activity against HIV1 isolate with RT 179G mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID649485	Inhibition of RNA-dependent DNA polymerase activity of wild type Human immunodeficiency virus 1 reverse transcriptase	2012	European journal of medicinal chemistry, Apr, Volume: 50	Identification of HIV-1 reverse transcriptase dual inhibitors by a combined shape-, 2D-fingerprint- and pharmacophore-based virtual screening approach.
AID1157584	Antiviral activity against A17-sensitive HIV1 harboring 103N, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID246301	Effective concentration of the compound to inhibit HIV-1 mutant Y188L replication in HIV-infected MT-4 cells	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1884538	Fold resistance, ratio of EC50 for antiviral activity against drug-resistant HIV-1 L100I mutant infected in human MT4 cells to EC50 for antiviral activity against NNRTI resistant wild type HIV-1 infected in human MT4 cells	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.
AID614142	Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	2011	Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17	Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs.
AID1157594	Antiviral activity against TMC120-resistant HIV1 harboring RT 100I, 138G mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID1884224	Antiviral activity against HIV-1 harboring L100I mutant infected in human MT4 cells assessed as reduction in virus induced cytotoxicity incubated for 5 to 7 days by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Chemical space exploration around indolylarylsulfone scaffold led to a novel class of highly active HIV-1 NNRTIs with spiro structural features.
AID573251	AUC (0 to t) in HIV-1 infected children at 12 mg/kg, po administered once daily by HPLC	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children?
AID1391082	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	The discovery of novel diarylpyri(mi)dine derivatives with high level activity against a wide variety of HIV-1 strains as well as against HIV-2.
AID496623	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase E138A/G18V, Q23P, V35T, E40D, V60I, S68G, D123E, I135V, S162A, K173T, Q174N, T200A, Q207E, R211K, F214L mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID1304403	Cytotoxicity against mock-infected human MT4 cells	2016	Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13	Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
AID1200843	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	2015	European journal of medicinal chemistry, Mar-26, Volume: 93	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.
AID1286672	Antiviral activity against HIV1 harboring reverse transcriptase Y181C/K103N double mutant infected in primary MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS assay	2016	Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5	Discovery of the Aryl-phospho-indole IDX899, a Highly Potent Anti-HIV Non-nucleoside Reverse Transcriptase Inhibitor.
AID431621	Cytotoxicity against human MT4 cells by MTT assay	2009	Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16	Synthesis and biological evaluation of imidazole thioacetanilides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID663305	Inhibition of HIV1 wild type recombinant reverse transcriptase assessed as [3H]dTTP incorporation into poly(rA)/oligo(dT)	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.
AID44798	In vitro concentration required to reduce the amount of p24 by 90% in WTIIIB infected C8166 cells	2004	Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15	Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations.
AID1185998	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
AID248256	In vitro inhibitory concentration against HIV F227C mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
AID576047	Reduction in ABCB1 mRNA expression in healthy human at 400 mg, po qd for 14 days by RT-PCR	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.
AID1249716	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 4 days by MTT assay	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue.
AID368564	Inhibition of wild type HIV1 free reverse transcriptase	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.
AID1687685	Antiviral activity against HIV-2 ROD strain infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities.
AID650687	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV 1 NL4-3	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
AID490369	Antiviral activity against wild type HIV1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect in presence of 40 % human serum	2010	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14	Discovery of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-benzyl derivatives with broad potency against resistant mutant viruses.
AID1152374	Selectivity index, ratio CC50 for human MT4 cells to EC50 for HIV 1 3B	2014	Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12	Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID198099	Inhibitory activity against HIV-1 reverse transcriptase enzyme	1999	Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19	Synthesis and evaluation of analogs of Efavirenz (SUSTIVA) as HIV-1 reverse transcriptase inhibitors.
AID518742	Selectivity ratio of EC50 for antiviral activity against HIV 1 subtype B harboring reverse transcriptase M230L mutant to EC50 for antiviral activity against HIV 1 subtype B harboring wild type reverse transcriptase	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity.
AID1446816	Antiviral activity against HIV1 harboring K103N mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured at 5 days post infection by MTT assay	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.
AID541128	Antiviral activity against HIV1 infected in SupT1 cells assessed as accumulation of integrated junction products after 48 hrs by Alu-PCR assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID368568	Inhibition of HIV1 recombinant reverse transcriptase K103N mutant-DNA binary complex expressed in Escherichia coli BL21	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.
AID1583020	Antiviral activity against NNRTI-resistant HIV1 RES056 containing reverse transcriptase K103N+Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3	Discovery and Characterization of Fluorine-Substituted Diarylpyrimidine Derivatives as Novel HIV-1 NNRTIs with Highly Improved Resistance Profiles and Low Activity for the hERG Ion Channel.
AID557036	Antiviral activity against HIV1 isolate R8 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs in presence of 50% human serum	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID1212883	Drug metabolism in microsomes expressing CYP2B6.1 (unknown origin) assessed as intrinsic clearance for enzyme-mediated 8-hydroxyefavirenz metabolite formation measured per pmol of P450 after 15 mins by HPLC/UV system in presence of Cyt b5 coexpression	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
AID508776	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase V179T mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID557045	Antiviral activity against HIV1 CRF17_BF harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID557020	Antiviral activity against HIV1 clade B harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID1561716	Antiviral activity against HIV1 3B infected in human MT4 cells grown under 30 passages in absence of test compound assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay
AID279449	Antiviral activity against HIV1 isolate with RT 98G, 188L mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID541109	Antiviral activity against HIV1 3B infected in human MT-2 cells by two fold dilution method in presence of 10% FBS	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID197933	HIV-1 reverse transcriptase inhibitory activity against Ile 100 mutant using (poly)rC600*(oligo)dGT as template primer.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues.
AID371900	Antiviral activity against HIV1 NL4-3 with K103N mutant in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay	2009	Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12	New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID246463	Compound concentration required to achieve 50% protection of infected MT-4 cells from Y181C strain was determined by the MTT method	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.
AID571976	Antiviral activity against HIV-1 subtype B V022807 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID267649	Antiviral activity against HIV1 L100I mutant	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1.
AID508625	Antiviral activity against Human immunodeficiency virus 1 subtype E isolate 93TH073 infected in human PBMC cells by cell based assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID619643	Ratio of EC50 for HIV-1 3B harboring RT L100I mutant infected in human MT4 cells to EC50 for wild type HIV-1 3B infected in human MT4 cells	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
AID94444	Potency of second-generation NNRTIs against Mutant HIV-1 K103N free drug	2000	Journal of medicinal chemistry, May-18, Volume: 43, Issue:10	Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID572177	Antiviral activity against HIV-1 subtype H V022828 harboring NNRTI K101Q and V179I mutant infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID1390714	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant	2018	Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8	First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain.
AID1456311	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV-1 3B wild type reverse transcriptase infected in human MT4 cells	2017	Bioorganic & medicinal chemistry, 04-15, Volume: 25, Issue:8	Structural modifications of diarylpyrimidines (DAPYs) as HIV-1 NNRTIs: Synthesis, anti-HIV activities and SAR.
AID1206939	Inhibition of HIV1 recombinant wild type reverse transcriptase p66/p51 assessed as reduction in biotin-labeled dUTP incorporation into DNA using polyr(A) x oligo(dT)16 template/primer hybrid	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	Discovery of piperidin-4-yl-aminopyrimidine derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID246153	Concentration required to achieve 50% protection of infected MT-4 cells from K103N-Y181C	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.
AID330487	Cytotoxicity against human MT4 cells	2008	Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7	Synthesis and biological evaluation of novel 6-substituted 5-alkyl-2-(arylcarbonylmethylthio)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID541165	Selectivity ratio of EC50 for antiviral activity against HIV1 harboring E138K mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1609104	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 4 days by MTT assay	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID586900	Activity at ABCB1	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Interaction potential of etravirine with drug transporters assessed in vitro.
AID1261342	Antiviral activity against Vaccinia virus	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID1157604	Antiviral activity against HIV1 MP1033 infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID88365	Antiviral activity against G190A mutant virus in the HeLa MAGI assay.	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID247723	Inhibitory concentration against 100I mutant was determined	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity.
AID1520059	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID1390712	Cytotoxicity against human MT4 cells after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8	First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain.
AID247496	Inhibitory activity against HIV-1 mutant strain 101E	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID1485970	Inhibition of HIV-1 reverse transcriptase K103N mutant assessed as reduction in dTTP incorporation using poly(rA)/oligo(dT)16 as template/primer after 40 mins by PicoGreen dye based spectrofluorometric analysis	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Searching for novel N
AID508751	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase Y181C, F227C mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID104411	Antiviral activity of Protein Binding of compound was evaluated for RF virus expressed MT-2 by RNA	2000	Journal of medicinal chemistry, May-18, Volume: 43, Issue:10	Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID586366	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase G118S mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficiency vi	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID1815396	Inhibition of wild type HIV1 reverse transcriptase using oligo(dT)16 as primer measured after 40 mins by picogreen-dye based spectrofluorimetric analysis	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID586905	Inhibition of ABCB1 activity	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Interaction potential of etravirine with drug transporters assessed in vitro.
AID576051	Ratio of drug concentration in PBMCs to plasma of healthy human administered at 400 mg, po qd for 14 days measured after 24 hrs post last dose	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.
AID1298246	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV-1 3B infected in human MT4 cells	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.
AID1743639	Resistance index, ratio of EC50 for antiviral activity against HIV1 expressing RT F227L/V106A mutant infected in human MT4 cells to EC50 for antiviral activity against HIV1 3B infected in human MT4 cells	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.
AID584030	Inhibition of HIV1 histidine-tagged reverse transcriptase L234I mutant activity by primer extension assay	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID1687688	Antiviral activity against wild type HIV1 assessed as inhibitory effect on virus producing cells at 10 uM by cell based inhibition assay	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Rational design and Structure-Activity relationship of coumarin derivatives effective on HIV-1 protease and partially on HIV-1 reverse transcriptase.
AID361905	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/P225H mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1357789	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID443707	Antiviral activity against HIV with reverse transcriptase K103N/Y181C/G190A mutant assessed as inhibition of viral replication relative to wild type	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
AID1637388	Antiviral activity against human HIV-1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathic effect measured 5 days post infection by MTT assay	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.
AID1443664	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV1 3B	2017	Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8	Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors.
AID1743621	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for antiviral activity against HIV1 3B infected in human MT4 cells	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.
AID573995	Ratio of EC50 for Human immunodeficiency virus 1 3B to EC50 for L-708,906-resistant Human immunodeficiency virus harboring T66I, L74M and S230R mutations in integrase	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.
AID1443666	Antiviral activity against HIV1 harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	2017	Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8	Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors.
AID1743627	Antiviral activity against HIV1 harboring RT K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.
AID1565096	Antiviral activity against drug resistant HIV-1 harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay
AID571985	Antiviral activity against HIV-1 subtype C V022817 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID464770	Half life in Beagle dog at 0.5 mg/kg, iv or 0.5 mg/kg, po	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	N1-Heterocyclic pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID279496	Antiviral activity against HIV1 isolate with RT K103N-G190A mutation	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID386490	Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in human MT4 cells assessed as reduction of virus-induced cytopathogenicity by MTT assay	2008	Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7	Thiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 1: Parallel synthesis, molecular modelling and structure-activity relationship studies on O-[2-(hetero)arylethyl]-N-phenylthiocarbamates.
AID104409	Antiviral activity of Protein Binding of compound was evaluated for E virus expressed MT-2 by yield	2000	Journal of medicinal chemistry, May-18, Volume: 43, Issue:10	Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID1729152	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for antiviral activity against HIV 3B infected in human MT4 cells	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp
AID448397	Fold resistance, ratio of IC50 for HIV reverse transcriptase with K103N mutant to IC50 for HIV wild type reverse transcriptase	2009	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19	Pyrazole NNRTIs 3: optimisation of physicochemical properties.
AID302264	Inhibition of HIV1 reverse transcriptase Y1811 mutant	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID1653629	Activation of recombinant human C-terminal 4His-tagged CYP46A1 delta(2 to 50) Y427A mutant expressed in Escherichia coli at 20 uM using cholesterol as substrate measured after 30 mins in presence of cytochrome P450 oxidoreductase by gas chromatography-mas	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds.
AID562120	Apparent oral volume of distribution in patient with HIV infection at 600 mg/kg QD	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients.
AID1574385	Inhibition of recombinant HIV-1 His-tagged reverse transcriptase p66/p51 K103N mutant expressed in Escherichia coli assessed as reduction in [3H]dTTP incorporation using poly(rA)/oligo(dT) as template/primer after 20 mins by scintillation counting analysi	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.
AID1410485	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 RES056 reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery.
AID443685	Antiviral activity against HIV with reverse transcriptase K103N/G190A double mutant assessed as inhibition of viral replication	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
AID519971	Selectivity ratio of EC50 for 0.005 MOI HIV1 NL4-3 harboring M184V mutant RT to EC50 for 0.005 MOI HIV1 NL4-3 harboring wild type RT infected in human MT2 cells	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID1687680	Antiviral activity against wild type HIV-1 strain 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities.
AID1627028	Cytotoxicity against HIV1 infected African green monkey Vero cells assessed as reduction in cell viability after 7 days by MTT assay	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Discovery, characterization, and lead optimization of 7-azaindole non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1596752	Antiviral activity against HIV-1 3B harboring reverse transcriptase E138K mutant infected in MT4 cells measured after 5 days by MTT assay	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Synthesis and biological evaluation of dihydroquinazoline-2-amines as potent non-nucleoside reverse transcriptase inhibitors of wild-type and mutant HIV-1 strains.
AID1815377	Anti-HIV activity against HIV-1 IIIB infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID1157602	Antiviral activity against HIV1 MP634 infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID1357802	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 harboring reverse transcriptase E138K mutant	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID1773441	Antiviral activity against wild type HIV2 ROD infected in human MT4 cells assessed as reduction in virus-induced cytopathogenic effect by MTT assay
AID757626	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2013	European journal of medicinal chemistry, Jul, Volume: 65	Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID368566	Inhibition of wild type HIV1 reverse transcriptase-DNA-dNTP ternary complex	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.
AID1485971	Inhibition of HIV-1 reverse transcriptase V106A mutant assessed as reduction in dTTP incorporation using poly(rA)/oligo(dT)16 as template/primer after 40 mins by PicoGreen dye based spectrofluorometric analysis	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Searching for novel N
AID443698	Antiviral activity against HIV with reverse transcriptase G190A mutant assessed as inhibition of viral replication relative to wild type	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
AID757621	Inhibition of recombinant wild type HIV1 RT using poly(rA)/oligo(dT)16 as template after 40 mins by spectrofluorometric analysis	2013	European journal of medicinal chemistry, Jul, Volume: 65	Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1761008	Selectivity index, ratio of CC50 for human TZM-bl cells to EC50 for wild type HIV1 NL4-3 infected in human TZM-bl cells	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Design, synthesis, and evaluation of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase.
AID519889	Selectivity ratio of EC50 for 0.005 MOI HIV1 NL4-3 infected in human MT2 cells by MTS assay to EC50 for 0.005 MOI HIV1 NL4-3 infected in human MT2 cells by RT assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID508760	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase K103N, V108I mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID523358	Antiviral activity against HIV1 with RT connection domain G190A/N348Ib mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID508759	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase K103N, Y181C mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1163253	Trypanocidal activity against nifurtimox-sensitive Trypanosoma cruzi Tulahuen CL2 infected in human MRC5 SV2 cells assessed as parasite growth inhibition after 168 hrs by beta-galactosidase assay	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID586381	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase S153Y mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficiency vi	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID1653633	Binding affinity to recombinant human C-terminal 4His-tagged CYP46A1 delta(2 to 50) mutant expressed in Escherichia coli at 15 to 30 uM in absence of substrate by UV-spectrophotometric method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds.
AID1558849	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for antiviral activity against HIV1 3B infected in human MT4 cells incubated for 5 days by MTT assay	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Ligand-Based Design of Nondimethylphenyl-Diarylpyrimidines with Improved Metabolic Stability, Safety, and Oral Pharmacokinetic Profiles.
AID663297	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.
AID370733	Therapeutic index, ratio of IC50 for HIV1 3B to TC50 for human C8166 cells	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations.
AID1373152	Inhibition of reverse transcriptase Y181C mutant in HIV1 infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3	Structural optimization of N
AID330490	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 RES053	2008	Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7	Synthesis and biological evaluation of novel 6-substituted 5-alkyl-2-(arylcarbonylmethylthio)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID279456	Antiviral activity against HIV1 isolate with RT 188H mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID302266	Resistance index, ratio of Ki for HIV1 RT K103N mutant to Ki for wild type HIV1 3B reverse transcriptase	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID586361	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase T66K mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficiency vir	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID366548	Inhibition of HIV1 wild-type reverse transcriptase by scintillation counting assay	2008	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 18, Issue:15	Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID621982	Inhibition of DNA-dependent DNA polymerase activity of HIV1 reverse transcriptase p66/p66 homodimer L100I mutant using activated DNA and [alpha-32P]dATP after 30 mins by liquid scintillation counting	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID1822275	Selectivity index, ratio of CC50 for cytotoxicity against human MT4 cells to EC50 for antiviral activity against HIV-1 IIIB infected in human MT4 cells	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.
AID586372	Antiviral activity against Human immunodeficiency virus 1 NL432 harboring integrase Y143H mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 2 to 3 days by PCR relative to wild type Human immunodeficiency vi	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
AID1275546	Antiviral activity against HIV1 3B expressing reverse transcriptase E138K mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
AID81766	Compound was evaluated for its ability to inhibit the wild type RF strain of HIV-1	2001	Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11	4,1-Benzoxazepinone analogues of efavirenz (Sustiva) as HIV-1 reverse transcriptase inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745855	NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745854	NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID977608	Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB	2002	European journal of biochemistry, Mar, Volume: 269, Issue:6	Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	131 (4.43)	18.2507
2000's	1071 (36.23)	29.6817
2010's	1416 (47.90)	24.3611
2020's	338 (11.43)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	631 (20.29%)	5.53%
Trials	0 (0.00%)	5.53%
Reviews	204 (6.56%)	6.00%
Reviews	0 (0.00%)	6.00%
Case Studies	201 (6.46%)	4.05%
Case Studies	0 (0.00%)	4.05%
Observational	64 (2.06%)	0.25%
Observational	0 (0.00%)	0.25%
Other	2,010 (64.63%)	84.16%
Other	12 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (317)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Open Label, Randomized Trial of TDF/FTC+Raltegravir Vs. TDF/FTC+Efavirenz in HIV-1-Infected Women: Differential Effects on Viral Suppression/Reservoir, & Immune Parameters in Different Compartments, Including Gut & Genital Tract [NCT00984152]	Phase 3	0 participants (Actual)	Interventional	2011-06-30	Withdrawn(stopped due to Decision not to go forth with study.)
Comparison of Virological and Immunological Results of Efavirenz-based Regimen in HIV-infected Patients With or Without Allergic Reactions to Nevirapine [NCT01044810]		559 participants (Actual)	Observational	2010-01-31	Completed
An Open-label Study of Liquid and Sprinkled Formulations of Efavirenz Administered in Combination With Didanosine and Emtricitabine in HIV-infected Infants and Children 3 Months to 6 Years of Age. [NCT00364793]	Phase 1/Phase 2	56 participants (Actual)	Interventional	2007-02-28	Completed
A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA™ [NCT00369941]	Phase 3	566 participants (Actual)	Interventional	2006-08-31	Completed
Bioavailability Mechanistic Study of Hot-Melt-Extruded Amorphous Solid Dispersions [NCT03886766]		16 participants (Actual)	Interventional	2019-04-30	Completed
Clinical Trial of CNS Penetrating ART to Prevent NeuroAIDS in China [NCT01340950]	Phase 4	250 participants (Actual)	Interventional	2010-07-31	Completed
A Randomized, Pilot Estimation Study to Compare the Safety and Efficacy of Raltegravir+TDF+3TC Versus TDF+3TC+EFV in HBV/HIV Co-infected Patients [NCT01318096]		60 participants (Anticipated)	Interventional	2011-03-31	Not yet recruiting
Pharmacokinetics of Tenofovir and Tenofovir-diphosphate, Emtricitabine and Emtricitabine-triphosphate, and Efavirenz Once Daily Over 10 Days Following Drug Intake Cessation in Healthy Volunteers [NCT01108926]	Phase 1	19 participants (Actual)	Interventional	2010-06-30	Completed
An Open-label, Parallel Drug Interaction Study to Evaluate the Effect of a CYP3A Moderate Inducer Efavirenz on the Pharmacokinetics of Quizartinib in Healthy Subjects [NCT04459598]	Phase 1	32 participants (Actual)	Interventional	2020-08-19	Completed
Phase 2 Comparison of Low-Dose Naltrexone vs ARV Effectiveness in HIV+ Progression [NCT01174914]	Phase 2	171 participants (Actual)	Interventional	2008-03-31	Completed
"Single-center, Randomized, Five-way Crossover Study to Investigate Low-dose Combinations of Caffeine, Efavirenz, Losartan, Omeprazole, Metoprolol, Chlorzoxazone and Midazolam (Basel Cocktail) for Simultaneous Phenotyping of CYP1A2, CYP2B6, CYP2C9, CYP2C1 [NCT01187862]	Phase 1	16 participants (Actual)	Interventional	2010-07-31	Completed
A Study to Evaluate the Potential Drug-Drug Interaction Between Efavirenz and Danoprevir With Low Dose Ritonavir When Administered Together in Healthy Adult Volunteers [NCT01588002]	Phase 1	40 participants (Actual)	Interventional	2012-04-30	Completed
The Effects of Maraviroc Versus Efavirenz in Combination With Zidovudine/Abacavir on the CD4/CD8 Ratio in Treatment-naïve HIV-infected Individuals [NCT03178084]	Phase 3	721 participants (Actual)	Interventional	2014-10-15	Completed
The Risk of Cardiovascular Events Among HIV Patients Initiating Efavirenz-containing Versus Efavirenz-free Antiretroviral Regimens [NCT02426866]		29,612 participants (Actual)	Observational	2014-12-31	Completed
Impact of a Dolutegravir-based Regimen on Early Mortality of Severely Immunocompromised AIDS Patients [NCT01837277]	Phase 2/Phase 3	186 participants (Actual)	Interventional	2017-12-15	Completed
A Phase I, Open-label, Fixed-sequence, Two-period, Crossover, Drug-drug Interaction Study to Investigate the Effect of Efavirenz on the Pharmacokinetics of Ganaplacide and Lumefantrine Combination in Healthy Participants [NCT05330273]	Phase 1	14 participants (Actual)	Interventional	2022-04-28	Completed
Efavirenz Pharmacokinetics and Pharmacogenomics in Older HIV-infected Patients [NCT01886404]		30 participants (Actual)	Observational [Patient Registry]	2013-12-01	Completed
"Safeguard the Household - A Study of HIV Antiretroviral Therapy Treatment Strategies Appropriate for a Resource Poor Country" [NCT00255840]		812 participants (Actual)	Interventional	2006-07-31	Completed
A PHASE 1, RANDOMIZED, OPEN LABEL, 2-WAY CROSSOVER STUDY TO ESTIMATE THE EFFECT OF MULTIPLE DOSE PF-06651600 ON THE PHARMACOKINETICS OF SINGLE DOSE MIDAZOLAM AND EFAVIRENZ IN HEALTHY PARTICIPANTS [NCT03762928]	Phase 1	12 participants (Actual)	Interventional	2018-12-07	Completed
A Phase IIIB, Randomized Trial of Open-Label Efavirenz or Atazanavir With Ritonavir in Combination With Double-Blind Comparison of Emtricitabine/Tenofovir or Abacavir/Lamivudine in Antiretroviral-Naive Subjects [NCT00118898]	Phase 3	1,864 participants (Actual)	Interventional	2005-09-30	Completed
A Phase 3, Randomized, Multicenter Study of the Treatment of Antiretroviral-Naive HIV-1 Infected Subjects Comparing Tenofovir Disoproxil Fumarate and Emtricitabine in Combination With Efavirenz vs Combivir (Lamivudine/Zidovudine) and Efavirenz [NCT00112047]	Phase 3	517 participants (Actual)	Interventional	2003-07-31	Completed
An Evaluation of the Uptake and Safety of, and Adherence to Antiretroviral Treatment Among Individuals With CD4 ≥ 250 Cells/mm3 and HIV Virus Load ≥ 50,000 cp/mL [NCT01583439]		11 participants (Actual)	Interventional	2012-09-30	Terminated(stopped due to Low Accrual.)
Bioequivalence Study of Efavirenz, Emtricitabine and Tenofovir in Healthy Volunteers, After Administering a Single Dose of a Fixed Dose Combination of the Test Formulation With Respect to the Reference Product, Atripla ® From Gador S.A [NCT03309566]	Phase 4	24 participants (Actual)	Interventional	2016-09-04	Completed
PI or NNRTI as First-line Treatment of HIV in a West African Population With Low Adherence - the PIONA Trial [NCT01192035]	Phase 4	400 participants (Actual)	Interventional	2011-05-31	Completed
Reverse Triple Negative Immune Resistant Breast Cancer [NCT05076682]	Phase 2	30 participants (Anticipated)	Interventional	2022-06-30	Recruiting
Switching Tenofovir/Emtricitabine/Efavirenz to Tenofovir/Emtricitabine/Rilpivirine Versus Continuing Tenofovir/Emtricitabine/Efavirenz in HIV1-infected Patients With Complete Virological Suppression [NCT03251690]		246 participants (Actual)	Interventional	2016-10-27	Completed
Daily Antiretroviral Therapy (DART 1): An Open-Label, Single-Arm, Prospective, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Didanosine Enteric Coated (Ddl-EC) in Combination With Lamivudine (3TC) and Efavirenz (EFV) Once Daily in Anti [NCT00116415]		65 participants	Interventional	2002-03-31	Completed
A Phase 3 Study Switching HIV-1 Infected Subjects With an Undetectable Viral Load From a HAART Regimen Dosed Twice Daily or More Frequently to a Once-Daily HAART Regimen [NCT00135369]	Phase 3	300 participants	Interventional	2002-09-30	Completed
Efficacy of Simultaneous Versus Sequential Antiretroviral Therapy and Antituberculosis Treatment in Patients With AIDS and Active Tuberculosis. Open, Randomized and Controlled, Multisite Clinical Trial. [NCT00737724]		63 participants (Actual)	Interventional	2008-03-31	Terminated(stopped due to Other published trials showed definitive expected superiority of Group 1)
[NCT00523458]	Phase 4	5 participants (Actual)	Interventional	2007-07-31	Terminated(stopped due to A delay in protocol approval and approval of laboratory sites in Salvador, Brazil left too little time for completion of enrollment into the study.)
Systematic Empirical vs. Test-guided Anti-tuberculosis Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating Antiretroviral Therapy With CD4 Cell Counts <100/mm3: the STATIS Randomized Controlled Trial [NCT02057796]	Phase 4	1,050 participants (Actual)	Interventional	2014-09-30	Completed
INFLAMMATION AND DRUG METABOLISM - Does the Effect of Drugs Decrease When Patients With Type 2 Diabetes Initiate Antidiabetic Treatment? [NCT04504045]	Phase 1	10 participants (Actual)	Interventional	2020-09-01	Terminated(stopped due to Slow recruitment due to COVID-19, the study was stopped when recruited numbers fulfilled the pre-defined lower sample size.)
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose [NCT01489046]	Phase 2	297 participants (Actual)	Interventional	2011-02-28	Terminated
The Safety and Antiviral Efficacy of Stavudine Extended Release Formulation as Compared to Stavudine Immediate Release Formulation, Each as Part of Potent Antiretroviral Combination Therapy [NCT00005918]	Phase 3	730 participants	Interventional	2000-06-30	Completed
A Single-centre, Single-dose, Open-label and Self-control Study to Evaluate the Effect of Efavirenz on Pharmacokinetic of SHR6390 in Healthy Chinese Subjects [NCT04973020]	Phase 1	20 participants (Actual)	Interventional	2021-09-01	Completed
Intensive Pharmacokinetic Studies of Antiretroviral Drug Combinations in Children [NCT00260078]	Phase 1/Phase 2	75 participants (Actual)	Interventional	2006-02-28	Completed
A Phase III, Randomized, Open-Label Trial to Evaluate Strategies for Providing Antiretroviral Therapy to Infants Shortly After Primary Infection in a Resource Poor Setting [NCT00102960]	Phase 3	377 participants (Actual)	Interventional	2005-07-31	Completed
A Study to Determine the Concentration-Electrocardiographic Effects of Efavirenz in Healthy Subjects Enriched for CYP2B6 Polymorphisms [NCT02164812]	Phase 1	58 participants (Actual)	Interventional	2014-07-31	Completed
A Phase 1, 3-Part, Open-label, Drug-Drug Interaction Study to Evaluate the Effect of a Moderate CYP3A4 Inhibitor, and of Strong and Moderate CYP3A4 Inducers on the Pharmacokinetics of TAK-279 in Healthy Subjects [NCT05995249]	Phase 1	48 participants (Anticipated)	Interventional	2023-08-11	Recruiting
Change in Sleep Architecture and Neuropsychological Performance Following Switch From Atripla to Stribild. [NCT02283060]	Phase 4	30 participants (Anticipated)	Interventional	2014-09-30	Recruiting
A Study to Compare Long-Term Safety and Tolerability of Stavudine (d4T) Extended Release (ER) Versus Conventional (Immediate Release, IR) Formulations, Each In Combination With Lamivudine (3TC) and Efavirenz (EFV) in Subjects Who Have Completed BMS Studie [NCT00116298]	Phase 3	900 participants	Interventional	2001-01-31	Completed
Peking Union Medical College Hospital [NCT04463784]		500 participants (Anticipated)	Interventional	2018-04-01	Active, not recruiting
Multicenter, Double-Blind, Randomized, Dose Ranging Study to Compare the Safety and Activity of MK0518 Plus Tenofovir and Lamivudine (3TC) Versus Efavirenz Plus Tenofovir and Lamivudine (3TC) in ART-Naive, HIV-Infected Patients [NCT00100048]	Phase 2	206 participants (Actual)	Interventional	2005-01-31	Completed
Role of Pharmacogenetics in Efavirenz and Nevirapine Pharmacokinetics, Efficacy and Safety in Mother-infant Pairs During Pregnancy and Lactation [NCT02269462]		460 participants (Actual)	Observational	2012-12-31	Completed
Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum [NCT00042289]		1,578 participants (Actual)	Observational	2003-06-09	Completed
Daily Antiretroviral Therapy (DART-II): An Open-Label, Single-Arm, Prospective, Multicenter Clinical Trial To Evaluate the Efficacy and Safety fo Stavudine Extended Release (d4T XR) in Combination With Lamivudine (3TC) and Efavirenz (EFV) Once Daily in An [NCT00116116]	Phase 4	70 participants	Interventional	2002-03-31	Completed
A Phase IV Open-label, Multi-centre, Randomised, Dual-arm, Pilot Study to Assess the Feasibility of Switching Individuals Receiving Efavirenz With Continuing Central Nervous System (CNS) Toxicity, to Dolutegravir [NCT02285374]	Phase 4	40 participants (Anticipated)	Interventional	2014-11-30	Not yet recruiting
A Phase 3 Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based Regimen [NCT00135382]	Phase 3	254 participants	Interventional	2002-06-30	Completed
A Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female Subjects [NCT01268839]	Phase 1	20 participants (Actual)	Interventional	2010-01-31	Completed
Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population [NCT01180075]		85 participants (Actual)	Observational	2010-05-31	Completed
A Pilot Evaluation of the Pharmacokinetics, Efficacy and Safety of Switching From Efavirenz to Maraviroc Administered at 600mg Then 300mg Twice-daily in Patients Suppressed on an Efavirenz-containing Regimen as Initial Therapy [NCT01190293]	Phase 4	12 participants (Actual)	Interventional	2010-01-31	Completed
The Effect of Dolutegravir-based ART on Plasma Etonogestrel Levels in HIV-infected Women Using Contraceptive Implants in Botswana [NCT03336346]		148 participants (Actual)	Observational	2017-11-15	Completed
Pharmacokinetics of EFV 400mg Once Daily During Pregnancy in HIV+ Women [NCT02499874]	Phase 1	26 participants (Actual)	Interventional	2015-08-31	Completed
Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants [NCT03048422]	Phase 3	643 participants (Actual)	Interventional	2018-01-19	Completed
Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals [NCT01293123]		2 participants (Actual)	Interventional	2011-12-31	Terminated(stopped due to Did not meet enrollment goals)
Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women [NCT00993031]	Phase 3	389 participants (Actual)	Interventional	2009-12-15	Completed
A Randomized Open Label Trial of HIV Protease Inhibitors for the Prevention of Malaria in HIV-Infected Children [NCT00978068]	Phase 3	176 participants (Actual)	Interventional	2009-09-30	Completed
Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in the Treatment of Tuberculosis Patient With HIV Infection in South Africa: A Phase II Trial [NCT00640887]	Phase 2	48 participants (Anticipated)	Interventional	2009-02-28	Completed
Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics, Autoinduction and Drug Interactions in Healthy Volunteers. [NCT00668395]		73 participants (Actual)	Interventional	2007-05-31	Completed
A Single-centre, Open-label Study to Assess the Effects of Steady-state Efavirenz 600 mg QD (Sustiva®) on Tipranavir Concentration When Tipranavir/Ritonavir Are Administered at Doses 500 mg/200 mg BID to Steady-state in Healthy Adult Volunteers [NCT02226991]	Phase 1	34 participants (Actual)	Interventional	2006-04-30	Completed
A Phase 2b Randomized, Double-Blind, Double-Dummy Trial of 100 or 200 mg Once-Daily Doses of Cenicriviroc (CVC, TBR 652) or Once-Daily EFV, Each With Open-Label FTC/TDF, in HIV 1-Infected, Antiretroviral Treatment-Naïve, Adult Patients With Only CCR5-Trop [NCT01338883]	Phase 2	143 participants (Actual)	Interventional	2011-06-30	Completed
Evaluation of the Capacity of a Weekly Strategy of 4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV-1 Infected Patients With Undetectable Viral Load for at Least 12 Months, to Maintain a Virological Success With This Intermittent M [NCT02157311]	Phase 3	100 participants (Actual)	Interventional	2014-07-31	Completed
A Randomized Study to Compare the Efficacy of Vorinostat/Hydroxychloroquine/Maraviroc (VHM) in Controlling HIV After Treatment Interruption in Subjects Who Initiated ART During Acute HIV Infection [NCT02475915]	Phase 1/Phase 2	15 participants (Actual)	Interventional	2015-01-31	Completed
Study of Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz in Antiretroviral-Naive, HIV-1 Infected Adult Subjects [NCT00549198]	Phase 4	392 participants (Actual)	Interventional	2007-06-30	Completed
Genetic Determinants of the Metabolism of Non-nucleoside Reverse Transcriptase Inhibitors [NCT00730223]	Phase 1	33 participants (Actual)	Interventional	2004-03-31	Completed
A Phase IIb Randomized, Partially Blinded, Dose-Finding Trial of TMC278 in Antiretroviral-Naive HIV-1 Infected Subjects [NCT00110305]	Phase 2	368 participants (Actual)	Interventional	2005-06-30	Completed
A Phase I, Double-blind, Double-dummy, Randomized, Placebo Controlled and Active Controlled Trial to Evaluate the Effect of TMC278 25 mg Daily at Steady-state and the Effect of Efavirenz (EFV) 600 mg Daily at Steady-state on the QT/QTc Interval, in 2 Rand [NCT00744809]	Phase 1	120 participants (Actual)	Interventional	2008-08-31	Completed
A Multicenter, Randomized, Double-Blind, Comparative Trial Of A Novel CCR5 Antagonist, UK-427,857, In Combination With Zidovudine/Lamivudine Versus Efavirenz In Combination With Zidovudine/Lamivudine For The Treatment Of Antiretroviral-Naive HIV-1 Infecte [NCT00098293]	Phase 3	916 participants (Actual)	Interventional	2004-11-30	Completed
Adherence to a One Pill, Once-a-day Antiretroviral Regimen [NCT00990600]	Phase 3	212 participants (Actual)	Interventional	2008-04-30	Completed
A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy Plus HIV Primary Care Versus HIV Primary Care Alone to Prevent the Sexual Transmission of HIV-1 in Serodiscordant Couples [NCT00074581]	Phase 3	3,526 participants (Actual)	Interventional	2005-02-28	Completed
The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants [NCT04424264]	Phase 1	18 participants (Actual)	Interventional	2019-12-05	Completed
Mecahnisms of Lipodystrophy in HIV-Infected Patients [NCT00457665]	Phase 4	56 participants (Actual)	Interventional	2002-02-28	Completed
A Phase 1, Open Label, Single Sequence, Three Period Study to Evaluate the Single Dose Pharmacokinetics of GSK1349572 100mg Versus 50mg and the Effect of Efavirenz 600mg Once Daily on the Pharmacokinetics, Safety and Tolerability of GSK1349572 50mg Once D [NCT01098526]	Phase 1	12 participants (Actual)	Interventional	2010-03-16	Completed
A Phase 4, Open Label, Randomized, Controlled Study to Assess the Effect on Lipid Profile of Switching From a Stable HAART Regimen of Fixed Dose Abacavir/Lamivudine (Kivexa) Plus Efavirenz, to Once Daily Atripla in Adult HIV-1 Infected Subjects With Raise [NCT00615810]	Phase 4	159 participants (Actual)	Interventional	2008-03-31	Completed
A Prospective Longitudinal Pilot Study to Measure the Effect of Intensification With Raltegravir +/- a Protease Inhibitor (PI) or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) on HIV-1 Levels in the Gut [NCT00884793]		8 participants (Actual)	Interventional	2008-09-30	Completed
Pharmacokinetic Interaction Between Coartem® and Either Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients [NCT00620438]	Phase 4	90 participants (Anticipated)	Interventional	2008-02-29	Active, not recruiting
A Single Sequence, 2-Period, Open-label Crossover Study in Healthy Subjects to Determine the Effect of a Moderate CYP3A4 Inducer on the Pharmacokinetics of Omaveloxolone [NCT05909644]	Phase 1	20 participants (Actual)	Interventional	2023-07-05	Completed
A Phase II Trial to Assess the Efficacy of Efavirenz as Second-line Monotherapy for the Treatment of Advanced Pancreatic Adenocarcinomas. [NCT00964171]	Phase 2	72 participants (Anticipated)	Interventional	2008-08-31	Recruiting
A Randomized, Double-Blind, Equivalence Trial Comparing Emtricitabine to Stavudine Within a Triple Drug Combination Containing Didanosine Plus Efavirenz in Antiretroviral-Drug Naive HIV-1 Infected Patients [NCT00006208]	Phase 3	0 participants	Interventional	2000-08-31	Active, not recruiting
Patient Preference, Sleep Quality, and Anxiety/Depression: Comparison of Raltegravir and Efavirenz [NCT00944957]		60 participants (Anticipated)	Interventional	2009-11-30	Recruiting
A Study Comparing Efficacy and Tolerance of Two Maintenance Strategies : a Monotherapy With Lopinavir/Ritonavir or a Single-tablet Triple Therapy by Efavirenz/Emtricitabin/Tenofovir in HIV-1 Infected Patients With HIV RNA Below 50 cp/mL [NCT00946595]	Phase 2/Phase 3	420 participants (Anticipated)	Interventional	2009-11-30	Completed
Cellular Pharmacology of Tenofovir and Emtricitabine for HIV Prophylaxis (Cell Prep) [NCT01040091]	Phase 1	34 participants (Actual)	Interventional	2009-12-31	Completed
"The Effect of Prior Short Course Combination Antiretroviral Therapy Administered for the Prevention of Mother-to-Child Transmission (pMTCT) of HIV-1 on Subsequent Treatment Efficacy in Treatment-Nearly Naive Participants" [NCT00442962]	Phase 4	54 participants (Actual)	Interventional	2007-05-31	Completed
A Phase III, Randomized, Double-blind Trial of TMC278 25mg q.d. Versus Efavirenz 600mg q.d. in Combination With a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-naive HIV-1 Infected Subjects. [NCT00543725]	Phase 3	680 participants (Actual)	Interventional	2008-06-30	Completed
A Phase III, Randomized, Double-blind Trial of TMC278 25 mg q.d. Versus Efavirenz 600mg q.d. in Combination With a Fixed Background Regimen Consisting of Tenofovir Disoproxil Fumarate and Emtricitabine in Antiretroviral-naive HIV-1 Infected Subjects. [NCT00540449]	Phase 3	694 participants (Actual)	Interventional	2008-05-31	Completed
A Phase I, Safety, Tolerability, and Pharmacokinetic Interaction Study of Single-Dose TMC207 and Efavirenz in Healthy Volunteers [NCT00992069]	Phase 1	37 participants (Actual)	Interventional	2009-12-31	Completed
The Stability and Bioequivalence of Tenofovir, Emtricitabine and Efavirenz (Atripla) in an Extemporaneously Prepared Oral Liquid Formulation Compared With the Commercially Available Tablet Formulation [NCT00862823]	Phase 4	14 participants (Actual)	Interventional	2009-02-28	Completed
Initiation of a Once Daily Regimen of Tenofovir, Lamivudine and Efavirenz After 4 Weeks Versus 12 Weeks of Tuberculosis Treatment in HIV-1 Infected Patients (Time Study) [NCT01014481]	Phase 4	156 participants (Actual)	Interventional	2009-10-31	Terminated(stopped due to this study was ended prematurely by ethical committees with a reason of the final outcome was achieved with no longer recruitment was needed.)
Pharmacokinetic Interactions Between Antiretroviral Agents, Lopinavir/Ritonavir and Efavirenz and Antimalarial Drug Combinations, Artesunate/Amodiaquine and Artemether/Lumefantrine. [NCT00697892]	Phase 1	38 participants (Actual)	Interventional	2005-07-31	Completed
Nucleoside-Sparing Combination Therapy With Lopinavir/Ritonavir (LPV/r) + Raltegravir (RAL) vs. Efavirenz (EFV) + Tenofovir Disoproxil Fumarate + Emtricitabine (TDF/FTC) in Antiretroviral-Naïve Patients [NCT00752856]	Phase 2	51 participants (Actual)	Interventional	2008-08-26	Completed
Pharmacokinetics of Efavirenz and Lopinavir Nano-formulations in HIV Negative Healthy Volunteers: an Adaptive Design Study [NCT02631473]	Phase 1	50 participants (Anticipated)	Interventional	2015-11-30	Suspended(stopped due to Study is on hold whilst a grant application for further funding is put together)
Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid Metabolism in ARV-naive HIV-infected Subjects [NCT00759070]	Phase 4	50 participants (Anticipated)	Interventional	2008-09-30	Active, not recruiting
TBTC Study 23C: Intensive Pharmacokinetic Study of Intermittent Rifabutin and Isoniazid With Daily Efavirenz in Combination With Two Nucleoside Analogs for Treatment of HIV and Tuberculosis Co-infections [NCT00023413]	Phase 2	20 participants	Interventional	1999-11-30	Completed
CID 0805 - Treatment of Acute HIV Infection With a Once Daily Regimen of Emtricitabine, Tenofovir and Efavirenz - A Pilot Study of Response to Therapy and HIV Pathogenesis [NCT00924898]	Phase 4	92 participants (Actual)	Interventional	2005-01-31	Completed
Adjusting Antiretroviral Therapy Dosage Using Therapeutic Drug Monitoring [NCT00836212]	Phase 4	12 participants (Anticipated)	Interventional	2008-03-31	Recruiting
Open Randomized Study to Assess the Evolution of Plasma Lipid Profile by Lipidomic in Patients Infected With Human Immunodeficiency Virus (HIV-1) With Viral Suppression That Change Atripla® to Eviplera® Compared to Continue With Atripla® [NCT02547844]	Phase 4	30 participants (Actual)	Interventional	2015-09-30	Completed
Pharmacokinetics and Safety of Antiretroviral Drugs in Lactating Women and Breastmilk Fed Infants [NCT04862975]		200 participants (Anticipated)	Observational	2024-01-08	Not yet recruiting
Decay Kinetics of HIV With the Integrase Inhibitor Raltegravir [NCT00863668]		0 participants (Actual)	Interventional	2009-03-31	Withdrawn
CID 0708 - Sex, Aging and Antiretroviral Pharmacokinetics [NCT00666055]		11 participants (Actual)	Observational	2008-03-31	Completed
Steady-state Pharmacokinetics of Efavirenz (Sustiva/Stocrin) 400 mg Once Daily in the Presence of Rifampicin and Isoniazid (Rifinah or the Local Generics) [NCT02832778]	Phase 1	35 participants (Anticipated)	Interventional	2016-11-21	Recruiting
A Phase IIb Study to Select a Once Daily Dose of GSK1349572 Administered With Either Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects [NCT00951015]	Phase 2	208 participants (Actual)	Interventional	2009-07-30	Completed
[NCT00525239]		60 participants (Anticipated)	Interventional	2004-03-31	Recruiting
A Phase I, Open-label, Randomized, Crossover Trial in 20 Healthy Subjects to Investigate the Pharmacokinetic Interactions Between the Combination of Efavirenz and Tenofovir Disoproxil Fumarate and Different Dosages of Telaprevir. [NCT00828789]	Phase 1	20 participants (Actual)	Interventional	2009-02-28	Completed
Antiretroviral Therapy and the Hepatitis C Virus [NCT00545558]	Phase 1	18 participants (Actual)	Interventional	2006-04-30	Completed
Phase 3, Single Center, Controlled, Investigator-blinded, Randomized Matched Pair Design Study of CD4 Cell Recovery in HIV-1 Patients With Sustained Virologic Response Comparing Protease Inhibitor and Non-nucleoside Reverse Transcriptase Inhibitor Based T [NCT00966160]	Phase 3	215 participants (Actual)	Interventional	1999-01-31	Completed
CCR5 Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients [NCT00988780]		276 participants (Anticipated)	Interventional	2009-12-31	Active, not recruiting
A Phase III, Double Blind, Mulit-centre, Randomised Placebo Controlled, Pilot Study to Assess the Feasibility of Switching Individuals Receiving Efavirez With Continuing Central Nervous System (CNS) Toxicity to TMC125. [NCT00792324]	Phase 3	24 participants (Actual)	Interventional	2008-06-30	Completed
A Phase 1, Open-label, 2-part Study to Evaluate the Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects [NCT03983239]	Phase 1	32 participants (Actual)	Interventional	2019-06-21	Completed
A Phase III Randomized, Open Label Trial to Evaluate Dolutegravir Versus Efavirenz 400 mg, Both Combined With Tenofovir Disoproxil Fumarate + Lamivudine for the Initial Management of HIV Infected Adults in Resource-limited Settings [NCT02777229]	Phase 3	616 participants (Actual)	Interventional	2016-07-31	Completed
A Phase 4 Study of the Effect on Immune Reconstitution of a Lopinavir/Ritonavir-Based Versus an Efavirenz-based HAART (Highly Active Antiretroviral Therapy) Regimen in Antiretroviral-Naïve Subjects With Advanced HIV Disease [NCT00775606]	Phase 4	15 participants (Actual)	Interventional	2008-10-31	Terminated(stopped due to Study stopped 12/2010 due to poor enrollment. Only 15 of 60 needed enrolled.)
Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among HIV/HCV-Coinfected Patients Receiving Two Nucleoside Analogs Plus Efavirenz: The Steral Study [NCT01900015]	Phase 4	45 participants (Actual)	Interventional	2014-02-03	Completed
Efavirenz and Ritonavir Influence on Human Brain Levo-acetylmethadol (LAAM) Disposition Assessed Using PET Imaging [NCT01935830]	Early Phase 1	10 participants (Actual)	Interventional	2013-08-31	Completed
Patient Preference, Sleep Quality, and Anxiety/Depression: A Randomized Comparison of Etravirine and Efavirenz [NCT00792584]		50 participants (Anticipated)	Interventional	2008-11-30	Completed
Study of Protease Inhibitor and/or Non-Nucleoside Reverse Transcriptase Inhibitor With Dual Nucleosides in Initial Therapy of HIV Infection [NCT00000919]		900 participants	Interventional		Completed
A Randomized, Open-Label Study of the Long-Term Effectiveness of Three Initial Highly Active Antiretroviral Therapy (HAART) Strategies in HAART-Niave, HIV-Infected Persons [NCT00000922]		1,710 participants	Interventional		Completed
A Phase III Randomized, Controlled Trial of Efavirenz (EFV) or Nelfinavir (NFV) in Combination With Fixed-Dose Combination Lamivudine/Zidovudine (3TC/ZDV) and Indinavir (IDV) in HIV-Infected Subjects With Less Than or Equal to 200 CD4 Cells/mm3 or Greater [NCT00000903]	Phase 3	444 participants	Interventional		Completed
Continued Salvage Anti-Retroviral Therapy With Abacavir, Amprenavir, and Efavirenz [NCT00001758]	Phase 2	25 participants	Interventional	1997-11-30	Completed
Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl. A Prospective, Randomized, Multicentre, Open Clinical Study. [NCT00532168]	Phase 4	108 participants (Actual)	Interventional	2007-09-30	Completed
Optimization of Antiretroviral Therapy [NCT02935075]	Phase 4	184 participants (Actual)	Interventional	2018-03-05	Completed
Optimizing Malaria Treatment for HIV-Malaria Co-Infected Individuals by Addressing Drug Interactions Between Artemether-Lumefantrine and Efavirenz; a Randomized Controlled Trial [NCT04708496]	Phase 4	888 participants (Anticipated)	Interventional	2021-01-18	Recruiting
Pharmacokinetics of Efavirenz During Treatment of HIV-1 Infected Subjects With Hepatic Impairment. [NCT00162097]	Phase 1	21 participants (Actual)	Interventional	2004-11-30	Completed
Multicentric Randomised Controlled Trial Assessing the Efficacy of Two Strategies of Structured Treatment Interruption of Highly Active Antiretroviral Therapy (HAART) Compared With a Continuous HAART in HIV- Infected Adults in Abidjan [NCT00158405]	Phase 3	840 participants (Actual)	Interventional	2002-12-31	Completed
A Randomised, Open-label, 96-week Study Comparing the Safety and Efficacy of Three Different Combination Antiretroviral Regimens as Initial Therapy for HIV Infection. [NCT00335322]	Phase 4	329 participants (Actual)	Interventional	2007-02-28	Completed
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PE [NCT00084136]	Phase 4	1,571 participants (Actual)	Interventional	2005-05-31	Completed
A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen [NCT00135343]	Phase 3	60 participants	Interventional	2004-04-30	Completed
A Single-Center, Single-Arm, Open-Label, Fixed-Sequence Phase I Drug-Drug Interaction Clinical Study of the Effect of Efavirenz on Pharmacokinetics of Maleate Pyrotinib in Chinese Healthy Subjects. [NCT04680091]	Phase 1	20 participants (Actual)	Interventional	2020-11-12	Active, not recruiting
Phase 3 Randomized Trial Evaluating the Virological Efficacy and the Tolerance of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Dakar and Yaounde [NCT00573001]	Phase 3	120 participants (Actual)	Interventional	2008-07-31	Completed
Hepatic Safety of Raltegravir-based and Efavirenz-based Antiretroviral Regimens in Antiretroviral-Naïve HIV-infected Subjects Co-Infected With Hepatitis C [NCT01147107]	Phase 4	80 participants (Actual)	Interventional	2014-02-28	Completed
A Randomized, Pilot Study on the Antiviral Activity and Immunological Effects of Lopinavir/Ritonavir vs. Efavirenz in Treatment-naïve HIV-Infected Patients With CD4 Cell Counts Below 100 Cells/mm3 [NCT00386659]	Phase 4	60 participants	Interventional		Terminated
Randomized, Controlled, Open Label, Multi-Center Phase III Trial Comparing the Safety and Antiviral Activity of a Protease-Containing Regimen (d4T/ddI/IDV/RTV) Versus a Protease-Sparing Regimen (d4T/ddI/EFV) and the Ability of Interleukin-2 to Purge HIV F [NCT00006154]	Phase 3	165 participants (Anticipated)	Interventional		Completed
The Study of Mechanisms of Lipodystrophy in HIV-Infected Patients [NCT00006190]	Phase 4	0 participants	Interventional	2000-11-30	Completed
Comparison of the Virologic Efficacy of Nelfinavir and/or DMP 266 (Efavirenz, EFV) in Combination With One or Two New Nucleoside Analogs in Nucleoside Experienced Subjects: A Roll-Over Study to ACTG 302/303 [NCT00001087]	Phase 2	300 participants	Interventional		Completed
Pharmacodynamics of Efavirenz 400mg in Treatment-naïve Chinese HIV-infected Patients in a Prospective Cohort Study [NCT04596488]		25 participants (Actual)	Interventional	2017-06-01	Completed
Treatment Outcome of Children With HIV Infection [NCT00476606]		1,000 participants (Anticipated)	Observational	2003-03-31	Active, not recruiting
Effect of Encapsulation Upon Efavirenz Pharmacokinetics [NCT01087814]	Phase 4	16 participants (Actual)	Interventional	2010-02-28	Completed
Effect of CYP2B6 Genotype and Efavirenz on the Disposition and Pharmacodynamic of Methadone and Tizanidine in Healthy Volunteers [NCT05789173]	Early Phase 1	60 participants (Anticipated)	Interventional	2023-10-06	Recruiting
Phase III Open-label Randomized Multicenter Trial to Assess the Non-inferiority of Raltegravir Compared With EFavirenz, Both in Combination With LAmivudine and TEnofovir, in ART-naïve HIV-1-infected Patients Receiving Rifampin for Active TuBerculosis [NCT02273765]	Phase 3	460 participants (Actual)	Interventional	2015-09-11	Completed
Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment Regimens (REMEMBER) [NCT01380080]	Phase 4	851 participants (Actual)	Interventional	2011-10-31	Completed
Effect of Cytochrome P450 2B6 Genetic Polymorphism and Voriconazole on CYP2B6 Activity in Healthy Volunteers [NCT01104376]		61 participants (Actual)	Interventional	2010-03-31	Completed
Phase II Open-label Randomized Multicenter Trial to Compare the Efficacy and Safety of Two Different Doses of Raltegravir and Efavirenz, All in Combination With Tenofovir and Lamivudine, in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuber [NCT00822315]	Phase 2	155 participants (Actual)	Interventional	2009-07-31	Completed
Safety and Efficacy of the Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations in Pregnant and Breastfeeding Women to Prevent mother-to Child Transmission of HIV-1 o, Resource-limited Settings: A Multicentre Randomized Phase 3 Clinical Trial [NCT00936195]	Phase 3	0 participants (Actual)	Interventional	2010-01-31	Withdrawn(stopped due to faillure to obtain insurance because of refusal from insurance companies)
Dose-Finding and Pharmacogenetic Study of Efavirenz in HIV-infected and HIV/TB Co-infected Infants and Children 3 Months to Less Than 36 Months of Age [NCT00802802]	Phase 1	67 participants (Actual)	Interventional	2010-02-10	Completed
Adjunctive Therapy With Telmisartan Instituted With ART During Acute HIV Infection to Reduce the Establishment of CNS Reservoirs of HIV and Lymph Node Fibrosis [NCT02750059]	Phase 2	21 participants (Actual)	Interventional	2015-01-31	Completed
A Phase IIb, Multi-centre, Randomised, Double-blind, Active-controlled Trial Comparing the Neuropsychiatric Adverse Event Profile of Etravirine 400mg qd Versus Efavirenz 600mg qd in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors [NCT00903682]	Phase 2	157 participants (Actual)	Interventional	2009-06-30	Completed
Trial for the Optimal Timing of HIV Therapy After Cryptococcal Meningitis [NCT01075152]	Phase 4	177 participants (Actual)	Interventional	2010-11-30	Completed
A Long Term Open-Label Extension Study Of Lersivirine For The Treatment Of HIV-1 Infection [NCT01254656]	Phase 2	108 participants (Actual)	Interventional	2011-02-28	Terminated(stopped due to See termination reason in detailed description.)
A Randomized, Phase II, Placebo Controlled Trial of Abacavir (ABC, 1592U89) in Combination With Open-Label Indinavir Sulfate (IDV) and Efavirenz (EFV, DMP-266) in HIV-Infected Subjects With Nucleoside Analog Experience: A Rollover Study for ACTG 320 [NCT00001086]	Phase 2	300 participants	Interventional		Completed
ART Drug Dosage Adjustment Using FSCII in Chinese HIV-infected Population [NCT02632474]	Phase 4	10 participants (Actual)	Interventional	2015-04-30	Completed
A Phase II, Randomized, Open-Label Study of Maximally Assisted Therapy (MAT) Compared to Self-Administered Therapy (SAT) for the Treatment of HIV Infection in Antiretroviral Naive Subjects With CD4 Greater Than or Equal to 200 Cells/mm3 [NCT00001122]	Phase 2	74 participants	Interventional		Completed
An Open-Label Drug Interaction Study to Investigate the Effects of Steady State Fenofibric Acid on the Single-Dose Pharmacokinetics of Efavirenz in Healthy Volunteers [NCT00960570]	Phase 1	30 participants (Actual)	Interventional	2008-02-29	Completed
Pharmacokinetics and Pharmacodynamics of the Etonogestrel Contraceptive Implant When Co-administered With Efavirenz [NCT01980342]	Phase 4	1 participants (Actual)	Interventional	2014-10-31	Terminated(stopped due to loss of funding)
Anti-retroviral Efficacy, Tolerance and Other Pharmacologic Interactions of the Non Nucleoside Analog Efavirenz in Association With Rifampicin to Treat Tuberculosis and AIDS [NCT00533390]	Phase 4	130 participants (Actual)	Interventional	2007-01-31	Terminated(stopped due to Lack of financial support and low inclusion rate)
Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin in Antiretroviral Naive Patients Co-infected With HIV and Tuberculosis in India. [NCT01805258]	Phase 3	135 participants (Actual)	Interventional	2007-06-30	Completed
A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE, 2-PERIOD STUDY TO ESTIMATE THE EFFECT OF MULTIPLE DOSE ABROCITINIB ON THE PHARMACOKINETICS OF SINGLE DOSES OF CAFFEINE, EFAVIRENZ, AND OMEPRAZOLE IN HEALTHY PARTICIPANTS [NCT05067439]	Phase 1	13 participants (Actual)	Interventional	2021-10-21	Completed
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266) [NCT00162227]		0 participants	Expanded Access	2000-09-30	No longer available
Analysis of Lipodystrophy in HIV-Infected Individuals A Prospective, Non-randomised, 48 Week Study of the Effect of PI Containing and Non-PI Containing Antiretroviral Regimens on the Expression of Adipocyte Specific Genes, Protein Levels and Cellular Stru [NCT00192660]	Phase 4	80 participants (Actual)	Interventional	2003-02-28	Completed
Implementing Anti-Retroviral Therapy in Resource-Constrained Settings: A Randomized Controlled Trial to Assess the Effect of Integrated Tuberculosis and HIV Care on the Incidence of AIDS-Defining Conditions or Mortality in Subjects Co-Infected With Tuberc [NCT00091936]		592 participants (Anticipated)	Interventional	2009-08-31	Completed
The Adult Antiretroviral Treatment and Resistance Study (Tshepo) [NCT00197613]	Phase 3	650 participants	Interventional	2002-12-31	Completed
Disulfiram Interactions With HIV Medications: Clinical Implications [NCT00878306]	Phase 1	40 participants (Actual)	Interventional	2008-11-30	Completed
A Randomized, Double-blind, Double-simulated, Active-controlled，Phase III Clinical Study Evaluating the Efficacy and Safety of Azvudine Combined With Tenofovir Fumarate and Efavirenz in Hiv-infected Treatment Naive Patients [NCT04303598]	Phase 3	720 participants (Anticipated)	Interventional	2020-04-01	Not yet recruiting
Pilot Trial to Evaluate the Efficacy and Tolerance of a Simple Once Daily Combined Regimen Including Tenofovir (TDF), Emtricitabine (FTC) and Efavirenz (EFV) in HIV-1 Infected Patients Naive to Prior Antiretroviral Treatment in Senegal [NCT00158457]	Phase 3	40 participants (Actual)	Interventional	2004-06-30	Completed
The Optimization of HAART for Chinese--a RCT Study [NCT02945163]	Phase 4	184 participants (Actual)	Interventional	2018-03-05	Completed
Phase 2b Study to Select a Once Daily Oral Dose of GSK2248761 Administered With Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects [NCT01231555]	Phase 2	23 participants (Actual)	Interventional	2010-11-18	Terminated
A Phase II Trial to Assess the Efficacy of Efavirenz in Metastatic Patients With Androgen-independent Prostate Cancer [NCT00964002]	Phase 2	61 participants (Actual)	Interventional	2008-05-31	Completed
A Phase II, Randomized, Open-Label Comparative Trial of Salvage Antiretroviral Therapies for HIV-Infected Individuals With Virological Evidence of Nelfinavir Treatment Failure as Reflected by Plasma HIV RNA Concentration of >= 1,000 Copies/ml [NCT00000918]	Phase 2	300 participants	Interventional		Completed
Early Antiretroviral Therapy in Resource Limited Settings in Patients With High CD4+ Cell Counts (EARLI) [NCT01479634]		279 participants (Actual)	Interventional	2011-10-31	Completed
The Pharmacokinetics of Co-formulated Emtricitabine/Tenofovir/Efavirenz in HIV-infected Patients With Smear-positive Pulmonary Tuberculosis in the Kilimanjaro Region, Tanzania [NCT00474435]	Phase 2	30 participants (Anticipated)	Interventional	2008-11-30	Recruiting
A Pharmacokinetic Study of Once Daily Efavirenz 400 mg Versus 600 mg in Thai HIV-1 Infected Subjects [NCT00476424]	Phase 2	28 participants (Actual)	Interventional	2007-06-30	Completed
Efavirenz-based Versus Nevirapine-based Antiretroviral Therapy Among HIV-infected Patients Receiving Rifampin [NCT00483054]	Phase 3	142 participants (Actual)	Interventional	2007-01-31	Completed
Randomized Non-inferiority Trial Comparing the Nevirapine-based Antiretroviral Therapy Versus the Standard Efavirenz-based ART for the Treatment of HIV-TB Co-infected Patients on Rifampicin-based Therapy (ANRS 12146 CARINEMO) [NCT00495326]	Phase 2/Phase 3	570 participants (Actual)	Interventional	2007-12-31	Completed
Randomized, Non-inferiority Trial Comparing a Dual Maintenance Therapy Strategy With Dolutegravir + Lamivudine (DTG/3TC) or Atazanavir/Ritonavir + Lamivudine (ATV/r+3TC) Versus the Standard WHO First Line Triple Therapy Tenofovir + Lamivudine + Efavirenz [NCT04022967]	Phase 3	480 participants (Actual)	Interventional	2020-09-21	Active, not recruiting
Randomized, Double-Blinded Clinical Trial to Evaluate the Incidence and Severity of Neuropsychiatric Side Effects and Antiviral Efficacy of Efavirenz Given as a Stepped Dosage Over 2 Weeks Versus the Usual Dosage in HIV-Infected Patients. [NCT00556634]	Phase 4	114 participants (Actual)	Interventional	2006-04-30	Completed
A Randomized Study to Evaluate the Effect of Switching From Efavirenz to Atazanavir/ Ritonavir on Lipoatrophy and Mitochondrial Dysfunction in HIV-infected Subjects With Good Virologic Suppression [NCT01194856]	Phase 4	1 participants (Actual)	Interventional	2010-10-31	Terminated(stopped due to Closed due to low enrollment)
A Pharmacokinetic Evaluation of Levonorgestrel Implant and Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based Antiretroviral Therapy in HIV-infected Ugandan Women [NCT01789879]	Phase 2	60 participants (Actual)	Interventional	2014-03-04	Completed
A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy [NCT00870363]	Phase 4	44 participants (Actual)	Interventional	2009-04-30	Completed
[NCT00810303]	Phase 1	12 participants (Actual)	Interventional	2009-03-31	Completed
A Phase II, Randomized Trial of Amprenavir as Part of Dual Protease Inhibitor Regimens (Placebo-Controlled) in Combination With Abacavir, Efavirenz, and Adefovir Dipivoxil Versus Amprenavir Alone in HIV-Infected Subjects With Prior Exposure to Approved Pr [NCT00000912]	Phase 2	475 participants	Interventional		Completed
Multi-Center, Open-Label Study of the Effect of Indinavir, Efavirenz, and Adefovir Dipivoxil Combination Therapy in Patients Who Have Failed Nelfinavir [NCT00002220]	Phase 3	120 participants	Interventional		Completed
Evaluation of Immune Reconstitution in HIV Infected Patients Treated With Fortovase (Saquinavir) SGC QD Plus Ritonavir QD Plus 2 NRTIs Vs Efavirenz QD Plus 2 NRTIs [NCT00002448]	Phase 3	40 participants	Interventional	1999-10-31	Completed
An Open Label, Randomized Study to Compare Antiretroviral Therapy (ART) Initiation When CD4 is Between 15% to 24% to ART Initiation When CD4 Falls Below 15% in Children With HIV Infection and Moderate Immune Suppression [NCT00234091]	Phase 3	300 participants (Actual)	Interventional	2006-04-30	Completed
An Open-Label, Randomized Study to Determine the Impact of Antiretroviral Treatment in HCV/HIV-Coinfected Subjects With High CD4+ Cell Count on the Efficacy of Hepatitis C Treatment With Pegylated Interferon Alfa-2A and Ribavirin [NCT00100581]		2 participants (Actual)	Interventional		Completed
A Multicenter, Randomized, Open Label, Clinical Trial Comparing a QD Regimen of Didanosine, Lamivudine and Efavirenz With a Standard BID Regimen of Zidovudine, Lamivudine and Efavirenz in the Starting Treatment of Human Immunodeficiency Virus Infection (G [NCT00256828]	Phase 4	360 participants	Interventional	2004-06-30	Completed
Open-label Randomized Multicenter Study of Once Daily Antiretroviral Treatment Regimen Comparing Ritonavir Boosted Atazanavir to Efavirenz [NCT00280969]	Phase 3	71 participants (Actual)	Interventional	2005-09-30	Completed
Safeguard the Household: A Study of HIV Antiretroviral Therapy Treatment Strategies Appropriate for a Resource Poor Country [NCT00080522]		813 participants	Interventional	2005-02-28	Completed
A Randomized Clinical Trial to Determine the Efficacy of Early Versus Standard Antiretroviral Therapy in HIV Infected Adults With CD4+ T Cell Counts Between 200 and 350 Cells/mm3 [NCT00120510]		816 participants (Actual)	Interventional	2007-07-31	Completed
A Randomized, Open-Label Study Assessing Safety, Tolerability and Efficacy of an Induction-Maintenance Treatment Strategy Including Lopinavir/Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine Versus Efavirenz Plus Tenofovir Disoproxil Fumarat [NCT00121017]	Phase 2	200 participants	Interventional		Withdrawn
HAART Regimen Comprising 3TC + ddI + EFV in Once-daily Administration in HIV-1 Infected Children in Burkina Faso [NCT00122538]	Phase 2	52 participants (Actual)	Interventional	2006-02-28	Completed
Multicentre, Open Label, Prospective, Randomised Clinical Trial of an Antiretroviral Simplification Treatment With Efavirenz + Abacavir + 3TC Once Daily [NCT00314626]	Phase 3	99 participants (Actual)	Interventional	2004-11-30	Completed
Virological and Clinical Anti-HBV Efficacy of Tenofovir and Emtricitabine in Antiretroviral Naïve Patients With HIV/HBV co-Infection [NCT00127959]	Phase 4	24 participants	Interventional	2004-03-31	Completed
A Pilot Study of Safety, Effectiveness, and Adherence of Lamivudine/Zidovudine and Efavirenz (3TC/ZDV + EFV) to Treat HIV-1 Infection in Senegal [NCT00100568]		44 participants (Actual)	Interventional	2006-07-31	Completed
A Randomized Comparison of Protease Inhibitor-based Versus Non-nucleoside Reverse Transcriptase Inhibitor-based Antiretroviral Therapy for Initial Treatment of Individuals With AIDS-related Kaposi's Sarcoma in Sub-Saharan Africa [NCT00444379]	Phase 4	224 participants (Actual)	Interventional	2007-04-30	Completed
A Phase I, 2-panel, Open-label, Randomized, Crossover Trial in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and Antiretroviral Agents, Efavirenz and Raltegravir, at Steady State [NCT01241773]	Phase 1	48 participants (Actual)	Interventional	2010-10-31	Completed
A Single-centre, Single-arm, Open-label and Fixed-sequence Drug-drug Interaction Study to Evaluate the Effect of Efavirenz on the Pharmacokinetics of SHR2150 in Healthy Chinese Subjects [NCT05141422]	Phase 1	20 participants (Actual)	Interventional	2021-12-13	Active, not recruiting
A Phase III, Double-Blind, Placebo-Controlled, Multicenter Study to Determine the Effectiveness and Tolerability of the Combination of DMP 266 and Indinavir Versus Indinavir in HIV-Infected Patients Receiving Nucleoside Analogue (NRTI) Therapy [NCT00002393]	Phase 3	300 participants	Interventional		Completed
A Study of the Effects of Combination Antiretroviral Therapy in Acute HIV-1 Infection With an Emphasis on Immunological Responses [NCT00001119]		288 participants	Interventional	1999-10-31	Completed
The Effect of Efavirenz and Nelfinavir on the Pharmacokinetics of Hydroxymethylglutaryl Coenzyme A Reductase Inhibitors [NCT00017758]	Phase 1	56 participants	Interventional		Completed
Canadian Sustiva Oral Liquid Expanded Access Program: An Open-Label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP266) [NCT00162188]		0 participants	Expanded Access	2001-05-31	No longer available
Pilot Study on Efficacy and Safety of a Once Daily FTC, ddI, Efavirenz Combination in Antiretroviral Naive HIV Infected Adults. ANRS 091 MONTANA [NCT00196599]	Phase 2	39 participants	Interventional	1999-02-28	Completed
Treatment Options for Protease Inhibitor-exposed Children [NCT01146873]	Phase 3	300 participants (Actual)	Interventional	2010-07-31	Completed
Randomised Controlled Trial of Immediate Versus Deferred Antiretroviral Therapy for HIV-Associated Tuberculous Meningitis [NCT00433719]		253 participants (Actual)	Interventional	2005-09-30	Active, not recruiting
Evaluation of Safety and Efficacy of Two Different Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis Treatment in Patients With HIV-1 and Tuberculosis [NCT00332306]	Phase 3	180 participants (Anticipated)	Interventional	2006-06-30	Active, not recruiting
A Pilot Study of the Pharmacokinetic Interactions Between the Hormonal Emergency Contraception, Plan B, and Efavirenz [NCT00482963]	Phase 1	24 participants (Actual)	Interventional	2007-05-31	Completed
Efficacy and Safety of 400 mg Efavirenz Versus Standard 600 mg Dose in HIV/TB Co-infected Patients Receiving Rifampicin Based Anti-TB Therapy [NCT04513379]	Phase 3	80 participants (Anticipated)	Interventional	2020-11-01	Not yet recruiting
A Randomized Controlled Trial to Compare the Effects of Highly Active Antiretroviral Therapy (HAART) Versus Statin Therapy on Endothelial Function and Markers of Inflammation/Coagulation In HIV-Infected Individuals With High CD4 Cell Counts [NCT01515813]	Phase 2	0 participants (Actual)	Interventional	2011-11-30	Withdrawn(stopped due to On 05/08/12, team working on revising protocol and re-open study under version 2.0)
The Neurocognitive Sub Study of Encore1:A Randomised, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Efficacy of Reduced Dose Efavirenz (EFV) With Standard Dose EFV Plus 2N(t)RTI in Antiretroviral-naïve HIV-Infected Individuals [NCT01516060]	Phase 3	71 participants (Actual)	Interventional	2012-01-31	Completed
Ex Vivo Study of Immune-Reconstitution Kinetics in HIV-infected ARV-naive Subjects, With Advanced Disease, Starting a Darunavir/Ritonavir or Efavirenz Based HAART (IMMUNO Study) [NCT01541085]		33 participants (Actual)	Observational	2011-12-31	Completed
A Feasibility Study of Lamivudine/Zidovudine (3TC/ZDV) Plus Efavirenz (EFV) as Initial Therapy of HIV-1 Infected Patients in a Rural Area of China [NCT00100594]		100 participants (Anticipated)	Interventional	2005-05-31	Completed
Pilot Trial Evaluating Once Daily Triple Combination Antiretroviral Therapy With Tenofovir-Emtricitabine and Efavirenz in HIV-1 Infected Patients With Mycobacterium Tuberculosis Infection ANRS129 BKVIR [NCT00115609]	Phase 3	70 participants (Actual)	Interventional	2006-01-31	Completed
Phase II, Randomized, Open-Label Study of Switching to Protease Inhibitor-Sparing Regimens for Improvement of Metabolic Abnormalities [NCT00021463]	Phase 2	342 participants	Interventional		Completed
Effect of Change to a Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimen of Efavirenz (EFV) and Lopinavir/Ritonavir (LPV/r) on Liver Histology in HIV-1-Infected Individuals With Lactic Acidemia and Persistent Alanine Aminotransferase (ALT) [NCT00023218]		0 participants (Actual)	Interventional		Withdrawn
A Phase IV Multicenter Study of the Efficacy and Safety of 48-Week Induction Treatment With TRIZIVIR (Abacavir 300 Mg/Lamivudine 150 Mg/Zidovudine 300 Mg Combination Tablet BID) With Efavirenz (600 Mg QD) Followed by 48-Week Randomized, Open-Label, Mainte [NCT00011895]	Phase 4	400 participants	Interventional	2001-02-28	Active, not recruiting
Randomized Study to Evaluate Immediate Potent Antiretroviral Therapy for HIV-Infected Subjects With CD4 Cell Counts Less Than 350 Cells/mm3 Admitted to Intensive Care Areas With an AIDS-Defining Illness, Pneumonia, or Sepsis [NCT00028327]	Phase 3	250 participants	Interventional		Completed
A Phase I/II, Open-Label, AUC-Controlled Study to Determine the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in Children [NCT00000893]	Phase 1	103 participants (Actual)	Interventional	1997-10-31	Completed
A Randomized, Controlled Trial of Two Potent, Simplified Regimens Utilizing A Protease Inhibitor-Sparing Regimen Versus A Nucleoside-Sparing Regimen for HIV-Infected Subjects Who Participated in ACTG 388 or Who Responded to A First Potent Combination Regi [NCT00014937]		240 participants	Interventional		Completed
Pharmacokinetic Interactions Between Ritonavir, Amprenavir and Efavirenz and Nelfinavir, Amprenavir, and Efavirenz in People Infected With HIV [NCT00001766]	Phase 1	22 participants	Interventional	1998-08-31	Completed
A Phase III, Randomized, Open-label, Multicenter Study of the Safety and Efficacy of Efavirenz Versus Tenofovir When Administered in Combination With the Abacavir/Lamivudine Fixed-dose Combination Tablet as a Once-daily Regimen in Antiretroviral-naive HIV [NCT00053638]	Phase 3	345 participants	Interventional	2003-02-28	Completed
A Comparative Trial of Protease-Containing and Protease-Sparing HAART Regimens in HIV-Infected Adolescents With an Evaluation of Therapeutic Drug Monitoring [NCT00075907]	Phase 3	240 participants	Interventional	2004-07-31	Completed
Study to Evaluate the Effect of Efavirenz Coadministration on the Pharmacokinetics of the Active Moieties of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate in Healthy Female Subjects [NCT00399685]	Phase 1	28 participants (Actual)	Interventional	2006-12-31	Completed
Phase III, Randomized, Double-Blind Comparison of Three Protease Inhibitor-Sparing Regimens for the Initial Treatment of HIV Infection [NCT00013520]	Phase 3	1,125 participants	Interventional		Completed
An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Between Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) and Selected Protease Inhibitor (PI) and Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) Therapies Among HIV-Infected W [NCT00016601]		76 participants	Interventional	2001-06-30	Completed
Intensive Pharmacokinetics of the Nelfinavir-Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen [NCT00018083]		0 participants	Interventional		Recruiting
A Phase I/II, Open Label Study to Evaluate the Ability of Combination Therapy With ABT-378/Ritonavir (Kaletra), Lamivudine (Epivir), Efavirenz (Sustiva)and Tenofovir DF to Completely Suppress Viral Replication in Subjects Infected With HIV-1 [NCT00038220]	Phase 2	40 participants	Interventional	2000-07-31	Completed
An Open Label, Phase II Study of Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART [NCT00038532]	Phase 2	24 participants	Interventional	2001-04-30	Completed
A Phase III, Randomized, Open-Label Comparison of Lopinavir/Ritonavir Plus Efavirenz Versus Lopinavir/Ritonavir Plus 2 NRTIs Versus Efavirenz Plus 2 NRTIs as Initial Therapy for HIV-1 Infection [NCT00050895]	Phase 3	775 participants	Interventional		Completed
Multicenter, Pilot Study of Telbivudine (LdT) Anti-HBV Treatment Prior to the Initiation of Highly Active Antiretroviral Therapy Containing Lamivudine in Subjects Coinfected With HBV and HIV [NCT00051090]		0 participants (Actual)	Interventional		Withdrawn
Augmenting the Magnitude of HAART-Induced Immune Restoration With the Use of Cyclosporine [NCT00031070]	Phase 2	40 participants	Interventional		Completed
A Retrospective Study to Compare the 3-Year Antiviral Efficacy of Nevirapine and Efavirenz in Combination With D4t and 3tc in 2NN Patients and of Trizivir Versus Trizivir Plus Nevirapine in CHARM Patients [NCT00127972]	Phase 4	763 participants (Actual)	Interventional	2004-02-29	Completed
A Randomized, Open-Label Study Exploring a Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects [NCT00075231]	Phase 2	150 participants	Interventional	2003-12-31	Completed
Feasibility Study of a Once Daily Antiretroviral Regimen for HIV-Infected Patients With CD4 Below 200/mm3, in Hô Chi Minh City, Vietnam [NCT00158470]	Phase 3	100 participants (Actual)	Interventional	2003-09-30	Completed
A Phase 3, Randomized, Double-Blind, Multicenter Study of the Treatment of Antiretroviral-naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination With Lamivudine and Efavirenz vs. Stavudine, Lamivudine and Efavir [NCT00158821]	Phase 3	180 participants (Anticipated)	Interventional	2000-03-31	Completed
Boosted PI VS. NNRTI Based Therapy as Initial Treatment for HIV-1 Infected Patients With Advanced Disease [NCT00162643]	Phase 4	300 participants	Interventional	2004-12-31	Recruiting
Virological and Clinical Anti-HBV Efficacy of Tenofovir in Antiretroviral naïve Patients With HIV/HBV Co-infection [NCT00192595]	Phase 4	36 participants (Actual)	Interventional	2004-01-31	Completed
Phase II Randomized Trial Comparing Efficacy and Safety of the Maintenance of a HAART Association Protease Inhibitor Containing Versus a Once Daily Antiretroviral Triple Association, in HIV Adult Patients With Undetectable Viral Load.ANRS 099 ALIZE [NCT00196612]	Phase 3	350 participants	Interventional	2001-04-30	Completed
Combination of Efavirenz & Truvada (COMET Study): Phase 4 Evaluation of Switching Twice Daily Combivir to Once-Daily Regimen Co-Formulated Truvada in Virologically Suppressed HIV Infected Patients Taking Efavirenz. [NCT00224458]	Phase 4	400 participants	Interventional	2004-09-30	Completed
Randomized, Open-Label 2x2 Factorial Study to Compare the Safety and Efficacy of Different Combination Antiretroviral Therapy Regimens in Treatment Naive Patients With Advanced HIV Disease and/or CD4+ Cell Counts Less Than 200 Cells/MicroL [NCT00342355]	Phase 4	1,771 participants (Actual)	Interventional	2004-01-31	Completed
A Phase IV 48-Week, Randomized, Open-Label, Multicenter Trial of Abacavir (300mg BID)/Efavirenz (600mg QD)/Didanosine (400mg QD) +/- Hydroxyurea (500mg BID) in HIV-1 Infected Subjects Failing Initial Therapy With 3TC/ZDV (or d4T) +/- Protease Inhibitor(s) [NCT00005018]	Phase 4	150 participants	Interventional	1999-07-31	Completed
Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya (6-12 Month RCT) [NCT00427297]	Phase 3	34 participants (Actual)	Interventional	2007-09-30	Terminated(stopped due to There is no longer equipoise. DSMB recommended termination.)
Open Label Randomized Controlled Trial to Assess the Impact of Prophylactic Exposure to Tenofovir Gel on the Efficacy of Subsequent Tenofovir-containing Antiretroviral Therapy on Viral Suppression [NCT01387022]		59 participants (Actual)	Interventional	2011-06-30	Completed
A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT [NCT00727597]	Phase 3	101 participants (Actual)	Interventional	2008-07-31	Completed
Influence of Nevirapine on HCV Viral Load Among HIV/HCV-coinfected Patients [NCT01277627]		60 participants (Anticipated)	Interventional	2011-01-31	Not yet recruiting
Pharmacokinetic Interactions Between Antiretroviral Agents, Lopinavir/Ritonavir and Efavirenz and Antimalarial Drug Combination, Artemether/Lumefantrine [NCT00266058]	Phase 1	33 participants (Actual)	Interventional	2005-12-31	Completed
Molecular, Biochemical and Clinical Differences Between Stavudine and Tenofovir, Each Combined With Lamivudine and Efavirenz in South African HIV-infected Patients [NCT01601899]	Phase 4	60 participants (Actual)	Interventional	2008-10-31	Terminated(stopped due to DSMB decision to begin closeout process in view of April 2010 SA HAART guideline)
Open, Parallel and Randomised Pilot Clinical Trial to Evaluate the Utility of the Therapeutic Monitoring of Plasma Levels of Efavirenz in Hiv-Infected Patients Initiating an Antiretroviral Treatment Regimen With Sustiva [NCT00299091]	Phase 4	31 participants (Actual)	Interventional	2006-09-30	Completed
Single-center, Randomized, Open-label Study to Investigate the Effect of Single-dose Famotidine and Multiple-dose Efavirenz on the Pharmacokinetics of Daridorexant in Healthy Male Subjects [NCT04390334]	Phase 1	24 participants (Actual)	Interventional	2020-05-13	Completed
Enfuvirtide for the Initial Phase of Antiretroviral Therapy in HIV-infected Patients With High Risk of Clinical Progression : ANRS 130 APOLLO [NCT00302822]	Phase 3	195 participants (Actual)	Interventional	2006-04-30	Completed
Cross-sectional Study for the Characterisation of the Pharmacokinetic Parameters of Protease Inhibitors and Non-nucleoside Analog Reverse Transcriptase Inhibitors in the Spanish Population of HIV-infected Subjects [NCT00307502]	Phase 1	675 participants (Actual)	Interventional	2005-01-31	Completed
Viral Decay Kinetics During Induction Therapy With or Without the Use of Enfuvirtide in HAART-naÃ-ve Patients With Advanced HIV [NCT00344760]	Phase 4	2 participants (Anticipated)	Interventional	2005-01-31	Completed
BREATHER (PENTA 16) Short-Cycle Therapy (SCT) (5 Days on/2 Days Off) in Young People With Chronic HIV-infection [NCT01641016]	Phase 2/Phase 3	160 participants (Anticipated)	Interventional	2011-04-30	Active, not recruiting
Comparative Bioavailability Study of Two Efavirenz 600 mg Formulations in Healthy Volunteers. [NCT01704898]	Phase 4	12 participants (Actual)	Interventional	2013-04-30	Completed
A Prospective, Multicenter, Open, Randomized Phase 2a Trial to Confirm a Sustained Virological Suppression Defined as HIV-RNA <50 Copies/ml of 3 Different Doses of Fozivudine in Context to a Standard Zidovudine Based Antiretroviral Therapy Regimen After 2 [NCT01714414]	Phase 2	120 participants (Actual)	Interventional	2012-12-31	Completed
Influence of Efavirenz and Ritonavir on Human Brain P-Glycoprotein Activity Using PET Imaging [NCT01668147]	Phase 1/Phase 2	13 participants (Actual)	Interventional	2012-08-31	Completed
Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine [NCT01778413]	Phase 4	60 participants (Actual)	Interventional	2013-05-31	Completed
The Efficacy and Safety of Biktarvy in Treatment-Naïve Late Presenters With HIV-1 Infection [NCT04296695]	Phase 4	250 participants (Anticipated)	Interventional	2021-07-14	Active, not recruiting
A Phase II Study of the Prolongation of Virologic Success (ACTG 372A) and Options for Virologic Failure (ACTG B/C/D) in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320 [NCT00000885]	Phase 2	440 participants	Interventional		Completed
Phase II Randomized, Open-Label Study of Maintenance of HIV RNA Suppression After Switching to ddI/d4T/HU vs. ddI/d4T/EFV vs. Continuing the Pre-Entry Protease Inhibitor Regimen [NCT00000939]	Phase 2	150 participants	Interventional		Completed
A Phase II, 48-Week, Open-Label Study Designed to Evaluate the Safety, Tolerability, and Efficacy of a Simplified Dosing Regimen of Viracept (Nelfinavir Mesylate) 1250 Mg BID, Crixivan (Indinavir Sulfate) 1200mg q12h, and Sustiva (Efavirenz; DMP-266) 600 [NCT00002235]	Phase 2	6 participants	Interventional		Completed
A Randomized Evaluation of Antiretroviral Therapy Alone or With Delayed Chemotherapy Versus Antiretroviral Therapy With Immediate Adjunctive Chemotherapy for Treatment of Limited Stage AIDS-KS in Resource-Limited Settings (REACT-KS) AMC 067 [NCT01352117]	Phase 3	192 participants (Actual)	Interventional	2011-11-18	Completed
A Study on ART Naïve Patients On Different Regimens to Treat Hiv (a Phase 4 Study) [NCT01445223]	Phase 4	242 participants (Actual)	Interventional	2004-04-30	Completed
A Randomised, Double-blind, Placebo-controlled, Trial to Compare the Safety and Efficacy of Reduced Dose Versus Standard Dose EFV Plus Two Nucleotides (N(t)RTI) in Antiretroviral-naïve HIV-infected Adults Over 96 Weeks [NCT01011413]	Phase 3	636 participants (Actual)	Interventional	2011-08-31	Completed
A Randomized, Open-Label Superiority Trial Comparing Emtricitabine to Abacavir Within a Triple Drug Combination in Antiretroviral-Drug Naive HIV-1 Infected Patients [NCT00002362]	Phase 3	0 participants	Interventional	1999-08-31	Suspended
A Randomized, Placebo-Controlled Study of the Safety and Efficacy of Efavirenz, Didanosine, and Stavudine in Combination With or Without Hydroxyurea in Antiretroviral Naive or Experienced HIV-Infected Patients [NCT00002230]	Phase 3	100 participants	Interventional		Completed
A Phase II/III 48-Week, Randomized, Double-Blind, Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Lamivudine 300mg Once Daily Vs. Lamivudine 150mg BID in Combination With Zidovudine 300mg BID and Efavirenz 600mg Once Daily in Antiretr [NCT00004852]	Phase 2	0 participants	Interventional	1999-09-30	Completed
An Open-Label Study to Evaluate the Safety, Tolerance, Antiviral Activity, and Pharmacokinetics of Emtricitabine in Combination With Efavirenz and Didanosine in a Once-Daily Regimen in HIV Infected, Antiretroviral Therapy Naive or Very Limited Antiretrovi [NCT00016718]	Phase 1/Phase 2	43 participants (Actual)	Interventional	2001-08-31	Completed
A Phase II Study of ABT-378/Ritonavir and Efavirenz in Multiple Protease Inhibitor-Experienced Subjects [NCT00004582]	Phase 2	0 participants	Interventional		Completed
A Phase III, Open-label, Single Centre, Single-arm, Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Efavirenz With Continuing Central Nervous System (CNS) Toxicity, to Raltegravir [NCT01195467]	Phase 3	40 participants (Actual)	Interventional	2010-10-31	Completed
The EFV Central Nervous System Exposure Sub-study of Encore1: A Randomised, Double-blind, Placebo-controlled, Clinical Trial to Compare the Safety and Efficacy of Reduced Dose Efavirenz (EFV) With Standard Dose EFV Plus Two Nucleotide Reverse Transcriptas [NCT01451333]	Phase 3	32 participants (Actual)	Interventional	2011-09-30	Completed
Effect of Moringa Oleifera (Moringa, Drumstick/Horseradish Tree) on The Pharmacokinetics of Efavirenz and Nevirapine In-vivo. [NCT01410058]		19 participants (Actual)	Observational	2013-01-31	Completed
A Proof-of-Concept Clinical Research Study of Efavirenz in Patients With Alzheimer's Disease [NCT03706885]	Phase 1	5 participants (Actual)	Interventional	2018-05-05	Completed
A Phase III Study Comparing the Antiviral Efficacy and Safety of BMS-232632 With Efavirenz; Each in Combination With Fixed Dose Zidovudine-Lamivudine [NCT00013897]	Phase 3	0 participants	Interventional	2001-02-28	Completed
A Phase I, Three-Arm Safety, Tolerability, and Pharmacokinetic Interaction Study of PA-824, an Investigational Nitroimidazole for the Treatment of Tuberculosis, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin [NCT01571414]	Phase 1	52 participants (Actual)	Interventional	2012-05-31	Completed
A Randomized Study of the Virologic Efficacy of Different Antiretroviral (AR) Treatment Strategies in HIV-Infected Individuals With Detectable Plasma HIV RNA Measurements After at Least 16 Weeks on Their Initial Protease Inhibitor-Containing AR Regimens [NCT00000914]		800 participants	Interventional		Completed
A Phase II, 48 Week, Open-Label Study Designed to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of a Simplified Dosing Regimen of Preveon (Adefovir Dipivoxil; bis-POM PMEA), Videx (Didanosine; ddI), Sustiva (Efavirenz; DMP-266), and Ep [NCT00002234]	Phase 2	25 participants	Interventional		Completed
A Phase II, 24-Week, Open-Label Study Designed to Evaluate the Safety, Tolerability, and Efficacy of Novel Quadruple-Combination Therapy With Preveon (Adefovir Dipivoxil; Bis-POM PMEA), Abacavir (1592U89), Sustiva (Efavirenz; DMP-266), and Amprenavir (141 [NCT00002419]	Phase 2	25 participants	Interventional		Completed
A Phase II, Open-Label, Multicenter Study to Characterize the Effectiveness and Safety of Efavirenz in Combination With Stavudine and Lamivudine in Antiretroviral Therapy-Naive HIV-Infected Patients [NCT00002227]	Phase 2	60 participants	Interventional		Completed
A Controlled Phase 2 Trial Assessing Three Doses of T-20 in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz in HIV-1 Infected Adults [NCT00002239]	Phase 2	68 participants	Interventional	1999-05-31	Completed
An Open-Label, Proof of Concept, Randomized Trial Comparing a LPV/r-Based to an nNRTI-Based Antiretroviral Therapy Regimen for Clearance of Plasmodium Falciparum Subclinical Parasitemia in HIV-infected Adults With CD4+ Counts >200 and <500 Cells/mm^3 [NCT01632891]	Phase 1/Phase 2	52 participants (Actual)	Interventional	2014-01-10	Completed
A Randomized, Open-Label, Study of Nelfinavir or Efavirenz in HIV-1 Infected, Antiretroviral Naive Patients [NCT00005000]	Phase 4	200 participants	Interventional	1999-12-31	Active, not recruiting
Pharmacokinetic Interaction Studies of Amprenavir (APV), Efavirenz (EFV), and a Second Protease Inhibitor in HIV-Seronegative Volunteers [NCT00005762]		90 participants	Interventional	2001-03-31	Completed
A Phase IV, Open-Label, Randomized Study to Compare the Efficacy and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) for 96 Weeks in the Treatment of HIV-1 Infe [NCT00005017]	Phase 4	300 participants	Interventional		Active, not recruiting
A Phase IV, Open-Label, Multicenter Study of the Efficacy and Safety of Quadruple Combination Antiretroviral Therapy With Combivir (Lamivudine 150mg/Zidovudine 300mg) BID, Ziagen (Abacavir) 300mg BID, and Sustiva (Efavirenz) 600mg QD for 24 Weeks, Followe [NCT00004585]	Phase 4	40 participants	Interventional	1999-10-31	Completed
A Multicenter, Open, Randomized, Forty-Eight-Week, Pilot Study to Evaluate the Activity, Safety, and Pharmacokinetics of Indinavir Sulfate, 1200 Mg q 12h and DMP 266, 300 Mg q 12h Versus Indinavir Sulfate, 1000 Mg q 8h and DMP 266, 600 Mg q.h.s. [NCT00002387]		80 participants	Interventional		Completed
An Open Label, Randomized, Multicenter Study to Evaluate Fortovase (Saquinavir) SGC QD, Norvir (Ritonavir) QD Plus Two NRTIs Vs Sustiva (Efavirenz) QD Plus Two NRTIs in HIV Infected Patients [NCT00002447]	Phase 3	146 participants	Interventional	1999-10-31	Completed
A Phase II Study Evaluating the Safety and Antiviral Activity of Combination Therapy With 1592U89, 141W94 and DMP 266 in HIV-1 Infected Subjects With Detectable HIV-1 Plasma RNA Despite Treatment With a Protease Inhibitor Containing Regimen [NCT00002213]	Phase 2	80 participants	Interventional		Completed
A Phase II, Open-Label, Multicenter Study to Characterize the Effectiveness and Safety of Efavirenz in Combination With Stavudine and Didanosine in Antiretroviral Therapy-Naive HIV-Infected Patients [NCT00002225]	Phase 2	60 participants	Interventional		Completed
Open-Label, Multiple Dose Study to Determine the Relative Bioavailability of Atazanavir (ATV) 400 mg Administered With Ritonavir (RTV) and Efavirenz (EFV) Compared to Atazanavir 300 mg Administered With Ritonavir Alone in Healthy Subjects [NCT00357188]	Phase 1	22 participants	Interventional	2006-07-31	Completed
Phase IV, Open-Label, Randomized, Multicenter Study Evaluating Efficacy and Tolerability of Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir DF Compared to Unmodified HAART in HIV-1 Infected Subjects Who Have Achieved Virological Suppression on [NCT00365612]	Phase 4	300 participants (Anticipated)	Interventional	2006-07-31	Completed
Neuropsychiatric Adverse Effects of Efavirenz in Children Living With HIV in Kilimanjaro, Tanzania [NCT03227653]		144 participants (Actual)	Observational	2017-06-19	Completed
Investigating Influence of Pregnancy-induced Changes in Antiretroviral Pharmacokinetics, Together With Polymorphisms in Drug Disposition Genes, on Viral Decay Dynamics in HIV Positive Women Starting Therapy Late in Pregnancy and Postpartum [NCT03284645]		194 participants (Actual)	Observational	2017-12-22	Completed
Pharmacokinetics Study of Tenofovir in HIV-infected Thai Children Using Tenofovir-based Regimen [NCT02404259]		32 participants (Actual)	Interventional	2010-06-30	Completed
Influence of Cytochrome P2B6 on Efavirenz Dose in HIV-infected Thai Patients in a Prospective Randomized Controlled Trial: a Proof-of-concept Study [NCT02421289]	Phase 1	190 participants (Anticipated)	Interventional	2013-04-30	Recruiting
A Randomized Controlled Trial Comparing Efavirenz With Rilpivirine on Changes in Endothelial Function, Inflammatory Markers, and Oxidative Stress in HIV-uninfected Healthy Volunteers [NCT01585038]	Phase 4	40 participants (Actual)	Interventional	2012-07-31	Completed
HIV Postexposure Prophylaxis With Darunavir/r (PEPDar) [NCT01516970]	Phase 3	312 participants (Actual)	Interventional	2011-11-25	Completed
An Open-Label, Randomized Comparison of Elvitegravir-Cobicistat-Tenofovir Alafenamide-Emtricitabine Versus Efavirenz-Tenofovir Disoproxil Fumarate-Lamivudine in Patients Starting Antiretroviral Therapy on the Day of HIV Diagnosis [NCT03405194]		0 participants (Actual)	Interventional	2018-05-01	Withdrawn(stopped due to Haiti gained access to dolutegravir as first-line ART, so we cancelled the study before any patient was enrolled (we didn't want SOC group to receive EFV))
Safety and Pharmacokinetics of Dolutegravir in Pregnant HIV Mothers and Their Neonates: A Pilot Study [NCT02245022]	Phase 2/Phase 3	60 participants (Actual)	Interventional	2017-03-14	Completed
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients [NCT01632345]	Phase 2	342 participants (Actual)	Interventional	2012-10-12	Completed
Phase I Dose Escalation Trial of Efavirenz for Patients With Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure. [NCT01878890]	Phase 1	25 participants (Actual)	Interventional	2011-09-05	Completed
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected Treatment-naive Participants. There is a 36 Week, Open-label, Extension Phase for Eligible Participants. [NCT00350272]	Phase 2	76 participants (Actual)	Interventional	2006-05-31	Completed
A Pharmacokinetic Evaluation of Increased Dose Levonorgestrel Implant and Efavirenz-Based Antiretroviral Therapy In HIV-Infected Ugandan Women [NCT02722421]	Phase 2	28 participants (Actual)	Interventional	2017-04-06	Completed
A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Raltegravir Therapy [NCT00661960]		25 participants (Actual)	Interventional	2008-03-31	Completed
Pilot Study of Raltegravir/Tenofovir/Emtricitabine Versus Efavirenz/Tenofovir/Emtricitabine for Adults With Acute HIV-1 Infection: Exploring the Role of Integrase Inhibition in Early HIV Pathogenesis [NCT00734344]		18 participants (Actual)	Interventional	2008-09-30	Completed
A Phase 3b, Randomized, Open-label Clinical Study to Demonstrate Non-inferiority in Virologic Response Rates of HIV-1 RNA Suppression <400 Copies/mL of TDF/FTC/RPV Versus TDF/FTC/EFV in First-line Antiretroviral NNRTI-based Suppressed Patients. Switching [NCT01709084]	Phase 3	426 participants (Actual)	Interventional	2013-10-02	Completed
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and Antiretroviral Therapy (ART) [NCT01903031]	Phase 2	84 participants (Actual)	Interventional	2014-12-30	Completed
The Intensive Pharmacokinetics Sub-study of Encore1: A Randomised, Double-blind, Placebo-controlled, Clinical Trial to Compare the Safety and Efficacy of Reduced Dose Efavirenz (EFV) With Standard Dose EFV Plus Two Nucleotide Reverse Transcriptase Inhibit [NCT01271894]	Phase 3	40 participants (Actual)	Interventional	2011-09-30	Completed
A Randomized Controlled Pilot Trial Comparing Continued Antiretroviral Therapy With Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) With Switch to Tenofovir/Emtricitabine/Raltegravir (TDF/FTC/RAL) on Changes in Endothelial Function and Markers of Bone Met [NCT01270802]	Phase 4	30 participants (Actual)	Interventional	2011-04-30	Completed
A Randomized Comparison of Three Regimens of Chemotherapy With Compatible Antiretroviral Therapy for Treatment of Advanced AIDS-KS in Resource-Limited Settings [NCT01435018]	Phase 3	334 participants (Actual)	Interventional	2013-10-01	Completed
Study of the Pharmacokinetic Effects of Efavirenz on the Pharmacokinetics of SHR1459 in Healthy Subjects [NCT05560360]	Phase 1	20 participants (Actual)	Interventional	2022-11-04	Completed
Flucloxacillin as an Inducer of CYP-enzymes [NCT04840641]	Phase 1	14 participants (Actual)	Interventional	2021-03-25	Completed
An Open Label, Randomized, Parallel Design Estimation Pilot Study to Compare the Efficacy and Safety of Raltegravir-based Versus Efavirenz-based Combination Therapy in Treatment-naïve Patients With HIV-1 Infection [NCT01989910]	Phase 4	107 participants (Actual)	Interventional	2013-09-30	Completed
The Effect of Efavirenz and Ritonavir-boosted Darunavir on the Pharmacokinetics of the HMG CoA Reductase Inhibitor Pitavastatin [NCT01695954]	Phase 1	34 participants (Actual)	Interventional	2012-05-31	Completed
Randomized Clinical Trial to Evaluate the Interest of a Down-scaled Treatment Strategy Using Dual Therapy (Nucleoside Analogs) in HIV Infected Patients Already Being Treated Using Triple Therapy, Who Present With a Successful Virological Control and for W [NCT02302547]	Phase 3	224 participants (Actual)	Interventional	2014-12-31	Completed
A Phase IV Randomized Trial to Evaluate the Virologic Response and Pharmacokinetics of Two Different Potent Regimens in HIV Infected Women Initiating Triple Antiretroviral Regimens Between 20 and 36 Weeks of Pregnancy for the Prevention of Mother-to-Child [NCT01618305]	Phase 4	408 participants (Actual)	Interventional	2013-09-05	Completed
An Open-label, Drug Interaction Study to Investigate the Effects of Steady-State Fenofibric Acid on the Single-Dose Pharmacokinetics of Efavirenz in Healthy Subjects [NCT01472380]	Phase 1	30 participants (Actual)	Interventional	2011-11-30	Completed
International, Multicenter, Randomized, Partially Blind Study to Evaluate Efficacy, Safety and Selection of the Optimal Dose for VM-1500 in Comparison to Efavirenz in Combination With Two NRTIs in Treatment-naïve, HIV-1 Infected Patients [NCT02489461]	Phase 2/Phase 3	150 participants (Actual)	Interventional	2014-08-05	Completed
Influence of Autoinhibition/Autoinduction and CYP2B6 Genetic Variations on CYP2B6 Activity and Drug Interactions in Healthy Volunteers [NCT02401256]	Phase 4	70 participants (Actual)	Interventional	2013-07-31	Completed
A Randomised Trial of Monitoring Practice and Induction Maintenance Drug Regimens in the Management of Antiretroviral Therapy in Children With HIV Infection in Africa [NCT02028676]	Phase 4	1,206 participants (Actual)	Interventional	2007-03-31	Completed
Decrease of Neuropsychiatric and Neurocognitive Side Effects Prevalence [NCT02447016]	Phase 4	25 participants (Actual)	Interventional	2015-05-31	Terminated(stopped due to no more participants taking atripla)
A Phase IIb, Dose Ranging Study of Oral GSK1265744 in Combination With Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus -1 (HIV-1) Virologic Suppression Followed by an Evaluation of Maintenance of Virologic Suppres [NCT01641809]	Phase 2	244 participants (Actual)	Interventional	2012-08-06	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00016718 (3) [back to overview]	Proportion of Participants With Suppression of HIV Viral Load to Less Than 50 Copies/ml at Week 16
NCT00016718 (3) [back to overview]	Proportion of Participants With Suppression of HIV Viral Load to Less Than 400 Copies/ml at Week 16
NCT00016718 (3) [back to overview]	Proportion of Participants Who Developed Grade 3 or 4 Adverse Events Attributed to the Study Treatment.
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (95% CI) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C12) With Geometric Mean (95% CI) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C12) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C12) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C24) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	Pharmacokinetic (PK) Parameter: Infant Plasma Washout Half-life (T1/2) of ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	Pharmacokinetic (PK) Parameter: Infant Plasma Washout Concentration of ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Geometric Mean (95% CI) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	Plasma Concentration for Contraceptives
NCT00042289 (26) [back to overview]	Area Under the Curve From 0 to 12 Hours (AUC12) of ARVs for Contraceptive Arms
NCT00042289 (26) [back to overview]	Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs
NCT00042289 (26) [back to overview]	Area Under the Curve From 0 to 24 Hours (AUC24) of ARVs for Contraceptive Arms
NCT00042289 (26) [back to overview]	Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs
NCT00074581 (2) [back to overview]	Linked Partner HIV Infection Rates in Early-ART and Delayed-ART Arms
NCT00074581 (2) [back to overview]	All Partner HIV Infection Rates in Early-ART and Delayed-ART Arms
NCT00084136 (18) [back to overview]	Time to Loss of Virologic Response by Week 48 (Defined by FDA TLOVR Algorithm - Excluding Study Allowed ARV Substitutions)(PI Comparison)
NCT00084136 (18) [back to overview]	Time to Treatment Failure (NRTI Comparison)
NCT00084136 (18) [back to overview]	Time to Treatment Failure (PI Comparison)
NCT00084136 (18) [back to overview]	Change in CD4 Count From Screening to Weeks 24, 48, 96 (NRTI Comparison)
NCT00084136 (18) [back to overview]	Change in CD4 Count From Screening to Weeks 24, 48, 96 (PI Comparison)
NCT00084136 (18) [back to overview]	Plasma HIV-1 Viral Load Fewer Than 400 Copies/ml (NRTI Comparison)
NCT00084136 (18) [back to overview]	Plasma HIV-1 Viral Load Fewer Than 400 Copies/ml (PI Comparison)
NCT00084136 (18) [back to overview]	Time to Discontinuation of Initial Antiretroviral (ARV) Therapy (NRTI Comparison)
NCT00084136 (18) [back to overview]	Time to Discontinuation of Initial Antiretroviral (ARV) Therapy (PI Comparison)
NCT00084136 (18) [back to overview]	Time to First Dose Modification or Grade 3 or 4 Adverse Event (NRTI Comparison)
NCT00084136 (18) [back to overview]	Time to First Dose Modification or Grade 3 or 4 Adverse Event (PI Comparison)
NCT00084136 (18) [back to overview]	Time to Immunologic Failure (PI Comparison)
NCT00084136 (18) [back to overview]	Time to Loss of Virologic Response at Week 48 (Defined by FDA TLOVR Algorithm - Excluding Study Allowed ARV Substitutions)(NRTI Comparison)
NCT00084136 (18) [back to overview]	Time to Loss of Virologic Response at Week 48 (Defined by FDA TLOVR Algorithm - Including All ARV Substitutions)(NRTI Comparison)
NCT00084136 (18) [back to overview]	Time to Loss of Virologic Response at Week 48 (Defined by FDA TLOVR Algorithm - Including All ARV Substitutions)(PI Comparison)
NCT00084136 (18) [back to overview]	Time to Immunologic Failure (NRTI Comparison)
NCT00084136 (18) [back to overview]	Time to Loss of Virologic Response at Week 96 (Defined by FDA TLOVR Algorithm - Excluding Study Allowed ARV Substitutions)(NRTI Comparison)
NCT00084136 (18) [back to overview]	Time to Loss of Virologic Response at Week 96 (Defined by FDA TLOVR Algorithm - Including All ARV Substitutions)(NRTI Comparison)
NCT00098293 (17) [back to overview]	Time-Averaged Difference (TAD) in log10-transformed HIV-1 RNA Levels
NCT00098293 (17) [back to overview]	Percentage of Participants With HIV-1 RNA Levels of Less Than 400 Copies/mL and Less Than 50 Copies/mL at Week 96 for Enhanced Sensitivity Trofile Assay (ESTA) R5 Participants
NCT00098293 (17) [back to overview]	Percentage of Participants With HIV-1 RNA Levels of Less Than 400 Copies/mL and Less Than 50 Copies/mL at Week 96 Analyzed Using Logistic Regression
NCT00098293 (17) [back to overview]	Percentage of Participants With HIV-1 RNA Levels of Less Than 400 Copies/mL and Less Than 50 Copies/mL at Week 48 for Enhanced Sensitivity Trofile Assay (ESTA) R5 Participants
NCT00098293 (17) [back to overview]	Percentage of Participants With HIV-1 RNA Levels of Less Than 400 Copies/mL and Less Than 50 Copies/mL at Week 48 Analyzed Using Logistic Regression
NCT00098293 (17) [back to overview]	Number of Participants With Phenotypic Resistance at Time of Treatment Failure Through Week 48 and 96
NCT00098293 (17) [back to overview]	Number of Participants With NRTI Associated Mutations at Time of Treatment Failure Through Week 48 and 96
NCT00098293 (17) [back to overview]	Time to Virologic Failure
NCT00098293 (17) [back to overview]	Percentage of Participants With Viral Load of Less Than 400 Copies/Milliliter [Copies/mL] and Less Than 50 Copies/mL of Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) at Week 48 for Full Analysis Set (FAS) Population
NCT00098293 (17) [back to overview]	Number of Participants Per Tropism Status at Baseline and at the Time of Treatment Failure Through Week 96
NCT00098293 (17) [back to overview]	Number of Participants Per Tropism Status at Baseline and at the Time of Treatment Failure Through Week 48
NCT00098293 (17) [back to overview]	Change From Baseline in Lymphocyte Cluster of Differentiation 8 (CD8) Count at Week 48 and 96
NCT00098293 (17) [back to overview]	Change From Baseline in Lymphocyte Cluster of Differentiation 4 (CD4) Count at Week 48 and 96
NCT00098293 (17) [back to overview]	Change From Baseline in Log 10-transformed Plasma Viral Load (HIV-1 RNA) Levels at Week 48 and 96
NCT00098293 (17) [back to overview]	Percentage of Participants With Viral Load of Less Than 400 Copies/mL and Less Than 50 Copies/mL of HIV-1 RNA at Week 96
NCT00098293 (17) [back to overview]	Percentage of Participants With Viral Load of Less Than 400 Copies/mL and Less Than 50 Copies/mL of HIV-1 RNA at Week 48 for Per Protocol (PP) Population
NCT00098293 (17) [back to overview]	Number of Participants With Efavirenz Associated Mutations at Time of Treatment Failure Through Week 48 and 96
NCT00100048 (26) [back to overview]	Number of Participants With HIV RNA Levels Below 400 Copies/mL at Week 48
NCT00100048 (26) [back to overview]	Number of Participants With HIV RNA Levels Below 50 Copies/mL at Week 24 (Cohort II)
NCT00100048 (26) [back to overview]	Number of Participants With Clinical Adverse Experiences (AEs)and Serious Adverse Experiences (SAEs)
NCT00100048 (26) [back to overview]	Number of Patients That Discontinued With CAEs
NCT00100048 (26) [back to overview]	Number of Patients That Discontinued With LAEs
NCT00100048 (26) [back to overview]	Number of Patients With Clinical Adverse Experiences (CAEs)
NCT00100048 (26) [back to overview]	Number of Patients With Clinical Adverse Experiences (CAEs) and Number of Patients With Serious CAEs at Day 10 (Cohort I)
NCT00100048 (26) [back to overview]	Number of Patients With Drug-related CAEs
NCT00100048 (26) [back to overview]	Number of Patients With Drug-related LAEs
NCT00100048 (26) [back to overview]	Number of Patients With HIV RNA Level Below 50 Copies/mL and HIV RNA Level Below 400 Copies/mL at Week 96
NCT00100048 (26) [back to overview]	Number of Patients With Laboratory Adverse Experiences (LAEs)
NCT00100048 (26) [back to overview]	Number of Patients With Serious CAEs (Cohort I and II Combined)
NCT00100048 (26) [back to overview]	Number of Patients With Serious CAEs and Non-serious CAEs at Week 144
NCT00100048 (26) [back to overview]	Number of Patients With Serious Drug-related CAEs
NCT00100048 (26) [back to overview]	Number of Patients With Serious LAEs
NCT00100048 (26) [back to overview]	Change From Baseline in CD4 (T-helper) Cell Count at Week 240
NCT00100048 (26) [back to overview]	Change From Baseline in CD4 Cell Count at Week 96
NCT00100048 (26) [back to overview]	Change From Baseline in Cluster of Differentiation 4 (CD4) Cell Count at Week 24 (Cohort II)
NCT00100048 (26) [back to overview]	Change From Baseline in Plasma HIV RNA at Week 24 (Cohort II)
NCT00100048 (26) [back to overview]	Change From Baseline in Plasma HIV RNA at Week 240
NCT00100048 (26) [back to overview]	Number of Patients With Serious Drug-related LAEs
NCT00100048 (26) [back to overview]	Change From Baseline in Plasma HIV RNA at Week 96
NCT00100048 (26) [back to overview]	Change From Baseline in Plasma Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) on Day 10 (Cohort I)
NCT00100048 (26) [back to overview]	Number of Participants With HIV RNA (Human Immunodeficiency Virus Ribonucleic Acid) Levels Below 50 Copies/mL at Week 240
NCT00100048 (26) [back to overview]	Number of Participants With HIV RNA Levels Below 400 Copies/mL at Week 24 (Cohort II)
NCT00100048 (26) [back to overview]	Number of Participants With HIV RNA Levels Below 400 Copies/mL at Week 240
NCT00102960 (13) [back to overview]	Number of Children Experiencing Severe CDC Stage B or Stage C Disease or Death (Cumulative After 3.5 Years)
NCT00102960 (13) [back to overview]	Hospitalization Rates
NCT00102960 (13) [back to overview]	Time to Failure of First Line Therapy or Death
NCT00102960 (13) [back to overview]	Number of Participants Who Experienced Regimen-limiting ART Drug Toxicity
NCT00102960 (13) [back to overview]	Total Occurrence of Grade 3 or 4 Laboratory Events
NCT00102960 (13) [back to overview]	Total Occurrence of Grade 3 or 4 Clinical Events
NCT00102960 (13) [back to overview]	Time From Randomization to Starting or Needing to Start Continuous Therapy
NCT00102960 (13) [back to overview]	Number of Participants Who Experienced Virological Failure Defined as Confirmed HIV-1 RNA Value of at Least 10,000 Copies Per/ml Recorded on Two Consecutive Separate Occasions After 24 Weeks of Treatment (Initial Therapy or Restart)
NCT00102960 (13) [back to overview]	Number of Participants Who Experienced Immunological Failure Defined as Failure of CD4% to Reach 20% or CD4% Falls Below 20% on Two Occasions, Within 4 Weeks, at Any Time After the First 24 Weeks of Therapy (Initial Therapy or Restart)
NCT00102960 (13) [back to overview]	Number of Participants Who Experienced Clinical Failure (Defined as Development of Severe CDC Stage B or Stage C Disease.) on Therapy.
NCT00102960 (13) [back to overview]	Time to First Hospitalization
NCT00102960 (13) [back to overview]	Time to Death Alone or Death Plus Life Threatening Stage C Events or HIV Events Associated With Permanent End-organ Damage.
NCT00102960 (13) [back to overview]	Duration of Hospitalisation
NCT00110305 (14) [back to overview]	Change From Baseline in CD4+ Cell Count (Relative) at Week 96
NCT00110305 (14) [back to overview]	Number of Participants With Virologic Response (Viral Load Less Than 50 Copies Per mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm, by Area Under the Plasma Concentration Time Curve From Time 0 to 24 Hours (AUC24h) Quartiles
NCT00110305 (14) [back to overview]	Number of Participants With Virologic Response at Week 240 (Viral Load Less Than 400 Copies/mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm
NCT00110305 (14) [back to overview]	Number of Participants With Virologic Response at Week 240 (Viral Load Less Than 50 Copies Per mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm
NCT00110305 (14) [back to overview]	Number of Participants With Virologic Response at Week 240 (Viral Load Less Than 50 Copies Per mL) - Snapshot Analysis
NCT00110305 (14) [back to overview]	Number of Participants With Virologic Response at Week 96 (Viral Load Less Than 50 Copies Per mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm
NCT00110305 (14) [back to overview]	Trough Plasma Concentration (Ctrough) for TMC278
NCT00110305 (14) [back to overview]	Number of Participants With Virologic Failure for the Resistance Determinations by Developing Mutations: First Available On-Treatment Genotypic Data After Failure
NCT00110305 (14) [back to overview]	Number of Participants With Virologic Response at Week 48 (Viral Load Less Than 50 Copies Per mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm
NCT00110305 (14) [back to overview]	Number of Participants With Virologic Response at Week 96 (Viral Load Less Than 50 Copies Per mL) - Snapshot Analysis
NCT00110305 (14) [back to overview]	Area Under the Plasma Concentration Time Curve From Time 0 to 24 Hours (AUC24h) for TMC278
NCT00110305 (14) [back to overview]	Change From Baseline in CD4+ Cell Count (Absolute) at Week 240
NCT00110305 (14) [back to overview]	Change From Baseline in CD4+ Cell Count (Absolute) at Week 96
NCT00110305 (14) [back to overview]	Change From Baseline in CD4+ Cell Count (Relative) at Week 240
NCT00112047 (53) [back to overview]	Percentage of Participants With Pure Virologic Failure (HIV-1 RNA < 50 c/mL) at Week 96
NCT00112047 (53) [back to overview]	Percentage of Participants With Pure Virological Failure (HIV-1 RNA < 400 c/mL) at Week 144
NCT00112047 (53) [back to overview]	Percentage of Participants With Pure Virological Failure (HIV-1 RNA < 400 c/mL) Through Week 240 (Atripla Week 96)
NCT00112047 (53) [back to overview]	Percentage of Participants With Pure Virological Failure (HIV-1 RNA < 50 c/mL) at Week 144
NCT00112047 (53) [back to overview]	Percentage of Participants With Pure Virological Failure (HIV-1 RNA < 50 c/mL) Through Week 240 (Atripla Week 96)
NCT00112047 (53) [back to overview]	Quality of Life (SF-12v2 Health Survey: Mental Component Summary) Change From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
NCT00112047 (53) [back to overview]	Quality of Life (SF-12v2 Health Survey: Physical Component Summary) Change From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
NCT00112047 (53) [back to overview]	Treatment Satisfaction Questionnaire (General Satisfaction With Current Treatment Regimen): Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.
NCT00112047 (53) [back to overview]	Treatment Satisfaction Questionnaire (Satisfaction With Convenience and Simplicity of Current Treatment Regimen): Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.
NCT00112047 (53) [back to overview]	Treatment Satisfaction Questionnaire (Satisfaction With Current Treatment Regimen to Control HIV): Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.
NCT00112047 (53) [back to overview]	Treatment Satisfaction Questionnaire (Satisfaction With Tolerability of Current Treatment Regimen) Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.
NCT00112047 (53) [back to overview]	Treatment Satisfaction Questionnaire (Bothered With the Side Effects of Current Treatment Regimen): Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.
NCT00112047 (53) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA < 50 c/mL at Week 144
NCT00112047 (53) [back to overview]	Percentage of Participants With Pure Virologic Failure (HIV-1 RNA < 400 c/mL) at Week 48
NCT00112047 (53) [back to overview]	Percentage of Participants With Pure Virologic Failure (HIV-1 RNA < 400 c/mL) at Week 96
NCT00112047 (53) [back to overview]	Change From Baseline in CD4 Cell Count (Cells/mm^3) at Week 240 (Atripla Week 96)
NCT00112047 (53) [back to overview]	Change From Study Baseline in CD4 Cell Count (Cells/mm^3) at Week 144
NCT00112047 (53) [back to overview]	Change From Study Baseline in CD4 Cell Count (Cells/mm^3) at Week 48
NCT00112047 (53) [back to overview]	Change From Study Baseline in CD4 Cell Count (Cells/mm^3) at Week 96
NCT00112047 (53) [back to overview]	Change From Study Baseline in HIV-1 RNA (Log10 c/mL) at Week 144
NCT00112047 (53) [back to overview]	Change From Study Baseline in HIV-1 RNA (Log10 c/mL) at Week 48
NCT00112047 (53) [back to overview]	Change From Study Baseline in HIV-1 RNA (Log10 c/mL) at Week 96
NCT00112047 (53) [back to overview]	Change in Limb Fat (kg) From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
NCT00112047 (53) [back to overview]	Change in Limb Fat (kg) From Week 48 to Week 144
NCT00112047 (53) [back to overview]	Change in Limb Fat (kg) From Week 48 to Week 96
NCT00112047 (53) [back to overview]	Change in Total Body Fat (kg) From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
NCT00112047 (53) [back to overview]	Change in Total Body Fat (kg) From Week 48 to Week 144
NCT00112047 (53) [back to overview]	Change in Total Body Fat (kg) From Week 48 to Week 96
NCT00112047 (53) [back to overview]	Change in Trunk Fat (kg) From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
NCT00112047 (53) [back to overview]	Change in Trunk Fat (kg) From Week 48 to Week 144
NCT00112047 (53) [back to overview]	Change in Trunk Fat (kg) From Week 48 to Week 96
NCT00112047 (53) [back to overview]	Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 144 (Defined by FDA TLOVR Algorithm)
NCT00112047 (53) [back to overview]	Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 240 (Atripla Week 96) Defined by the FDA TLOVR Algorithm
NCT00112047 (53) [back to overview]	Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response [TLOVR] Algorithm
NCT00112047 (53) [back to overview]	Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 96 (Defined by FDA TLOVR Algorithm)
NCT00112047 (53) [back to overview]	Percentage of Participants With Confirmed Plasma HIV-1 RNA < 50 c/mL at Week 144 (Defined by FDA TLOVR Algorithm)
NCT00112047 (53) [back to overview]	Percentage of Participants With Confirmed Plasma HIV-1 RNA < 50 c/mL at Week 240 (Atripla Week 96) Defined by the FDA TLOVR Algorithm
NCT00112047 (53) [back to overview]	Percentage of Participants With Confirmed Plasma HIV-1 RNA < 50 c/mL at Week 48 (Defined by FDA TLOVR Algorithm)
NCT00112047 (53) [back to overview]	Percentage of Participants With Confirmed Plasma HIV-1 RNA < 50 c/mL at Week 96 (Defined by FDA TLOVR Algorithm)
NCT00112047 (53) [back to overview]	Percentage of Participants With HIV-1 RNA < 50 c/mL at Week 48
NCT00112047 (53) [back to overview]	Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 400 c/mL) at Week 144
NCT00112047 (53) [back to overview]	Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 400 c/mL) at Week 48
NCT00112047 (53) [back to overview]	Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 400 c/mL) at Week 96
NCT00112047 (53) [back to overview]	Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 400 c/mL) From Week 144 (Atripla Baseline) Through Week 240 (Atripla Week 96)
NCT00112047 (53) [back to overview]	Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 50 c/mL) at Week 144
NCT00112047 (53) [back to overview]	Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 50 c/mL) at Week 48
NCT00112047 (53) [back to overview]	Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 50 c/mL) at Week 96
NCT00112047 (53) [back to overview]	Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 50 c/mL) From Week 144 (Atripla Baseline) Through Week 240 (Atripla Week 96)
NCT00112047 (53) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA < 400 c/mL at Week 144
NCT00112047 (53) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA < 400 c/mL at Week 240 (Atripla Week 96)
NCT00112047 (53) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA < 400 c/mL at Week 48.
NCT00112047 (53) [back to overview]	Percentage of Participants With Pure Virologic Failure (HIV-1 RNA < 50 c/mL) at Week 48
NCT00112047 (53) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA < 50 c/mL at Week 240 (Atripla Week 96)
NCT00118898 (22) [back to overview]	Cumulative Probability of Not Experiencing Regimen Failure
NCT00118898 (22) [back to overview]	Cumulative Probability of Not Experiencing Treatment Modification
NCT00118898 (22) [back to overview]	Cumulative Probability of Not Experiencing Virologic Failure
NCT00118898 (22) [back to overview]	Number of Participants Experiencing Certain Targeted Clinical Events, Including Death, AIDS-defining Illness, and HIV-1 Related Events.
NCT00118898 (22) [back to overview]	Number of Participants With HIV-1 RNA Levels Less Than 200 Copies/mL
NCT00118898 (22) [back to overview]	The Number of Participants With HIV-1 RNA Levels Less Than 50 Copies/mL
NCT00118898 (22) [back to overview]	Time From Randomization to Virologic Failure
NCT00118898 (22) [back to overview]	Time From Treatment Dispensation to a Grade 3/4 Safety Event
NCT00118898 (22) [back to overview]	Time From Treatment Dispensation to Regimen Failure (First Occurrence of Virologic Failure or Treatment Modification)
NCT00118898 (22) [back to overview]	Time From Treatment Dispensation to Treatment Modification
NCT00118898 (22) [back to overview]	Amount of Study Follow-up
NCT00118898 (22) [back to overview]	Number of Participants With a Grade 3/4 Safety Event
NCT00118898 (22) [back to overview]	Number of Participants With Regimen Failure
NCT00118898 (22) [back to overview]	Number of Participants With Treatment Modification
NCT00118898 (22) [back to overview]	Number of Participants With Virologic Failure
NCT00118898 (22) [back to overview]	Number of Participants With Virologic Failure and Emergence of Major Resistance
NCT00118898 (22) [back to overview]	Change in CD4 Count (Cells/mm3) From Baseline
NCT00118898 (22) [back to overview]	Change in Fasting High-density Lipoprotein (HDL) Cholesterol Level From Baseline
NCT00118898 (22) [back to overview]	Change in Fasting Non-high Density Lipoprotein (Non-HDL) Cholesterol Level From Baseline
NCT00118898 (22) [back to overview]	Change in Fasting Total Cholesterol Level From Baseline
NCT00118898 (22) [back to overview]	Change in Fasting Triglyceride Level From Baseline
NCT00118898 (22) [back to overview]	Cumulative Probability of Not Experiencing a Grade 3/4 Safety Event
NCT00162097 (13) [back to overview]	Number of Participants With Identified Electrocardiogram (ECG) Abnormalities
NCT00162097 (13) [back to overview]	Number of Participants Who Experienced AEs Leading to Study Drug Discontinuation
NCT00162097 (13) [back to overview]	Number of Participants With Abnormal Physical Examination Findings at Baseline (Screening and/or Day 1)
NCT00162097 (13) [back to overview]	Number of Participants With Clinically Meaningful Vital Signs Measures
NCT00162097 (13) [back to overview]	Time to Reach Maximum Observed Plasma Concentration (Tmax)
NCT00162097 (13) [back to overview]	Number of Participants Who Experienced AEs
NCT00162097 (13) [back to overview]	Number of Participants Who Died or Experienced Other Serious Adverse Events (SAEs)
NCT00162097 (13) [back to overview]	Number of Participants With Marked Abnormalities (MAs) in Hematology Measurements
NCT00162097 (13) [back to overview]	Number of Participants With Serum Chemistry MAs
NCT00162097 (13) [back to overview]	Number of Participants With Urinalysis MAs
NCT00162097 (13) [back to overview]	Area Under the Plasma Concentration-time Curve Over the Dosing Interval of 24 Hours (AUC[TAU])
NCT00162097 (13) [back to overview]	Maximum Plasma Concentration (Cmax)
NCT00162097 (13) [back to overview]	Minimum Plasma Concentration (Cmin)
NCT00255840 (1) [back to overview]	Cumulative Treatment Failure Rate of Participants on First Line Antiretroviral Therapy Monitored by Primary Health Care Nurses (Investigative Arm)is Not Inferior to the Cumulative Treatment Failure Rate of Participants Monitored by Doctors (Control Arm).
NCT00335322 (2) [back to overview]	Time Weighted Mean Change From Baseline Plasma HIV-RNA
NCT00335322 (2) [back to overview]	Time-weighted Mean Change From Baseline Plasma HIV-RNA.
NCT00342355 (2) [back to overview]	Serious Adverse Events
NCT00342355 (2) [back to overview]	Progression to AIDS or Death in tx naïve Pts With Adv HIV dx in the Four Randomly Assigned Regimens.
NCT00350272 (2) [back to overview]	The Proportion Of Participants With Virologic Response For 10 mg/Day Elvucitabine In HIV-1-Infected Participants By 12 Weeks Compared With The Proportion Of Participants With Lamivudine 300 mg/Day
NCT00350272 (2) [back to overview]	The Safety Profile Of Elvucitabine.
NCT00364793 (28) [back to overview]	Percent of CD4 Cells Change From Baseline at Weeks 60, 72, 84, and 96 - Treated Participants
NCT00364793 (28) [back to overview]	The Number of Participants With Plasma HIV RNA < 400 Copies Per Milliliter (c/mL) at Week 48 as Analyzed by Different Algorithms - All Treated Participants
NCT00364793 (28) [back to overview]	The Number of Participants With Plasma HIV RNA Levels < 400 c/mL at Week 24 as Analyzed by Different Algorithms - All Treated Participants
NCT00364793 (28) [back to overview]	The Number of Participants With Plasma HIV RNA Levels < 400 c/mL at Weeks 60, 72, 84 and 96 (Observed Cases) - All Treated Participants
NCT00364793 (28) [back to overview]	CD4 Cell Count Change From Baseline at Weeks 24 and 48 - Treated Participants
NCT00364793 (28) [back to overview]	The Number of Participants With Plasma HIV RNA Levels < 50 c/mL at Week 48 as Analyzed by Different Algorithms - All Treated Participants
NCT00364793 (28) [back to overview]	The Number of Participants With Plasma HIV RNA Levels < 50 c/mL at Weeks 60, 72, 84 and 96 (Observed Cases) - All Treated Participants
NCT00364793 (28) [back to overview]	Apparent Oral Clearance Adjusted for Body Weight (CLT/F/kg) of EFV at Week 2 - Pharmacokinetic Evaluable Population
NCT00364793 (28) [back to overview]	Area Under the Plasma Concentration Time Curve (AUC) Over One Dosing Interval From Time Zero to 24 Hours Post-dose(TAU) at Week 2 - Pharmacokinetic Evaluable Population
NCT00364793 (28) [back to overview]	AUC (TAU) of Didanosine (ddI) at Week 2 - Pharmacokinetic Evaluable Population
NCT00364793 (28) [back to overview]	The Number of Participants With Plasma HIV RNA Levels < 50 c/mL at Week 24 as Analyzed by Different Algorithms - All Treated Participants
NCT00364793 (28) [back to overview]	CLT/F of Didanosine (ddI) at Week 2 - Pharmacokinetic Evaluable Population
NCT00364793 (28) [back to overview]	CLT/F/kg of Didanosine (ddI) at Week 2 - Pharmacokinetic Evaluable Population
NCT00364793 (28) [back to overview]	Apparent Oral Clearance (CLT/F) of EFV at Week 2 - Pharmacokinetic Evaluable Population
NCT00364793 (28) [back to overview]	Terminal Phase Elimination Half-life (T-HALF) in Didanosine (ddI) at Week 2 - Pharmacokinetic Evaluable Population
NCT00364793 (28) [back to overview]	CD4 Cell Count Change From Baseline at Weeks 60, 72, 84, and 96 - Treated Participants
NCT00364793 (28) [back to overview]	Cmax and Cmin of Didanosine (ddI) at Week 2 - Pharmacokinetic Evaluable Population
NCT00364793 (28) [back to overview]	Log10 c/mL HIV RNA Changes From Baseline at Weeks 60, 72, 84 and 96 - Treated Participants
NCT00364793 (28) [back to overview]	Log10 c/mL HIV RNA Changes From Baseline Through Week 48 - Treated Participants
NCT00364793 (28) [back to overview]	Maximum Observed Plasma Concentration (Cmax) and Plasma Concentration 24 Hours Post-dose (Cmin) of EFV at Week 2 - Pharmacokinetic Evaluable Population
NCT00364793 (28) [back to overview]	Number of Participants With Acquisition of Resistance to EFV Categorized by AUC Relationship - Evaluable Pharmacokinetic Population
NCT00364793 (28) [back to overview]	Number of Treated Participants With Resistance Associated Genotypic and Phenotypic Changes in Viruses - Participants With Virologic Failure, Lack of Suppression or Viral Load Rebound
NCT00364793 (28) [back to overview]	Number of Participants With Hematologic Abnormalities - Treated Participants
NCT00364793 (28) [back to overview]	Number of Participants With Lipid and Glucose Laboratory Abnormalities - Treated Participants
NCT00364793 (28) [back to overview]	Number of Participants With Liver Function Test Laboratory Abnormalities - Treated Population
NCT00364793 (28) [back to overview]	Number of Participants With On-Treatment Adverse Events (AEs), Related Adverse Events, Serious Adverse Events (SAEs), Death, Discontinuation Due to Adverse Events, and CDC Class C AIDS Events
NCT00364793 (28) [back to overview]	Number of Participants With Serum Chemistry Abnormalities - Treated Participants
NCT00364793 (28) [back to overview]	Percent of CD4 Cells Change From Baseline at Weeks 24 and 48 - Treated Participants
NCT00369941 (73) [back to overview]	Change From Baseline in CD4 Cell Count at Week 156
NCT00369941 (73) [back to overview]	Change From Baseline in CD4 Cell Count at Week 240
NCT00369941 (73) [back to overview]	Change From Baseline in CD4 Cell Count at Week 96
NCT00369941 (73) [back to overview]	Change From Baseline in Cluster of Differentiation Antigen 4 (CD4) Cell Count at Week 48
NCT00369941 (73) [back to overview]	Number of Participants Who Achieved HIV RNA <400 Copies/mL at Week 156
NCT00369941 (73) [back to overview]	Number of Participants Who Achieved HIV RNA <400 Copies/mL at Week 240
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With Drug-related CAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants Discontinued With Drug-related LAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants Discontinued With Drug-related LAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants Who Achieved Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) <50 Copies/mL at Week 48
NCT00369941 (73) [back to overview]	Number of Participants Who Achieved HIV RNA <50 Copies/mL at Week 96
NCT00369941 (73) [back to overview]	Number of Participants Who Achieved HIV RNA <50 Copies/mL at Week 240
NCT00369941 (73) [back to overview]	Number of Participants Who Achieved HIV RNA <50 Copies/mL at Week 156
NCT00369941 (73) [back to overview]	Number of Participants Who Achieved HIV RNA <400 Copies/mL at Week 96
NCT00369941 (73) [back to overview]	Number of Participants Who Achieved HIV RNA <400 Copies/mL at Week 48
NCT00369941 (73) [back to overview]	Number of Participants With Drug-related CAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants With Drug-related LAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants With Serious LAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants With Serious LAEs at Week 48
NCT00369941 (73) [back to overview]	Number of Participants With Serious LAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants With Serious LAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants With Serious Drug-related LAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants With Serious Drug-related LAEs at Week 48
NCT00369941 (73) [back to overview]	Number of Participants With Serious Drug-related LAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants With Serious Drug-related LAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants With Serious Drug-related CAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants With Serious Drug-related CAEs at Week 48
NCT00369941 (73) [back to overview]	Number of Participants With Serious Drug-related CAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants With Serious Drug-related CAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants With Drug-related CAEs at Week 48
NCT00369941 (73) [back to overview]	Number of Participants With Drug-related CAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants With Drug-related CAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants With Clinical Adverse Experiences (CAEs) at Week 48
NCT00369941 (73) [back to overview]	Number of Participants With CAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants With CAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants With CAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With Serious Drug-related CAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With Serious Drug-related CAEs at Week 48
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With Serious Drug-related CAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With Serious Drug-related CAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With Serious CAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With Serious CAEs at Week 48
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With Serious CAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With Serious CAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With Drug-related CAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With Drug-related CAEs at Week 48
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With Drug-related CAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With CAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With CAEs at Week 48
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With CAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants With Serious CAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants With Serious CAEs at Week 48
NCT00369941 (73) [back to overview]	Number of Participants With Serious CAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With CAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants That Died by Week 96
NCT00369941 (73) [back to overview]	Number of Participants That Died by Week 48
NCT00369941 (73) [back to overview]	Number of Participants That Died by Week 240
NCT00369941 (73) [back to overview]	Number of Participants That Died by Week 156
NCT00369941 (73) [back to overview]	Number of Participants Discontinued With LAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants With Serious CAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants With Nervous System Symptoms Assessed by Review of Accumulated Safety Data up to Week 8
NCT00369941 (73) [back to overview]	Number of Participants With LAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants With LAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants With LAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants With Laboratory Adverse Experiences (LAEs) at Week 48
NCT00369941 (73) [back to overview]	Number of Participants With Drug-related LAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants With Drug-related LAEs at Week 48
NCT00369941 (73) [back to overview]	Number of Participants With Drug-related LAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants Discontinued With LAEs at Week 48
NCT00369941 (73) [back to overview]	Number of Participants Discontinued With LAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants Discontinued With LAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants Discontinued With Drug-related LAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants Discontinued With Drug-related LAEs at Week 48
NCT00427297 (4) [back to overview]	Incidence of Severe Adverse Events (Excluding Mortality)
NCT00427297 (4) [back to overview]	Viral Failure
NCT00427297 (4) [back to overview]	Incidence of Mortality
NCT00427297 (4) [back to overview]	Immunologic Failure
NCT00442962 (11) [back to overview]	Late Change in CD4 Count From Baseline
NCT00442962 (11) [back to overview]	Time to Initial Virological Failure
NCT00442962 (11) [back to overview]	Time to Loss of Virologic Response by Week 48 (Defined by FDA TLOVR Algorithm)
NCT00442962 (11) [back to overview]	Time to Initial Virologic Response
NCT00442962 (11) [back to overview]	Time to First Safety Event
NCT00442962 (11) [back to overview]	Time to First Dose Modification
NCT00442962 (11) [back to overview]	Early Changes in CD4 Count From Baseline
NCT00442962 (11) [back to overview]	Percentage of Participants With Late Virologic Response
NCT00442962 (11) [back to overview]	Percentage of Participants With Early Virologic Suppression
NCT00442962 (11) [back to overview]	Percentage of Participants With Early Virologic Response
NCT00442962 (11) [back to overview]	Percentage of Participants With Late Virologic Suppression
NCT00457665 (1) [back to overview]	Effect of Drug Regimens on Serum Triglycerides.
NCT00540449 (9) [back to overview]	The Number of Participants With Virological Response (Intent-to-Treat - Snapshot, <50 Copies/ml) at Week 96
NCT00540449 (9) [back to overview]	The Number of Participants With Virological Response (Intent-to-Treat - Snapshot, <50 Copies/ml) at Week 48
NCT00540449 (9) [back to overview]	Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies/ml) at Week 96
NCT00540449 (9) [back to overview]	Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies/ml) at Week 48
NCT00540449 (9) [back to overview]	Number of Participants With Virologic Failure for the Resistance Determination by Emerging Resistance Associated Mutations: First Available On-Treatment Genotypic Data After Failure
NCT00540449 (9) [back to overview]	Mean Change From Baseline to Week 48 and Week 96 in Absolute and Relative CD4+ Cell Counts (Using Imputed Data)
NCT00540449 (9) [back to overview]	Number of Participants With Virological Response (Observed, <50 Copies/ml) at Last On-Treatment Visit (Post-Week 96).
NCT00540449 (9) [back to overview]	Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <400 Copies/ml) at Week 96
NCT00540449 (9) [back to overview]	Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <400 Copies/ml) at Week 48
NCT00543725 (9) [back to overview]	Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies Per mL) at Week 96
NCT00543725 (9) [back to overview]	Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies Per mL) at Week 48
NCT00543725 (9) [back to overview]	Number of Participants With Virological Response (Intent-to-Treat - Snapshot, <50 Copies Per mL) at Week 96
NCT00543725 (9) [back to overview]	Number of Participants With Virological Response (Intent-to-Treat - Snapshot, <50 Copies Per mL) at Week 48
NCT00543725 (9) [back to overview]	Number of Participants With Virologic Failure for the Resistance Determinations by Developing Mutations: First Available On-Treatment Genotypic Data After Failure
NCT00543725 (9) [back to overview]	Mean Change From Baseline to Week 48 and Week 96 in Absolute and Relative CD4+ Cell Counts (Using Imputed Data)
NCT00543725 (9) [back to overview]	Number of Participants With Virological Response (Observed, <50 Copies/mL) at Last On-Treatment Visit (Post-Week 96).
NCT00543725 (9) [back to overview]	Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <400 Copies Per mL) at Week 96
NCT00543725 (9) [back to overview]	Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <400 Copies Per mL) at Week 48
NCT00549198 (58) [back to overview]	Mean Change From Baseline in Estimated Glomerular Filtration Rate (GFR), Calculated by Modification of Diet in Renal Disease (MDRD) Equation, at Week 96
NCT00549198 (58) [back to overview]	Mean Change From Baseline in Estimated Glomerular Filtration Rate (GFR), Calculated by Modification of Diet in Renal Disease (MDRD) Equation, at Week 48
NCT00549198 (58) [back to overview]	Mean Change From Baseline in Estimated Glomerular Filtration Rate (GFR), Calculated by Modification of Diet in Renal Disease (MDRD) Equation, at Week 24
NCT00549198 (58) [back to overview]	Mean Change From Baseline in Estimated GFR, Calculated by Cockcroft-Gault Equation, at Week 96
NCT00549198 (58) [back to overview]	Mean Change From Baseline in Estimated GFR, Calculated by Cockcroft-Gault Equation, at Week 48
NCT00549198 (58) [back to overview]	Number of Participants With National Kidney Foundation Chronic Kidney Disease Stage 1, 2, 3, 4, or 5 Categories of Renal Function at Week 24
NCT00549198 (58) [back to overview]	Change From Baseline in Cluster Difference 4 (CD4+) Cell Count at Week 24
NCT00549198 (58) [back to overview]	Change From Baseline in Cluster Difference 4 (CD4+) Cell Count at Week 48
NCT00549198 (58) [back to overview]	Change From Baseline in Cluster Difference 4 (CD4+) Cell Count at Week 96
NCT00549198 (58) [back to overview]	Exploratory Analysis of Change From Baseline in Albumin as a Ratio to Urine Creatinine at Week 96
NCT00549198 (58) [back to overview]	Exploratory Analysis of Change From Baseline in Beta 2 Microglobulin (B2M) as a Ratio to Urine Creatinine at Week 96
NCT00549198 (58) [back to overview]	Exploratory Analysis of Change From Baseline in Bone Specific Alkaline Phosphatase (BSAP) at Week 96
NCT00549198 (58) [back to overview]	Exploratory Analysis of Change From Baseline in N-acetyl-B-glucosaminidase (NAG) as a Ratio to Urine Creatinine at Week 96
NCT00549198 (58) [back to overview]	Exploratory Analysis of Change From Baseline in Osteocalcin at Week 96
NCT00549198 (58) [back to overview]	Exploratory Analysis of Change From Baseline in Procollagen Type 1 Amino-terminal Propeptide (P1NP) at Week 96
NCT00549198 (58) [back to overview]	Exploratory Analysis of Change From Baseline in Retinol Binding Protein (RBP) as a Ratio to Urine Creatinine at Week 96
NCT00549198 (58) [back to overview]	Exploratory Analysis of Change From Baseline in Type 1 Collagen Cross-linked C-telopeptide at Week 96
NCT00549198 (58) [back to overview]	Mean Change From Baseline in Estimated GFR, Calculated by Cockcroft-Gault Equation, at Week 24
NCT00549198 (58) [back to overview]	Number of Participants With HIV-1 RNA <50 Copies/Milliliter (c/mL) and 400 c/mL at Week 48
NCT00549198 (58) [back to overview]	Number of Participants With HIV-1 RNA <50 Copies/Milliliter (c/mL) and 400 c/mL at Week 96
NCT00549198 (58) [back to overview]	Number of Participants With National Kidney Foundation Chronic Kidney Disease Stage 1, 2, 3, 4, or 5 Categories of Renal Function at Week 48
NCT00549198 (58) [back to overview]	Number of Participants With National Kidney Foundation Chronic Kidney Disease Stage 1, 2, 3, 4, or 5 Categories of Renal Function at Week 96
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting High-density Lipoprotein (HDL) at Week 24
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting High-density Lipoprotein (HDL) at Week 96
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Total Cholesterol at Week 24
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Total Cholesterol at Week 48
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Total Cholesterol at Week 96
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Triglycerides at Week 24
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Triglycerides at Week 48
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Triglycerides at Week 96
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Low-density Lipoprotein (LDL) at Week 24
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Low-density Lipoprotein (LDL) at Week 48
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Low-density Lipoprotein (LDL) at Week 96
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Treatment-emergent Division of AIDS (DAIDS) Toxicities at Week 24
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Treatment-emergent Division of AIDS (DAIDS) Toxicities at Week 48
NCT00549198 (58) [back to overview]	Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 48
NCT00549198 (58) [back to overview]	Number of Participants Meeting World Health Organization (WHO) Criteria for Osteopenia (T-score of -2.5 to -1.0) and Osteoporosis (T-score of <-2.5) at Week 24
NCT00549198 (58) [back to overview]	Number of Participants Experiencing an Adverse Event (AE) Leading to Discontinuation by Week 96
NCT00549198 (58) [back to overview]	Number of Participants Meeting World Health Organization (WHO) Criteria for Osteopenia (T-score of -2.5 to -1.0) and Osteoporosis (T-score of <-2.5) at Week 48
NCT00549198 (58) [back to overview]	Number of Participants Meeting World Health Organization (WHO) Criteria for Osteopenia (T-score of -2.5 to -1.0) and Osteoporosis (T-score of <-2.5) at Week 96
NCT00549198 (58) [back to overview]	Number of Participants With a Decline From Baseline in Lumbar Spine and Hip Bone Mineral Density (BMD) >=2.0% and >=6.0% at Week 24
NCT00549198 (58) [back to overview]	Number of Participants With a Decline From Baseline in Lumbar Spine and Hip Bone Mineral Density (BMD) >=2.0% and >=6.0% at Week 48
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting High-density Lipoprotein (HDL) at Week 48
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Treatment-emergent Division of AIDS (DAIDS) Toxicities at Week 96
NCT00549198 (58) [back to overview]	Number of Participants With a Decline From Baseline in Lumbar Spine and Hip Bone Mineral Density (BMD) >=2.0% and >=6.0% at Week 96
NCT00549198 (58) [back to overview]	Number of Participants With Decline From Baseline in Estimated GFR, Calculated by MDRD and Cockcroft-Gault Equations, of >=10 mL/Min/1.73 m^2 (mL/Min for Cockcroft-Gault), >=20 mL/Min/1.72 m^2, >=10%, and >=20% at Week 24
NCT00549198 (58) [back to overview]	Number of Participants With Decline From Baseline in Estimated GFR, Calculated by MDRD and Cockcroft-Gault Equations, of >=10 mL/Min/1.73m^2 (mL/Min for Cockcroft-Gault), >=20 mL/Min/1.72m^2, >=10%, and >=20% at Week 48
NCT00549198 (58) [back to overview]	Number of Participants With Decline From Baseline in Estimated GFR, Calculated by MDRD and Cockcroft-Gault Equations, of >=10 mL/Min/1.73m^2 (mL/Min for Cockcroft-Gault), >=20 mL/Min/1.72m^2, >=10%, and >=20% at Week 96
NCT00549198 (58) [back to overview]	Number of Participants With HIV-1 RNA <50 Copies/Milliliter (c/mL) and 400 c/mL at Week 24
NCT00549198 (58) [back to overview]	Number of Participants Experiencing an Adverse Event (AE) Leading to Discontinuation by Week 48
NCT00549198 (58) [back to overview]	Number of Participants Experiencing an Adverse Event (AE) Leading to Discontinuation by Week 24
NCT00549198 (58) [back to overview]	Number of Participants Classified as Protocol-defined Failures With Treatment-emergent Resistance to Study Drug in the Indicated Viruses at Week 96
NCT00549198 (58) [back to overview]	"Number of Participants Who Indicated Yes or No to the Question of Whether Unplanned Healthcare Resources Were Utilized"
NCT00549198 (58) [back to overview]	Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 96
NCT00549198 (58) [back to overview]	Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 24
NCT00549198 (58) [back to overview]	Percent Change From Baseline in Hip Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 96
NCT00549198 (58) [back to overview]	Percent Change From Baseline in Hip Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 48
NCT00549198 (58) [back to overview]	Percent Change From Baseline in Hip Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 24
NCT00661960 (1) [back to overview]	the Percentage of CD3+/CD4+ Cells Per Cubic Millimeter at the Effector Sites in the Duodenal Tissues Obtained From Volunteers to the Antiretroviral Therapy Regimen Over Time.
NCT00668395 (1) [back to overview]	Effect of CYP2B6 Genotype on Efavirenz Clearance
NCT00727597 (2) [back to overview]	Number of Subjects Developing Any Treatment-related Grade 3-4 Adverse Events
NCT00727597 (2) [back to overview]	Number of Subjects Needing to Switch Comparator Drugs (FPV/r or EFV)
NCT00734344 (32) [back to overview]	Mean Platelet Count Between Treatment Groups at 2 Months
NCT00734344 (32) [back to overview]	Mean Platelet Count Between Treatment Groups at 4 Months
NCT00734344 (32) [back to overview]	Mean Platelet Count Between Treatment Groups at 6 Months
NCT00734344 (32) [back to overview]	Mean Platelet Count Between Treatment Groups at 8 Months
NCT00734344 (32) [back to overview]	Mean White Blood Cell Count Between Treatment Groups at 10 Months
NCT00734344 (32) [back to overview]	Mean Hematocrit Between Treatment Groups at 4 Months
NCT00734344 (32) [back to overview]	Mean Hematocrit Between Treatment Groups at 6 Months
NCT00734344 (32) [back to overview]	Mean Hematocrit Between Treatment Groups at 8 Months
NCT00734344 (32) [back to overview]	Mean Platelet Count Between Treatment Groups at 10 Months
NCT00734344 (32) [back to overview]	Mean Platelet Count Between Treatment Groups at 12 Months
NCT00734344 (32) [back to overview]	Mean White Blood Cell Count Between Treatment Groups at 4 Months
NCT00734344 (32) [back to overview]	Mean White Blood Cell Count Between Treatment Groups at 2 Months
NCT00734344 (32) [back to overview]	Mean White Blood Cell Count Between Treatment Groups at 14 Months
NCT00734344 (32) [back to overview]	Mean White Blood Cell Count Between Treatment Groups at 12 Months
NCT00734344 (32) [back to overview]	Mean Hematocrit Between Treatment Groups at 2 Months
NCT00734344 (32) [back to overview]	Mean White Blood Cell Count Between Treatment Groups at 8 Months
NCT00734344 (32) [back to overview]	Mean CD4 Count Between Treatment Groups at 10 Months
NCT00734344 (32) [back to overview]	Mean White Blood Cell Count Between Treatment Groups at 6 Months
NCT00734344 (32) [back to overview]	Mean CD4 Count Between Treatment Groups at 1 Months
NCT00734344 (32) [back to overview]	Mean Platelet Count Between Treatment Groups at 14 Months
NCT00734344 (32) [back to overview]	Mean CD4 Count Between Treatment Groups at 11 Months
NCT00734344 (32) [back to overview]	Mean CD4 Count Between Treatment Groups at 2 Months
NCT00734344 (32) [back to overview]	Mean Hematocrit Between Treatment Groups at 12 Months
NCT00734344 (32) [back to overview]	Mean CD4 Count Between Treatment Groups at 3 Months
NCT00734344 (32) [back to overview]	Mean CD4 Count Between Treatment Groups at 4 Months
NCT00734344 (32) [back to overview]	Mean CD4 Count Between Treatment Groups at 5 Months
NCT00734344 (32) [back to overview]	Mean CD4 Count Between Treatment Groups at 6 Months
NCT00734344 (32) [back to overview]	Mean CD4 Count Between Treatment Groups at 7 Months
NCT00734344 (32) [back to overview]	Mean CD4 Count Between Treatment Groups at 8 Months
NCT00734344 (32) [back to overview]	Mean CD4 Count Between Treatment Groups at 9 Months
NCT00734344 (32) [back to overview]	Mean Hematocrit Between Treatment Groups at 10 Months
NCT00734344 (32) [back to overview]	Mean Hematocrit Between Treatment Groups at 14 Months
NCT00752856 (4) [back to overview]	Compare Early Activated CD4+ T-cell Recovery Rates From Baseline to Week 4.
NCT00752856 (4) [back to overview]	Compare Late Activated CD4+ T-cell Recovery Rates Between Treatment Regimens From Baseline to Week 48
NCT00752856 (4) [back to overview]	Viral Suppression Efficacy at 48 Weeks
NCT00752856 (4) [back to overview]	To Compare the Phase 1 Viral Decay Rates Between LPV/r + RAL vs. EFV/TDF/FTC Treatment Combinations.
NCT00775606 (6) [back to overview]	Naive, Central Memory, Effector Memory, and T Reg CD4+ T-cell Frequency
NCT00775606 (6) [back to overview]	Activated and Regulatory CD4+ and CD8+ T-cell Frequencies
NCT00775606 (6) [back to overview]	CD4+ T-cell Change
NCT00775606 (6) [back to overview]	CD4+ (Cluster of Differentiation 4) T-cell Apoptosis
NCT00775606 (6) [back to overview]	Naive, Central Memory, Effector Memory, and T Reg CD4+ T-cell Frequency
NCT00775606 (6) [back to overview]	Activation and Proliferation of CD4+ and CD8+ T-cell Frequencies
NCT00810303 (18) [back to overview]	AUC of Efavirenz (Single Dose Pharmacokinetic After Treatment With 400 mg Efavirenz) on Study Days 1-5
NCT00810303 (18) [back to overview]	AUC0-24h of Efavirenz (Steady State Pharmacokinetic After Chronic Treatment With 400 mg Efavirenz and Concomitant Chronic Treatment of 10 mg Ezetimibe) on Study Day 30
NCT00810303 (18) [back to overview]	AUC0-24h of Ezetimibe Glucuronide (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe and Concomitant Chronic Treatment With 400 mg Efavirenz) on Study Day 30
NCT00810303 (18) [back to overview]	AUC0-24h of Ezetimibe Glucuronide (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe) on Study Day 15
NCT00810303 (18) [back to overview]	AUC0-24h of Free Ezetimibe (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe and Concomitant Chronic Treatment With 400 mg Efavirenz) on Study Day 30
NCT00810303 (18) [back to overview]	AUC0-24h of Free Ezetimibe (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe and Concomitant Single Dose Administration of 400 mg Efavirenz) on Study Day 16
NCT00810303 (18) [back to overview]	AUC0-24h of Free Ezetimibe (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe) on Study Day 15
NCT00810303 (18) [back to overview]	Cmax of Efavirenz (Single Dose Pharmacokinetic After Treatment With 400 mg Efavirenz and Concomitant Chronic Treatment of 10 mg Ezetimibe) on Study Days 16-20
NCT00810303 (18) [back to overview]	Cmax of Efavirenz (Single Dose Pharmacokinetic After Treatment With 400 mg Efavirenz) on Study Days 1-5
NCT00810303 (18) [back to overview]	Cmax of Efavirenz (Steady State Pharmacokinetic After Chronic Treatment With 400 mg Efavirenz and Concomitant Chronic Treatment of 10 mg Ezetimibe) on Study Day 30
NCT00810303 (18) [back to overview]	Cmax of Ezetimibe Glucuronide (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe and Concomitant Chronic Treatment With 400 mg Efavirenz) on Study Day 30
NCT00810303 (18) [back to overview]	Cmax of Ezetimibe Glucuronide (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe and Concomitant Single Dose Administration of 400 mg Efavirenz) on Study Day 16
NCT00810303 (18) [back to overview]	Cmax of Ezetimibe Glucuronide (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe) on Study Day 15
NCT00810303 (18) [back to overview]	Cmax of Free Ezetimibe (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe and Concomitant Chronic Treatment With 400 mg Efavirenz) on Study Day 30
NCT00810303 (18) [back to overview]	Cmax of Free Ezetimibe (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe and Concomitant Single Dose Administration of 400 mg Efavirenz) on Study Day 16
NCT00810303 (18) [back to overview]	Cmax of Free Ezetimibe (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe) on Study Day 15
NCT00810303 (18) [back to overview]	AUC0-24h of Ezetimibe Glucuronide (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe and Concomitant Single Dose Administration of 400 mg Efavirenz) on Study Day 16
NCT00810303 (18) [back to overview]	AUC of Efavirenz (Single Dose Pharmacokinetic After Treatment With 400 mg Efavirenz and Concomitant Chronic Treatment of 10 mg Ezetimibe) on Study Days 16-20
NCT00862823 (2) [back to overview]	Maximum Concentration for Tenofovir, Emtricitabine and Efavirenz
NCT00862823 (2) [back to overview]	Area Under the Concentration Time Curve for Tenofovir, Emtricitabine and Efavirenz
NCT00870363 (4) [back to overview]	Trough Plasma and Tissue Drug Levels in Volunteers at the Time of the Upper Endoscopy
NCT00870363 (4) [back to overview]	Change in the Density of CD3+/CD4+ Cells Per Cubic Millimeter at the Effector Sites in the Duodenal Tissues Following Antiretroviral Therapy Regimen
NCT00870363 (4) [back to overview]	Changes in CD4+ T-cell Numbers by Treatment Regimen
NCT00870363 (4) [back to overview]	Change in HIV DNA Per 10^6 Cells in Duodenal Tissue Versus PBMC by Drug Regimen Received
NCT00884793 (4) [back to overview]	Number of Subjects Who Had a Decrease in HIV RNA Per Million CD4+ T Cells in the Ileum
NCT00884793 (4) [back to overview]	Number of Subjects Who Experienced an Increase in CD4+ T Cells (as a % of All Cells) in the Ileum.
NCT00884793 (4) [back to overview]	Number of Subjects Who Experienced an Increase in CD4% in the Ileum.
NCT00884793 (4) [back to overview]	"Average Change in Activated (CD38+HLADR+) CD8+ T Cells in the Ileum"
NCT00903682 (7) [back to overview]	Resistance Determinations
NCT00903682 (7) [back to overview]	Mean Change From Baseline in CD4+ Cell Count
NCT00903682 (7) [back to overview]	Proportion of Patients With at Least 1 Treatment-emergent Grade 1-4 Central Nervous System or Psychiatric Adverse Event
NCT00903682 (7) [back to overview]	Neuropsychiatric Adverse Events by Week 48
NCT00903682 (7) [back to overview]	Antiviral Activity of ETR vs. EFV
NCT00903682 (7) [back to overview]	Antiviral Activity of ETR vs. EFV
NCT00903682 (7) [back to overview]	Mean Change From Baseline in Neuropsychiatric and Total Tolerabililty Score
NCT00924898 (6) [back to overview]	Time to HIV RNA Suppression <50 Copies/mL
NCT00924898 (6) [back to overview]	Number of Participants Without Virologic Failure at Week 48
NCT00924898 (6) [back to overview]	Number of Participants Without Virologic Failure at Week 24
NCT00924898 (6) [back to overview]	Number of Participants With HIV RNA Suppression at Week 96
NCT00924898 (6) [back to overview]	Number of Participants With Baseline Genotypic Resistance to One or More Antiretroviral Drugs in the Study Treatment
NCT00924898 (6) [back to overview]	Number of Participants With Baseline Genotypic Resistance to Antiretroviral Medications
NCT00951015 (22) [back to overview]	Relationship Between the Change From Baseline in CD4+ Cell Counts at Week 96 and the Indicated Plasma DTG PK Parameters
NCT00951015 (22) [back to overview]	Number of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 16
NCT00951015 (22) [back to overview]	Relationship Between the Change From Baseline in Plasma HIV-1 RNA at Week 2 and the Indicated Plasma DTG PK Parameters
NCT00951015 (22) [back to overview]	Relationship Between the Indicated Safety Parameters at Week 96 and the Indicated Plasma DTG PK Parameters
NCT00951015 (22) [back to overview]	Pre-dose Concentration (C0) and C0 Avg of DTG
NCT00951015 (22) [back to overview]	Relationship Between Gastrointestinal System Organ Class AEs of Special Interest at Week 96 and the Indicated Plasma DTG PK Parameters
NCT00951015 (22) [back to overview]	Plasma DTG Concentration
NCT00951015 (22) [back to overview]	Number of Participants With the Indicated Type of HIV-1 Disease Progression (AIDS or Death)
NCT00951015 (22) [back to overview]	Number of Participants With the Indicated Treatment-emergent Integrase (IN) Mutations Detected at the Time of Protocol-defined Virologic Failure (PDVF), as a Measure of Genotypic Resistance
NCT00951015 (22) [back to overview]	Number of Participants With the Indicated Grade 1 to Grade 4 Treatment-emergent Clinical Chemistry and Hematology Toxicities
NCT00951015 (22) [back to overview]	Time to Maximal Drug Concentration (Tmax) of DTG
NCT00951015 (22) [back to overview]	Number of Participants With the Indicated Treatment-emergent Major Mutations of Other Classes Detected at the Time of Protocol-defined Virologic Failure (PDVF), as a Measure of Genotypic Resistance
NCT00951015 (22) [back to overview]	Number of Participants With the Indicated Fold Increase in DTG FC (Fold Change in IC50 Relative to Wild-type Virus) at the Time of PDVF, as a Measure of Post-Baseline Phenotypic Resistance
NCT00951015 (22) [back to overview]	Viral Change Over the Initial 2 Weeks of Treatment
NCT00951015 (22) [back to overview]	Change From Baseline in Cluster of Differentiation 4+ (CD4+) Cell Counts at the Indicated Time Points
NCT00951015 (22) [back to overview]	AUC(0-tau) of DTG
NCT00951015 (22) [back to overview]	Change From Baseline in HIV-1 RNA at the Indicated Time Points
NCT00951015 (22) [back to overview]	Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Events (SAE)
NCT00951015 (22) [back to overview]	Number of Participants With New HIV-associated Conditions of the Indicated Class
NCT00951015 (22) [back to overview]	Number of Participants With Plasma HIV-1 RNA <400 c/mL
NCT00951015 (22) [back to overview]	Number of Participants With Plasma HIV-1 RNA <50 c/mL
NCT00951015 (22) [back to overview]	Maximal Concentration (Cmax), Minimal Concentration (Cmin), and Concentration at the End of Dosing Interval (Ctau) of DTG
NCT00960570 (3) [back to overview]	Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]
NCT00960570 (3) [back to overview]	Maximum Plasma Concentration (Cmax) of Efavirenz
NCT00960570 (3) [back to overview]	Area Under the Concentration Versus Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)]
NCT00964002 (2) [back to overview]	Percentage of Participants Without Prostate-specific Antigen Progression at 3 Months
NCT00964002 (2) [back to overview]	Percentage of Participants Without Prostate-specific Antigen Progression at 6 Months
NCT00978068 (6) [back to overview]	Incidence-density of Malaria Defined as the Number of Incident Episodes of Malaria Per Time at Risk.
NCT00978068 (6) [back to overview]	Percentage of Uncomplicated Malaria Episodes With Accompanying Adverse Events That Occurred in the 28 Days Following Antimalarial Therapy
NCT00978068 (6) [back to overview]	28-day Risk of Recurrent Parasitemia
NCT00978068 (6) [back to overview]	63-day Risk of Recurrent Malaria
NCT00978068 (6) [back to overview]	Estimates of the 6-month Risk of a First Episode of Malaria
NCT00978068 (6) [back to overview]	Incidence-density of Malaria Defined as the Number of Incident Episodes of Complicated Malaria Per Time at Risk.
NCT00993031 (14) [back to overview]	Prevalence of Malaria Defined as Positive Placental Blood Smear
NCT00993031 (14) [back to overview]	Prevalence of Malaria Defined as Positive Placental Blood PCR
NCT00993031 (14) [back to overview]	Prevalence of Composite Clinical Outcome Defined by LBW, Stillbirth(Intrauterine Fetal Demise >20wks GA), Late Spontaneous Abortion(Miscarriage 12-20wks GA), Preterm Delivery(<37wks Gestation), Neonatal Death(Death of Liveborn Infant Within First 28days)
NCT00993031 (14) [back to overview]	Number of Participants With Grade 3 or 4 Toxicity in the Two Treatment Groups in Women
NCT00993031 (14) [back to overview]	Maternal Malaria Defined as the Number of Treatments for New Episodes of Malaria Per Time at Risk After Pregnancy
NCT00993031 (14) [back to overview]	Incidence of Pre-eclampsia Defined by Hypertension > 140/90 on Two Occasions Measured > 6 Hours Apart With ≥1+ Proteinuria on Clean Catch Urine Dipstick
NCT00993031 (14) [back to overview]	Change in Maternal CD4 Cell Counts
NCT00993031 (14) [back to overview]	ART Levels in Hair Samples at Delivery
NCT00993031 (14) [back to overview]	Maternal Malaria Defined as the Number of Treatments for New Episodes of Malaria Per Time at Risk During Pregnancy
NCT00993031 (14) [back to overview]	Placental Malaria Defined Placental Histopathologic Analysis
NCT00993031 (14) [back to overview]	Placental Malaria Defined as Positive Placental RDT
NCT00993031 (14) [back to overview]	Number of Participants With Severe Maternal Anemia Defined by Hemoglobin < 8g/dl at Any Point During the Trial in Each Treatment Group
NCT00993031 (14) [back to overview]	Number of Participants With Maternal to Child Transmission of HIV, Measured by Infant HIV DNA PCR
NCT00993031 (14) [back to overview]	Number of Participants With Maternal HIV RNA Suppression of <400 Copies/mL
NCT01011413 (8) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <400 Copies/mL and <50 Copies/mL at 48 and 96 Weeks After Randomisation
NCT01011413 (8) [back to overview]	Change From Baseline in Estimate Creatinine Clearance
NCT01011413 (8) [back to overview]	Mean Change From Baseline in CD4+ T-cell Count
NCT01011413 (8) [back to overview]	Change From Baseline in Fasted Insulin Levels
NCT01011413 (8) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <200 Copies/mL 48 Weeks After Randomisation
NCT01011413 (8) [back to overview]	Change in Selected Serum Biochemical Parameters
NCT01011413 (8) [back to overview]	Change From Baseline in Metabolic Endpoints
NCT01011413 (8) [back to overview]	Steady-state Efavirenz Concentrations
NCT01075152 (10) [back to overview]	Safety of ART Initiation
NCT01075152 (10) [back to overview]	Percentage of Participants, Per CSF WBC Subgroup, Who Died by Week 26
NCT01075152 (10) [back to overview]	Microbiologic Clearance
NCT01075152 (10) [back to overview]	Karnofsky Functional Status
NCT01075152 (10) [back to overview]	46-week Survival
NCT01075152 (10) [back to overview]	Antiretroviral Therapy Tolerability
NCT01075152 (10) [back to overview]	HIV-1 Viral Suppression
NCT01075152 (10) [back to overview]	Incidence of Cryptococcal-relapse
NCT01075152 (10) [back to overview]	Incidence of Immune Reconstitution Inflammatory Syndrome
NCT01075152 (10) [back to overview]	Mortality
NCT01087814 (1) [back to overview]	Serum Levels of Efavirenz
NCT01104376 (1) [back to overview]	Measure Efavirenz Clearance
NCT01146873 (5) [back to overview]	Percentage of Participants With Elevated Total Cholesterol, Elevated LDL, Abnormal HDL, or Abnormal Triglycerides at 40 Weeks After Randomization
NCT01146873 (5) [back to overview]	Highest Grade ALT After Randomization
NCT01146873 (5) [back to overview]	Viral Rebound
NCT01146873 (5) [back to overview]	Viral Failure
NCT01146873 (5) [back to overview]	CD4 Cell Percentage at 48 Weeks After Randomization
NCT01147107 (1) [back to overview]	Rates of Grade 2 and Higher Alanine Aminotransferase (ALT) Elevations
NCT01195467 (2) [back to overview]	The Rate of Neuropsychiatric and Central Nervous System (CNS) Toxicity of Raltegravir Therapy After 12 Weeks on Treatment
NCT01195467 (2) [back to overview]	The Rate of Neuropsychiatric and Central Nervous System (CNS) Toxicity of Raltegravir Therapy After 4 Weeks on Treatment
NCT01231555 (13) [back to overview]	Change From Baseline (Day 1) in Plasma HIV-1 RNA Over Period
NCT01231555 (13) [back to overview]	Number of Participants Discontinuing the Study Drugs Due to AEs
NCT01231555 (13) [back to overview]	Change From Baseline (Day 1) in Plasma HIV-1 RNA Over Period
NCT01231555 (13) [back to overview]	Number of Participants With HIV Disease Progression
NCT01231555 (13) [back to overview]	Minimum and Maximum Plasma GSK2248761 Concentration at Week 2
NCT01231555 (13) [back to overview]	Number of Participants With Serious Adverse Events (SAEs) and Adverse Events (AEs)
NCT01231555 (13) [back to overview]	Number of Participants With Plasma HIV-1 RNA Below 50 Copies/mL as a Function of Viral Load
NCT01231555 (13) [back to overview]	Number of Participants With HIV Associated Conditions
NCT01231555 (13) [back to overview]	Number of Participants With Plasma HIV-1 RNA Below 50 Copies/mL as a Function of Viral Load
NCT01231555 (13) [back to overview]	Number of Participants With Changes in Electrocardiogram (ECG) From Baseline (Day 1) Over 16 Weeks
NCT01231555 (13) [back to overview]	Number of Participants With Changes in Electrocardiogram (ECG) From Baseline (Day 1) Over 16 Weeks
NCT01231555 (13) [back to overview]	Change From Baseline (Day 1) in Plasma HIV-1 RNA Over Period
NCT01231555 (13) [back to overview]	Number of Participants With Plasma HIV-1 RNA Below 50 Copies/mL as a Function of Viral Load
NCT01254656 (7) [back to overview]	Change From Baseline in CD4+ Lymphocyte Counts (Absolute) at 192 Weeks From Day 1 of the Parent Protocol
NCT01254656 (7) [back to overview]	Change From Baseline in CD4+ Lymphocyte Counts (Absolute) at 144 Weeks From Day 1 of the Parent Protocol
NCT01254656 (7) [back to overview]	Change From Baseline in CD4+ Lymphocyte Counts (Percentage) at 144 Weeks From Day 1 of the Parent Protocol
NCT01254656 (7) [back to overview]	Change From Baseline in CD4+ Lymphocyte Counts (Percentage) at 192 Weeks From Day 1 of the Parent Protocol
NCT01254656 (7) [back to overview]	Number of Participants With Plasma HIV-1 RNA Level <50 Copies/mL up to Week 208
NCT01254656 (7) [back to overview]	Number of Participants With Plasma Human Immunodeficiency Virus - 1 (HIV-1) Ribonucleic Acid (RNA) Level <50 Copies/mL at 144 Weeks From Day 1 of the Parent Protocol
NCT01254656 (7) [back to overview]	Virology Analysis Participant Accountability From Week 96 Through Study Termination
NCT01270802 (2) [back to overview]	Change in Flow-mediated Dilation (FMD) of the Brachial Artery
NCT01270802 (2) [back to overview]	Change in Serum Levels of Vitamin D
NCT01352117 (12) [back to overview]	Percentage of Participants With Etoposide Dose Modification
NCT01352117 (12) [back to overview]	Percentage of Participants With HIV-1 RNA Suppression
NCT01352117 (12) [back to overview]	Percentage of Participants With HIV-1 RNA Suppression
NCT01352117 (12) [back to overview]	Cumulative Incidence of Initial KS Partial or Complete Response by Week 96
NCT01352117 (12) [back to overview]	Cumulative Incidence of Initial KS Progressive Disease by Week 96
NCT01352117 (12) [back to overview]	Cumulative Incidence of KS Progressive Disease After Initiation of Delayed Etoposide in Arm A
NCT01352117 (12) [back to overview]	Cumulative Incidence of KS Response After Initiation of Delayed Etoposide in Arm A
NCT01352117 (12) [back to overview]	Cumulative Incidence of KS-IRIS
NCT01352117 (12) [back to overview]	Number of Participants With Grade 3 or Higher Adverse Events
NCT01352117 (12) [back to overview]	Change in Peripheral Blood CD4+ Lymphocyte Cell Count
NCT01352117 (12) [back to overview]	Change in Peripheral Blood CD4+ Lymphocyte Cell Count
NCT01352117 (12) [back to overview]	Percentage of Participants With ARV Dose Modification
NCT01380080 (16) [back to overview]	Cumulative Probability of Death by Week 24
NCT01380080 (16) [back to overview]	Cumulative Probability of Death or AIDS Progression by Week 24
NCT01380080 (16) [back to overview]	Cumulative Probability of Death or AIDS Progression by Week 48
NCT01380080 (16) [back to overview]	CD4+ T-cell Count Change From Baseline
NCT01380080 (16) [back to overview]	Proportion of Participants With HIV-1 RNA Level <400 Copies/mL
NCT01380080 (16) [back to overview]	CD4+ T-cell Count
NCT01380080 (16) [back to overview]	Time to Initiation of TB Treatment by Week 96
NCT01380080 (16) [back to overview]	Proportion of Participants With TB Diagnosis by Week 96
NCT01380080 (16) [back to overview]	Proportion of Participants With Reportable Hospitalization by Week 48
NCT01380080 (16) [back to overview]	Proportion of Participants With Immune Reconstitution Inflammatory Syndrome (IRIS) by Week 48
NCT01380080 (16) [back to overview]	Proportion of Participants With at Least One New Grade 3 or 4 Targeted Laboratory Value That is at Least a One-grade Increase From Baseline by Week 48
NCT01380080 (16) [back to overview]	Proportion of Participants With at Least One New Grade 3 or 4 Adverse Event That is at Least a One-grade Increase From Baseline by Week 48
NCT01380080 (16) [back to overview]	Proportion of Participants Who Prematurely Discontinued Antiretroviral Therapy by Week 48
NCT01380080 (16) [back to overview]	Proportion of Participants Who Prematurely Discontinued Any Component of TB Treatment by Week 48
NCT01380080 (16) [back to overview]	Cumulative Probability of First AIDS Progression by Week 96
NCT01380080 (16) [back to overview]	Cumulative Probability of Death or Unknown Vital Status by Week 24
NCT01387022 (4) [back to overview]	The Antiretroviral Treatment Failure Rate at 12 Months.
NCT01387022 (4) [back to overview]	Tenofovir Resistance, Defined as Presence of K65R, K70E or Any of the TAMS Mutations
NCT01387022 (4) [back to overview]	Reported Adverse Events With Severity Grades 3 and 4 Based on the DAIDS Toxicity Grading Tables
NCT01387022 (4) [back to overview]	Change in CD4+ Cell Count From Randomisation to 12 Months Post-randomisation
NCT01410058 (3) [back to overview]	AUC
NCT01410058 (3) [back to overview]	C12h
NCT01410058 (3) [back to overview]	Cmax
NCT01435018 (37) [back to overview]	Cumulative Rate of KS Progression, Death, AIDS Defining Event, or Virologic Failure by Week 48 for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of KS Progression, Death, AIDS Defining Event, or Virologic Failure by Week 48 for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of IERC-confirmed KS Progression by Week 48 for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of HIV-1 RNA Virologic Failure by Week 48 for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of HIV-1 RNA Virologic Failure by Week 48 for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of Death for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of Death for BV+ART vs PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of KS Progression, Death, or AIDS Defining Event by Week 48 for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of IERC-confirmed KS Progression by Week 48 for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of Death by Week 48 for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of Change in KS Treatment by Week 48 for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of Change in KS Treatment by Week 48 for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of AIDS-defining Event by Week 48 for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of AIDS-defining Event by Week 48 for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of KS Progression, Death, or AIDS Defining Event by Week 48 for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of Death by Week 48 for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of KS Progression, Death, AIDS Defining Event, Virologic Failure, or KS-IRIS by Week 48 for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of KS Progression, Death, AIDS Defining Event, Virologic Failure, or KS-IRIS by Week 48 for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Self-reported Adherence to ART Therapy
NCT01435018 (37) [back to overview]	Number of Participants With Treatment-related Toxicities and Adverse Events (AEs)
NCT01435018 (37) [back to overview]	Number of Participants With Symptomatic Peripheral Neuropathy (SPN)
NCT01435018 (37) [back to overview]	Number of Participants With Peripheral Neuropathy (PN)
NCT01435018 (37) [back to overview]	Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 4
NCT01435018 (37) [back to overview]	Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 3
NCT01435018 (37) [back to overview]	Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 2
NCT01435018 (37) [back to overview]	Changes in CD4+ Lymphocyte Cell Count for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Changes in CD4+ Lymphocyte Cell Count for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Time to IERC-confirmed KS Progression or Death for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Time to IERC-confirmed KS Progression or Death for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Number of Participants With Objective Response for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Number of Participants With Objective Response for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Number of Participants With Kaposi's Sarcoma-Immune Reconstitution Inflammatory Syndrome (KS-IRIS) for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Number of Participants With Kaposi's Sarcoma-Immune Reconstitution Inflammatory Syndrome (KS-IRIS) for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Duration of Objective Response for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Duration of Objective Response for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of Progression-Free Survival by Week 48 for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of Progression-Free Survival by Week 48 for BV+ART vs. PTX+ART
NCT01472380 (3) [back to overview]	Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time 0 to Time t[AUC(0-t)]
NCT01472380 (3) [back to overview]	Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time 0 Extrapolated to Infinity [AUC(0-infinity]
NCT01472380 (3) [back to overview]	Pharmacokinetics: Maximum Plasma Concentration (Cmax)
NCT01516970 (4) [back to overview]	Percentage of Participants Who Developed Detectable HIV Antibodies
NCT01516970 (4) [back to overview]	Worst Sheehan Disability Scale (SDS) Score for the Safety Population
NCT01516970 (4) [back to overview]	Number of Participants With Early Discontinuation From Randomized Human Immunodeficiency Virus Postexposure Prophylaxis (HIV PEP)
NCT01516970 (4) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
NCT01585038 (4) [back to overview]	Oxidative Stress Markers
NCT01585038 (4) [back to overview]	Change in Flow-mediated Dilation of the Brachial Artery
NCT01585038 (4) [back to overview]	Endothelial Activation Markers
NCT01585038 (4) [back to overview]	Inflammatory Markers
NCT01618305 (17) [back to overview]	Proportion of Women With HIV-1 Drug Resistance Mutations at Screening, 2-4 Weeks Postpartum in Women Who Stopped Antiretroviral Therapy, and at the Time of Inadequate Virologic Response Using Standard and Ultrasensitive Methods.
NCT01618305 (17) [back to overview]	Proportion of Women Who Achieved HIV-1 RNA Virologic Suppression Below the Lower Limit of Quantification of the Assay at Delivery
NCT01618305 (17) [back to overview]	Proportion of Women With 1) Successful Viral Load (Plasma HIV-1 RNA VL) Decrease From Entry to Week 2 and VL Less Than 1,000 Copies/ml at All Time Points After 4 Weeks on Study Drugs, Until Delivery; and 2) Who Remain on the Assigned Study Regimen
NCT01618305 (17) [back to overview]	Proportion of Women With HIV-1 Drug Resistance Mutations at Screening, 2-4 Weeks Postpartum in Women Who Stopped Antiretroviral Therapy, and at the Time of Inadequate Virologic Response Using Standard and Ultrasensitive Methods.
NCT01618305 (17) [back to overview]	Proportion of Women With HIV-1 RNA Plasma Viral Load Less Than 200 Copies/mL at Weeks 4 and 6 From Treatment Initiation
NCT01618305 (17) [back to overview]	Proportion of Women With HIV-1 RNA Vaginal Viral Load Less Than 1200 Copies/mL at Weeks 4 and 6 From Treatment Initiation
NCT01618305 (17) [back to overview]	Proportion of Deliveries With a Low Birth Weight (Less Than 2,500 Grams)
NCT01618305 (17) [back to overview]	Proportion of Deliveries That Had an Outcome of a Stillbirth/Fetal Demise.
NCT01618305 (17) [back to overview]	Proportion of Deliveries That Were Extremely Premature (Less Than 34 Weeks Gestation).
NCT01618305 (17) [back to overview]	Proportion of Deliveries That Were Premature (Less Than 37 Weeks Gestation)
NCT01618305 (17) [back to overview]	Proportion of Women Who Experienced at Least One New Adverse Event of Greater Than or Equal to Grade 3 as Defined in the Division of AIDS (DAIDS) Toxicity Table
NCT01618305 (17) [back to overview]	Proportion of Deliveries With an Extremely Low Birth Weight (<1,500 Grams).
NCT01618305 (17) [back to overview]	Proportion of Infants Who Experienced at Least One Adverse Event of Greater Than or Equal to Grade 3.
NCT01618305 (17) [back to overview]	Proportion of Participants Who Discontinued Randomized Study Drug Prior to Labor and Delivery.
NCT01618305 (17) [back to overview]	Proportion of Women With Plasma HIV-1 RNA Viral Load Less Than 200 Copies/mL at Delivery
NCT01618305 (17) [back to overview]	Log10 Change in Viral Load From Entry to Each Time Point Prior to Delivery
NCT01618305 (17) [back to overview]	Proportion of HIV-infected Infants With Genotypic Resistance to Study Drugs
NCT01632345 (19) [back to overview]	Change From Baseline in CD4 Cell Count at Week 24: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)
NCT01632345 (19) [back to overview]	Change From Baseline in CD4 Cell Count at Week 48: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)
NCT01632345 (19) [back to overview]	Change From Baseline in CD4 Cell Count at Week 96: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)
NCT01632345 (19) [back to overview]	Change From Baseline in CD4 T Lymphocyte Cell Count at Week 24: Doravirine (All Doses) vs Efavirenz (Part I)
NCT01632345 (19) [back to overview]	Percentage of Participants Who Discontinued Study Therapy Due to AEs in Weeks 0-24: Doravirine (All Doses) vs Efavirenz (Part I)
NCT01632345 (19) [back to overview]	Percentage of Participants With At Least 1 AE in Weeks 0-24: Doravirine (All Doses) vs Efavirenz (Part I)
NCT01632345 (19) [back to overview]	Percentage of Participants With At Least 1 AE in Weeks 0-24: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)
NCT01632345 (19) [back to overview]	Percentage of Participants With CNS Events by Week 24: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)
NCT01632345 (19) [back to overview]	Percentage of Participants With Virologic Response (HIV-1 RNA <200 Copies/mL) at Week 24: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)
NCT01632345 (19) [back to overview]	Percentage of Participants With CNS Events by Week 8: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)
NCT01632345 (19) [back to overview]	Percentage of Participants With At Least 1 AE in Weeks 0-96: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)
NCT01632345 (19) [back to overview]	Percentage of Participants With At Least 1 AE in Weeks 0-48: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)
NCT01632345 (19) [back to overview]	Percentage of Participants With Virologic Response (HIV-1 RNA) < 40 Copies/mL) at Week 24: Doravirine (All Doses) vs Efavirenz (Part I)
NCT01632345 (19) [back to overview]	Percentage of Participants With Virologic Response (HIV-1 RNA <40 Copies/mL) at Week 96: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)
NCT01632345 (19) [back to overview]	Percentage of Participants With Virologic Response (HIV-1 RNA <40 Copies/mL) at Week 48: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)
NCT01632345 (19) [back to overview]	Percentage of Participants With Virologic Response (HIV-1 RNA <40 Copies/mL) at Week 24: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)
NCT01632345 (19) [back to overview]	Percentage of Participants With Virologic Response (HIV-1 RNA <200 Copies/mL) at Week 96: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)
NCT01632345 (19) [back to overview]	Percentage of Participants With Virologic Response (HIV-1 RNA <200 Copies/mL) at Week 48: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)
NCT01632345 (19) [back to overview]	Percentage of Participants With Virologic Response (HIV-1 RNA <200 Copies/mL) at Week 24: Doravirine (All Doses) vs Efavirenz (Part I)
NCT01632891 (7) [back to overview]	Change in log10(Pf Parasite Density) From Entry to Day 30
NCT01632891 (7) [back to overview]	Number of Participants With Uncomplicated Clinical Malaria
NCT01632891 (7) [back to overview]	Time to First Pf SCP Clearance
NCT01632891 (7) [back to overview]	Log10(Pf Parasite Density)
NCT01632891 (7) [back to overview]	Proportion of Participants With Plasmodium Falciparum (Pf) Subclinical Parasitemia (SCP) Clearance
NCT01632891 (7) [back to overview]	Number of Participants With Detectable Pf Gametocyte Density
NCT01632891 (7) [back to overview]	Change in log10(Pf Gametocyte Density) From Entry to Day 30
NCT01641809 (57) [back to overview]	Number of Participants With Adherence to Study Treatment
NCT01641809 (57) [back to overview]	Number of Participants With Adherence to Study Treatment
NCT01641809 (57) [back to overview]	Change From Baseline in Total Neutrophils, Platelet Count and WBC Count Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in Total Neutrophils, Platelet Count and WBC Count Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in Plasma log10 HIV-1 RNA Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in Plasma log10 HIV-1 RNA Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in Hemoglobin Level Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in Hemoglobin Level Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in Estimated Creatinine Clearance Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in Estimated Creatinine Clearance Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in Estimated Creatinine Clearance Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in Creatinine and Total Bilirubin Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in Creatinine and Total Bilirubin Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in CD4+ Cell Count Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in CD4+ Cell Count Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in ALT, AST and CK Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in ALT, AST and CK Over Time by Visit
NCT01641809 (57) [back to overview]	Absolute Values for Platelet Count, Total Neutrophils and WBC Count During Double-blind Randomized Treatment Until Week 96
NCT01641809 (57) [back to overview]	Absolute Values for Plasma Logarithm to the Base 10 (log10) HIV-1 RNA Over Time by Visit
NCT01641809 (57) [back to overview]	Absolute Values for Plasma Logarithm to the Base 10 (log10) HIV-1 RNA Over Time by Visit
NCT01641809 (57) [back to overview]	Absolute Values for Hemoglobin During Double-blind Randomized Treatment Until Week 96
NCT01641809 (57) [back to overview]	Absolute Values for Estimated Creatinine Clearance During Double-blind Randomized Treatment Until Week 96
NCT01641809 (57) [back to overview]	Absolute Values for Estimated Creatinine Clearance During Double-blind Randomized Treatment Until Week 96
NCT01641809 (57) [back to overview]	Absolute Values for Estimated Creatinine Clearance During Double-blind Randomized Treatment Until Week 96
NCT01641809 (57) [back to overview]	Absolute Values for Estimated Creatinine Clearance During Double-blind Randomized Treatment Until Week 96
NCT01641809 (57) [back to overview]	Absolute Values for Creatinine and Total Bilirubin During Double-blind Randomized Treatment Until Week 96
NCT01641809 (57) [back to overview]	Absolute Values for Cluster of Differentiation 4+ (CD4+) Cell Count During Double-blind Randomized Treatment Until Week 96
NCT01641809 (57) [back to overview]	Absolute Values for ALT, AST, CK During Double-blind Randomized Treatment Until Week 96
NCT01641809 (57) [back to overview]	Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/Milliliter (mL) at Week 48 Using the Missing, Switch, Discontinuation Equals Failure (MSDF) Algorithm
NCT01641809 (57) [back to overview]	Percentage of Participants Who Discontinued Treatment Due to Adverse Events-Maintenance Phase
NCT01641809 (57) [back to overview]	Percentage of Participants Who Discontinued Treatment Due to Adverse Events-Induction Phase
NCT01641809 (57) [back to overview]	Percentage of Participants Who Discontinued Investigational Product Due to Adverse Events
NCT01641809 (57) [back to overview]	Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings
NCT01641809 (57) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <50 Copies/mL Over Time by Visit Using Observed Case Analysis
NCT01641809 (57) [back to overview]	Area Under the Concentration Time Curve Over the Dosing Interval (AUC[0-tau]) for GSK1265744 at Week 2
NCT01641809 (57) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <50 Copies/mL Over Time by Visit Using Observed Case Analysis
NCT01641809 (57) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <400 Copies/mL Until Week 96 Using the Observed Case Analysis
NCT01641809 (57) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <400 Copies/mL Until Week 96 Using the MSDF Algorithm
NCT01641809 (57) [back to overview]	Percentage of Participants With HIV-1 RNA <50 Copies/mL From Week 24 Through Week 96 by Visit Using MSDF Algorithm-Maintenance Phase
NCT01641809 (57) [back to overview]	Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 16 and Week 24 Using MSDF Algorithm-Induction Phase
NCT01641809 (57) [back to overview]	Number of Participants With Treatment Emergent Phenotypic Resistance
NCT01641809 (57) [back to overview]	Number of Participants With Treatment Emergent Genotypic Mutations Associated With Development of Resistance
NCT01641809 (57) [back to overview]	Number of Participants With Post-Baseline HIV-1 Associated Conditions Progression of Disease
NCT01641809 (57) [back to overview]	Number of Participants With Maximum Treatment-emergent Hematology Toxicities-Maintenance Phase
NCT01641809 (57) [back to overview]	Change From Baseline in Estimated Creatinine Clearance Over Time by Visit
NCT01641809 (57) [back to overview]	Maximum Observed Concentration (Cmax) for GSK1265744 at Week 2
NCT01641809 (57) [back to overview]	Concentration at the End of a Dosing Interval (Ctau) for GSK1265744 at Week 2
NCT01641809 (57) [back to overview]	Number of Participants With Maximum Treatment-emergent Hematology Toxicities-Induction Phase
NCT01641809 (57) [back to overview]	Number of Participants With Maximum Treatment-emergent Hematology Toxicities Over Time
NCT01641809 (57) [back to overview]	Number of Participants With Maximum Treatment-emergent Clinical Chemistry Toxicity-Induction Phase
NCT01641809 (57) [back to overview]	Number of Participants With Maximum Treatment-emergent Clinical Chemistry Toxicities-Maintenance Phase
NCT01641809 (57) [back to overview]	Number of Participants With Maximum Treatment-emergent Clinical Chemistry Toxicities Over Time
NCT01641809 (57) [back to overview]	Number of Participants With AEs and SAEs-Induction Phase
NCT01641809 (57) [back to overview]	Number of Participants With AEs and SAEs Over Time
NCT01641809 (57) [back to overview]	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Maintenance Phase
NCT01641809 (57) [back to overview]	Number of Participants With Adherence to Study Treatment
NCT01641809 (57) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <50 Copies/mL Over Time by Visit Using the MSDF Algorithm
NCT01695954 (3) [back to overview]	GMR of Cmax of Pitavastatin When Coadministered With Efavirenz or With Darunavir/Ritonavir
NCT01695954 (3) [back to overview]	GMR of 24- Hour AUC of Pitavastatin When Coadministered With Efavirenz or With Darunavir/Ritonavir Over 24 Hour AUC of Pitavastatin
NCT01695954 (3) [back to overview]	AUC
NCT01709084 (6) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA Levels < 50 Copies/mL at Week 48
NCT01709084 (6) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA Levels >= 50 Copies Per Milliliter (Copies/mL) at Week 48 Based on Time to Loss of Virologic Response (TLOVR) [Non-virologic Failure Censored] Imputation Method.
NCT01709084 (6) [back to overview]	Percentage of Participants With Plasma Human Immunodeficiency Virus - Type 1 Ribonucleic Acid (HIV-1 RNA) Levels Less Than (<) 400 Copies Per Milliliter (Copies/mL) at Week 48
NCT01709084 (6) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA Levels More Than or Equal to (>=) 400 Copies/mL at Week 48 Based on Time to Loss of Virologic Response (TLOVR) [Non-virologic Failure Censored] Imputation Method.
NCT01709084 (6) [back to overview]	Number of Participants With Treatment-Emergent Nucleoside Reverse Transcriptase Inhibitor (N[t]RTI) or Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (NNRTI) Mutations
NCT01709084 (6) [back to overview]	Percentage of Participant With Treatment Adherence Based on Tablet Count
NCT01837277 (1) [back to overview]	Early Mortality
NCT01878890 (4) [back to overview]	Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)
NCT01878890 (4) [back to overview]	Maximum Tolerated Dose (MTD) of Efavirenz
NCT01878890 (4) [back to overview]	12-week Objective Response Rate
NCT01878890 (4) [back to overview]	12-week Non-progression Rate
NCT01903031 (21) [back to overview]	EFV PK Parameter Minimum Plasma Concentration (Cmin) Determined Based on EFV Levels From Individual Participants Enrolled in Arm B
NCT01903031 (21) [back to overview]	RTV PK Parameter Tmax Determined Based on RTV Levels From Individual Participants Enrolled in Arm C
NCT01903031 (21) [back to overview]	RTV PK Parameter Cmin Determined Based on RTV Levels From Individual Participants Enrolled in Arm C
NCT01903031 (21) [back to overview]	RTV PK Parameter Cmax Determined Based on RTV Levels From Individual Participants Enrolled in Arm C
NCT01903031 (21) [back to overview]	RTV PK Parameter CLss/F Determined Based on RTV Levels From Individual Participants Enrolled in Arm C
NCT01903031 (21) [back to overview]	Ritonavir (RTV) PK Parameter AUC(0-24h) Calculated Based on Intensive RTV PK Samples Obtained From Individual Participants Enrolled in Arm C
NCT01903031 (21) [back to overview]	Proportion of Participants With Progesterone Levels Greater Than 5 ng/mL.
NCT01903031 (21) [back to overview]	Proportion of Participants With Plasma HIV-1 RNA Levels <40 Copies/mL
NCT01903031 (21) [back to overview]	Etonogestrel Concentrations Obtained on Study Days 7 and 14
NCT01903031 (21) [back to overview]	Ethinyl Estradiol Concentrations Obtained on Study Days 7 and 14.
NCT01903031 (21) [back to overview]	EFV PK Parameter Maximum Plasma Concentration (Cmax) Determined Based on EFV Levels From Individual Participants Enrolled in Arm B
NCT01903031 (21) [back to overview]	EFV PK Parameter Clearance (CLss/F) Determined Based on EFV Levels From Individual Participants Enrolled in Arm B
NCT01903031 (21) [back to overview]	EFV PK Parameter Area Under the Concentration-Time Curve (AUC0-24hours) Calculated Based on Intensive EFV PK Samples Obtained From Individual Participants Enrolled in Arm B
NCT01903031 (21) [back to overview]	ATV PK Parameter Time to Cmax (Tmax) Determined Based on ATV Levels From Individual Participants Enrolled in Arm C
NCT01903031 (21) [back to overview]	ATV PK Parameter Cmin Determined Based on ATV Levels From Individual Participants Enrolled in Arm C
NCT01903031 (21) [back to overview]	ATV PK Parameter Cmax Determined Based on ATV Levels From Individual Participants Enrolled in Arm C
NCT01903031 (21) [back to overview]	ATV PK Parameter CLss/F Determined Based on ATV Levels From Individual Participants Enrolled in Arm C
NCT01903031 (21) [back to overview]	ATV PK Parameter AUC(0-24h) Calculated Based on Intensive Atazanavir (ATV) PK Samples Obtained From Individual Participants Enrolled in Arm C
NCT01903031 (21) [back to overview]	Percentage of Participants With Signs and Symptoms of Grade 2 or Higher Deemed Possibly, Probably or Definitely Related to Study Treatment
NCT01903031 (21) [back to overview]	Etonogestrel Concentrations at Study Day 21
NCT01903031 (21) [back to overview]	Ethinyl Estradiol Concentrations at Study Day 21
NCT01989910 (3) [back to overview]	The Proportion of Treatment Failure at Week 48 for Both Arms.
NCT01989910 (3) [back to overview]	The Proportion of Patients Who Can Achieve of Less Than 20 HIV RNA Copies Per ml at Week 48 of Both Arms.
NCT01989910 (3) [back to overview]	The Proportion of Patients With Achievement of Less Than 400 HIV RNA Copies Per ml at Week 48 for Both Arms.
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: Body Mass Index-for-age Z-score
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: Cessation of First-line Regimen for Clinical/Immunological Failure
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: Change From Baseline in Absolute CD4 to Week 72
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: Height-for-age Z-score
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: New ART-modifying Adverse Event
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: New Grade 3 or 4 Adverse Event Definitely/Probably or Uncertainly Related to ART
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: New or Recurrent WHO Stage 3 or 4 Event or Death
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: New Serious Adverse Events Not Solely Related to HIV
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: New WHO Stage 3 or 4 Event or Death
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: Weight-for-age Z-score
NCT02028676 (58) [back to overview]	LCM vs CDM: Change From Baseline in CD4% to Week 144
NCT02028676 (58) [back to overview]	LCM vs CDM: Change From Baseline in CD4% to Week 72
NCT02028676 (58) [back to overview]	LCM vs CDM: Disease Progression to a New WHO Stage 4 Event or Death
NCT02028676 (58) [back to overview]	LCM vs CDM: New Grade 3 or 4 Adverse Event (AE), Not Solely Related to HIV
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Adherence to ART as Measured by Self-reported Questionnaire (Missing Any Pills in the Last 4 Weeks)
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Adherence to ART as Measured by Self-reported Questionnaire (Missing Any Pills in the Last 4 Weeks) at 48 Weeks
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Adherence to ART as Measured by Self-reported Questionnaire (Missing Any Pills in the Last 4 Weeks) at 96 Weeks
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: All-cause Mortality
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Body Mass Index-for-age Z-score
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Change From Baseline in Absolute CD4 to Week 48
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Change From Baseline in Absolute CD4 to Week 72
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Change From Baseline in Absolute CD4 to Week 96
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Change From Baseline in CD4% to Week 48
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Change From Baseline in CD4% to Week 72
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Change From Baseline in CD4% to Week 96
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Height-for-age Z-score
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: New Grade 3 or 4 Adverse Event (AE), Not Solely Related to HIV
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: New Grade 3 or 4 Adverse Event (AE), Not Solely Related to HIV, Judged Definitely/Probably or Uncertain Whether Related to Lamivudine or Abacavir
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: New Serious Adverse Events Not Solely Related to HIV
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: New WHO Stage 3 or 4 Event or Death
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: New WHO Stage 4 Event or Death
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Suppressed HIV RNA Viral Load 48 Weeks After Randomisation
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Weight-for-age Z-score
NCT02028676 (58) [back to overview]	Cotrimoxazole: Change From Baseline in CD4% to Week 72
NCT02028676 (58) [back to overview]	Cotrimoxazole: New Hospitalisation or Death
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Suppression of HIV RNA Viral Load 96 Weeks After Randomisation
NCT02028676 (58) [back to overview]	CDM vs LCM, Induction ART: Suppression of HIV RNA Viral Load 144 Weeks After Baseline
NCT02028676 (58) [back to overview]	CDM vs LCM, Induction ART: Suppression of HIV RNA Viral Load 72 Weeks After Baseline
NCT02028676 (58) [back to overview]	Cotrimoxazole: All-cause Mortality
NCT02028676 (58) [back to overview]	Cotrimoxazole: Body Mass Index-for-age Z-score
NCT02028676 (58) [back to overview]	Cotrimoxazole: Change From Baseline in Absolute CD4 to Week 72
NCT02028676 (58) [back to overview]	Cotrimoxazole: Height-for-age Z-score
NCT02028676 (58) [back to overview]	Cotrimoxazole: New Clinical and Diagnostic Positive Malaria
NCT02028676 (58) [back to overview]	Cotrimoxazole: New Grade 3 or 4 Adverse Event (AE), Not Solely Related to HIV
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: Change From Baseline in Absolute CD4 to Week 144
NCT02028676 (58) [back to overview]	Cotrimoxazole: New Serious Adverse Events Not Solely Related to HIV
NCT02028676 (58) [back to overview]	Cotrimoxazole: Adherence to ART as Measured by Self-reported Questionnaire (Missing Any Pills in the Last 4 Weeks)
NCT02028676 (58) [back to overview]	Cotrimoxazole: New Severe Pneumonia
NCT02028676 (58) [back to overview]	Cotrimoxazole: New WHO Stage 3 or 4 Event or Death
NCT02028676 (58) [back to overview]	Cotrimoxazole: New WHO Stage 3 Severe Recurrent Pneumonia or Diarrhoea
NCT02028676 (58) [back to overview]	Cotrimoxazole: New WHO Stage 4 Event or Death
NCT02028676 (58) [back to overview]	Cotrimoxazole: Weight-for-age Z-score
NCT02028676 (58) [back to overview]	Induction ART: Change From Baseline in CD4% 72 Weeks After ART Initiation
NCT02028676 (58) [back to overview]	Induction ART: Change From Baseline in CD4% to 144 Weeks From ART Initiation
NCT02028676 (58) [back to overview]	Induction ART: New Grade 3 or 4 Adverse Event (AE), Not Solely Related to HIV
NCT02028676 (58) [back to overview]	Induction ART: New WHO Stage 4 Event or Death
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: Adherence to ART as Measured by Self-reported Questionnaire (Missing Any Pills in the Last 4 Weeks)
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: All-cause Mortality
NCT02401256 (1) [back to overview]	Efavirenz AUC0-inf (Single Dose) and AUC0-24(Multiple Dose)
NCT03048422 (23) [back to overview]	Cumulative Probability of Infant Deaths
NCT03048422 (23) [back to overview]	Count of Infants With HIV-1 Antiretroviral Drug Resistance Mutations at the Time of Infant HIV Diagnosis
NCT03048422 (23) [back to overview]	Maternal Change in Creatinine Clearance
NCT03048422 (23) [back to overview]	Change in Maternal Weight Overall
NCT03048422 (23) [back to overview]	Change in Maternal Weight Antepartum
NCT03048422 (23) [back to overview]	Cumulative Probability of Women Experiencing Grade 3 or Higher Adverse Event
NCT03048422 (23) [back to overview]	Cumulative Probability of Infants Experiencing Grade 3 or Higher Adverse Event
NCT03048422 (23) [back to overview]	Cumulative Probability of Infants Experiencing Grade 3 or Higher Adverse Event
NCT03048422 (23) [back to overview]	Cumulative Probability of Infant HIV-infection
NCT03048422 (23) [back to overview]	Percentage of Mothers With HIV-1 RNA Viral Load Less Than 200 Copies/mL at Delivery
NCT03048422 (23) [back to overview]	Infant Creatinine Clearance
NCT03048422 (23) [back to overview]	Time to First HIV-1 RNA Less Than 200 Copies/mL Through Delivery
NCT03048422 (23) [back to overview]	Percentage of Mothers With Virologic Success of HIV-1 RNA Less Than 200 Copies/mL at Delivery Based on FDA Snapshot Algorithm
NCT03048422 (23) [back to overview]	Percentage of Mothers With Virologic Success of HIV-1 RNA Less Than 200 Copies/mL at 50 Weeks Postpartum Based on FDA Snapshot Algorithm
NCT03048422 (23) [back to overview]	Percentage of Mothers With HIV-1 RNA Less Than 50 Copies/mL at Delivery Measured at Central Laboratory
NCT03048422 (23) [back to overview]	Change in Maternal Weight Postpartum
NCT03048422 (23) [back to overview]	Percentage of Mothers With HIV-1 RNA Less Than 200 Copies/mL at 50 Weeks Postpartum
NCT03048422 (23) [back to overview]	Percentage of Mothers With HIV-1 ARV Drug Resistance Mutations at the Time of Maternal Virologic Failure
NCT03048422 (23) [back to overview]	Percentage of Mother-Infant Pairs With Preterm Deliveries
NCT03048422 (23) [back to overview]	Percentage of Mother-infant Pairs With an Adverse Pregnancy Outcome or Major Congenital Anomaly
NCT03048422 (23) [back to overview]	Percentage of Mother-Infant Pairs With an Adverse Pregnancy Outcome
NCT03048422 (23) [back to overview]	Percentage of Mother-infant Pairs With an Adverse Pregnancy Outcome
NCT03048422 (23) [back to overview]	Percentage of Infants Born Small for Gestational Age
NCT04459598 (9) [back to overview]	Total Apparent Clearance (CL/F) for Quizartinib Following Single Dose of Quizartinib With or Without Efavirenz
NCT04459598 (9) [back to overview]	Area Under the Plasma Concentration-Time Curve up to the Last Quantifiable Concentration Post-Dose (AUClast) Following Single Dose of Quizartinib With or Without Efavirenz
NCT04459598 (9) [back to overview]	Time to Maximum Plasma Concentration (Tmax) Following Single Dose of Quizartinib With or Without Efavirenz
NCT04459598 (9) [back to overview]	Volume of Distribution in the Terminal Phase (Vz/F) for Quizartinib Following Single Dose of Quizartinib With or Without Efavirenz
NCT04459598 (9) [back to overview]	Area Under the Plasma Concentration-Time Curve up to Infinity (AUCinf) Following Single Dose of Quizartinib With or Without Efavirenz
NCT04459598 (9) [back to overview]	Terminal Half-Life (t1/2) Following Single Dose of Quizartinib With or Without Efavirenz
NCT04459598 (9) [back to overview]	Metabolite to Parent Ratio (MPR) Based on Area Under the Curve for Active Metabolite AC886 Following Single Dose of Quizartinib With or Without Efavirenz
NCT04459598 (9) [back to overview]	Number of Participants With Treatment-emergent Adverse Events Following Single Dose of Quizartinib With or Without Efavirenz
NCT04459598 (9) [back to overview]	Maximum Plasma Concentration (Cmax) Following Single Dose of Quizartinib With or Without Efavirenz

Proportion of Participants With Suppression of HIV Viral Load to Less Than 50 Copies/ml at Week 16

Proportion was calculated as number of participants with HIV-1 RNA <= 50 copies/ml relative to the number of participants with HIV-1 RNA measured at that time point. (NCT00016718)
Timeframe: At week 16

Intervention	proportion of participants (Number)
Age Group 1	0.50
Age Group 2	0.76
Age Group 3	0.75

Intervention	mg/L (Median)
	2nd Trimester	3rd Trimester	Postpartum
ETR 200mg b.i.d.	0.70	1.01	0.63
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.	8.4	10.7	14.6
RAL 400mg b.i.d.	2.250	1.770	3.035
RPV 25mg q.d.	0.145	0.134	0.134

Intervention	hour (Median)
DTG 50mg q.d.	32.8
EVG/COBI 150/150mg q.d.	7.6
DRV/COBI 800/150 mg q.d.	NA
EFV 600 mg q.d. (Outside THA)	65.6

Intervention	mcg/mL (Median)
	2-10 hours after birth	18-28 hours after birth	36-72 hours after birth	5-9 days after birth
DRV/COBI 800/150 mg q.d.	0.35	1.43	1.87	1.72
DTG 50mg q.d.	1.73	1.53	1.00	0.06
EFV 600 mg q.d. (Outside THA)	1.1	1.0	0.9	0.4
EVG/COBI 150/150mg q.d.	0.132	0.032	0.005	0.005

Intervention	unitless (Median)
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.	0.15
DTG 50mg q.d.	1.25
EVG/COBI 150/150mg q.d.	0.91
DRV/COBI 800/150 mg q.d.	0.07
ATV/COBI 300/150 mg q.d.	0.07
TFV 300mg q.d.	0.88

Intervention	unitless (Median)
TAF 10mg q.d. w/COBI	0.97
EFV 600 mg q.d. (Outside THA)	0.67
EFV 600mg q.d.	0.49
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.	0.2
RAL 400mg b.i.d.	1.5
ETR 200mg b.i.d.	0.52
MVC 150 or 300mg b.i.d.	0.33
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.	0.14
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.	0.16
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.	0.19
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)	0.12
RPV 25mg q.d.	0.55
ATV/RTV 300/100mg q.d. or TFV/ATV/RTV 300/300/100mg q.d.	0.18
DRV/RTV 800/100mg q.d. or DRV/RTV 600/100mg b.i.d.	0.18

Intervention	pg/mL (Median)
ATV/RTV/TFV 300/100/300mg q.d. With ENG	604
LPV/RTV 400/100 b.i.d. With ENG	428
EFV 600mg q.d. With ENG	125

Intervention	mcg*hr/mL (Median)
	Before contraceptive initiation	After contraceptive initiation
LPV/RTV 400/100 b.i.d. With ENG	115.97	100.20

Intervention	weeks (Number)
	5th percentile	10th percentile	25th percentile
ddI+FTC+ATV	0	0	48
ZDV/3TC+EFV	0	16	NA

Intervention	cells/mm^3 (Median)
	Change from screening to week 24 (N=490; N=498)	Change from screening to week 48 (N=480; N=485)	Change from screening to week 96 (N=458; N=471)
TDF/FTC+EFV	120.5	159	226
ZDV/3TC+EFV	112.5	151.5	220.5

Intervention	cells/mm^3 (Median)
	Change from screening to week 24 (N=490; N=502)	Change from screening to week 48 (N=474; N=477)	Change from screening to week 96 (N= 188; N=188)
ddI+FTC+ATV	146.5	187.0	256.0
ZDV/3TC+EFV	112.5	152.0	216.0

Intervention	participants (Number)
	Week 24: Number with RNA <400 c/mL (N=495; N=500)	Week 48: Number with RNA <400 c/mL (N=482; N=487)
TDF/FTC+EFV	448	455
ZDV/3TC+EFV	459	442

Intervention	participants (Number)
	Week 24: Number with RNA <400 c/mL (N=495; N=506)	Week 48: Number with RNA <400 c/mL (N=476; N=478)
ddI+FTC+ATV	431	424
ZDV/3TC+EFV	459	437

Intervention	weeks (Number)
	10th percentile	25th percentile	50th percentile
TDF/FTC+EFV	4	32	224
ZDV/3TC+EFV	4	12	112

Intervention	weeks (Number)
	1st percentile	5th percentile	10th percentile
TDF/FTC+EFV	48	104	NA
ZDV/3TC+EFV	48	128	NA

Intervention	log10 copies/mL (Least Squares Mean)
	Week 48	Week 96
Efavirenz Once Daily + CBV (DB)	-2.262	-2.034
Maraviroc Twice Daily + CBV (DB)	-2.152	-1.945

Intervention	Percentage of participants (Number)
	Less than 400 copies/mL	Less than 50 copies/mL
Efavirenz Once Daily + CBV (DB)	64.4	62.7
Maraviroc Twice Daily + CBV (DB)	64.0	58.8

Intervention	participants (Number)
	Resistance to Zidovudine: Week 48 (n= 20, 43, 15)	Resistance to Lamivudine: Week 48 (n= 20, 43, 15)	Resistance to Efavirenz: Week 48 (n= 20, 43, 15)	Resistance to Maraviroc: Week 48 (n= 20, 43, 15)	Resistance to Zidovudine: Week 96 (n= 27, 55, 23)	Resistance to Lamivudine: Week 96 (n= 27, 55, 23)	Resistance to Efavirenz: Week 96 (n= 27, 55, 23)	Resistance to Maraviroc: Week 96 (n= 27, 55, 23)
Efavirenz Once Daily + CBV (DB)	0	3	7	NA	0	8	13	NA
Maraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL)	0	14	0	NA	0	20	0	NA
Maraviroc Twice Daily + CBV (DB)	0	27	0	12	0	33	0	NA

Intervention	participants (Number)
	Any Zid/Lam Mutation: Week 48 (n= 20, 43, 15)	Any TAM Mutation: Week 48 (n= 20, 43, 15)	K65R Mutation: Week 48 (n= 20, 43, 15)	M184V/I Mutation: Week 48 (n= 20, 43, 15)	Other NRTI Mutation: Week 48 (n= 20, 43, 15)	Any Zid/Lam Mutation: Week 96 (n= 27, 55, 23)	Any TAM Mutation: Week 96 (n= 27, 55, 23)	K65R Mutation: Week 96 (n= 27, 55, 23)	M184V/I Mutation: Week 96 (n= 27, 55, 23)	Other NRTI Mutation: Week 96 (n= 27, 55, 23)
Efavirenz Once Daily + CBV (DB)	3	0	0	3	0	8	2	0	8	0
Maraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL)	14	1	0	14	0	20	3	0	20	0
Maraviroc Twice Daily + CBV (DB)	27	6	1	27	1	33	6	1	33	1

Intervention	participants (Number)
	Baseline: R5; Treatment failure: R5	Baseline: R5; Treatment failure: X4	Baseline: R5; Treatment failure: DM	Baseline: R5; Treatment failure: NR/NP	Baseline: DM; Treatment failure: R5	Baseline: DM; Treatment failure: X4	Baseline: DM; Treatment failure: DM	Baseline: DM; Treatment failure: NR/NP	Baseline: NR/NP; Treatment failure: R5	Baseline: NR/NP; Treatment failure: X4	Baseline: NR/NP; Treatment failure: DM	Baseline: NR/NP; Treatment failure: NR/NP
Efavirenz Once Daily + CBV (DB)	10	0	0	5	1	0	0	0	0	0	0	0
Maraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL)	9	0	4	6	0	0	5	0	0	0	0	0
Maraviroc Twice Daily + CBV (DB)	14	1	11	7	1	2	4	0	1	0	0	1

Intervention	cells/µL (Mean)
	Baseline	Change at Week 48	Change at Week 96
Efavirenz Once Daily + CBV (DB)	935.78	-126.83	-150.27
Maraviroc Twice Daily + CBV (DB)	938.80	38.34	20.74

efavirenz

Description

Cross-References

Synonyms (202)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (5)

Protein Targets (87)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (339)

Molecular Functions (129)

Ceullar Components (77)

Bioassays (2857)

Research

Studies (2,956)

Market Indicators

Research Demand Index: 83.44

Study Types

Clinical Trials (317)

Trial Overview

Trial Outcomes

Proportion of Participants With Suppression of HIV Viral Load to Less Than 50 Copies/ml at Week 16

Proportion of Participants With Suppression of HIV Viral Load to Less Than 400 Copies/ml at Week 16

Proportion of Participants Who Developed Grade 3 or 4 Adverse Events Attributed to the Study Treatment.

PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (Range) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (95% CI) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (IQR) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C12) With Geometric Mean (95% CI) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C12) With Median (IQR) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C12) With Median (Range) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C24) With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic (PK) Parameter: Infant Plasma Washout Half-life (T1/2) of ARVs and TB Drugs

PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic (PK) Parameter: Infant Plasma Washout Concentration of ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Geometric Mean (95% CI) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (IQR) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (Range) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (IQR) for ARVs and TB Drugs

PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (IQR) for ARVs and TB Drugs

PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (Range) for ARVs and TB Drugs

Plasma Concentration for Contraceptives

Area Under the Curve From 0 to 12 Hours (AUC12) of ARVs for Contraceptive Arms

Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs

Area Under the Curve From 0 to 24 Hours (AUC24) of ARVs for Contraceptive Arms

Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs

Linked Partner HIV Infection Rates in Early-ART and Delayed-ART Arms

All Partner HIV Infection Rates in Early-ART and Delayed-ART Arms

Time to Loss of Virologic Response by Week 48 (Defined by FDA TLOVR Algorithm - Excluding Study Allowed ARV Substitutions)(PI Comparison)

Time to Treatment Failure (NRTI Comparison)

Time to Treatment Failure (PI Comparison)

Change in CD4 Count From Screening to Weeks 24, 48, 96 (NRTI Comparison)

Change in CD4 Count From Screening to Weeks 24, 48, 96 (PI Comparison)

Plasma HIV-1 Viral Load Fewer Than 400 Copies/ml (NRTI Comparison)

Plasma HIV-1 Viral Load Fewer Than 400 Copies/ml (PI Comparison)

Time to Discontinuation of Initial Antiretroviral (ARV) Therapy (NRTI Comparison)

Time to Discontinuation of Initial Antiretroviral (ARV) Therapy (PI Comparison)

Time to First Dose Modification or Grade 3 or 4 Adverse Event (NRTI Comparison)

Time to First Dose Modification or Grade 3 or 4 Adverse Event (PI Comparison)

Time to Immunologic Failure (PI Comparison)

Time to Loss of Virologic Response at Week 48 (Defined by FDA TLOVR Algorithm - Excluding Study Allowed ARV Substitutions)(NRTI Comparison)

Time to Loss of Virologic Response at Week 48 (Defined by FDA TLOVR Algorithm - Including All ARV Substitutions)(NRTI Comparison)

Time to Loss of Virologic Response at Week 48 (Defined by FDA TLOVR Algorithm - Including All ARV Substitutions)(PI Comparison)

Time to Immunologic Failure (NRTI Comparison)

Time to Loss of Virologic Response at Week 96 (Defined by FDA TLOVR Algorithm - Excluding Study Allowed ARV Substitutions)(NRTI Comparison)

Time to Loss of Virologic Response at Week 96 (Defined by FDA TLOVR Algorithm - Including All ARV Substitutions)(NRTI Comparison)

Time-Averaged Difference (TAD) in log10-transformed HIV-1 RNA Levels

Percentage of Participants With HIV-1 RNA Levels of Less Than 400 Copies/mL and Less Than 50 Copies/mL at Week 96 for Enhanced Sensitivity Trofile Assay (ESTA) R5 Participants

Intervention	participants (Number)
	L100I Mutation: Week 48 (n= 43, 15)	K103N Mutation: Week 48 (n= 43, 15)	V106M Mutation: Week 48 (n= 43, 15)	V108I Mutation: Week 48 (n= 43, 15)	Y181C/I Mutation: Week 48 (n= 43, 15)	Y188L Mutation: Week 48 (n= 43, 15)	G190S/A Mutation: Week 48 (n= 43, 15)	P225H Mutation: Week 48 (n= 43, 15)	L100I Mutation: Week 96 (n= 55, 23)	K103N Mutation: Week 96 (n= 55, 23)	V106M Mutation: Week 96 (n= 55, 23)	V108I Mutation: Week 96 (n= 55, 23)	Y181C/I Mutation: Week 96 (n= 55, 23)	Y188L Mutation: Week 96 (n= 55, 23)	G190S/A Mutation: Week 96 (n= 55, 23)	P225H Mutation: Week 96 (n= 55, 23)
Efavirenz Once Daily + CBV (DB)	0	6	0	0	0	0	1	0	0	12	1	1	0	0	2	1
Maraviroc Twice Daily + CBV (DB)	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0

Intervention	participants (Number)
MK0518 100 mg b.i.d.	38
MK0518 200 mg b.i.d	34
MK0518 400 mg b.i.d.	40
MK0518 600 mg b.i.d.	36
EFV Combo Therapy	33

Intervention	Participants (Number)
	Adverse experiences	Serious adverse experiences
EVF Combo Therapy	35	4
MK-0518 b.i.d.	154	25

Intervention	participants (Number)
	Discontinued with CAEs	Did Not Discontinue with CAEs
EFV Combo Therapy	0	38
MK0518 100 mg b.i.d.	0	39
MK0518 200 mg b.i.d	0	40
MK0518 400 mg b.i.d.	0	41
MK0518 600 mg b.i.d.	0	40

Intervention	participants (Number)
	Discontinued With LAEs	Did Not Discontinue With LAEs
EFV Combo Therapy	0	38
MK0518 100 mg b.i.d.	0	39
MK0518 200 mg b.i.d	0	40
MK0518 400 mg b.i.d.	0	41
MK0518 600 mg b.i.d.	1	39

Intervention	participants (Number)
	With CAEs	Without CAEs
EFV Combo Therapy	34	4
MK0518 100 mg b.i.d.	31	8
MK0518 200 mg b.i.d.	35	5
MK0518 400 mg b.i.d.	36	5
MK0518 600 mg b.i.d.	35	5

Intervention	participants (Number)
	With CAEs	Without CAEs	With Serious CAEs	Without Serious CAEs
MK0518 100 mg b.i.d.	4	3	0	7
MK0518 200 mg b.i.d.	2	5	0	7
MK0518 400 mg b.i.d.	3	3	0	6
MK0518 600 mg b.i.d.	5	3	0	8
Placebo	5	2	0	7

Intervention	participants (Number)
	With drug-related CAEs	Without drug-related CAEs
EFV Combo Therapy	27	11
MK0518 100 mg b.i.d.	18	21
MK0518 200 mg b.i.d	20	20
MK0518 400 mg b.i.d.	19	22
MK0518 600 mg b.i.d.	19	21

Intervention	participants (Number)
	With drug-related LAEs	Without drug-related LAEs
EFV Combo Therapy	3	35
MK0518 100 mg b.i.d.	3	36
MK0518 200 mg b.i.d.	6	34
MK0518 400 mg b.i.d.	4	37
MK0518 600 mg b.i.d.	2	38

Intervention	participants (Number)
	HIV RNA <50 copies/mL	HIV RNA <400 copies/mL
EFV Combo Therapy	32	32
MK0518 b.i.d.	133	135